FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU LEWIS, EN
LESTER, DS
LEVIN, IW
AF LEWIS, EN
LESTER, DS
LEVIN, IW
TI DRUG-INDUCED CHANGES OF PURKINJE-CELLS WITHIN THE CEREBELLAR CORTEX OF
RAT BRAINS - A VIBRATIONAL IMAGING MICROSCOPIC STUDY
SO BIOPHYSICAL JOURNAL
LA English
DT Meeting Abstract
C1 NIDDKD,BETHESDA,MD 20892.
US FDA,CDER,DRT,LAUREL,MD 20708.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BIOPHYSICAL SOCIETY
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0006-3495
J9 BIOPHYS J
JI Biophys. J.
PD FEB
PY 1994
VL 66
IS 2
BP A373
EP A373
PN 2
PG 1
WC Biophysics
SC Biophysics
GA MU462
UT WOS:A1994MU46202163
ER
PT J
AU MACDONALD, VW
BROCKNERRYAN, BA
GOMEZ, C
ALAYASH, AI
AF MACDONALD, VW
BROCKNERRYAN, BA
GOMEZ, C
ALAYASH, AI
TI OXIDATION OF NITROSYLHEMOGLOBIN BY OXYGEN AND OXYHEMOGLOBIN BY
NITROPRUSSIDE WITHOUT PEROXIDATIVE INTERMEDIATES
SO BIOPHYSICAL JOURNAL
LA English
DT Meeting Abstract
C1 US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892.
USA,BLOOD RES DETACHMENT,WRAIR,WASHINGTON,DC 20307.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BIOPHYSICAL SOCIETY
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0006-3495
J9 BIOPHYS J
JI Biophys. J.
PD FEB
PY 1994
VL 66
IS 2
BP A362
EP A362
PN 2
PG 1
WC Biophysics
SC Biophysics
GA MU462
UT WOS:A1994MU46202099
ER
PT J
AU MAKHOV, A
HANNAH, J
BRENNAN, M
TRUS, B
KOCSIS, E
CONWAY, J
WINGFIELD, P
SIMON, M
STEVEN, A
AF MAKHOV, A
HANNAH, J
BRENNAN, M
TRUS, B
KOCSIS, E
CONWAY, J
WINGFIELD, P
SIMON, M
STEVEN, A
TI FILAMENTOUS HEMAGGLUTININ OF BORDETELLA-PERTUSSIS - MONOMERIC HAIRPIN
MODEL OF A BACTERIAL ADHESIN
SO BIOPHYSICAL JOURNAL
LA English
DT Meeting Abstract
C1 NIAMS,BETHESDA,MD 20892.
US FDA,DBP,BETHESDA,MD 20892.
NIH,DCRT,BETHESDA,MD 20892.
NIH,OD,BETHESDA,MD 20892.
BROOKHAVEN NATL LAB,UPTON,NY 11973.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU BIOPHYSICAL SOCIETY
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0006-3495
J9 BIOPHYS J
JI Biophys. J.
PD FEB
PY 1994
VL 66
IS 2
BP A341
EP A341
PN 2
PG 1
WC Biophysics
SC Biophysics
GA MU462
UT WOS:A1994MU46201983
ER
PT J
AU PACKARD, BZ
AF PACKARD, BZ
TI INDUCED INTEGRIN CELL-SURFACE EXPRESSION AND CHEMOTACTIC RESPONSIVENESS
BY ONCOIMMUNIN-M
SO BIOPHYSICAL JOURNAL
LA English
DT Meeting Abstract
C1 US FDA,CBER,DCB,BETHESDA,MD 20892.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU BIOPHYSICAL SOCIETY
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0006-3495
J9 BIOPHYS J
JI Biophys. J.
PD FEB
PY 1994
VL 66
IS 2
BP A172
EP A172
PN 2
PG 1
WC Biophysics
SC Biophysics
GA MU462
UT WOS:A1994MU46200994
ER
PT J
AU ROGERS, MS
BROCKNERRYAN, BA
ALAYASH, AI
AF ROGERS, MS
BROCKNERRYAN, BA
ALAYASH, AI
TI FUNCTIONAL CHARACTERIZATIONS OF A POLYMERIZED, CROSS-LINKED HUMAN
HEMOGLOBIN
SO BIOPHYSICAL JOURNAL
LA English
DT Meeting Abstract
C1 US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU BIOPHYSICAL SOCIETY
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0006-3495
J9 BIOPHYS J
JI Biophys. J.
PD FEB
PY 1994
VL 66
IS 2
BP A361
EP A361
PN 2
PG 1
WC Biophysics
SC Biophysics
GA MU462
UT WOS:A1994MU46202093
ER
PT J
AU WEAVER, JL
MCKINNEY, L
SCHOENLEIN, PV
GOLDENBERG, S
GOTTESMAN, MM
ASZALOS, A
AF WEAVER, JL
MCKINNEY, L
SCHOENLEIN, PV
GOLDENBERG, S
GOTTESMAN, MM
ASZALOS, A
TI VOLUME REGULATION AND MDR1 PROTEIN FUNCTION IN MDR1-TRANSFECTED AND
PARENTAL CELL-LINES
SO BIOPHYSICAL JOURNAL
LA English
DT Meeting Abstract
C1 US FDA,CDER,DRT,WASHINGTON,DC 20204.
AFRRI,DEPT PHYSIOL,BETHESDA,MD.
MED COLL GEORGIA,DEPT ANAT & CELL BIOL,AUGUSTA,GA 30912.
NCI,CELL BIOL LAB,BETHESDA,MD 20892.
NR 1
TC 3
Z9 3
U1 0
U2 0
PU BIOPHYSICAL SOCIETY
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0006-3495
J9 BIOPHYS J
JI Biophys. J.
PD FEB
PY 1994
VL 66
IS 2
BP A217
EP A217
PN 2
PG 1
WC Biophysics
SC Biophysics
GA MU462
UT WOS:A1994MU46201265
ER
PT J
AU XIAO, JM
KNUTTEL, A
PACKARD, BS
KNUTSON, JR
AF XIAO, JM
KNUTTEL, A
PACKARD, BS
KNUTSON, JR
TI FREQUENCY-DOMAIN FLUORESCENCE LIFETIME MICROSCOPE WITH GHZ RESPONSE
SO BIOPHYSICAL JOURNAL
LA English
DT Meeting Abstract
C1 NHLBI,BETHESDA,MD 20892.
US FDA,CBER,BETHESDA,MD 20892.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BIOPHYSICAL SOCIETY
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0006-3495
J9 BIOPHYS J
JI Biophys. J.
PD FEB
PY 1994
VL 66
IS 2
BP A161
EP A161
PN 2
PG 1
WC Biophysics
SC Biophysics
GA MU462
UT WOS:A1994MU46200930
ER
PT J
AU WISE, CK
HASS, BS
AF WISE, CK
HASS, BS
TI HPLC ANALYSIS FOR 5-METHYLDEOXYCYTIDINE IN CELLULAR DNA OBTAINED
DIRECTLY FROM THE CULTURE FLASK
SO BIOTECHNIQUES
LA English
DT Note
ID BRONCHIAL EPITHELIAL-CELLS; RAT-LIVER; DECREASES
RP WISE, CK (reprint author), NATL CTR TOXICOL RES,DIV NUTR TOXICOL,3900 NCTR RD,JEFFERSON,AR 72079, USA.
NR 9
TC 5
Z9 5
U1 0
U2 0
PU EATON PUBLISHING CO
PI NATICK
PA 154 E. CENTRAL ST, NATICK, MA 01760
SN 0736-6205
J9 BIOTECHNIQUES
JI Biotechniques
PD FEB
PY 1994
VL 16
IS 2
BP 218
EP &
PG 0
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA MV768
UT WOS:A1994MV76800009
PM 8179879
ER
PT J
AU TOSATO, G
SGADARI, C
TAGA, K
JONES, KD
PIKE, SE
ROSENBERG, A
SECHLER, JMG
MAGRATH, IT
LOVE, LA
BHATIA, K
AF TOSATO, G
SGADARI, C
TAGA, K
JONES, KD
PIKE, SE
ROSENBERG, A
SECHLER, JMG
MAGRATH, IT
LOVE, LA
BHATIA, K
TI REGRESSION OF EXPERIMENTAL BURKITTS-LYMPHOMA INDUCED BY
EPSTEIN-BARR-VIRUS IMMORTALIZED HUMAN B-CELLS
SO BLOOD
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; NUDE-MICE; GENE-TRANSFER; FACTOR-ALPHA; REDUCED
TUMORIGENICITY; T-CELLS; EXPRESSION; LINES; INVIVO; IMMUNITY
C1 US FDA,CTR BIOL EVALUAT & RES,DIV HEMATOL PROD,BETHESDA,MD 20014.
US FDA,CTR FOOD SAFETY & APPL NUTR,BETHESDA,MD 20014.
NCI,PEDIAT ONCOL BRANCH,BETHESDA,MD 20892.
RI Sgadari, Cecilia/H-4302-2016
OI Sgadari, Cecilia/0000-0003-0364-4912
NR 47
TC 31
Z9 31
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
19106-3399
SN 0006-4971
J9 BLOOD
JI Blood
PD FEB 1
PY 1994
VL 83
IS 3
BP 776
EP 784
PG 9
WC Hematology
SC Hematology
GA MU302
UT WOS:A1994MU30200022
PM 8298139
ER
PT J
AU FU, PP
DOOLEY, KL
VONTUNGELN, LS
BUCCI, T
HART, RW
KADLUBAR, FF
AF FU, PP
DOOLEY, KL
VONTUNGELN, LS
BUCCI, T
HART, RW
KADLUBAR, FF
TI CALORIC RESTRICTION PROFOUNDLY INHIBITS LIVER-TUMOR FORMATION AFTER
INITIATION BY 6-NITROCHRYSENE IN MALE-MICE
SO CARCINOGENESIS
LA English
DT Article
ID ADDUCT FORMATION; NEWBORN MICE; MOUSE; RATS; TUMORIGENICITY;
CARCINOGENESIS; BENZOPYRENE; FAT
AB Caloric restriction (CR) inhibited strongly the incidence of chemically-induced tumors in the neonatal B6C3F(1) mouse tumorigenicity bioassay, when begun 3 months after treatment with the potent carcinogen 6-nitrochrysene, These data indicate that CR can have a profound inhibitory effect on tumor development even long after metabolic activation and DNA repair have occurred.
RP FU, PP (reprint author), NATL CTR TOXICOL RES,DIV BIOCHEM TOXICOL,JEFFERSON,AR 72079, USA.
NR 27
TC 30
Z9 30
U1 0
U2 0
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD FEB
PY 1994
VL 15
IS 2
BP 159
EP 161
DI 10.1093/carcin/15.2.159
PG 3
WC Oncology
SC Oncology
GA MW782
UT WOS:A1994MW78200003
PM 8313502
ER
PT J
AU CULP, SJ
BELAND, FA
AF CULP, SJ
BELAND, FA
TI COMPARISON OF DNA ADDUCT FORMATION IN MICE FED COAL-TAR OR
BENZO[A]PYRENE
SO CARCINOGENESIS
LA English
DT Article
ID COVALENT BINDING; MOUSE; SKIN; BENZO(A)PYRENE; COMPONENTS; EXPOSURE;
CREOSOTE; SMOKING; BITUMEN; TISSUES
AB Coal tar is a complex mixture containing hundreds of compounds, including the carcinogenic polycyclic aromatic hydrocarbon, benzo[a]pyrene. In order to compare the metabolic activation of a single carcinogen versus a complex mixture containing the carcinogen, we determined the DNA adduct profiles in B6C3F(1) mice fed doses of coal tar or benzo[a]pyrene at concentrations corresponding to the amount of benzo[a]pyrene found in the respective coal tar treatments. DNA adduct formation was quantified in liver, lungs and forestomach by P-32-postlabeling and was found to increase as a function of dose in each tissue with both coal tar and benzo[a]pyrene. In mice fed benzo[a]pyrene, a major adduct was detected with the same elution characteristics by TLC and HPLC as the major adduct, 10 beta-(deoxyguanosin-N-2-yl)-7 beta,8 alpha,9 alpha-trihydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene (dG-N-2-BPDE), obtained from reacting (+/-)-antibenzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE) with DNA. DNA binding was in the order forestomach greater than or equal to liver > lung, except at the highest dose group where the order was liver > forestomach > lung. In mice fed coal tar, a diagonal zone of radioactivity with a number of discrete adducts was observed. One area of radioactivity contained the major BPDE adduct, dG-N-2-BPDE, based on co-elution by TLC and HPLC with the synthesized adduct. Total DNA binding was greater in the coal tar-fed mice than in the mice fed benzo[a]pyrene, and the adduct levels were in the order lung > liver > forestomach. These results indicate that there are tissue-specific differences in the activation of coal tar components when compared to a representative carcinogen contained within the mixture.
RP CULP, SJ (reprint author), NATL CTR TOXICOL RES,DIV BIOCHEM TOXICOL,JEFFERSON,AR 72079, USA.
NR 32
TC 33
Z9 34
U1 0
U2 0
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD FEB
PY 1994
VL 15
IS 2
BP 247
EP 252
DI 10.1093/carcin/15.2.247
PG 6
WC Oncology
SC Oncology
GA MW782
UT WOS:A1994MW78200017
PM 8313515
ER
PT J
AU HARTER, JG
KATZPER, M
AF HARTER, JG
KATZPER, M
TI REFINEMENTS IN MODELING PAIN AND ITS RESPONSE TO ANALGESICS
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 US FDA,CDER,ROCKVILLE,MD 20857.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1994
VL 55
IS 2
BP 123
EP 123
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MY421
UT WOS:A1994MY42100001
ER
PT J
AU STEIN, RA
HARTER, JG
AF STEIN, RA
HARTER, JG
TI ORAL NSAID ANALGESICS - ISSUES OF RELATIVE EFFICACY
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 US FDA,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1994
VL 55
IS 2
BP 125
EP 125
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MY421
UT WOS:A1994MY42100007
ER
PT J
AU WEINTRAUB, M
AF WEINTRAUB, M
TI INDIVIDUAL-RESPONSES TO ASSESS THE ONSET OF ACTION OF OTC ANALGESICS
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 MCGILL UNIV,MONTREAL,PQ,CANADA.
US FDA,CDER,OFF OVER COUNTER OTC DRUG EVALUAT,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1994
VL 55
IS 2
BP 125
EP 125
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MY421
UT WOS:A1994MY42100008
ER
PT J
AU BASHAW, ED
HARTER, JG
AF BASHAW, ED
HARTER, JG
TI THE EFFECT OF ENCAPSULATION OF TABLETS FOR BLINDING ON ANALGESIA TRIALS
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 US FDA,PILOT DRUG EVALUAT STAFF,ROCKVILLE,MD.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1994
VL 55
IS 2
BP 126
EP 126
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MY421
UT WOS:A1994MY42100013
ER
PT J
AU HALE, VG
BORGA, O
HARTER, JG
KATZPER, M
AF HALE, VG
BORGA, O
HARTER, JG
KATZPER, M
TI SULINDAC - EXPLORATORY MODELING AND BIOEQUIVALENCE IMPLICATIONS
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 US FDA,CDER,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1994
VL 55
IS 2
BP 140
EP 140
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MY421
UT WOS:A1994MY42100069
ER
PT J
AU MUKHERJEE, A
LE, K
LIEBERMAN, R
AF MUKHERJEE, A
LE, K
LIEBERMAN, R
TI RELEVANCE OF PRECLINICAL PK-PD TO THE CLINICAL IMMUNOMODULATORY (IMMOD)
EFFECTS OF FK-506 IN TRANSPLANTATION (TX) AND AUTOIMMUNITY (AL)
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 US FDA,CDER,ROCKVILLE,MD 20857.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1994
VL 55
IS 2
BP 149
EP 149
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MY421
UT WOS:A1994MY42100105
ER
PT J
AU SPYKER, DA
HYDE, JE
HARTER, JG
AF SPYKER, DA
HYDE, JE
HARTER, JG
TI MYOCARDIAL-INFARCTION IN PATIENTS WHO SMOKE WHILE WEARING A NICOTINE
PATCH - REPORTING KINETICS
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 US FDA,CTR DRUG EVALUAT & RES,ROCKVILLE,MD 20857.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1994
VL 55
IS 2
BP 155
EP 155
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MY421
UT WOS:A1994MY42100129
ER
PT J
AU RINSLER, S
HANOVER, E
LOVE, PY
STADEL, BV
STEIN, RA
HARTER, JG
AF RINSLER, S
HANOVER, E
LOVE, PY
STADEL, BV
STEIN, RA
HARTER, JG
TI CATEGORIZATION OF NSAID ASSOCIATED ADRS REPORTED TO THE FDA, AS
ANAPHYLACTOID REACTIONS
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 SANDOZ PHARMACEUT INC,E HANOVER,NJ.
US FDA,ROCKVILLE,MD.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1994
VL 55
IS 2
BP 156
EP 156
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MY421
UT WOS:A1994MY42100132
ER
PT J
AU HARTER, JG
STEIN, RA
LOVE, PY
AF HARTER, JG
STEIN, RA
LOVE, PY
TI ANALYSIS OF NASAL CORTICOID TREATMENTS IN HAY-FEVER STUDIES
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 US FDA,ROCKVILLE,MD.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1994
VL 55
IS 2
BP 157
EP 157
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MY421
UT WOS:A1994MY42100136
ER
PT J
AU LESKO, LJ
WILLIAMS, RL
AF LESKO, LJ
WILLIAMS, RL
TI PHARMACEUTICAL RESEARCH IN A REGULATORY ENVIRONMENT
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 US FDA,OFF GENER DRUGS,ROCKVILLE,MD.
US FDA,CTR DRUG EVULAT & RES,ROCKVILLE,MD.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1994
VL 55
IS 2
BP 159
EP 159
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MY421
UT WOS:A1994MY42100143
ER
PT J
AU SALE, M
BARBEY, JT
SHAH, VP
WILLIAMS, RL
WOOSLEY, RL
AF SALE, M
BARBEY, JT
SHAH, VP
WILLIAMS, RL
WOOSLEY, RL
TI INSENSITIVITY OF DISSOLUTION TESTING FOR DIFFERENCES IN DIGOXIN
BIOAVAILABILITY/BIOEQUIVALENCE (BBE)
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 GEORGETOWN UNIV,FDA,DEPT MED,WASHINGTON,DC.
GEORGETOWN UNIV,FDA,DEPT PHARMACOL,WASHINGTON,DC.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1994
VL 55
IS 2
BP 167
EP 167
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MY421
UT WOS:A1994MY42100177
ER
PT J
AU GRAUMLICH, JF
LUDDEN, TM
CANTILENA, CC
LEVINE, M
WELCH, RW
WANG, Y
DHARIWAL, K
PARK, J
WASHKO, P
LAZAREV, A
KING, J
CANTILENA, LR
AF GRAUMLICH, JF
LUDDEN, TM
CANTILENA, CC
LEVINE, M
WELCH, RW
WANG, Y
DHARIWAL, K
PARK, J
WASHKO, P
LAZAREV, A
KING, J
CANTILENA, LR
TI PHARMACOKINETIC MODEL OF ASCORBIC-ACID IN DEPLETION AND REPLETION
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
C1 UNIFORMED SERV UNIV HLTH SCI,DIV CLIN PHARMACOL,BETHESDA,MD.
US FDA,CDER,ROCKVILLE,MD 20857.
NIDDK,BETHESDA,MD.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 1994
VL 55
IS 2
BP 200
EP 200
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MY421
UT WOS:A1994MY42100308
ER
PT J
AU CARSON, MM
BEELER, J
KREZOLEK, M
SPADY, D
PABST, H
AF CARSON, MM
BEELER, J
KREZOLEK, M
SPADY, D
PABST, H
TI SEROCONVERSION AFTER MEASLES VACCINATION AT 6 MONTHS OF AGE
SO CLINICAL RESEARCH
LA English
DT Meeting Abstract
C1 UNIV ALBERTA,DEPT PEDIAT,EDMONTON T6G 2E1,ALBERTA,CANADA.
US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20014.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086
SN 0009-9279
J9 CLIN RES
JI Clin. Res.
PD FEB
PY 1994
VL 42
IS 1
BP A83
EP A83
PG 1
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MR214
UT WOS:A1994MR21400447
ER
PT J
AU EMMETT, EA
RISBY, TH
TAYLOR, J
CHEN, CL
JIANG, L
FEINMAN, SE
AF EMMETT, EA
RISBY, TH
TAYLOR, J
CHEN, CL
JIANG, L
FEINMAN, SE
TI SKIN ELICITATION THRESHOLD OF ETHYLBUTYL THIOUREA AND
MERCAPTOBENZOTHIAZOLE WITH RELATIVE LEACHING FROM SENSITIZING PRODUCTS
SO CONTACT DERMATITIS
LA English
DT Article
DE RUBBER; ALLERGIC CONTACT DERMATITIS; ETHYLBUTYL THIOUREA;
2-MERCAPTOBENZOTHIAZOLE; 2,2-DITHIO-BIS-BENZOTHIAZOLE; LEACHING STUDIES;
PATCH TEST ELICITATION THRESHOLDS; CONSUMER PROTECTION; PREVENTION
ID ALLERGIC CONTACT-DERMATITIS; PATCH TESTS
AB We studied 3 contact sensitizers present in rubber products, ethylbutyl thiourea (EBT), 2-mercaptobenzothiazole (MBT) and 2,2-dithio-bis-benzothiazole (MBTS), to relate the amount of sensitizer eliciting allergic contact dermatitis to the quantity leaching from a product into various biological fluids: normal saline, human plasma and 3 synthetic sweat solutions of pH 5.5 to 7.5. To determine the amount of sensitizer remaining after leaching, Soxhlet extraction with acetonitrile was subsequently performed. High-performance liquid chromatography was used for chemical analysis. 12 MBT-sensitive patients were patch tested with serial dilutions of MBT and MBTS in petrolatum. A Latin Square design was used in statistical analysis of variance of the patch test results. Large amounts of thioureas leached from 2 rubber articles eliciting thiourea dermatitis, the literature suggesting that these would have been well above the elicitation threshold. Leaching of MBTS was relatively greater than MBT into most media, whereas MBT was a more potent elicitor than MBTS at equivalent concentrations. The lowest eliciting concentration of MBT in 1 subject was 0.01%. Such information should prove helpful to manufacturers in designed products that do not release allergens sufficiently to cause reactions in consumers. (C) Munksgaard, 1994.
C1 JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,BALTIMORE,MD 21205.
CLEVELAND CLIN,CLEVELAND,OH 44106.
SHANGHAI MED UNIV,SHANGHAI,PEOPLES R CHINA.
US FDA,WASHINGTON,DC 20204.
NR 18
TC 25
Z9 25
U1 1
U2 1
PU MUNKSGAARD INT PUBL LTD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 0105-1873
J9 CONTACT DERMATITIS
JI Contact Dermatitis
PD FEB
PY 1994
VL 30
IS 2
BP 85
EP 90
DI 10.1111/j.1600-0536.1994.tb00569.x
PG 6
WC Allergy; Dermatology
SC Allergy; Dermatology
GA NA641
UT WOS:A1994NA64100005
PM 8187508
ER
PT J
AU PAGE, N
MARZULLI, F
GREEN, S
AF PAGE, N
MARZULLI, F
GREEN, S
TI SYMPOSIUM - CHEMICALLY-INDUCED DERMAL TOXICITY - ALLERGY, IRRITATION,
URTICARIA, CANCER - ANIMALS, HUMANS AND ALTERATIONS, HELD AT BETHESDA,
MARYLAND, 25 JUNE 1990 - INTRODUCTION
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Editorial Material
C1 US FDA,WASHINGTON,DC 20204.
RP PAGE, N (reprint author), PAGE ASSOCIATES,GAITHERSBURG,MD, USA.
NR 3
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0278-6915
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD FEB
PY 1994
VL 32
IS 2
BP 91
EP 91
DI 10.1016/0278-6915(94)90167-8
PG 1
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA NC650
UT WOS:A1994NC65000001
ER
PT J
AU BRONAUGH, RL
ROBERTS, CD
MCCOY, JL
AF BRONAUGH, RL
ROBERTS, CD
MCCOY, JL
TI DOSE-RESPONSE RELATIONSHIP IN SKIN SENSITIZATION
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
ID GUINEA-PIG; SENSITIVITY
AB The dose-response relationship (challenge phase) of the skin sensitization response was investigated in previously sensitized Hartley guinea pigs. Larger numbers of animals were used per group at the lower doses so that statistically significant observations could be made. Model compounds known to be skin sensitizers were used: a strong sensitizer, dinitrochlorobenzene (DNCB), and a weaker sensitizer, p-phenylenediamine (PPDA). A gradation in response to changing DNCB doses was easily observed by using either the open epicutaneous test (OET) or the Buehler occlusive patch test. The Buehler test was used to study the dose-response relationship of DNCB sensitization. The sensitivity of the OET and Buehler test was judged not adequate to measure the dose response for PPDA, because at high doses a high incidence of responders was not obtained. Therefore, the maximization test was used to evaluate PPDA. Similar, non-linear dose-response curves were obtained with each compound. The higher doses produced a somewhat linear relationship, but at lower doses the curves flattened out and more slowly approached a zero response. Thus, for potent sensitizers, concentrations found in exposure situations might be in the linear portion of the dose-response curve. For weak responders, use concentrations might be in the shallow portion of the curve, where reactions would be underestimated if a linear dose-response curve were assumed.
C1 IMMUQUEST LABS INC,ROCKVILLE,MD.
RP BRONAUGH, RL (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,DIV SCI & APPL TECHNOL,HFS-128,WASHINGTON,DC 20204, USA.
NR 8
TC 15
Z9 17
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0278-6915
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD FEB
PY 1994
VL 32
IS 2
BP 113
EP 117
DI 10.1016/0278-6915(94)90171-6
PG 5
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA NC650
UT WOS:A1994NC65000005
PM 7510660
ER
PT J
AU SHELANSKI
MARZULLI
BRONAUGH
BUEHLER
SEABAUGH
GREEN, S
MAIBACH
MERSHON, M
AF SHELANSKI
MARZULLI
BRONAUGH
BUEHLER
SEABAUGH
GREEN, S
MAIBACH
MERSHON, M
TI SYMPOSIUM - CHEMICALLY-INDUCED DERMAL TOXICITY - ALLERGY, IRRITATION,
URTICARIA, CANCER - ANIMALS, HUMANS AND ALTERATIONS HELD AT BETHESDA,
MARYLAND, 25 JUNE 1990 - PANEL DISCUSSION
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Discussion
C1 US FDA,CTR FOOD SAFETY & APPL NUTR,WASHINGTON,DC 20204.
US EPA,WASHINGTON,DC 20460.
HILL TOP BIOLABS INC,CINCINNATI,OH 45242.
UNIV CALIF SAN FRANCISCO,DEPT DERMATOL,SAN FRANCISCO,CA 94143.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0278-6915
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD FEB
PY 1994
VL 32
IS 2
BP 129
EP 132
PG 4
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA NC650
UT WOS:A1994NC65000007
ER
PT J
AU KORNHAUSER, A
WAMER, WG
LAMBERT, LA
WEI, RR
AF KORNHAUSER, A
WAMER, WG
LAMBERT, LA
WEI, RR
TI BETA-CAROTENE INHIBITION OF CHEMICALLY-INDUCED TOXICITY IN-VIVO AND
IN-VITRO
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
ID CANCER
AB In the past several years there has been a great deal of interest in the antioxidant beta-carotene and other micronutrients for their protective potential against various toxic insults. Two studies concerning the protective effects of beta-carotene, which were conducted in our laboratory, are reported here. The first involved the role of beta-carotene in modifying two-stage skin tumorigenesis initiated by 7,12-dimethylbenz[a]anthracene (DMBA) and promoted by phorbol 12-myristate 13-acetate (PMA, TPA). In this study, the protective effects of two types of dietary beta-carotene, a beadlet formulation and crystalline beta-carotene, were compared in two strains of mice (Skh:HR-1 and CR:ORL Sencar). Mice were maintained on food fortified with 3% beta-carotene or on control diets. Mice receiving the beta-carotene-supplemented diets had fewer tumours than mice in the control groups. However, only in the Skh strain of mice was this difference statistically significant. In the second study, an in vitro experiment, BALBc 3T3 mouse fibroblasts were used to determine beta-carotene's accumulation in cells and the ability of these cells to metabolize beta-carotene to vitamin A. This in vitro model was also used to show a beta-carotene protective effect towards 8-MOP phototoxicity. These studies contributed to the increasing evidence of in vivo and in vitro protection by beta-carotene against chemically induced toxicity.
RP KORNHAUSER, A (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,WASHINGTON,DC 20204, USA.
NR 24
TC 8
Z9 8
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0278-6915
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD FEB
PY 1994
VL 32
IS 2
BP 149
EP 154
DI 10.1016/0278-6915(94)90176-7
PG 6
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA NC650
UT WOS:A1994NC65000010
PM 8132174
ER
PT J
AU PAGE, N
SHELANSKI
OSBORNE, R
SEABAUGH
BRONAUGH
AF PAGE, N
SHELANSKI
OSBORNE, R
SEABAUGH
BRONAUGH
TI SYMPOSIUM - CHEMICALLY-INDUCED DERMAL TOXICITY - ALLERGY, IRRITATION,
URTICARIA, CANCER - ANIMALS, HUMANS AND ALTERATIONS HELD AT BETHESDA,
MARYLAND, 25 JUNE 1990 - PANEL DISCUSSION
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Discussion
C1 US EPA,WASHINGTON,DC 20460.
US FDA,CTR FOOD SAFETY & APPL NUTR,WASHINGTON,DC 20204.
PROCTER & GAMBLE CO,MIAMI VALLEY LABS,DIV HUMAN & ENVIRONM SAFETY,CINCINNATI,OH 45239.
RP PAGE, N (reprint author), PAGE ASSOCIATES,GAITHERSBURG,MD, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0278-6915
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD FEB
PY 1994
VL 32
IS 2
BP 155
EP 157
PG 3
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA NC650
UT WOS:A1994NC65000011
ER
PT J
AU MOORE, MA
DATTA, AR
AF MOORE, MA
DATTA, AR
TI DNA-FINGERPRINTING OF LISTERIA-MONOCYTOGENES STRAINS BY PULSED-FIELD
GEL-ELECTROPHORESIS
SO FOOD MICROBIOLOGY
LA English
DT Article
ID MULTILOCUS ENZYME ELECTROPHORESIS; EPIDEMIOLOGIC INVESTIGATIONS;
RESTRICTION ENDONUCLEASES; SPORADIC LISTERIOSIS; FOOD; PATHOGEN
C1 US FDA,DIV MOLEC BIOL RES & EVALUAT,200 C ST SW,WASHINGTON,DC 20204.
NR 27
TC 25
Z9 25
U1 0
U2 1
PU ACADEMIC PRESS LTD
PI LONDON
PA 24-28 OVAL RD, LONDON, ENGLAND NW1 7DX
SN 0740-0020
J9 FOOD MICROBIOL
JI Food Microbiol.
PD FEB
PY 1994
VL 11
IS 1
BP 31
EP 38
DI 10.1006/fmic.1994.1005
PG 8
WC Biotechnology & Applied Microbiology; Food Science & Technology;
Microbiology
SC Biotechnology & Applied Microbiology; Food Science & Technology;
Microbiology
GA NB348
UT WOS:A1994NB34800005
ER
PT J
AU GUERRY, P
POPE, PM
BURR, DH
LEIFER, J
JOSEPH, SW
BOURGEOIS, AL
AF GUERRY, P
POPE, PM
BURR, DH
LEIFER, J
JOSEPH, SW
BOURGEOIS, AL
TI DEVELOPMENT AND CHARACTERIZATION OF RECA MUTANTS OF CAMPYLOBACTER-JEJUNI
FOR INCLUSION IN ATTENUATED VACCINES
SO INFECTION AND IMMUNITY
LA English
DT Article
ID MOLECULAR-CLONING; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; FLAGELLIN
GENES; VIBRIO-CHOLERAE; ANTIGENIC VARIATION; EXPRESSION; ENTERITIS;
STRAIN; COLONIZATION
AB Isogenic recA mutants of Campylobacter jejuni have been constructed for evaluation of their usefulness in attenuated vaccines against this major worldwide cause of diarrhea. The recA(+) gene of C. jejuni 81-176 was cloned by using degenerate primers to conserved regions of other RecA proteins in a PCR. The C. jejuni recA(+) gene encodes a predicted protein with an M, of 37,012 with high sequence similarity to other RecA proteins. The termination codon of the recA(+) gene overlaps with the initiation codon of another open reading frame which encodes a predicted protein which has >50% identity with the N terminus of the Escherichia coli enolase protein. A kanamycin resistance gene was inserted into the cloned vecA(+) gene in E. coli and returned to C. jejuni VC83 by natural transformation, resulting in allelic replacement of the wild-type recA gene. The resulting VC83 recA mutant displayed increased sensitivity to W light and a defect in generalized recombination as determined by natural transformation frequencies. The mutated recA gene was amplified from VC83 recA by PCR, and the product was used to transfer the mutation by natural transformation into C. jejuni 81-176 and 81-116, resulting in isogenic recA mutants with phenotypes similar to VC83 recA. After oral feeding, strain 81-176 recA colonized rabbits at levels comparable to wild-type 81-176 and was capable of eliciting the same degree of protection as wild-type 81-176 against subsequent homologous challenge in the RITARD (removable intestinal tie adult rabbit diarrhea) model.
C1 UNIV MARYLAND,DEPT MICROBIOL,COLL PK,MD 20742.
US FDA,WASHINGTON,DC 20204.
RP GUERRY, P (reprint author), USN,MED RES INST,ENTER PROGRAM,12300 WASHINGTON AVE,ROCKVILLE,MD 20852, USA.
NR 56
TC 40
Z9 45
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD FEB
PY 1994
VL 62
IS 2
BP 426
EP 432
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA MR841
UT WOS:A1994MR84100014
PM 8300203
ER
PT J
AU KELLNER, H
WEN, J
WANG, J
RAYBOURNE, RB
WILLIAMS, KM
YU, DTY
AF KELLNER, H
WEN, J
WANG, J
RAYBOURNE, RB
WILLIAMS, KM
YU, DTY
TI SERUM ANTIBODIES FROM PATIENTS WITH ANKYLOSING-SPONDYLITIS AND
REITERS-SYNDROME ARE REACTIVE WITH HLA-B27 CELLS TRANSFECTED WITH THE
MYCOBACTERIUM-TUBERCULOSIS HSP60 GENE
SO INFECTION AND IMMUNITY
LA English
DT Article
ID CHLAMYDIA-TRACHOMATIS; PEPTIDE; MHC; ARTHRITIS; MECHANISM; COMPLEX;
DISEASE; ANTIGEN
AB HLA-B27-related arthritis is probably mediated by an immune response against HLA-B27 complexed with peptides derived from proteins of arthritis-causing bacteria. Immunogenic proteins,vith a high degree of homology among bacteria, such as in the hsp60 family, are likely candidates. To create such complexes experimentally, we transfected an HLA-B27 cell line with the Mycobacterium tuberculosis hsp60 gene. Because of previous observations that HLA-B27-peptide complexes can be distinguished by antibodies, we tested the transfected cell line with a panel of sera from 24 HW-B27(+) arthritis patients. Significant antibodies were detected in at least eight of the sera. Several cell lines and peptides were used as negative controls to ensure that the antibody reactivity was specific to HLA-BZ7-peptide complexes. A panel of nine peptides derived from the sequence of the Mycobacterium hsp60 were synthesized and tested. At least three were identified as being responsible for the serological activities.
C1 UNIV CALIF LOS ANGELES,DEPT MED,DIV RHEUMATOL,CTR REHABIL 3540,LOS ANGELES,CA 90024.
US FDA,IMMUNOL BRANCH,LAUREL,MD 20708.
FU NCI NIH HHS [CA-16042]; NIAMS NIH HHS [NIAMS P01 AR40919]
NR 20
TC 10
Z9 11
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD FEB
PY 1994
VL 62
IS 2
BP 484
EP 491
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA MR841
UT WOS:A1994MR84100022
PM 7905462
ER
PT J
AU RAYBOURNE, RB
BUNNING, VK
AF RAYBOURNE, RB
BUNNING, VK
TI BACTERIUM-HOST CELL-INTERACTIONS AT THE CELLULAR-LEVEL - FLUORESCENT
LABELING OF BACTERIA AND ANALYSIS OF SHORT-TERM BACTERIUM-PHAGOCYTE
INTERACTION BY FLOW-CYTOMETRY
SO INFECTION AND IMMUNITY
LA English
DT Article
ID LISTERIA-MONOCYTOGENES; SALMONELLA-TYPHIMURIUM; INTRACELLULAR GROWTH;
MEDIATED-IMMUNITY; MACROPHAGE; MUTANTS; VIRULENCE; INFECTION; SURVIVAL;
HEMOLYSIN
AB Flow cytometry is a potentially powerful tool for analyzing the interactions of facultative intracellular bacteria and macrophages on a cellular level, particularly when fluorochromes are used to label the bacteria. We labeled Listeria monocytogenes and Salmonella typhimurium with a lipophilic dye, PKH-2, and used flow cytometry to investigate phagocytosis by J774A.1 cells and short-term bacterial survival. Labeled and unlabeled bacteria were identical in terms of viability, growth kinetics, and survival within macrophages, although recovery per macrophage was much greater for L. monocytogenes than for S. typhimurium. Using L. monocytogenes as a prototypical facultative intracellular bacterium, we estimated bacterial survival during phagocytosis on the basis of linear fluorescence measurements of infected J774A.1 cells and recovery of L. monocytogenes from sorted cells. The lower percentage of surviving L. monocytogenes in macrophages containing higher bacterial loads indicated the accumulation of nonviable bacteria within phagocytes. Removal of the external source of viable bacteria by washes and gentamicin treatment reduced the percentage of surviving intracellular L. monocytogenes to a baseline level, and all baseline levels mere similar, regardless of bacterial load. Listeria enrichment recoveries, derived from individually sorted J774A.1 cells, demonstrated the heterogeneity of macrophages in intracellular bacterial survival, especially within heavily infected cells. These results indicated that survival of L. monocytogenes was dependent on the adaptations of a small fraction of bacteria within a population of macrophages which permit intracellular growth.
RP RAYBOURNE, RB (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,DIV VIRULENCE ASSESSMENT,IMMONOBIOL BRANCH,LAUREL,MD 20708, USA.
NR 27
TC 34
Z9 36
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD FEB
PY 1994
VL 62
IS 2
BP 665
EP 672
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA MR841
UT WOS:A1994MR84100044
PM 8300223
ER
PT J
AU SHAHIN, RD
HAMEL, J
LEEF, MF
BRODEUR, BR
AF SHAHIN, RD
HAMEL, J
LEEF, MF
BRODEUR, BR
TI ANALYSIS OF PROTECTIVE AND NONPROTECTIVE MONOCLONAL-ANTIBODIES SPECIFIC
FOR BORDETELLA-PERTUSSIS LIPOOLIGOSACCHARIDE
SO INFECTION AND IMMUNITY
LA English
DT Note
ID INFLUENZAE TYPE-B; HEMOPHILUS-INFLUENZAE; BACTERICIDAL ACTIVITY;
IMMUNIZATION; INFECTION; CLEARANCE; FEATURES
AB In this study, it has been determined that immunoglobulin G1 (IgG1) and IgG3 monoclonal antibodies directed to the lipooligosaccharide A of Bordetella pertussis were able to protect mice from fatal aerosol infection. No correlation was found between the bactericidal activity in vitro in the presence of complement and the protection in mice, since a bactericidal IgG3 did not elicit protection. In addition, no significant difference in protective capacity was observed with bactericidal and nonbactericidal IgG1 antibodies, indicating that bactericidal activity is not a requirement for protection mediated by certain anti-lipooligosaccharide A antibodies. A reduction in protection in C5-deficient mice was observed, suggesting a significant role for complement in certain host defense mechanisms against B. pertussis infection.
C1 LAB CTR DIS CONTROL,NATL LAB IMMUNOL,OTTAWA K1A 0L2,ON,CANADA.
RP SHAHIN, RD (reprint author), US FDA,CTR BIOL EVALUAT & RES,PERTUSSIS LAB,BLDG 29,ROOM 414,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.
NR 21
TC 17
Z9 18
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD FEB
PY 1994
VL 62
IS 2
BP 722
EP 725
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA MR841
UT WOS:A1994MR84100055
PM 8300232
ER
PT J
AU KHARAZI, AI
JAMES, SJ
TAYLOR, JMG
LUBINSKI, JM
NAKAMURA, LT
MAKINODAN, T
AF KHARAZI, AI
JAMES, SJ
TAYLOR, JMG
LUBINSKI, JM
NAKAMURA, LT
MAKINODAN, T
TI COMBINED CHRONIC LOW-DOSE RADIATION CALORIC RESTRICTION - A MODEL FOR
REGRESSION OF SPONTANEOUS MAMMARY-TUMOR
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
DE LOW DOSE RADIATION; CALORIC RESTRICTION; MODULATION OF MOUSE MAMMARY
TUMOR; TUMOR INFILTRATING LYMPHOCYTES
ID IONIZING-RADIATION; ADAPTIVE RESPONSE; HUMAN-LYMPHOCYTES;
AUTOIMMUNE-PRONE; MICE; EXPOSURE; POTENTIATION; CELLS
AB Purpose: This study was carried out to determine whether chronic low dose radiation can act alone or in synergy with restricted diet in down-regulating spontaneously occurring mammary tumor in tumor-susceptible female C3H/ He mice and whether immune cells are involved.
Methods and Materials: At 7 months of age, one-half of the experimental mice were maintained on an ad lib diet, and the other half was adapted over a period of 1 month to a diet of 70% of the daily amount of food consumed by the ad lib-fed mice. The food of the restricted diet was enriched such that the vitamin and mineral intake was the same for both groups. Half of the mice in each group was then subjected to chronic low dose radiation (0.04 Gy per exposure from a Co-60 source, 3 X-per-week for 4 weeks) and the other half was sham irradiated. The 70% calorically restricted diet was maintained throughout the study. Results: Chronic low dose radiation alone was ineffective in down-regulating spontaneous mammary tumor, unlike caloric restriction. However, chronic low dose radiation when combined with caloric restriction promoted regression of mammary tumors, which were infiltrated with massive numbers of CD8(+) T cells. These phenomena were not seen in mice subjected to caloric restriction alone.
Conclusion: Combined chronic low dose radiation-caloric restriction appears to be a useful model for promoting spontaneous mammary tumor regression.
C1 US FDA,NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024.
UNIV CALIF LOS ANGELES,DEPT BIOSTAT,LOS ANGELES,CA 90024.
UNIV CALIF LOS ANGELES,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024.
RP KHARAZI, AI (reprint author), VA MED CTR W LOS ANGLES,GRECC 11G,WILSHIRE & SAWTELLE BLVDS,LOS ANGELES,CA 90073, USA.
NR 21
TC 8
Z9 8
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0360-3016
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD FEB 1
PY 1994
VL 28
IS 3
BP 641
EP 647
PG 7
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA NA836
UT WOS:A1994NA83600010
PM 8113107
ER
PT J
AU GARRA, BS
INSANA, MF
SESTERHENN, IA
HALL, TJ
WAGNER, RF
ROTELLAR, C
WINCHESTER, J
ZEMAN, RK
AF GARRA, BS
INSANA, MF
SESTERHENN, IA
HALL, TJ
WAGNER, RF
ROTELLAR, C
WINCHESTER, J
ZEMAN, RK
TI QUANTITATIVE ULTRASONIC-DETECTION OF PARENCHYMAL STRUCTURAL-CHANGE IN
DIFFUSE RENAL-DISEASE
SO INVESTIGATIVE RADIOLOGY
LA English
DT Article
DE ULTRASOUND; KIDNEY; GLOMERULAR SIZE; TISSUE CHARACTERIZATION; RENAL
TRANSPLANT; TRANSPLANT REJECTION
ID TRANSPLANTS; DIFFERENTIATION; LIVER; US
AB OBJECTIVE. The authors determined whether quantitative ultrasound could be useful in the evaluation of diffuse renal disease.
METHODS. Digitized radiofrequency ultrasound data were acquired from the kidneys of patients with biopsy-proven diffuse renal disease and transplant rejection (37 patients plus 18 normal volunteers). The results of the quantitative analysis were compared with histology results to determine if microscopic renal structure could be correlated with quantitative features such as scatterer size and scatterer spacing. The results also were analyzed using receiver operating characteristic analysis to determine if diffuse disease could be detected reliably using quantitative methods.
RESULTS. The three most useful features in the native kidneys were mean scatterer spacing (MSS), sigma's, and average scatterer size (D). Using these features, it was possible to detect diffuse renal disease causing a decrease in renal function with an area under the ROC curve (Az) of 0.93. The feature D corresponded closely to histologically measured average glomerular diameters. For normals, D = 216 mu m and glomerular diameter = 211 mu m. No histologic correlate was found for scatterer spacing. In transplants, MSS and integrated backscatter were most useful for detecting rejection (Az = 0.87), and D in rejection was similar to the values for normal kidney and normally functioning transplants.
CONCLUSIONS. The D value corresponds to glomerular diameter, and glomerular enlargement can be detected readily using quantitative ultrasound, Combinations of two to four quantitative features can detect diffuse renal disease and transplant rejection reliably.
C1 UNIV KANSAS,MED CTR,DEPT RADIOL,KANSAS CITY,KS.
ARMED FORCES INST PATHOL,DEPT GENITOURINARY PATHOL,WASHINGTON,DC.
US FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD.
GEORGETOWN UNIV,MED CTR,DEPT MED,WASHINGTON,DC.
RP GARRA, BS (reprint author), GEORGETOWN UNIV,MED CTR,DEPT RADIOL,3800 RESERVOIR RD NW,WASHINGTON,DC 20007, USA.
RI Hall, Timothy/K-3632-2012
NR 38
TC 32
Z9 33
U1 0
U2 1
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0020-9996
J9 INVEST RADIOL
JI Invest. Radiol.
PD FEB
PY 1994
VL 29
IS 2
BP 134
EP 140
DI 10.1097/00004424-199402000-00002
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA NA658
UT WOS:A1994NA65800002
PM 8169086
ER
PT J
AU KLINMAN, DM
AF KLINMAN, DM
TI CROSS-REACTIVITY OF IGG AND IGM SECRETING B-CELLS IN NORMAL AND
AUTOIMMUNE MICE
SO JOURNAL OF AUTOIMMUNITY
LA English
DT Article
ID SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTI-DNA ANTIBODIES; MONOCLONAL
AUTOANTIBODIES; NATURAL AUTOANTIBODIES; MURINE AUTOANTIBODIES; VIABLE
MOTHEATEN; SELF ANTIGENS; HELPER-CELLS; LYMPHOCYTE-B; BALB/C MICE
RP KLINMAN, DM (reprint author), US FDA,CBER,DIV VIRAL PROD,RETROVIRAL IMMUNOL SECT,BLDG 29A,RM 3D16,BETHESDA,MD 20205, USA.
NR 54
TC 7
Z9 7
U1 0
U2 0
PU ACADEMIC PRESS LTD
PI LONDON
PA 24-28 OVAL RD, LONDON, ENGLAND NW1 7DX
SN 0896-8411
J9 J AUTOIMMUN
JI J. Autoimmun.
PD FEB
PY 1994
VL 7
IS 1
BP 1
EP 11
DI 10.1006/jaut.1994.1001
PG 11
WC Immunology
SC Immunology
GA NC555
UT WOS:A1994NC55500001
PM 8198696
ER
PT J
AU ARAKERE, G
LEE, AL
FRASCH, CE
AF ARAKERE, G
LEE, AL
FRASCH, CE
TI INVOLVEMENT OF PHOSPHOLIPID END-GROUPS OF GROUP-C NEISSERIA-MENINGITIDIS
AND HAEMOPHILUS-INFLUENZAE TYPE-B POLYSACCHARIDES IN ASSOCIATION WITH
ISOLATED OUTER MEMBRANES AND IN IMMUNOASSAYS
SO JOURNAL OF BACTERIOLOGY
LA English
DT Article
ID ESCHERICHIA-COLI; CAPSULAR POLYSACCHARIDE; SPECIFICITY; PROTECTION;
CARRIERS; BACTERIA; ANTIGENS; DISEASE
AB There are several bacterial polysaccharides (PSs) which contain a terminal lipid moiety. It has been postulated that these terminal lipid moieties anchor the PSs to the outer membrane of the bacteria. Our studies have shown that incubation of native PS from group C Neisseria meningitidis or Haemophilus influenzae type b with isolated outer membrane vesicles results in association of a portion of the PS with the vesicles. Removal of the terminal lipid from the PS by treatment with phospholipase A(2) or phospholipase D eliminates this association. In other studies, it was shown that delipidated PSs are not suitable as solid-phase antigens in a currently used enzyme-linked immunosorbent assay (ELISA). Measurement of antibody units in the reference sera by using delipidated PSs as antigens in an ELISA yielded negligible absorbance compared with native PSs when methylated human serum albumin was used to coat the PSs to the plate. Nevertheless, phospholipase A(2) and phospholipase D treatment did not noticeably affect antigenic epitopes, since soluble group C PS without the terminal lipid bound antibody as effectively as the native PS did, as measured by a competitive inhibition assay. Both hydrophobic and electrostatic interactions are important for the binding of group C N. meningitidis PS to the ELISA plate, while charge interactions seem to be sufficient for binding the more negatively charged H. influenzae type b PS.
C1 CTR BIOL EVALUAT & RES,DIV BACTERIAL PROD,ROCKVILLE,MD 20852.
MERCK SHARP & DOHME LTD,RES LABS,W POINT,PA 19486.
NR 24
TC 19
Z9 19
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0021-9193
J9 J BACTERIOL
JI J. Bacteriol.
PD FEB
PY 1994
VL 176
IS 3
BP 691
EP 695
PG 5
WC Microbiology
SC Microbiology
GA MU151
UT WOS:A1994MU15100018
PM 8300524
ER
PT J
AU KHAN, AS
MOE, CL
GLASS, RI
MONROE, SS
ESTES, MK
CHAPMAN, LE
JIANG, X
HUMPHREY, C
PON, E
ISKANDER, JK
SCHONBERGER, LB
AF KHAN, AS
MOE, CL
GLASS, RI
MONROE, SS
ESTES, MK
CHAPMAN, LE
JIANG, X
HUMPHREY, C
PON, E
ISKANDER, JK
SCHONBERGER, LB
TI NORWALK VIRUS-ASSOCIATED GASTROENTERITIS TRACED TO ICE CONSUMPTION
ABOARD A CRUISE SHIP IN HAWAII - COMPARISON AND APPLICATION OF MOLECULAR
METHOD-BASED ASSAYS
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID VIRAL GASTROENTERITIS; OUTBREAK; TRANSMISSION; RESTAURANT
AB Investigation of an outbreak of acute nonbacterial gastroenteritis on a cruise ship provided an opportunity to assess new molecular method-based diagnostic methods for Norwalk virus (NV) and the antibody response to NV infection. The outbreak began within 36 h of embarkation and affected 30% of 672 passengers and crew. No single meal, seating, or food item was implicated in the transmission of NV, but a passenger's risk of illness was associated with the amount of ice (but not water) consumed (chi-square for trend, P = 0.009). Of 19 fecal specimens examined, 7 were found to contain 27-nm NV-like particles by electron microscopy and 16 were positive by PCR with very sensitive NV-specific primers, but only 5 were positive by a new highly specific antigen enzyme immunoassay for NV. Ten of 12 serum specimen pairs demonstrated a fourfold or greater rise in antibody titer io recombinant baculovirus-expressed NV antigen. The amplified PCR band shared only 81% nucleotide sequence homology with the reference NV strain, which may explain the lack of utility of the fecal specimen enzyme immunoassay. This report, the first to document the use of these molecular method-based assays for investigation of an outbreak, demonstrates the importance of highly sensitive viral diagnostics such as PCR and serodiagnosis for the epidemiologic investigation of NV gastroenteritis.
C1 CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333.
CTR DIS CONTROL & PREVENT,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30333.
US FDA,OFF PLANT & DAIRY FOODS & BEVERAGES,DIV MICROANALYT EVALUAT,WASHINGTON,DC 20204.
BAYLOR COLL MED,HOUSTON,TX 77030.
HAWAII DEPT HLTH,HONOLULU,HI 96813.
OI Monroe, Stephan/0000-0002-5424-716X
FU NIAID NIH HHS [AI 30448]
NR 26
TC 70
Z9 71
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD FEB
PY 1994
VL 32
IS 2
BP 318
EP 322
PG 5
WC Microbiology
SC Microbiology
GA MR792
UT WOS:A1994MR79200007
PM 8150941
ER
PT J
AU PECK, CC
BARR, WH
BENET, LZ
COLLINS, J
DESJARDINS, RE
FURST, DE
HARTER, JG
LEVY, G
LUDDEN, T
RODMAN, JH
SANATHANAN, L
SCHENTAG, JJ
SHAH, VP
SHEINER, LB
SKELLY, JP
STANSKI, DR
TEMPLE, RJ
VISWANATHAN, CT
WEISSINGER, J
YACOBI, A
AF PECK, CC
BARR, WH
BENET, LZ
COLLINS, J
DESJARDINS, RE
FURST, DE
HARTER, JG
LEVY, G
LUDDEN, T
RODMAN, JH
SANATHANAN, L
SCHENTAG, JJ
SHAH, VP
SHEINER, LB
SKELLY, JP
STANSKI, DR
TEMPLE, RJ
VISWANATHAN, CT
WEISSINGER, J
YACOBI, A
TI OPPORTUNITIES FOR INTEGRATION OF PHARMACOKINETICS, PHARMACODYNAMICS, AND
TOXICOKINETICS IN RATIONAL DRUG DEVELOPMENT
SO JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Editorial Material
C1 US FDA, CTR DRUG EVALUAT & RES, ROCKVILLE, MD 20857 USA.
VIRGINIA COMMONWEALTH UNIV, SCH PHARM, RICHMOND, VA USA.
UNIV CALIF SAN FRANCISCO, SCH PHARM, SAN FRANCISCO, CA 94143 USA.
AMER CYANAMID CO, PEARL RIVER, NY USA.
CIBA GEIGY PHARMACEUT CORP, SUMMIT, NJ USA.
SUNY BUFFALO, AMHERST, NY USA.
ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN USA.
SUNY BUFFALO, MILLARD FILLMORE HOSP, CLIN PHARMACOKINET LAB, BUFFALO, NY USA.
UNIV CALIF SAN FRANCISCO, MED CTR, SAN FRANCISCO, CA 94143 USA.
VA HOSP, DEPT ANESTHESIA, PALO ALTO, CA USA.
RI Benet, Leslie/K-8286-2016
NR 0
TC 35
Z9 35
U1 0
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0091-2700
J9 J CLIN PHARMACOL
JI J. Clin. Pharmacol.
PD FEB
PY 1994
VL 34
IS 2
BP 111
EP 119
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MX069
UT WOS:A1994MX06900003
PM 8163710
ER
PT J
AU HARDY, BJ
PASTOR, RW
AF HARDY, BJ
PASTOR, RW
TI CONFORMATIONAL SAMPLING OF HYDROCARBON AND LIPID CHAINS IN AN ORIENTING
POTENTIAL
SO JOURNAL OF COMPUTATIONAL CHEMISTRY
LA English
DT Article
ID MONTE-CARLO SIMULATIONS; MOLECULAR-DYNAMICS SIMULATION; DEUTERIUM
MAGNETIC-RESONANCE; LIQUID NORMAL-BUTANE; BROWNIAN DYNAMICS;
PHOSPHATIDYLCHOLINE BILAYERS; PHOSPHOLIPID BILAYER; MODEL; MEMBRANES;
ALGORITHMS
AB A Distribution Biased Monte Carlo (DBMC) sampling procedure is developed for the efficient generation of chain conformations in the oriented environment of lipid membranes and other liquid crystalline systems. Conformations of the sn-l chain of dipalmitoyl phosphatidylcholine (DPPC) were generated by independently sampling torsion angles from continuous distributions in an orienting potential based on a Marcelja mean field; depending on the chain position, the convergence in the deuterium order parameters (S-CD) was 100 to 3000 times more efficient with DBMC than with Brownian dynamics. Optimization using joint distribution and torsional potentials of mean force yielded a further threefold increase in sampling efficiency. Overall chain tilt was included using Euler angle rotations and a separate field strength for the anchor. A segmental DBMC procedure was used to generate a set of complete DPPC conformations with well-converged conformationally averaged S-CD consistent with experimental values. These conformations show considerable flexibility, not only in the hydrocarbon tails, but additionally in both the glycerol and head-group portions of the lipid. An appendix compares DBMC with a number of other Monte Carlo and stochastic dynamics algorithms using the example of a bistable oscillator, and illustrates the tuning of parameters for optimal convergence. (C) 1994 by John Wiley and Sons, Inc.
C1 US FDA,CTR BIOL EVALUAT & RES,BIOPHYS LAB,BETHESDA,MD 20892.
NR 62
TC 24
Z9 24
U1 0
U2 2
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0192-8651
J9 J COMPUT CHEM
JI J. Comput. Chem.
PD FEB
PY 1994
VL 15
IS 2
BP 208
EP 226
DI 10.1002/jcc.540150211
PG 19
WC Chemistry, Multidisciplinary
SC Chemistry
GA MT222
UT WOS:A1994MT22200010
ER
PT J
AU GECAN, JS
BANDLER, R
STARUSZKIEWICZ, WF
AF GECAN, JS
BANDLER, R
STARUSZKIEWICZ, WF
TI FRESH AND FROZEN SHRIMP - A PROFILE OF FILTH, MICROBIOLOGICAL
CONTAMINATION, AND DECOMPOSITION
SO JOURNAL OF FOOD PROTECTION
LA English
DT Article
ID LISTERIA; PRODUCTS
AB A 2-year nationwide survey was conducted by the Food and Drug Administration to provide current information about filth, decomposition, and microbiological contamination of domestic and imported fresh and frozen shrimp. Whole or equivalent filth insects, mostly ants, were found in 14.4% of the samples. Of countries contributing at least 10 samples for filth analysis, India had the highest percentage positive for filth insects (45.5%); the United States had the lowest (6.3%). Filth insect fragments were present in 5.4% of the samples. Incidental insects were present in 6.3% of the samples, with flies the most commonly found. Of countries contributing at least 10 samples for filth analysis, India had the highest percentage positive for incidental insects (27.3%); Ecuador had the lowest (2.3%). Unidentified insect fragments were found in 33.3% of the samples; cockroach excreta pellets were present in 2.1%, rat or mouse hairs in 5.7%, and other striated animal hairs in 15.3%. Of countries contributing at least 10 samples for filth analysis, the Philippines had the highest percentages positive (30.0 and 50.0%) for rat or mouse hairs and other striated hairs, respectively; Malaysia was close behind with 23.1 and 46.2%. Samples from the United States had the lowest percentage positive for rat or mouse hairs (0.9%) and other striated hairs (7.2%). Listeria spp. were found in 6.8% of the samples; Salmonella spp. were found in 8.1%. Some level of decomposition was observed in 15.4% of the samples tested organoleptically.
C1 US FDA,DIV SCI & APPL TECHNOL,OFF SEAFOOD,WASHINGTON,DC 20204.
RP GECAN, JS (reprint author), US FDA,DIV MICROANALYT EVALUAT,OFF PLANT & DAIRY FOODS & BEVERAGES,WASHINGTON,DC 20204, USA.
NR 9
TC 13
Z9 14
U1 1
U2 9
PU INT ASSOC MILK FOOD ENVIRONMENTAL SANITARIANS, INC
PI DES MOINES
PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2838
SN 0362-028X
J9 J FOOD PROTECT
JI J. Food Prot.
PD FEB
PY 1994
VL 57
IS 2
BP 154
EP &
PG 0
WC Biotechnology & Applied Microbiology; Food Science & Technology
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA MW756
UT WOS:A1994MW75600012
ER
PT J
AU KAYSNER, CA
ABEYTA, C
JINNEMAN, KC
HILL, WE
AF KAYSNER, CA
ABEYTA, C
JINNEMAN, KC
HILL, WE
TI ENUMERATION AND DIFFERENTIATION OF VIBRIO-PARAHAEMOLYTICUS AND
VIBRIO-VULNIFICUS BY DNA-DNA COLONY HYBRIDIZATION USING THE HYDROPHOBIC
GRID MEMBRANE FILTRATION TECHNIQUE FOR ISOLATION
SO JOURNAL OF FOOD PROTECTION
LA English
DT Note
AB We have developed a means of differentiating and enumerating Vibrio parahaemolyticus and Vibrio vulnificus by DNA-DNA colony, hybridization directly on HGMF filters. V. parahaemolyticus can be detected by a tdh-3-radiolabeled gene probe and V. vulnificus detected by a specific cytotoxin-hemolysin-radiolabeled probe with enumeration directly from autoradiograms. This procedure is more rapid than current techniques allowing enumeration and identification of these two species in samples as diverse as seawater, oyster (Crassostrea gigas), and shrimp (Pandalidae family) within 4 d. Our method is based on a rapid technique (18 h) for isolation and enumeration of V. parahaemolyticus from food using a membrane filtration technique with hydrophobic grid filters (HGMF). With the HGMF method, however, it is not possible to differentiate V. parahaemolyticus from V. vulnificus since on the HGMF-sucrose-based agar used, the two species are indistinguishable as both species are unable to ferment sucrose. Using a combination of the HGMF and selective gene probes, these two species can be differentiated.
RP KAYSNER, CA (reprint author), US FDA,SEAFOOD PROD RES CTR,BOTHELL,WA 98041, USA.
NR 12
TC 2
Z9 2
U1 1
U2 2
PU INT ASSOC MILK FOOD ENVIRONMENTAL SANITARIANS, INC
PI DES MOINES
PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2838
SN 0362-028X
J9 J FOOD PROTECT
JI J. Food Prot.
PD FEB
PY 1994
VL 57
IS 2
BP 163
EP 165
PG 3
WC Biotechnology & Applied Microbiology; Food Science & Technology
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA MW756
UT WOS:A1994MW75600014
ER
PT J
AU FUKAZAWA, T
WANG, J
HUANG, F
WEN, J
TYAN, D
WILLIAMS, KM
RAYBOURNE, RB
YU, DTY
AF FUKAZAWA, T
WANG, J
HUANG, F
WEN, J
TYAN, D
WILLIAMS, KM
RAYBOURNE, RB
YU, DTY
TI TESTING THE IMPORTANCE OF EACH RESIDUE IN A HLA-B27-BINDING PEPTIDE
USING MONOCLONAL-ANTIBODIES
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID ANKYLOSING-SPONDYLITIS; HLA-B27; ASSOCIATION; ANTIGEN; MHC
AB When a peptide derived from histone 3.3 was incubated with mouse L cells transfected with HLA-B27, the cells became highly reactive with Ye-2, an anti-HLA-B27 mAb. The critical residues were analyzed by testing analogues in which each of the nine residues in the peptide was consecutively substituted by 19 other amino acids. The conclusions were separately verified using a different HLA-B27-positive cell line. The ability of some of these peptides to bind to HLA-B27 was also assayed by their ability to stabilize HLA-B27 in a mutant cell line which required HLA-B27-binding peptides to express HLA-B27 at 37-degrees-C. These experiments showed that in P4, P5, P6, P7, P8, and P9, all 20 different amino acids could be substituted without eliminating the ability of the analogues to bind to HLA-B27. The residues which were responsible for the HLA-B27-peptide complex reacting with the Ye-2 antibody were P8 and P9. The latter might mediate its effect by altering either the surface conformation of the closely associated HLA-B27 heavy chain or the conformation of the peptide itself.
C1 UNIV CALIF LOS ANGELES,CTR REHABIL,DEPT MED,DIV RHEUMATOL,1000 VET AVE,LOS ANGELES,CA 90024.
CEDARS SINAI MED CTR,DEPT MED,DIV MED GENET,LOS ANGELES,CA 90048.
CEDARS SINAI MED CTR,DEPT PEDIAT,LOS ANGELES,CA 90048.
US FDA,DIV MICROBIOL,LAUREL,MD 20708.
FU NCI NIH HHS [CA-16042]; NIAMS NIH HHS [P01 AR40919]
NR 8
TC 18
Z9 20
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD FEB 1
PY 1994
VL 152
IS 3
BP 1190
EP 1196
PG 7
WC Immunology
SC Immunology
GA MV630
UT WOS:A1994MV63000026
PM 8301123
ER
PT J
AU WANG, J
YU, DTY
FUKAZAWA, T
KELLNER, H
WEN, J
CHENG, XK
ROTH, G
WILLIAMS, KM
RAYBOURNE, RB
AF WANG, J
YU, DTY
FUKAZAWA, T
KELLNER, H
WEN, J
CHENG, XK
ROTH, G
WILLIAMS, KM
RAYBOURNE, RB
TI A MONOCLONAL-ANTIBODY THAT RECOGNIZES HLA-B27 IN THE CONTEXT OF PEPTIDES
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID MAJOR HISTOCOMPATIBILITY COMPLEX; MHC; ANTIGEN
AB The T2 mutant cell line is unable to load peptides into the MHC class I Ags inside the cells. These ''empty'' MHC class I Ags are not expressed on the cell surface unless the cells are cultured at low temperatures. Expression will occur at 37-degrees-C only in the presence of peptides that bind to and stabilize the class I Ags. T2 cells transfected with the B*2705 gene were tested with a panel of anti-HLA-B27 mAb. Two of the antibodies, ME1 and KS3, reacted with the ''empty'' HLA-B27 expressed at low culture temperatures. Three antibodies, B27.M1, B27.M2, and Ye-2, were unreactive with these ''empty'' HLA-B27. The cells were then incubated with a panel of HLA-B27-binding peptides. One of the antibodies, Ye-2, became reactive when the cells were incubated with a peptide derived from HIV gp120 and to a less degree with a peptide derived from histone H3.3. Mouse L cells transfected with the B*2705 and the human beta2m genes also reacted very poorly with B27.M1, B27.M2, and Ye-2. Those two peptides were also able to induce high increase in Ye-2 reactivity. Alternately, increase in Ye-2 reactivity was also observed when the L cells were incubated with IFN-gamma or TNF-alpha. These experiments indicate that the Ye-2 anti-HLA-B27 mAb recognizes HLA-B27 in the context of certain residing peptides either added exogenously or expressed endogenously. The B27.M1 and B27.M2 antibodies might share similar characteristics.
C1 UNIV CALIF LOS ANGELES,CTR REHABIL,DEPT MED,DIV RHEUMATOL,1000 VET AVE,LOS ANGELES,CA 90024.
US FDA,DIV MICROBIOL,LAUREL,MD 20708.
FU NCI NIH HHS [CA-16042]; NIAMS NIH HHS [P01 AR40919]
NR 18
TC 44
Z9 45
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD FEB 1
PY 1994
VL 152
IS 3
BP 1197
EP 1205
PG 9
WC Immunology
SC Immunology
GA MV630
UT WOS:A1994MV63000027
PM 8301124
ER
PT J
AU GRUBER, MF
WILLIAMS, CC
GERRARD, TL
AF GRUBER, MF
WILLIAMS, CC
GERRARD, TL
TI MACROPHAGE-COLONY-STIMULATING FACTOR EXPRESSION BY ANTI-CD45 STIMULATED
HUMAN MONOCYTES IS TRANSCRIPTIONALLY UP-REGULATED BY IL-1-BETA AND
INHIBITED BY IL-4 AND IL-10
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID TUMOR NECROSIS FACTOR; BLOOD MONOCYTES; GROWTH-FACTOR; HUMAN CSF-1;
CELL-LINE; INTERLEUKIN-1; PROLIFERATION; PRECURSORS; SECRETION; TRIGGERS
AB Macrophage (M)-CSF is a survival and differentiation factor for mononuclear phagocytes. Stimulation of human monocytes with immobilized mAb directed to CD45 induces M-CSF message and small amounts of protein, which is strongly augmented by costimulation with IL-1beta. This study was undertaken to study the mechanisms leading to the IL-1beta-induced up-regulation of M-CSF production and to determine how the antiinflammatory cytokines, IL-4 and IL-10, affect M-CSF production in this system. We demonstrate that IL-1beta enhanced M-CSF mRNA levels, in part, by increasing M-CSF gene transcription but had no effect on M-CSF message half-life. The enhancement of M-CSF message levels in the presence of IL-1beta was blocked by cycloheximide, suggesting that de novo protein synthesis was required. Moreover, soluble IL-1 receptors inhibited the effect of IL-1beta on M-CSF production thus confirming that these effects were IL-1 receptor mediated. Both IL-4 and IL-10 strongly inhibited M-CSF secretion by anti-CD45/IL-1beta-induced monocytes that was accompanied by decreased M-CSF message levels. IL-4 and IL-10 repressed M-CSF gene transcription but did not affect M-CSF message half-life. These findings demonstrate that IL-1beta, at least in part, transcriptionally up-regulates M-CSF production in anti-CD45-stimulated human monocytes, a process that can be negatively regulated by both IL-4 and IL-10. These results suggest that IL-1beta, IL-4, and IL-10 control the survival and differentiation of human monocytes through a regulation of autocrine M-CSF production.
RP GRUBER, MF (reprint author), US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BLDG 29A,RM 2A-21,BETHESDA,MD 20014, USA.
NR 27
TC 37
Z9 37
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD FEB 1
PY 1994
VL 152
IS 3
BP 1354
EP 1361
PG 8
WC Immunology
SC Immunology
GA MV630
UT WOS:A1994MV63000045
PM 8301137
ER
PT J
AU NEDJAR, S
MITCHELL, F
BISWAS, R
AF NEDJAR, S
MITCHELL, F
BISWAS, R
TI SIMULTANEOUS AMPLIFICATION AND DETECTION OF SPECIFIC HEPATITIS-B VIRUS
AND HEPATITIS-C VIRUS GENOMIC SEQUENCES IN SERUM SAMPLES
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE HBV-DNA; HCV-RNA; PCR COAMPLIFICATION DETECTION
ID NON-A; CHIMPANZEES; INFECTION; ASSAY
AB A sensitive and specific two-stage polymerase chain reaction (PCR) technique was developed for the simultaneous amplification and detection of specific genomic sequences of hepatitis B virus (HBV) and hepatitis C virus (HCV) in serum samples. Initially, HCV-RNA was reverse transcribed to cDNA. This cDNA and DNA from HBV were then co-amplified using primer pairs derived from conserved regions of HBV and HCV nucleotide sequences. The specificity of PCR products was confirmed by liquid hybridization analysis using P-32 end-labeled oligomer probes specific for the target HBV and HCV nucleotide sequences. Independent human serum samples, positive and negative by PCR for both HBV-DNA and HCV-RNA, were used as controls. We tested sera from nine donors, of which seven were reactive for HBsAg, anti-HBc, and anti-HCV (multi-antigen test), one of whom was reactive for anti-HCV and anti-HBc, and one of whom was reactive for HBsAg and anti-HBc. The assay detected HBV- and HCV-specific genomic sequences in eight of eight sera reactive for both HBV and HCV serological markers and also in the serum that was reactive for HBV markers only. (C) 1994 Wiley-Liss, Inc.
C1 US FDA,CTR BIOL EVALUAT & RES,DIV TRANSFUS TRANSMITTED DIS,HEPATITIS LAB,BETHESDA,MD.
NR 12
TC 10
Z9 10
U1 0
U2 1
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0146-6615
J9 J MED VIROL
JI J. Med. Virol.
PD FEB
PY 1994
VL 42
IS 2
BP 212
EP 216
DI 10.1002/jmv.1890420221
PG 5
WC Virology
SC Virology
GA MT785
UT WOS:A1994MT78500020
PM 8158116
ER
PT J
AU CHIARELLI, MP
LAY, JO
AF CHIARELLI, MP
LAY, JO
TI DIFFERENTIATION OF ISOMERIC C8-SUBSTITUTED AND N2-DEOXYGUANOSINE ADDUCTS
OF 2-ACETYLAMINOFLUORENE BY FAST-ATOM-BOMBARDMENT AND TANDEM
MASS-SPECTROMETRY
SO JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY
LA English
DT Article
ID DNA ADDUCTS; RAT-LIVER; CARCINOGEN; IDENTIFICATION
AB Product-ion studies of source-produced ions corresponding to acetylated and nonacetylated N2- and C8-substituted aminofluorene adducts of deoxyguanosine were conducted to identify specific fragmentation pathways differentiating the isomers and to determine the influence of the acetyl group on the fragmentation of the arylamide modified deoxyguanosine adducts. The collision-induced dissociation spectra of the BH2+ ion and other significant source-produced ions showed no evidence to suggest that ketene loss (deacetylation) resulted in significant alteration of the structure of the adducts. However, other significant ion formation processes, particularly loss of water from the N2-substituted arylamide did appear to require rearrangement, likely involving bond formation between the carcinogen moiety (acetyl group) and the N1 or N2 position of the guanine base. The combined loss of ketene and water constitute a fragmentation pattern specific for the N2-arylamide, 3-(deoxyguanosin-N2-yl)-2-acetylaminofluorene.
C1 NATL CTR TOXICOL RES,DIV CHEM,HFT 154,JEFFERSON,AR 72079.
UNIV ARKANSAS,DEPT CHEM,LITTLE ROCK,AR 72204.
RI Lay, Jackson/G-1007-2011
OI Lay, Jackson/0000-0003-3789-2527
NR 17
TC 7
Z9 7
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010
SN 1044-0305
J9 J AM SOC MASS SPECTR
JI J. Am. Soc. Mass Spectrom.
PD FEB
PY 1994
VL 5
IS 2
BP 58
EP 63
DI 10.1016/1044-0305(94)85037-2
PG 6
WC Chemistry, Analytical; Chemistry, Physical; Spectroscopy
SC Chemistry; Spectroscopy
GA MX063
UT WOS:A1994MX06300002
PM 24222516
ER
PT J
AU PEDERSOLI, WM
RAVIS, WR
JACKSON, J
SHAIKH, B
AF PEDERSOLI, WM
RAVIS, WR
JACKSON, J
SHAIKH, B
TI DISPOSITION AND BIOAVAILABILITY OF NEOMYCIN IN HOLSTEIN CALVES
SO JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID COMPARATIVE PHARMACOKINETICS; AMINOGLYCOSIDE ANTIBIOTICS; GENTAMICIN
AB The disposition and absorption kinetics of neomycin were studied in healthy ruminating dairy calves (n = 6), approximately 3-months-old. The calves were treated with single intravenous (i.v.) (12 mg/kg), intramuscular (i.m.) (24 mg/kg), oral (p.o.) (96 mg/kg) and repeated p.o. (96 mg/kg, b.i.d., 15 1/2 days) doses of neomycin. A 3-week rest period was allowed between treatments A and B, and B and C. Baseline and serial venous blood samples were collected from each calf. Plasma concentrations of neomycin were determined by a high performance liquid chromatography procedure. The resulting data were evaluated by using compartmental pharmacokinetic models and nonlinear least squares regression analysis. The mean of some selected parameters were t1/2lambda3 7.48 +/- 2.02 h, Cl(t) = 0.25 +/- 0.04 L/h/kg, V(d(ss)) = 1.17 +/- 0.23 L/kg, and MRT = 4.63 +/- 0.87 h for the i.v. data and t1/2 = 11.5 +/- 3.8 h, MRT(abs) = 0.960 +/- 1.001 h, F = 127 +/- 35.2%, and Cl(t)/F = 0.199 +/- 0.047 L/h/kg for the i.m. data, respectively. Only one calf absorbed neomycin to any significant degree (F = 0.0042) after a single p.o. dose. Selected mean parameters determined after repeated oral dosing were: F = 0.45 +/- 0.45%, C(max) = 0.26 +/- 0.37 mug/ml, and t(max) = 2.6 +/- 2.9 h. Terminal half-lives determined for the i.v. and i.m. treatments were considerably longer than those reported previously in the literature.
C1 US FDA,CVM,OSB,DIV RESIDUE CHEM,BELTSVILLE,MD 20705.
AUBURN UNIV,SCH PHARM,DEPT PHARMACAL SCI,AUBURN,AL 36849.
RP PEDERSOLI, WM (reprint author), US FDA,CVM,OSB,DEPT ANIM RES,BARC E,BLDG 328-A,BELTSVILLE,MD 20705, USA.
NR 21
TC 2
Z9 2
U1 0
U2 6
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0140-7783
J9 J VET PHARMACOL THER
JI J. Vet. Pharmacol. Ther.
PD FEB
PY 1994
VL 17
IS 1
BP 5
EP 11
DI 10.1111/j.1365-2885.1994.tb00514.x
PG 7
WC Pharmacology & Pharmacy; Veterinary Sciences
SC Pharmacology & Pharmacy; Veterinary Sciences
GA MZ003
UT WOS:A1994MZ00300002
PM 8196095
ER
PT J
AU PETRICOIN, E
DAVID, M
FANG, H
GRIMLEY, P
LARNER, AC
POL, SV
AF PETRICOIN, E
DAVID, M
FANG, H
GRIMLEY, P
LARNER, AC
POL, SV
TI HUMAN CANCER CELL FINES EXPRESS A NEGATIVE TRANSCRIPTIONAL REGULATOR OF
THE INTERFERON REGULATORY FACTOR FAMILY OF DNA-BINDING PROTEINS
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID HUMAN PAPILLOMAVIRUS TYPE-16; VIRUS-40 LARGE-T; ADENOVIRUS E1A PROTEINS;
FC-GAMMA RECEPTOR; ALPHA-INTERFERON; TYROSINE KINASE; GENE-EXPRESSION;
FACTOR ISGF3; SIGNAL TRANSDUCTION; INVITRO ACTIVATION
AB Members of the interferon regulatory factor (IRF) family of DNA binding transcription factors have roles in growth regulation, antiviral responses, and transcriptional induction of interferon (IFN)-activated early response genes. The IRF family member ISGF3 gamma is the DNA binding component of IFN-stimulated gene factor 3 (ISGF3), a multicomponent complex responsible for the stimulation of IFN-alpha-responsive genes. IFN-alpha-stimulated formation of ISGF3 and subsequent gene expression can be inhibited by phorbol esters or expression of the adenovirus E1A protein. We have investigated IFN signaling in human malignant tumor cell lines of the lung, colon, ovary, cervix, and hematopoietic organs and found some of these cells to be defective for IFN-alpha-induced formation of ISGF3. In many cases, an inhibitory activity termed transcriptional knockout (TKO) correlated with nonresponsiveness. TKO purified from a human papiliomavirus-negative cervical carcinoma cell line has a molecular size of 19 kDa. The purified protein interacted with the ISGF3 gamma component of ISGF3, preventing binding of ISGF3 to DNA. Purified TKO displaced ISGF3 from its DNA binding site in vitro and prevented ISGF3 gamma, IRF-1, and IRF-2 from interacting with the IFN-stimulated response element. Partially purified TKO can also directly interact with ISGF3 gamma in the absence of DNA. This protein may be involved with the development of malignancies and the inability of IFN to exert its antiproliferative and antiviral effects.
C1 UNIFORMED SERV UNIV HLTH SCI,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20892.
UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,BETHESDA,MD 20892.
NCI,TUMOR VIRUS BIOL LAB,BETHESDA,MD 20892.
NR 49
TC 33
Z9 33
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0270-7306
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD FEB
PY 1994
VL 14
IS 2
BP 1477
EP 1486
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA NK734
UT WOS:A1994NK73400063
PM 8289823
ER
PT J
AU SNAWDER, JE
ROE, AL
BENSON, RW
CASCIANO, DA
ROBERTS, DW
AF SNAWDER, JE
ROE, AL
BENSON, RW
CASCIANO, DA
ROBERTS, DW
TI CYTOCHROME P450-DEPENDENT METABOLISM OF ACETAMINOPHEN IN 4 HUMAN
TRANSGENIC LYMPHOBLASTOID CELL-LINES
SO PHARMACOGENETICS
LA English
DT Note
ID NITROSODIMETHYLAMINE DEMETHYLASE; MOUSE-LIVER; PROTEIN; ASSAY;
ACTIVATION; OXIDATION; COMPETENT; TOXICITY; ENZYMES; ADDUCTS
C1 UNIV ARKANSAS MED SCI HOSP,DEPT PHARMACOL & TOXICOL,DIV TOXICOL,LITTLE ROCK,AR 72205.
UNIV ARKANSAS MED SCI HOSP,DEPT MOLEC BIOL & BIOCHEM,LITTLE ROCK,AR 72205.
NATL CTR TOXICOL RES,DIV GENET TOXICOL,JEFFERSON,AR 72079.
RP SNAWDER, JE (reprint author), NATL CTR TOXICOL RES,DIV BIOCHEM TOXICOL,JEFFERSON,AR 72079, USA.
NR 28
TC 21
Z9 21
U1 1
U2 1
PU CHAPMAN HALL LTD
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN
SN 0960-314X
J9 PHARMACOGENETICS
JI Pharmacogenetics
PD FEB
PY 1994
VL 4
IS 1
BP 43
EP 46
DI 10.1097/00008571-199402000-00006
PG 4
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology
& Pharmacy
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology
& Pharmacy
GA ND091
UT WOS:A1994ND09100006
PM 8004132
ER
PT J
AU MEDLOCK, KL
FORRESTER, TM
SHEEHAN, DM
AF MEDLOCK, KL
FORRESTER, TM
SHEEHAN, DM
TI PROGESTERONE AND ESTRADIOL INTERACTION IN THE REGULATION OF RAT UTERINE
WEIGHT AND ESTROGEN-RECEPTOR CONCENTRATION
SO PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article
ID BREAST-CANCER CELLS; DOWN-REGULATION; MESSENGER-RNA; UTERUS; MECHANISM;
TURNOVER
AB Autologous down-regulation of hormone receptors has been shown for several steroid hormones. We have previously shown estradiol (E(2)) regulates estrogen receptor (ER) in ovarlectomized (OVX) rats. These studies have been extended to investigate the interaction between progesterone (P) and E(2) in the regulation of ER and uterine weight. We implanted Silastic capsules containing varying concentrations of E(2) (0.0005 mg E(2)/ml to 5.0 mg E(2)/ml of sesame oil) Into adult female Sprague-Dawley rats one week after OVX. Simultaneously with implantation, P injections were started (sc in sesame oil) at doses of 1-40 mg/day for three days. In the absence of P, the 0.05 mg E(2)/ml implant significantly increased total ER levels (measured by cytosol and nuclear exchange assays) by 25%, while the two highest concentrations of E(2) (0.5 and 5.0 mg E(2)/ml) significantly decreased cytosol and total ER levels by at least 40%. No P dose altered ER levels in OVX rats or in rats given E(2) implants of 0.01 mg E(2)/ml or lower. At E(2) implant concentrations of 0.05 mg E(2)/ml and higher, P decreased total ER levels 30%-50% compared to the appropriate E(2)-only controls. P increased uterine weight by 25% in OVX controls end in rats treated with E(2) implants of 0.01 mg E(2)/ml and below. In contrast, P inhibited uterine weight gain induced by 0.05-5.0 mg/E(2) ml implants by 20%-30%; maximal inhibition occurred at 5 mg/day of P and above. These data demonstrate that P increases uterine weight but does not alter ER concentration in rats with low E(2) levels (OVX or low E(2) concentration implants) but decreases uterine weight and down-regulates ER at higher E(2) levels, regardless of whether ER is upregulated or down-regulated by E(2).
C1 AGCY TOX SUBST & DIS REGISTRY,DIV HLTH ASSESSMENT & CONSULTAT,REMEDIAL PROGRAMS BRANCH,ATLANTA,GA 30333.
UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM,LITTLE ROCK,AR 72205.
UNIV ARKANSAS MED SCI HOSP,DEPT PHARMACOL & TOXICOL,LITTLE ROCK,AR 72205.
RP MEDLOCK, KL (reprint author), NATL CTR TOXICOL RES,DIV REPROD & DEV TOXICOL,HFT-130,JEFFERSON,AR 72079, USA.
NR 21
TC 20
Z9 20
U1 0
U2 4
PU BLACKWELL SCIENCE INC
PI CAMBRIDGE
PA 238 MAIN ST, CAMBRIDGE, MA 02142
SN 0037-9727
J9 P SOC EXP BIOL MED
JI Proc. Soc. Exp. Biol. Med.
PD FEB
PY 1994
VL 205
IS 2
BP 146
EP 153
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NF385
UT WOS:A1994NF38500007
PM 8108464
ER
PT J
AU YORK, JL
WOLFF, GL
AF YORK, JL
WOLFF, GL
TI GLUTATHIONE-S-TRANSFERASE ACTIVITY AND ISOENZYME CONCENTRATIONS IN OBESE
A(VY)/A AND LEAN A/A MICE
SO PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article
ID BUTYLATED HYDROXYANISOLE; GENETIC OBESITY; INDUCTION; SUSCEPTIBILITY;
ENZYMES
AB To assist in defining the mechanism(s) by which the activity of hepatic glutathione S-transferase (GST) is decreased in obese rodents, the cytosolic concentrations of individual GST isozymes were determined by high-performance liquid chromatography. For this purpose, liver cytosols from 8- and 16-week-old obese yellow A(vy)/a and lean black a/a male and female mice of the inbred VY/WffC3Hf/Nctr-A(vy) strain were assayed. Obese yellow males contained less hepatic GT-9.0 than lean black males; however, there were no differences between the obese and lean females. GT-9.0 concentration, which is induced by testosterone, was several-fold higher in males than in females, regardless of genotype or body weight. No differences in concentrations of other isozymes were detected. Hepatic GST activity towards 1-chloro-2,4-dinitrobenzene was significantly higher in lean males than In obese males; however, there were no differences between obese and lean females. Lean males had higher activity than lean females; but obese males and females had similar enzyme activities. These changes in enzyme activity can be accounted for by the changes In GT-9.0 concentration measured by HPLC. Lung and testes cytosols were also assayed for GST Isozyme concentrations. No differences in any isozyme concentration were found between the sexes or the genotypes in the lung or between genotypes in the testes.
C1 NATL CTR TOXICOL RES,DIV NUTR TOXICOL,JEFFERSON,AR 72079.
UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205.
NR 12
TC 3
Z9 3
U1 0
U2 0
PU BLACKWELL SCIENCE INC
PI CAMBRIDGE
PA 238 MAIN ST, CAMBRIDGE, MA 02142
SN 0037-9727
J9 P SOC EXP BIOL MED
JI Proc. Soc. Exp. Biol. Med.
PD FEB
PY 1994
VL 205
IS 2
BP 186
EP 189
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NF385
UT WOS:A1994NF38500013
PM 8108470
ER
PT J
AU ALTEKRUSE, S
HYMAN, F
KLONTZ, K
TIMBO, B
TOLLEFSON, L
AF ALTEKRUSE, S
HYMAN, F
KLONTZ, K
TIMBO, B
TOLLEFSON, L
TI FOODBORNE BACTERIAL-INFECTIONS IN INDIVIDUALS WITH THE
HUMAN-IMMUNODEFICIENCY-VIRUS
SO SOUTHERN MEDICAL JOURNAL
LA English
DT Review
ID IMMUNE-DEFICIENCY SYNDROME; LISTERIA-MONOCYTOGENES; SALMONELLA
BACTEREMIA; SPORADIC LISTERIOSIS; EPIDEMIC LISTERIOSIS;
CAMPYLOBACTER-JEJUNI; UNITED-STATES; AIDS; PATIENT; MENINGITIS
AB The literature contains reports documenting a foodborne etiology for bacterial infections caused by Salmonella spp, Listeria monocytogenes, Campylobacter jejuni, and Vibrio spp in individuals with the human immunodeficiency virus (HIV). The incidence of these infections and the life-threatening complications that result are elevated in people with HIV infection. We present practical recommendations to prevent foodborne illnesses and the resulting complications, including gastroenteritis, bacteremia, meningitis, and death. We suggest that patients with HIV infection be counseled to avoid foods at high risk for harboring bacterial pathogens and to use careful sanitary practices in food preparation.
RP ALTEKRUSE, S (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,DIV MARKET STUDIES,EPIDEMIOL BRANCH,HFS-728,WASHINGTON,DC 20204, USA.
NR 59
TC 18
Z9 18
U1 0
U2 1
PU SOUTHERN MEDICAL ASSN
PI BIRMINGHAM
PA 35 LAKESHORE DR PO BOX 190088, BIRMINGHAM, AL 35219
SN 0038-4348
J9 SOUTHERN MED J
JI South.Med.J.
PD FEB
PY 1994
VL 87
IS 2
BP 169
EP 173
DI 10.1097/00007611-199402000-00003
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA MZ120
UT WOS:A1994MZ12000003
PM 8115877
ER
PT J
AU LUECKE, RH
WOSILAIT, WD
PEARCE, BA
YOUNG, JF
AF LUECKE, RH
WOSILAIT, WD
PEARCE, BA
YOUNG, JF
TI A PHYSIOLOGICALLY-BASED PHARMACOKINETIC COMPUTER-MODEL FOR
HUMAN-PREGNANCY
SO TERATOLOGY
LA English
DT Article
ID RAT; DISPOSITION; EQUATIONS; ACID
AB A physiologically based pharmacokinetic (PBPK) model for human pregnancy must incorporate many factors that are not usually encountered in PBPK models of mature animals. Models for pregnancy must include the large changes that take place in the mother, the placenta and the embryo/fetus over the period of pregnancy. The embryo/fetal weight change was modeled using the Gompertz equation for growth which gave a good fit to extensive pooled weight data of the human embryo/fetus from 25 to 300 days of gestation. This equation is based on a growth rate that is proportional to the total weight of the organism with the proportionality factor decreasing exponentially with time. Allometric equations, which are widely used to relate organ weights, blood flow rates and other attributes of mature animals to total weight, were adapted to correlate fetal organ weights with total fetal weight. Allometric relationships were also developed for plasma flow rates and other organ-related parameters. The computer model, written in FORTRAN 77, included 27 compartments for the mother and 16 for the fetus; it also accommodates two substances allowing representation of a parent compound and a metabolite (or a second drug or environmental substance). Although this model is large, the inherent sparsity in the equations allow it to be solved numerically in a reasonable time on currently available, reasonably priced desktop computers. A nonlinear regression routine is included to fit key model parameters to experimental data. Concentrations of chemicals administered and measured in the mother may be simulated in both maternal and fetal organs at any day(s) between 25 days and 300 days of gestation. Allometric relationships are also utilized to adopt this human model for use with data obtained from animal experiments. (C) 1994 Wiley-Liss, Inc.*
C1 NATL CTR TOXICOL RES,DIV REPROD & DEV TOXICOL,JEFFERSON,AR 72079.
UNIV MISSOURI,DEPT CHEM ENGN,COLUMBIA,MO 65211.
UNIV MISSOURI,DEPT PHARMACOL,COLUMBIA,MO 65211.
FU FDA HHS [FDA 224-89-0008]
NR 30
TC 49
Z9 49
U1 0
U2 5
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0040-3709
J9 TERATOLOGY
JI Teratology
PD FEB
PY 1994
VL 49
IS 2
BP 90
EP 103
DI 10.1002/tera.1420490205
PG 14
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA MZ112
UT WOS:A1994MZ11200004
PM 8016750
ER
PT J
AU BISWAS, RM
NEDJAR, S
WILSON, LT
MITCHELL, FD
SNOY, PJ
FINLAYSON, JS
TANKERSLEY, DL
AF BISWAS, RM
NEDJAR, S
WILSON, LT
MITCHELL, FD
SNOY, PJ
FINLAYSON, JS
TANKERSLEY, DL
TI THE EFFECT ON THE SAFETY OF INTRAVENOUS IMMUNOGLOBULIN OF TESTING PLASMA
FOR ANTIBODY TO HEPATITIS-C
SO TRANSFUSION
LA English
DT Article
ID VIRUS; INFECTION; FRACTIONATION; CHIMPANZEES; PREVENTION; PATTERNS;
IMMUNITY
AB Background: The safety of intravenous immunoglobulin (IGIV), manufactured from units testing negative for antibody to hepatitis C virus !anti-HCV), was investigated.
Study Design and Methods: A study involving five chimpanzees was performed to determine whether the safety of IGIV would be compromised if units of plasma that reacted for anti-HCV were withheld from pools from which IGIV is manufactured. In the first phase of the experiment, two chimpanzees were infused with 25 mt per kg of unprocessed, pooled plasma from 2887 donors who did not react for anti-HCV in single-antigen (c100-3) enzyme-linked immunosorbent assays. In the second phase, each of three chimpanzees was Infused with 1000 mg per kg of IGIV manufactured from the same plasma units. The immunoglobulin was made by seven United States-licensed manufacturers, each using its own approved method. Each chimpanzee received an equal dose of each manufacturer's IGIV.
Results: The two chimpanzees that received anti-c100-3-nonreactive, unprocessed pooled plasma became infected with HCV. The three chimpanzees infused with IGIV did not show any evidence of infection with HCV 15 months after inoculation. Two of these animals were challenged with human non-A,non-B hepatitis-infectious plasma, and both subsequently showed evidence of HCV infection.
Conclusion: These studies demonstrate that, as determined by infectivity for chimpanzees, 1) the withholding of plasma units that react for anti-c100-3 from pools from which plasma products are manufactured does not render the source material noninfectious, and 2) the safety of IGIV manufactured from such plasma pools is not compromised by withholding the units that react for anti-c100-3.
C1 US FDA,CBER,DIV VET SCI,BETHESDA,MD.
US FDA,CBER,DIV HEMATOL,BETHESDA,MD.
RP BISWAS, RM (reprint author), US FDA,CTR BIOL EVALUAT & RES,DIV TRANSFUS TRANSMITTED DIS,HEPATITIS LAB,BETHESDA,MD 20852, USA.
NR 15
TC 23
Z9 23
U1 0
U2 0
PU AMER ASSOC BLOOD BANKS
PI BETHESDA
PA 8101 GLENBROOK RD, BETHESDA, MD 20814-2749
SN 0041-1132
J9 TRANSFUSION
JI Transfusion
PD FEB
PY 1994
VL 34
IS 2
BP 100
EP 104
DI 10.1046/j.1537-2995.1994.34294143934.x
PG 5
WC Hematology
SC Hematology
GA MW156
UT WOS:A1994MW15600003
PM 7508642
ER
PT J
AU ZOON, KC
AF ZOON, KC
TI MINNESOTA DRUG SALES
SO SCIENCE
LA English
DT Letter
RP ZOON, KC (reprint author), US FDA,CTR BIOL EVALUAT & RES,ROCKVILLE,MD 20857, USA.
NR 1
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005
SN 0036-8075
J9 SCIENCE
JI Science
PD JAN 28
PY 1994
VL 263
IS 5146
BP 453
EP 453
DI 10.1126/science.8290945
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MT966
UT WOS:A1994MT96600002
PM 8290945
ER
PT J
AU BROWNSTEIN, A
FRICKE, W
AF BROWNSTEIN, A
FRICKE, W
TI HIV TRANSMISSION BETWEEN 2 ADOLESCENT BROTHERS WITH HEMOPHILIA
(REPRINTED FROM MMWR, VOL 42, PG 948-951, 1993)
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
C1 US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20014.
CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333.
RP BROWNSTEIN, A (reprint author), NATL HEMOPHILIA FDN,NEW YORK,NY, USA.
NR 12
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JAN 26
PY 1994
VL 271
IS 4
BP 262
EP 264
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA MR221
UT WOS:A1994MR22100006
ER
PT J
AU WEISZ, A
SCHER, AL
SHINOMIYA, K
FALES, HM
ITO, Y
AF WEISZ, A
SCHER, AL
SHINOMIYA, K
FALES, HM
ITO, Y
TI A NEW PREPARATIVE-SCALE PURIFICATION TECHNIQUE - PH-ZONE-REFINING
COUNTERCURRENT CHROMATOGRAPHY
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID DISPLACEMENT CHROMATOGRAPHY
AB A novel countercurrent chromatographic technique is described for the preparative separation-with excellent resolution-of up to multigram quantities of organic acids. This separation is accomplished by addition of a simple acid (e.g., trifluoroacetic acid) to the sample solution or stationary phase, followed by isocratic elution with a basic mobile phase. The acids elute as well-resolved rectangularly shaped peaks. This technique should rind widespread application in any organic chemistry laboratory for the separation of crude mixtures and for the purification of isolated acids.
C1 NHLBI,BIOPHYS CHEM LAB,BETHESDA,MD 20892.
US FDA,OFF COSMET & COLORS,WASHINGTON,DC 20204.
NR 12
TC 100
Z9 101
U1 2
U2 13
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD JAN 26
PY 1994
VL 116
IS 2
BP 704
EP 708
DI 10.1021/ja00081a035
PG 5
WC Chemistry, Multidisciplinary
SC Chemistry
GA MV283
UT WOS:A1994MV28300035
ER
PT J
AU NIGHTINGALE, SL
AF NIGHTINGALE, SL
TI WARNING ABOUT UNSAFE ELECTRODE LEAD WIRES AND PATIENT CABLES USED WITH
MEDICAL DEVICES
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
RP NIGHTINGALE, SL (reprint author), US FDA, OFF HLTH AFFAIRS, PARKLAWN BLDG, 5600 FISHERS LANE, ROCKVILLE, MD 20857 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JAN 19
PY 1994
VL 271
IS 3
BP 179
EP 179
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA MQ645
UT WOS:A1994MQ64500008
ER
PT J
AU NIGHTINGALE, SL
AF NIGHTINGALE, SL
TI NEW MAMMOGRAPHY QUALITY STANDARDS ISSUED
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
RP NIGHTINGALE, SL (reprint author), US FDA, OFF HLTH AFFAIRS, PARKLAWN BLDG, 5600 FISHERS LANE, ROCKVILLE, MD 20857 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JAN 19
PY 1994
VL 271
IS 3
BP 179
EP 179
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA MQ645
UT WOS:A1994MQ64500007
ER
PT J
AU CONRAD, C
HEMPHILL, K
WILSON, S
MCFARLAND, L
COULBOURNE, K
QARNI, S
POSTER, S
GROVES, C
SLEMP, C
BUTLER, E
MATUSZAK, D
DWYER, D
ISRAEL, E
CIRINO, J
CUMBERLAND, D
POLLACK, L
CURRIER, M
MORRIS, H
BISSETT, M
EVANS, S
RESPESS, B
JENKINS, B
MAILLARD, J
MERIWETHER, R
MACCORMACK, JN
CREASY, B
VEAZEY, J
CALCI, K
RIPPEY, S
HOSKIN, G
AF CONRAD, C
HEMPHILL, K
WILSON, S
MCFARLAND, L
COULBOURNE, K
QARNI, S
POSTER, S
GROVES, C
SLEMP, C
BUTLER, E
MATUSZAK, D
DWYER, D
ISRAEL, E
CIRINO, J
CUMBERLAND, D
POLLACK, L
CURRIER, M
MORRIS, H
BISSETT, M
EVANS, S
RESPESS, B
JENKINS, B
MAILLARD, J
MERIWETHER, R
MACCORMACK, JN
CREASY, B
VEAZEY, J
CALCI, K
RIPPEY, S
HOSKIN, G
TI MULTISTATE OUTBREAK OF VIRAL GASTROENTERITIS RELATED TO CONSUMPTION OF
OYSTERS - 1993 (REPRINTED FROM MORBIDITY AND MORTALITY WEEKLY REPORT,
VOL 42, PG 945, 1993)
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Reprint
C1 LOUISIANA DEPT HLTH & HOSP,MOLLUSCAN SHELLFISH PROGRAM,BATON ROUGE,LA 70821.
LOUISIANA DEPT HLTH & HOSP,OFF PUBL HLTH,BATON ROUGE,LA 70821.
TALBOT CTY HLTH DEPT,EASTON,MD.
BALTIMORE CTY DEPT HLTH,BALTIMORE,MD.
HARFORD CTY HLTH DEPT,BEL AIR,MD.
MARYLAND DEPT HLTH & MENTAL HYG,BALTIMORE,MD.
MISSISSIPPI DEPT HLTH,BUR MARINE RESOURCES,JACKSON,MS.
BEAUFORT CTY HLTH DEPT,WASHINGTON,DC.
N CAROLINA DEPT ENVIRONM HLTH & NAT RESOURCES,RALEIGH,NC.
CTR DIS CONTROL,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333.
US FDA,EPIDEMIOL PROGRAM OFF,DIV FIELD EPIDEMIOL,WASHINGTON,DC 20204.
RP CONRAD, C (reprint author), LOUISIANA DEPT HLTH & HOSP,SEAFOOD SANITAT PROGRAM,BATON ROUGE,LA 70821, USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JAN 19
PY 1994
VL 271
IS 3
BP 183
EP &
PG 0
WC Medicine, General & Internal
SC General & Internal Medicine
GA MQ645
UT WOS:A1994MQ64500011
ER
PT J
AU BISHOP, KD
BLOCKER, FJH
EGAN, W
JAMES, TL
AF BISHOP, KD
BLOCKER, FJH
EGAN, W
JAMES, TL
TI HEPATITIS-B VIRUS DIRECT REPEAT SEQUENCE - IMINO PROTON-EXCHANGE RATES
AND DISTANCE AND TORSION ANGLE RESTRAINTS FROM NMR
SO BIOCHEMISTRY
LA English
DT Article
ID NUCLEAR-MAGNETIC-RESONANCE; RELAXATION MATRIX ANALYSIS; 2-DIMENSIONAL
NOE SPECTROSCOPY; OVERHAUSER EFFECT SPECTRA; PEAK FINE-STRUCTURES;
CONFORMATIONAL-ANALYSIS; SIGNAL SUPPRESSION; COUPLING-CONSTANTS; H-1-NMR
SPECTRA; DNA OCTAMER
AB Structural features of a trisdecamer duplex, [d(GGCAGAGGTGAAA).d(TTTCACCTCTGCC)], in solution are being investigated by proton one-dimensional (1D) and two-dimensional (2D) NMR spectroscopy. This DNA sequence is comprised of the 11-base-pair direct repeat sequence found in the hepatitis B viral genome with an additional base pair from the genome included on each end to minimize end effects on the 11-bp sequence of interest. The direct repeat sequence occurs twice in the viral genome; both are essential for initiation of DNA synthesis. The critical nature of this sequence suggests it may be a target to control replication of the virus. Elucidation of the structure of the direct repeat sequence could prove to be beneficial in targeting efforts. Structural determination via restrained molecular dynamics requires experimentally derived distance restraints. The ability to determine solution structures of biomolecules by NMR spectroscopy is limited by the quality and quantity of distance and torsion angle restraints that can be extracted from the NMR data. Techniques used to establish these restraints are constantly evolving and improving. Modifications in procedure are applied to the trisdecamer duplex to yield improvements in the determination of sugar conformations from COSY data and a substantial increase in the number of distance restraints typically garnered from 2D NOE intensity data. This increase in the number of distance restraints normally obtained from 2D NOE intensities was accomplished by utilizing a new version of the iterative complete relaxation matrix program MARDIGRAS with intensities extracted from a 2D NOE data set acquired in 90% H2O. The exchange rate of the imino and amino protons with the solvent water protons can now be included in the relaxation matrix calculations, thereby providing more accurate distances when utilizing the 2D NOE cross-peaks involving at least one exchangeable proton. In this lab, analysis of two-quantum-filtered correlation (2QF-COSY) spectra to determine the conformational states of the sugar moieties typically employs the program package SPHINX/LINSHA to simulate the scalar coupling effects manifest in the cross-peaks. With enough data, we typically find that a single conformer is inadequate to describe sugar pucker, but a rapid two-state equilibrium is consistent with all the data. In the process, a large number of cross-peaks are simulated with a range of possible sugar conformation ratios, amplitudes, and line widths. A limitation of this procedure is the possibility of producing a nonunique solution. These methods rely on the ability to match the appearance of simulated cross-peaks with real data. The method described here utilizes the same program for simulating 2QF-COSY peaks, but uses some measured coupling constants and estimated line widths from E.COSY spectra as input for synthesis of the cross-peaks. The validity of the measurements was checked by comparing the simulated cross-peaks with experimental cross-peaks. Results of the COSY analysis and MARDIGRAS calculations provided 501 interproton distance restraints and deoxyribose torsion angle restraints for 22 of the 26 residues. Some interesting features are apparent in the d(CACC).(GTGG) region of the duplex. Two residues in this region exhibit an unusually small amount of C2'-endo sugar conformational characteristics, and the thymidine imino has an exchange rate twice that of the other nonterminal thymidine residues.
C1 UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143.
US FDA,CTR BIOL EVALUAT & RES,BIOPHYS LAB,BETHESDA,MD 20892.
FU NCRR NIH HHS [RR01695]; NIGMS NIH HHS [GM39247, GM41639]
NR 52
TC 10
Z9 10
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD JAN 18
PY 1994
VL 33
IS 2
BP 427
EP 438
DI 10.1021/bi00168a006
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA MR493
UT WOS:A1994MR49300006
PM 8286373
ER
PT J
AU WEISZ, A
ANDRZEJEWSKI, D
HIGHET, RJ
ITO, Y
AF WEISZ, A
ANDRZEJEWSKI, D
HIGHET, RJ
ITO, Y
TI PREPARATIVE SEPARATION OF COMPONENTS OF THE COLOR ADDITIVE FD-AND-C RED
NO-3 (ERYTHROSINE) BY PH-ZONE-REFINING COUNTERCURRENT CHROMATOGRAPHY
SO JOURNAL OF CHROMATOGRAPHY A
LA English
DT Article; Proceedings Paper
CT 10th International Symposium on Preparative Chromatography
CY JUN 14-16, 1993
CL ARLINGTON, VA
SP WASHINGTON CHROMATOG DISCUSS GRP
ID PURIFICATION
AB The components in 3 g of the commercial color additive FD&C Red No. 3 were separated by pH-zone-refining counter-current chromatography. The main component, 2',4',5',7' -tetraiodofluorescein, and two positional isomeric lower-iodinated subsidiary colors, 2',4',5'-triiodofluorescein and 2',4',7'-triiodoffuorescein, were isolated and characterized by H-1 NMR and chemical ionization mass spectrometry.
C1 US FDA,OFF SCI ANAL & SUPPORT,WASHINGTON,DC 20204.
NHLBI,BIOPHYS CHEM LAB,BETHESDA,MD 20892.
RP WEISZ, A (reprint author), US FDA,OFF COSMET & COLORS,WASHINGTON,DC 20204, USA.
NR 18
TC 27
Z9 28
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0021-9673
J9 J CHROMATOGR A
JI J. Chromatogr. A
PD JAN 14
PY 1994
VL 658
IS 2
BP 505
EP 510
DI 10.1016/0021-9673(94)80042-1
PG 6
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA MW231
UT WOS:A1994MW23100031
ER
PT J
AU ASAFUADJAYE, EB
SU, SY
SHIU, GK
AF ASAFUADJAYE, EB
SU, SY
SHIU, GK
TI SWITCHING-VALVE FILTER TECHNIQUE FOR THE DIRECT-INJECTION AND ANALYSIS
OF DRUGS IN PLASMA USING HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY
SO JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS
LA English
DT Article
ID SERUM; PRECOLUMN; ELUENTS
AB An automated technique involving switching valves and a filter assembly has been developed and evaluated for the on-line precipitation of proteins and peptides from plasma samples. In the set-up, the proteins were precipitated on-line by injecting the plasma sample into a stream of organic precipitating agent. The precipitates so formed are filtered on-line by a set of filter assemblies consisting of ordinary in-line HPLC solvent filters. Evaluation of the technique was performed using ibuprofen and a mixture of three estrogens, estradiol, equilin and estrone, spiked in dog plasma. The coefficients of variation (C.V.) for system suitability parameters were below 10%. Absolute recovery of ibuprofen in plasma ranged from 80% for 100 mug/ml to 114% for 5 mug/ml spiked concentrations, respectively. Resolution for equilin and estrone, two closely eluting peaks, was 1.79 (C.V. = 5.8%, n = 7). The switching-valve-filter assembly had no significant effect on the efficiency of the HPLC system.
RP ASAFUADJAYE, EB (reprint author), US FDA,CDER,OGD,GENER DRUGS RES,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 12
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-4347
J9 J CHROMATOGR B
JI J. Chromatogr. B-Biomed. Appl.
PD JAN 14
PY 1994
VL 652
IS 1
BP 35
EP 42
DI 10.1016/0378-4347(93)E0372-W
PG 8
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA ND216
UT WOS:A1994ND21600005
PM 8014225
ER
PT J
AU WEISZ, K
SHAFER, RH
EGAN, W
JAMES, TL
AF WEISZ, K
SHAFER, RH
EGAN, W
JAMES, TL
TI SOLUTION STRUCTURE OF THE OCTAMER MOTIF IN IMMUNOGLOBULIN GENES VIA
RESTRAINED MOLECULAR-DYNAMICS CALCULATIONS
SO BIOCHEMISTRY
LA English
DT Article
ID NUCLEAR-MAGNETIC-RESONANCE; OVERHAUSER EFFECT SPECTRA; RELAXATION MATRIX
ANALYSIS; INTERPROTON DISTANCE RESTRAINTS; NOE-BASED REFINEMENT; B-DNA;
CURVED DNA; A-DNA; OLIGONUCLEOTIDE STRUCTURES; CRYSTAL-STRUCTURES
AB The solution structure of the DNA decamer d(CATTTGCATC).d(GATGCAAATG), comprising the octamer motif of immunoglobulin genes, is determined by restrained molecular dynamics (rMD) simulations. The restraint data set includes interproton distances and torsion angles for the deoxyribose sugar ring which were previously obtained by a complete relaxation matrix analysis of the two-dimensional nuclear Overhauser enhancement (2D NOE) intensities and by the quantitative simulation of cross-peaks in double-quantum-filtered correlated (2QF-COSY) spectra. The influence of torsion angles and the number of experimental distance restraints on the structural refinement has been systematically examined. Omitting part of the experimental NOE-derived distances results in reduced restraint violations and lower R factors but impairs structural convergence in the rMD refinement. Eight separate restrained molecular dynamics simulations were carried out for 20 ps each, starting from either energy-minimized A- or B-DNA. Mutual atomic root-mean-square (rms) differences among the refined structures are well below 1 angstrom and comparable to the rms fluctuations of the atoms about their average position, indicating convergence to essentially identical structures. The average refined structure was subjected to an additional 100 ps of rMD simulations and analyzed in terms of average torsion angles and helical parameters. The B-type duplex exhibits clear sequence-dependent variations in its geometry with a narrow minor groove at the T3.A3 tract and a large positive roll at the subsequent TG.CA step. This is accompanied by a noticeable bend of the global helix axis into the major groove. There is also evidence of significant flexibility of the sugar-phosphate backbone with rapid interconversion among different conformers.
C1 UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143.
UNIV CALIF SAN FRANCISCO,DEPT RADIOL,SAN FRANCISCO,CA 94143.
US FDA,CTR BIOL EVALUAT & RES,BIOPHYS LAB,BETHESDA,MD 20892.
FU NCI NIH HHS [CA27343]; NCRR NIH HHS [1 P41 RR06009]; NIGMS NIH HHS
[GM39247]
NR 88
TC 83
Z9 83
U1 0
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD JAN 11
PY 1994
VL 33
IS 1
BP 354
EP 366
DI 10.1021/bi00167a046
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA MQ877
UT WOS:A1994MQ87700047
PM 8286357
ER
PT J
AU ZHANG, K
MAX, EE
CHEAH, HK
SAXON, A
AF ZHANG, K
MAX, EE
CHEAH, HK
SAXON, A
TI COMPLEX ALTERNATIVE RNA SPLICING OF EPSILON-IMMUNOGLOBULIN TRANSCRIPTS
PRODUCES MESSENGER-RNAS ENCODING 4 POTENTIAL SECRETED PROTEIN ISOFORMS
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID IGE PRODUCTION; SINGLE GENE; B-CELLS; PATHWAYS; EXONS
AB In RNA from human IgE-producing lymphocytes, we previously discovered two alternatively spliced epsilon-immunoglobulin mRNA isoforms that encode a novel secreted form of IgE and a membrane-bound species. Further analysis using epsilon-specific reverse transcriptase polymerase chain reactions has elucidated several additional alternatively spliced species of epsilon mRNA. One RNA isoform is generated by splicing the CH4 exon to a novel distal splice acceptor site, forming an epsilon RNA species (designated CH4-M2'') that encodes a secreted epsilon protein 6 amino acids larger than the classic secreted epsilon protein. The other three novel epsilon RNAs are generated by splicing from within CH4 to a new exon structure (designated CH5) that is located between CH4 and the membrane exons. Since the three new mRNAs using CH5 share the same stop codon in CH5, they all encode the same novel protein, which is 10 amino acids shorter than the classic secreted epsilon heavy chain. The new alternatively spliced epsilon mRNAs reported here, in addition to the previously reported forms encoding membrane and larger secreted IgE, appear to reflect the normal splicing pattern in humans, as we have detected all these epsilon RNAs in all the human IgE-secreting cells and cell lines tested.
C1 US FDA, CTR BIOL EVALUAT & RES, BETHESDA, MD 20892 USA.
RP ZHANG, K (reprint author), UNIV CALIF LOS ANGELES, SCH MED,DEPT MED,DIV CLIN IMMUNOL ALLERGY, HART & LOUISE LYON LAB, CTR HLTH SCI 52175, LOS ANGELES, CA 90024 USA.
FU NCI NIH HHS [CA-30515]; NIAID NIH HHS [AI-34567, AI-15251]
NR 21
TC 41
Z9 41
U1 0
U2 0
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 7
PY 1994
VL 269
IS 1
BP 456
EP 462
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA MR219
UT WOS:A1994MR21900076
PM 8276835
ER
PT J
AU KADLUBAR, FF
AF KADLUBAR, FF
TI RETHINKING THE ROLE OF INTESTINAL MICROFLORA IN BIOACTIVATION OF
FOOD-BORNE HETEROCYCLIC AMINE CARCINOGENS
SO JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Editorial Material
RP KADLUBAR, FF (reprint author), NATL CTR TOXICOL RES,HFT-100,JEFFERSON,AR 72079, USA.
NR 7
TC 2
Z9 2
U1 0
U2 1
PU NATL CANCER INSTITUTE
PI BETHESDA
PA 9030 OLD GEORGETOWN RD, BETHESDA, MD 20814
SN 0027-8874
J9 J NATL CANCER I
JI J. Natl. Cancer Inst.
PD JAN 5
PY 1994
VL 86
IS 1
BP 5
EP 5
DI 10.1093/jnci/86.1.5
PG 1
WC Oncology
SC Oncology
GA MP650
UT WOS:A1994MP65000002
PM 8271284
ER
PT J
AU MERKEL, T
STIBITZ, S
AF MERKEL, T
STIBITZ, S
TI GENETIC-ANALYSIS OF VIRULENCE REGULATION IN BORDETELLA-PERTUSSIS
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Meeting Abstract
C1 US FDA,CBER,BETHESDA,MD 20892.
RP MERKEL, T (reprint author), NIDR,BETHESDA,MD 20892, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN 4
PY 1994
SU 18A
BP 66
EP 66
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA MV412
UT WOS:A1994MV41200232
ER
PT J
AU STIBITZ, S
CARBONETTI, N
AF STIBITZ, S
CARBONETTI, N
TI GENETIC-MAPPING BY CONJUGATION IN BORDETELLA-PERTUSSIS - IDENTIFICATION
OF A NEW LOCUS AFFECTING TOXIN EXPRESSION
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Meeting Abstract
C1 US FDA,CBER,DIV BACTERIAL PROD,BETHESDA,MD 20014.
UMAB,SCH MED,DEPT MICROBIOL & IMMUNOL,BALTIMORE,MD 21201.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN 4
PY 1994
SU 18A
BP 67
EP 67
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA MV412
UT WOS:A1994MV41200234
ER
PT J
AU BURNS, DL
JOHNSON, FD
AF BURNS, DL
JOHNSON, FD
TI IDENTIFICATION AND LOCALIZATION OF ACCESSORY PROTEINS NECESSARY FOR
EXPORT OF PERTUSSIS TOXIN FROM BORDETELLA-PERTUSSIS
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Meeting Abstract
C1 US FDA,CTR BIOL EVALUAT & RES,DIV BACTERIAL PROD,BETHESDA,MD 20892.
NR 3
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN 4
PY 1994
SU 18A
BP 68
EP 68
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA MV412
UT WOS:A1994MV41200238
ER
PT J
AU SGADARI, C
ANGIOLILLO, A
TAGA, K
LOVE, LA
BATHIA, K
TOSATO, G
AF SGADARI, C
ANGIOLILLO, A
TAGA, K
LOVE, LA
BATHIA, K
TOSATO, G
TI REGRESSION OF EXPERIMENTAL BURKITTS-LYMPHOMA INDUCED BY EBV IMMORTALIZED
B-CELLS
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Meeting Abstract
C1 US FDA,CBER,IMMUNOL LAB,BETHESDA,MD 20892.
RI Sgadari, Cecilia/H-4302-2016
OI Sgadari, Cecilia/0000-0003-0364-4912
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN 4
PY 1994
SU 18A
BP 329
EP 329
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA MV412
UT WOS:A1994MV41201124
ER
PT S
AU LEVERICH, MK
SILBERBERG, JL
WEININGER, S
AF LEVERICH, MK
SILBERBERG, JL
WEININGER, S
GP IEEE COMP SOC
TI DESIGN AND DEVELOPMENT OF A MULTICHANNEL SIGNAL-ACQUISITION SYSTEM FOR
RECORDING AN APNEA WAVE-FORM DATABASE
SO 1994 IEEE SEVENTH SYMPOSIUM ON COMPUTER-BASED MEDICAL SYSTEMS,
PROCEEDINGS
SE COMPUTER-BASED MEDICAL SYSTEMS : PROCEEDINGS OF THE ANNUAL IEEE
SYMPOSIUM
LA English
DT Proceedings Paper
CT 7th Annual IEEE Symposium on Computer-Based Medical Systems
CY JUN 11-12, 1994
CL WINSTON SALEM, NC
SP IEEE, COMP SOC, IEEE, ENGN MED & BIOL SOC, IEEE, WINSTON SALEM CHAPTER, WAKE FOREST UNIV, BOWMAN GRAY SCH MED
C1 US FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20857.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU I E E E, COMPUTER SOC PRESS
PI LOS ALAMITOS
PA 10662 LOS VAQUEROS CIRCLE, LOS ALAMITOS, CA 90720
SN 1063-7125
BN 0-8186-6257-3
J9 COMP MED SY
PY 1994
BP 213
EP 216
DI 10.1109/CBMS.1994.316014
PG 4
WC Computer Science, Information Systems; Computer Science,
Interdisciplinary Applications; Medicine, General & Internal
SC Computer Science; General & Internal Medicine
GA BB17X
UT WOS:A1994BB17X00039
ER
PT S
AU HARRIS, GR
AF HARRIS, GR
BE Levy, M
Schneider, SC
McAvoy, BR
TI PRESSURE PULSE DISTORTION BY HYDROPHONES DUE TO DIMINISHED LOW FREQUENCY
RESPONSE
SO 1994 IEEE ULTRASONICS SYMPOSIUM PROCEEDINGS, VOLS 1-3
SE ULTRASONICS SYMPOSIUM
LA English
DT Proceedings Paper
CT 1994 IEEE Ultrasonics Symposium
CY NOV 01-04, 1994
CL CANNES, FRANCE
SP IEEE, ULTRASON FERROELECT & FREQUENCY CONTROL SOC
C1 US FDA,CTR DEVICES & READIOL HLTH,ROCKVILLE,MD 20852.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU I E E E
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017
SN 1051-0117
BN 0-7803-2012-3
J9 ULTRASON
PY 1994
BP 1751
EP 1755
PG 5
WC Acoustics; Engineering, Biomedical; Engineering, Electrical &
Electronic; Engineering, Mechanical; Remote Sensing; Telecommunications
SC Acoustics; Engineering; Remote Sensing; Telecommunications
GA BC66H
UT WOS:A1994BC66H00358
ER
PT J
AU AZIZ, K
SHOEMAKER, B
AF AZIZ, K
SHOEMAKER, B
BE Healy, S
TI CLIA-88 AND THE EVALUATION OF IMMUNOASSAY SYSTEMS
SO 20TH NATIONAL MEETING, CLINICAL LIGAND ASSAY SOCIETY, APRIL 26-30, 1994,
KISSIMMEE, FLORIDA: SYLLABUS
LA English
DT Proceedings Paper
CT 20th National Meeting of the Clinical Ligand Assay Society
CY APR 26-30, 1994
CL KISSIMMEE, FL
SP CLIN LIGAND ASSAY SOC
C1 US FDA,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU CLINICAL LIGAND ASSAY SOC INC
PI WAYNE
PA PO BOX 67, WAYNE, MI 48184
PY 1994
BP 98
EP 98
PG 1
WC Endocrinology & Metabolism; Medical Laboratory Technology
SC Endocrinology & Metabolism; Medical Laboratory Technology
GA BA98L
UT WOS:A1994BA98L00018
ER
PT J
AU FLEISCHMAN, GJ
AF FLEISCHMAN, GJ
GP INT MICROWAVE POWER INST
TI TEMPERATURE RANGES IN SOLIDS UNDERGOING PROLONGED LOW-POWER MICROWAVE
HEATING
SO 29TH MICROWAVE POWER SYMPOSIUM - PROCEEDINGS: A FORUM ON ELECTROMAGNETIC
TECHNOLOGY & APPLICATIONS FROM AROUND THE WORLD
LA English
DT Proceedings Paper
CT 29th Microwave Power Symposium
CY JUL 25-27, 1994
CL CHICAGO, IL
SP INT MICROWAVE POWER INST
C1 US FDA,NATL CTR FOOD SAFETY & TECHNOL,SUMMIT ARGO,IL 60501.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU INT MICROWAVE POWER INST
PI MANASSAS
PA 10210 LEATHERLEAF COURT, MANASSAS, VA 22111
PY 1994
BP 205
EP 206
PG 2
WC Engineering, Electrical & Electronic
SC Engineering
GA BB84X
UT WOS:A1994BB84X00060
ER
PT J
AU SCHWARZ, TL
AF SCHWARZ, TL
GP R & D ASSOC MILITARY FOOD & PACKAGING SYST
TI FOOD SAFETY CONCERNS OF FDA
SO ACTIVITIES REPORT AND MINUTES OF WORK GROUPS & SUB-WORK GROUPS OF THE R
& D ASSOCIATES: ACTIVITIES REPORT OF THE R & D ASSOCIATION
SE ACTIVITIES REPORT OF THE R&D ASSOCIATES
LA English
DT Proceedings Paper
CT 1993 Fall Meeting of R and D Associates - Food Safety: A Comprehensive
View
CY OCT 05-07, 1993
CL BOSTON, MA
SP R & D ASSOC MILITARY FOOD & PACKING SYST
C1 US FDA,CTR FOOD SAFETY & APPL NUTR,WASHINGTON,DC 20204.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU RESEARCH & DEVELOPMENT ASSOC MILITARY FOOD PACKAGING SYSTEM
PI SAN ANTONIO
PA 16607 BLANCO RD, SUITE 305, SAN ANTONIO, TX 78232
SN 0198-0181
J9 ACT REP R&D
PY 1994
VL 46
IS 1
BP 14
EP 18
PG 5
WC Food Science & Technology
SC Food Science & Technology
GA BB01G
UT WOS:A1994BB01G00003
ER
PT J
AU SPILLER, P
AF SPILLER, P
GP R & D ASSOC MILITARY FOOD & PACKAGING SYST
TI FDA SEAFOOD HACCP INSPECTION
SO ACTIVITIES REPORT AND MINUTES OF WORK GROUPS & SUB-WORK GROUPS OF THE R
& D ASSOCIATES: ACTIVITIES REPORT OF THE R & D ASSOCIATION
SE ACTIVITIES REPORT OF THE R&D ASSOCIATES
LA English
DT Proceedings Paper
CT 1993 Fall Meeting of R and D Associates - Food Safety: A Comprehensive
View
CY OCT 05-07, 1993
CL BOSTON, MA
SP R & D ASSOC MILITARY FOOD & PACKING SYST
C1 US FDA,CTR FOOD SAFETY & APPL NUTR,OFF SEAFOOD,WASHINGTON,DC 20204.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU RESEARCH & DEVELOPMENT ASSOC MILITARY FOOD PACKAGING SYSTEM
PI SAN ANTONIO
PA 16607 BLANCO RD, SUITE 305, SAN ANTONIO, TX 78232
SN 0198-0181
J9 ACT REP R&D
PY 1994
VL 46
IS 1
BP 19
EP 24
PG 6
WC Food Science & Technology
SC Food Science & Technology
GA BB01G
UT WOS:A1994BB01G00004
ER
PT J
AU CALVO, MS
AF CALVO, MS
TI THE EFFECTS OF HIGH PHOSPHORUS INTAKE ON CALCIUM HOMEOSTASIS
SO ADVANCES IN NUTRITIONAL RESEARCH, VOL 9
SE ADVANCES IN NUTRITIONAL RESEARCH
LA English
DT Article
ID PARATHYROID-HORMONE SECRETION; SERUM IONIZED CALCIUM; BONE-MINERAL
CONTENT; VITAMIN-D AXIS; POSTMENOPAUSAL WOMEN; DIETARY CALCIUM; ORAL
PHOSPHATE; CONTROLLED TRIAL; URINARY CALCIUM; YOUNG-ADULTS
RP CALVO, MS (reprint author), US FDA,PUBL HLTH SERV,WASHINGTON,DC 20204, USA.
NR 88
TC 34
Z9 36
U1 0
U2 2
PU PLENUM PRESS DIV PLENUM PUBLISHING CORP
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013
SN 0149-9483
J9 ADV NUTR RES
PY 1994
VL 9
BP 183
EP 207
PG 25
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA BC44X
UT WOS:A1994BC44X00011
PM 7747666
ER
PT J
AU DUFFY, PH
FEUERS, RJ
PIPKIN, JL
HART, RW
AF DUFFY, PH
FEUERS, RJ
PIPKIN, JL
HART, RW
TI EFFECT OF CHRONIC CALORIC RESTRICTION - PHYSIOLOGICAL AND
BEHAVIORAL-RESPONSE TO ALTERNATE-DAY FEEDING IN OLD FEMALE B6C3F1 MICE
SO AGE
LA English
DT Article
ID SCHEDULE-INDUCED-POLYDIPSIA; MALE FISCHER-344 RAT; DIETARY RESTRICTION;
FOOD RESTRICTION; METABOLIC-RATE; HEAT-SHOCK; MAMMARY-TUMORS;
EXPRESSION; PROTEINS; ACQUISITION
AB Physiological and behavioral performance was monitored in old (24 month) female B6C3F1 hybrid mice that were fed either a caloric restricted (CR) diet (60% of ad libitum) or fed ad libitum (AL). The CR group was fed (CR1) and then fasted (CR2) on alternate days starting at 12-14 weeks of age. The main objective of the study was to determine if the effects of intermittent feeding were different from those for daily CR feeding. The average daily body weight, body temperature, oxygen consumption per gram of lean body mass (LBM), and respiratory quotient were higher on the feed day (CR1) than on the fast day (CR2), whereas the average daily body weight, temperature, activity, and oxygen metabolism per gram of LBM were lower on CR1 than in AL. The daily range in temperature, oxygen metabolism per gram of LBM, and RQ was greater on CR1 and CR2 than in AL; the exception was RQ on CR1. No food was eaten on CR2, and water consumption was reduced by 60% compared to CR1. Average food consumption per meal, and average time eating and drinking per meal was greater in CR mice than in AL mice. The results of this study indicated that mice responded to alternate day CR by changing average daily metabolic output per gram of LBM in direct response to food consumption, whereas when CR mice were fed daily, no change was seen in average metabolism per gram of LBM. The fact that a significant reduction in energy output and temperature occurred in CR mice when metabolic pathways shifted from carbohydrate to fat metabolism may indicate that decreased glucose utilization may have triggered these CR-induced effects.
RP DUFFY, PH (reprint author), US FDA,NATL CTR TOXICOL RES,DEPT HLTH & HUMAN SERV,DIV BIOMETRY & RISK ASSESSMENT,JEFFERSON,AR 72079, USA.
NR 56
TC 5
Z9 5
U1 1
U2 1
PU AMER AGING ASSOC
PI CHESTER
PA 2129 PROVIDENCE AVENUE, CHESTER, PA 19013
SN 0161-9152
J9 AGE
JI Age
PD JAN
PY 1994
VL 17
IS 1
BP 13
EP 21
DI 10.1007/BF02435045
PG 9
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA NU373
UT WOS:A1994NU37300006
ER
PT S
AU TURTURRO, A
BLANK, K
MURASKO, D
HART, R
AF TURTURRO, A
BLANK, K
MURASKO, D
HART, R
BE Pierpaoli, W
Regelson, W
Fabris, N
TI MECHANISMS OF CALORIC RESTRICTION AFFECTING AGING AND DISEASE
SO AGING CLOCK: THE PINEAL GLAND AND OTHER PACEMAKERS IN THE PROGRESSION OF
AGING AND CARCINOGENESIS - THIRD STROMBOLI CONFERENCE ON AGING AND
CANCER
SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Article; Proceedings Paper
CT Conference on The Aging Clock: The Pineal Gland and Other Pacemakers in
the Progression of Aging and Carcinogenesis/3rd Stromboli Conference on
Aging and Cancer (NATO Advanced Research Workshop)
CY JUN 04-09, 1993
CL STROMBOLI, ITALY
SP NATO
ID RATS
C1 HAHNEMANN UNIV,DEPT PATHOL,PHILADELPHIA,PA 19102.
MED COLL PENN,DEPT MICROBIOL,PHILADELPHIA,PA 19129.
RP TURTURRO, A (reprint author), NATL CTR TOXICOL RES,DIV BIOMETRY & RISK ASSESSMENT,JEFFERSON,AR 72079, USA.
NR 24
TC 49
Z9 50
U1 1
U2 2
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021
SN 0077-8923
BN 0-89766-860-X
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 1994
VL 719
BP 159
EP 170
DI 10.1111/j.1749-6632.1994.tb56827.x
PG 12
WC Oncology; Endocrinology & Metabolism; Immunology; Multidisciplinary
Sciences; Physiology
SC Oncology; Endocrinology & Metabolism; Immunology; Science & Technology -
Other Topics; Physiology
GA BA43X
UT WOS:A1994BA43X00011
PM 8010591
ER
PT S
AU LEAKEY, JEA
CHEN, S
MANJGALADZE, M
TURTURRO, A
DUFFY, PH
PIPKIN, JL
HART, RW
AF LEAKEY, JEA
CHEN, S
MANJGALADZE, M
TURTURRO, A
DUFFY, PH
PIPKIN, JL
HART, RW
BE Pierpaoli, W
Regelson, W
Fabris, N
TI ROLE OF GLUCOCORTICOIDS AND CALORIC STRESS IN MODULATING THE EFFECTS OF
CALORIC RESTRICTION IN RODENTS
SO AGING CLOCK: THE PINEAL GLAND AND OTHER PACEMAKERS IN THE PROGRESSION OF
AGING AND CARCINOGENESIS - THIRD STROMBOLI CONFERENCE ON AGING AND
CANCER
SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Article; Proceedings Paper
CT Conference on The Aging Clock: The Pineal Gland and Other Pacemakers in
the Progression of Aging and Carcinogenesis/3rd Stromboli Conference on
Aging and Cancer (NATO Advanced Research Workshop)
CY JUN 04-09, 1993
CL STROMBOLI, ITALY
SP NATO
ID CORTICOTROPIN-RELEASING-FACTOR; INSULIN-INDUCED HYPOGLYCEMIA; MALE
FISCHER-344 RAT; PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; STIMULATES
CORTICOSTERONE SECRETION; DIMINISHED DIURNAL SECRETION;
DRUG-METABOLIZING ENZYMES; INHIBIT GLUCOSE-TRANSPORT; PITUITARY-ADRENAL
AXIS; BROWN-ADIPOSE-TISSUE
C1 NATL CTR TOXICOL RES,DIV GENET TOXICOL,JEFFERSON,AR 72079.
RP LEAKEY, JEA (reprint author), NATL CTR TOXICOL RES,DIV BIOMETRY & RISK ASSESSMENT,JEFFERSON,AR 72079, USA.
NR 159
TC 43
Z9 45
U1 0
U2 2
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021
SN 0077-8923
BN 0-89766-860-X
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 1994
VL 719
BP 171
EP 194
DI 10.1111/j.1749-6632.1994.tb56828.x
PG 24
WC Oncology; Endocrinology & Metabolism; Immunology; Multidisciplinary
Sciences; Physiology
SC Oncology; Endocrinology & Metabolism; Immunology; Science & Technology -
Other Topics; Physiology
GA BA43X
UT WOS:A1994BA43X00012
PM 8010592
ER
PT J
AU MCNAMARA, JG
ROGERS, M
GOLDENTHAL, K
JACKSON, JB
ROSSI, P
FENTON, T
FAST, PE
AF MCNAMARA, JG
ROGERS, M
GOLDENTHAL, K
JACKSON, JB
ROSSI, P
FENTON, T
FAST, PE
TI CONFERENCE ON ADVANCES IN AIDS VACCINE DEVELOPMENT - 1993 REPORT OF
PERINATAL INTERVENTION WORKING GROUP
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article; Proceedings Paper
CT Advances in AIDS Vaccine Development - 6th Annual Meeting of the
National-Cooperative-Vaccine-Development-Group-for-AIDS
CY OCT 30-NOV 04, 1993
CL ALEXANDRIA, VA
SP NATL COOPERAT VACCINE DEV GRP AIDS, NIAID, DIV AIDS, VACCINE TEAM, FOGARTY INT CTR, AIDS INT TRAINING RES PROGRAM, CTR DIS CONTROL & PREVENT, FDA, NIDA, US AGCY INT DEV, NIAID, OFF TROP MED & INT RES, WHO, GLOBAL PROGRAMME AIDS
C1 NIAID,DIV AIDS,BETHESDA,MD 20852.
CTR DIS CONTROL,DIV HIV AIDS,ATLANTA,GA 30333.
US FDA,CTR BIOL EVALUAT & RES,ROCKVILLE,MD 20857.
CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106.
UNIV ROME,ROME,ITALY.
HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115.
RI rossi, paolo/D-6504-2012
NR 1
TC 1
Z9 1
U1 0
U2 1
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PY 1994
VL 10
SU 2
BP S161
EP S164
PG 4
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA PT118
UT WOS:A1994PT11800090
PM 7865292
ER
PT J
AU MCVITTIE, LD
CHANDLER, DKF
AF MCVITTIE, LD
CHANDLER, DKF
TI FDA PERSPECTIVE ON THE DEVELOPMENT OF AIDS VACCINES - PREREQUISITES FOR
INITIATION OF CLINICAL-TRIALS
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
C1 US FDA,CTR BIOL EVALUAT & RES,OFF VACCINES RES & REVIEW,ROCKVILLE,MD 20852.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PY 1994
VL 10
SU 2
BP S115
EP S115
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA PT118
UT WOS:A1994PT11800053
ER
PT J
AU HENDRICKS, TC
PENNINGTON, JAT
AF HENDRICKS, TC
PENNINGTON, JAT
TI INTERNATIONAL INTERFACE STANDARD FOR FOOD DATABASES
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Meeting Abstract
DE DIETARY ASSESSMENT; INTERNATIONAL DATA EXCHANGE
C1 US FDA, CTR FOOD SAFETY & APPL NUTR, WASHINGTON, DC 20204 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD JAN
PY 1994
VL 59
IS 1
SU S
BP 302S
EP 302S
PG 1
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA MQ079
UT WOS:A1994MQ07900097
ER
PT J
AU GULYA, AJ
CHRISTMAN, CL
CHEUNG, DD
STEVENS, DM
AF GULYA, AJ
CHRISTMAN, CL
CHEUNG, DD
STEVENS, DM
TI COMPUTER-ASSISTED ASSESSMENT OF COCHLEAR NERVE-FIBERS
SO AMERICAN JOURNAL OF OTOLOGY
LA English
DT Article
AB Quantitative assessment of cochlear nerve fibers, with statistical analysis of histologic specimens, is facilitated by the application of computer image processing techniques. Three algorithms, developed for the evaluation of cochlear sections, are presented, MANUAL, AIDED, and AUTO, in order of increasing degree of automation and decreasing requirement for operator intervention. All three algorithms demonstrate high accuracy and consistency in identifying cochlear nerve fibers and quickly provide statistics regarding the target nerve fiber population. These algorithms have potential utility in the study of cochlear nerve pathologic alterations, as for example, with intracochlear electrical stimulation.
C1 US FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20857.
JOHNS HOPKINS UNIV,DEPT BIOMED ENGN,BALTIMORE,MD.
USN HOSP,DEPT OTOLARYNGOL HEAD & NECK SURG,BETHESDA,MD.
RP GULYA, AJ (reprint author), GEORGETOWN UNIV,DEPT OTOLARYNGOL HEAD & NECK SURG,3800 RESEVOIR RD NW,WASHINGTON,DC 20007, USA.
NR 7
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0192-9763
J9 AM J OTOL
JI Am. J. Otol.
PD JAN
PY 1994
VL 15
IS 1
BP 86
EP 90
PG 5
WC Otorhinolaryngology
SC Otorhinolaryngology
GA MP900
UT WOS:A1994MP90000019
PM 8109637
ER
PT J
AU GOLDING, B
ZAITSEVA, M
GOLDING, H
AF GOLDING, B
ZAITSEVA, M
GOLDING, H
TI THE POTENTIAL FOR RECRUITING IMMUNE-RESPONSES TOWARD TYPE-1 OR TYPE-2
T-CELL HELP
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article; Proceedings Paper
CT Symposium on Strategy for Plasmodium Falciparum Blood-Stage Vaccine
Development and Clinical Trials, at Annual Meeting of the
Amer-Soc-of-Tropical-Medicine-and-Hygiene
CY NOV 19, 1992
CL SEATTLE, WA
SP AMER SOC TROP MED & HYGIENE
ID BRUCELLA-ABORTUS; MALARIA VACCINE; SPOROZOITE VACCINE; GAMMA-INTERFERON;
IFN-GAMMA; ISOTYPE; ANTIBODIES; ADJUVANT; SUBSETS; MICE
AB The design of vaccine strategies in general, and those for malaria in particular, need to take into account the balance of T helper subsets (TH) they induce. The TH1 cells, which secrete interferon-gamma and interleukin-2 (IL-2), are associated with cell-mediated immunity (CMI), rather than humoral responses, and afford protection against intracellular infections, including those caused by parasites. In contrast, The TH2 cells secrete IL-4, IL-5, and IL-10, elicit high titer antibody responses, provide poor CMI, and are often correlated with susceptibility to infection. Depending on the type of TH cell bias required, it is possible to manipulate the immune response to a protein/peptide by 1) using different adjuvants, 2) conjugating the protein to various carriers, 3) immunizing in the presence of cytokines, or 4) using alternative routes of administration. To apply these approaches to malarial vaccines, it is necessary to identify which stage(s) of the parasite to target and what type of TH cell bias is protective against that particular stage. We favor using carriers such as Brucella abortus, which focus the antigen on a specific particle and which can trigger a TH1 cell response.
C1 US FDA,CTR BIOL EVALUAT & RES,DIV VIROL,ROCKVILLE,MD 20852.
RP GOLDING, B (reprint author), US FDA,CTR BIOL EVALUAT & RES,DIV HEMATOL,1401 ROCKVILLE PIKE,ROCKVILLE,MD 20852, USA.
NR 35
TC 37
Z9 37
U1 0
U2 2
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DRIVE SUITE 130, MCLEAN, VA 22101
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PY 1994
VL 50
IS 4
SU S
BP 33
EP 40
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA NK901
UT WOS:A1994NK90100006
PM 8172330
ER
PT B
AU BALCH, AH
AF BALCH, AH
GP AMER STAT ASSOC
TI Moving to higher dimensions, 3 not equal 2
SO AMERICAN STATISTICAL ASSOCIATION 1994 PROCEEDINGS OF THE
BIOPHARMACEUTICAL SECTION
LA English
DT Proceedings Paper
CT Spring Meeting of the Eastern-North-American-Region of the
Biometric-Society
CY APR 09-13, 1994
CL CLEVELAND, OH
SP Biometric Soc, E N Amer Reg, Amer Stat Assoc, Sect Stat & Environm
DE SYNERGY; ISOBOLOGRAM; MULTIDRUG THERAPY
C1 US FDA,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER STATISTICAL ASSOC
PI ALEXANDRIA
PA 1429 DUKE ST, ALEXANDRIA, VA 22314
BN 1-883276-05-5
PY 1994
BP 45
EP 50
PG 6
WC Pharmacology & Pharmacy; Statistics & Probability
SC Pharmacology & Pharmacy; Mathematics
GA BE02M
UT WOS:A1994BE02M00007
ER
PT B
AU CHAKRAVARTY, AG
HARKINS, RD
AF CHAKRAVARTY, AG
HARKINS, RD
GP AMER STAT ASSOC
TI Some approaches to the evaluation of laboratory data to identify
potential adverse events
SO AMERICAN STATISTICAL ASSOCIATION 1994 PROCEEDINGS OF THE
BIOPHARMACEUTICAL SECTION
LA English
DT Proceedings Paper
CT Spring Meeting of the Eastern-North-American-Region of the
Biometric-Society
CY APR 09-13, 1994
CL CLEVELAND, OH
SP Biometric Soc, E N Amer Reg, Amer Stat Assoc, Sect Stat & Environm
DE ADVERSE EVENTS; LABORATORY DATA; CHANGES FROM BASE-LINE; SUBGROUP
ANALYSIS
C1 US FDA,CDER,DIV BIOMETR,ROCKVILLE,MD 20857.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER STATISTICAL ASSOC
PI ALEXANDRIA
PA 1429 DUKE ST, ALEXANDRIA, VA 22314
BN 1-883276-05-5
PY 1994
BP 73
EP 76
PG 4
WC Pharmacology & Pharmacy; Statistics & Probability
SC Pharmacology & Pharmacy; Mathematics
GA BE02M
UT WOS:A1994BE02M00012
ER
PT B
AU HUNG, HMJ
DERN, P
AF HUNG, HMJ
DERN, P
GP AMER STAT ASSOC
TI On combining information from randomized clinical studies for
combination therapy
SO AMERICAN STATISTICAL ASSOCIATION 1994 PROCEEDINGS OF THE
BIOPHARMACEUTICAL SECTION
LA English
DT Proceedings Paper
CT Spring Meeting of the Eastern-North-American-Region of the
Biometric-Society
CY APR 09-13, 1994
CL CLEVELAND, OH
SP Biometric Soc, E N Amer Reg, Amer Stat Assoc, Sect Stat & Environm
DE METAANALYSIS; MIN TEST; CONFIDENCE INTERVAL
C1 US FDA,DIV BIOMETR,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER STATISTICAL ASSOC
PI ALEXANDRIA
PA 1429 DUKE ST, ALEXANDRIA, VA 22314
BN 1-883276-05-5
PY 1994
BP 77
EP 81
PG 5
WC Pharmacology & Pharmacy; Statistics & Probability
SC Pharmacology & Pharmacy; Mathematics
GA BE02M
UT WOS:A1994BE02M00013
ER
PT B
AU NURI, WA
CHI, GYH
AF NURI, WA
CHI, GYH
GP AMER STAT ASSOC
TI Using the GEE method to construct linear models for ordinal responses
SO AMERICAN STATISTICAL ASSOCIATION 1994 PROCEEDINGS OF THE
BIOPHARMACEUTICAL SECTION
LA English
DT Proceedings Paper
CT Spring Meeting of the Eastern-North-American-Region of the
Biometric-Society
CY APR 09-13, 1994
CL CLEVELAND, OH
SP Biometric Soc, E N Amer Reg, Amer Stat Assoc, Sect Stat & Environm
DE ORDINAL DATA; GENERALIZED ESTIMATING EQUATIONS; QUASI-LIKELIHOOD;
REPEATED MEASURES
C1 US FDA,DIV BIOMETR,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER STATISTICAL ASSOC
PI ALEXANDRIA
PA 1429 DUKE ST, ALEXANDRIA, VA 22314
BN 1-883276-05-5
PY 1994
BP 82
EP 87
PG 6
WC Pharmacology & Pharmacy; Statistics & Probability
SC Pharmacology & Pharmacy; Mathematics
GA BE02M
UT WOS:A1994BE02M00014
ER
PT B
AU CHI, GYH
HUNG, J
DUBEY, SD
LIPICKY, RJ
AF CHI, GYH
HUNG, J
DUBEY, SD
LIPICKY, RJ
GP AMER STAT ASSOC
TI Dose response studies and special populations
SO AMERICAN STATISTICAL ASSOCIATION 1994 PROCEEDINGS OF THE
BIOPHARMACEUTICAL SECTION
LA English
DT Proceedings Paper
CT Spring Meeting of the Eastern-North-American-Region of the
Biometric-Society
CY APR 09-13, 1994
CL CLEVELAND, OH
SP Biometric Soc, E N Amer Reg, Amer Stat Assoc, Sect Stat & Environm
DE DOSE RESPONSE; SPECIAL POPULATIONS
C1 US FDA,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER STATISTICAL ASSOC
PI ALEXANDRIA
PA 1429 DUKE ST, ALEXANDRIA, VA 22314
BN 1-883276-05-5
PY 1994
BP 88
EP 93
PG 6
WC Pharmacology & Pharmacy; Statistics & Probability
SC Pharmacology & Pharmacy; Mathematics
GA BE02M
UT WOS:A1994BE02M00015
ER
PT B
AU AHN, H
CHEN, JJ
AF AHN, H
CHEN, JJ
GP AMER STAT ASSOC
TI Modeling developmental toxic effects through recursive partitioning
SO AMERICAN STATISTICAL ASSOCIATION 1994 PROCEEDINGS OF THE
BIOPHARMACEUTICAL SECTION
LA English
DT Proceedings Paper
CT Spring Meeting of the Eastern-North-American-Region of the
Biometric-Society
CY APR 09-13, 1994
CL CLEVELAND, OH
SP Biometric Soc, E N Amer Reg, Amer Stat Assoc, Sect Stat & Environm
DE BOOTSTRAP; DOSE-RESPONSE MODEL; OVER-DISPERSION; REGRESSION TREE
C1 US FDA,NATL CTR TOXICOL RES,DIV BIOMETRY & RISK ASSESSMENT,JEFFERSON,AR.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER STATISTICAL ASSOC
PI ALEXANDRIA
PA 1429 DUKE ST, ALEXANDRIA, VA 22314
BN 1-883276-05-5
PY 1994
BP 130
EP 135
PG 6
WC Pharmacology & Pharmacy; Statistics & Probability
SC Pharmacology & Pharmacy; Mathematics
GA BE02M
UT WOS:A1994BE02M00023
ER
PT B
AU LIN, TYD
AF LIN, TYD
GP AMER STAT ASSOC
TI Applicability of matrix and bracket approach to stability study design
SO AMERICAN STATISTICAL ASSOCIATION 1994 PROCEEDINGS OF THE
BIOPHARMACEUTICAL SECTION
LA English
DT Proceedings Paper
CT Spring Meeting of the Eastern-North-American-Region of the
Biometric-Society
CY APR 09-13, 1994
CL CLEVELAND, OH
SP Biometric Soc, E N Amer Reg, Amer Stat Assoc, Sect Stat & Environm
DE EXPIRATION DATING PERIOD; FULL FACTORIAL DESIGN; REDUCED DESIGN;
FRACTIONAL FACTORIAL DESIGN
C1 US FDA,DIV BIOMETR,HFD-715,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER STATISTICAL ASSOC
PI ALEXANDRIA
PA 1429 DUKE ST, ALEXANDRIA, VA 22314
BN 1-883276-05-5
PY 1994
BP 142
EP 147
PG 6
WC Pharmacology & Pharmacy; Statistics & Probability
SC Pharmacology & Pharmacy; Mathematics
GA BE02M
UT WOS:A1994BE02M00025
ER
PT B
AU HUQUE, MF
HARRISON, FD
SANKOH, AJ
DUBEY, SD
AF HUQUE, MF
HARRISON, FD
SANKOH, AJ
DUBEY, SD
GP AMER STAT ASSOC
TI Longitudinal data analysis for heartburn clinical trials
SO AMERICAN STATISTICAL ASSOCIATION 1994 PROCEEDINGS OF THE
BIOPHARMACEUTICAL SECTION
LA English
DT Proceedings Paper
CT Spring Meeting of the Eastern-North-American-Region of the
Biometric-Society
CY APR 09-13, 1994
CL CLEVELAND, OH
SP Biometric Soc, E N Amer Reg, Amer Stat Assoc, Sect Stat & Environm
DE HEARTBURN; CLINICAL TRIALS; BINARY LONGITUDINAL DATA; GENERALIZED
ESTIMATING EQUATIONS; SIMULATIONS
C1 US FDA,CDER,ROCKVILLE,MD.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER STATISTICAL ASSOC
PI ALEXANDRIA
PA 1429 DUKE ST, ALEXANDRIA, VA 22314
BN 1-883276-05-5
PY 1994
BP 182
EP 187
PG 6
WC Pharmacology & Pharmacy; Statistics & Probability
SC Pharmacology & Pharmacy; Mathematics
GA BE02M
UT WOS:A1994BE02M00032
ER
PT B
AU LAO, CS
AF LAO, CS
GP AMER STAT ASSOC
TI Statistical analysis for estimating relative risk of first cancer
progression by monitoring carcinoembryonic antigen (CEA) levels for
stage IV breast cancer patients
SO AMERICAN STATISTICAL ASSOCIATION 1994 PROCEEDINGS OF THE
BIOPHARMACEUTICAL SECTION
LA English
DT Proceedings Paper
CT Spring Meeting of the Eastern-North-American-Region of the
Biometric-Society
CY APR 09-13, 1994
CL CLEVELAND, OH
SP Biometric Soc, E N Amer Reg, Amer Stat Assoc, Sect Stat & Environm
DE CARCINOEMBRYONIC ANTIGEN; COX MODEL; RELATIVE RISK; LEAD TIMES
C1 US FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20850.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER STATISTICAL ASSOC
PI ALEXANDRIA
PA 1429 DUKE ST, ALEXANDRIA, VA 22314
BN 1-883276-05-5
PY 1994
BP 206
EP 210
PG 5
WC Pharmacology & Pharmacy; Statistics & Probability
SC Pharmacology & Pharmacy; Mathematics
GA BE02M
UT WOS:A1994BE02M00036
ER
PT B
AU YI, T
AF YI, T
GP AMER STAT ASSOC
TI Statistical issues in drug quality control based on dissolution testing
SO AMERICAN STATISTICAL ASSOCIATION 1994 PROCEEDINGS OF THE
BIOPHARMACEUTICAL SECTION
LA English
DT Proceedings Paper
CT Spring Meeting of the Eastern-North-American-Region of the
Biometric-Society
CY APR 09-13, 1994
CL CLEVELAND, OH
SP Biometric Soc, E N Amer Reg, Amer Stat Assoc, Sect Stat & Environm
DE DISSOLUTION TESTING; QUALITY CONTROL; LOT RELEASE
C1 US FDA,CDER,DIV BIOMETR,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER STATISTICAL ASSOC
PI ALEXANDRIA
PA 1429 DUKE ST, ALEXANDRIA, VA 22314
BN 1-883276-05-5
PY 1994
BP 295
EP 300
PG 6
WC Pharmacology & Pharmacy; Statistics & Probability
SC Pharmacology & Pharmacy; Mathematics
GA BE02M
UT WOS:A1994BE02M00053
ER
PT B
AU ANELLO, C
AF ANELLO, C
GP AMER STAT ASSOC
TI Statistical issues in postmarketing surveillance at FDA
SO AMERICAN STATISTICAL ASSOCIATION 1994 PROCEEDINGS OF THE
BIOPHARMACEUTICAL SECTION
LA English
DT Proceedings Paper
CT Spring Meeting of the Eastern-North-American-Region of the
Biometric-Society
CY APR 09-13, 1994
CL CLEVELAND, OH
SP Biometric Soc, E N Amer Reg, Amer Stat Assoc, Sect Stat & Environm
DE SURVEILLANCE; OBSERVATIONAL STUDIES; MONITORING; STATISTICAL ASPECTS
C1 US FDA,CTR DRUG EVALUAT & RES,OFF EPIDEMIOL & BIOSTAT,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER STATISTICAL ASSOC
PI ALEXANDRIA
PA 1429 DUKE ST, ALEXANDRIA, VA 22314
BN 1-883276-05-5
PY 1994
BP 452
EP 459
PG 8
WC Pharmacology & Pharmacy; Statistics & Probability
SC Pharmacology & Pharmacy; Mathematics
GA BE02M
UT WOS:A1994BE02M00082
ER
PT B
AU CHOUDHURY, J
BALCH, AH
AF CHOUDHURY, J
BALCH, AH
GP AMER STAT ASSOC
TI Assessing the robustness of clinical trial results
SO AMERICAN STATISTICAL ASSOCIATION 1994 PROCEEDINGS OF THE
BIOPHARMACEUTICAL SECTION
LA English
DT Proceedings Paper
CT Spring Meeting of the Eastern-North-American-Region of the
Biometric-Society
CY APR 09-13, 1994
CL CLEVELAND, OH
SP Biometric Soc, E N Amer Reg, Amer Stat Assoc, Sect Stat & Environm
DE STANDARDIZATION AND AUTOMATION; ALTERNATIVE ANALYSES; PROTOCOL
VIOLATION; MISSING OBSERVATION; SURROGATE END-POINT; CART
C1 US FDA,DIV BIOMETR,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER STATISTICAL ASSOC
PI ALEXANDRIA
PA 1429 DUKE ST, ALEXANDRIA, VA 22314
BN 1-883276-05-5
PY 1994
BP 484
EP 486
PG 3
WC Pharmacology & Pharmacy; Statistics & Probability
SC Pharmacology & Pharmacy; Mathematics
GA BE02M
UT WOS:A1994BE02M00087
ER
PT B
AU ETTE, EI
SUN, H
LUDDEN, TM
AF ETTE, EI
SUN, H
LUDDEN, TM
GP AMER STAT ASSOC
TI Design of population pharmacokinetic studies
SO AMERICAN STATISTICAL ASSOCIATION 1994 PROCEEDINGS OF THE
BIOPHARMACEUTICAL SECTION
LA English
DT Proceedings Paper
CT Spring Meeting of the Eastern-North-American-Region of the
Biometric-Society
CY APR 09-13, 1994
CL CLEVELAND, OH
SP Biometric Soc, E N Amer Reg, Amer Stat Assoc, Sect Stat & Environm
DE POPULATION PHARMACOKINETICS; SAMPLING DESIGN; SAMPLE SIZE; PARAMETER
ESTIMATION; BIAS AND PRECISION; SIMULATION; NONMEM
C1 US FDA,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER STATISTICAL ASSOC
PI ALEXANDRIA
PA 1429 DUKE ST, ALEXANDRIA, VA 22314
BN 1-883276-05-5
PY 1994
BP 487
EP 492
PG 6
WC Pharmacology & Pharmacy; Statistics & Probability
SC Pharmacology & Pharmacy; Mathematics
GA BE02M
UT WOS:A1994BE02M00088
ER
PT B
AU LIU, PT
ALBERT, RH
SPRINGER, JA
AF LIU, PT
ALBERT, RH
SPRINGER, JA
GP AMER STAT ASSOC
TI Is one sample enough?
SO AMERICAN STATISTICAL ASSOCIATION 1994 PROCEEDINGS OF THE SECTION ON
BAYESIAN STATISTICAL SCIENCE
LA English
DT Proceedings Paper
CT ASA 1994 Winter Conference
CY JAN 06-09, 1994
CL ATLANTA, GA
SP Amer Stat Assoc, Sect Qual & Prod
DE SCREENING TEST; DIAGNOSTIC TEST; BAYESIAN; FALSE POSITIVE;
IDENTIFICATION
C1 US FDA,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER STATISTICAL ASSOC
PI ALEXANDRIA
PA 1429 DUKE ST, ALEXANDRIA, VA 22314
BN 1-883276-03-9
PY 1994
BP 18
EP 22
PG 5
WC Statistics & Probability
SC Mathematics
GA BE02J
UT WOS:A1994BE02J00004
ER
PT B
AU SPRINGER, JA
LIU, PT
ALBERT, RH
CHOW, LP
AF SPRINGER, JA
LIU, PT
ALBERT, RH
CHOW, LP
GP AMER STAT ASSOC
TI Construction of a spectrum lifetable
SO AMERICAN STATISTICAL ASSOCIATION 1994 PROCEEDINGS OF THE SOCIAL
STATISTICS SECTION
LA English
DT Proceedings Paper
CT Annual Meeting of the American-Statistical-Association,
Social-Statistics-Section
CY AUG 13-18, 1994
CL TORONTO, CANADA
SP Amer Stat Assoc, Social Stat Sect
DE MORTALITY; MORBIDITY; LIFETIME RISK; QUALITY LIFE; HEALTHY LIFE
C1 US FDA,WASHINGTON,DC 20204.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER STATISTICAL ASSOC
PI ALEXANDRIA
PA 1429 DUKE ST, ALEXANDRIA, VA 22314
BN 1-883276-09-8
PY 1994
BP 82
EP 87
PG 6
WC Social Sciences, Mathematical Methods; Statistics & Probability
SC Mathematical Methods In Social Sciences; Mathematics
GA BD51B
UT WOS:A1994BD51B00016
ER
PT B
AU BLODGETT, RJ
AF BLODGETT, RJ
GP AMER STAT ASSOC
TI Rank tests with weighted data
SO AMERICAN STATISTICAL ASSOCIATION - 1994 PROCEEDINGS OF THE STATISTICAL
COMPUTING SECTION
LA English
DT Proceedings Paper
CT Annual Meeting of the American-Statistical-Association,
Statistical-Computing-Section
CY AUG 13-18, 1994
CL TORONTO, CANADA
SP Amer Stat Assoc, Stat Comp Sect
DE MANN-WHITNEY; NONPARAMETRIC; SURVEYS; WILCOXON
C1 US FDA,WASHINGTON,DC 20204.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER STATISTICAL ASSOC
PI ALEXANDRIA
PA 1429 DUKE ST, ALEXANDRIA, VA 22314
BN 1-883276-06-3
PY 1994
BP 200
EP 204
PG 5
WC Statistics & Probability
SC Mathematics
GA BD83T
UT WOS:A1994BD83T00029
ER
PT J
AU WARE, GM
UMRIGAR, PP
CARMAN, AS
KUAN, SS
AF WARE, GM
UMRIGAR, PP
CARMAN, AS
KUAN, SS
TI EVALUATION OF FUMONITEST IMMUNOAFFINITY COLUMNS
SO ANALYTICAL LETTERS
LA English
DT Article
DE FUMONISIN; IMMUNOAFFINITY COLUMNS; DETERMINATION; HPLC; FLUORESCENCE;
AND DERIVATIZATION
ID FUMONISIN-B1
AB A method for the determination of fumonisins B1 and B2 in corn was developed. The method involves sample extraction with methanol:water (80:20) and the use of a commercially available Fumonitest column for sample cleanup, The capacity, selectivity, column-to-column and lot-to-lot reproducibility of the Fumonitest columns were evaluated. The total capacity of the column was found to be 1.2 mu g fumonisin. Both fumonisins B1 and B2 had an equal affinity toward the Fumonitest column, with the sample matrix demonstrating little effect on the column performance. The maximum sample size was 0.5 g for samples containing total fumonisins of less than 2 ppm. After elution from the immunoaffinity column, fumonisins B1 and B2 were reacted with naphthalene-2,3-dicarboxaldehyde (NDA) to produce a highly fluorescent derivative, 1-cyano-2-alkyl-benz[f]isoindole (CBI). The derivatives were then separated from the sample matrix on a reverse phase C-18 column with a mobile phase consisting of acetonitrile:water:acetic acid (55:45:1) Average recoveries of fumonisins B1 and B2 from corn samples spiked at a level of 1000 ng (500ng B1 + 500ng B2)/g were 85.4 and 87.1%, respectively. The detection limit for B1 and B2 was estimated to be 10 and 4 ppb, respectively. The coefficient of variations for fumonisins B1 and B2 were determined to be 10.2% and 10.6%, respectively.
RP WARE, GM (reprint author), US FDA,NAT TOXINS RES CTR,4298 ELYSIAN FIELDS AVE,NEW ORLEANS,LA 70122, USA.
NR 8
TC 32
Z9 33
U1 0
U2 3
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 0003-2719
J9 ANAL LETT
JI Anal. Lett.
PY 1994
VL 27
IS 4
BP 693
EP 715
PG 23
WC Chemistry, Analytical
SC Chemistry
GA NA891
UT WOS:A1994NA89100004
ER
PT J
AU KATZ, L
WRIGHT, C
HARTER, J
ZUNG, M
SCALLY, D
SPYKER, D
AF KATZ, L
WRIGHT, C
HARTER, J
ZUNG, M
SCALLY, D
SPYKER, D
TI REVISED LABEL REGARDING USE OF SUCCINYLCHOLINE IN CHILDREN AND
ADOLESCENTS .2. IN REPLY
SO ANESTHESIOLOGY
LA English
DT Letter
RP KATZ, L (reprint author), CTR DRUG EVALUAT & RES,PILOT DRUG EVALUAT STAFF,ROOM 9B-45 PARKLAWN BLDG,5600 FISHERS LAN,ROCKVILLE,MD 20857, USA.
NR 0
TC 9
Z9 9
U1 0
U2 0
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0003-3022
J9 ANESTHESIOLOGY
JI Anesthesiology
PD JAN
PY 1994
VL 80
IS 1
BP 243
EP 244
DI 10.1097/00000542-199401000-00048
PG 2
WC Anesthesiology
SC Anesthesiology
GA MR300
UT WOS:A1994MR30000048
ER
PT B
AU CAVAGNARO, JA
BAUER, SR
AF CAVAGNARO, JA
BAUER, SR
BE Kobayashi, T
Kitagawa, Y
Okumura, K
TI FDA PERSPECTIVE ON THE USE OF TRANSGENIC ANIMALS IN THE MANUFACTURE OF
THERAPEUTIC PRODUCTS INTENDED FOR HUMAN USE - SAFETY CONCERNS
SO ANIMAL CELL TECHNOLOGY: BASIC & APPLIED ASPECTS, VOL 6
LA English
DT Proceedings Paper
CT 6th International Meeting of the
Japanese-Association-for-Animal-Cell-Technology; Animal Cell Technology
- Basic and Applied Aspects
CY NOV 09-12, 1993
CL NAGOYA, JAPAN
SP JAPANESE ASSOC ANIM CELL TECHNOL
C1 US FDA,CTR BIOL EVALUAT & RES,WASHINGTON,DC 20204.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
BN 0-7923-3156-7
PY 1994
BP 95
EP 95
PG 1
WC Biotechnology & Applied Microbiology; Cell Biology; Zoology
SC Biotechnology & Applied Microbiology; Cell Biology; Zoology
GA BB98H
UT WOS:A1994BB98H00013
ER
PT J
AU KOMOLPRASERT, V
LAWSON, A
AF KOMOLPRASERT, V
LAWSON, A
GP SOC PLAST ENGINEERS
TI EFFECTS OF AQUEOUS-BASED WASHING ON REMOVAL OF HYDROCARBONS FROM
RECYCLED POLYETHYLENE TEREPHTHALATE (PETE)
SO ANTEC 94 - PLASTICS: GATE WAY TO THE FUTURE, VOLS 1-3
LA English
DT Proceedings Paper
CT 52nd Annual Technical Conference of the Society-of-Plastics-Engineers on
Plastics: Gateway to the Future
CY MAY 01-05, 1994
CL SAN FRANCISCO, CA
SP SOC PLAST ENGINEERS
C1 US FDA,NATL CTR FOOD SAFETY & TECHNOL,SUMMIT ARGO,IL 60501.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC PLASTICS ENGINEERS
PI BROOKFIELD CENTER
PA 14 FAIRFIELD DR, BROOKFIELD CENTER, CT 06805
PY 1994
BP 2906
EP 2909
PG 4
WC Materials Science, Multidisciplinary; Polymer Science
SC Materials Science; Polymer Science
GA BA73Y
UT WOS:A1994BA73Y00572
ER
PT J
AU VICK, J
WEISS, L
ELLIS, S
AF VICK, J
WEISS, L
ELLIS, S
TI CARDIOVASCULAR STUDIES OF PHENYLPROPANOLAMINE
SO ARCHIVES INTERNATIONALES DE PHARMACODYNAMIE ET DE THERAPIE
LA English
DT Article
AB Phenylpropanolamine is found in a number of over-the-counter preparations commonly used for appetite control or as a cold remedy. Even though widely used, some questions still exist as to its effect on the cardiovascular system of man. Both anesthetized and unanesthetized adult beagle dogs were used in this study. In the unanesthetized conditioned dog, blood pressure and heart rate were measured using an inflatable tall cuff. In the first group, consisting of 12 dogs, phenylpropanolamine was given (0.0, 3.1, 6.25 and 12.5 mg/kg) via a stomach tube and the animals were followed for 300 minutes. Each dose of phenylpropanolamine was given to 4 groups made up of 3 dogs each. It produced dose-dependent increases in blood pressure and decreases of heart rate. Maximum changes were noted at 30 to 60 minutes, lasting for 3 to 5 hours. A second group of 9 unanesthetized dogs was given repeated oral doses of phenylpropanolamine (3 groups of 3 animals each). Doses of 3 mg/kg and 6 mg/kg, given orally, produced approximately the same increase in blood pressure and decrease of heart rate as previously observed. At 6 hours, these same doses of phenylpropanolamine produced little or no change in either parameter. At 24 hours after the first dose, however, the dogs responded in much the same manner as with the first administration of phenylpropanolamine. Control dogs given water did not exhibit any degree of tachyphylaxis. Dogs anesthetized with Na pentobarbital were given oral and intravenous doses of phenylpropanolamine (0.0-25 mg/kg). The overall response was like that observed in the unanesthetized preparation with the important exception that low doses (0.1-3 mg/kg) produced significant increases in both heart rate and blood pressure, while higher doses (6-25 mg/kg) resulted in a lesser overall effect. Six anesthetized animals were used to study the effects of phenylpropanolamine and norepinephrine on the cardiovascular function.
Both the increase in blood pressure and left ventricular force of contraction, produced by the first dose of phenylpropanolamine, were markedly reduced or absent with the second administration of the drug. In addition, the classic blood pressure response to norepinephrine was likewise increased by prior administration of phenylpropanolamine. These results indicate that phenylpropanolamine has rather interesting and, in some instances, dramatic effects on the cardiovascular system of both anesthetized and unanesthetized dogs, and might explain, in part, the clinical reports that have implicated phenylpropanolamine in lethal cardiovascular accidents.
RP VICK, J (reprint author), US FDA,CTR DRUG EVALUAT & RES,DIV RES & TESTING,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 6
TC 20
Z9 20
U1 0
U2 0
PU ARCH INT PHARMACODYNAMIE
PI GHENT
PA DE PINTELAAN 185, B-9000 GHENT, BELGIUM
SN 0003-9780
J9 ARCH INT PHARMACOD T
JI Arch. Int. Pharmacodyn. Ther.
PD JAN-FEB
PY 1994
VL 327
IS 1
BP 13
EP 24
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NQ325
UT WOS:A1994NQ32500003
PM 7944824
ER
PT J
AU HIGLEY, JD
MEHLMAN, PT
TAUB, D
SUOMI, SJ
HIGLEY, SB
VICKERS, JM
LINNOILA, M
AF HIGLEY, JD
MEHLMAN, PT
TAUB, D
SUOMI, SJ
HIGLEY, SB
VICKERS, JM
LINNOILA, M
TI ARE STRESS HORMONES AND SEROTONIN RELATED TO AGGRESSION IN PRIMATES - IN
REPLY
SO ARCHIVES OF GENERAL PSYCHIATRY
LA English
DT Letter
C1 LAB ANIMAL BREEDERS & SERV,YEMASSEE,SC.
US FDA,PATHOBIOL & PRIMATOL LAB,BETHESDA,MD.
NIAAA,OFF SCI DIRECTOR,BETHESDA,MD.
NICHHD,COMPARAT ETHOL LAB,BETHESDA,MD 20892.
RP HIGLEY, JD (reprint author), NIAAA,CLIN STUDIES LAB,ANIM CTR BLDG 112,POB 289,POOLESVILLE,MD 20837, USA.
NR 4
TC 0
Z9 0
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0003-990X
J9 ARCH GEN PSYCHIAT
JI Arch. Gen. Psychiatry
PD JAN
PY 1994
VL 51
IS 1
BP 73
EP 73
PG 1
WC Psychiatry
SC Psychiatry
GA MR516
UT WOS:A1994MR51600011
ER
PT J
AU POGUE, GP
HUNTLEY, CC
HALL, TC
AF POGUE, GP
HUNTLEY, CC
HALL, TC
TI COMMON REPLICATION STRATEGIES EMERGING FROM THE STUDY OF DIVERSE GROUPS
OF POSITIVE-STRAND RNA VIRUSES
SO ARCHIVES OF VIROLOGY
LA English
DT Article; Proceedings Paper
CT 3rd International Symposium on Positive-Strand RNA Viruses
CY SEP, 1992
CL CLEARWATER, FL
ID BROME MOSAIC-VIRUS; STEM-LOOP STRUCTURE; VIRAL REPLICATION; PROTEINS;
REQUIREMENT; POLYMERASE; SEQUENCES; SITE; END
AB Studies using brome mosaic virus (BMV), Sindbis virus and poliovirus have provided evidence that disparate groups of plant and animal positive strand RNA viruses have remarkably similar replication strategies. The conservation of several functional domains within virus-encoded nonstructural proteins implies that, although the precise character of these and interacting host components varies for each virus, they employ similar mechanisms for RNA replication. For (+) strand replication, similarities in cis-acting sequence motifs and RNA secondary structures within 5' termini of genomic (+) strands have been identified and have been shown to participate in binding of host factors. The model presented for replication of BMV RNA suggests that binding of these factors to internal control region (ICR) sequence motifs in the double-stranded replication intermediate releases a single-stranded 3' terminus on the (-) strand that may be essential for initiation of genomic (+) strand synthesis. ICR sequences internal to the BMV genome were also found to be required for efficient replication. Asymmetric production of excess genomic (+) over (-) strand RNA, characteristic of all (+) strand viruses, may be accomplished through transition of the replicase from competence for (-) to (+) strand synthesis by the recruitment of additional host factors.
C1 TEXAS A&M UNIV,INST DEV & MOLEC BIOL,COLLEGE STN,TX 77843.
US FDA,CBER,OTRR,DIV HEMATOL PROD,BETHESDA,MD 20014.
NR 25
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER-VERLAG WIEN
PI VIENNA
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA
SN 0304-8608
J9 ARCH VIROL
JI Arch. Virol.
PY 1994
SU 9
BP 181
EP 194
PG 14
WC Virology
SC Virology
GA NQ963
UT WOS:A1994NQ96300019
ER
PT J
AU NAKHASI, HL
SINGH, NK
POGUE, GP
CAO, XQ
ROUAULT, TA
AF NAKHASI, HL
SINGH, NK
POGUE, GP
CAO, XQ
ROUAULT, TA
TI IDENTIFICATION AND CHARACTERIZATION OF HOST FACTOR INTERACTIONS WITH
CIS-ACTING ELEMENTS OF RUBELLA-VIRUS RNA
SO ARCHIVES OF VIROLOGY
LA English
DT Article; Proceedings Paper
CT 3rd International Symposium on Positive-Strand RNA Viruses
CY SEP, 1992
CL CLEARWATER, FL
ID GENOME RNA; STRAND RNA; PROTEINS; TRANSLATION; BINDING; REGION
AB We have analyzed the function of cis-acting elements of rubella virus RNA and the components which interact with these elements in viral RNA replication. We demonstrated that the 5'- and 3'-terminal sequences from RV RNA promote translation and negative-strand RNA synthesis of chimeric chloroamphenicol acetyltransferase (CAT) RNAs. These sequences have a potential to form stem-loop (SL) structures and bind cellular proteins specifically in RNA gel-shift and UV cross-linking assays. The 5' end binding proteins were identified to be Ro/SSA-associated antigens by virtue of being recognized in an RNA complex by an autoimmune patient serum with Ro antigen type specificity. Purification and sequence analysis of the 3' end binding protein revealed that it is a homologue of human calreticulin. The role of host proteins in RV replication is discussed.
C1 NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892.
RP NAKHASI, HL (reprint author), US FDA,CTR BIOL EVALUAT & RES,DIV HEMATOL PROD,BLDG 29,RM 107,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.
NR 16
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER-VERLAG WIEN
PI VIENNA
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA
SN 0304-8608
J9 ARCH VIROL
JI Arch. Virol.
PY 1994
SU 9
BP 255
EP 267
PG 13
WC Virology
SC Virology
GA NQ963
UT WOS:A1994NQ96300027
ER
PT J
AU PAULUS, HE
AF PAULUS, HE
TI FDA ARTHRITIS ADVISORY-COMMITTEE MEETING - JUVENILE RHEUMATOID-ARTHRITIS
DRUG-EVALUATION GUIDELINES - OVER-THE-COUNTER NAPROXEN
SO ARTHRITIS AND RHEUMATISM
LA English
DT Editorial Material
RP PAULUS, HE (reprint author), UNIV CALIF LOS ANGELES, SCH MED,DEPT MED,DIV RHEUMATOL, FDA ARTHRITIS ADVISORY COMM, 1000 VET AVE, LOS ANGELES, CA 90024 USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD JAN
PY 1994
VL 37
IS 1
BP 137
EP 138
DI 10.1002/art.1780370119
PG 2
WC Rheumatology
SC Rheumatology
GA MR523
UT WOS:A1994MR52300018
PM 8129753
ER
PT J
AU ALAYASH, AI
RYAN, BAB
FRATANTONI, JC
CASHON, RE
AF ALAYASH, AI
RYAN, BAB
FRATANTONI, JC
CASHON, RE
TI REDOX REACTIVITY OF MODIFIED HEMOGLOBINS WITH HYDROGEN-PEROXIDE AND
NITRIC-OXIDE - TOXICOLOGICAL IMPLICATIONS
SO ARTIFICIAL CELLS BLOOD SUBSTITUTES AND IMMOBILIZATION BIOTECHNOLOGY
LA English
DT Article; Proceedings Paper
CT Vth International Symposium on Blood Substitutes
CY MAR 17-20, 1993
CL SAN DIEGO, CA
ID BLOOD SUBSTITUTE; SUPEROXIDE; RADICALS; INJURY
AB The rapid unloading of oxygen to tissue and the prevention of subunit dissociation have been the main concerns in the search for an effective hemoglobin-based red cell substitute. The presence of redox active iron however, raises some questions about its potential to enter into reactions that mediate the formation of cytotoxic oxygen free radicals. We tested the propensity of modified hemoglobins to undergo oxidative damage by peroxide (H2O2). We found differences in their susceptibility to oxidative modification and in their ability to form the highly cytotoxic ferryl species. This protein-associated oxidant may be a physiologically important contributor to reperfusion injury. Another potential mechanism of toxicity involves the reaction of cell-free hemoglobin with endothelium derived nitric oxide (NO). Marked hypertensive responses in intact animals infused with some of these hemoglobins were reported. Cell-free hemoglobin has the potential to bind the endothelial generated NO yielding methemoglobin and nitrate, an extremely rapid reaction in vivo. We describe subsequent redox reactions between NO and methemoglobin which may further deplete NO as a biological transducer, leading to greater effects on the extent of endothelial-dependent responses. The consequences of a potential linkage between oxidative toxicity of cell-free hemoglobin and its interaction with NO is addressed.
C1 DUKE UNIV,MARINE LAB,BEAUFORT,NC 28516.
RP ALAYASH, AI (reprint author), US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892, USA.
NR 26
TC 14
Z9 14
U1 0
U2 0
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 1073-1199
J9 ARTIF CELL BLOOD SUB
JI Artif. Cells Blood Substit. Immobil. Biotechnol.
PY 1994
VL 22
IS 3
BP 373
EP 386
DI 10.3109/10731199409117868
PG 14
WC Biotechnology & Applied Microbiology; Engineering, Biomedical; Materials
Science, Biomaterials
SC Biotechnology & Applied Microbiology; Engineering; Materials Science
GA NZ321
UT WOS:A1994NZ32100002
PM 7994362
ER
PT J
AU SHAHIN, RD
COWELL, JL
AF SHAHIN, RD
COWELL, JL
TI MOUSE RESPIRATORY-INFECTION MODELS FOR PERTUSSIS
SO BACTERIAL PATHOGENESIS, PT A
SE METHODS IN ENZYMOLOGY
LA English
DT Review
ID BORDETELLA-PERTUSSIS; FILAMENTOUS HEMAGGLUTININ; MICE; COLONIZATION
C1 LEDERLEPRAXIS BIOL INC,DEPT BACTERIAL VACCINE RES,W HENRIETTA,NY 14586.
RP SHAHIN, RD (reprint author), US FDA,CTR BIOL EVALUAT & RES,DIV BACTERIAL PROD,BETHESDA,MD 20892, USA.
NR 23
TC 10
Z9 10
U1 0
U2 1
PU ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495
SN 0076-6879
J9 METHOD ENZYMOL
JI Methods Enzymol.
PY 1994
VL 235
BP 47
EP 58
PG 12
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA BA88R
UT WOS:A1994BA88R00004
PM 8057918
ER
PT J
AU FRASCH, CE
AF FRASCH, CE
TI SEROGROUP AND SEROTYPE CLASSIFICATION OF BACTERIAL PATHOGENS
SO BACTERIAL PATHOGENESIS, PT A
SE METHODS IN ENZYMOLOGY
LA English
DT Review
ID NEISSERIA-MENINGITIDIS; GROUP-B; CAPSULAR POLYSACCHARIDES;
STREPTOCOCCUS-PNEUMONIAE; PSEUDOMONAS-AERUGINOSA; MENINGOCOCCAL DISEASE;
MONOCLONAL-ANTIBODIES; GROUP-A; VACCINE; LIPOPOLYSACCHARIDE
RP FRASCH, CE (reprint author), US FDA,CTR BIOL EVALUAT & RES,DIV BACTERIAL PROD,BETHESDA,MD 20892, USA.
NR 46
TC 4
Z9 4
U1 0
U2 0
PU ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495
SN 0076-6879
J9 METHOD ENZYMOL
JI Methods Enzymol.
PY 1994
VL 235
BP 159
EP 174
PG 16
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA BA88R
UT WOS:A1994BA88R00012
PM 8057893
ER
PT J
AU VANN, WF
FREESE, SJ
AF VANN, WF
FREESE, SJ
TI PURIFICATION OF ESCHERICHIA-COLI K-ANTIGENS
SO BACTERIAL PATHOGENESIS, PT A
SE METHODS IN ENZYMOLOGY
LA English
DT Review
ID CAPSULAR POLYSACCHARIDE; HEPARIN
RP VANN, WF (reprint author), US FDA,CTR BIOL EVALUAT & RES,DIV BACTERIAL PROD,BETHESDA,MD 20892, USA.
NR 24
TC 14
Z9 14
U1 0
U2 2
PU ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495
SN 0076-6879
J9 METHOD ENZYMOL
JI Methods Enzymol.
PY 1994
VL 235
BP 304
EP 311
PG 8
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA BA88R
UT WOS:A1994BA88R00023
PM 8057903
ER
PT J
AU STIBITZ, S
AF STIBITZ, S
TI USE OF CONDITIONALLY COUNTERSELECTABLE SUICIDE VECTORS FOR ALLELIC
EXCHANGE
SO BACTERIAL PATHOGENESIS, PT A
SE METHODS IN ENZYMOLOGY
LA English
DT Review
ID BORDETELLA-PERTUSSIS; ESCHERICHIA-COLI; CONSTRUCTION; MUTAGENESIS;
EXPRESSION; PROTEINS; CLONING; GENE
RP STIBITZ, S (reprint author), US FDA,CTR BIOL EVALUAT & RES,DIV BACTERIAL PROD,BETHESDA,MD 20892, USA.
NR 11
TC 89
Z9 90
U1 0
U2 4
PU ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495
SN 0076-6879
J9 METHOD ENZYMOL
JI Methods Enzymol.
PY 1994
VL 235
BP 458
EP 465
PG 8
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA BA88R
UT WOS:A1994BA88R00035
PM 8057916
ER
PT J
AU GUERRY, P
YAO, RJ
ALM, RA
BURR, DH
TRUST, TJ
AF GUERRY, P
YAO, RJ
ALM, RA
BURR, DH
TRUST, TJ
TI SYSTEMS OF EXPERIMENTAL GENETICS FOR CAMPYLOBACTER SPECIES
SO BACTERIAL PATHOGENESIS, PT A
SE METHODS IN ENZYMOLOGY
LA English
DT Review
ID FLAGELLIN GENES; JEJUNI; TRANSFORMATION; CONSTRUCTION; BACTERIA;
EXCHANGE; VECTORS
C1 UNIV QUEENSLAND,CTR MOLEC BIOL & BIOTECHNOL,ST LUCIA,QLD 40723,AUSTRALIA.
US FDA,CTR FOOD SAFETY & APPL NUTR,DIV VIRULENCE ASSESSMENT,WASHINGTON,DC 20204.
UNIV VICTORIA,DEPT BIOCHEM & MICROBIOL,VICTORIA V8W 3P6,BC,CANADA.
RP GUERRY, P (reprint author), USN,MED RES INST,ENTER PROGRAM,ROCKVILLE,MD 20852, USA.
NR 16
TC 48
Z9 48
U1 0
U2 2
PU ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495
SN 0076-6879
J9 METHOD ENZYMOL
JI Methods Enzymol.
PY 1994
VL 235
BP 474
EP 481
PG 8
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA BA88R
UT WOS:A1994BA88R00037
PM 8057919
ER
PT S
AU BURNS, DL
JOHNSON, FD
WEISS, AA
AF BURNS, DL
JOHNSON, FD
WEISS, AA
BE Freer, J
Aitken, R
Alouf, JE
Boulnois, G
Falmagne, P
Fehrenbach, F
Montecucco, C
Piemont, Y
Rappuoli, R
Wadstrom, T
Witholt, B
TI EXPORT OF PERTUSSIS TOXIN FROM BORDETELLA-PERTUSSIS
SO BACTERIAL PROTEIN TOXINS: SIXTH EUROPEAN WORKSHOP
SE ZENTRALBLATT FUR BAKTERIOLOGIE : SUPPLEMENT
LA English
DT Proceedings Paper
CT 6th European Workshop on Bacterial Protein Toxins
CY JUN 27-JUL 02, 1993
CL STIRLING, SCOTLAND
SP FEDERAT EUROPEAN MICROBIOL SOC
DE PERTUSSIS TOXIN; SECRETION; TRANSPORT
C1 US FDA,CTR BIOL EVALUAT & RES,DIV BACTERIAL PROD,BETHESDA,MD 20892.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU GUSTAV FISCHER VERLAG
PI STUTTGART 70
PA WOLLGRASWEG 49, W-7000 STUTTGART 70, GERMANY
SN 0172-5629
BN 3-437-11535-9
J9 ZBL BAKT S
PY 1994
VL 24
BP 195
EP 203
PG 9
WC Biochemistry & Molecular Biology; Microbiology; Toxicology
SC Biochemistry & Molecular Biology; Microbiology; Toxicology
GA BA51D
UT WOS:A1994BA51D00035
ER
PT S
AU JOHNSON, VG
NICHOLLS, PJ
HABIG, WH
YOULE, RJ
AF JOHNSON, VG
NICHOLLS, PJ
HABIG, WH
YOULE, RJ
BE Freer, J
Aitken, R
Alouf, JE
Boulnois, G
Falmagne, P
Fehrenbach, F
Montecucco, C
Piemont, Y
Rappuoli, R
Wadstrom, T
Witholt, B
TI THE ROLE OF PROLINE 345 IN DIPHTHERIA-TOXIN TRANSLOCATION
SO BACTERIAL PROTEIN TOXINS: SIXTH EUROPEAN WORKSHOP
SE ZENTRALBLATT FUR BAKTERIOLOGIE : SUPPLEMENT
LA English
DT Proceedings Paper
CT 6th European Workshop on Bacterial Protein Toxins
CY JUN 27-JUL 02, 1993
CL STIRLING, SCOTLAND
SP FEDERAT EUROPEAN MICROBIOL SOC
DE DIPHTHERIA TOXIN; MEMBRANE TRANSLOCATION; CIS-TRANS ISOMERIZATION
C1 CBER,FOOD & DRUG ADM,DIV BACTERIAL PROD,BACTERIAL TOXINS,BETHESDA,MD 20892.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU GUSTAV FISCHER VERLAG
PI STUTTGART 70
PA WOLLGRASWEG 49, W-7000 STUTTGART 70, GERMANY
SN 0172-5629
BN 3-437-11535-9
J9 ZBL BAKT S
PY 1994
VL 24
BP 527
EP 528
PG 2
WC Biochemistry & Molecular Biology; Microbiology; Toxicology
SC Biochemistry & Molecular Biology; Microbiology; Toxicology
GA BA51D
UT WOS:A1994BA51D00115
ER
PT B
AU BRAUNBERG, RC
AF BRAUNBERG, RC
BE Llewellyn, GC
Dashek, WV
ORear, CE
TI THE BIOCHEMICAL EFFECTS OF CITRININ - A REVIEW
SO BIODETERIORATION RESEARCH 4: MYCOTOXINS, WOOD DECAY, PLANT STRESS,
BIOCORROSION, AND GENERAL BIODETERIORATION
LA English
DT Proceedings Paper
CT 4th Meeting of the Pan-American-Biodeterioration-Society
CY AUG 20-25, 1991
CL ELECTR NETWORK
SP PAN AMER BIODETERIORAT SOC, GEORGE WASHINGTON UNIV, SMITHSONIAN INST, CLARK ATLANTA UNIV, DEPT BIOL, USDA, RES SERV, UNIV GEORGIA, MORRIS BROWN COLL, SPELLMAN COLL, MOREHOUSE COLL, NORTH CAROLINA STATE UNIV RALEIGH, US FDA, TOXICOL STUDIES, USDA, FOREST SERV, PENN STATE UNIV, UNIV LA PLATA ARGENTINA
C1 US FDA,BELTSVILLE RES LABS,BELTSVILLE,MD 20708.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU PLENUM PRESS DIV PLENUM PUBLISHING CORP
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013
BN 0-306-44638-3
PY 1994
BP 11
EP 25
PG 15
WC Agronomy; Microbiology; Mycology; Parasitology; Toxicology
SC Agriculture; Microbiology; Mycology; Parasitology; Toxicology
GA BA79F
UT WOS:A1994BA79F00001
ER
PT B
AU LEGRENADE, CEF
BEAN, GA
AF LEGRENADE, CEF
BEAN, GA
BE Llewellyn, GC
Dashek, WV
ORear, CE
TI STUDIES ON FUSARIUM-MONILIFORME - CAUSAL AGENT OF EQUINE
LEUKOENCEPHALOMALACIA
SO BIODETERIORATION RESEARCH 4: MYCOTOXINS, WOOD DECAY, PLANT STRESS,
BIOCORROSION, AND GENERAL BIODETERIORATION
LA English
DT Proceedings Paper
CT 4th Meeting of the Pan-American-Biodeterioration-Society
CY AUG 20-25, 1991
CL ELECTR NETWORK
SP PAN AMER BIODETERIORAT SOC, GEORGE WASHINGTON UNIV, SMITHSONIAN INST, CLARK ATLANTA UNIV, DEPT BIOL, USDA, RES SERV, UNIV GEORGIA, MORRIS BROWN COLL, SPELLMAN COLL, MOREHOUSE COLL, NORTH CAROLINA STATE UNIV RALEIGH, US FDA, TOXICOL STUDIES, USDA, FOREST SERV, PENN STATE UNIV, UNIV LA PLATA ARGENTINA
C1 US FDA,DEPT MICROBIOL,WASHINGTON,DC 20204.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU PLENUM PRESS DIV PLENUM PUBLISHING CORP
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013
BN 0-306-44638-3
PY 1994
BP 105
EP 113
PG 9
WC Agronomy; Microbiology; Mycology; Parasitology; Toxicology
SC Agriculture; Microbiology; Mycology; Parasitology; Toxicology
GA BA79F
UT WOS:A1994BA79F00008
ER
PT J
AU AHN, H
AF AHN, H
TI TREE-STRUCTURED EXPONENTIAL REGRESSION MODELING
SO BIOMETRICAL JOURNAL
LA English
DT Article
DE BOOTSTRAP; EXPONENTIAL REGRESSION; RECURSIVE PARTITIONING; SURVIVAL
ANALYSIS
ID CENSORED-DATA; LINEAR-REGRESSION; SURVIVAL-DATA
AB A method for fitting piecewise exponential regression models to censored survival data is described. Stratification is performed recursively, using a combination of statistical tests and residual analysis. The splitting criterion employed in cross-validation is the average squared error of the residuals. The bootstrap is employed to keep the probability of a type I error (the error of discovering two or more strata when there is only one) of the method close to a predetermined value. The proposed method can thus also serve as a formal goodness-of-fit test for the exponential regression model. Real and simulated data are used for illustration.
C1 NATL CTR TOXICOL RES,DIV BIOMETRY & RISK ASSESSMENT,JEFFERSON,AR 72079.
NR 21
TC 2
Z9 2
U1 3
U2 3
PU AKADEMIE VERLAG GMBH
PI BERLIN
PA MUHLENSTRASSE 33-34, D-13187 BERLIN, GERMANY
SN 0323-3847
J9 BIOMETRICAL J
JI Biom. J.
PY 1994
VL 36
IS 1
BP 43
EP 61
DI 10.1002/bimj.4710360106
PG 19
WC Mathematical & Computational Biology; Statistics & Probability
SC Mathematical & Computational Biology; Mathematics
GA MT720
UT WOS:A1994MT72000004
ER
PT J
AU GOSWAMI, BB
KOCH, WH
CEBULA, TA
AF GOSWAMI, BB
KOCH, WH
CEBULA, TA
TI COMPETITOR TEMPLATE RNA FOR DETECTION AND QUANTITATION OF HEPATITIS-A
VIRUS BY PCR
SO BIOTECHNIQUES
LA English
DT Article
ID POLYMERASE CHAIN-REACTION; MESSENGER-RNA; A-VIRUS; GENE-EXPRESSION;
ASSAY
AB PCR was used to introduce a 63-bp deletion into the putative RNA replicase coding sequence of hepatitis A virus. RNA was synthesized in vitro from the deletion mutant cloned into a transcription vector. Upon amplication by PCR, cDNA made from the competitor RNA generated an amplified fragment that could be easily distinguished from the product generated front wild-type hepatitis A virus genomic RNA by gel electrophoresis, when the same primers were used, without further. manipulation. The competitor RNA was used as a positive control in PCR-based detection of very low copy numbers of hepatitis A virus genomic RNA in rite presence of unrelated hard-shell clam RNA. When the competitor RNA was used for competitive PCR to quantitate wild-type RNA, the presence of one template at a 10-fold to 100-fold higher level almost completely inhibited product formation from the underrepresented template. The competitor RNA should be useful as a control for reverse transcription and PCRs to determine hepatitis A virus genome RNA when accidental contamination of test samples by a wild-type positive control template would compromise the results.
RP GOSWAMI, BB (reprint author), US FDA,DIV MOLEC BIOL RES & EVALUAT HFS237,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 18
TC 20
Z9 20
U1 0
U2 0
PU EATON PUBLISHING CO
PI NATICK
PA 154 E. CENTRAL ST, NATICK, MA 01760
SN 0736-6205
J9 BIOTECHNIQUES
JI Biotechniques
PD JAN
PY 1994
VL 16
IS 1
BP 114
EP &
PG 0
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA MQ935
UT WOS:A1994MQ93500026
PM 8136124
ER
PT J
AU KENYON, TA
KENYON, AS
SIBIYA, T
AF KENYON, TA
KENYON, AS
SIBIYA, T
TI DRUG QUALITY SCREENING IN DEVELOPING-COUNTRIES - ESTABLISHMENT OF AN
APPROPRIATE LABORATORY IN SWAZILAND
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
AB A simple, low-cost, accurate thin-layer chromatography (TLC) method has been used to establish the first drug quality screening laboratory in Swaziland. For this purpose, office space at the central medical stores was first converted into a simple laboratory. Basic equipment, supplies, and materials were pur chased, existing manpower was trained to perform accurately the TLC procedure, and a system was established for the qualitative/quantitative screening of selected drugs purchased by the Ministry of Health prior to their distribution to user facilities. The TLC method described can be used to set up similar low-cost, drug quality screening laboratories in other developing countries where analytical chemistry expertise is lacking, resources are scarce, and sophisticated analytical laboratories to assess drug quality are not available.
C1 US FDA,DIV DRUG ANAL,ST LOUIS,MO.
NR 5
TC 16
Z9 16
U1 0
U2 0
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA DISTRIBUTION AND SALES, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PY 1994
VL 72
IS 4
BP 615
EP 620
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA PG585
UT WOS:A1994PG58500008
PM 7923541
ER
PT J
AU SIEGEL, JP
AF SIEGEL, JP
BE Rusthoven, J
Feld, R
TI CLINICAL DEVELOPMENT OF BIOLOGICAL RESPONSE MODIFIERS
SO CANADIAN JOURNAL OF INFECTIOUS DISEASES, VOL 5 SUPPLEMENT A, FEBRUARY
1994: PROCEEDINGS OF THE SECOND INTERNATIONAL CONGRESS ON BIOLOGICAL
RESPONSE MODIFIERS
LA English
DT Proceedings Paper
CT 2nd International Congress on Biological Response Modifiers
CY JAN 29-31, 1993
CL SAN DIEGO, CA
SP INTER AMER SOC CHEMOTHERAPY
DE BIOLOGICAL RESPONSE MODIFIERS; BIOLOGICALS; CLINICAL TRIALS; DRUG
DEVELOPMENT
C1 US FDA,CBER,OTRR,DCTDA,ROCKVILLE,MD 20852.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU PULSUS GROUP INC
PI OAKVILLE
PA 2902 S SHERIDAN WAY, OAKVILLE ON L6J 7L6, CANADA
PY 1994
BP A5
EP A8
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA BC39U
UT WOS:A1994BC39U00001
ER
PT J
AU KOCH, WH
HENRIKSON, EN
KUPCHELLA, E
CEBULA, TA
AF KOCH, WH
HENRIKSON, EN
KUPCHELLA, E
CEBULA, TA
TI SALMONELLA-TYPHIMURIUM STRAIN TA100 DIFFERENTIATES SEVERAL CLASSES OF
CARCINOGENS AND MUTAGENS BY BASE SUBSTITUTION SPECIFICITY
SO CARCINOGENESIS
LA English
DT Review
ID APURINIC-APYRIMIDINIC SITES; OLIGODEOXYRIBONUCLEOTIDE COLONY
HYBRIDIZATION; DIPLOID HUMAN FIBROBLASTS; SINGLE-STRANDED-DNA; HAMSTER
OVARY CELLS; COLI LACI GENE; ESCHERICHIA-COLI; SEQUENCE SPECIFICITY;
MUTATIONAL SPECIFICITY; EXCISION-REPAIR
AB The mutational specificity of N-methylnitrosourea (MNU), nitrosoguanidine (MNNG), methyl methanesulfonate (MMS), sodium azide (NaN3), 4-nitroquinoline oxide (4NQO), benzo[a]pyrene (BP), nitrofurantoin (NF), alfatoxin B-1 (AFB(1)), adriamycin (ADM) and WA-activated angelicin in Salmonella typhimurium strain TA100 has been examined using allele-specific oligonucleotide hybridization and DNA sequence analyses. These ten mutagens produced five unique classes of reversion spectra, distinct from spontaneous, or the previously characterized 5-azacytidine, ultraviolet light(UV), 8-methoxypsoralen plus UVA (PUVA) and Co-60-induced mutation spectra. For example, 90% of MNU and MNNG-induced mutations in sh ain TA100 revertants were G:C-A:T transitions with the majority (82%) occurring in the first position of the CCC codon. In contrast, NaN3 preferentially induced G:C-->A:T transitions at the second codon position (78%). Although MMS, NQO, BP, NP, ADM and AFB(1) induced primarily G:C-->T:A transversions (73-86%), these mutagens fall into two classes based on site preference: NF and AFB(1) yielded almost exclusively position two transversions (69-78%) whereas ADM, NQO, BP and MMS exhibited a two-fold preference for site 2 over site 1 (on average 52% versus 22%). Angelicin photomutagenesis resulted in the recovery of G:C-->A:T and G:C-->T:A mutations at both codon positions in roughly equal proportions (similar to 20-25% each). Approximately 1% of the mutagen-induced revertants occurred via extragenic tRNA suppressor mutations, while 1% were multiple (usually tandem double) base substitutions. Ultraviolet mutagenesis experiments demonstrated that tandem base substitutions are promoted by pKM101-encoded mucAB gene products. A comparison of the mutagenic specificity derived for several carcinogens in hisG46 with the responses of several eukaryotic gene targets (e.g. HPRT, aprt, supF) revealed a high concordance between these targets. Thus, the Salmonella hirG46 locus provides a rapid, simple system for determining base substitution specificity and for studying mechanisms of mutagenesis.
RP KOCH, WH (reprint author), US FDA,DIV MOLEC BIOL RES & EVALUAT HFS237,MOLEC BIOL BRANCH,WASHINGTON,DC 20204, USA.
NR 118
TC 64
Z9 64
U1 2
U2 15
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD JAN
PY 1994
VL 15
IS 1
BP 79
EP 88
DI 10.1093/carcin/15.1.79
PG 10
WC Oncology
SC Oncology
GA MR103
UT WOS:A1994MR10300014
PM 8293552
ER
PT B
AU LU, MH
ALI, SF
HE, DS
TURTURRO, A
HART, RW
AF LU, MH
ALI, SF
HE, DS
TURTURRO, A
HART, RW
BE Hu, VW
TI CELL-PROLIFERATION AS A BIOMARKER OF AGE AND DEVELOPMENT
SO CELL CYCLE: REGULATORS, TARGETS, AND CLINICAL APPLICATIONS
SE GWUMC DEPARTMENT OF BIOCHEMISTRY ANNUAL SPRING SYMPOSIA
LA English
DT Proceedings Paper
CT 13th Washington International Spring Symposium on Cell Cycle:
Regulators, Targets, and Clinical Applications
CY MAY 10-14, 1993
CL WASHINGTON, DC
C1 US FDA,NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
NR 0
TC 1
Z9 2
U1 0
U2 0
PU PLENUM PRESS DIV PLENUM PUBLISHING CORP
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013
BN 0-306-44672-3
J9 GWUMC DEPT
PY 1994
BP 263
EP 269
PG 7
GA BA55Y
UT WOS:A1994BA55Y00031
ER
PT S
AU BINIENDA, Z
ROUNTREE, RL
TAYLOR, NR
SLIKKER, W
SCALLET, AC
AF BINIENDA, Z
ROUNTREE, RL
TAYLOR, NR
SLIKKER, W
SCALLET, AC
BE Das, DK
TI THE EFFECTS OF REDUCED PERFUSION AND REPERFUSION ON C-FOS PROTEIN
IMMUNOHISTOCHEMISTRY IN GESTATIONAL DAY-21 RAT BRAINS
SO CELLULAR, BIOCHEMICAL, AND MOLECULAR ASPECTS OF REPERFUSION INJURY
SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Note
CT Conference on Cellular, Biochemical, and Molecular Aspects of
Reperfusion Injury
CY JUL 11-14, 1993
CL NEW YORK, NY
SP NEW YORK ACAD SCI
RP BINIENDA, Z (reprint author), US FDA,NATL CTR TOXICOL RES,DIV NEUROTOXICOL,JEFFERSON,AR 72079, USA.
NR 6
TC 2
Z9 2
U1 0
U2 0
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021
SN 0077-8923
BN 0-89766-883-9
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 1994
VL 723
BP 457
EP 461
DI 10.1111/j.1749-6632.1994.tb36777.x
PG 5
WC Biochemistry & Molecular Biology; Multidisciplinary Sciences; Physiology
SC Biochemistry & Molecular Biology; Science & Technology - Other Topics;
Physiology
GA BA67G
UT WOS:A1994BA67G00066
PM 8030912
ER
PT J
AU MCLAUGHLIN, MA
AF MCLAUGHLIN, MA
TI ANALYSIS, CEREAL-GRAINS, AND DECIMALS
SO CEREAL FOODS WORLD
LA English
DT Editorial Material
RP MCLAUGHLIN, MA (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CEREAL CHEMISTS
PI ST PAUL
PA 3340 PILOT KNOB RD, ST PAUL, MN 55121-2097
SN 0146-6283
J9 CEREAL FOOD WORLD
JI Cereal Foods World
PD JAN
PY 1994
VL 39
IS 1
BP 43
EP 44
PG 2
WC Food Science & Technology
SC Food Science & Technology
GA MU839
UT WOS:A1994MU83900009
ER
PT S
AU CALLAHAN, TJ
GANTENBERG, JB
SANDS, BE
AF CALLAHAN, TJ
GANTENBERG, JB
SANDS, BE
BE Horowitz, E
Parr, JE
TI CALCIUM-PHOSPHATE (CA-P) COATING DRAFT GUIDANCE FOR PREPARATION OF
FOOD-AND-DRUG-ADMINISTRATION (FDA) SUBMISSIONS FOR ORTHOPEDIC AND DENTAL
ENDOSSEOUS IMPLANTS
SO CHARACTERIZATION AND PERFORMANCE OF CALCIUM PHOSPHATE COATINGS FOR
IMPLANTS
SE AMERICAN SOCIETY FOR TESTING AND MATERIALS SPECIAL TECHNICAL PUBLICATION
LA English
DT Proceedings Paper
CT Symposium on Characterization and Performance of Calcium Phosphate
Coatings for Implants
CY NOV 17, 1992
CL MIAMI, FL
SP AMER SOC TESTING & MAT, COMM MED & SURG MAT & DEVICE
DE FDA DRAFT GUIDANCE; CALCIUM PHOSPHATE COATINGS; LABELING CLAIMS; TEST
METHODS
C1 US FDA,DIV GEN & RESTORAT DEVICES,ROCKVILLE,MD 20850.
NR 0
TC 7
Z9 7
U1 1
U2 1
PU AMERICAN SOCIETY TESTING AND MATERIALS
PI W CONSHOHOCKEN
PA 100 BARR HARBOR DRIVE, W CONSHOHOCKEN, PA 19428-2959
SN 1071-5827
BN 0-8031-1854-6
J9 AM SOC TEST MATER
PY 1994
VL 1196
BP 185
EP 197
DI 10.1520/STP25193S
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA BA28L
UT WOS:A1994BA28L00017
ER
PT J
AU MANOHAR, V
HUPPI, K
LIZZIO, E
HOFFMAN, T
AF MANOHAR, V
HUPPI, K
LIZZIO, E
HOFFMAN, T
TI MURINE SPLENIC HEMATOPOIETIC SUBPOPULATIONS - THE ENLARGED
UNDIFFERENTIATED SUBSET IN NEW-ZEALAND BLACK MICE IS MULTIPOTENT
STEM-CELLS
SO CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY
LA English
DT Article
ID MONOCLONAL-ANTIBODY; DIFFERENTIATION ANTIGENS; SURFACE; LYMPHOCYTES;
GENES
AB We recently reported that a significant population of the murine splenic non-T, non-B ''null'' cell compartment consists of non-lineage-specific, undifferentiated cells which are in the G(0) and G(1) phases of the cell cycle and that their numbers are particularly high in the spleens of New Zealand Black mice. A highly enriched population of these non-lineage-specific cells obtained by successive elimination of differentiated cells was further purified to homogeneity by fluorescence-activated cell sorting. The morphologic, phenotypic, and histochemical characteristics of this purified population suggest that these cells may be primitive hematopoietic Stem cells. The germ line configuration of the genomic DNA establishes that these are uncommitted stem cells. In vivo, these cells form day 12 colonies in the spleen and liver of lethally irradiated recipients and confer radioprotection. These cells also differentiate into T- and B-cell lineages and reconstitute the immunodeficiency in mice with severe combined immunodeficiency. In response to a combination of a very few early-acting lymphokines and/or stromal cell-conditioned medium in vitro, these tells differentiate into both myeloid and lymphoid cell types. More of these cells are obtained from the enlarged spleens of New Zealand Black mice than from those of BALB/c mice. The presence of a comparatively higher number of stem cells in the spleen than in the marrow or fetal liver provides an alternative, and possibly superior, source of uncommitted stem cells for a variety of experimental investigations or therapeutic manipulations.
C1 US FDA,CTR BIOL EVALUAT & RES,DIV MONOCLONAL ANTIBODIES,CELL BIOL LAB,BETHESDA,MD 20892.
NCI,GENET LAB,BETHESDA,MD 20892.
NR 36
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 1071-412X
J9 CLIN DIAGN LAB IMMUN
JI Clin. Diagn. Lab. Immunol.
PD JAN
PY 1994
VL 1
IS 1
BP 99
EP 108
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA PT561
UT WOS:A1994PT56100019
PM 7496931
ER
PT J
AU OBIRI, NI
SIEGEL, JP
VARRICCHIO, F
PURI, RK
AF OBIRI, NI
SIEGEL, JP
VARRICCHIO, F
PURI, RK
TI EXPRESSION OF HIGH-AFFINITY IL-4 RECEPTORS ON HUMAN-MELANOMA, OVARIAN
AND BREAST-CARCINOMA CELLS
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE IL-4 RECEPTORS; SOLID HUMAN TUMORS; TUMOR GROWTH; MHC REGULATION
ID TUMOR-NECROSIS-FACTOR; STIMULATORY FACTOR-I; ACTIVATED KILLER-CELLS;
HUMAN INTERLEUKIN-4; GAMMA-INTERFERON; LYMPHOCYTES-T; UP-REGULATION;
IFN-GAMMA; B-CELLS; GROWTH
AB It has previously been shown that murine sarcoma cells express high-affinity IL-4 receptors (IL-4R) which are internalized after binding to the ligand (Purl ct al., Cancer Res 1991; 51:3011-7). We have also reported that human renal cell carcinoma cells express high-affinity IL-4R, and IL-4 inhibits tumour growth in vitro (Obiri ct al., J Clin Invest 1993; 91:88). In this study we investigated the expression and function of IL-4R on other human solid tumours. Human melanoma, ovarian carcinoma and breast carcinoma cell lines were assessed for the cell surface expression of IL-4R by radio-ligand receptor binding and for IL-4R gene expression by Northern blot analysis. Primary cultures of mesothelioma and neurofibrosarcoma cells were similarly investigated. Human melanoma, ovarian carcinoma and breast carcinoma cell lines expressed IL-4R on their cell surface with a dissociation constant (K-d) of 140-549 PM. These tumour lines expressed a single 4 kb species of mRNA for IL-4R. Similarly, primary cultures of mesothelioma and neurofibrosarcoma cells were positive for the IL-4R mRNA by Northern blot analysis. Fresh, non-cultured mesothelioma and neurofibrosarcoma tumour sections were also positive for the presence of IL-4R as determined by immunohistochemistry of frozen sections using anti-IL-4R antibody. In order to study possible functions of IL-4R, we evaluated the effects of IL-4 on cell growth and its effect on MHC antigen expression in the presence or absence of interferon-gamma (IFN-gamma). In tissue culture, IL-4 reduced the growth of tumour cell lines and primary cell cultures studied. IL-4 had very little effect on MHC class I antigen expression on ovarian, breast and melanoma cell lines; however, MHC class II (HLA-DR) expression was enhanced on melanoma and breast carcinoma cells. IL-4 also enhanced the IFN-gamma-induced class II expression on melanoma and breast carcinoma cells. Taken together, our observations indicate that IL-4R are expressed on a variety of human solid tumours and these receptors may be functional. IL-4 alone and in combination with IFN-gamma may play a role in host immune response against cancers.
C1 US FDA,CTR BIOL EVALUAT & RES,DIV CELLULAR & GENE THERAPIES,MOLEC TUMOUR BIOL LAB,BETHESDA,MD 20892.
US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20892.
NR 50
TC 100
Z9 101
U1 1
U2 2
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD JAN
PY 1994
VL 95
IS 1
BP 148
EP 155
PG 8
WC Immunology
SC Immunology
GA MQ997
UT WOS:A1994MQ99700025
PM 8287600
ER
PT J
AU AHN, HS
AF AHN, HS
TI TREE-STRUCTURED EXTREME-VALUE MODEL REGRESSION
SO COMMUNICATIONS IN STATISTICS-THEORY AND METHODS
LA English
DT Article
DE BOOTSTRAP; RECURSIVE PARTITIONING; SURVIVAL ANALYSIS; EXPONENTIAL
REGRESSION; WEIBULL REGRESSION
ID CENSORED-DATA; LINEAR-REGRESSION
AB This paper gives a method for fitting piecewise Weibull regression models to censored survival data. Recursive stratification is performed using statistical tests for variances and residual analysis. The average squared error of the residuals is used as a splitting criterion in cross-validation. The bootstrap resampling is used to keep the probability of a type I error of the method (the error of finding two or more strata when there is one). Real and simulated data are used for illustration.
C1 NATL CTR TOXICOL RES,DIV BIOMETRY & RISK ASSESSMENT,JEFFERSON,AR 72079.
NR 15
TC 4
Z9 4
U1 3
U2 3
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 0361-0926
J9 COMMUN STAT THEORY
JI Commun. Stat.-Theory Methods
PY 1994
VL 23
IS 1
BP 153
EP 174
DI 10.1080/03610929408831245
PG 22
WC Statistics & Probability
SC Mathematics
GA MR990
UT WOS:A1994MR99000011
ER
PT J
AU HEDAYAT, AS
CHI, GYH
MAHJOOB, K
AF HEDAYAT, AS
CHI, GYH
MAHJOOB, K
TI BLENDS OF STATISTICAL DESIGNS FOR DOSE-RESPONSE STUDIES
SO COMMUNICATIONS IN STATISTICS-THEORY AND METHODS
LA English
DT Article
DE CONFIRMATORY TRIAL; SUPPORTIVE TRIAL; REPEATED MEASUREMENTS DESIGN;
PARALLEL-GROUP DESIGN; DOSE-RESPONSE; DOSE-TITRATION; FORCED TITRATION;
VARIABLE TREATMENT DURATION; COMBINATION DRUG; FACTORIAL DESIGN;
POPULATION MEAN-DOSE RESPONSE CURVE; OVERALL POPULATION DOSE
RESPONSE-CURVE
ID COMBINATION THERAPY; TITRATION; SURFACE; TRIALS
AB It is becoming increasingly apparent that for reasons of safety, efficacy and cost, accurate and useful dose-response/dose-titration information should be provided by clinical trials and included in the drug product labeling. In this exposition, we discuss some design related issues and focus our attention on trial designs primarily meant to gather dose-response or dose-titration information. We consider blends of repeated measurements, parallel-group, and titration designs, a titration design with variable treatment duration, and factorial designs for studying combination drugs. Our goal is to search for optimal and efficient clinical trial designs that will address as many of these clinical questions as possible and at the same time provide supportive evidence on the efficacy of the drug. Although our discussion is very general, we are cognizant of the limitations of these designs and the complexity of their associated analyses in practice, and hope that they might prove to be applicable and useful in some situations.
C1 UNIV CHICAGO,DEPT MATH STAT & COMP SCI,CHICAGO,IL 60637.
US FDA,DIV BIOMETR,ROCKVILLE,MD 20857.
NR 21
TC 0
Z9 0
U1 1
U2 3
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 0361-0926
J9 COMMUN STAT THEORY
JI Commun. Stat.-Theory Methods
PY 1994
VL 23
IS 2
BP 341
EP 360
DI 10.1080/03610929408831259
PG 20
WC Statistics & Probability
SC Mathematics
GA MU155
UT WOS:A1994MU15500004
ER
PT J
AU HUNG, HMJ
CHI, GYH
LIPICKY, RJ
AF HUNG, HMJ
CHI, GYH
LIPICKY, RJ
TI ON SOME STATISTICAL-METHODS FOR ANALYSIS OF COMBINATION-DRUG STUDIES
SO COMMUNICATIONS IN STATISTICS-THEORY AND METHODS
LA English
DT Article
DE FACTORIAL TRIAL; MIN TEST; 2-STAGE TEST; MAX TEST; AVE TEST; DOSE
RESPONSE; CONFIDENCE REGION; CONFIDENCE SURFACE; RESPONSE SURFACE
ID RESPONSE-SURFACE; THERAPY
AB To be discussed are the practical considerations in the use of some statistical methods to evaluate clinical data for combination antihypertensive agents. The issues of interest concern efficacy and dose-response in a factorial clinical trial for multiple dose combinations. Discussions cover fixed-dose combination studies.
C1 US FDA,CDER,DIV BIOMETR,SERB,ROCKVILLE,MD 20857.
US FDA,CDER,DIV CARDIORENAL DRUG PROD,ROCKVILLE,MD 20857.
NR 18
TC 9
Z9 9
U1 1
U2 1
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 0361-0926
J9 COMMUN STAT THEORY
JI Commun. Stat.-Theory Methods
PY 1994
VL 23
IS 2
BP 361
EP 376
DI 10.1080/03610929408831260
PG 16
WC Statistics & Probability
SC Mathematics
GA MU155
UT WOS:A1994MU15500005
ER
PT J
AU HUQUE, MF
DUBEY, SD
AF HUQUE, MF
DUBEY, SD
TI A METAANALYSIS METHODOLOGY FOR UTILIZING STUDY-LEVEL
COVARIATE-INFORMATION FROM CLINICAL-TRIALS
SO COMMUNICATIONS IN STATISTICS-THEORY AND METHODS
LA English
DT Article
DE METAANALYSIS; CLINICAL TRIALS; STUDY-COVARIATES; MIXED-EFFECTS MODELING;
HETEROGENEOUS TREATMENT EFFECTS
ID MYOCARDIAL-INFARCTION; RANDOMIZED TRIALS; ODDS RATIO; TESTS;
METAANALYSIS; ASSOCIATION; HOMOGENEITY; SPARSE
AB Covariate information at the patient level is generally not available for a meta-analysis of clinical trials. Published papers, or unpublished reports of clinical trials selected for a meta-analysis generally do not include such information at the patient level. However, such papers and reports usually include design and covariate information at the study level. For example, they generally report important patient population characteristics for the study in the form of descriptive statistics including design information. such as, dose levels, duration of treatment information, gender and race proportions, etc. This paper addresses a meta-analysis methodology for binary responses based on mixed-effects modeling which makes use of such study-level covariate information. This paper also reviews fixed and random effects meta-analysis methods which become special cases of the mixed-effects methodology.
C1 US FDA,CTR DRUG EVALUAT & RES,ROCKVILLE,MD 20857.
NR 24
TC 3
Z9 3
U1 0
U2 1
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 0361-0926
J9 COMMUN STAT THEORY
JI Commun. Stat.-Theory Methods
PY 1994
VL 23
IS 2
BP 377
EP 394
DI 10.1080/03610929408831261
PG 18
WC Statistics & Probability
SC Mathematics
GA MU155
UT WOS:A1994MU15500006
ER
PT J
AU TEMPLE, RJ
AF TEMPLE, RJ
TI SPECIAL STUDY DESIGNS - EARLY ESCAPE, ENRICHMENT, STUDIES IN
NONRESPONDERS
SO COMMUNICATIONS IN STATISTICS-THEORY AND METHODS
LA English
DT Article
DE ENRICHMENT; RANDOMIZED WITHDRAWAL; EARLY ESCAPE
ID MYOCARDIAL-INFARCTION; DOUBLE-BLIND; PLACEBO; TRIAL; SUPPRESSION;
ENCAINIDE; ASPIRIN; ANGINA
AB In a number of situations, a simple randomized trial in unselected patients may not be possible or efficient. Randomized withdrawal of therapy in patients previously treated, studies that allow early escape/early advance of patients doing poorly, and enrichment of study populations with potential responders may increase the feasibility of a trial and its chances for success.
C1 US FDA,CTR DRUG EVALUAT & RES,OFF DRUG EVALUAT 1,ROCKVILLE,MD 20857.
NR 13
TC 39
Z9 39
U1 1
U2 4
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 0361-0926
J9 COMMUN STAT THEORY
JI Commun. Stat.-Theory Methods
PY 1994
VL 23
IS 2
BP 499
EP 531
DI 10.1080/03610929408831269
PG 33
WC Statistics & Probability
SC Mathematics
GA MU155
UT WOS:A1994MU15500014
ER
PT J
AU WENG, TS
AF WENG, TS
TI TOWARD A DYNAMIC ANALYSIS OF DISEASE-STATE TRANSITION MONITORED BY
SERIAL CLINICAL LABORATORY TESTS
SO COMMUNICATIONS IN STATISTICS-THEORY AND METHODS
LA English
DT Article; Proceedings Paper
CT Workshop on Statistical Issues in Drug Testing and Drug Evaluation
CY DEC 02-03, 1991
CL BETHESDA, MD
SP NIDA
DE DYNAMIC ANALYSIS; COMPARTMENTAL MODEL; STOCHASTIC PROCESS; RANDOMIZED
CLINICAL TRIAL; BUPRENORPHINE; METHADONE
ID FAILURE TIME DATA; REGRESSION-ANALYSIS; MULTIVARIATE
AB A closed stochastic 3-compartment system is proposed to model data from a randomized comparative clinical trial with the purpose of evaluating the efficacy of the new drug Buprenorphine against that of the commercially available drug Methadone for the treatment of opiate addiction. The results showed that, relative to Methadone, Buprenorphine, was more efficacious with steadfast drug action---patients on Buprenorphine treatment tended to achieve an opiate-negative state faster and upon reaching that state they stayed there longer.
C1 US FDA,CDRH,OST,DBS,STAT BRANCH,ROCKVILLE,MD 20852.
NR 15
TC 0
Z9 0
U1 0
U2 0
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 0361-0926
J9 COMMUN STAT THEORY
JI Commun. Stat.-Theory Methods
PY 1994
VL 23
IS 2
BP 643
EP 660
DI 10.1080/03610929408831277
PG 18
WC Statistics & Probability
SC Mathematics
GA MU155
UT WOS:A1994MU15500022
ER
PT J
AU KODELL, RL
CHEN, JJ
MOORE, GE
AF KODELL, RL
CHEN, JJ
MOORE, GE
TI COMPARING DISTRIBUTIONS OF TIME TO ONSET OF DISEASE IN ANIMAL
TUMORIGENICITY EXPERIMENTS
SO COMMUNICATIONS IN STATISTICS-THEORY AND METHODS
LA English
DT Article
DE CARCINOGENICITY BIOASSAY; CAUSE-OF-DEATH; PETO-ET-AL TEST; POLY-3 TEST;
SCORE TEST
ID SURVIVAL SACRIFICE EXPERIMENTS; NONPARAMETRIC-ESTIMATION;
STATISTICAL-ANALYSIS; CARCINOGENICITY; TESTS; MORTALITY; MODELS
AB The cause-of-death test of Peto et al. (1980) pools information from a Hoel-Walburg test on incidental tumors with information from a logrank test on fatal tumors in order to compare the tumor rate of a group of rodents exposed to a carcinogen against the tumor rate of a group of unexposed animals. The cause-of-death test, which can arise as a partial likelihood score test from a model that assumes proportional odds for tumor prevalence and proportional hazards for tumor mortality, is not, in general, a direct test for equality of tumor onset distributions for occult tumors that are observed in both fatal and incidental contexts. This paper develops a direct cause-of-death test for comparing distributions of time to onset of occult tumors. The test is derived as a partial likelihood score test under an assumed proportional hazards model for tumor onset distributions. The size and power of the proposed test are compared in a Monte Carlo simulation study to the size and power of competitive procedures, including procedures that do not require cause-of-death information.
C1 NATL CTR TOXICOL RES,DIV BIOMETRY & RISK ASSESSMENT,JEFFERSON,AR 72079.
NATL CTR TOXICOL RES,COMP BASED SYST INC,JEFFERSON,AR 72079.
NR 29
TC 12
Z9 12
U1 0
U2 0
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 0361-0926
J9 COMMUN STAT THEORY
JI Commun. Stat.-Theory Methods
PY 1994
VL 23
IS 4
BP 959
EP 980
DI 10.1080/03610929408831298
PG 22
WC Statistics & Probability
SC Mathematics
GA NA878
UT WOS:A1994NA87800001
ER
PT J
AU CHEN, JJ
MOORE, GE
AF CHEN, JJ
MOORE, GE
TI IMPACT OF SURVIVING TIME ON TESTS FOR CARCINOGENICITY
SO COMMUNICATIONS IN STATISTICS-THEORY AND METHODS
LA English
DT Article
DE LOGRANK TEST; HOEL-WALBURG TEST; PETO ONSET TEST
ID STATISTICAL-ANALYSIS; TUMOR; MORTALITY; MODELS
AB In tumorigenicity experiments, each animal begins in a tumor-free state and then either develops a tumor or dies before developing a tumor. Animals that develop a tumor either die from the tumor or from other competing causes. All surviving animals are sacrificed at the end of the experiment, normally two years. The two most commonly used statistical tests are the logrank test for comparing hazards of death from rapidly lethal tumors and the Hoel-Walburg test for comparing prevalences of nonlethal tumors. However, the data obtained from a carcinogenicity experiment generally contains a mixture of fatal and incidental tumors. Peto et al, (1980) suggested combining the fatal and incidental tests for a comparison of tumor onset distributions.
Extensive simulations show that the trend test for tumor onset using the Peto procedure has the proper size, under the simulation constraints, when each group has identical mortality patterns, and the test with continuity correction tends to be conservative. When the animals in the dosed groups have reduced survival rates, the type I error rate is likely to exceed the nominal level. The continuity correction is recommended for a small reduction in survival time among the dosed groups to ensure the proper size. However, when there is a large reduction in survival times in the dosed groups, the onset test does not have the proper size.
C1 NATL CTR TOXICOL RES,DIV BIOMETRY & RISK ASSESSMENT,JEFFERSON,AR 72079.
NATL CTR TOXICOL RES,COMP BASED SYST INC,JEFFERSON,AR 72079.
NR 13
TC 2
Z9 2
U1 0
U2 0
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 0361-0926
J9 COMMUN STAT THEORY
JI Commun. Stat.-Theory Methods
PY 1994
VL 23
IS 5
BP 1375
EP 1386
DI 10.1080/03610929408831328
PG 12
WC Statistics & Probability
SC Mathematics
GA NF539
UT WOS:A1994NF53900010
ER
PT J
AU HOLDER, CL
SLIKKER, W
THOMPSON, HC
AF HOLDER, CL
SLIKKER, W
THOMPSON, HC
TI COMPARISON OF THE METABOLISM AND ELIMINATION OF PYRILAMINE MALEATE IN
THE RAT, MOUSE AND FEMALE RHESUS-MONKEY
SO COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-PHARMACOLOGY TOXICOLOGY &
ENDOCRINOLOGY
LA English
DT Article
DE PYRILAMINE; N-DESMETHYL PYRILAMINE; GLUCURONIDE PRODUCTS; O-DEALKYLATED
PYRILAMINE
ID METHAPYRILENE HYDROCHLORIDE; ANTIHISTAMINES; THENYLDIAMINE
AB Elimination and metabolic profiles of the O-glucuronide conjugated products of pyrilamine and their nonconjugated O-dealkylated and N-desmethyl pyrilamine products were determined after the oral administration of (C-14)-pyrilamine maleate to Fischer 344 rats, B(6)C(3)F1 mice and female rhesus monkeys by stomach tube or i.v. The total cumulative urinary and fecal pyrilamine products were determined. The conjugated pyrilamine metabolites, isolated and identified were the glucuronide products of O-dealkylated pyrilamine and ring-hydroxylated pyrilamine, and the nonconjugated metabolites were predominately the N-desmethylpyrilamine and O-dealkylated pyrilamine and their ring-hydroxylated products. Statistically significant differences were observed in the percentages of the conjugated and nonconjugated metabolites of pyrilamine excreted by the three species studied.
C1 NATL CTR TOXICOL RES,DIV REPROD & DEV TOXICOL,JEFFERSON,AR 72079.
RP HOLDER, CL (reprint author), US FDA,NATL CTR TOXICOL RES,DIV CHEM,HFT 230,JEFFERSON,AR 72079, USA.
NR 15
TC 0
Z9 0
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0742-8413
J9 COMP BIOCHEM PHYS C
JI Comp. Biochem. Physiol. C-Pharmacol. Toxicol. Endocrinol.
PD JAN
PY 1994
VL 107
IS 1
BP 159
EP 164
DI 10.1016/1367-8280(94)90022-1
PG 6
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
Toxicology; Zoology
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
Toxicology; Zoology
GA NC175
UT WOS:A1994NC17500021
ER
PT J
AU SHANK, FR
CARSON, K
AF SHANK, FR
CARSON, K
TI THE REGULATORY ENVIRONMENT PAST AND FUTURE - INCENTIVE OR IMPEDIMENT TO
DEVELOPMENTS IN FOOD-SCIENCE AND TECHNOLOGY - A PERSPECTIVE FROM FDA
SO CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
LA English
DT Article
DE FDA; FOOD SAFETY; INNOVATION; TECHNOLOGICAL CHANGE; HARMONIZATION
AB The best system for protecting public health is one that involves two layers of control before food reaches the consumer. The first layer of control is the industry's clear responsibility to prepare food that is safe. The second layer of control is the monitoring that is provided by government to ensure that the industry is doing its job and is in fact producing safe food.
While some may view this ''second layer'' as an impediment in the development and marketing of new technologies, there is another way to look at the ''regulatory environment''. The regulatory environment itself, is not an impediment to the development of food science and technology.
The regulatory environment, with all its components - scientists, consumers, industry, and Congress - defines ''safety'' within the context of today's technology, scientific capability, and tolerance level of the lay public. The entire regulatory environment serves to guide the development of food science and technology by providing signposts, in the form of scientifically sound regulatory decisions. The scientific basis of these decisions becomes building blocks on which to rest further refinement of the technology, product, ingredient, or packaging material or on which research in related technologies or research in innovative directions can build.
This scientific groundwork becomes very important as more and more companies move away from having self-contained research laboratories toward using commercial laboratories and academic institutions, as well as participating in cooperative research endeavors to meet food safety and product development research needs. These changes in the way industry is doing business today clearly indicate a direction that will impact on the ''regulatory environment'' in the next few years - a direction that will include deeper commitment of private/public sector cooperation in generating the data and information that defines safety for any given technology or product. The shift to commercial labs and academic institutions is occurring at the same time the consumer continues to believe that food is ''safe'', novel technologies and products are entering die market at an ever increasing rate, the market is moving toward a more global food supply, and significant changes are taking place in the food safety/inspection infrastructure. To meet these challenges, the academic institutions will take on more importance. To the extent that food scientists from industry dissipate, other food scientists - particularly those in academic settings - must assume additional responsibilities. Further changes will come in the way we do business.
In the words of Robert McVicker, Kraft General Foods' Dr. VP of Technology, Quality Assurance and Scientific Relations, describing one public/private sector cooperative effort, the National Center for Food Safety and Technology, ''It is clear that in forming the National Center our key objective is the generation and fostering of scientific and technical knowledge and the exchange of this knowledge among the agency, industry, and academic partners. In working side by side, I believe we will learn that our goals are very similar and are, in fact, identical. Through partnerships and strategic alliances such as we are forging, we will continue to deliver safe and wholesome foods to American consumers.''
RP SHANK, FR (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,WASHINGTON,DC 20204, USA.
NR 0
TC 4
Z9 4
U1 0
U2 5
PU CRC PRESS INC
PI BOCA RATON
PA 2000 CORPORATE BLVD NW, JOURNALS CUSTOMER SERVICE, BOCA RATON, FL 33431
SN 1040-8398
J9 CRIT REV FOOD SCI
JI Crit. Rev. Food Sci. Nutr.
PY 1994
VL 34
IS 2
BP 207
EP 214
PG 8
WC Food Science & Technology; Nutrition & Dietetics
SC Food Science & Technology; Nutrition & Dietetics
GA NE745
UT WOS:A1994NE74500006
PM 8011145
ER
PT J
AU LEE, CJ
WANG, TR
AF LEE, CJ
WANG, TR
TI PNEUMOCOCCAL INFECTION AND IMMUNIZATION IN CHILDREN
SO CRITICAL REVIEWS IN MICROBIOLOGY
LA English
DT Review
DE PNEUMOCOCCAL INFECTION; IMMUNIZATION IN CHILDREN; IMMUNITY TO
POLYSACCHARIDE (PS); PS-PROTEIN CONJUGATE
ID CAPSULAR POLYSACCHARIDE VACCINE; CONTRASUPPRESSOR T-CELLS; GROUP-C
POLYSACCHARIDES; STREPTOCOCCUS-PNEUMONIAE; OTITIS-MEDIA;
ANTIBODY-RESPONSE; TYPE-19F POLYSACCHARIDE; CHARLESTON COUNTY;
IMMUNOGLOBULIN-G; SOUTH-CAROLINA
AB Pneumococcal infection persists as a major cause of pneumonia, bacteremia, and otitis media and is the important cause of meningitis in young children. Children less than 2 years of age show the highest incidence of pneumococcal diseases. Pneumococcal types 6A + 6B, 7F, 9V, 14, 18C, 19F + 19A, and 23F account for the large majority of disease isolates in the pediatric population.
Bacterial clearance and antibody response were studied in young mice from mothers injected with pneumococcal type 9V polysaccharide (PS) conjugated with the inactivated pneumolysin to examine the protective immunity of young mice to pneumococcal infection. The injection of mice with pneumococcal PS-protein conjugate conferred the protective immunity to pneumococcal infection. The efficacy of pneumococcal vaccine might be enhanced by addition of inactivated pneumolysin in the form of PS-protein conjugate. The molecular size of pneumococcal type 19F PS or oligosaccharide used for preparing the PS-protein conjugate has a profound effect on the antibody response to the PS. The conjugate immunogen prepared from a large molecule of 19F PS produced a high antibody response to the PS in young mice.
Development of a PS-protein conjugate vaccine for selected pneumococcal types will help in solving problems of poor immunogenicity of pneumococcal PS vaccine in young children.
RP LEE, CJ (reprint author), US FDA,CTR BIOL EVALUAT & RES,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.
NR 85
TC 28
Z9 31
U1 0
U2 2
PU CRC PRESS INC
PI BOCA RATON
PA 2000 CORPORATE BLVD NW, JOURNALS CUSTOMER SERVICE, BOCA RATON, FL 33431
SN 1040-841X
J9 CRIT REV MICROBIOL
JI Crit. Rev. Microbiol.
PY 1994
VL 20
IS 1
BP 1
EP 12
DI 10.3109/10408419409113544
PG 12
WC Microbiology
SC Microbiology
GA MX766
UT WOS:A1994MX76600001
PM 8185832
ER
PT J
AU POLOTSKY, Y
DRAGUNSKY, E
KHAVKIN, T
AF POLOTSKY, Y
DRAGUNSKY, E
KHAVKIN, T
TI MORPHOLOGIC EVALUATION OF THE PATHOGENESIS OF BACTERIAL ENTERIC
INFECTIONS
SO CRITICAL REVIEWS IN MICROBIOLOGY
LA English
DT Review
DE ESCHERICHIA COLI; SALMONELLA; SHIGELLA; VIBRIO CHOLERAE; YERSINIA;
PATHOGENESIS OF INFECTIONS
ID ENTEROPATHOGENIC ESCHERICHIA-COLI; INTESTINAL EPITHELIAL-CELLS;
SHIGELLA-DYSENTERIAE 1; PERIPHERAL-BLOOD LYMPHOCYTES; VASCULAR
ENDOTHELIAL-CELLS; INVASION PLASMID ANTIGENS; HEMOLYTIC-UREMIC SYNDROME;
ORAL CHOLERA VACCINATION; TYPHI GIFU 10007; SHIGA-LIKE TOXIN
AB Current advances in the understanding of the pathogenicity of the agents of diarrheal infections, Vibrio cholerae, diarrheagenic E. coli, Shigella, Salmonella, and enteropathogenic Yersinia, have, to a great extent, become possible due to morphological studies of host-pathogen interactions in natural and experimental infections. Despite a multigenic nature and a diversity of pathogenic features in the bacterial species and even in serogroups of the same species, it is now possible to delineate four major patterns of interaction of enteric pathogens with their cellular targets, the enterocytes, and with the immune apparatus of the gut. These patterns, epicellular cytotonic, epicellular restructuring cytotonic, invasive intraepithelial cytotonic and cytotoxic, and invasive transcellular cytotonic and cytotoxic bacteremic, underlie early pathogenesis and clinical manifestations in the respective diarrheal diseases. In this review, the results of the morphological analyses of these patterns over the last 3 decades as well as some methodological problems encountered in the interpretation of morphological observations are discussed.
C1 INTERFERON SCI INC,NEW BRUNSWICK,NJ 08901.
WALTER REED ARMY INST RES,DIV PATHOL,WASHINGTON,DC.
US FDA,BETHESDA,MD 20592.
NR 411
TC 14
Z9 14
U1 2
U2 3
PU CRC PRESS INC
PI BOCA RATON
PA 2000 CORPORATE BLVD NW, JOURNALS CUSTOMER SERVICE, BOCA RATON, FL 33431
SN 1040-841X
J9 CRIT REV MICROBIOL
JI Crit. Rev. Microbiol.
PY 1994
VL 20
IS 3
BP 161
EP 208
DI 10.3109/10408419409114553
PG 48
WC Microbiology
SC Microbiology
GA PF256
UT WOS:A1994PF25600001
PM 7802956
ER
PT J
AU TOURNAS, V
AF TOURNAS, V
TI HEAT-RESISTANT FUNGI OF IMPORTANCE TO THE FOOD AND BEVERAGE INDUSTRY
SO CRITICAL REVIEWS IN MICROBIOLOGY
LA English
DT Review
DE HEAT-RESISTANT FUNGI; ISOLATION; IDENTIFICATION; CANNED FRUIT SPOILAGE;
HEAT DESTRUCTION; GROWTH INHIBITION; TOXIC METABOLITES
ID NEOSARTORYA-FISCHERI ASCOSPORES; TALAROMYCES-FLAVUS; BYSSOCHLAMYS-FULVA;
TEMPERATURE; PATULIN; ASPERGILLUS; GROWTH; MOLDS; JUICE; NIVEA
AB Spoilage of pasteurized and canned fruit and fruit products caused by heat-resistant molds have been reported repeatedly in recent years. Species most commonly implicated in fruit and fruit product disintegration are Byssochlamys fulva, Byssochlamys nivea, Neosartorya fischeri, Talaromyces flavus, and Eupenicillium brefeldianum. These organisms are saprophytic rather than parasitic and usually contaminate fruits on or near the ground. They can survive heat treatments used for fruit processing and can grow and spoil the products during storage at room temperature, which results in great economic losses. Mold heat resistance is attributed to the formation of sexual spores, ascospores. Ascospores have a wide range of heat resistance, depending on species, strain, age of organism, heating medium, pH, presence of sugars, fats, and acids in heating medium, growth conditions, etc. The mechanism(s) of thermoresistance are not clear; probably some very stable compound(s) critical to germination and outgrowth are present in the heat-resistant ascospores. Besides spoilage, the heat-resistant molds produce a number of toxic secondary metabolites, such as byssotoxin A; byssochlamic acid; the carcinogen, patulin, the tremorgenic substances, fumitremorgin A and C, and verruculogen; fischerin, which caused fatal peritonitis in mice; and eupenifeldin, a compound possessing cytotoxicity as well as in vivo antitumor activity. Growth of heat-resistant fungi can be controlled by lowering the water activity, adding sulfur dioxide, sorbate, or benzoate; washing of fruits in hypochlorite solution before heat treatment reduces the number of ascospores and makes the heat destruction more successful. More research is needed to elucidate the mechanism(s) of thermoresistance and develop new methods for the complete inactivation of resistant ascospores.
C1 US FDA,WASHINGTON,DC 20204.
NR 115
TC 84
Z9 93
U1 5
U2 46
PU CRC PRESS INC
PI BOCA RATON
PA 2000 CORPORATE BLVD NW, JOURNALS CUSTOMER SERVICE, BOCA RATON, FL 33431
SN 1040-841X
J9 CRIT REV MICROBIOL
JI Crit. Rev. Microbiol.
PY 1994
VL 20
IS 4
BP 243
EP 263
DI 10.3109/10408419409113558
PG 21
WC Microbiology
SC Microbiology
GA PV140
UT WOS:A1994PV14000001
PM 7857517
ER
PT J
AU SANDBERG, JA
ECKHOFF, C
NAU, H
SLIKKER, W
AF SANDBERG, JA
ECKHOFF, C
NAU, H
SLIKKER, W
TI PHARMACOKINETICS OF 13-CIS-, ALL-TRANS-, 13-CIS-4-OXO-, AND
ALL-TRANS-4-OXO RETINOIC ACID AFTER INTRAVENOUS ADMINISTRATION IN THE
CYNOMOLGUS MONKEY
SO DRUG METABOLISM AND DISPOSITION
LA English
DT Article
ID 13-CIS-RETINOIC ACID; 4-OXO-13-CIS-RETINOIC ACID; PLASMA-LEVELS;
VITAMIN-A; ISOTRETINOIN; MICE; TERATOGENICITY; DISPOSITION;
IDENTIFICATION; METABOLISM
AB The intravenous pharmacokinetics of 13-cis-, all trans-, 13-cis-4-oxo, and all-trans-4-oxo retinoic acid (RA) were determined in nonpregnant female cynomolgus monkeys. All-trans- and 13-cis-RA were injected at two doses (0.25 or 0.0125 mg/kg) end all-trans-4-oxo RA and 13-cis-4-oxo RA at 0.25 mg/kg. Total body clearance, volume of distribution, and volume of distribution at steady state of all-trans-RA were dose-dependent with greater values at the lower dose. Elimination half life was longer for the cis-compounds and not dose-dependent (N = 1 for 13-cis-4-oxo RA, N = 3 for other compounds, harmonic mean +/- pseudostandard deviation, min): 13-cis-4-oxo RA (837) greater than or equal to 13-cis-RA (301 +/- 204). all-trans-PA (38 e 3), all-trans-4- oxo RA (11 +/- 2). Secondary plasma peaks were noted only after administration of 13-cis-4-oxo RA. The low area under the time concentration curves for observable metabolites after intravenous injection of the oxidated compounds suggests further metabolism plays a minimal role in the elimination of these compounds from the monkey. Plasma-time concentration curves were fitted to multicompartmental models and suggested <30% of each compound was available in the central compartment for elimination in the postdistribution phase. A comparison of the kinetics of the isomers indicated oxidation of all-trans-RA to all-trans-4-oxo RA increased mean total body clearance values 4-fold. Elimination half-life was longer and volume of distribution was greater for 13-cis-RA compared with all trans-RA in the cynomolgus monkey. The similarity of RA pharmacokinetics and teratogenic susceptibility in the human, monkey, and hamster may be related to similarities in volume distribution and biotransformation.
C1 US FDA,NATL CTR TOXICOL RES,DIV NEUROTOXICOL,JEFFERSON,AR 72079.
FREE UNIV BERLIN,INST TOXICOL & EMBRYOPHARMACOL,W-1000 BERLIN,GERMANY.
NR 34
TC 18
Z9 18
U1 0
U2 0
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0090-9556
J9 DRUG METAB DISPOS
JI Drug Metab. Dispos.
PD JAN-FEB
PY 1994
VL 22
IS 1
BP 154
EP 160
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NA670
UT WOS:A1994NA67000026
PM 8149876
ER
PT J
AU KADLUBAR, FF
AF KADLUBAR, FF
TI BIOCHEMICAL INDIVIDUALITY AND ITS IMPLICATIONS FOR DRUG AND CARCINOGEN
METABOLISM - RECENT INSIGHTS FROM ACETYLTRANSFERASE AND CYTOCHROME
P4501A2 PHENOTYPING AND GENOTYPING IN HUMANS
SO DRUG METABOLISM REVIEWS
LA English
DT Article; Proceedings Paper
CT Arkansas Toxicology Symposium, Honoring the Research Contributions of Dr
Elizabeth C Miller and Dr James A Miller
CY DEC 10-11, 1992
CL LITTLE ROCK, AR
SP IMOV ARKANSAS MED SCI, DEPT PHARM & TOXICOL, DIV TOXICOL
ID ARYLAMINE N-ACETYLTRANSFERASE; URINARY-BLADDER; AROMATIC-AMINES;
HUMAN-LIVER; O-ACETYLATION; DNA; ACTIVATION; OXIDATION; CAFFEINE; COLON
RP KADLUBAR, FF (reprint author), NATL CTR TOXICOL RES,OFF RES HFT100,JEFFERSON,AR 72079, USA.
NR 38
TC 76
Z9 77
U1 0
U2 0
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 0360-2532
J9 DRUG METAB REV
JI Drug Metab. Rev.
PY 1994
VL 26
IS 1-2
BP 37
EP 46
DI 10.3109/03602539409029783
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NK834
UT WOS:A1994NK83400003
PM 8082575
ER
PT J
AU POIRIER, LA
AF POIRIER, LA
TI METHYL-GROUP DEFICIENCY IN HEPATOCARCINOGENESIS
SO DRUG METABOLISM REVIEWS
LA English
DT Article; Proceedings Paper
CT Arkansas Toxicology Symposium, Honoring the Research Contributions of Dr
Elizabeth C Miller and Dr James A Miller
CY DEC 10-11, 1992
CL LITTLE ROCK, AR
SP IMOV ARKANSAS MED SCI, DEPT PHARM & TOXICOL, DIV TOXICOL
ID ADENOSYL-L-METHIONINE; CHOLINE-DEVOID DIET; ACID-DEFINED DIETS;
RAT-LIVER CARCINOGENESIS; HEPATOCYTE-LIKE CELLS; S-ADENOSYLMETHIONINE;
DNA METHYLATION; FOLATE-DEFICIENCY; TUMOR PROMOTION; GROUP METABOLISM
RP POIRIER, LA (reprint author), NATL CTR TOXICOL RES,DIV NUTR TOXICOL,HFT-140,JEFFERSON,AR 72079, USA.
NR 96
TC 60
Z9 62
U1 0
U2 1
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 0360-2532
J9 DRUG METAB REV
JI Drug Metab. Rev.
PY 1994
VL 26
IS 1-2
BP 185
EP 199
DI 10.3109/03602539409029790
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NK834
UT WOS:A1994NK83400010
PM 8082564
ER
PT B
AU MILIOTIS, MD
TALL, BD
GRAY, RT
AF MILIOTIS, MD
TALL, BD
GRAY, RT
BE Jouffrey, B
Colliex, C
TI Invasion of HeLa cells by Vibrio hollisae
SO ELECTRON MICROSCOPY 1994, VOLS 3A AND 3B: APPLICATIONS IN BIOLOGICAL
SCIENCES
LA English
DT Proceedings Paper
CT 13th International Congress on Electron Microscopy
CY JUL 17-22, 1994
CL PARIS, FRANCE
SP Int Federat Soc Electron Microscopy, Minist Enseignement Super & Recher, Acad Sci, Minist Affaires Etrangeres, European Union, CNRS, INSERM, CEA
C1 US FDA,DIV VIRULENCE ASSESSMENT,WASHINGTON,DC 20204.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU EDITIONS PHYSIQUE
PI LES ULIS
PA AVENUE DU HOGGAR, ZONE INDUSTRIELLE COURTABOEUF, BP112 91944 LES ULIS,
FRANCE
BN 2-86883-228-8
PY 1994
BP 1329
EP 1330
PG 2
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA BE09Z
UT WOS:A1994BE09Z00628
ER
PT B
AU HANES, DE
GRAY, RT
TALL, BD
AF HANES, DE
GRAY, RT
TALL, BD
BE Jouffrey, B
Colliex, C
TI Salmonella enteritidis adherence to and invasion of tissue culture cells
SO ELECTRON MICROSCOPY 1994, VOLS 3A AND 3B: APPLICATIONS IN BIOLOGICAL
SCIENCES
LA English
DT Proceedings Paper
CT 13th International Congress on Electron Microscopy
CY JUL 17-22, 1994
CL PARIS, FRANCE
SP Int Federat Soc Electron Microscopy, Minist Enseignement Super & Recher, Acad Sci, Minist Affaires Etrangeres, European Union, CNRS, INSERM, CEA
C1 US FDA,DIV VIRULENCE ASSESSMENT,WASHINGTON,DC 20204.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU EDITIONS PHYSIQUE
PI LES ULIS
PA AVENUE DU HOGGAR, ZONE INDUSTRIELLE COURTABOEUF, BP112 91944 LES ULIS,
FRANCE
BN 2-86883-228-8
PY 1994
BP 1331
EP 1332
PG 2
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA BE09Z
UT WOS:A1994BE09Z00629
ER
PT J
AU KRAGIE, L
AF KRAGIE, L
TI MEMBRANE IODOTHYRONINE TRANSPORTERS .1. REVIEW OF PHYSIOLOGY
SO ENDOCRINE RESEARCH
LA English
DT Review
ID RAT-LIVER CELLS; THYROID-HORMONE TRANSPORT; CARRIER-MEDIATED TRANSPORT;
AMINO-ACID-TRANSPORT; L-TRI-IODOTHYRONINE; CEREBRAL-CORTEX;
TRIIODOTHYRONINE TRANSPORT; ACTIVE-TRANSPORT; CELLULAR UPTAKE;
CHOROID-PLEXUS
RP KRAGIE, L (reprint author), US FDA,CDER,DIV CARDIORENAL DRUG PROD,ROCKVILLE,MD 20852, USA.
NR 100
TC 25
Z9 25
U1 0
U2 0
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 0743-5800
J9 ENDOCR RES
JI Endocr. Res.
PY 1994
VL 20
IS 4
BP 319
EP 341
PG 23
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA PX526
UT WOS:A1994PX52600001
PM 7882896
ER
PT J
AU SOTOMAYOR, RE
SEGA, GA
KADLUBAR, F
AF SOTOMAYOR, RE
SEGA, GA
KADLUBAR, F
TI INDUCTION OF DNA-DAMAGE BY URETHANE IN MOUSE TESTES - DNA-BINDING AND
UNSCHEDULED DNA-SYNTHESIS
SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS
LA English
DT Article
DE DNA ALKYLATION; DNA REPAIR; SPERMATOGENESIS
ID ETHYL CARBAMATE URETHANE; GERM-CELLS; MALE-MICE; METHANESULFONATE;
MUTAGENICITY; METABOLISM; BEVERAGES; PROTAMINE; ADDUCTS; FOODS
AB The extent and persistence of DNA damage and repair were investigated in mouse spermatogenic cells exposed in vivo to urethane (ethyl carbamate, EC). Adult male mice exposed to [H-3]EC at 10-1,000 mg/kg were sacrificed 12 hr later. EC/metabolite binding to liver and testicular DNA and to sperm heads from the vasa deferentia was measured. Other male mice were exposed to EC at 50-750 mg/kg, and unscheduled DNA synthesis (UDS) induction was investigated in early spermatid stages. Similar experiments were conducted with vinyl carbamate (VC; putative EC metabolite) at 10-75 mg/kg. [H-3]EC bound to liver and testicular DNA and to whole sperm heads. Testicular DNA binding increased linearly with dose, although binding was at least 2 orders of magnitude lower than with liver DNA. Sperm head binding also increased linearly with dose. Dose response studies with the UDS assay showed that EC and VC induced a small but significant increase of the UDS response in early spermatid stages. However, the induced UDS responses were quite variable and did not consistently increase with the administered dose. To determine the time kinetics of UDS induction, [H-3]dThd was injected at various times after treatment with 500 mg/kg of EC or 60 mg/kg of VC. A slight but significant UDS increase was observed 4 hr after treatment with EC but not with VC. Overall, these results suggest that EC metabolites bind to testis DNA and cause low-level DNA damage in mouse spermatogenic cells. This type of DNA damage apparently does not have significant genetic consequences. (C) 1994 Wiley-Liss, Inc.*
C1 OAK RIDGE NATL LAB,OAK RIDGE,TN.
US FDA,NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
RP SOTOMAYOR, RE (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,MOD-1,8301 MUIRKIRK RD,LAUREL,MD 20708, USA.
NR 33
TC 5
Z9 5
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0893-6692
J9 ENVIRON MOL MUTAGEN
JI Environ. Mol. Mutagen.
PY 1994
VL 24
IS 1
BP 68
EP 74
DI 10.1002/em.2850240109
PG 7
WC Environmental Sciences; Genetics & Heredity; Toxicology
SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology
GA NZ310
UT WOS:A1994NZ31000008
PM 8050418
ER
PT J
AU HARTMAN, Z
HENRIKSON, EN
HARTMAN, PE
CEBULA, TA
AF HARTMAN, Z
HENRIKSON, EN
HARTMAN, PE
CEBULA, TA
TI MOLECULAR-MODELS THAT MAY ACCOUNT FOR NITROUS-ACID MUTAGENESIS IN
ORGANISMS CONTAINING DOUBLE-STRANDED DNA
SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS
LA English
DT Article
DE ALKYLATION; ALLELE-SPECIFIC OLIGONUCLEOTIDES; BACTERIA; CROSS-LINKED
BASES; DEAMINATION; DUPLEX DNA; MUTATIONAL SPECTRA; NUCLEOTIDE EXCISION
REPAIR; PCR; URACIL-DNA GLYCOSYLASE
ID NUCLEOTIDE EXCISION REPAIR; ESCHERICHIA-COLI; STREPTOCOCCUS-PNEUMONIAE;
SALMONELLA-TYPHIMURIUM; CYTOSINE RESIDUES; TARGET SEQUENCES;
NITRIC-OXIDE; GLYCOSYLASE; MUTATIONS; HYPOXANTHINE
AB Nitrous acid (NA) is often presumed to cause base substitutions in organisms with double-stranded DNA as a direct consequence of oxidative deamination of adenine and of cytosine residues. Here we summarize evidence indicating that other mechanisms are involved in the ca se of NA-induced G/C --> A/T transition mutations. We present several models for pathways of NA mutagenesis that may account for our experimental results and overlapping data noted in the literature. One model proposes that the base substitution mutations observed are due to DNA alkylation damage mediated via nitrosation of polyamines and/or other ubiquitous cellular molecules. Other models assume that pre-disposing lesions, such as G-to-G cross-links, ore first formed. The cross-links are pictured as leading to perturbations in DNA structure that allow subsequent opportunity for NA-induced deaminations of cytosine residues in their immediate vicinity. The deaminations preferentially result in G/C-->A/T transition mutations at sites highly dependent on adjoining base sequence context (i.e., in NA ''mutational hotspots''). A final model proposes that NA-induced G/C-->A/T transition mutations arise mainly from oxidative deamination of guanosine residues and not from deamination of cytosine residues in duplex DNA. (C) 1994 Wiley-Liss, Inc.
C1 US FDA,CTR FOOD SAFETY & APPL NUTR,MOLEC BIOL BRANCH,WASHINGTON,DC 20204.
RP HARTMAN, Z (reprint author), JOHNS HOPKINS UNIV,DEPT BIOL,144 MUDD HALL,BALTIMORE,MD 21218, USA.
NR 59
TC 19
Z9 19
U1 0
U2 2
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0893-6692
J9 ENVIRON MOL MUTAGEN
JI Environ. Mol. Mutagen.
PY 1994
VL 24
IS 3
BP 168
EP 175
DI 10.1002/em.2850240305
PG 8
WC Environmental Sciences; Genetics & Heredity; Toxicology
SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology
GA QF993
UT WOS:A1994QF99300004
PM 7957120
ER
PT J
AU AIDOO, A
LYNCOOK, LE
LENSING, S
WAMER, W
AF AIDOO, A
LYNCOOK, LE
LENSING, S
WAMER, W
TI ASCORBIC-ACID (VITAMIN-C) MODULATES THE MUTAGENIC EFFECTS PRODUCED BY AN
ALKYLATING AGENT IN-VIVO
SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS
LA English
DT Article
DE ASCORBIC ACID; ANTIMUTAGENICITY; N-ETHYL-N-NITROSOUREA; SPLEEN AND
THYMUS LYMPHOCYTES
ID ETHYL-N-NITROSOUREA; BETA-CAROTENE; CHROMOSOMAL-ABERRATIONS;
SALMONELLA-TYPHIMURIUM; CELL-PROLIFERATION; FISCHER-344 RATS; COVALENT
BINDING; BONE-MARROW; LYMPHOCYTES; INHIBITION
AB Recent reports suggest that ascorbic acid (vitamin C) inhibits tumorigenesis as well as exerts a protective effect against mutagenesis in vitro; however, there is no information on its ability to affect gene mutations induced in vivo. In this study, we have investigated the antimutagenic effects of ascorbic acid on the frequency of 6-thioguanine-resistant (6-TG(r)) T-lymphocytes produced in Fischer 344 rats dosed with the direct-acting alkylating agent, N-ethyl-N-nitrosourea (ENU). The frequency of 6-TG(r) T-lymphocytes from the spleen measured five weeks after ENU treatment indicated that ENU produced a substantial mutagenic response. Pretreatment and/or post-treatment of mts with ascorbic acid administered in the drinking water appeared to inhibit the response, but the inhibition was statistically significant only when data from the various dosing schedules were pooled. In addition, there was no clear dose-dependency to the inhibitory effect of ascorbic acid. To further evaluate the time effects of the vitamin supplement on ENU mutagenicity, rats were exposed to the mutagen together with ascorbic acid, which was given continuously for the entire duration of the experiment. At specific times after ENU treatment, the frequency of 6-TG(r) T-cells was determined in lymphocytes isolated from the spleen and the thymus. Time-dependent increases in the frequency of 6-TG(r) T-cells were observed with ENU treatment; ascorbic acid significantly reduced the ENU-mediated mutagenic responses, most dramatically in the spleen at weeks 6 and 8 (P < 0.0001), and to a lesser extent in the thymus (P < 0.01 at week 6 and P < 0.006 at week 8). Our data suggest that ascorbic acid intake affects the in vivo mutagenicity of ENU, a direct-acting mutagen/carcinogen, and that the reported inhibitory effects of the antioxidant on carcinogenesis may be partially mediated by its effects on mutagenesis. Although it is difficult to extrapolate from rodent studies to humans, the results presented suggest an explanation for epidemiological data that link vitamin C ingestion with decreased cancer risk. (C) 1994 Wiley-Liss, Inc.*
C1 COMP BASED SYST INC,JEFFERSON,AR.
US FDA,CTR FOOD & NUTR SAFETY,WASHINGTON,DC 20204.
RP AIDOO, A (reprint author), US FDA,NATL CTR TOXICOL RES,DEPT HLTH & HUMAN SERV,DIV GENET TOXICOL,HTF 120,3900 NCTR RD,JEFFERSON,AR 72079, USA.
NR 51
TC 33
Z9 34
U1 0
U2 1
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0893-6692
J9 ENVIRON MOL MUTAGEN
JI Environ. Mol. Mutagen.
PY 1994
VL 24
IS 3
BP 220
EP 228
DI 10.1002/em.2850240311
PG 9
WC Environmental Sciences; Genetics & Heredity; Toxicology
SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology
GA QF993
UT WOS:A1994QF99300010
PM 7957125
ER
PT J
AU ELESPURU, R
ONEILL, P
AF ELESPURU, R
ONEILL, P
TI IN COMMEMORATION OF THE 25TH ANNIVERSARY OF THE
ENVIRONMENTAL-MUTAGEN-SOCIETY
SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS
LA English
DT Editorial Material
C1 UNIV VERMONT,BURLINGTON,VT 05405.
RP ELESPURU, R (reprint author), US FDA,WASHINGTON,DC 20204, USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0893-6692
J9 ENVIRON MOL MUTAGEN
JI Environ. Mol. Mutagen.
PY 1994
VL 23
SU 24
BP 1
EP 1
DI 10.1002/em.2850230602
PG 1
WC Environmental Sciences; Genetics & Heredity; Toxicology
SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology
GA NJ844
UT WOS:A1994NJ84400001
ER
PT J
AU KUPCHELLA, E
KOCH, WH
CEBULA, TA
AF KUPCHELLA, E
KOCH, WH
CEBULA, TA
TI MUTANT ALLELES OF TRANSFER RNA(THR) GENES SUPPRESS THE HISG46 MISSENSE
MUTATION IN SALMONELLA-TYPHIMURIUM
SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS
LA English
DT Article
DE SUPPRESSOR MUTATIONS; MISSENSE SUPPRESSION; THREONINE TRANSFER RNA;
THRT; THRV; SALMONELLA-TYPHIMURIUM; HIS-G46; ALLELE-SPECIFIC COLONY
HYBRIDIZATION
ID OLIGODEOXYRIBONUCLEOTIDE COLONY HYBRIDIZATION; TRANSFER RNA-SYNTHETASE;
THREONINE TRANSFER-RNA; ESCHERICHIA-COLI; FRAMESHIFT MUTATIONS;
NUCLEOTIDE-SEQUENCE; MUTAGENICITY TEST; TARGET SEQUENCES; HISTIDINE
OPERON; MESSENGER-RNA
AB Extragenic suppressors of the hisG46 missense mutation were mapped to the 71 and 88 min regions of the Salmonella typhimurium chromosome, positions that in Escherichia coli contain the thrV (tRNA(Thr1)) and thrT (tRNA(Thr3)) genes, respectively. The suppressor loci were identified as mutant alleles of thrV and thrT, using allele-specific colony hybridization. An oligomer, based on the conserved 5' sequence of the thrT and thrV genes in E. coli and designed to contain the putative mutant anticodon, discriminated between suppressor-containing and wild-type strains. Similarly, probes specific for the thrV[SuGGG] and thrT[SuGGG] were used to differentiate the two suppressors. To date, all extragenic suppressors of hisG46 have been identified as either thrV[SuGGG] or thrT[SuGGG]. A near equal distribution of thrV[SuGGG] and thrT[SuGGG] suppressors was found among 29 spontaneous and 43 mutagen-induced hisG46 extragenic suppressor revertants. It was concluded, therefore, that mutant alleles of thrV and thrT are predominantly, if not solely, responsible for intergenic suppression of the hisG46 mutation. (C) 1994 Wiley-Liss, Inc.
C1 US FDA,CTR FOOD SAFETY & APPL NUTR,DIV MOLEC BIOL RES & EVALUAT,WASHINGTON,DC 20204.
NR 44
TC 35
Z9 35
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0893-6692
J9 ENVIRON MOL MUTAGEN
JI Environ. Mol. Mutagen.
PY 1994
VL 23
IS 2
BP 81
EP 88
DI 10.1002/em.2850230202
PG 8
WC Environmental Sciences; Genetics & Heredity; Toxicology
SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology
GA NB788
UT WOS:A1994NB78800001
PM 8143705
ER
PT J
AU SAHU, SC
AF SAHU, SC
TI DUAL ROLE OF FLAVONOIDS IN MUTAGENESIS AND CARCINOGENESIS
SO ENVIRONMENTAL CARCINOGENESIS & ECOTOXICOLOGY REVIEWS-PART C OF JOURNAL
OF ENVIRONMENTAL SCIENCE AND HEALTH
LA English
DT Review
ID EPIDERMAL ORNITHINE DECARBOXYLASE; SISTER-CHROMATID EXCHANGES;
SQUAMOUS-CELL CARCINOMA; OXYGEN FREE-RADICALS; NUCLEAR-DNA DAMAGE; TUMOR
PROMOTION; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; CULTURED-CELLS;
LIPOXYGENASE INHIBITION
RP SAHU, SC (reprint author), US FDA,DIV TOXICOL RES,LAUREL,MD, USA.
NR 108
TC 8
Z9 8
U1 0
U2 0
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 1059-0501
J9 ENVIRON CARCIN ECO R
JI Environ. Carcinog. Ecotoxical. Rev.-Pt. C J. Env. Sci. Health
PY 1994
VL 12
IS 1
BP 1
EP 21
PG 21
WC Oncology; Environmental Sciences; Toxicology
SC Oncology; Environmental Sciences & Ecology; Toxicology
GA NR368
UT WOS:A1994NR36800001
ER
PT B
AU GAYLOR, DW
AF GAYLOR, DW
BE Cothern, CR
Ross, NP
TI STATISTICAL ISSUES FOR DEVELOPMENT TOXICITY DATA
SO ENVIRONMENTAL STATISTICS, ASSESSMENT, AND FORECASTING
LA English
DT Proceedings Paper
CT Symposium on Environmental Statistics, Assessment, and Forecasting, at
the National Meeting of the American-Chemical-Society
CY AUG 26, 1992
CL WASHINGTON, DC
SP AMER CHEM SOC, ENVIRONMENTAL DIV
C1 US FDA,NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LEWIS PUBLISHERS INC
PI BOCA RATON
PA 2000 CORPORATE BLVD NW, BOCA RATON, FL 33431
BN 0-87371-936-0
PY 1994
BP 181
EP 191
PG 11
WC Environmental Sciences; Statistics & Probability
SC Environmental Sciences & Ecology; Mathematics
GA BA62A
UT WOS:A1994BA62A00010
ER
PT J
AU SETH, A
PALLI, D
MARIANO, JM
METCALF, R
VENANZONI, MC
BIANCHI, S
KOTTARIDIS, SD
PAPAS, TS
AF SETH, A
PALLI, D
MARIANO, JM
METCALF, R
VENANZONI, MC
BIANCHI, S
KOTTARIDIS, SD
PAPAS, TS
TI P53 GENE-MUTATIONS IN WOMEN WITH BREAST-CANCER AND A PREVIOUS HISTORY OF
BENIGN BREAST DISEASE
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE BREAST CANCER; BENIGN BREAST DISEASE; P53 TUMOR SUPPRESSOR GENE;
MUTATIONS
ID MEDICAL PROGRESS; CARCINOMAS
AB Mutations of the p53 tumour suppressor gene are the most common genetic lesions in human cancers and have been reported in breast cancer as part of the Li-Fraumeni syndrome. In the present study, we determined frequencies and types of the p53 mutations in breast cancer tissues in women with a history of benign breast disease (BBD) identified in Florence, Italy, with (n = 6) or without (n = 10) a family history of breast cancer. Among the cases with a family history of breast cancer and BBD, 2 out of 6 had p53 gene mutations in cancer samples. 1 patient had a mutation at codon 248 and the other had double mutations at codons 243 and 241. In these cases, the p53 gene was also analysed in the tissue samples from previous BBD lesions; however, no mutations were observed (0 out of 6). These results suggest that the p53 mutations occur during advanced stages of tumour progression. In sporadic breast cancer cases with a history of BBD, p53 point mutations were observed in four samples (4 out of 10). Two of these mutations turned out to be silent changes and one of the samples showed triple mutations at amino acid positions 267, 277 and 296. No p53 gene mutations were found in the breast tumour tissues of 10 additional women from the same area with a family history of breast cancer, but no previous BBD (0 out of 10). Family history of breast cancer does not appear to affect the frequency of p53 mutations in women with a previous history of BBD.
C1 CSPO,EPIDEMIOL UNIT,FLORENCE,ITALY.
US FDA,CTR BIOL EVALUAT & RES,MOLEC MED GENET LAB,BETHESDA,MD 20892.
UNIV FLORENCE,DEPT PATHOL,FLORENCE,ITALY.
PAPANIKOLAOU RES CTR ONCOL & EXPTL SURG,HELLENIC ANTICANC INST,ATHENS,GREECE.
RP SETH, A (reprint author), NCI,MOLEC ONCOL LAB,POB B,FREDERICK,MD 21702, USA.
OI PALLI, Domenico/0000-0002-5558-2437
NR 24
TC 9
Z9 10
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0959-8049
J9 EUR J CANCER
JI Eur. J. Cancer
PY 1994
VL 30A
IS 6
BP 808
EP 812
DI 10.1016/0959-8049(94)90297-6
PG 5
WC Oncology
SC Oncology
GA NW063
UT WOS:A1994NW06300017
PM 7917542
ER
PT J
AU BADAWI, AF
COOPER, DP
MOSTAFA, MH
ABOULAZM, T
BARNARD, R
MARGISON, GP
OCONNOR, PJ
AF BADAWI, AF
COOPER, DP
MOSTAFA, MH
ABOULAZM, T
BARNARD, R
MARGISON, GP
OCONNOR, PJ
TI O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE ACTIVITY IN
SCHISTOSOMIASIS-ASSOCIATED HUMAN BLADDER-CANCER
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
ID PROMUTAGENIC METHYLATION DAMAGE; UPPER GASTROINTESTINAL-TRACT;
CELL-SPECIFIC METHYLATION; DNA; REPAIR;
N-METHYL-N'-NITRO-N-NITROSOGUANIDINE; AGENTS; METHYLTRANSFERASE;
O-6-METHYLGUANINE; EXTRACTS
AB O-6-Alkylguanine-DNA-alkyltransferase (ATase) activity was measured in extracts of 55 bladder tissue samples (46 tumour and nine uninvolved mucosal tissue) from Egyptian patients with schistosome-associated bladder carcinoma. Activity varied from 2.0 to 16.2 fmole ATase/mu g DNA (mean +/- S.D.; 5.6 +/- 4.0) or from 28 to 351 fmole ATase/mg protein (117 +/- 71). ATase levels in schistosome-associated bladder cancer tissues (5.6 +/- 4.0 fmole ATase/mu g DNA) tended to be lower than those observed in normal human bladder mucosal tissue (8.5 +/- 4.4 fmole ATase/mu g DNA). In a previous study (Badawi et al., Carcinogenesis, 1992, 13, 877-881) DNA-alkylation damage (O-6-methyldeoxyguanosine) was found in 44/46 of these schistomosome-associated bladder cancer samples at levels ranging from 0.012 to 0.485 mu mole O-6-MedG/mole deoxyguanosine. We now report an inverse correlation between the levels of methylation damage and ATase activity (r = - 0.67; P < 0.001). These observations encourage further investigations of the possible role of environmental alkylating agents in the aetiology of early bladder cancer associated with schistosomiasis.
C1 CHRISTIE HOSP NATL HLTH SERV TRUST,PATERSON INST CANC RES,DEPT CARCINOGENESIS,CANC RES CAMPAIGN,MANCHESTER M20 9BX,LANCS,ENGLAND.
INST GRAD STUDIES RES,ALEXANDRIA,EGYPT.
UNIV ALEXANDRIA,FAC MED,ALEXANDRIA,EGYPT.
NATL CTR TOXICOL RES,JEFFERSON,AR.
WITHINGTON HOSP,DEPT UROL,MANCHESTER M20 8LR,LANCS,ENGLAND.
NR 31
TC 25
Z9 25
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0959-8049
J9 EUR J CANCER
JI Eur. J. Cancer
PY 1994
VL 30A
IS 9
BP 1314
EP 1319
DI 10.1016/0959-8049(94)90180-5
PG 6
WC Oncology
SC Oncology
GA PM859
UT WOS:A1994PM85900023
PM 7999420
ER
PT J
AU KLINMAN, DM
SHIRAI, A
CONOVER, J
STEINBERG, AD
AF KLINMAN, DM
SHIRAI, A
CONOVER, J
STEINBERG, AD
TI CROSS-REACTIVITY OF IGG ANTI-DNA-SECRETING B-CELLS IN PATIENTS WITH
SYSTEMIC LUPUS-ERYTHEMATOSUS
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE ANTI-DNA; AUTOANTIBODY; CROSS-REACTIVE; IGG; SYSTEMIC LUPUS
ERYTHEMATOSUS
ID AUTOIMMUNE-DISEASE; PERIPHERAL-BLOOD; AUTOANTIBODIES; ANTIBODIES; MICE;
ACTIVATION; EXPANSION; SERUM; VIRUS; SLE
AB This study is the first to analyze the cross-reactivity of in vivo activated B cells from patients with systemic lupus erythematosus. A chamber ELIspot assay was used to determine whether lymphocytes secreting antibodies that bound to DNA or 2,4,6-trinitrophenol (TNP)-keyhole limpet-hemocyanin (KLH) could simultaneously bind to the unrelated antigens actin or ovalbumin.
IgM anti-DNA-, IgM anti-TNP-KLH- and IgG anti-TNP-KLH-secreting B cells from patients and controls showed similar levels of cross-reactivity (ranging from 6% to 23%, depending upon the antibody isotype and antigen pair examined). In general, IgG-producing cells were less cross-reactive than IgM producers from the same individual (on the average threefold, p <0.001).
In contrast, IgG anti-DNA-secreting B cells from lupus patients (i) showed no decrease in cross-reactivity when compared to IgM anti-DNA-secreting cells and (ii) were significantly more cross-reactive than control IgG anti-DNA-secreting cells and IgG anti-TNP-KLH secreting cells from patients (p < 0.001). The degree of IgG anti-DNA cross-reactivity correlated with disease activity (r = 0.52, p < 0.02). The implications of these findings with respect to repertoire expression and disease pathogenesis are discussed.
C1 MITRE CORP,MCLEAN,VA.
RP KLINMAN, DM (reprint author), US FDA,CTR BIOL EVALUAT & RES,DIV VIRAL PROD,BLDG 29A,RM 3,D 10,BETHESDA,MD 20892, USA.
NR 37
TC 7
Z9 7
U1 0
U2 1
PU VCH PUBLISHERS INC
PI DEERFIELD BEACH
PA 303 NW 12TH AVE, DEERFIELD BEACH, FL 33442-1788
SN 0014-2980
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD JAN
PY 1994
VL 24
IS 1
BP 53
EP 58
DI 10.1002/eji.1830240109
PG 6
WC Immunology
SC Immunology
GA MT838
UT WOS:A1994MT83800008
PM 8020571
ER
PT S
AU THOMAS, DP
GODAR, DE
AF THOMAS, DP
GODAR, DE
BE Bailey, GW
GarrattReed, AJ
TI ULTRAVIOLET-A1 RADIATION INDUCED IMMEDIATE APOPTOSIS IN A HUMAN LEUKEMIA
T-CELL LINE (JURKAT)
SO FIFTY-SECOND ANNUAL MEETING - MICROSCOPY SOCIETY OF AMERICA/TWENTY-NINTH
ANNUAL MEETING - MICROBEAM ANALYSIS SOCIETY, PROCEEDINGS
SE PROCEEDINGS - ANNUAL MEETING OF THE MICROSCOPY SOCIETY OF AMERICA
LA English
DT Proceedings Paper
CT 52nd Annual Meeting of the Microscopy-Society-of-America/29th Annual
Meeting of the Microbeam-Analysis-Society
CY JUL 31-AUG 05, 1994
CL NEW ORLEANS, LA
SP MICROSCOPY SOC AMER, MICROBEAM ANAL SOC
C1 US FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20857.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU SAN FRANCISCO PRESS INC
PI SAN FRANCISCO
PA BOX 426800, SAN FRANCISCO, CA 94142-6800
SN 0424-8201
J9 PROC ANN MEET MSA
PY 1994
BP 206
EP 207
PG 2
WC Instruments & Instrumentation
SC Instruments & Instrumentation
GA BC03U
UT WOS:A1994BC03U00103
ER
PT J
AU MAZIK, PM
PLAKAS, SM
STEHLY, GR
AF MAZIK, PM
PLAKAS, SM
STEHLY, GR
TI EFFECTS OF DORSAL AORTA CANNULATION ON THE STRESS-RESPONSE OF CHANNEL
CATFISH (ICTALURUS-PUNCTATUS)
SO FISH PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE CHANNEL CATFISH; CANNULATION; STRESS; OSMOREGULATION; CORTISOL; GLUCOSE;
CHLORIDE
ID TROUT SALMO-GAIRDNERI; RAINBOW-TROUT; HANDLING STRESS; CORTISOL;
ETOMIDATE; GLUCOSE
AB The stress response to dorsal aorta cannulation and serial blood sampling was examined in the channel catfish Ictalurus punctatus. Channel catfish cannulated and repetitively sampled once a day for 7 days did not exhibit a change in response to surgery or to the 24h sample regime as measured by plasma cortisol, glucose, and chloride. In fish that were either serially bled (0, 1, 3, 6, 9, 12, 24, and 48h) immediately after surgery or allowed to recover 6 days before being serially bled, overall plasma cortisol levels were higher than those of fish bled every 24h. Catfish serially bled immediately after surgery had significantly higher plasma glucose levels compared with catfish allowed to recover from surgery 6 days before serial sampling. Although channel catfish recover from cannulation surgery in 24h, a longer recovery period may be needed prior to serial sampling if the samples are taken more frequently than every 24h.
C1 US FDA,GULF COAST SEAFOOD LAB,DAUPHIN ISL,AL 36528.
RP MAZIK, PM (reprint author), US FISH & WILDLIFE SERV,SE FISH CULTURAL LAB,ROUTE 3,BOX 86,MARION,AL 36756, USA.
NR 19
TC 8
Z9 8
U1 0
U2 0
PU KUGLER PUBLICATIONS BV
PI LELYSTAD
PA PLATINASTRAAT 33, 8211 AR LELYSTAD, NETHERLANDS
SN 0920-1742
J9 FISH PHYSIOL BIOCHEM
JI Fish Physiol. Biochem.
PD JAN
PY 1994
VL 12
IS 5
BP 439
EP 444
DI 10.1007/BF00004308
PG 6
WC Biochemistry & Molecular Biology; Fisheries; Physiology
SC Biochemistry & Molecular Biology; Fisheries; Physiology
GA MV563
UT WOS:A1994MV56300009
PM 24202974
ER
PT J
AU BERG, TF
BREEN, PJ
FEUERS, RJ
ORIAKU, ET
CHEN, FX
HART, RW
AF BERG, TF
BREEN, PJ
FEUERS, RJ
ORIAKU, ET
CHEN, FX
HART, RW
TI ACUTE TOXICITY OF GANCICLOVIR - EFFECT OF DIETARY RESTRICTION AND
CHRONOBIOLOGY
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
ID CHRONIC CALORIC RESTRICTION; DRUG-METABOLIZING ENZYMES; MALE FISCHER-344
RAT; CANCER-CHEMOTHERAPY; DNA-REPAIR; LIFE-SPAN; FLOXURIDINE; INFUSION;
AGE
AB The effect of diet, age and time of dose delivery on the mortality of female B6C3F(1) mice from ganciclovir sodium (DHPG) was determined for both single (SD; 400 mg DHPG/kg, ip) and multiple doses (MD; same dose ip for 10 additional days) of the drug. Young (7-10 months) and middle-aged (MA; 19-22 months) mice (B6C3F(1)), both fed ad lib. (AL) and calorie restricted (CR), were dosed at 0, 6, 12 and 18 hr after lights on (HALO; SD study) and at 12.00 hr (MD study). The SD study mortality rate was 38% (AL) and 1.7% (CR) (P < 0.00001). Mortality was 53% (AL, young; P < 0.00001), over 20% (AL, MA), over 1.8% (CR, MA; P = 0.00004) or more than 1.7% (CR, young; P = 0.00002). Effects were independent of lean body mass differences between AL and CR mice. In the SD study, comparing AL mice only, the greatest mortality was seen in young mice at 6 HALO, (73%; P = 0.0034) and lowest mortality in MA mice at 12 HALO (8%; P = 0.026), whereas in the MD study mortality was 63% AL and 33% CR (P = 0.015). By age, MD mortality was 80% (AL, young; P = 0.0035), 50% (CR, MA), 47% (AL, MA), and 15% (CR, young; P = 0.0013). CR protected both young and MA mice in SD and young mice in MD. Lowest mortality for AL was at 12 HALO. It is suggested that dosing at 12 HALO may protect by decreasing DHPG uptake during a period of minimal DNA synthesis in the affected organ(s). CR and timing of DHPG dose may obviate the necessity to discontinue DHPG because of toxicity in humans. The most significant finding of this study is the impact of diet on mortality.
C1 NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
RP BERG, TF (reprint author), UNIV ARKANSAS,4031 W MARKHAM,SLOT 522,LITTLE ROCK,AR 72295, USA.
NR 30
TC 23
Z9 25
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0278-6915
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD JAN
PY 1994
VL 32
IS 1
BP 45
EP 50
DI 10.1016/0278-6915(84)90035-8
PG 6
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA NA163
UT WOS:A1994NA16300007
PM 8132163
ER
PT J
AU WHITE, PB
AF WHITE, PB
TI INTERNATIONAL MEMORANDA OF UNDERSTANDING ON INSPECTIONS
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article
C1 US FDA,CTR DEVICES & RADIOL HLTH,OFF STAND & REGULAT,WASHINGTON,DC 20204.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
SN 0015-6361
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1994
VL 49
IS 1
BP 171
EP 174
PG 4
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA PH108
UT WOS:A1994PH10800009
ER
PT J
AU BURLINGTON, DB
AF BURLINGTON, DB
TI AN OVERVIEW FROM THE DIRECTOR OF THE CENTER FOR DEVICES AND RADIOLOGICAL
HEALTH
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article
RP BURLINGTON, DB (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,WASHINGTON,DC 20204, USA.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
SN 0015-6361
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1994
VL 49
IS 1
BP 175
EP 181
PG 7
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA PH108
UT WOS:A1994PH10800010
ER
PT J
AU DYKSTRA, GJ
AF DYKSTRA, GJ
TI ELECTRONIC PROCESSING OF IMPORT ENTRIES
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article; Proceedings Paper
CT Seminar of the Food-and-Drug-Law-Institute on Import and Export of
FDA-Regulated Products
CY MAY 18, 1994
CL WASHINGTON, DC
SP FOOD & DRUG LAW INST
RP DYKSTRA, GJ (reprint author), US FDA,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
SN 0015-6361
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1994
VL 49
IS 2
BP 425
EP 431
PG 7
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA PP637
UT WOS:A1994PP63700011
ER
PT J
AU BAUMGARTNER, KC
AF BAUMGARTNER, KC
TI GETTING A GRIP ON MATERIAL TIME AND EXTENT
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article; Proceedings Paper
CT 37th Annual Educational Conference of the Food-and-Drug-Law-Institute
CY DEC 13-15, 1993
CL WASHINGTON, DC
SP FOOD & DRUG LAW INST
RP BAUMGARTNER, KC (reprint author), US FDA,WASHINGTON,DC 20204, USA.
NR 10
TC 2
Z9 2
U1 0
U2 0
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1994
VL 49
IS 3
BP 433
EP 440
PG 8
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA PY699
UT WOS:A1994PY69900001
ER
PT J
AU COOPER, JM
AF COOPER, JM
TI ISSUES ASSOCIATED WITH REVISION OF INAD AND NADA PROCEDURAL REGULATIONS
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article; Proceedings Paper
CT 37th Annual Educational Conference of the Food-and-Drug-Law-Institute
CY DEC 13-15, 1993
CL WASHINGTON, DC
SP FOOD & DRUG LAW INST
RP COOPER, JM (reprint author), US FDA,CTR VET MED,OFF NEW ANIM DRUG EVALUAT,DIV THERAPEUT DRUGS FOOD ANIM,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1994
VL 49
IS 3
BP 441
EP 447
PG 7
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA PY699
UT WOS:A1994PY69900002
ER
PT J
AU JACOBSON, ED
AF JACOBSON, ED
TI KEYNOTE ADDRESS FROM THE OFFICE OF THE DIRECTOR OF CDRH
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article; Proceedings Paper
CT 37th Annual Educational Conference of the Food-and-Drug-Law-Institute
CY DEC 13-15, 1993
CL WASHINGTON, DC
SP FOOD & DRUG LAW INST
RP JACOBSON, ED (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,WASHINGTON,DC 20204, USA.
NR 6
TC 0
Z9 0
U1 0
U2 0
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1994
VL 49
IS 3
BP 463
EP 468
PG 6
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA PY699
UT WOS:A1994PY69900004
ER
PT J
AU SHROFF, AP
AF SHROFF, AP
TI FDA ENFORCEMENT INITIATIVES IN THE UNITED-STATES AND ABROAD
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article
RP SHROFF, AP (reprint author), US FDA,OFF ENFORCEMENT,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1994
VL 49
IS 4
BP 575
EP 580
PG 6
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA QG546
UT WOS:A1994QG54600004
ER
PT J
AU HAFFNER, ME
AF HAFFNER, ME
TI ORPHAN PRODUCTS - 10 YEARS LATER AND THEN SOME
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Article
RP HAFFNER, ME (reprint author), US FDA,OFF COMMISSIONER,OFF ORPHAN PROD DEV,WASHINGTON,DC 20204, USA.
NR 4
TC 9
Z9 9
U1 0
U2 1
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PY 1994
VL 49
IS 4
BP 593
EP 601
PG 9
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology &
Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics;
Pharmacology & Pharmacy
GA QG546
UT WOS:A1994QG54600007
ER
PT S
AU BETZ, JM
FOX, WD
AF BETZ, JM
FOX, WD
BE Huang, MT
Osawa, T
Ho, CT
Rosen, RT
TI HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF GLUCOSINOLATES
IN BRASSICA VEGETABLES
SO FOOD PHYTOCHEMICALS FOR CANCER PREVENTION I: FRUITS AND VEGETABLES
SE ACS SYMPOSIUM SERIES
LA English
DT Article; Proceedings Paper
CT Symposium on Food Phytochemicals for Cancer Prevention I: Fruits and
Vegetables, at the 204th National Meeting of the
American-Chemical-Society
CY AUG 23-28, 1992
CL WASHINGTON, DC
SP AMER CHEM SOC, DIV AGR & FOOD CHEM
ID GLUTATHIONE S-TRANSFERASE; CHEMICAL FLAVOR COMPOSITION; NATURALLY
OCCURRING INDOLES; SINAPIS-ALBA L; MASS-SPECTROMETRY; CRUCIFEROUS
VEGETABLES; GAS-CHROMATOGRAPHY; BENZYL ISOTHIOCYANATE; BRUSSELS-SPROUTS;
DIFFERENTIAL INDUCTION
AB Glucosinolates are naturally occurring constituents of Brassica vegetables. The term refers to a class of more than 100 sulfur-containing glycosides that yield thiocyanate, nitrile, or isothiocyanate derivatives upon enzymatic hydrolysis. These compounds are important because of their potential toxicity and because epidemiologic and other evidence indicates that some of them may inhibit some carcinogenic processes when consumed as part of the normal diet. Accordingly, quantitation of these compounds in processed and unprocessed foods has become important. Existing analytical methods are time consuming and labor intensive. Solid phase extraction (SPE) of broccoli extracts, followed by reverse phase ion pair high performance liquid chromatography (HPLC) of intact, nonderivatized glucosinolates, provides a rapid and simple method for evaluation of glucosinolate loss during food processing.
RP BETZ, JM (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,WASHINGTON,DC 20204, USA.
NR 180
TC 16
Z9 16
U1 0
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 SIXTEENTH ST NW, WASHINGTON, DC 20036
SN 0097-6156
BN 0-8412-2768-3
J9 ACS SYM SER
PY 1994
VL 546
BP 181
EP 196
PG 16
WC Chemistry, Multidisciplinary; Chemistry, Analytical; Food Science &
Technology; Public, Environmental & Occupational Health; Medicine,
Research & Experimental; Nutrition & Dietetics
SC Chemistry; Food Science & Technology; Public, Environmental &
Occupational Health; Research & Experimental Medicine; Nutrition &
Dietetics
GA BA14P
UT WOS:A1994BA14P00014
ER
PT J
AU MADDEN, JM
AF MADDEN, JM
TI THE ENTERICS AS FOODBORNE PATHOGENS
SO FOOD RESEARCH INTERNATIONAL
LA English
DT Article
DE VIBRIO-CHOLERAE; SALMONELLA-TYPHI; EMERGING PATHOGENS; CHARACTERISTICS
OF VIRULENCE
ID UNITED-STATES; DIARRHEAL DISEASE; OUTBREAK; CHOLERA; DEATHS
AB The pathogenicity of enteric bacteria such as Vibrio cholerae and Salmonella typhi is undisputed and has been widely recognized by microbiologists and the public in general for many years. However, very little is known about the mechanisms that attribute the characteristics of virulence to these microbes, except perhaps for cholera toxin, which is required for V. cholerae to produce Asiatic (Epidemic) cholera. Cholera and typhoid fever basically have been controlled in Europe and North America by proper water and sewage treatment, leaving a niche to be filled by other bacteria. These microbes, the so-called 'emerging pathogens', which include members of the genera Vibrio, Salmonella, and other enteric bacteria, account for the vast majority of gastroenteritis cases reported in Europe and North America. Their emergence as pathogens may be due to their mutation, which enables them to co-exist with certain animals (S. enteritidis may fall into this category), or to the transfer of plasmids bearing virulence determinants between various enteric genera.
RP MADDEN, JM (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,DIV MICROBIOL,WASHINGTON,DC 20204, USA.
NR 28
TC 4
Z9 4
U1 1
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0963-9969
J9 FOOD RES INT
JI Food Res. Int.
PY 1994
VL 27
IS 3
BP 227
EP 232
DI 10.1016/0963-9969(94)90088-4
PG 6
WC Food Science & Technology
SC Food Science & Technology
GA NF919
UT WOS:A1994NF91900003
ER
PT J
AU REDDY, NR
PIERSON, MD
AF REDDY, NR
PIERSON, MD
TI REDUCTION IN ANTINUTRITIONAL AND TOXIC COMPONENTS IN PLANT FOODS (A) BY
FERMENTATION
SO FOOD RESEARCH INTERNATIONAL
LA English
DT Article
DE FERMENTATION; PLANT FOODS; ANTINUTRIENTS; TOXICANTS
ID PHYTIC ACID; TRYPSIN-INHIBITORS; ETHYL CARBAMATE; SAPONIN CONTENT;
BREADMAKING; TEMPEH; HYDROLYSIS; BEVERAGES; PRODUCTS; TANNINS
AB Cereals, legumes, and tubers that are used for the production of fermented foods may contain significant amounts of antinutritional or toxic components such as phytates, tannins, cyanogenic glycosides, oxalates, saponins, lectins, and inhibitors of enzymes such as alpha-amylase, trypsin, and chymotrypsin. These substances reduce the nutritional value of foods by interfering with the mineral bioavailability and digestibility of proteins and carbohydrates. In natural or pure mixed-culture fermentations of plant foods by yeasts, molds, and bacteria, antinutritional components (e.g. phytate in whole wheat breads) can be reduced by up to 50%; toxic components, such as lectins in tempe and other fermented foods made from beans, can be reduced up to 95%. These reductions in anti-nutritional and toxic components in plant foods during fermentation are discussed.
C1 VIRGINIA POLYTECH INST & STATE UNIV,DEPT FOOD SCI & TECHNOL,BLACKSBURG,VA 24061.
RP REDDY, NR (reprint author), US FDA,NATL CTR FOOD SAFETY & TECHNOL,DIV FOOD PROC & PACKAGING,6502 S ARCHER AVE,SUMMIT ARGO,IL 60501, USA.
NR 47
TC 110
Z9 116
U1 3
U2 32
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0963-9969
J9 FOOD RES INT
JI Food Res. Int.
PY 1994
VL 27
IS 3
BP 281
EP 290
DI 10.1016/0963-9969(94)90096-5
PG 10
WC Food Science & Technology
SC Food Science & Technology
GA NF919
UT WOS:A1994NF91900010
ER
PT J
AU ALAYASH, AI
AF ALAYASH, AI
TI HEMOGLOBIN-BASED BLOOD SUBSTITUTES - POTENTIAL FREE-RADICAL TOXICITY
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Letter
RP ALAYASH, AI (reprint author), US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892, USA.
NR 8
TC 8
Z9 8
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0891-5849
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD JAN
PY 1994
VL 16
IS 1
BP 137
EP 138
DI 10.1016/0891-5849(94)90253-4
PG 2
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA MM363
UT WOS:A1994MM36300039
PM 8299990
ER
PT S
AU CHIU, YYH
AF CHIU, YYH
BE Brown, F
Lubiniecki, AS
TI GENETIC STABILITY OF RDNA PRODUCTION SYSTEMS - A CASE REPORT
SO GENETIC STABILITY AND RECOMBINANT PRODUCT CONSISTENCY
SE DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION
LA English
DT Proceedings Paper
CT Symposium on Genetic Stability and Recombinant Product Consistency
CY JUL 08-09, 1993
CL ANNECY, FRANCE
SP INT ASSOC BIOL STANDARDIZAT, ARES SERONO SYMP & FDN, MARCEL MERIEUX
DE PLASMID; DELETANT; INSERTION ELEMENT; TRANSPOSITION; RECOMBINATION
RP CHIU, YYH (reprint author), US FDA,CTR DRUG EVALUAT & RES,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU KARGER
PI BASEL
PA POSTFACH, CH-4009 BASEL, SWITZERLAND
SN 0301-5149
BN 3-8055-5998-4
J9 DEV BIOL STAND
JI Dev.Biol.Stand.
PY 1994
VL 83
BP 93
EP 97
PG 5
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA BB81Z
UT WOS:A1994BB81Z00012
PM 7883104
ER
PT B
AU HOPPE, PA
AF HOPPE, PA
BE Sibinga, CTS
Heiniger, HJ
TI STANDARDS AND EXTERNAL QUALITY AUDIT SYSTEMS
SO GOOD MANUFACTURING PRACTICE IN TRANSFUSION MEDICINE
SE DEVELOPMENTS IN HEMATOLOGY AND IMMUNOLOGY
LA English
DT Proceedings Paper
CT 18th International Symposium on Blood Transfusion
CY 1993
CL GRONINGEN, NETHERLANDS
SP RED CROSS BLOOD BANK GRONINGEN DRENTHE
C1 US FDA,ROCKVILLE,MD 20857.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
BN 0-7923-3009-9
J9 DEV HEMATOL
PY 1994
VL 29
BP 85
EP 90
PG 6
WC Hematology; Medical Laboratory Technology
SC Hematology; Medical Laboratory Technology
GA BB63D
UT WOS:A1994BB63D00010
ER
PT B
AU MYERS, KJ
WAGNER, RF
HANSON, KM
BARRETT, HH
ROLLAND, JP
AF MYERS, KJ
WAGNER, RF
HANSON, KM
BARRETT, HH
ROLLAND, JP
BE Kundel, HL
TI HUMAN AND QUASI-BAYESIAN OBSERVERS OF IMAGES LIMITED BY QUANTUM-NOISE,
OBJECT VARIABILITY, AND ARTIFACTS
SO IMAGE PERCEPTION
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
(SPIE)
LA English
DT Proceedings Paper
CT Conference on Image Perception: Medical Imaging 1994
CY FEB 17-18, 1994
CL NEWPORT BEACH, CA
SP SOC PHOTO OPT INSTRUMENTAT ENGINEERS, AMER ASSOC PHYSICISTS MED, BIOMED OPT SOC, US FDA, CTR DEVICES & RADIOL HLTH, NATL ELECT MANUFACTURERS ASSOC, DIAGNOST IMAGING & THERAPY SYST DIV, SOC IMAGING SCI & TECHNOL, RADIOL INFORMAT SYST CONSORTIUM, RADIOL SOC N AMER, SOC COMP APPLICAT RADIOL
C1 US FDA,CDRH,ROCKVILLE,MD 20857.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU SPIE - INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA PO BOX 10, BELLINGHAM, WA 98227-0010
BN 0-8194-1461-1
J9 P SOC PHOTO-OPT INS
PY 1994
VL 2166
BP 180
EP 190
DI 10.1117/12.171740
PG 11
WC Optics; Radiology, Nuclear Medicine & Medical Imaging
SC Optics; Radiology, Nuclear Medicine & Medical Imaging
GA BA43K
UT WOS:A1994BA43K00021
ER
PT B
AU WAGNER, RF
BROWN, DG
GUEDON, JP
MYERS, KJ
WEAR, KA
AF WAGNER, RF
BROWN, DG
GUEDON, JP
MYERS, KJ
WEAR, KA
BE Loew, MH
TI ON COMBINING A FEW DIAGNOSTIC-TESTS OF FEATURES
SO IMAGE PROCESSING: MEDICAL IMAGING 1994
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
(SPIE)
LA English
DT Proceedings Paper
CT Conference on Image Processing
CY FEB 15-18, 1994
CL NEWPORT BEACH, CA
SP SOC PHOTO OPT INSTRUMENTAT ENGINEERS, AMER ASSOC PHYSICISTS MED, BIOMED OPT SOC, FDA, CTR DEVICES & RADIOL HLTH, NATL ELECT MANUFACTURERS ASSOC, DIAGNOST IMAGING & THERAPY SYST DIV, SOC IMAGING SCI & TECHNOL, RADIOL INFORMAT SYST CONSORTIUM, RADIOL SOC N AMER, SOC COMP APPLICAT RADIOL
C1 FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20857.
NR 0
TC 4
Z9 4
U1 0
U2 0
PU SPIE - INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA PO BOX 10, BELLINGHAM, WA 98227-0010
BN 0-8194-1462-X
J9 P SOC PHOTO-OPT INS
PY 1994
VL 2167
BP 503
EP 512
DI 10.1117/12.175084
PG 10
WC Engineering, Biomedical; Optics; Radiology, Nuclear Medicine & Medical
Imaging
SC Engineering; Optics; Radiology, Nuclear Medicine & Medical Imaging
GA BB27L
UT WOS:A1994BB27L00045
ER
PT B
AU BROWN, DG
ANDERSON, MP
MYERS, KJ
WAGNER, RF
AF BROWN, DG
ANDERSON, MP
MYERS, KJ
WAGNER, RF
BE Loew, MH
TI COMPARISON OF NEURAL-NETWORK, HUMAN, AND SUBOPTIMAL BAYESIAN PERFORMANCE
ON A CONSTRAINED RECONSTRUCTION TASK
SO IMAGE PROCESSING: MEDICAL IMAGING 1994
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
(SPIE)
LA English
DT Proceedings Paper
CT Conference on Image Processing
CY FEB 15-18, 1994
CL NEWPORT BEACH, CA
SP SOC PHOTO OPT INSTRUMENTAT ENGINEERS, AMER ASSOC PHYSICISTS MED, BIOMED OPT SOC, FDA, CTR DEVICES & RADIOL HLTH, NATL ELECT MANUFACTURERS ASSOC, DIAGNOST IMAGING & THERAPY SYST DIV, SOC IMAGING SCI & TECHNOL, RADIOL INFORMAT SYST CONSORTIUM, RADIOL SOC N AMER, SOC COMP APPLICAT RADIOL
C1 FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20857.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU SPIE - INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA PO BOX 10, BELLINGHAM, WA 98227-0010
BN 0-8194-1462-X
J9 P SOC PHOTO-OPT INS
PY 1994
VL 2167
BP 614
EP 622
DI 10.1117/12.175096
PG 9
WC Engineering, Biomedical; Optics; Radiology, Nuclear Medicine & Medical
Imaging
SC Engineering; Optics; Radiology, Nuclear Medicine & Medical Imaging
GA BB27L
UT WOS:A1994BB27L00056
ER
PT B
AU BROWN, DG
SCHNEIDER, AC
ANDERSON, MP
WAGNER, RF
AF BROWN, DG
SCHNEIDER, AC
ANDERSON, MP
WAGNER, RF
BE Loew, MH
TI EFFECTS OF FINITE-SAMPLE SIZE AND CORRELATED NOISY INPUT FEATURES ON
NEURAL-NETWORK PATTERN-CLASSIFICATION
SO IMAGE PROCESSING: MEDICAL IMAGING 1994
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
(SPIE)
LA English
DT Proceedings Paper
CT Conference on Image Processing
CY FEB 15-18, 1994
CL NEWPORT BEACH, CA
SP SOC PHOTO OPT INSTRUMENTAT ENGINEERS, AMER ASSOC PHYSICISTS MED, BIOMED OPT SOC, FDA, CTR DEVICES & RADIOL HLTH, NATL ELECT MANUFACTURERS ASSOC, DIAGNOST IMAGING & THERAPY SYST DIV, SOC IMAGING SCI & TECHNOL, RADIOL INFORMAT SYST CONSORTIUM, RADIOL SOC N AMER, SOC COMP APPLICAT RADIOL
C1 FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20857.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU SPIE - INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA PO BOX 10, BELLINGHAM, WA 98227-0010
BN 0-8194-1462-X
J9 P SOC PHOTO-OPT INS
PY 1994
VL 2167
BP 642
EP 651
DI 10.1117/12.175100
PG 10
WC Engineering, Biomedical; Optics; Radiology, Nuclear Medicine & Medical
Imaging
SC Engineering; Optics; Radiology, Nuclear Medicine & Medical Imaging
GA BB27L
UT WOS:A1994BB27L00059
ER
PT S
AU KLINMAN, DM
SHIRAI, A
ISHIGATSUBO, Y
AF KLINMAN, DM
SHIRAI, A
ISHIGATSUBO, Y
BE Atassi, MZ
TI POLYCLONAL, B-CELL ACTIVATION AND B-CELL CROSS-REACTIVITY DURING
AUTOANTIBODY PRODUCTION IN SYSTEMIC LUPUS-ERYTHEMATOSUS
SO IMMUNOBIOLOGY OF PROTEINS AND PEPTIDES VII: UNWANTED IMMUNE RESPONSES
SE ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY
LA English
DT Proceedings Paper
CT 7th International Symposium on the Immunobiology of Proteins and
Peptides
CY OCT 01-06, 1992
CL EDMONTON, CANADA
SP APPLIED BIOSYST, CONNAUGHT LABS, SCHERING PLOUGH RES, UPJOHN, IMMULOGIC
RP KLINMAN, DM (reprint author), US FDA,CTR BIOL EVALUAT & RES,DIV VIROL,BETHESDA,MD 20892, USA.
NR 0
TC 6
Z9 6
U1 0
U2 0
PU PLENUM PRESS DIV PLENUM PUBLISHING CORP
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013
SN 0065-2598
BN 0-306-44665-0
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 1994
VL 347
BP 115
EP 123
PG 9
WC Biochemistry & Molecular Biology; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA BA74G
UT WOS:A1994BA74G00013
PM 7976727
ER
PT J
AU WEAVER, JL
PINE, PS
ASZALOS, A
AF WEAVER, JL
PINE, PS
ASZALOS, A
TI THE INTERACTIONS OF IMMUNOSUPPRESSIVE COMPOUNDS IN TANDEM STIMULATED
PERIPHERAL HUMAN-LYMPHOCYTES
SO IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
LA English
DT Article
ID MYCOPHENOLIC-ACID; CYCLOSPORINE-A; ALLOGRAFT-REJECTION; MACROLIDES
FK-506; T-CELLS; INVITRO; RAPAMYCIN; SURAMIN; PROLIFERATION; RAT
AB We have developed an in vitro system to model the interactions of drugs used to treat transplant rejection. This system consists of stimulation of human lymphocytes with a primary mitogen (anti-T-cell receptor complex antibodies (OKT3 or wt31)) and treatment with a primary immunosuppressive drug (ISD) (Cyclosporine A (CsA) or FK-506)). This is later followed by stimulation with a secondary mitogen (Interleukin-2 or anti-CD28), and treatment with a second ISD. This system allows a variety of concentrations and compounds to be rapidly tested.
We have used this system to study the effect of various compounds when used as either primary or secondary ISDs. Our results show that when CsA is used as the primary ISD, further proliferation can be inhibited by rapamycin, mycophenolic acid, or suramin. When FK-506 is the primary ISD, inhibition of proliferation by rapamycin is variable depending on the primary and secondary mitogens. If rapamycin is the primary ISD, both CsA and FK-506 show antagonistic interactions.
These results suggest that the order in which combinations of ISDs are administered in transplantation may have significant effects on the clinical outcome.
C1 US FDA,CTR DRUG EVALUAT & RES,DIV RES & TESTING,WASHINGTON,DC 20204.
NR 30
TC 3
Z9 3
U1 0
U2 0
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 0892-3973
J9 IMMUNOPHARM IMMUNOT
JI Immunopharmacol. Immunotoxicol.
PY 1994
VL 16
IS 2
BP 179
EP 190
DI 10.3109/08923979409007089
PG 12
WC Immunology; Pharmacology & Pharmacy; Toxicology
SC Immunology; Pharmacology & Pharmacy; Toxicology
GA NN361
UT WOS:A1994NN36100005
PM 7521360
ER
PT J
AU LUMPKIN, MM
AF LUMPKIN, MM
TI CLINICAL-TRIALS FROM A REGULATORS PERSPECTIVE
SO INFECTION
LA English
DT Discussion
RP LUMPKIN, MM (reprint author), US FDA,CTR DRUG EVALUAT & RES,DIV ANTIINFECT DRUG PROD,5600 FISHERS LANE,ROOM 12 B-45,HFD-520,ROCKVILLE,MD 20857, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MMW MEDIZIN VERLAG GMBH
PI MUNICH 80
PA NEUMARKTER STRASSE 18, W-8000 MUNICH 80, GERMANY
SN 0300-8126
J9 INFECTION
JI Infection
PY 1994
VL 22
SU 1
BP S61
EP S61
DI 10.1007/BF01716051
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA NH920
UT WOS:A1994NH92000029
PM 8050801
ER
PT J
AU OLIVERO, OA
BELAND, FA
POIRIER, MC
AF OLIVERO, OA
BELAND, FA
POIRIER, MC
TI IMMUNOFLUORESCENT LOCALIZATION AND QUANTITATION OF
3'-AZIDO-2',3'-DIDEOXYTHYMIDINE (AZT) INCORPORATED INTO CHROMOSOMAL DNA
OF HUMAN, HAMSTER AND MOUSE-CELL LINES
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE 3'-AZIDO-2',3'-DIDEOXYTHYMIDINE; AZT; IMMUNOFLUORESCENCE;
RADIOIMMUNOASSAY; CHROMOSOMES
ID VIRUS REVERSE-TRANSCRIPTASE; AZIDOTHYMIDINE TRIPHOSPHATE;
POLYMERASE-ALPHA; 3'-AZIDO-3'-DEOXYTHYMIDINE; REPLICATION;
5'-TRIPHOSPHATE; PHARMACOLOGY; ZIDOVUDINE; TELOMERASE; ANALOGS
AB The incorporation of [H-3] AZT into the DNA of cultured hamster (Chinese hamster ovary, CHO) mouse (NIH 3T3) and human (HL60) cells, was studied by radiolabeling, radioimmunoassay, and localization of the drug in chromosomes by immunohistochemistry. Incorporation of AZT into DNA, in cells exposed to 0.8 mM [H-3] AZT for 24 hours, showed values of 0.82 pmol/mug DNA for HL60, 0.84 pmol/mug DNA for CHO and 4.49 pmol/mug for NIH 3T3 cells. Similar results were obtained by radioimmunoassay with an anti-AZT antibody. Indirect immunofluorescence using the same anti-AZT antiserum demonstrated the chromosomal localization of AZT and showed higher concentrations of AZT in the telomeric regions of CHO cell chromosomes.
C1 NATL CTR TOXICOL RES,DIV BIOCHEM TOXICOL,JEFFERSON,AR 72079.
RP OLIVERO, OA (reprint author), NCI,CELLULAR CARCINOGENESIS & TUMOR PROMO LAB,BLDG 37,ROOM 3B12,BETHESDA,MD 20892, USA.
NR 24
TC 31
Z9 31
U1 0
U2 0
PU INT JOURNAL ONCOLOGY
PI ATHENS
PA C/O PROFESSOR D A SPANDIDOS, EDITORIAL OFFICE, 1, S MERKOURI ST, ATHENS
116 35, GREECE
SN 1019-6439
J9 INT J ONCOL
JI Int. J. Oncol.
PD JAN
PY 1994
VL 4
IS 1
BP 49
EP 54
PG 6
WC Oncology
SC Oncology
GA MN493
UT WOS:A1994MN49300008
PM 21566888
ER
PT B
AU WHITE, PB
AF WHITE, PB
GP ASSOC ADV MED INSTRUMENTAT
TI Standards as building blocks for regulatory harmonization
SO INTERNATIONAL STANDARDS AND REGULATORY HARMONIZATION - CONFERENCE REPORT
LA English
DT Proceedings Paper
CT 4th Annual AAMI International Standards Conference on Medical Devices -
International Standards and Regulatory Harmonization
CY 1994
CL WASHINGTON, DC
SP Assoc Adv Med Instrumentat
C1 US FDA,CTR DEVICES & RADIOL HLTH,OFF STAND & REGULAT,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC ADVANCEMENT MEDICAL INSTRUMENTATION
PI ARLINGTON
PA 3330 WASHINGTON BLVD, STE 400, ARLINGTON, VA 22201-4598
BN 1-57020-021-1
PY 1994
BP 15
EP 18
PG 4
WC Engineering, Biomedical; Instruments & Instrumentation; Public
Administration
SC Engineering; Instruments & Instrumentation; Public Administration
GA BD86Q
UT WOS:A1994BD86Q00002
ER
PT B
AU ALPERT, S
AF ALPERT, S
GP ASSOC ADV MED INSTRUMENTAT
TI How FDA's office of device evaluation uses standards and guidance
documents
SO INTERNATIONAL STANDARDS AND REGULATORY HARMONIZATION - CONFERENCE REPORT
LA English
DT Proceedings Paper
CT 4th Annual AAMI International Standards Conference on Medical Devices -
International Standards and Regulatory Harmonization
CY 1994
CL WASHINGTON, DC
SP Assoc Adv Med Instrumentat
C1 US FDA,CTR DEVICES & RADIOL HLTH,OFF DEVICE EVALUAT,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC ADVANCEMENT MEDICAL INSTRUMENTATION
PI ARLINGTON
PA 3330 WASHINGTON BLVD, STE 400, ARLINGTON, VA 22201-4598
BN 1-57020-021-1
PY 1994
BP 34
EP 40
PG 7
WC Engineering, Biomedical; Instruments & Instrumentation; Public
Administration
SC Engineering; Instruments & Instrumentation; Public Administration
GA BD86Q
UT WOS:A1994BD86Q00005
ER
PT B
AU HOOTEN, WF
AF HOOTEN, WF
GP ASSOC ADV MED INSTRUMENTAT
TI How FDA's proposed new GMP regulations relate to ISO 9000
SO INTERNATIONAL STANDARDS AND REGULATORY HARMONIZATION - CONFERENCE REPORT
LA English
DT Proceedings Paper
CT 4th Annual AAMI International Standards Conference on Medical Devices -
International Standards and Regulatory Harmonization
CY 1994
CL WASHINGTON, DC
SP Assoc Adv Med Instrumentat
C1 US FDA,CTR DEVICES & RADIOL HLTH,DIV ENFORCEMENT 3,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC ADVANCEMENT MEDICAL INSTRUMENTATION
PI ARLINGTON
PA 3330 WASHINGTON BLVD, STE 400, ARLINGTON, VA 22201-4598
BN 1-57020-021-1
PY 1994
BP 73
EP 82
PG 10
WC Engineering, Biomedical; Instruments & Instrumentation; Public
Administration
SC Engineering; Instruments & Instrumentation; Public Administration
GA BD86Q
UT WOS:A1994BD86Q00010
ER
PT B
AU CALLAHAN, T
PHILLIPS, P
MUELLER, E
STAGG, A
STRATMEYER, M
AF CALLAHAN, T
PHILLIPS, P
MUELLER, E
STAGG, A
STRATMEYER, M
GP ASSOC ADV MED INSTRUMENTAT
TI Biomaterials and biocompatibility testing
SO INTERNATIONAL STANDARDS AND REGULATORY HARMONIZATION - CONFERENCE REPORT
LA English
DT Proceedings Paper
CT 4th Annual AAMI International Standards Conference on Medical Devices -
International Standards and Regulatory Harmonization
CY 1994
CL WASHINGTON, DC
SP Assoc Adv Med Instrumentat
C1 US FDA,CTR DEVICES & RADIOL HLTH,OFF DEVICE EVALUAT,DIV CARDIOVASC RESP & NEUROL DEVICES,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC ADVANCEMENT MEDICAL INSTRUMENTATION
PI ARLINGTON
PA 3330 WASHINGTON BLVD, STE 400, ARLINGTON, VA 22201-4598
BN 1-57020-021-1
PY 1994
BP 170
EP 195
PG 26
WC Engineering, Biomedical; Instruments & Instrumentation; Public
Administration
SC Engineering; Instruments & Instrumentation; Public Administration
GA BD86Q
UT WOS:A1994BD86Q00016
ER
PT B
AU CHAMBERLAIN, V
SCHULTZ, J
AF CHAMBERLAIN, V
SCHULTZ, J
GP ASSOC ADV MED INSTRUMENTAT
TI Sterilization, including sterile packaging and EO residuals
SO INTERNATIONAL STANDARDS AND REGULATORY HARMONIZATION - CONFERENCE REPORT
LA English
DT Proceedings Paper
CT 4th Annual AAMI International Standards Conference on Medical Devices -
International Standards and Regulatory Harmonization
CY 1994
CL WASHINGTON, DC
SP Assoc Adv Med Instrumentat
C1 US FDA,CTR DEVICES & RADIOL HLTH,OFF COMPLIANCE & SURVEILLANCE,DIV ENFORCEMENT 2,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC ADVANCEMENT MEDICAL INSTRUMENTATION
PI ARLINGTON
PA 3330 WASHINGTON BLVD, STE 400, ARLINGTON, VA 22201-4598
BN 1-57020-021-1
PY 1994
BP 196
EP 210
PG 15
WC Engineering, Biomedical; Instruments & Instrumentation; Public
Administration
SC Engineering; Instruments & Instrumentation; Public Administration
GA BD86Q
UT WOS:A1994BD86Q00017
ER
PT B
AU ALTMAN, M
BERGEN, JV
KIMMELMAN, E
AF ALTMAN, M
BERGEN, JV
KIMMELMAN, E
GP ASSOC ADV MED INSTRUMENTAT
TI In vitro diagnostics
SO INTERNATIONAL STANDARDS AND REGULATORY HARMONIZATION - CONFERENCE REPORT
LA English
DT Proceedings Paper
CT 4th Annual AAMI International Standards Conference on Medical Devices -
International Standards and Regulatory Harmonization
CY 1994
CL WASHINGTON, DC
SP Assoc Adv Med Instrumentat
C1 US FDA,CTR DEVICES & RADIOL HLTH,OFF STAND & REGULAT,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC ADVANCEMENT MEDICAL INSTRUMENTATION
PI ARLINGTON
PA 3330 WASHINGTON BLVD, STE 400, ARLINGTON, VA 22201-4598
BN 1-57020-021-1
PY 1994
BP 211
EP 228
PG 18
WC Engineering, Biomedical; Instruments & Instrumentation; Public
Administration
SC Engineering; Instruments & Instrumentation; Public Administration
GA BD86Q
UT WOS:A1994BD86Q00018
ER
PT B
AU CHIACCHIERINI, R
FUSON, R
AF CHIACCHIERINI, R
FUSON, R
GP ASSOC ADV MED INSTRUMENTAT
TI Clinical trials
SO INTERNATIONAL STANDARDS AND REGULATORY HARMONIZATION - CONFERENCE REPORT
LA English
DT Proceedings Paper
CT 4th Annual AAMI International Standards Conference on Medical Devices -
International Standards and Regulatory Harmonization
CY 1994
CL WASHINGTON, DC
SP Assoc Adv Med Instrumentat
C1 US FDA,CTR DEVICES & RADIOL HLTH,OFF SURVEILLANCE & BIOMETR,DIV BIOMETR SCI,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC ADVANCEMENT MEDICAL INSTRUMENTATION
PI ARLINGTON
PA 3330 WASHINGTON BLVD, STE 400, ARLINGTON, VA 22201-4598
BN 1-57020-021-1
PY 1994
BP 229
EP 244
PG 16
WC Engineering, Biomedical; Instruments & Instrumentation; Public
Administration
SC Engineering; Instruments & Instrumentation; Public Administration
GA BD86Q
UT WOS:A1994BD86Q00019
ER
PT J
AU LOESSNER, MJ
ESTELA, LA
ZINK, R
SCHERER, S
AF LOESSNER, MJ
ESTELA, LA
ZINK, R
SCHERER, S
TI TAXONOMICAL CLASSIFICATION OF 20 NEWLY ISOLATED LISTERIA BACTERIOPHAGES
BY ELECTRON-MICROSCOPY AND PROTEIN-ANALYSIS
SO INTERVIROLOGY
LA English
DT Article
DE BACTERIOPHAGES; LISTERIA; TAXONOMY; ELECTRON MICROSCOPY; SODIUM DODECYL
SULFATE POLYACRYLAMIDE GEL ELECTROPHORESIS; ISOELECTRIC FOCUSING
ID PHAGE-TYPING SYSTEM; MONOCYTOGENES; MORPHOLOGY; INNOCUA; GELS; DNA
AB A set of 20 newly isolated temperate bacteriophages for phage typing of the pathogen Listeria monocytogenes has been investigated by means of electron microscopy and electrophoretic analysis of phage structural proteins. All phages had isometric capsids (60-64 nm diameter), and long contractile or non-contractile tails of 170-320 nm length. They could be classified into 2 morphotypes (A1 and B1) and were assigned to 3 listeriaphage species (4211, 2671, and 2389). Individual protein profiles were generated by SDS-PAGE of viral polypeptides, as well as isoelectric focusing of solubilized phage proteins in immobilized pH gradient gels. The major structural proteins ranged in size from approximately 15 to 38 kD, and showed isoelectric points from pi 4.3 to 6.2. Protein compositions permitted the differentiation of individual phages as well as the recognition and grouping of similar viruses.
C1 UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80262.
US FDA,DENVER DIST LAB,DENVER,CO.
RP LOESSNER, MJ (reprint author), TECH UNIV MUNICH,FORSCHUNGSZENTRUM MILCH & LEBENSMITTEL WEIHENSTEP,INST MIKROBIOL,D-85350 FREISING,GERMANY.
RI Scherer, Siegfried/I-1320-2013; Loessner, Martin/B-4316-2012
NR 21
TC 9
Z9 10
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0300-5526
J9 INTERVIROLOGY
JI Intervirology
PD JAN-FEB
PY 1994
VL 37
IS 1
BP 31
EP 35
PG 5
WC Virology
SC Virology
GA NV589
UT WOS:A1994NV58900006
PM 7928287
ER
PT J
AU KIJAK, PJ
AF KIJAK, PJ
TI CONFIRMATION OF CHLORAMPHENICOL RESIDUES IN BOVINE-MILK BY
GAS-CHROMATOGRAPHY MASS-SPECTROMETRY
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
ID TISSUES; MEAT
AB A gas chromatographic/mass spectrometric method was developed to confirm the presence of chloramphenicol (CAP) at 0.5 ng/mL in bovine milk meta-Nitrochloramphenicol (20 ng) is added to 10 mL milk as a surrogate standard. The milk is mixed with ethyl acetate and then loaded onto a diatomaceous earth-filled, solid-phase extraction (SPE) column; CAP is eluted with additional ethyl acetate. A solution of 4% NaCl in water is added to the eluant, and ethyl acetate is removed by evaporation under a flow of N-2. The sample is defatted with hexane and then loaded onto a C-18-SPE column. The column is washed with water, and CAP is eluted with methanol. The methanol is evaporated under a flow of Na, and the trimethylsilyl derivative is prepared with Sylon HTP (hexamethyldisilazane-trimethylchlorosilane-pyridine, 3 + 1 + 9). The excess reagent is evaporated under N-2, and the residue is taken up in cyclohexane-hexane (60 + 40). CAP is separated on a 30 m x 0.25 mm id methytsilicone column having a film thickness of 0.25 mu m and analyzed by methane negative chemical ionization with selected ion monitoring. The ions with m/z 304, 322, 358, 360, 466, and 468 are monitored. Confirmation is based on the presence of 5 ions with relative ion abundances within 10% of that obtained by using standards.
RP KIJAK, PJ (reprint author), US FDA,CTR VET MED,BARC E,BLDG 328-A,BELTSVILLE,MD 20705, USA.
NR 17
TC 30
Z9 39
U1 1
U2 2
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1994
VL 77
IS 1
BP 34
EP 40
PG 7
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA MX271
UT WOS:A1994MX27100006
ER
PT J
AU DANIELSON, JW
PEELER, JT
OXBORROW, GS
AF DANIELSON, JW
PEELER, JT
OXBORROW, GS
TI SPORICIDAL ACTIVITY OF CHEMICAL GERMICIDES ON BACILLUS-SUBTILIS SPORES
UNDER VARIOUS CONDITIONS
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
AB Sporicidal tests were conducted on chemical germicides used for reprocessing hemodialyzers. The germicides that were tested for sporicidal activity contain some of the same active ingredients as many other commercial germicides, although instructions for dilution and exposure time may vary according to intended use. Cidex-Dialyzer(TM) (glutaraldehyde), formaldehyde, Renalin(TM) (peracetic acid), and RenNew-D(TM) (chlorine dioxide) were each tested under the following conditions: at 50, 100, and 150% of the recommended concentration in soft water at 22 degrees C; and at 1x the recommended concentration in soft water at 26.7 degrees C, in hard water at 22 degrees C, and in hard water containing 5% bovine serum at 22 degrees C. Sporicidin-HD(TM) (glutaraldehyde-phenol) was tested only at the recommended concentration in soft water at 22 degrees C. The time required for a 2-log reduction in the initial concentration of spores ranged from 1.8 min for Renalin at 150% of the recommended concentration to 26.4 h for formaldehyde in hard water containing 5% bovine serum. Cidex-Dialyzer at 50% of the recommended concentration and Sporicidin-HD at the recommended concentration were ineffective against Bacillus subtilis var. niger spores. The sporicidal activities of RenNew-D and formaldehyde were greatly reduced when bovine serum was added to hard water. Renalin had the highest sporicidal activity and was the least affected by each of the conditions tested.
C1 US FDA,WASHINGTON,DC 20204.
THREE M CO CTR,ST PAUL,MN 55144.
RP DANIELSON, JW (reprint author), US FDA,STERIL ANAL RES CTR,240 HENNEPIN AVE,MINNEAPOLIS,MN 55401, USA.
NR 12
TC 3
Z9 3
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1994
VL 77
IS 1
BP 53
EP 57
PG 5
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA MX271
UT WOS:A1994MX27100009
ER
PT J
AU PARFITT, CH
AF PARFITT, CH
TI WIDE-BORE CAPILLARY GAS-CHROMATOGRAPHIC DETERMINATION OF
ORGANOPHOSPHORUS PESTICIDE-RESIDUES IN FOODS - INTERLABORATORY TRIAL
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
ID PACKED-COLUMNS
AB Wide-Bore capillary columns are often used as alternatives to traditionally packed columns for gas chromatographic (GC) determination of pesticide residues in foods. Fused silica columns with crosslinked, bonded stationary phases are reproducible, rugged, and easy to use and are substantially more inert than their packed column equivalents. An interlaboratory trial was conducted in 5 U.S. Food and Drug Administration laboratories to determine the practicability of using isothermal wide-bore capillary GC as an alternative to the packed column GC systems used in AOAC Official Methods for determining pesticide residues in foods. Two wide-bore capillary columns with frame photometric detection were evaluated with respect to the following: linearity of detector response; repeatability of response for equal and unequal injection volumes of standard solutions; accuracy of quantitating pesticides in food extracts when the injection volumes or analyte concentrations of the standard solution and the food extract are different; recoveries of 23 pesticides from 5 fortified food extracts, calculated from both duplicate and single injections; and relative retention times. Before shipment, food extracts supplied to participants were fortified with pesticides after preparation and extraction of the foods by Official Method 985.22. The performance of wide-bore capillary columns with cross-linked bonded methyl silicone and methyl phenyl silicone stationary phases was equal or superior to that of the packed columns specified in the Official Method.
RP PARFITT, CH (reprint author), US FDA,DIV CONTAMINANTS CHEM,WASHINGTON,DC 20204, USA.
NR 16
TC 3
Z9 3
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1994
VL 77
IS 1
BP 92
EP 101
PG 10
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA MX271
UT WOS:A1994MX27100016
ER
PT J
AU SCHENCK, FJ
WAGNER, R
HENNESSY, MK
OKRASINSKI, JL
AF SCHENCK, FJ
WAGNER, R
HENNESSY, MK
OKRASINSKI, JL
TI SCREENING OF ORGANOCHLORINE PESTICIDE AND POLYCHLORINATED BIPHENYL
RESIDUES IN NONFATTY SEAFOOD PRODUCTS BY TANDEM SOLID-PHASE EXTRACTION
CLEANUP
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
ID SEDIMENT; FISH
AB A rapid multiresidue solid-phase extraction (SPE) technique for the isolation and subsequent gas chromatographic (GC) determination of organochlorine pesticide and polychlorinated biphenyl (PCB) residues in nonfatty fish, crabmeat, shrimp, and scallops is described. Samples are extracted with acetonitrile, and the extract is subjected to a cleanup using both C-18 and Florisil SPE columns. The residues are determined by GC with electron capture detection. Because the injected extracts are free from matrix interferences, the amount of residue present is easily calculated. The average recoveries of 9 spiked (0.01-0.40 ppm) organochlorine pesticide residues from 6 different seafood products ranged from 93.8 to 98.4%. The average recoveries of spiked (0.50 ppm) PCB mixtures from 4 different seafood products ranged from 88.5 to 107.2%. This SPE method and the AOAC multiresidue method for organochlorine residues in fish produced comparable results for nonfatty seafood samples containing incurred organochlorine pesticide and PCB residues. The SPE method reduces organic solvent consumption by 95% and hazardous waste by 85% compared with the AOAC method. We were able to carry 10 seafood samples through the extraction and cleanup in less than 2 h by using the SPE method.
RP SCHENCK, FJ (reprint author), US FDA,900 MADISON AVE,BALTIMORE,MD 21201, USA.
NR 12
TC 18
Z9 19
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1994
VL 77
IS 1
BP 102
EP 106
PG 5
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA MX271
UT WOS:A1994MX27100017
ER
PT J
AU KIRCHHOEFER, RD
AF KIRCHHOEFER, RD
TI GAS-CHROMATOGRAPHIC MASS-SPECTROMETRIC IDENTIFICATION OF A
PYRIDINEDICARBOXYLIC ACID IMPURITY IN NIACIN AS THE TRIMETHYLSILYL ESTER
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
AB A pyridinedicarboxylic acid impurity in bulk niacin was identified by derivatization and comparison with reference materials by using gas chromatography/mass spectrometry. The niacin bulk material was dissolved in pyridine and derivatized with N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) reagent. The resulting trimethylsilyl (TMS) esters of niacin and its associated impurities were chromatographed on a cross-linked methyl silicone capillary column with temperature programming. Derivatization and injection of the 6 pyridinedicarboxylic acid geometric isomers showed that 3 of the dicarboxylic acids, 2,3- (also known as quinolinic acid), 2,5-, and 2,6-pyridinedicarboxylic acid, all rearrange to give a component with a mass spectrum identical to that of the impurity. The other 3 isomers, 2,4-, 3,4-, and 3,5-pyridinecarboxylic acid, do not rearrange, and therefore, cannot be the impurity detected in the niacin bulk material. The amount of pyridinedicarboxylic acid impurity in the bulk niacin is less than 0.02%.
RP KIRCHHOEFER, RD (reprint author), US FDA,CTR DRUG EVALUAT & RES,DIV DRUG ANAL,1114 MARKET ST,ST LOUIS,MO 63101, USA.
NR 11
TC 2
Z9 2
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1994
VL 77
IS 1
BP 117
EP 120
PG 4
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA MX271
UT WOS:A1994MX27100019
ER
PT J
AU ALEXANDER, TG
AF ALEXANDER, TG
TI DRUGS-V
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP ALEXANDER, TG (reprint author), US FDA,CTR DRUG EVALUAT & RES,HFD-473,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1994
VL 77
IS 1
BP 128
EP 129
PG 2
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA MX271
UT WOS:A1994MX27100027
ER
PT J
AU NG, LL
AF NG, LL
TI DRUGS-IV
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP NG, LL (reprint author), US FDA,CTR DRUG EVALUAT & RES,ROCKVILLE,MD 20857, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1994
VL 77
IS 1
BP 128
EP 128
PG 1
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA MX271
UT WOS:A1994MX27100026
ER
PT J
AU CICHOWICZ, SM
AF CICHOWICZ, SM
TI FORENSIC SCIENCES
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP CICHOWICZ, SM (reprint author), US FDA,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1994
VL 77
IS 1
BP 129
EP 129
PG 1
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA MX271
UT WOS:A1994MX27100028
ER
PT J
AU FAZIO, T
AF FAZIO, T
TI FOOD-ADDITIVES
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP FAZIO, T (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1994
VL 77
IS 1
BP 131
EP 134
PG 4
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA MX271
UT WOS:A1994MX27100031
ER
PT J
AU TRUCKSESS, MW
AF TRUCKSESS, MW
TI MYCOTOXINS
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Review
ID LIQUID-CHROMATOGRAPHIC DETERMINATION; LINKED-IMMUNOSORBENT-ASSAY; FLOUR
REFERENCE MATERIALS; SOLID-PHASE EXTRACTION; ION-TRAP DETECTION;
CYCLOPIAZONIC ACID; MONOCLONAL-ANTIBODY; GAS-CHROMATOGRAPHY;
OCHRATOXIN-A; AFLATOXIN-B1 DETERMINATION
RP TRUCKSESS, MW (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,DIV NAT PROD,WASHINGTON,DC 20204, USA.
NR 113
TC 6
Z9 6
U1 0
U2 1
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1994
VL 77
IS 1
BP 135
EP 142
PG 8
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA MX271
UT WOS:A1994MX27100033
ER
PT J
AU BETZ, JM
AF BETZ, JM
TI PLANT TOXINS
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
ID PYRROLIZIDINE ALKALOIDS; TYROSINE PHOSPHORYLATION;
LIQUID-CHROMATOGRAPHY; POTATO GLYCOALKALOIDS; ALPHA-CHACONINE; HUMAN
URINE; ISOFLAVONES; GENISTEIN; PRODUCTS; CELLS
RP BETZ, JM (reprint author), US FDA,DIV NAT PROD,WASHINGTON,DC 20204, USA.
NR 65
TC 0
Z9 0
U1 0
U2 1
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1994
VL 77
IS 1
BP 142
EP 145
PG 4
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA MX271
UT WOS:A1994MX27100034
ER
PT J
AU HUNGERFORD, JM
AF HUNGERFORD, JM
TI SEAFOOD TOXINS
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
ID CHROMATOGRAPHY MASS-SPECTROMETRY; DIATOM PSEUDONITZSCHIA-AUSTRALIS;
PARALYTIC SHELLFISH POISONS; FLOW-INJECTION ANALYSIS; DOMOIC ACID;
OKADAIC ACID; MARINE TOXINS; CAPILLARY ELECTROPHORESIS; CELL-GROWTH;
ASSAY
RP HUNGERFORD, JM (reprint author), US FDA,22201 23RD DR SE,POB 3012,BOTHELL,WA 98041, USA.
NR 58
TC 2
Z9 2
U1 0
U2 1
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1994
VL 77
IS 1
BP 145
EP 150
PG 6
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA MX271
UT WOS:A1994MX27100035
ER
PT J
AU FIRESTONE, D
AF FIRESTONE, D
TI FATS AND OILS
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
ID INFRARED SPECTROPHOTOMETRY; EDIBLE OILS; FOREIGN FAT; OLIVE OIL;
MILK-FAT; QUALITY; ACIDS; MARGARINES; PRODUCTS; ISOMERS
RP FIRESTONE, D (reprint author), US FDA,DIV PESTICIDES & IND CHEM,WASHINGTON,DC 20204, USA.
NR 27
TC 1
Z9 1
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1994
VL 77
IS 1
BP 151
EP 154
PG 4
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA MX271
UT WOS:A1994MX27100037
ER
PT J
AU PROSKY, L
AF PROSKY, L
TI DIETARY FIBER
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP PROSKY, L (reprint author), US FDA,DIV PROGRAMS & ENFORCEMENT POLICY,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1994
VL 77
IS 1
BP 151
EP 151
PG 1
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA MX271
UT WOS:A1994MX27100036
ER
PT J
AU BUENO, MP
AF BUENO, MP
TI INFANT FORMULA AND MEDICAL DIETS
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP BUENO, MP (reprint author), US FDA,DIV SCI & APPL TECHNOL,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1994
VL 77
IS 1
BP 155
EP 155
PG 1
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA MX271
UT WOS:A1994MX27100038
ER
PT J
AU DEUTSCH, MJ
AF DEUTSCH, MJ
TI VITAMINS AND OTHER NUTRIENTS
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP DEUTSCH, MJ (reprint author), US FDA,OFF FOOD LABELING,HFS-155,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1994
VL 77
IS 1
BP 156
EP 157
PG 2
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA MX271
UT WOS:A1994MX27100040
ER
PT J
AU BOLAND, FE
AF BOLAND, FE
TI FRUITS AND FRUIT PRODUCTS
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP BOLAND, FE (reprint author), US FDA,DIV PROGRAM ENFORCEMENT POLICY,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1994
VL 77
IS 1
BP 160
EP 162
PG 3
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA MX271
UT WOS:A1994MX27100064
ER
PT J
AU MULVANEY, TR
AF MULVANEY, TR
TI PROCESSED VEGETABLE PRODUCTS
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP MULVANEY, TR (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,OFF PLANT & DAIRY FOODS & BEVERAGES,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1994
VL 77
IS 1
BP 167
EP 168
PG 2
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA MX271
UT WOS:A1994MX27100043
ER
PT J
AU HUNGERFORD, JM
AF HUNGERFORD, JM
TI SEAFOOD PRODUCTS
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; TETRACYCLINE ANTIBIOTICS; SPECIES
IDENTIFICATION; LUMINESCENCE DETECTION; MUSCLE-TISSUE; FATTY-ACIDS;
OXYTETRACYCLINE; FISH; HPLC; PROFILES
RP HUNGERFORD, JM (reprint author), US FDA,22201 23RD DR SE,POB 3012,BOTHELL,WA 98041, USA.
NR 43
TC 3
Z9 3
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1994
VL 77
IS 1
BP 168
EP 172
PG 5
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA MX271
UT WOS:A1994MX27100044
ER
PT J
AU MCMAHON, BM
AF MCMAHON, BM
TI ORGANOHALOGEN PESTICIDES AND FUMIGANTS
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP MCMAHON, BM (reprint author), US FDA,DIV CONTAMINANTS CHEM,WASHINGTON,DC 20204, USA.
NR 5
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1994
VL 77
IS 1
BP 179
EP 181
PG 3
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA MX271
UT WOS:A1994MX27100047
ER
PT J
AU BARATTA, EJ
AF BARATTA, EJ
TI RADIOACTIVITY
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP BARATTA, EJ (reprint author), US FDA,WINCHESTER ENGN & ANALYT CTR,WINCHESTER,MA 01890, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1994
VL 77
IS 1
BP 182
EP 182
PG 1
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA MX271
UT WOS:A1994MX27100049
ER
PT J
AU CICHOWICZ, SM
AF CICHOWICZ, SM
TI ANALYTICAL MYCOLOGY AND MICROSCOPY
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP CICHOWICZ, SM (reprint author), US FDA,DIV CONTAMINANTS CHEM,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1994
VL 77
IS 1
BP 183
EP 183
PG 1
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA MX271
UT WOS:A1994MX27100050
ER
PT J
AU HITCHINS, AD
AF HITCHINS, AD
TI COSMETIC MICROBIOLOGY
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP HITCHINS, AD (reprint author), US FDA,DIV MICROBIOL STUDIES,HFS-516,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1994
VL 77
IS 1
BP 183
EP 184
PG 2
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA MX271
UT WOS:A1994MX27100051
ER
PT J
AU PLACENCIA, AM
AF PLACENCIA, AM
TI DRUG-RELATED AND DEVICE-RELATED MICROBIOLOGY
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP PLACENCIA, AM (reprint author), US FDA,240 HENNEPIN AVE,MINNEAPOLIS,MN 55401, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1994
VL 77
IS 1
BP 184
EP 186
PG 3
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA MX271
UT WOS:A1994MX27100052
ER
PT J
AU BOESE, JL
AF BOESE, JL
TI FILTH AND EXTRANEOUS MATERIALS IN FOODS AND DRUGS
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
RP BOESE, JL (reprint author), US FDA,DIV MICROANALYT EVALUAT,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1994
VL 77
IS 1
BP 186
EP 186
PG 1
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA MX271
UT WOS:A1994MX27100053
ER
PT J
AU ANDREWS, WH
AF ANDREWS, WH
TI FOOD MICROBIOLOGY (NONDAIRY)
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
ID ENRICHMENT MEDIUM; SALMONELLA; PRODUCTS
RP ANDREWS, WH (reprint author), US FDA,DIV MICROBIOL STUDIES,WASHINGTON,DC 20204, USA.
NR 15
TC 3
Z9 3
U1 0
U2 1
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD JAN-FEB
PY 1994
VL 77
IS 1
BP 187
EP 194
PG 8
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA MX271
UT WOS:A1994MX27100055
ER
PT J
AU BRUCK, SD
SCHROEDER, LW
AF BRUCK, SD
SCHROEDER, LW
TI UNTITLED
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Letter
C1 US FDA,ROCKVILLE,MD 20852.
RP BRUCK, SD (reprint author), STEPHEN D BRUCK ASS INC,MAT & MED DEVICES CONSULTING GRP,POB 828,ROCKVILLE,MD 20848, USA.
NR 1
TC 1
Z9 1
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD JAN
PY 1994
VL 28
IS 1
BP 133
EP 134
DI 10.1002/jbm.820280117
PG 2
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA MM133
UT WOS:A1994MM13300017
PM 8126024
ER
PT J
AU KELLOFF, GJ
JOHNSON, JR
CROWELL, JA
BOONE, CW
DEGEORGE, JJ
STEELE, VE
MEHTA, MU
TEMECK, JW
SCHMIDT, WJ
BURKE, G
GREENWALD, P
TEMPLE, RJ
AF KELLOFF, GJ
JOHNSON, JR
CROWELL, JA
BOONE, CW
DEGEORGE, JJ
STEELE, VE
MEHTA, MU
TEMECK, JW
SCHMIDT, WJ
BURKE, G
GREENWALD, P
TEMPLE, RJ
TI GUIDANCE FOR DEVELOPMENT OF CHEMOPREVENTIVE AGENTS
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
C1 US FDA,CTR DRUG EVALUAT & RES,ROCKVILLE,MD 20852.
RP KELLOFF, GJ (reprint author), NCI,DIV CANC PREVENT & CONTROL,CHEMOPREVENT BRANCH,9000 ROCKVILLE PIKE,SUITE 201,BETHESDA,MD 20892, USA.
NR 1
TC 1
Z9 1
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PY 1994
SU 20
BP 25
EP 31
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA QQ805
UT WOS:A1994QQ80500003
ER
PT J
AU RICE, CM
GRAKOUI, A
CHAMBERS, TJ
LIN, C
AMBERG, SM
KOLYKHALOV, AA
AGAPOV, YV
REED, K
NESTOROWICZ, AC
MCCOURT, DW
WYCHOWSKI, C
FEINSTONE, SM
AF RICE, CM
GRAKOUI, A
CHAMBERS, TJ
LIN, C
AMBERG, SM
KOLYKHALOV, AA
AGAPOV, YV
REED, K
NESTOROWICZ, AC
MCCOURT, DW
WYCHOWSKI, C
FEINSTONE, SM
TI FLAVIVIRUS PROTEINASES
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Meeting Abstract
C1 WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110.
US FDA,DEPT VIROL,BETHESDA,MD 20014.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PY 1994
SU 18D
BP 125
EP 125
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA NE254
UT WOS:A1994NE25400364
ER
PT J
AU RACKE, MK
MCFARLIN, DE
SCOTT, DE
AF RACKE, MK
MCFARLIN, DE
SCOTT, DE
TI MODIFICATION OF CYTOKINE PRODUCTION BY T-CELLS ACTIVATED IN THE PRESENCE
OF RETINOIC ACID
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Meeting Abstract
C1 NIH,NEUROIMMUNOL BRANCH,BETHESDA,MD 20892.
US FDA,BETHESDA,MD 20892.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PY 1994
SU 18D
BP 320
EP 320
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA NE254
UT WOS:A1994NE25401044
ER
PT J
AU BHATIADEY, N
DIRKSEN, ML
ADELSTEIN, RS
JAMRICH, M
AF BHATIADEY, N
DIRKSEN, ML
ADELSTEIN, RS
JAMRICH, M
TI FORKHEAD DOMAIN-CONTAINING TRANSCRIPTION FACTOR EXPRESSED IN PRESOMITIC
MESODERM OF XENOPUS-EMBRYOS
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Meeting Abstract
C1 NHLBI,MOLEC CARDIOL LAB,BETHESDA,MD 20892.
US FDA,DEV BIOL LAB,ROCKVILLE,MD 20852.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PY 1994
SU 18D
BP 487
EP 487
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA NE254
UT WOS:A1994NE25401682
ER
PT J
AU MILLER, HI
TART, MA
BOZZO, TS
AF MILLER, HI
TART, MA
BOZZO, TS
TI MANUFACTURING NEW BIOTECH PRODUCTS - GAINS AND GROWING PAINS
SO JOURNAL OF CHEMICAL TECHNOLOGY AND BIOTECHNOLOGY
LA English
DT Note
C1 US FDA,CBER,DIV ESTAB LICENSING,ROCKVILLE,MD 20852.
US FDA,OFF BIOTECHNOL,ROCKVILLE,MD 20857.
US FDA,CBER,OFF COMPLIANCE,ROCKVILLE,MD 20852.
NR 0
TC 6
Z9 6
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI W SUSSEX
PA BAFFINS LANE CHICHESTER, W SUSSEX, ENGLAND PO19 1UD
SN 0268-2575
J9 J CHEM TECHNOL BIOT
JI J. Chem. Technol. Biotechnol.
PD JAN
PY 1994
VL 59
IS 1
BP 3
EP 7
DI 10.1002/jctb.280590103
PG 5
WC Biotechnology & Applied Microbiology; Chemistry, Multidisciplinary;
Engineering, Environmental; Engineering, Chemical
SC Biotechnology & Applied Microbiology; Chemistry; Engineering
GA MR541
UT WOS:A1994MR54100002
PM 7764495
ER
PT J
AU SANTOS, N
RIEPENHOFFTALTY, M
CLARK, HF
OFFIT, P
GOUVEA, V
AF SANTOS, N
RIEPENHOFFTALTY, M
CLARK, HF
OFFIT, P
GOUVEA, V
TI VP4 GENOTYPING OF HUMAN ROTAVIRUS IN THE UNITED-STATES
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID POLYMERASE CHAIN-REACTION; REACTION AMPLIFICATION; REVERSE
TRANSCRIPTION; STOOL SPECIMENS; UNIQUE VP4; 4TH GENE; INFECTIONS;
IDENTIFICATION; NEUTRALIZATION; CHILDREN
AB The VP4 (P) and VP7 (G) types of 171 rotavirus isolates obtained from children with diarrhea in the United States were characterized by PCR typing assays. Strains P1G1 predominated (71%); this was followed by strains P1G3 (20%) and P2G2 and P1G4 (2% each). Mixed types were identified in five (3%) specimens. Two (1%) strains bearing the P3 genotype (P3G1 and P3G2) were found in children with severe dehydrating diarrhea, although the P3 genotype has been regarded as a possible marker for virus attenuation.
C1 US FDA,DIV MOLEC BIOL RES & EVALUAT HSF 237,200 C ST SW,WASHINGTON,DC 20204.
CHILDRENS HOSP BUFFALO,BUFFALO,NY 14222.
CHILDRENS HOSP PHILADELPHIA,PHILADELPHIA,PA 19104.
RI Santos, Norma/H-6986-2015
OI Santos, Norma/0000-0002-5123-9172
NR 33
TC 48
Z9 48
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD JAN
PY 1994
VL 32
IS 1
BP 205
EP 208
PG 4
WC Microbiology
SC Microbiology
GA MP316
UT WOS:A1994MP31600039
PM 8126181
ER
PT J
AU QURESHI, MN
JOSHI, B
HEWLETT, I
HENRARD, D
QIU, Z
BARR, CE
AF QURESHI, MN
JOSHI, B
HEWLETT, I
HENRARD, D
QIU, Z
BARR, CE
TI PREVALENCE OF HIV-I PROVIRAL DNA AND VIRION-ASSOCIATED RNA IN SALIVA
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Meeting Abstract
C1 BETH ISRAEL MED CTR,NEW YORK,NY 10003.
US FDA,CBER,BETHESDA,MD 20014.
ABBOTT LABS,CHICAGO,IL.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER ASSOC DENTAL RESEARCH
PI ALEXANDRIA
PA 1619 DUKE ST, ALEXANDRIA, VA 22314
SN 0022-0345
J9 J DENT RES
JI J. Dent. Res.
PY 1994
VL 73
SI SI
BP 422
EP 422
PG 1
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA MT325
UT WOS:A1994MT32502558
ER
PT J
AU LI, BG
CLARK, HF
GOUVEA, V
AF LI, BG
CLARK, HF
GOUVEA, V
TI AMINO-ACID-SEQUENCE SIMILARITY OF THE VP7 PROTEIN OF HUMAN ROTAVIRUS
HCR3 TO THAT OF CANINE AND FELINE ROTAVIRUSES
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID PLAQUE-REDUCTION NEUTRALIZATION; RNA-RNA HYBRIDIZATION; G-SEROTYPE;
GENOMIC CHARACTERIZATION; MONOCLONAL-ANTIBODIES; NUCLEOTIDE-SEQUENCE;
ANIMAL ROTAVIRUSES; GLYCOPROTEIN VP7; RHESUS ROTAVIRUS; GENE
AB The sequence of the VP7 gene of human rotavirus strain HCR3 was determined and its predicted amino acid sequence was compared with that of other rotavirus strains. The VP7 gene is 1062 nucleotides long and contains a single open reading frame of 981 nucleotides capable of encoding a protein of 326 amino acids. The VP7 amino acid sequence similarity of strain HCR3 to those of various human and animal G3 serotypes ranged from 88.7 to 99.4%, and from 60.4 to 88.3% to strains representing each of the other 13 G serotypes. Alignment of four variable regions [VR4, VR5(A), VR7(B) and VR8(C)] of HCR3 with those of G3 strains of different host species showed that HCR3 possesses a sequence almost identical to that of canine rotaviruses and feline rotavirus strain CAT97 in all four regions. A considerable divergence in regions VR4, VR7(B) and VR8(C) was found with strains of human, mouse, monkey, horse and rabbit rotaviruses. This observation together with results of our previous study on VP4 indicated that human rotavirus HCR3 is genetically more closely related to animal rotaviruses than to other human rotaviruses.
C1 CHILDRENS HOSP PHILADELPHIA,DIV INFECT DIS,PHILADELPHIA,PA 19104.
RP LI, BG (reprint author), US FDA,DIV MOLEC BIOL RES & EVALUAT,MOLEC BIOL BRANCH,WASHINGTON,DC 20204, USA.
NR 28
TC 17
Z9 17
U1 0
U2 1
PU SOC GENERAL MICROBIOLOGY
PI READING
PA HARVEST HOUSE 62 LONDON ROAD, READING, BERKS, ENGLAND RG1 5AS
SN 0022-1317
J9 J GEN VIROL
JI J. Gen. Virol.
PD JAN
PY 1994
VL 75
BP 215
EP 219
DI 10.1099/0022-1317-75-1-215
PN 1
PG 5
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA MR202
UT WOS:A1994MR20200028
PM 8113730
ER
PT J
AU HOLCOMB, M
THOMPSON, HC
LIPE, G
HANKINS, LJ
AF HOLCOMB, M
THOMPSON, HC
LIPE, G
HANKINS, LJ
TI HPLC WITH ELECTROCHEMICAL AND FLUORESCENCE DETECTION OF THE OPA
2-METHYL-2-PROPANETHIOL DERIVATIVE OF FUMONISIN B-1
SO JOURNAL OF LIQUID CHROMATOGRAPHY
LA English
DT Article
ID FUSARIUM-MONILIFORME; LIQUID-CHROMATOGRAPHY
AB The o-phthalaldehyde (OPA) derivative of fumonisin B-1 was prepared in the presence of 2-methyl-2-propanethiol (tert-butyl thiol). A hydrodynamic voltammogram for the derivative indicated that the optimum voltage for maximum electrochemical response was +0.7 V. The electrochemical response of the OPA/tert-butyl derivative was unstable. However, the fluorescence response was found to be stable for over an hour after an initial 30 minute reaction time. The minimum detectable limit (MDL) of the OPA/tert-butyl derivative using fluorescence detection was 30 ng/ml as compared to 250 ng/ml for electrochemical detection.
C1 US FDA,NATL CTR TOXICOL RES,OFF RES SERV,DIV NEUROTOXICOL,JEFFERSON,AR 72079.
RP HOLCOMB, M (reprint author), US FDA,NATL CTR TOXICOL RES,OFF RES SERV,DIV CHEM,JEFFERSON,AR 72079, USA.
NR 8
TC 5
Z9 5
U1 0
U2 0
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 0148-3919
J9 J LIQ CHROMATOGR
JI J. Liq. Chromatogr.
PY 1994
VL 17
IS 19
BP 4121
EP 4129
DI 10.1080/10826079408013605
PG 9
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA PV102
UT WOS:A1994PV10200006
ER
PT J
AU LUMBARDO, DF
KOENEMAN, JB
LONGO, JA
AF LUMBARDO, DF
KOENEMAN, JB
LONGO, JA
TI MEASUREMENTS OF LONG-TERM PERIPROSTHETIC BONE CHANGES AROUND A UNIQUE
COMPOSITE IMPLANT
SO JOURNAL OF LONG-TERM EFFECTS OF MEDICAL IMPLANTS
LA English
DT Article
DE BONE REMODELING; HIP PROSTHESIS; STRESS SHIELDING
AB Periprosthetic bone changes around a non-bonded composite implant were measured after 6.5 years of implantation. The implanted and unimplanted femora of three canines were cut simultaneously at 3-mm increments. Cortical bone changes at all levels were determined from contact radiographs of the sections using an image analysis system. Alternating sections were cut into 3-mm cubes. The elastic properties of the cancellous bone cubes were determined using ultrasonic techniques. The method of directed secants was used to determine the cancellous bone orientation. The proximal cortical wall thickness on the implanted side increases by an average of 30%. The cancellous bone directly adjacent to the implant was an almost continuous shell encircling the prosthesis. The periprosthetic orientation was circumferential around the implant. The elastic and shear moduli of the cancellous bone increased on the implanted side. The bone changes are currently being correlated with results from finite element calculations.
C1 ORTHOLOGIC,PHOENIX,AZ 85034.
SCOTTSDALE SPECIALISTS,SCOTTSDALE,AZ 85251.
RP LUMBARDO, DF (reprint author), US FDA,2094 GAITHER RD,HFZ341,ROCKVILLE,MD 20850, USA.
FU NIAMS NIH HHS [AR40558]
NR 15
TC 1
Z9 1
U1 0
U2 0
PU BEGELL HOUSE INC
PI NEW YORK
PA 79 MADISON AVE, STE 1202, NEW YORK, NY 10016-7892
SN 1050-6934
J9 J LONG-TERM EFF MED
JI J. Long-Term Eff. Med. Implants
PY 1994
VL 4
IS 4
BP 209
EP 222
PG 14
WC Engineering, Biomedical; Medicine, Research & Experimental; Orthopedics;
Pathology
SC Engineering; Research & Experimental Medicine; Orthopedics; Pathology
GA RT903
UT WOS:A1994RT90300004
PM 10155141
ER
PT J
AU BURLINGTON, DB
AF BURLINGTON, DB
TI SELECTED ABSTRACTS OF THE SYMPOSIUM, TOWARDS AN INTERNATIONAL IMPLANT
TRACKING AND DATA SYSTEM, MELBOURNE, AUSTRALIA, JANUARY 29-30, 1995
SO JOURNAL OF LONG-TERM EFFECTS OF MEDICAL IMPLANTS
LA English
DT Article
RP BURLINGTON, DB (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20857, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BEGELL HOUSE INC
PI NEW YORK
PA 79 MADISON AVE, STE 1202, NEW YORK, NY 10016-7892
SN 1050-6934
J9 J LONG-TERM EFF MED
JI J. Long-Term Eff. Med. Implants
PY 1994
VL 4
IS 4
BP 225
EP 239
PG 15
WC Engineering, Biomedical; Medicine, Research & Experimental; Orthopedics;
Pathology
SC Engineering; Research & Experimental Medicine; Orthopedics; Pathology
GA RT903
UT WOS:A1994RT90300005
ER
PT J
AU CHUMAKOV, KM
DRAGUNSKY, EM
NORWOOD, LP
DOUTHITT, MP
RAN, YX
TAFFS, RE
RIDGE, J
LEVENBOOK, IS
AF CHUMAKOV, KM
DRAGUNSKY, EM
NORWOOD, LP
DOUTHITT, MP
RAN, YX
TAFFS, RE
RIDGE, J
LEVENBOOK, IS
TI CONSISTENT SELECTION OF MUTATIONS IN THE 5'-UNTRANSLATED REGION OF ORAL
POLIOVIRUS VACCINE UPON PASSAGING IN-VITRO
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE MONKEY NEUROVIRULENCE TEST; PCR; CELL CULTURES
ID 5' NONCODING REGION; HUMAN NEURO-BLASTOMA; ATTENUATING MUTATION; TYPE-2
POLIOVIRUS; TRANSLATION; RNA; STRAINS; NEUROVIRULENCE; DETERMINANTS;
TEMPERATURE
AB We have previously found that upon passaging type 3 oral poliovirus vaccine (OPV) in cell cultures the proportion of revertants at nucleotide 472 rapidly increases [Chumakov et al.: Proceedings of the National Academy of Sciences of the United States of America 88:199-203 1991]. Systematic study on the accumulation of these revertants showed that it was dependent on the multiplicity of infection and the temperature at which virus was grown. Revertants at position 472 of type 3 OPV accumulated faster in vaccines derived from Sabin Original (SO) substrain than from RNA-plaque purified (RSO) substrain. The rate of accumulation of 472-C revertants differed among cell lines and was higher in overgrown cell cultures suggesting that host factors are involved in the selection of mutants. We also found that accumulation of mutants occurred in vitro at position 480 in type 1 and position 481 in type 2 OPV, making the selection for revertants in domain F of the 5'-noncoding region a general phenomenon for all three Sabin strains. Assessment of the abundance of these mutants may be used for evaluation of the quality of OPV lots.
RP CHUMAKOV, KM (reprint author), US FDA,CBER,NIH CAMPUS BLDG 29,HFM-255,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.
NR 29
TC 37
Z9 37
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0146-6615
J9 J MED VIROL
JI J. Med. Virol.
PD JAN
PY 1994
VL 42
IS 1
BP 79
EP 85
DI 10.1002/jmv.1890420115
PG 7
WC Virology
SC Virology
GA MN700
UT WOS:A1994MN70000014
PM 8308524
ER
PT J
AU ALI, SF
AF ALI, SF
TI LOW ENVIRONMENTAL TEMPERATURES OR PHARMACOLOGICAL AGENTS WHICH PRODUCE
HYPOTHERMIA DECREASE METHAMPHETAMINE NEUROTOXICITY IN MICE
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Meeting Abstract
C1 US FDA,NATL CTR TOXICOL RES,DIV NEUROTOXICOL,NEUROCHEM LAB,JEFFERSON,AR 72070.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PY 1994
VL 63
SU 2
BP S12
EP S12
PG 1
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA PF065
UT WOS:A1994PF06500047
ER
PT J
AU CADET, JL
SHENG, PL
ALI, S
ROTHMAN, R
CARLSON, E
EPSTEIN, C
AF CADET, JL
SHENG, PL
ALI, S
ROTHMAN, R
CARLSON, E
EPSTEIN, C
TI ATTENUATION OF METHAMPHETAMINE-INDUCED NEUROTOXICITY IN COPPER/ZINC
SUPEROXIDE-DISMUTASE TRANSGENIC MICE
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Note
DE TRANSGENIC MICE; SUPEROXIDE DISMUTASE; METHAMPHETAMINE; NEUROTOXICITY;
FREE RADICALS; FRONTAL CORTEX; STRIATUM; DOPAMINE; SEROTONIN
ID TYROSINE-HYDROXYLASE ACTIVITY; RAT-BRAIN; DOPAMINE; 6-HYDROXYDOPAMINE;
TOXICITY
AB Administration of methamphetamine (METH) to rats and nonhuman primates causes loss of terminals in the nigrostriatal dopaminergic system. The mechanism by which METH causes its neurotoxicity is not known. To evaluate further the role of oxyradicals in METH-induced neurotoxicity, we have tested its effects in CuZn superoxide dismutase (SOD) transgenic (Tg) mice, which express the human CuZnSOD gene. In non-Tg mice, acute METH administration causes significant decreases in levels of dopamine (DA) and 3,4-dihydroxyphenylacetic acid (DOPAC) in the striata and cortices of non-Tg mice. In contrast, there were no significant decreases in cortical or striatal DA in the SOD-Tg mice. The effects of METH on DOPAC were also attenuated in both structures of these SOD-Tg mice. Chronic METH administration caused decreases in levels of striatal DA and DOPAC in the non-Tg mice, whereas the SOD-Tg mice were not affected. These results suggest that METH-induced dopaminergic toxicity in mice may be secondary to increased production of reactive oxygen species such as the superoxide radical.
C1 NIDA,ADDICT RES CTR,CLIN PSYCHOPHARMACOL SECT,BALTIMORE,MD 21224.
NATL CTR TOXICOL RES,DIV NEUROTOXICOL,JEFFERSON,AR 72079.
UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143.
RP CADET, JL (reprint author), NIDA,ADDICT RES CTR,MOLEC NEUROPSYCHIAT SECT,POB 5180,BALTIMORE,MD 21224, USA.
FU NIA NIH HHS [AG-09838]
NR 24
TC 223
Z9 224
U1 0
U2 1
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD JAN
PY 1994
VL 62
IS 1
BP 380
EP 383
PG 4
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA MM536
UT WOS:A1994MM53600048
PM 7505315
ER
PT J
AU DACUNHA, A
NESKOVIC, N
PINE, PS
VITKOVIC, L
AF DACUNHA, A
NESKOVIC, N
PINE, PS
VITKOVIC, L
TI POTENTIAL ROLE OF GAP-43 IN MEMBRANE SYNTHESIS
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Meeting Abstract
C1 CTR NEUROCHIM,F-67084 STRASBOURG,FRANCE.
US FDA,WASHINGTON,DC 20204.
NIMH,DIV NEUROSCI & BEHAV SCI,ROCKVILLE,MD 20857.
RP DACUNHA, A (reprint author), NIMH,CELL BIOL LAB,BETHESDA,MD 20892, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PY 1994
VL 62
SU S
BP S66
EP S66
PG 1
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA NQ959
UT WOS:A1994NQ95900260
ER
PT J
AU PEDEN, KWC
AF PEDEN, KWC
TI ASPECTS OF TROPISM OF HUMAN-IMMUNODEFICIENCY-VIRUS
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Meeting Abstract
C1 US FDA,CBER,RETROVIRUS RES LAB,BETHESDA,MD 20892.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PY 1994
VL 62
SU S
BP S90
EP S90
PG 1
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA NQ959
UT WOS:A1994NQ95900359
ER
PT J
AU YAMABE, T
DHIR, G
COWAN, EP
WOLF, AL
BERGEY, GK
KRUMHOLZ, A
BARRY, E
HOFFMAN, PM
DHIBJALBUT, S
AF YAMABE, T
DHIR, G
COWAN, EP
WOLF, AL
BERGEY, GK
KRUMHOLZ, A
BARRY, E
HOFFMAN, PM
DHIBJALBUT, S
TI CYTOKINE-GENE EXPRESSION IN MEASLES-INFECTED ADULT HUMAN GLIAL-CELLS
SO JOURNAL OF NEUROIMMUNOLOGY
LA English
DT Article
DE MICROGLIA; INTERLEUKIN-1-BETA; INTERLEUKIN-6; TUMOR NECROSIS FACTOR
ALPHA; MEASLES VIRUS
ID TUMOR NECROSIS FACTOR; MICROGLIAL CELLS; MESSENGER-RNAS; CLASS-II;
CULTURES; ASTROCYTES; MONOCYTES; INVITRO; VIRUS
AB The expression of interleukin (IL)-1 beta, IL-6 and tumor necrosis factor (TNF) alpha transcripts in cultured human glial cells was examined using reverse transcription followed by polymerase chain reaction (PCR) amplification and Southern blot quantitation. Microglial cultures derived from brain biopsy specimens from three different individuals expressed transcripts for the three cytokines under basal culture conditions. This expression was enhanced in response to measles virus (MV) infection (IL-1 beta, 2.2-8.8-fold; IL-6, 2.5-8.4-fold; TNF alpha, 2.2-3.2-fold). Neither IL-1 beta nor TNF alpha transcripts were detectable in undissociated brain tissue from two individuals, suggesting that the basal expression of these cytokines in culture may have been induced by tissue dissociation or by the culture conditions. Oligodendrocytes did not express cytokine transcripts under basal culture conditions, and IL-1 beta and IL-6 but not TNF alpha transcripts could be induced by MV. Similarly, meningeal fibroblasts expressed IL-1 beta and IL-6 but not TNF alpha in response to MV-infection, suggesting that the production of TNF alpha is more cell type-restricted than either IL-1 beta or IL-6. The results indicate that adult human microglia can participate in the inflammatory response to MV infection in the CNS by producing cytokines that contribute to inflammation and demyelination. In addition, besides their role in myelination, oligodendrocytes can potentially influence immunoreactivity in the CNS by producing IL-1 beta and IL-6.
C1 BALTIMORE VET ADM MED CTR,RETROVIRUS RES CTR,BALTIMORE,MD.
US FDA,CTR BIOL EVALUAT & RES,BALTIMORE,MD.
UNIV MARYLAND,DEPT NEUROSURG,BALTIMORE,MD.
UNIV MARYLAND HOSP,DEPT NEPHROL,BALTIMORE,MD 21201.
FU NINDS NIH HHS [2 P50 NS 20022-09A1]
NR 22
TC 41
Z9 41
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-5728
J9 J NEUROIMMUNOL
JI J. Neuroimmunol.
PD JAN
PY 1994
VL 49
IS 1-2
BP 171
EP 179
DI 10.1016/0165-5728(94)90193-7
PG 9
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA MU323
UT WOS:A1994MU32300020
PM 8294554
ER
PT J
AU KESSLER, DA
AF KESSLER, DA
TI INTRODUCING MEDWATCH - A NEW APPROACH TO REPORTING MEDICATION AND DEVICE
ADVERSE-EFFECTS AND PRODUCT PROBLEMS (REPRINTED FROM JAMA, VOL 269,
1993)
SO JOURNAL OF THE AMERICAN PODIATRIC MEDICAL ASSOCIATION
LA English
DT Reprint
RP KESSLER, DA (reprint author), US FDA,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER PODIATRIC MED ASSN
PI BETHESDA
PA 9312 OLD GEORGETOWN ROAD, BETHESDA, MD 20814-1621
SN 0003-0538
J9 J AM PODIAT MED ASSN
JI J. Am. Podiatr. Med. Assoc.
PD JAN
PY 1994
VL 84
IS 1
BP 35
EP 38
PG 4
WC Orthopedics
SC Orthopedics
GA NJ612
UT WOS:A1994NJ61200008
PM 8295131
ER
PT J
AU ALTEKRUSE, SF
HUNT, JM
TOLLEFSON, LK
MADDEN, JM
AF ALTEKRUSE, SF
HUNT, JM
TOLLEFSON, LK
MADDEN, JM
TI FOOD AND ANIMAL SOURCES OF HUMAN CAMPYLOBACTER-JEJUNI INFECTION
SO JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION
LA English
DT Article
ID FETUS SUBSP-JEJUNI; THERMOPHILIC CAMPYLOBACTERS;
YERSINIA-ENTEROCOLITICA; RISK-FACTORS; WILD BIRDS; RAW-MILK; DOGS;
ENTERITIS; PREVALENCE; CATS
C1 US FDA,OFF POLICY PLANNING & STRATEG INITIAT,WASHINGTON,DC 20204.
US FDA,CINCINNATI DIST OFF,CINCINNATI,OH 45202.
US FDA,CTR VET MED,ROCKVILLE,MD 20855.
RP ALTEKRUSE, SF (reprint author), US FDA,EPIDEMIOL BRANCH,WASHINGTON,DC 20204, USA.
NR 87
TC 67
Z9 67
U1 2
U2 9
PU AMER VETERINARY MEDICAL ASSOC
PI SCHAUMBURG
PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360
SN 0003-1488
J9 J AM VET MED ASSOC
JI J. Am. Vet. Med. Assoc.
PD JAN 1
PY 1994
VL 204
IS 1
BP 57
EP 61
PG 5
WC Veterinary Sciences
SC Veterinary Sciences
GA MN978
UT WOS:A1994MN97800016
PM 8125823
ER
PT J
AU GRIEVE, AP
POCOCK, SJ
ABRAMS, K
ASHBY, D
HEALY, MJR
JENNISON, C
LEWIS, JA
LINDLEY, DV
MACHIN, D
NEWMAN, GB
BATHER, JA
BAILEY, RA
EVANS, SJW
KEIDING, N
MATTHEWS, JNS
GORE, SM
SENN, S
HERSON, J
TURNBULL, BW
ALTMAN, DG
ARMITAGE, P
ATKINSON, AC
BERRY, DA
BUYSE, ME
CARLIN, BP
DEMETS, DL
DEMPSTER, AP
DUNSTAN, FDJ
ELLENBERG, SS
FAYERS, P
GAIL, MH
GEORGE, SL
GREENHOUSE, JB
WASSERMAN, LA
HARRELL, FE
JOSEPH, L
SHAPIRO, SH
KADANE, JB
LEHMANN, HP
MARUBINI, E
MARIANI, L
PATER, JL
PETTIT, LI
YOUNG, KDS
ROSNER, GL
WHITEHEAD, J
WIEAND, HS
AF GRIEVE, AP
POCOCK, SJ
ABRAMS, K
ASHBY, D
HEALY, MJR
JENNISON, C
LEWIS, JA
LINDLEY, DV
MACHIN, D
NEWMAN, GB
BATHER, JA
BAILEY, RA
EVANS, SJW
KEIDING, N
MATTHEWS, JNS
GORE, SM
SENN, S
HERSON, J
TURNBULL, BW
ALTMAN, DG
ARMITAGE, P
ATKINSON, AC
BERRY, DA
BUYSE, ME
CARLIN, BP
DEMETS, DL
DEMPSTER, AP
DUNSTAN, FDJ
ELLENBERG, SS
FAYERS, P
GAIL, MH
GEORGE, SL
GREENHOUSE, JB
WASSERMAN, LA
HARRELL, FE
JOSEPH, L
SHAPIRO, SH
KADANE, JB
LEHMANN, HP
MARUBINI, E
MARIANI, L
PATER, JL
PETTIT, LI
YOUNG, KDS
ROSNER, GL
WHITEHEAD, J
WIEAND, HS
TI BAYESIAN APPROACHES TO RANDOMIZED TRIALS - DISCUSSION
SO JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-STATISTICS IN SOCIETY
LA English
DT Discussion
ID SEQUENTIAL CLINICAL-TRIALS; PROGNOSTIC FACTORS; INTERIM ANALYSES;
STOPPING RULES; OPINION; TESTS; ALLOCATION; DESIGN
C1 UNIV LONDON LONDON SCH HYG & TROP MED, LONDON WC1E 7HT, ENGLAND.
UNIV LEICESTER, LEICESTER LE1 7RH, ENGLAND.
UNIV LIVERPOOL, LIVERPOOL L69 3BX, ENGLAND.
INST EDUC, LONDON, ENGLAND.
UNIV BATH, BATH BA2 7AY, AVON, ENGLAND.
UNIV KENT, CANTERBURY CT2 7NZ, KENT, ENGLAND.
MRC, CANC TRIALS OFF, CAMBRIDGE, ENGLAND.
UNIV SUSSEX, BRIGHTON BN1 9RH, E SUSSEX, ENGLAND.
GOLDSMITHS COLL, LONDON, ENGLAND.
UNIV LONDON LONDON HOSP, COLL MED, LONDON E1 1BB, ENGLAND.
UNIV COPENHAGEN, DK-1168 COPENHAGEN, DENMARK.
UNIV NEWCASTLE UPON TYNE, NEWCASTLE UPON TYNE NE1 7RU, TYNE & WEAR, ENGLAND.
MRC, BIOSTAT UNIT, CAMBRIDGE, ENGLAND.
CIBA GEIGY AG, DIV PHARMACEUT, CH-4002 BASEL, SWITZERLAND.
APPL LOG ASSOCIATES, HOUSTON, TX USA.
CORNELL UNIV, ITHACA, NY 14853 USA.
IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND.
UNIV LONDON LONDON SCH ECON & POLIT SCI, LONDON WC2A 2AE, ENGLAND.
DUKE UNIV, DURHAM, NC 27706 USA.
INT INST DRUG DEV, BRUSSELS, BELGIUM.
LIMBURGS UNIV CENTRUM, B-3610 DIEPENBEEK, BELGIUM.
UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA.
UNIV WISCONSIN, MADISON, WI 53706 USA.
UNIV WASHINGTON, SEATTLE, WA USA.
HARVARD UNIV, CAMBRIDGE, MA 02138 USA.
UNIV WALES COLL MED, CARDIFF CF4 4XN, S GLAM, WALES.
US FDA, ROCKVILLE, MD 20857 USA.
NCI, BETHESDA, MD 20892 USA.
DUKE UNIV, MED CTR, DURHAM, NC 27710 USA.
MCGILL UNIV, MONTREAL, PQ H3A 2T5, CANADA.
CARNEGIE MELLON UNIV, PITTSBURGH, PA 15213 USA.
JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21205 USA.
UNIV MILAN, I-20122 MILAN, ITALY.
QUEENS UNIV, KINGSTON, ON K7L 3N6, CANADA.
GOLDSMITHS COLL, LONDON, ENGLAND.
UNIV SURREY, GUILDFORD GU2 5XH, SURREY, ENGLAND.
UNIV READING, READING RG6 2AH, BERKS, ENGLAND.
MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA.
RP GRIEVE, AP (reprint author), ZENECA PHARMACEUT, MACCLESFIELD, ENGLAND.
RI Senn, Stephen/A-8101-2008; Fayers, Peter/A-5999-2010; Senn,
Stephen/B-2903-2013;
OI Senn, Stephen/0000-0002-7558-8473; Grieve, Andrew/0000-0003-3143-2554
NR 82
TC 2
Z9 2
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0964-1998
EI 1467-985X
J9 J R STAT SOC A STAT
JI J. R. Stat. Soc. Ser. A-Stat. Soc.
PY 1994
VL 157
BP 387
EP 416
PN 3
PG 30
WC Social Sciences, Mathematical Methods; Statistics & Probability
SC Mathematical Methods In Social Sciences; Mathematics
GA PX871
UT WOS:A1994PX87100005
ER
PT J
AU GREEN, S
AF GREEN, S
TI PROGRESS OF VARIOUS US REGULATORY AGENCIES IN REVIEWING ALTERNATIVE TEST
METHODS
SO JOURNAL OF TOXICOLOGY-CUTANEOUS AND OCULAR TOXICOLOGY
LA English
DT Article; Proceedings Paper
CT Satellite Meeting of the Society-of-Toxicology on New Horizons in In
Vitro Toxicology
CY MAR 15, 1994
CL DALLAS, TX
SP SOC TOXICOL
C1 US FDA,WASHINGTON,DC 20204.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 0731-3829
J9 J TOXICOL-CUTAN OCUL
JI J. Toxicol.-Cutan. Ocul. Toxicol.
PY 1994
VL 13
IS 4
BP 339
EP 343
PG 5
WC Ophthalmology; Toxicology
SC Ophthalmology; Toxicology
GA PQ824
UT WOS:A1994PQ82400010
ER
PT J
AU WHITTAKER, P
CHANDERBHAN, R
CALVERT, R
DUNKEL, V
AF WHITTAKER, P
CHANDERBHAN, R
CALVERT, R
DUNKEL, V
TI CELLULAR AND MOLECULAR RESPONSES IN THE SPRAGUE-DAWLEY RAT TO CHRONIC
IRON OVERLOAD
SO JOURNAL OF TRACE ELEMENTS IN EXPERIMENTAL MEDICINE
LA English
DT Article
DE HEPATOCELLULAR HYPERTROPHY; IRON TOXICITY; LIPID PEROXIDATION; DNA; RATS
ID LIPID-PEROXIDATION; HEMOCHROMATOSIS; FERRITIN; LIVER; BRAIN;
LOCALIZATION; PROTEINS
AB Hepatotoxicity produced in Sprague-Dawley rats by dietary Fe overload was manifested as hypertrophy of the liver. The enlarged hepatocytes were located predominantly in the periportal region of the liver lobules and contained large amounts of granular cytoplasmic Fe. There was a direct relationship between dietary level of Fe and liver nonheme Fe which correlated with liver DNA content, lipid peroxidation, and thymidine kinase. After 12 weeks of feeding animals diets supplemented with 35, 350, 3,500, and 20,000 mu g Fe/g, there was a dose-related decrease in liver DNA content from 1,526 to 1,291 mu g/g. Liver lipid-conjugated dienes increased from 0.019 to 0.039 mu mol/mg lipid and directly correlated with nonheme liver Fe. TK-specific activity rose to 2.09 pmol . min(-1) . mg(-1) protein in rats fed the high Fe diet; the level in the control group was 0.85 pmol . min(-1) . mg(-1). Also, an evaluation of the heart showed a progressive increase in the ratio of heart wt/body wt and in the amount of Fe deposited in this organ. At the 3,500 and 20,000 mu g Fe/g dose levels, two animals that died before termination of the study had marked myocardial damage. These results show that toxicity resulting from Fe overload mediates lipid peroxidation, hepatomegaly, decreased cellular DNA content, and increased TK activity in the liver. The results also indicate that Fe affects heart function. (C) 1994 Wiley-Liss, Inc.
RP WHITTAKER, P (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR HFS465,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 34
TC 20
Z9 20
U1 0
U2 3
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0896-548X
J9 J TRACE ELEM EXP MED
JI J. Trace Elem. Exp. Med.
PY 1994
VL 7
IS 1
BP 19
EP 31
PG 13
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA NW929
UT WOS:A1994NW92900003
ER
PT J
AU SANTOS, N
GOUVEA, V
AF SANTOS, N
GOUVEA, V
TI IMPROVED METHOD FOR PURIFICATION OF VIRAL-RNA FROM FECAL SPECIMENS FOR
ROTAVIRUS DETECTION
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE VIRAL RNA; PURIFICATION; ROTAVIRUS DIAGNOSIS
ID POLYMERASE CHAIN-REACTION; NUCLEIC-ACID; FECES; DNA
AB An improved procedure to recover and purify double-stranded RNA (dsRNA) from fecal specimens is described. Guanidine isothiocyanate, hydroxyapatite, and cetyltrimethylammonium bromide were used to extract and purify rotavirus dsRNA from fecal specimens. The method is very efficient and easy to perform, and precludes the use of toxic substances such as phenol, chloroform, and Freon. It yields RNA free of enzymatic inhibitors, permitting its detection by reverse transcription-polymerase chain reaction assays. In addition, it was demonstrated that during initial clarification of the fecal suspension, the pellet must be washed at least twice to avoid massive losses of virus, viral protein, or viral nucleic acid retained in the solid debris.
C1 US FDA,DIV MOLEC BIOL RES & EVALUAT,WASHINGTON,DC 20204.
OI Santos, Norma/0000-0002-5123-9172
NR 22
TC 32
Z9 34
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
J9 J VIROL METHODS
JI J. Virol. Methods
PD JAN
PY 1994
VL 46
IS 1
BP 11
EP 21
DI 10.1016/0166-0934(94)90012-4
PG 11
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Virology
GA MW142
UT WOS:A1994MW14200002
PM 8175943
ER
PT J
AU GRAFF, J
NORMANN, A
FEINSTONE, SM
FLEHMIG, B
AF GRAFF, J
NORMANN, A
FEINSTONE, SM
FLEHMIG, B
TI NUCLEOTIDE-SEQUENCE OF WILD-TYPE HEPATITIS A VIRUS GBM IN COMPARISON
WITH 2 CELL CULTURE-ADAPTED VARIANTS
SO JOURNAL OF VIROLOGY
LA English
DT Note
ID 5' NONTRANSLATED REGION; A-VIRUS; GROWTH-CHARACTERISTICS; PERSISTENT
INFECTION; MOLECULAR-CLONING; STRAIN HM175; REPLICATION; MUTATIONS;
INVITRO; RNA
AB In order to study cell tropism and attenuation of hepatitis A virus (HAV), the genome of HAV wild-type GBM and two cell culture-adapted variants, GBM/FRhK and GBM/HFS, were cloned and sequenced after amplification by reverse transcriptase-PCR, During virus cultivation, the HAV variant GBM/FRhK had a strict host range for FRhK-4 cells, in contrast to GBM/HFS, which can be grown in HFS and FRhK-4 cells. The HAV variant GBM/HFS was shown to be attenuated when inoculated into chimpanzees (B. Flehmig, R. F. Mauler, G; Noll, E. Weinmann, and J. P. Gregerson, p. 87-90, in A. Zuckerman, ed., Viral Hepatitis and Liver Disease, 1988). On the basis of this biological background, the comparison of the nucleotide sequences of these three HAV GBM variants should elucidate differences which may be of importance for cell tropism and attenuation. The comparison of the genome between the GBM wild type and HAV wild types HM175 (J. I. Cohen, J. R. Ticehurst, R. H. Purcell, A. Buckler-White, and B. M. Baroudy, J. Virol. 61:50-59, 1987) and HAV-LA (R. Najarian, O. Caput, W. Gee, S. J. Potter, A. Renard, J. Merryweather, G. Van Nest, and D. Dina, Proc. Natl. Acad. Sci. USA 82:2627-2631, 1985) showed a 92 to 96.3% identity, whereas the identity was 99.3 to 99.6% between the GBM variants. Nucleotide differences between the wild-type and the cell culture-adapted variants, which were identical in both cell culture-adapted GBM variants, were localized in the 5' noncoding region; in 2B, 3B, and 3D; and in the 3' noncoding region. Our result concerning the 2B/2C region confirms a mutation at position 3889 (C-->T, alanine to valine), which had been shown to be of importance for cell culture adaptation (S. U. Emerson, C. McRill, B. Rosenblum, S. M. Feinstone, and R. H. Purcell, J. Virol. 65:4882-4886, 1991; S. U. Emerson, Y. K. Huang, C. McRill, M. Lewis, and R. H. Purcell, J. Virol, 66:650-653, 1992), whereas other mutations differ from published HAV sequence data and may be cell specific. Further comparison of the two cell culture-adapted GBM variants showed cell-specific mutations resulting in deletions of six amino acids in the VP1 region and three amino acids in the 3A region of the GBM variant GBM/FRhK.
C1 US FDA,CBER,BETHESDA,MD 20892.
RP GRAFF, J (reprint author), UNIV TUBINGEN,INST HYG,DEPT VIROL & EPIDEMIOL VIRUS DIS,SILCHERSTR 7,D-72076 TUBINGEN,GERMANY.
NR 37
TC 71
Z9 76
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD JAN
PY 1994
VL 68
IS 1
BP 548
EP 554
PG 7
WC Virology
SC Virology
GA MW251
UT WOS:A1994MW25100064
PM 8254770
ER
PT J
AU GIORDANO, TJ
NORMANNO, N
MERINO, MJ
SCHNITT, SJ
GULLICK, WJ
JOHNSON, G
SALOMON, DS
AF GIORDANO, TJ
NORMANNO, N
MERINO, MJ
SCHNITT, SJ
GULLICK, WJ
JOHNSON, G
SALOMON, DS
TI AMPHIREGULIN AND CRIPTO EXPRESSION IN MAMMARY DUCTAL CARCINOMA IN-SITU
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
C1 NCI,PATHOL LAB,BETHESDA,MD 20892.
NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892.
BETH ISRAEL HOSP,DEPT PATHOL,BOSTON,MA.
HAMMERSMITH HOSP,IMPERIAL CANC RES FUND,LONDON,ENGLAND.
US FDA,DIV CYTOKINE BIOL,BETHESDA,MD.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD JAN
PY 1994
VL 70
IS 1
BP A16
EP A16
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA MW426
UT WOS:A1994MW42600087
ER
PT J
AU QURESHI, MN
BAGASRA, O
JOSHI, B
HEWLETT, I
BARR, CE
HENRARD, D
AF QURESHI, MN
BAGASRA, O
JOSHI, B
HEWLETT, I
BARR, CE
HENRARD, D
TI HIGH PREVALENCE OF HIV DNA AND RNA AND LOCALIZATION OF HIV-PROVIRAL DNA
IN ORAL MUCOSAL EPITHELIAL-CELLS IN SALIVA FROM HIV(+) SUBJECTS
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
C1 BETH ISRAEL MED CTR,NEW YORK,NY 10003.
THOMAS JEFFERSON UNIV,PHILADELPHIA,PA 19107.
US FDA,CBER,BETHESDA,MD.
ABBOTT LABS,N CHICAGO,IL 60064.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD JAN
PY 1994
VL 70
IS 1
BP A127
EP A127
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA MW426
UT WOS:A1994MW42600756
ER
PT J
AU DURFOR, CN
TURNER, DC
GEORGER, JH
PEEK, BM
STENGER, DA
AF DURFOR, CN
TURNER, DC
GEORGER, JH
PEEK, BM
STENGER, DA
TI FORMATION AND NAPHTHOYL DERIVATIZATION OF AROMATIC AMINOSILANE
SELF-ASSEMBLED MONOLAYERS - CHARACTERIZATION BY ATOMIC-FORCE MICROSCOPY
AND ULTRAVIOLET SPECTROSCOPY
SO LANGMUIR
LA English
DT Article
ID LANGMUIR-BLODGETT-FILMS; COPLANAR MOLECULAR ASSEMBLIES; RESOLUTION;
ELLIPSOMETRY; ADHESION; SURFACES; ORDER
AB Self-assembled monolayers (SAMs) prepared from short chain aminoalkyl- and aromatic aminoalkysilanes have recently proven valuable in controlling the adhesive properties of silica substrates for chemical, biological, and microelectronic applications. To gain insight to the structure and amine reactivity of these films, we have studied the formation of SAMs formed on silica surfaces from ((((aminoethyl) amino)methyl) phenethyl) trimethoxysilane (PEDA), and their modification with 2-naphthoyl chloride (NAP-C1). Atomic force microscopy was used to demonstrate that PEDA and PEDA-NAP SAMs do not pack in a periodic or regular array on the surface but in fact are highly disordered relative to surface-deposited Langmuir-Blodgett (LB) phospholipid films, organothiol SAMs on gold, and at least one perfluorinated alkyl monochlorosilane SAM. In contrast to chromophores in well-ordered monolayers, the UV absorbance lineshapes and ratio of peaks corresponding to the (1)A-B-1(b) and (1)A-(1)L(a) transitions of the NAP chromophore remain relatively unchanged after immobilization. A simple first-order model, used to estimate molecular densities and reaction stoichiometries, suggests that in reaction-site-limited PEDA SAMs, the amine reactivity is limited by the maximum packing density of the NAP chromophore.
C1 USN,RES LAB,CTR BIOMOLEC SCI & ENGN,WASHINGTON,DC 20375.
GEOCENTERS INC,FT WASHINGTON,MD 20744.
RP DURFOR, CN (reprint author), US FDA,CBER,HFM 594,BETHESDA,MD 20892, USA.
NR 32
TC 37
Z9 37
U1 2
U2 8
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD JAN
PY 1994
VL 10
IS 1
BP 148
EP 152
DI 10.1021/la00013a022
PG 5
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
Multidisciplinary
SC Chemistry; Materials Science
GA MT810
UT WOS:A1994MT81000023
ER
PT J
AU EDIGER, MN
PETTIT, GH
HAHN, DW
AF EDIGER, MN
PETTIT, GH
HAHN, DW
TI ENHANCED ARF LASER-ABSORPTION IN A COLLAGEN TARGET UNDER ABLATIVE
CONDITIONS
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Article
DE CORNEA; FREE-RADICALS; PHOTOREFRACTIVE SURGERY
ID CORNEA; LENS
AB The time-resolved transmission of collagen targets during ArF excimer laser ablation has been measured. The transmitted excimer pulse measurements demonstrate enhanced media attenuation that is a nonlinear function of incident laser fluence. Forward scattering of the transmitted pulse has been assessed to be a negligible contributor to the observed phenomena. Results of pump/probe interrogation of the ablation site indicate that the onset of enhanced attenuation occurs on the time course of the ablating laser pulse and persists for times on the order of hundreds of microseconds. (C) 1994 Wiley-Liss, Inc.
C1 FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20857.
NR 10
TC 12
Z9 12
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0196-8092
J9 LASER SURG MED
JI Lasers Surg. Med.
PY 1994
VL 15
IS 1
BP 107
EP 111
DI 10.1002/lsm.1900150114
PG 5
WC Dermatology; Surgery
SC Dermatology; Surgery
GA PP488
UT WOS:A1994PP48800013
PM 7997043
ER
PT J
AU ROYSTON, DD
TORRES, JH
THOMSEN, S
SRIRAM, PS
WELCH, AJ
AF ROYSTON, DD
TORRES, JH
THOMSEN, S
SRIRAM, PS
WELCH, AJ
TI COMPARISON OF THE THERMAL TISSUE EFFECTS PRODUCED BY AGED SAPPHIRE AND
SILICA HEMISPHERICAL TIPS
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Article
DE ND-YAG LASER; FIBER OPTICS; LASER ABLATION; LASER COAGULATION; CHICKEN
BREAST MODEL; CONTACT LASER SURGERY
ID ND-YAG LASER; MODIFIED FIBER TIPS; OPTICAL-PROPERTIES; RECANALIZATION;
CONTACT; TEMPERATURE; MYOCARDIUM; HYPERTHERMIA; IRRADIATION; INVITRO
AB This study evaluated the performance of sapphire and fused silica hemispherical tips under the same exposure conditions. Lesions produced in the chicken breast and a blood field were sectioned for light and transmission polarizing microscopy. Lesion size and thermal damage area were recorded as a function of the tips accumulated exposure. The tips transmission was measured after every 1,000 J of exposure. Fused silica tips lasted for similar to 5,000 J and experienced significant surface and transmission deterioration. The sapphire hemispherical tips lasted for > 12,000 J with no surface and transmission deterioration. Lesions produced with the fused silica tips generally increased in depth with use, and depths of 6 mm were common. Lesions produced by the sapphire tips were subsurface spherical areas of coagulation with the tissue surface relatively intact. This difference in resulting lesions may be attributed to the higher thermal conductivity of sapphire. (C) 1994 Wiley-Liss, Inc.
C1 UNIV TEXAS,MD ANDERSON CANC CTR,HOUSTON,TX 77030.
UNIV TEXAS,COLL ENGN,AUSTIN,TX 78712.
RP ROYSTON, DD (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,FISHERS LANE HFZ-134,ROCKVILLE,MD 20857, USA.
NR 33
TC 4
Z9 4
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0196-8092
J9 LASER SURG MED
JI Lasers Surg. Med.
PY 1994
VL 14
IS 1
BP 47
EP 58
DI 10.1002/lsm.1900140112
PG 12
WC Dermatology; Surgery
SC Dermatology; Surgery
GA MR979
UT WOS:A1994MR97900009
PM 8127207
ER
PT J
AU BUCK, JD
MCCARTHY, SA
AF BUCK, JD
MCCARTHY, SA
TI OCCURRENCE OF NON-O1 VIBRIO-CHOLERAE IN TEXAS GULF-COAST DOLPHINS
(TURSIOPS-TRUNCATUS)
SO LETTERS IN APPLIED MICROBIOLOGY
LA English
DT Article
ID DELPHINAPTERUS-LEUCAS; AQUATIC BIRDS; FLORIDA; ENVIRONMENT; BACTERIA;
ESTUARY; CITY
AB Non-01 Yibrio cholerae, commonly found in water, sediment, shellfish and birds along the northern Gulf of Mexico coastline, was isolated from the anus and/or blowhole of five apparently healthy Atlantic bottlenose dolphins (Tursiops truncatus) in July 1992, in Matagorda Bay, Texas. Dolphins may provide a continuing source of non-01 V. cholerae to the environment. The extent of the spread of the organism is probably influenced by the limited home range of the dolphins.
C1 US FDA,GULF COAST SEAFOOD LAB,DAUPHIN ISL,AL 36528.
RP BUCK, JD (reprint author), MOTE MARINE LAB,SARASOTA,FL 34236, USA.
NR 26
TC 2
Z9 2
U1 0
U2 1
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0266-8254
J9 LETT APPL MICROBIOL
JI Lett. Appl. Microbiol.
PD JAN
PY 1994
VL 18
IS 1
BP 45
EP 46
DI 10.1111/j.1472-765X.1994.tb00797.x
PG 2
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA MU638
UT WOS:A1994MU63800014
ER
PT J
AU GAGNE, RM
QUINN, PW
JENNINGS, RJ
AF GAGNE, RM
QUINN, PW
JENNINGS, RJ
TI COMPARISON OF BEAM-HARDENING AND K-EDGE FILTERS FOR IMAGING BARIUM AND
IODINE DURING FLUOROSCOPY
SO MEDICAL PHYSICS
LA English
DT Article
DE FLUOROSCOPY; X-RAY FILTERS; AUTOMATIC BRIGHTNESS CONTROL ALGORITHM
ID X-RAY-SPECTRA; DIAGNOSTIC-RADIOLOGY; PATIENT EXPOSURE; REDUCTION
AB This study investigated the dose reduction performance of several beam-hardening and K-edge filter materials for the imaging of barium or iodine during fluoroscopy. A computer model was developed to simulate the effect of added filtration on entrance exposure rate (X(p)), integral dose rate (D-i), contrast (C), signal to noise ratio (SNR), imaging performance per dose (SNR(2)/D-i), and tube load. The model incorporated the response characteristics, in both manual and automatic control modes of operation, of fluoroscopic systems to increasing or decreasing x-ray intensity at the input of the image intensifier. Input parameters to the computer model included choice of filter material and thickness, a barium or iodine test object, tube potential, phantom thickness, a CsI input phosphor, and a set of algorithms for controlling the fluoroscopic system. In all cases, the performance of systems with added filtration was judged with respect to a reference system operating under comparable conditions. In general, either beam-hardening or K-edge filters provided a significant reduction in entrance exposure and integral dose rates; but with an attendant increase in tube load. For a fluoroscopic system constrained to follow a representative automatic brightness control algorithm, added filtration provided a reduction in entrance exposure and integral dose rates for all phantom or uniformly distributed barium thicknesses. However, the imaging performance per dose, in some cases, decreased rapidly and was less than that of the reference system at large thicknesses. Only a change in the algorithm controlling the kVcp and mA operating points on the fluoroscopic system provided an imaging performance per dose greater than the reference system's at large thicknesses. The practical implementation of adding filtration to fluoroscopic systems is most simply accomplished with beam-hardening filters rather than K-edge filters. However, the systems with K-edge added filtration can provide slightly better performance when used over a limited range of phantom thicknesses such as the range normally associated with pediatric patients.
RP GAGNE, RM (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,OFF SCI & TECHNOL,ROCKVILLE,MD 20857, USA.
NR 21
TC 16
Z9 16
U1 0
U2 0
PU AMER INST PHYSICS
PI WOODBURY
PA CIRCULATION FULFILLMENT DIV, 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2999
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD JAN
PY 1994
VL 21
IS 1
BP 107
EP 121
PG 15
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA MU896
UT WOS:A1994MU89600015
PM 8164575
ER
PT B
AU HASS, BS
MCDANIEL, LP
POIRIER, LA
LITTLEFIELD, NA
AF HASS, BS
MCDANIEL, LP
POIRIER, LA
LITTLEFIELD, NA
BE Collery, P
Poirier, LA
Littlefield, NA
Etienne, JC
TI EFFECT OF MAGNESIUM CONCENTRATION ON THE SOFT AGAR GROWTH OF NORMAL AND
TRANSFORMED-CELLS
SO METAL IONS IN BIOLOGY AND MEDICINE, VOL 3: PROCEEDINGS OF THE THIRD
INTERNATIONAL SYMPOSIUM ON METAL IONS IN BIOLOGY AND MEDICINE
SE METAL IONS IN BIOLOGY AND MEDICINE
LA English
DT Proceedings Paper
CT 3rd International Symposium on Metal Ions in Biology and Medicine
CY MAY 17-21, 1994
CL MONTREAL, CANADA
SP US FDA, NCI, AGENCE REG RECH & DEV CHAMPAGNE ARDENNE, INT RES INST MET IONS, UNIV MONTREAL, UNIV QUEBEC, MERAM LAB
C1 US FDA,NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN LIBBEY EUROTEXT LTD
PI MONTROUGE
PA 127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE
BN 2-7420-0054-2
J9 MET ION BIO
PY 1994
VL 3
BP 489
EP 493
PG 5
WC Chemistry, Physical; Environmental Sciences; Toxicology
SC Chemistry; Environmental Sciences & Ecology; Toxicology
GA BA81W
UT WOS:A1994BA81W00084
ER
PT B
AU LITTLEFIELD, NA
HASS, BS
AF LITTLEFIELD, NA
HASS, BS
BE Collery, P
Poirier, LA
Littlefield, NA
Etienne, JC
TI EFFECT OF MAGNESIUM ON DNA-DAMAGE FROM CADMIUM, NICKEL, MERCURY AND LEAD
SO METAL IONS IN BIOLOGY AND MEDICINE, VOL 3: PROCEEDINGS OF THE THIRD
INTERNATIONAL SYMPOSIUM ON METAL IONS IN BIOLOGY AND MEDICINE
SE METAL IONS IN BIOLOGY AND MEDICINE
LA English
DT Proceedings Paper
CT 3rd International Symposium on Metal Ions in Biology and Medicine
CY MAY 17-21, 1994
CL MONTREAL, CANADA
SP US FDA, NCI, AGENCE REG RECH & DEV CHAMPAGNE ARDENNE, INT RES INST MET IONS, UNIV MONTREAL, UNIV QUEBEC, MERAM LAB
C1 US FDA,NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU JOHN LIBBEY EUROTEXT LTD
PI MONTROUGE
PA 127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE
BN 2-7420-0054-2
J9 MET ION BIO
PY 1994
VL 3
BP 507
EP 512
PG 6
WC Chemistry, Physical; Environmental Sciences; Toxicology
SC Chemistry; Environmental Sciences & Ecology; Toxicology
GA BA81W
UT WOS:A1994BA81W00087
ER
PT S
AU GUILFOYLE, DE
HIRSHFIELD, IN
AF GUILFOYLE, DE
HIRSHFIELD, IN
BE Ades, EW
Rest, RF
Morse, SA
TI THE MOLECULAR RESPONSE OF ESCHERICHIA-COLI TO THE SHORT-CHAIN
ORGANIC-ACID BUTYRATE
SO MICROBIAL PATHOGENESIS AND IMMUNE RESPONSE
SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Article; Proceedings Paper
CT Conference on Microbial Pathogenesis and Immune Response
CY SEP 08-11, 1993
CL LAKE BUENA VISTA, FL
SP NEW YORK ACAD SCI
C1 ST JOHNS UNIV,DEPT BIOL SCI,JAMAICA,NY 11439.
US FDA,NE REG LAB,BROOKLYN,NY 11232.
NR 8
TC 2
Z9 2
U1 0
U2 1
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021
SN 0077-8923
BN 0-89766-895-2
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 1994
VL 730
BP 246
EP 248
DI 10.1111/j.1749-6632.1994.tb44254.x
PG 3
WC Immunology; Microbiology; Multidisciplinary Sciences; Pathology
SC Immunology; Microbiology; Science & Technology - Other Topics; Pathology
GA BB02T
UT WOS:A1994BB02T00022
PM 8080175
ER
PT S
AU BUNNING, VK
RAYBOURNE, RB
AF BUNNING, VK
RAYBOURNE, RB
BE Ades, EW
Rest, RF
Morse, SA
TI FLUORESCENT LABELING OF LISTERIA AND SALMONELLA - ANALYSIS OF
BACTERIA-HOST CELL-INTERACTIONS BY FLOW MICROFLUORIMETRY
SO MICROBIAL PATHOGENESIS AND IMMUNE RESPONSE
SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Article; Proceedings Paper
CT Conference on Microbial Pathogenesis and Immune Response
CY SEP 08-11, 1993
CL LAKE BUENA VISTA, FL
SP NEW YORK ACAD SCI
ID TYPHIMURIUM; GROWTH
RP BUNNING, VK (reprint author), US FDA,IMMUNOBIOL HFS326,8301 MUIRKIRK RD,LAUREL,MD 20708, USA.
NR 7
TC 1
Z9 1
U1 0
U2 0
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021
SN 0077-8923
BN 0-89766-895-2
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 1994
VL 730
BP 273
EP 275
DI 10.1111/j.1749-6632.1994.tb44263.x
PG 3
WC Immunology; Microbiology; Multidisciplinary Sciences; Pathology
SC Immunology; Microbiology; Science & Technology - Other Topics; Pathology
GA BB02T
UT WOS:A1994BB02T00031
PM 8080184
ER
PT J
AU ZHANG, YH
PASTOR, RW
AF ZHANG, YH
PASTOR, RW
TI A COMPARISION OF METHODS FOR COMPUTING TRANSITION RATES FROM
MOLECULAR-DYNAMICS SIMULATION
SO MOLECULAR SIMULATION
LA English
DT Article
DE ISOMERIZATION RATE; CORRELATION FUNCTION; RELAXATION FUNCTION; COUNTING;
MOLECULAR DYNAMICS SIMULATION; POISSON PROCESS
ID ISOMERIZATION DYNAMICS; LANGEVIN DYNAMICS; BROWNIAN DYNAMICS; BUTANE;
KINETICS; LIQUIDS
AB Correlation function and direct counting methods for the evaluation of the isomerization rates in equilibrium molecular dynamics (MD) simulations are studied for a system of 64 independent particles, each undergoing transitions between two stable states according to a Poisson process. Three different numerical implementations of the number correlation function and two different counting formulas based on different ordering of averages over trajectory and particles are tested. All methods yield correct results for sufficiently long simulations. However, for simulations where a given particle undergoes a small (<5-10) number of transitions, accurate rates are obtained only when the correlation function is normalized after averaging over particles; this correlation function is shown to be equivalent to the relaxation function of Brown and Clarke (J. Chem. Phys. 92, 3062, 1990). Similarily, accurate rates are obtained with a counting formula where the average first passage time is first calculated over all particles and inverted, as opposed to calculating rates for each particle and then averaging. These distinctions are shown to be significant when calculating isomerization rates from 500 ps MD simulations of n-butane. Correction of overcounts is also illustrated for the butane system, where ''glassy'' or low friction dynamics is evident.
C1 US FDA,CTR BIOL EVALUAT & RES,BIOPHYS LAB,8800 ROCKVILLE PIKE,BETHESDA,MD 20892.
NR 21
TC 14
Z9 14
U1 1
U2 11
PU GORDON BREACH SCI PUBL LTD
PI READING
PA C/O STBS LTD PO BOX 90, READING, BERKS, ENGLAND RG1 8JL
SN 0892-7022
J9 MOL SIMULAT
JI Mol. Simul.
PY 1994
VL 13
IS 1
BP 25
EP 38
DI 10.1080/08927029408022182
PG 14
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA NN565
UT WOS:A1994NN56500003
ER
PT J
AU JACKSON, LS
HARGRAVES, WA
STROUP, WH
DIACHENKO, GW
AF JACKSON, LS
HARGRAVES, WA
STROUP, WH
DIACHENKO, GW
TI HETEROCYCLIC AROMATIC AMINE CONTENT OF SELECTED BEEF FLAVORS
SO MUTATION RESEARCH
LA English
DT Article
DE HETEROCYCLIC AROMATIC AMINE; FLAVOR; AMES ASSAY; MUTAGENIC ACTIVITY;
AMINOIMIDAZOAZAARENE; HPLC; CREATINE; CREATININE
ID COOKED GROUND-BEEF; MAILLARD-REACTION-PRODUCTS; AMES SALMONELLA TEST;
LIQUID-CHROMATOGRAPHY; MUTAGENIC FRACTIONS; MASS-SPECTROMETRY;
FOOD-PRODUCTS; FRIED BEEF; IDENTIFICATION; EXTRACT
AB Previous work has shown that meat extracts contain potent mutagenic and/or carcinogenic heterocyclic aromatic amines (HAAs). Because meat extracts and some beef flavors are produced from similar precursors and processing steps, the beef flavors may also contain HAAs. This study analyzed 24 commercial beef flavors and 2 food-grade beef extracts for creatine and creatinine concentrations, mutagenic activity and HAA concentrations (IQ, MeIQ, MeIQ(x), DiMeIQ(x), Glu-P-1, Glu-P-2 and PhIP). The creatine and creatinine levels of the flavors ranged from 0 to 73 and from 0 to 21 mg/g (dry wt.), respectively. The mutagenic activities of the flavors ranged from 0 to 3200-Salmonella typhimurium TA98 revertants/g (dry wt.). No direct relationship was found between creatine and/or creatinine concentrations and mutagenic activities. However, flavors with high creatine (>1.5 mg/g) or creatinine(>2 mg/g) levels exhibited higher mutagenic activities than did flavors with low levels of these compounds. Flavors with high mutagenic activities (> 1500 revertants/g) contained measurable amounts of HAAs. Three flavors contained MeIQ(x) (7.2-21.2 ng/g [dry wt.]) and one contained DiMeIQ(x) (4.2 ng/g [dry wt.]).
C1 US FDA,WASHINGTON,DC 20204.
RP JACKSON, LS (reprint author), NATL CTR FOOD SAFETY & TECHNOL,6502 S ARCHER RD,SUMMIT ARGO,IL 60501, USA.
NR 35
TC 34
Z9 34
U1 1
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-8262
J9 MUTAT RES
PD JAN
PY 1994
VL 320
IS 1-2
BP 113
EP 124
DI 10.1016/0165-1218(94)90063-9
PG 12
WC Genetics & Heredity; Toxicology
SC Genetics & Heredity; Toxicology
GA MT330
UT WOS:A1994MT33000010
PM 7506378
ER
PT J
AU SUTHERLAND, JB
EVANS, FE
FREEMAN, JP
WILLIAMS, AJ
DECK, J
CERNIGLIA, CE
AF SUTHERLAND, JB
EVANS, FE
FREEMAN, JP
WILLIAMS, AJ
DECK, J
CERNIGLIA, CE
TI IDENTIFICATION OF METABOLITES PRODUCED FROM ACRIDINE BY
CUNNINGHAMELLA-ELEGANS
SO MYCOLOGIA
LA English
DT Article
DE ACRIDINE; ACRIDINE TRANS-1,2-DIHYDRODIOL; AZAARENES;
CUNNINGHAMELLA-ELEGANS; 2-HYDROXYACRIDINE
ID CELL-EXTRACTS; ANTHRACENE; PHENANTHRENE; TOXICITY; NITROGEN; MUTAGENS;
DAPHNIA; ENZYMES; FUNGI
AB Mycelia of Cunninghamella elegans were incubated in liquid Sabouraud medium containing 56 muM acridine. After 3 days, the culture medium was extracted with ethyl acetate and two metabolites were purified by high-performance liquid chromatography. Acridine trans-1,2-dihydrodiol and 2-hydroxyacridine were identified by ultraviolet-visible absorption spectrophotometry, mass spectrometry, and proton nuclear magnetic resonance spectroscopy. The data support a proposed pathway in which acridine is oxidized to a transient arene oxide, which is then hydrated to form the dihydrodiol or rearranged to form the phenol.
RP SUTHERLAND, JB (reprint author), NATL CTR TOXICOL RES,JEFFERSON,AR 72079, USA.
NR 27
TC 14
Z9 14
U1 0
U2 0
PU NEW YORK BOTANICAL GARDEN
PI BRONX
PA PUBLICATIONS DEPT, BRONX, NY 10458
SN 0027-5514
J9 MYCOLOGIA
JI Mycologia
PD JAN-FEB
PY 1994
VL 86
IS 1
BP 117
EP 120
DI 10.2307/3760726
PG 4
WC Mycology
SC Mycology
GA NF128
UT WOS:A1994NF12800011
ER
PT S
AU ALAYASH, AI
CASHON, RE
AF ALAYASH, AI
CASHON, RE
BE Chiueh, CC
Gilbert, DL
Colton, CA
TI REACTIONS OF NITRIC-OXIDE AND HYDROGEN-PEROXIDE WITH HEMOGLOBIN-BASED
BLOOD SUBSTITUTES
SO NEUROBIOLOGY OF NO- AND -OH
SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Article; Proceedings Paper
CT 1993 Symposium on the Neurobiology of NO- and -OH
CY NOV 07, 1993
CL NIH, BETHESDA, MD
SP NIH, NIMH, NINDS, NIA, NHLBI, NCI
HO NIH
C1 UNIV MAINE,DEPT BIOCHEM MICROBIOL & MOLEC BIOL,ORONO,ME 04469.
RP ALAYASH, AI (reprint author), US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892, USA.
NR 6
TC 15
Z9 15
U1 0
U2 0
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021
SN 0077-8923
BN 0-89766-873-1
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 1994
VL 738
BP 378
EP 381
PG 4
WC Biochemistry & Molecular Biology; Multidisciplinary Sciences;
Neurosciences
SC Biochemistry & Molecular Biology; Science & Technology - Other Topics;
Neurosciences & Neurology
GA BD10R
UT WOS:A1994BD10R00043
PM 7530423
ER
PT S
AU CADET, JL
ALI, S
EPSTEIN, C
AF CADET, JL
ALI, S
EPSTEIN, C
BE Chiueh, CC
Gilbert, DL
Colton, CA
TI INVOLVEMENT OF OXYGEN-BASED RADICALS IN METHAMPHETAMINE-INDUCED
NEUROTOXICITY - EVIDENCE FROM THE USE OF CUZNSOD TRANSGENIC MICE
SO NEUROBIOLOGY OF NO- AND -OH
SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Article; Proceedings Paper
CT 1993 Symposium on the Neurobiology of NO- and -OH
CY NOV 07, 1993
CL NIH, BETHESDA, MD
SP NIH, NIMH, NINDS, NIA, NHLBI, NCI
HO NIH
ID RAT-BRAIN; DOPAMINE; 6-HYDROXYDOPAMINE
C1 NATL CTR TOXICOL RES,DIV NEUROTOXICOL,JEFFERSON,AR 72079.
UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143.
RP CADET, JL (reprint author), NIDA,ADDICT RES CTR,MOLEC NEUROPSYCHIAT SECT,POB 5180,BALTIMORE,MD 21224, USA.
FU NIA NIH HHS [AG-09838]
NR 18
TC 36
Z9 36
U1 0
U2 1
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021
SN 0077-8923
BN 0-89766-873-1
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 1994
VL 738
BP 388
EP 391
PG 4
WC Biochemistry & Molecular Biology; Multidisciplinary Sciences;
Neurosciences
SC Biochemistry & Molecular Biology; Science & Technology - Other Topics;
Neurosciences & Neurology
GA BD10R
UT WOS:A1994BD10R00045
PM 7530424
ER
PT S
AU HAVERY, DC
CHOU, HJ
AF HAVERY, DC
CHOU, HJ
BE Loeppky, RN
Michejda, CJ
TI NITROSAMINES IN SUNSCREENS AND COSMETIC PRODUCTS - OCCURRENCE,
FORMATION, AND TRENDS
SO NITROSAMINES AND RELATED N-NITROSO COMPOUNDS: CHEMISTRY AND BIOCHEMISTRY
SE ACS SYMPOSIUM SERIES
LA English
DT Article; Proceedings Paper
CT Symposium on Nitrosamines and Related N-Nitroso Compounds: Chemistry and
Biochemistry, at the 204th National Meeting of the
American-Chemical-Society
CY AUG 23-28, 1992
CL WASHINGTON, DC
SP AMER CHEM SOC
ID VOLATILE N-NITROSAMINES; NITROSO COMPOUNDS; UNITED-STATES;
NITROSODIETHANOLAMINE; RATS; SKIN; PENETRATION;
NITROSOMETHYLDODECYLAMINE; NITROSODIMETHYLAMINE; DIETHANOLAMINE
AB Several nitrosamines, most of which have been shown to be carcinogenic in laboratory animals, have been identified in cosmetic products over the last fifteen years. These compounds are primarily formed from amine precursors and nitrosating agents in the cosmetic product but are also introduced into the product through cosmetic raw materials. Market surveys of sunscreens and cosmetics have revealed levels of nitrosodiethanolamine up to 45 ppm and levels of 2-ethylhexyl 4-(N-methyl-N-nitrosamino) benzoate up to 21 ppm. Results from market surveys of cosmetic products over the past fifteen years do not suggest any trend in the nitrosamine levels in these products. A summary of the occurrence and levels of nitrosamines in cosmetic products along with strategies for the reduction or elimination of these compounds is presented.
RP HAVERY, DC (reprint author), US FDA,MAIL STOP HFS 127,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 64
TC 7
Z9 7
U1 2
U2 12
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 SIXTEENTH ST NW, WASHINGTON, DC 20036
SN 0097-6156
BN 0-8412-2856-6
J9 ACS SYM SER
PY 1994
VL 553
BP 20
EP 33
PG 14
WC Biochemistry & Molecular Biology; Oncology; Chemistry,
Multidisciplinary; Food Science & Technology; Toxicology
SC Biochemistry & Molecular Biology; Oncology; Chemistry; Food Science &
Technology; Toxicology
GA BA19W
UT WOS:A1994BA19W00003
ER
PT J
AU LAMBERT, LA
WAMER, WG
WEI, RR
LAVU, S
CHIRTEL, SJ
KORNHAUSER, A
AF LAMBERT, LA
WAMER, WG
WEI, RR
LAVU, S
CHIRTEL, SJ
KORNHAUSER, A
TI THE PROTECTIVE BUT NONSYNERGISTIC EFFECT OF DIETARY BETA-CAROTENE AND
VITAMIN-E ON SKIN TUMORIGENESIS IN SKH MICE
SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
LA English
DT Article
ID ARACHIDONIC-ACID METABOLISM; ALPHA-TOCOPHEROL; EXPERIMENTAL CANCER;
BREAST-CANCER; MOUSE SKIN; INHIBITION; RISK; PLASMA; CARCINOGENESIS;
CELLS
AB Various epidemiological and experimental studies have indicated that beta-carotene and vitamin E protect against a variety of cancers. This investigation determined whether a synergistic protective effect could be observed against chemically induced skin tumorigenesis in Skh mice by combining these two antioxidants in the diet. Forty-five mice were used in each of four diet groups. Control animals were fed standard mouse chow. Three other groups received the chow supplemented with one of the following: 0.5% beta-carotene, 0.12% vitamin E (added as d-alpha-tocopheryl succinate), or 0.5% beta-carotene + 0.12% vitamin E. Mice were topically treated with a single application of the initiator 7,12-dimethylbenz[a]anthracene and promoted with multiple applications of phorbol 12-myristate 13-acetate. Mice were observed for tumors each week for 27 weeks after initiation. The protective effect of each diet was determined by the decrease in the number of skin rumors in supplemented diet groups compared with that of the control diet group. Decreases in the number of cumulative tumors at Week 27 were 32% for beta-carotene-, 25% for vitamin E-, and 21% for beta-carotene + vitamin E-supplemented diet groups. However, differences in the number of tumors among the three groups supplemented with beta-carotene and/or vitamin E were not statistically significant. Thus, although protection was provided by the individual supplements, there was no synergistic effect for a decrease in the number of chemically induced skin tumors by the simultaneous dietary administration of beta-carotene and vitamin E.
C1 US FDA,CTR FOOD SAFETY & APPL NUTR,DIV MATH,WASHINGTON,DC 20204.
RP LAMBERT, LA (reprint author), US FDA,DIV SCI & APPL TECHNOL,COSMET TOXICOL BRANCH,HFS-128,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 45
TC 32
Z9 34
U1 0
U2 0
PU LAWRENCE ERLBAUM ASSOC INC
PI MAHWAH
PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA
SN 0163-5581
J9 NUTR CANCER
JI Nutr. Cancer
PY 1994
VL 21
IS 1
BP 1
EP 12
PG 12
WC Oncology; Nutrition & Dietetics
SC Oncology; Nutrition & Dietetics
GA MX498
UT WOS:A1994MX49800001
PM 8183718
ER
PT J
AU CIARDIELLO, F
TORTORA, G
BIANCO, C
SELVAM, MP
BASOLO, F
FONTANINI, G
PACIFICO, F
NORMANNO, N
BRANDT, R
PERSICO, MG
SALOMON, DS
BIANCO, AR
AF CIARDIELLO, F
TORTORA, G
BIANCO, C
SELVAM, MP
BASOLO, F
FONTANINI, G
PACIFICO, F
NORMANNO, N
BRANDT, R
PERSICO, MG
SALOMON, DS
BIANCO, AR
TI INHIBITION OF CRIPTO EXPRESSION AND TUMORIGENICITY IN HUMAN COLON-CANCER
CELLS BY ANTISENSE RNA AND OLIGODEOXYNUCLEOTIDES
SO ONCOGENE
LA English
DT Article
ID GROWTH-FACTOR-ALPHA; MAMMARY EPITHELIAL-CELLS; C-HA-RAS; INVITRO
TRANSFORMATION; COLORECTAL TUMORS; LINES; PROLIFERATION; GENE;
OLIGONUCLEOTIDES; AMPHIREGULIN
AB CRIPTO is an epidermal growth factor-related gene expressed in a majority of human colorectal tumors. To assess the role of CRIPTO in the growth control of human colon cancer, we have treated human colon carcinoma GEO and CBS cells, that possess high levels of CRIPTO, and WIDR colon cancer cells, that are negative for CRIPTO expression, with two antisense phosphorothioate oligodeoxynucleotides complementary to the 5' end of the human CRIPTO mRNA. Both antisense oligodeoxynucleotides significantly reduced endogenous CRIPTO protein levels and inhibited GEO and CBS cell growth in monolayer and in semisolid medium, whereas they did not affect WIDR cell growth. In addition, GEO, CBS and WIDR cells were infected with a recombinant retroviral vector containing the hygromycin-resistance gene and a 900 bp EcoRI-EcoRI coding fragment of the human CRIPTO cDNA oriented in the 3' to 5' direction. GEO and CBS CRIPTO antisense infectants exhibited a 60 to 70% reduction in CRIPTO protein expression, in monolayer growth and in soft agar cloning efficiency as compared to parental noninfected cells. In contrast, infection of WIDR cells with the CRIPTO antisense retrovirus did not alter their growth. Finally, GEO CRIPTO antisense infectants formed tumors in nude mice that were significantly smaller and had a larger latency period as compared to noninfected GEO cells.
C1 US FDA,DIV TRANSFUS SCI,BETHESDA,MD 20892.
UNIV PISA,FAC MED & CHIRURG,IST ANAT & ISTOL PATOL,I-56100 PISA,ITALY.
CNR,IST INT GENET & BIOFIS,I-80125 NAPLES,ITALY.
NCI,TUMOR IMMUNOL & BIOL LAB,TUMOR GROWTH FACTOR SECT,BETHESDA,MD 20892.
RP CIARDIELLO, F (reprint author), UNIV NAPOLI FEDERICO II,FAC MED & CHIRURG,CATTEDRA ONCOL MED,I-80131 NAPLES,ITALY.
RI Fontanini, Gabriella/O-7636-2015;
OI Fontanini, Gabriella/0000-0003-1957-2052; Pacifico, Francesco
Maria/0000-0001-9563-3596; Normanno, Nicola/0000-0002-7158-2605
NR 42
TC 63
Z9 63
U1 1
U2 4
PU STOCKTON PRESS
PI BASINGSTOKE
PA HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD JAN
PY 1994
VL 9
IS 1
BP 291
EP 298
PG 8
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
GA MW247
UT WOS:A1994MW24700035
PM 8302592
ER
PT J
AU OBIRI, NI
PURI, RK
AF OBIRI, NI
PURI, RK
TI CHARACTERIZATION OF INTERLEUKIN-4 RECEPTORS EXPRESSED ON HUMAN
RENAL-CELL CARCINOMA-CELLS
SO ONCOLOGY RESEARCH
LA English
DT Article
DE INTERLEUKIN-2 RECEPTOR; SURFACE BINDING; RECYCLING; RECEPTOR STRUCTURE;
RENAL CELL CARCINOMA; CROSS-LINKING
ID GROWTH-PROMOTING ACTIVITY; TUMOR-NECROSIS-FACTOR; HIGH-AFFINITY;
GAMMA-INTERFERON; IDENTIFICATION; LYMPHOKINE; DISTINCT; PROTEINS
AB We have recently reported that a variety of solid human tumor cells express high-affinity interleukin-4 receptors (IL-4R). In this study, we have compared structural characteristics of IL-4R expressed on human renal cell carcinoma cells (RCC-WS) and the lymphoid cell lines RAJI (B-cell line) and H9 (T-cell line). In crosslinking studies, the three cell types expressed a predominant 140 kDa IL-4R band. In addition, a 70 kDa band was expressed strongly in H9 cells but only faintly on RCC-WS and RAJI cells. These different species of IL-4R were not observed when crosslinking studies were performed in the presence of excess interleukin-4 (IL-4), indicating IL-4 specificity. A polyclonal anti-IL-4R antibody immunoprecipitated the two species (140 and 70 kDa) in H9 and predominantly the 140 kDa species in RCC-WS tumor cells and RAJI cells. A faint band for the 70 kDa protein was also observed. The affinity of IL-4 binding to its receptor in RCC-WS cells was similar to the binding affinity observed in H9 and RAJI cells examined. However, the RCC tumor cells and B lymphoid cells internalized IL-4R more rapidly compared to T lymphoid cells. Although IL-4R synthesis was similarly inhibited by cycloheximide in all three cell lines, IL-4R expression was more sensitive to actinomycin D inhibition on the RCC-WS and RAJI cells than on H9 cells. Our results suggest that IL-4R expressed on RCC-WS tumor cells are structurally different from those expressed on lymphoid cells because the proportions of IL-4R subunits differ in these cells. Further studies should be performed to determine the identity and functional significance of IL-4R proteins expressed on RCC and immune cells.
C1 NIH,CTR BIOL EVALUAT & RES,DIV CELLULAR & GENE THERAPIES,MOLEC TUMOR BIOL LAB,BETHESDA,MD 20852.
NR 37
TC 21
Z9 21
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0965-0407
J9 ONCOL RES
JI Oncol. Res.
PY 1994
VL 6
IS 9
BP 419
EP 427
PG 9
WC Oncology
SC Oncology
GA QC489
UT WOS:A1994QC48900004
PM 7703528
ER
PT B
AU SHEININ, EB
AF SHEININ, EB
BE MacRae, M
Schier, J
Steward, S
Krewson, BK
Montgomery, A
TI How to present new technologies to the FDA
SO PHARMANALYSIS CONFERENCE & EXHIBITION PROCEEDINGS '94
LA English
DT Proceedings Paper
CT PharmAnalysis Conference and Exhibition
CY JUN 20-22, 1994
CL ATLANTIC CITY, NJ
C1 US FDA,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ADVANSTAR COMMUNICATIONS
PI EUGENE
PA 859 WILLAMETTE ST, EUGENE, OR 97401-6806
BN 0-943330-46-7
PY 1994
BP 398
EP 403
PG 6
WC Pharmacology & Pharmacy; Spectroscopy
SC Pharmacology & Pharmacy; Spectroscopy
GA BE22F
UT WOS:A1994BE22F00035
ER
PT J
AU HART, RW
XIAO, Y
VONTUNGELN, LS
CHOU, MW
ZHAN, DJ
FU, PP
AF HART, RW
XIAO, Y
VONTUNGELN, LS
CHOU, MW
ZHAN, DJ
FU, PP
TI EFFECT OF CALORIC RESTRICTION ON METABOLISM OF POLYCYCLIC
AROMATIC-HYDROCARBONS BY MALE B6C3F1 MOUSE-LIVER MICROSOMES
SO POLYCYCLIC AROMATIC COMPOUNDS
LA English
DT Proceedings Paper
CT 14th International Symposium on Polycyclic Aromatic Compounds
CY SEP 08-11, 1993
CL LAKE OZARKS, MO
SP INT SOC POLYCYCL AROMAT COMPOUNDS
DE CALORIC RESTRICTION; 7-FLUOROBENZ[A]ANTHRACENE;
7-CHLOROBENZ[A]ANTHRACENE; 7-BROMOBENZ[A]ANTHRACENE;
7-NITROBENZ[A]ANTHRACENE; MOUSE LIVER MICROSOMAL METABOLISM
ID RAT
C1 NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
NR 12
TC 12
Z9 12
U1 0
U2 0
PU GORDON BREACH SCI PUBL LTD
PI READING
PA C/O STBS LTD PO BOX 90, READING, BERKS, ENGLAND RG1 8JL
SN 1040-6638
J9 POLYCYCL AROMAT COMP
JI Polycycl. Aromat. Compd.
PY 1994
VL 7
IS 1-3
BP 19
EP 26
DI 10.1080/10406639408014708
PG 8
WC Chemistry, Organic
SC Chemistry
GA PG343
UT WOS:A1994PG34300004
ER
PT J
AU VONTUNGELN, LS
EWING, DG
WEITKAMP, R
CHENG, E
HERRENOSAENZ, D
EVANS, FE
FU, PP
AF VONTUNGELN, LS
EWING, DG
WEITKAMP, R
CHENG, E
HERRENOSAENZ, D
EVANS, FE
FU, PP
TI METABOLIC-ACTIVATION OF THE POTENT MUTAGEN AND TUMORIGEN
2-NITROBENZO[A]PYRENE
SO POLYCYCLIC AROMATIC COMPOUNDS
LA English
DT Proceedings Paper
CT 14th International Symposium on Polycyclic Aromatic Compounds
CY SEP 08-11, 1993
CL LAKE OZARKS, MO
SP INT SOC POLYCYCL AROMAT COMPOUNDS
DE NITRO-POLYCYCLIC AROMATIC HYDROCARBONS; 2-NITROBENZO[A]PYRENE
(2-NITRO-BAP); 2-NITRO-BAP TRANS-9,10-DIHYDRODIOL; 2-NITRO-BAP
TRANS-7,8-DIHYDRODIOL; METABOLIC ACTIVATION; MOUSE LIVER MICROSOMES
ID POLYCYCLIC AROMATIC-HYDROCARBONS; DIHYDRODIOL; SUBSTITUENT; AXIS
C1 NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
NR 17
TC 2
Z9 2
U1 0
U2 0
PU GORDON BREACH SCI PUBL LTD
PI READING
PA C/O STBS LTD PO BOX 90, READING, BERKS, ENGLAND RG1 8JL
SN 1040-6638
J9 POLYCYCL AROMAT COMP
JI Polycycl. Aromat. Compd.
PY 1994
VL 7
IS 1-3
BP 91
EP 98
DI 10.1080/10406639408014717
PG 8
WC Chemistry, Organic
SC Chemistry
GA PG343
UT WOS:A1994PG34300013
ER
PT J
AU MAO, YL
ZENG, HW
LIN, TY
VONTUNGELN, LS
CHIU, LH
FU, PP
AF MAO, YL
ZENG, HW
LIN, TY
VONTUNGELN, LS
CHIU, LH
FU, PP
TI MICROSOMAL METABOLISM OF 7-NITRODIBENZ[A,H]ANTHRACENE - EFFECT OF THE
NITRO SUBSTITUENT ON REGIOSELECTIVE OXIDATIVE-METABOLISM
SO POLYCYCLIC AROMATIC COMPOUNDS
LA English
DT Proceedings Paper
CT 14th International Symposium on Polycyclic Aromatic Compounds
CY SEP 08-11, 1993
CL LAKE OZARKS, MO
SP INT SOC POLYCYCL AROMAT COMPOUNDS
DE 7-NITRODIBENZ[A,H]ANTHRACENE (7-NITRO-DB[A,H]A); 7-NITRO-DB[A,H]A
TRANS-1,2-DIHYDRODIOL; 7-NITRO-DB[A,H]A TRANS-3,4-DIHYDRODIOL;
2-HYDROXY-7-NITRO-DB[A,H]A; 4-HYDROXY-7-NITRO-DB[A,H]A; MICROSOMAL
METABOLISM
ID POLYCYCLIC AROMATIC-HYDROCARBONS; MUTAGENICITY; ACTIVATION
C1 SOOCHOW UNIV,DEPT CHEM,TAIPEI,TAIWAN.
S CHINA UNIV TECHNOL,DEPT APPL CHEM,SHIPAI,PEOPLES R CHINA.
NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
NR 18
TC 2
Z9 2
U1 0
U2 0
PU GORDON BREACH SCI PUBL LTD
PI READING
PA C/O STBS LTD PO BOX 90, READING, BERKS, ENGLAND RG1 8JL
SN 1040-6638
J9 POLYCYCL AROMAT COMP
JI Polycycl. Aromat. Compd.
PY 1994
VL 7
IS 1-3
BP 99
EP 106
DI 10.1080/10406639408014718
PG 8
WC Chemistry, Organic
SC Chemistry
GA PG343
UT WOS:A1994PG34300014
ER
PT J
AU UENG, TH
UENG, YF
CHEN, W
CHOU, MW
AF UENG, TH
UENG, YF
CHEN, W
CHOU, MW
TI REGIOSELECTIVE AND STEREOSELECTIVE METABOLISM OF BENZO[A]PYRENE AND
7-CHLOROBENZ[A]ANTHRACENE BY FISH LIVER-MICROSOMES
SO POLYCYCLIC AROMATIC COMPOUNDS
LA English
DT Proceedings Paper
CT 14th International Symposium on Polycyclic Aromatic Compounds
CY SEP 08-11, 1993
CL LAKE OZARKS, MO
SP INT SOC POLYCYCL AROMAT COMPOUNDS
DE BENZO[A]PYRENE (BAP); 7-CHLOROBENZ[A]ANTHRACENE (7-CL-BA); METABOLISM;
FISH MICROSOMES; REGIOSELECTIVITY; STEREOSELECTIVITY
ID AROMATIC-HYDROCARBONS; DIOL EPOXIDES; RAINBOW-TROUT; METABOLISM
C1 TAIWAN NATL UNIV,COLL MED,INST TOXICOL,TAIPEI,TAIWAN.
NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
NR 17
TC 0
Z9 0
U1 0
U2 1
PU GORDON BREACH SCI PUBL LTD
PI READING
PA C/O STBS LTD PO BOX 90, READING, BERKS, ENGLAND RG1 8JL
SN 1040-6638
J9 POLYCYCL AROMAT COMP
JI Polycycl. Aromat. Compd.
PY 1994
VL 7
IS 1-3
BP 107
EP 114
DI 10.1080/10406639408014719
PG 8
WC Chemistry, Organic
SC Chemistry
GA PG343
UT WOS:A1994PG34300015
ER
PT J
AU FU, PP
HERRENOSAENZ, D
VONTUNGELN, LS
HART, RW
LIN, SD
AF FU, PP
HERRENOSAENZ, D
VONTUNGELN, LS
HART, RW
LIN, SD
TI DNA-ADDUCTS AND CARCINOGENICITY OF NITRO-POLYCYCLIC
AROMATIC-HYDROCARBONS
SO POLYCYCLIC AROMATIC COMPOUNDS
LA English
DT Proceedings Paper
CT 14th International Symposium on Polycyclic Aromatic Compounds/1st
Biennial Meeting of the
International-Society-for-Polycyclic-Aromatic-Compounds
CY SEP 08-11, 1993
CL LAKE OZARKS, MO
SP INT SOC POLYCYCL AROMAT COMPOUNDS, NIH, US EPA, NIST, UNIV NEBRASKA MED CTR, EPPLEY INST RES CANC & ALLIED DIS, ELECT POWER RES INST, MILLIPORE WATER CHROMATOG DIV & STRATAGENE
DE NITRO-POLYCYCLIC AROMATIC HYDROCARBONS; NITROBENZO[A]PYRENE; IN-VITRO
METABOLISM; DNA ADDUCT; TUMORIGENICITY; DIOL-EPOXIDE
ID 3-NITROBENZOPYRENE
C1 PROVIDENCE UNIV,INST APPL CHEM,TAICHUNG,TAIWAN.
NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
NR 12
TC 3
Z9 3
U1 0
U2 1
PU GORDON BREACH SCI PUBL LTD
PI READING
PA C/O STBS LTD PO BOX 90, READING, BERKS, ENGLAND RG1 8JL
SN 1040-6638
J9 POLYCYCL AROMAT COMP
JI Polycycl. Aromat. Compd.
PY 1994
VL 6
IS 1-4
BP 71
EP 78
DI 10.1080/10406639408031169
PG 8
WC Chemistry, Organic
SC Chemistry
GA PG342
UT WOS:A1994PG34200010
ER
PT J
AU HERRENOSAENZ, D
HEFLICH, RH
VONTUNGELN, LS
LEWTAS, J
FU, PP
AF HERRENOSAENZ, D
HEFLICH, RH
VONTUNGELN, LS
LEWTAS, J
FU, PP
TI DNA ADDUCT FORMATION BY 2-NITROFLUORANTHENE IN SALMONELLA-TYPHIMURIUM
AND NEONATAL B6C3F1 MICE
SO POLYCYCLIC AROMATIC COMPOUNDS
LA English
DT Proceedings Paper
CT 14th International Symposium on Polycyclic Aromatic Compounds/1st
Biennial Meeting of the
International-Society-for-Polycyclic-Aromatic-Compounds
CY SEP 08-11, 1993
CL LAKE OZARKS, MO
SP INT SOC POLYCYCL AROMAT COMPOUNDS, NIH, US EPA, NIST, UNIV NEBRASKA MED CTR, EPPLEY INST RES CANC & ALLIED DIS, ELECT POWER RES INST, MILLIPORE WATER CHROMATOG DIV & STRATAGENE
DE DNA ADDUCTS; 2-NITROFLUORANTHENE; NITRATED POLYCYCLIC AROMATIC
HYDROCARBONS; P-32-POSTLABELING
ID PARTICULATE ORGANIC-MATTER; 2-NITROPYRENE; FLUORANTHENE
C1 NCTR,JEFFERSON,AR 72079.
US EPA,RES TRIANGLE PK,NC 27711.
NR 11
TC 7
Z9 7
U1 0
U2 0
PU GORDON BREACH SCI PUBL LTD
PI READING
PA C/O STBS LTD PO BOX 90, READING, BERKS, ENGLAND RG1 8JL
SN 1040-6638
J9 POLYCYCL AROMAT COMP
JI Polycycl. Aromat. Compd.
PY 1994
VL 6
IS 1-4
BP 79
EP 85
DI 10.1080/10406639408031170
PG 7
WC Chemistry, Organic
SC Chemistry
GA PG342
UT WOS:A1994PG34200011
ER
PT J
AU CHOU, MW
CHEN, W
NICHOLS, J
ZHOU, YG
HART, RW
CHUNG, KT
AF CHOU, MW
CHEN, W
NICHOLS, J
ZHOU, YG
HART, RW
CHUNG, KT
TI EFFECT OF CALORIC RESTRICTION ON THE METABOLISM OF BENZO[A]PYRENE (BAP)
AND THE FORMATION OF BAP-DNA ADDUCTS IN MALE FISCHER-344 RATS
SO POLYCYCLIC AROMATIC COMPOUNDS
LA English
DT Proceedings Paper
CT 14th International Symposium on Polycyclic Aromatic Compounds/1st
Biennial Meeting of the
International-Society-for-Polycyclic-Aromatic-Compounds
CY SEP 08-11, 1993
CL LAKE OZARKS, MO
SP INT SOC POLYCYCL AROMAT COMPOUNDS, NIH, US EPA, NIST, UNIV NEBRASKA MED CTR, EPPLEY INST RES CANC & ALLIED DIS, ELECT POWER RES INST, MILLIPORE WATER CHROMATOG DIV & STRATAGENE
DE CALORIC RESTRICTION; BENZO[A]PYRENE (BAP); RAT LIVER MICROSOMES; DNA
BINDING; BAP-DNA ADDUCT; BAP METABOLISM
ID FOOD RESTRICTION; INDUCTION; ENZYMES; BINDING; SYSTEM
C1 NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
MEMPHIS STATE UNIV,DEPT BIOL,MEMPHIS,TN 38152.
NR 19
TC 2
Z9 2
U1 0
U2 0
PU GORDON BREACH SCI PUBL LTD
PI READING
PA C/O STBS LTD PO BOX 90, READING, BERKS, ENGLAND RG1 8JL
SN 1040-6638
J9 POLYCYCL AROMAT COMP
JI Polycycl. Aromat. Compd.
PY 1994
VL 6
IS 1-4
BP 127
EP 134
DI 10.1080/10406639408031176
PG 8
WC Chemistry, Organic
SC Chemistry
GA PG342
UT WOS:A1994PG34200017
ER
PT J
AU YANG, DTC
CHOU, A
CHEN, E
CHIU, LH
NI, YC
AF YANG, DTC
CHOU, A
CHEN, E
CHIU, LH
NI, YC
TI PHOTODECOMPOSITION OF ENVIRONMENTAL NITRO-POLYCYCLIC
AROMATIC-HYDROCARBONS
SO POLYCYCLIC AROMATIC COMPOUNDS
LA English
DT Proceedings Paper
CT 14th International Symposium on Polycyclic Aromatic Compounds
CY SEP 08-11, 1993
CL LAKE OZARKS, MO
SP INT SOC POLYCYCL AROMAT COMPOUNDS
DE NITRO-POLYCYCLIC AROMATIC HYDROCARBONS; NITROBENZO[A]PYRENE;
NITROPYRENE; NITROANTHRACENE; PHOTODECOMPOSITION; MUTAGENICITY
ID 1-NITROPYRENE
C1 UNIV ARKANSAS,DEPT CHEM,LITTLE ROCK,AR 72204.
NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
NR 10
TC 10
Z9 10
U1 0
U2 0
PU GORDON BREACH SCI PUBL LTD
PI READING
PA C/O STBS LTD PO BOX 90, READING, BERKS, ENGLAND RG1 8JL
SN 1040-6638
J9 POLYCYCL AROMAT COMP
JI Polycycl. Aromat. Compd.
PY 1994
VL 5
IS 1-4
BP 201
EP 208
DI 10.1080/10406639408015172
PG 8
WC Chemistry, Organic
SC Chemistry
GA PD544
UT WOS:A1994PD54400023
ER
PT J
AU SAGRIPANTI, JL
HUGHESDILLON, MK
AF SAGRIPANTI, JL
HUGHESDILLON, MK
TI STABILITY OF 5 PLASTICS USED IN MEDICAL DEVICES TO OXIDATION PRODUCED BY
COPPER OR IRON IONS AND REDUCING AGENTS
SO POLYMER DEGRADATION AND STABILITY
LA English
DT Article
ID DNA DAMAGE; BRONCHOSCOPY; OUTBREAK; PEROXIDE; VIRUS
AB Metal-based formulations containing Cu(II) or Fe(III) ions plus a reducing agent, have been shown to be effective microbicidal agents and suggested for liquid disinfection or sterilization of reusable medical devices. In this study, we examined, by optical and scanning electron microscopy, the stability of five polymeric materials, commonly used in the manufacture of implantable, exploratory, and other medical devices, to oxidative challenge by metal-based formulations. No damage of any of the polymers could be attributed to repeated treatment with metal-based formulations under 'in use' conditions. However, a poly(vinyl acetate-vinyl chloride) copolymer (PVC) was found to be unstable to 10 wetting/drying cycles. The polymers were also challenged once for a longer time, at higher temperature, and with reagents at concentrations far exceeding those expected to be used in disinfecting medical devices. The only damage observed after this 'accelerated' testing consisted in minor pitting, or erosion, observed in polyamide and polyurethane samples exposed to formulations containing Fe(III) ions.
Our results after 'in-use' and 'accelerated' testing indicate that silicone rubber, polyethylene, polyamide, and polyurethane polymers should be stable to treatment with Cu(II) plus hydrogen peroxide or ascorbic acid under conditions likely to be encountered in the decontamination of medical devices. The stability of these polymeric materials suggests the feasibility of using metal-based formulations for repeated disinfection of a broad range of medical devices without deleterious effects on the polymeric components.
C1 US FDA,CTR DEVICES & RADIOL HLTH,OFF SCI & TECHNOL,DIV MECH & MAT SCI,ROCKVILLE,MD 20852.
RP SAGRIPANTI, JL (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,OFF SCI & TECHNOL,DIV LIFE SCI,HFZ-113,5600 FISHERS LANE,ROCKVILLE,MD 20852, USA.
NR 17
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0141-3910
J9 POLYM DEGRAD STABIL
JI Polym. Degrad. Stabil.
PY 1994
VL 46
IS 2
BP 241
EP 246
DI 10.1016/0141-3910(94)90056-6
PG 6
WC Polymer Science
SC Polymer Science
GA PZ471
UT WOS:A1994PZ47100012
ER
PT S
AU LIU, TY
MINETTI, CAS
FORTESDIAS, CL
LIU, T
LIN, LW
LIN, Y
AF LIU, TY
MINETTI, CAS
FORTESDIAS, CL
LIU, T
LIN, LW
LIN, Y
BE Beck, G
Cooper, EL
Habicht, GS
Marchalonis, JJ
TI C-REACTIVE PROTEINS, LIMUNECTIN, LIPOPOLYSACCHARIDE-BINDING PROTEIN, AND
COAGULIN - MOLECULES WITH LECTIN AND AGGLUTININ ACTIVITIES FROM
LIMULUS-POLYPHEMUS
SO PRIMORDIAL IMMUNITY: FOUNDATIONS FOR THE VERTEBRATE IMMUNE SYSTEM
SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Article; Proceedings Paper
CT Conference on Primordial Immunity: Foundations for the Vertebrate Immune
System
CY MAY 02-05, 1993
CL WOODS HOLE, MA
SP NEW YORK ACAD SCI
ID INHIBITORY ACTIVITY; CELL-ADHESION; SEQUENCE; CDNA; FIBRONECTIN;
SIMILARITY; AMEBOCYTES; SURFACE; ACID; DNA
RP LIU, TY (reprint author), US FDA,CTR BIOL EVALUAT & RES,OFF VACCINES RES & REVIEW,DIV ALLERGEN PROD & PARASITOL,ROCKVILLE,MD 20852, USA.
RI Fortes-Dias, Consuelo/I-4896-2012; Minetti, Conceicao/B-5077-2009
OI Fortes-Dias, Consuelo/0000-0002-4494-5108; Minetti,
Conceicao/0000-0002-9682-2898
NR 34
TC 15
Z9 15
U1 0
U2 1
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021
SN 0077-8923
BN 0-89766-839-1
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 1994
VL 712
BP 146
EP 154
DI 10.1111/j.1749-6632.1994.tb33569.x
PG 9
WC Immunology; Multidisciplinary Sciences; Zoology
SC Immunology; Science & Technology - Other Topics; Zoology
GA BA22R
UT WOS:A1994BA22R00013
PM 8192328
ER
PT B
AU KANTOR, G
ALON, G
HO, HS
AF KANTOR, G
ALON, G
HO, HS
BE Sheppard, NF
Eden, M
Kantor, G
TI SIMULATED TISSUE LOADS FOR TESTING OF TRANSCUTANEOUS ELECTRICAL
STIMULATORS
SO PROCEEDINGS OF THE 16TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE
ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY - ENGINEERING ADVANCES: NEW
OPPORTUNITIES FOR BIOMEDICAL ENGINEERS, PTS 1&2
LA English
DT Proceedings Paper
CT 16th Annual International Conference of the IEEE
Engineering-in-Medicine-and-Biology-Society on Engineering Advances: New
Opportunities for Biomedical Engineers
CY NOV 03-06, 1994
CL BALTIMORE, MD
SP IEEE, ENGN MED & BIOL SOC
C1 US FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20857.
NR 0
TC 1
Z9 2
U1 0
U2 0
PU I E E E
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017
BN 0-7803-2050-6
PY 1994
BP 784
EP 785
DI 10.1109/IEMBS.1994.415291
PG 2
WC Engineering, Biomedical
SC Engineering
GA BC56Q
UT WOS:A1994BC56Q00391
ER
PT B
AU WITTERS, DM
RUGGERA, PS
AF WITTERS, DM
RUGGERA, PS
BE Sheppard, NF
Eden, M
Kantor, G
TI ELECTROMAGNETIC COMPATIBILITY (EMC) OF POWERED WHEELCHAIRS AND SCOOTERS
SO PROCEEDINGS OF THE 16TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE
ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY - ENGINEERING ADVANCES: NEW
OPPORTUNITIES FOR BIOMEDICAL ENGINEERS, PTS 1&2
LA English
DT Proceedings Paper
CT 16th Annual International Conference of the IEEE
Engineering-in-Medicine-and-Biology-Society on Engineering Advances: New
Opportunities for Biomedical Engineers
CY NOV 03-06, 1994
CL BALTIMORE, MD
SP IEEE, ENGN MED & BIOL SOC
C1 US FDA,OFF SCI & TECHNOL,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20852.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU I E E E
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017
BN 0-7803-2050-6
PY 1994
BP 894
EP 895
DI 10.1109/IEMBS.1994.415200
PG 2
WC Engineering, Biomedical
SC Engineering
GA BC56Q
UT WOS:A1994BC56Q00447
ER
PT B
AU BASSEN, H
RUGGERA, P
CASAMENTO, J
WITTERS, D
AF BASSEN, H
RUGGERA, P
CASAMENTO, J
WITTERS, D
BE Sheppard, NF
Eden, M
Kantor, G
TI SOURCES OF RADIOFREQUENCY INTERFERENCE FOR MEDICAL DEVICES IN THE
NONCLINICAL ENVIRONMENT
SO PROCEEDINGS OF THE 16TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE
ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY - ENGINEERING ADVANCES: NEW
OPPORTUNITIES FOR BIOMEDICAL ENGINEERS, PTS 1&2
LA English
DT Proceedings Paper
CT 16th Annual International Conference of the IEEE
Engineering-in-Medicine-and-Biology-Society on Engineering Advances: New
Opportunities for Biomedical Engineers
CY NOV 03-06, 1994
CL BALTIMORE, MD
SP IEEE, ENGN MED & BIOL SOC
C1 US FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20852.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU I E E E
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017
BN 0-7803-2050-6
PY 1994
BP 896
EP 897
DI 10.1109/IEMBS.1994.415201
PG 2
WC Engineering, Biomedical
SC Engineering
GA BC56Q
UT WOS:A1994BC56Q00448
ER
PT S
AU WOODS, TO
REGNAULT, WF
AF WOODS, TO
REGNAULT, WF
GP SOC EXPTL MECH
TI Mechanical testing and behavior of intracranial aneurysm clips
SO PROCEEDINGS OF THE 1994 SEM SPRING CONFERENCE ON EXPERIMENTAL MECHANICS
SE PROCEEDINGS OF THE INTERNATIONAL CONGRESS ON EXPERIMENTAL MECHANICS
LA English
DT Proceedings Paper
CT 1994 SEM Spring Conference on Experimental Mechanics
CY JUN 06-08, 1994
CL BALTIMORE, MD
SP Soc Exptl Mech
C1 US FDA,DIV MECH & MAT SCI,ROCKVILLE,MD 20852.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU SOC EXPERIMENTAL MECHANICS INC
PI BETHEL
PA 7 SCHOOL ST, BETHEL, CT 06801
SN 1046-672X
BN 0-912053-46-1
J9 P INT CONG EXPERIT M
PY 1994
BP 49
EP 55
PG 7
WC Engineering, Civil; Materials Science, Multidisciplinary; Mechanics;
Materials Science, Characterization & Testing; Materials Science,
Composites; Optics; Polymer Science
SC Engineering; Materials Science; Mechanics; Optics; Polymer Science
GA BD88E
UT WOS:A1994BD88E00007
ER
PT B
AU GIRI, CP
OGAWA, H
SPILLARE, B
HARRIS, CC
AF GIRI, CP
OGAWA, H
SPILLARE, B
HARRIS, CC
BE Rao, RS
Deo, MG
Sanghvi, LD
Mittra, I
TI CDNA SUBTRACTION LIBRARY CONSTRUCTION APPROACH TO MOLECULARLY CLONE
TGFB1-INDUCIBLE GENES AS CDNAS OF 14-17 KBP FROM HUMAN BRONCHIAL
EPITHELIAL CELLS
SO PROCEEDINGS OF THE XVI INTERNATIONAL CANCER CONGRESS - FREE PAPERS AND
POSTERS, TOMES 1-4
LA English
DT Proceedings Paper
CT XVI International Cancer Congress
CY OCT 30-NOV 05, 1994
CL NEW DELHI, INDIA
RP GIRI, CP (reprint author), US FDA,LAUREL,MD, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MONDUZZI EDITORE
PI 40128 BOLOGNA
PA VIA FERRARESE 119/2, 40128 BOLOGNA, ITALY
BN 88-323-1030-9
PY 1994
BP 189
EP 195
PG 7
WC Oncology
SC Oncology
GA BD09K
UT WOS:A1994BD09K00037
ER
PT B
AU LAVU, S
SRIVASTAVA, M
KORNHAUSER, A
SRIVASTAVA, S
AF LAVU, S
SRIVASTAVA, M
KORNHAUSER, A
SRIVASTAVA, S
BE Rao, RS
Deo, MG
Sanghvi, LD
Mittra, I
TI STATUS OF THE TUMOR SUPPRESSOR GENE P53 IN XERODERMA-PIGMENTOSUM
FIBROBLASTS
SO PROCEEDINGS OF THE XVI INTERNATIONAL CANCER CONGRESS - FREE PAPERS AND
POSTERS, TOMES 1-4
LA English
DT Proceedings Paper
CT XVI International Cancer Congress
CY OCT 30-NOV 05, 1994
CL NEW DELHI, INDIA
RP LAVU, S (reprint author), US FDA,LAUREL,MD, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MONDUZZI EDITORE
PI 40128 BOLOGNA
PA VIA FERRARESE 119/2, 40128 BOLOGNA, ITALY
BN 88-323-1030-9
PY 1994
BP 2457
EP 2461
PG 5
WC Oncology
SC Oncology
GA BD09K
UT WOS:A1994BD09K00485
ER
PT J
AU JENSEN, PS
VITIELLO, B
LEONARD, H
LAUGHREN, TP
AF JENSEN, PS
VITIELLO, B
LEONARD, H
LAUGHREN, TP
TI CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY - EXPANDING THE RESEARCH BASE
SO PSYCHOPHARMACOLOGY BULLETIN
LA English
DT Article; Proceedings Paper
CT 33rd NCDEU Meeting
CY JUN 01-04, 1993
CL BOCA RATON, FL
SP NIMH, DIV CLIN & TREATMENT RES, NEW CLIN DRUG EVALUAT UNIT
DE CHILD PSYCHOPHARMACOLOGY; MEDICATION DEVELOPMENT; DRUG EFFICACY; DRUG
SAFETY
ID EFFICACY
C1 NIH,DIV INTRAMURAL RES PROGRAMS,CHILD PSYCHIAT BRANCH,BETHESDA,MD 20892.
US FDA,CTR DRUG EVALUAT & RES,DIV NEUROPHARMACOL DRUG PROD,ROCKVILLE,MD 20857.
RP JENSEN, PS (reprint author), NIMH,DIV CLIN & TREATMENT RES,CHILD & ADOLESCENT DISRODERS RES BRANCH,ROOM 18C-17,ROCKVILLE,MD 20857, USA.
OI Jensen, Peter/0000-0003-2387-0650
NR 5
TC 33
Z9 33
U1 0
U2 0
PU US GOVERNMENT PRINTING OFFICE
PI WASHINGTON
PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325
SN 0048-5764
J9 PSYCHOPHARMACOL BULL
JI Psychopharmacol. Bull.
PY 1994
VL 30
IS 1
BP 3
EP 8
PG 6
WC Pharmacology & Pharmacy; Psychiatry
SC Pharmacology & Pharmacy; Psychiatry
GA PE048
UT WOS:A1994PE04800002
PM 7972627
ER
PT J
AU LEBER, P
AF LEBER, P
TI PSYCHOTHERAPEUTIC MEDICATIONS DEVELOPMENT PROGRAM WORKSHOP ON NMDA
RECEPTOR ANTAGONISTS - NEUROTOXICITY EVALUATION - INTRODUCTION
SO PSYCHOPHARMACOLOGY BULLETIN
LA English
DT Editorial Material
DE NMDA ANTAGONISTS; ISCHEMIA; NEUROTOXICITY; NEUROPROTECTION
RP LEBER, P (reprint author), US FDA,ROCKVILLE,MD 20857, USA.
NR 18
TC 3
Z9 3
U1 0
U2 0
PU US GOVERNMENT PRINTING OFFICE
PI WASHINGTON
PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325
SN 0048-5764
J9 PSYCHOPHARMACOL BULL
JI Psychopharmacol. Bull.
PY 1994
VL 30
IS 4
BP 527
EP 532
PG 6
WC Pharmacology & Pharmacy; Psychiatry
SC Pharmacology & Pharmacy; Psychiatry
GA RQ450
UT WOS:A1994RQ45000003
PM 7770616
ER
PT J
AU PAULE, MG
AF PAULE, MG
TI ACUTE BEHAVIORAL TOXICITY OF MK-801 AND PHENCYCLIDINE - EFFECTS ON
RHESUS-MONKEY PERFORMANCE IN AN OPERANT TEST BATTERY
SO PSYCHOPHARMACOLOGY BULLETIN
LA English
DT Article
DE LEARNING; MEMORY; TIME PERCEPTION; COLOR AND POSITION DISCRIMINATION;
MOTIVATION
AB Monkey performance of operant tasks was used to model several brain functions and monitor the acute effects of MK-801 and phencyclidine (PCP), MK-801 is a relatively selective N-methyl-D-aspartate (NMDA) receptor antagonist, while PCP is an NMDA antagonist that is also active at sigma opiate receptors. A comparison of these drugs' effects may indicate the relative importance of certain neurotransmitter receptor systems for specific behaviors, Learning and time perception behaviors are more sensitive (affected at lower doses) to the disruptive effects of MK-801 than are behaviors that model short-term memory, motivation, and color and position discrimination. Such selective disruption was not obtained for PCP: learning, short-term memory and attention, time perception, and motivation tasks are all equally sensitive to disruption, These findings suggest that specific brain functions are differentially affected by modulation of the NMDA and sigma opiate systems.
RP PAULE, MG (reprint author), NATL CTR TOXICOL RES,DIV NEUROTOXICOL,BEHAV TOXICOL LAB,3900 NCTR RD,HFT-132,JEFFERSON,AR 72079, USA.
NR 18
TC 15
Z9 15
U1 0
U2 0
PU US GOVERNMENT PRINTING OFFICE
PI WASHINGTON
PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325
SN 0048-5764
J9 PSYCHOPHARMACOL BULL
JI Psychopharmacol. Bull.
PY 1994
VL 30
IS 4
BP 613
EP 621
PG 9
WC Pharmacology & Pharmacy; Psychiatry
SC Pharmacology & Pharmacy; Psychiatry
GA RQ450
UT WOS:A1994RQ45000014
PM 7770627
ER
PT B
AU Billy, TJ
AF Billy, TJ
BE Sylvia, G
Shriver, AL
Morrissey, MT
TI Report from the Office of Seafood: An issues update
SO QUALITY CONTROL & QUALITY ASSURANCE FOR SEAFOOD
LA English
DT Proceedings Paper
CT Conference on Quality Control and Quality Assurance for Seafood
CY MAY 16-18, 1993
CL NEWPORT, OR
SP Pacific NW Seafood Assoc, Oregon Econ Dev Dept
C1 US FDA,OFF SEAFOOD,WASHINGTON,DC 20005.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OREGON SEA GRANT
PI CORVALLIS
PA OREGON STATE UNIVERSITY ADMINISTRATIVE SERVICES A402, CORVALLIS, OR
97331-2134
BN 1-881826-08-2
PY 1994
BP 1
EP 6
PG 6
WC Fisheries; Food Science & Technology
SC Fisheries; Food Science & Technology
GA BE54H
UT WOS:A1994BE54H00001
ER
PT B
AU Lowell, R
AF Lowell, R
BE Sylvia, G
Shriver, AL
Morrissey, MT
TI Food and Drug Administration inspection programs for seafood
SO QUALITY CONTROL & QUALITY ASSURANCE FOR SEAFOOD
LA English
DT Proceedings Paper
CT Conference on Quality Control and Quality Assurance for Seafood
CY MAY 16-18, 1993
CL NEWPORT, OR
SP Pacific NW Seafood Assoc, Oregon Econ Dev Dept
C1 US FDA,BOTHELL,WA 98041.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OREGON SEA GRANT
PI CORVALLIS
PA OREGON STATE UNIVERSITY ADMINISTRATIVE SERVICES A402, CORVALLIS, OR
97331-2134
BN 1-881826-08-2
PY 1994
BP 39
EP 43
PG 5
WC Fisheries; Food Science & Technology
SC Fisheries; Food Science & Technology
GA BE54H
UT WOS:A1994BE54H00007
ER
PT B
AU MIED, PA
AF MIED, PA
BE Spencer, RC
Wright, EP
Newsom, SWB
TI US REGULATIONS FOR THE APPROVAL OF LABORATORY TESTS FOR THE DETECTION OF
HEPATITIS AND RETROVIRUSES AND FOR INTERNAL AND EXTERNAL QUALITY
ASSURANCE MEASUREMENTS
SO RAPID METHODS AND AUTOMATION IN MICROBIOLOGY AND IMMUNOLOGY
LA English
DT Proceedings Paper
CT 7th International Congress on Rapid Methods and Automation in
Microbiology and Immunology (RAMI-93)
CY 1993
CL LONDON, ENGLAND
C1 US FDA,CTR BIOL EVALUAT & RES,OFF BLOOD RES & REVIEW,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU INTERCEPT LTD
PI ANDOVER
PA PO BOX 716, ANDOVER, HANTS, ENGLAND SP10 1YG
BN 0-946707-78-2
PY 1994
BP 45
EP 53
PG 9
WC Immunology; Microbiology
SC Immunology; Microbiology
GA BA26V
UT WOS:A1994BA26V00006
ER
PT B
AU BENNETT, RW
AF BENNETT, RW
BE Spencer, RC
Wright, EP
Newsom, SWB
TI UREA RENATURATION AND IDENTIFICATION OF STAPHYLOCOCCAL-ENTEROTOXIN
SO RAPID METHODS AND AUTOMATION IN MICROBIOLOGY AND IMMUNOLOGY
LA English
DT Proceedings Paper
CT 7th International Congress on Rapid Methods and Automation in
Microbiology and Immunology (RAMI-93)
CY 1993
CL LONDON, ENGLAND
C1 US FDA,DIV MICROBIOL STUDIES,WASHINGTON,DC 20204.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU INTERCEPT LTD
PI ANDOVER
PA PO BOX 716, ANDOVER, HANTS, ENGLAND SP10 1YG
BN 0-946707-78-2
PY 1994
BP 401
EP 411
PG 11
WC Immunology; Microbiology
SC Immunology; Microbiology
GA BA26V
UT WOS:A1994BA26V00044
ER
PT S
AU CEBULA, TA
PAYNE, WL
FENG, P
AF CEBULA, TA
PAYNE, WL
FENG, P
BE Karmali, MA
Goglio, AG
TI MAMA/MULTIPLEX-PCR - A SPECIFIC MEANS FOR SHIGA-LIKE TOXIN TYPING AND
IDENTIFICATION OF THE O157-H7 SEROTYPE
SO RECENT ADVANCES IN VEROCYTOTOXIN-PRODUCING ESCHERICHIA COLI INFECTIONS
SE INTERNATIONAL CONGRESS SERIES
LA English
DT Proceedings Paper
CT 2nd International Symposium and Workshop on Verocytotoxin (Shiga-like
Toxin)-Producing Escherichia Coli Infections
CY JUN 27-30, 1994
CL BERGAMO, ITALY
SP Assoc Microbiol Clin Italiani, Hosp Sick Children, Res Inst, Toronto, Ospedali Riuniti, Bergamo, Ist Ric Farmacol Mario Negri, Bergamo, Ist Super Sanita, Roma, Lois Joy Galler Fdn Hemolyt Urem Syndrome Inc, New York, US Israael Binatl Sci Fdn
C1 US FDA, CTR FOOD SAFETY & APPL NUTR, WASHINGTON, DC 20204 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0531-5131
BN 0-444-81840-5
J9 INT CONGR SER
JI Int. Congr. Ser.
PY 1994
VL 1072
BP 105
EP 108
PG 4
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA BC58C
UT WOS:A1994BC58C00025
ER
PT S
AU MARCUSSEKURA, CJ
AF MARCUSSEKURA, CJ
BE Brown, F
TI REGULATORY ISSUES RELATING TO THE USE OF RECOMBINANT VECTORS IN
PRODUCTION OF HUMAN VACCINES
SO RECOMBINANT VECTORS IN VACCINE DEVELOPMENT
SE DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION
LA English
DT Proceedings Paper
CT Symposium on Recombinant Vectors in Vaccine Development
CY MAY 23-26, 1993
CL ALBANY, NY
SP NUCL ACID TECHNOL FDN, INT ASSOC BIOL STAND, US FDA, USDA ANIM & PLANT HLTH INSPECT SERV, NIAID
C1 US FDA,CTR BIOL EVALUAT & RES,DIV VIRAL PROD,OFF VACCINES RES & REVIEW,BETHESDA,MD.
RP MARCUSSEKURA, CJ (reprint author), BIOTECHNOL ASSESSMENT SERV INC,7413 OTTENBROOK TERRACE,ROCKVILLE,MD 20855, USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU KARGER
PI BASEL
PA POSTFACH, CH-4009 BASEL, SWITZERLAND
SN 0301-5149
BN 3-8055-5997-6
J9 DEV BIOL STAND
JI Dev.Biol.Stand.
PY 1994
VL 82
BP 107
EP 112
PG 6
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Genetics & Heredity; Immunology; Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Genetics & Heredity; Immunology; Virology
GA BA82W
UT WOS:A1994BA82W00012
PM 7958464
ER
PT S
AU LIU, DT
AF LIU, DT
BE Kurth, R
Haustein, D
Rode, H
TI Regulation of allergenic products in the USA; CBER initiatives
SO REGULATORY CONTROL AND STANDARDIZATION OF ALLERGENIC EXTRACTS
SE ARBEITEN AUS DEM PAUL-EHRLICH-INSTITUT (BUNDESANT FUR SERA UND
IMPFSTOFFE), DEM GEORG-SPEYER-HAUS UND DEM FERDINAND-BLUM-INSTITUT ZU
FRANKFURT A.M.
LA English
DT Proceedings Paper
CT 7th International Paul Ehrlich Seminar
CY SEP 07-10, 1993
CL LANGEN, GERMANY
SP Paul Ehrlich Inst
C1 US FDA,CTR BIOL EVALUAT & RES,DIV ALLERGEN PROD & PARASITOL,ROCKVILLE,MD 20852.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU GUSTAV FISCHER VERLAG
PI STUTTGART 70
PA WOLLGRASWEG 49, W-7000 STUTTGART 70, GERMANY
SN 0936-8671
BN 3-437-11622-3
J9 ARB PEI GSH
PY 1994
VL 87
BP 7
EP 12
PG 6
WC Allergy
SC Allergy
GA BD88X
UT WOS:A1994BD88X00001
ER
PT S
AU TURKELTAUB, PC
AF TURKELTAUB, PC
BE Kurth, R
Haustein, D
Rode, H
TI Use of skin testing for evaluation of potency, composition, and
stability of allergenic products
SO REGULATORY CONTROL AND STANDARDIZATION OF ALLERGENIC EXTRACTS
SE ARBEITEN AUS DEM PAUL-EHRLICH-INSTITUT (BUNDESANT FUR SERA UND
IMPFSTOFFE), DEM GEORG-SPEYER-HAUS UND DEM FERDINAND-BLUM-INSTITUT ZU
FRANKFURT A.M.
LA English
DT Proceedings Paper
CT 7th International Paul Ehrlich Seminar
CY SEP 07-10, 1993
CL LANGEN, GERMANY
SP Paul Ehrlich Inst
C1 US FDA,CTR BIOL EVALUAT & RES,ROCKVILLE,MD 20852.
NR 0
TC 7
Z9 7
U1 0
U2 0
PU GUSTAV FISCHER VERLAG
PI STUTTGART 70
PA WOLLGRASWEG 49, W-7000 STUTTGART 70, GERMANY
SN 0936-8671
BN 3-437-11622-3
J9 ARB PEI GSH
PY 1994
VL 87
BP 79
EP 87
PG 9
WC Allergy
SC Allergy
GA BD88X
UT WOS:A1994BD88X00008
ER
PT S
AU DEVRIES, YL
AF DEVRIES, YL
BE Kurth, R
Haustein, D
Rode, H
TI Production and testing of allergenic extracts for diagnostic and
therapeutic use in humans: Regulatory considerations
SO REGULATORY CONTROL AND STANDARDIZATION OF ALLERGENIC EXTRACTS
SE ARBEITEN AUS DEM PAUL-EHRLICH-INSTITUT (BUNDESANT FUR SERA UND
IMPFSTOFFE), DEM GEORG-SPEYER-HAUS UND DEM FERDINAND-BLUM-INSTITUT ZU
FRANKFURT A.M.
LA English
DT Proceedings Paper
CT 7th International Paul Ehrlich Seminar
CY SEP 07-10, 1993
CL LANGEN, GERMANY
SP Paul Ehrlich Inst
C1 US FDA,CTR BIOL EVALUAT & RES,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU GUSTAV FISCHER VERLAG
PI STUTTGART 70
PA WOLLGRASWEG 49, W-7000 STUTTGART 70, GERMANY
SN 0936-8671
BN 3-437-11622-3
J9 ARB PEI GSH
PY 1994
VL 87
BP 199
EP 202
PG 4
WC Allergy
SC Allergy
GA BD88X
UT WOS:A1994BD88X00017
ER
PT S
AU BERKOWER, I
AF BERKOWER, I
BE Kurth, R
Haustein, D
Rode, H
TI Synthetic T cell epitope peptides used for desensitization: Theoretical
and clinical considerations
SO REGULATORY CONTROL AND STANDARDIZATION OF ALLERGENIC EXTRACTS
SE ARBEITEN AUS DEM PAUL-EHRLICH-INSTITUT (BUNDESANT FUR SERA UND
IMPFSTOFFE), DEM GEORG-SPEYER-HAUS UND DEM FERDINAND-BLUM-INSTITUT ZU
FRANKFURT A.M.
LA English
DT Proceedings Paper
CT 7th International Paul Ehrlich Seminar
CY SEP 07-10, 1993
CL LANGEN, GERMANY
SP Paul Ehrlich Inst
C1 US FDA,CTR BIOL EVALUAT & RES,IMMUNOREGULAT LAB,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU GUSTAV FISCHER VERLAG
PI STUTTGART 70
PA WOLLGRASWEG 49, W-7000 STUTTGART 70, GERMANY
SN 0936-8671
BN 3-437-11622-3
J9 ARB PEI GSH
PY 1994
VL 87
BP 251
EP 256
PG 6
WC Allergy
SC Allergy
GA BD88X
UT WOS:A1994BD88X00023
ER
PT B
AU CHIACCHIERINI, RP
AF CHIACCHIERINI, RP
BE Grundfest, WS
TI MEDICAL DEVICE CLINICAL TRIAL DESIGN, CONDUCT, AND ANALYSIS
SO ROLE OF TECHNOLOGY IN THE COST OF HEALTH CARE: HEALTH CARE TECHNOLOGY
POLICY I
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
(SPIE)
LA English
DT Proceedings Paper
CT Conference on Health Care Technology Policy I - The Role of Technology
in the Cost of Health Care
CY APR 27-29, 1994
CL ARLINGTON, VA
SP IEEE, USA ACTIV BOARD, WHITAKER FDN, MEDALLIONS CHARITABLE FUND, SOC PHOTO OPT INSTRUMENTAT ENGINEERS, HAMAMATSU CORP
C1 CTR DEVICES & RADIOL HLTH,DIV BIOMETR SCI,OSB,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SPIE - INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA PO BOX 10, BELLINGHAM, WA 98227-0010
BN 0-8194-1631-2
J9 P SOC PHOTO-OPT INS
PY 1994
VL 2307
BP 278
EP 285
DI 10.1117/12.195457
PG 8
WC Health Policy & Services
SC Health Care Sciences & Services
GA BC03K
UT WOS:A1994BC03K00031
ER
PT B
AU REAMER, L
AF REAMER, L
BE Grundfest, WS
TI PROBLEMS CAUSED BY REGULATORY DELAYS AND LACK OF REGULATION
SO ROLE OF TECHNOLOGY IN THE COST OF HEALTH CARE: HEALTH CARE TECHNOLOGY
POLICY I
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
(SPIE)
LA English
DT Proceedings Paper
CT Conference on Health Care Technology Policy I - The Role of Technology
in the Cost of Health Care
CY APR 27-29, 1994
CL ARLINGTON, VA
SP IEEE, USA ACTIV BOARD, WHITAKER FDN, MEDALLIONS CHARITABLE FUND, SOC PHOTO OPT INSTRUMENTAT ENGINEERS, HAMAMATSU CORP
C1 US FDA,OFF DEVICE EVALUAT,CTR DEVICES & RADIOL HLTH,DIV CARDIOVASC RESP & NEUROL DEVICES,ROCKVILLE,MD 20850.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPIE - INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA PO BOX 10, BELLINGHAM, WA 98227-0010
BN 0-8194-1631-2
J9 P SOC PHOTO-OPT INS
PY 1994
VL 2307
BP 297
EP 300
DI 10.1117/12.195459
PG 4
WC Health Policy & Services
SC Health Care Sciences & Services
GA BC03K
UT WOS:A1994BC03K00033
ER
PT B
AU YIN, L
AF YIN, L
BE Grundfest, WS
TI TRAINING AND EDUCATION OF REGULATORY REQUIREMENTS TO INCREASE THE
EFFECTIVENESS OF TECHNOLOGY INTRODUCTION
SO ROLE OF TECHNOLOGY IN THE COST OF HEALTH CARE: HEALTH CARE TECHNOLOGY
POLICY I
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
(SPIE)
LA English
DT Proceedings Paper
CT Conference on Health Care Technology Policy I - The Role of Technology
in the Cost of Health Care
CY APR 27-29, 1994
CL ARLINGTON, VA
SP IEEE, USA ACTIV BOARD, WHITAKER FDN, MEDALLIONS CHARITABLE FUND, SOC PHOTO OPT INSTRUMENTAT ENGINEERS, HAMAMATSU CORP
C1 US FDA,OFF DEVICE EVALUAT,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPIE - INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA PO BOX 10, BELLINGHAM, WA 98227-0010
BN 0-8194-1631-2
J9 P SOC PHOTO-OPT INS
PY 1994
VL 2307
BP 370
EP 377
DI 10.1117/12.195468
PG 8
WC Health Policy & Services
SC Health Care Sciences & Services
GA BC03K
UT WOS:A1994BC03K00041
ER
PT J
AU CAREY, RF
AF CAREY, RF
TI CONDOM SAFETY AND HIV - IN RESPONSE
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Letter
RP CAREY, RF (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,DIV PHYS SCI,ROCKVILLE,MD, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0148-5717
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JAN-FEB
PY 1994
VL 21
IS 1
BP 60
EP 60
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA MU295
UT WOS:A1994MU29500014
ER
PT B
AU KATZPER, M
AF KATZPER, M
BE Anderson, JG
Katzper, M
TI VISUAL PROGRAMMING OF PHARMACOMETRIC MODELS
SO SIMULATION IN THE HEALTH SCIENCES: PROCEEDINGS OF THE 1994 WESTERN
MULTICONFERENCE
LA English
DT Proceedings Paper
CT 1994 Western Multiconference - Simulation in the Health Sciences
CY JAN 24-26, 1994
CL TEMPE, AZ
SP SOC COMP SIMULAT
C1 US FDA,CTR DRUG EVAL & RES,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC COMPUTER SIMULATION INT
PI SAN DIEGO
PA PO BOX 17900, SAN DIEGO, CA 92177
BN 1-56555-068-4
PY 1994
BP 84
EP 84
PG 1
WC Computer Science, Information Systems; Health Policy & Services;
Information Science & Library Science
SC Computer Science; Health Care Sciences & Services; Information Science &
Library Science
GA BB73Q
UT WOS:A1994BB73Q00015
ER
PT B
AU KATZPER, M
HALE, VG
BORGA, O
HARTER, JG
AF KATZPER, M
HALE, VG
BORGA, O
HARTER, JG
BE Anderson, JG
Katzper, M
TI HEURISTIC MODELING OF SULINDAC PHARMACOKINETICS
SO SIMULATION IN THE HEALTH SCIENCES: PROCEEDINGS OF THE 1994 WESTERN
MULTICONFERENCE
LA English
DT Proceedings Paper
CT 1994 Western Multiconference - Simulation in the Health Sciences
CY JAN 24-26, 1994
CL TEMPE, AZ
SP SOC COMP SIMULAT
C1 US FDA,CTR DRUG EVALUAT & RES,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC COMPUTER SIMULATION INT
PI SAN DIEGO
PA PO BOX 17900, SAN DIEGO, CA 92177
BN 1-56555-068-4
PY 1994
BP 107
EP 112
PG 6
WC Computer Science, Information Systems; Health Policy & Services;
Information Science & Library Science
SC Computer Science; Health Care Sciences & Services; Information Science &
Library Science
GA BB73Q
UT WOS:A1994BB73Q00020
ER
PT B
AU HAMMERSTROM, T
AF HAMMERSTROM, T
BE Anderson, JG
Katzper, M
TI SIMULATING MODELS FOR RECORD LINKAGE DATA AND POTENTIAL BIASES IN
RELATIVE RISK ESTIMATES
SO SIMULATION IN THE HEALTH SCIENCES: PROCEEDINGS OF THE 1994 WESTERN
MULTICONFERENCE
LA English
DT Proceedings Paper
CT 1994 Western Multiconference - Simulation in the Health Sciences
CY JAN 24-26, 1994
CL TEMPE, AZ
SP SOC COMP SIMULAT
C1 US FDA,DIV BIOMETR,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC COMPUTER SIMULATION INT
PI SAN DIEGO
PA PO BOX 17900, SAN DIEGO, CA 92177
BN 1-56555-068-4
PY 1994
BP 120
EP 125
PG 6
WC Computer Science, Information Systems; Health Policy & Services;
Information Science & Library Science
SC Computer Science; Health Care Sciences & Services; Information Science &
Library Science
GA BB73Q
UT WOS:A1994BB73Q00022
ER
PT B
AU LIEBERMAN, R
LUDDEN, T
MCMICHAEL, J
STARZL, T
AF LIEBERMAN, R
LUDDEN, T
MCMICHAEL, J
STARZL, T
BE Anderson, JG
Katzper, M
TI PHARMACODYNAMIC MODELS, CONTINUOUS (SURROGATE) ENDPOINTS AND COMPUTER
SIMULATIONS - AN ANALYSIS OF DOSE AND CONCENTRATION CONTROLLED TRIAL
DESIGNS
SO SIMULATION IN THE HEALTH SCIENCES: PROCEEDINGS OF THE 1994 WESTERN
MULTICONFERENCE
LA English
DT Proceedings Paper
CT 1994 Western Multiconference - Simulation in the Health Sciences
CY JAN 24-26, 1994
CL TEMPE, AZ
SP SOC COMP SIMULAT
C1 US FDA,COLL STAFF,CTR DRUG EVALUAT & RES,ROCKVILLE,MD 20857.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU SOC COMPUTER SIMULATION INT
PI SAN DIEGO
PA PO BOX 17900, SAN DIEGO, CA 92177
BN 1-56555-068-4
PY 1994
BP 137
EP 142
PG 6
WC Computer Science, Information Systems; Health Policy & Services;
Information Science & Library Science
SC Computer Science; Health Care Sciences & Services; Information Science &
Library Science
GA BB73Q
UT WOS:A1994BB73Q00024
ER
PT J
AU CHEN, JJ
LI, LA
AF CHEN, JJ
LI, LA
TI DOSE-RESPONSE MODELING OF TRINOMIAL RESPONSES FROM DEVELOPMENTAL
EXPERIMENTS
SO STATISTICA SINICA
LA English
DT Article
DE BETA-BINOMIAL; DIRICHLET-TRINOMIAL; INTRALITTER CORRELATION;
QUASI-LIKELIHOOD
ID TOXICOLOGICAL EXPERIMENTS; LINEAR-MODELS; TOXICITY
AB Two frequently used toxicity endpoints for evaluation of developmental effects are the proportion of deaths/resorptions and the proportion of malformations. Either a double beta-binomial model or a Dirichlet-trinomial model can be used to model the two developmental endpoints in the presence of intralitter correlation. Both models assume that the proportion of death/resorption and the proportion of malformation are two independent developmental effects. A quasi-likelihood model is proposed under both double beta-binomial and Dirichlet-trinomial variations. This approach allows for modeling a dependency between the two proportions. The examples are given for illustration.
C1 ACAD SINICA,INST STAT SCI,TAIPEI 11529,TAIWAN.
RP CHEN, JJ (reprint author), US FDA,NATL CTR TOXICOL RES,JEFFERSON,AR 72079, USA.
NR 14
TC 6
Z9 6
U1 0
U2 1
PU STATISTICA SINICA
PI WINNIPEG
PA C/O DR S W CHENG,MANAG EDITOR DEPT STAT UNIV MANTOBA, WINNIPEG MB R3T
2N2, CANADA
SN 1017-0405
J9 STAT SINICA
JI Stat. Sin.
PD JAN
PY 1994
VL 4
IS 1
BP 265
EP 274
PG 10
WC Statistics & Probability
SC Mathematics
GA ND382
UT WOS:A1994ND38200015
ER
PT B
AU ANTHONY, BF
AF ANTHONY, BF
GP ABBOTT LAB, ROSS PROD DIV
TI REGULATORY ASPECTS OF CURRENT VACCINES AND DEVELOPMENT OF NEW VACCINES
SO STRATEGIES FOR PEDIATRIC VACCINES: CONVENTIONAL AND MOLECULAR
APPROACHES: REPORT OF THE 104TH ROSS CONFERENCE ON PEDIATRIC RESEARCH
LA English
DT Proceedings Paper
CT 104th Ross Conference on Pediatric Research - Strategies for Pediatric
Vaccines: Conventional and Molecular Approaches
CY SEP 18-21, 1993
CL SAN DIEGO, CA
SP ABBOTT LAB, ROSS PROD DIV
C1 US FDA,PUBL HLTH SERV,CTR BIOL EVALUAT & RES,DIV BACTERIAL PROD,BETHESDA,MD 20014.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ROSS PRODUCTS DIV ABBOTT LABORATORIES
PI COLUMBUS
PA COLUMBUS, OH 43215-1724
PY 1994
BP 253
EP 256
PG 4
WC Immunology; Pediatrics
SC Immunology; Pediatrics
GA BC29F
UT WOS:A1994BC29F00029
ER
PT S
AU BLOCK, E
CALVEY, EM
AF BLOCK, E
CALVEY, EM
BE Mussinan, CJ
Keelan, ME
TI FACTS AND ARTIFACTS IN ALLIUM CHEMISTRY
SO SULFUR COMPOUNDS IN FOODS
SE ACS SYMPOSIUM SERIES
LA English
DT Article; Proceedings Paper
CT Symposium on Sulfur Compounds in Foods, at the 206th National Meeting of
the American-Chemical-Society
CY AUG 22-27, 1993
CL CHICAGO, IL
SP AMER CHEM SOC, DIV AGR & FOOD CHEM
ID CHROMATOGRAPHY MASS-SPECTROMETRY; L VARIETY CAESPITOSUM;
GAS-CHROMATOGRAPHY; ORGANOSULFUR COMPOUNDS; VOLATILE CONSTITUENTS;
PLATELET-AGGREGATION; GARLIC PRODUCTS; CHINESE CHIVE; HPLC ANALYSIS;
ESSENTIAL OIL
AB Problems associated with distinguishing genuine genus Allium flavorants from artifacts formed by analytical methods and sampling techniques are considered. For flavorant isolation and extraction, methods such as supercritical carbon dioxide extraction and room temperature steam distillation are recommended. For determination of thermally unstable thiosulfinate esters and their breakdown products, methods such as gas chromatography (GC), high-performance liquid chromatography (HPLC), and supercritical fluid chromatography (SFC), as well as GC-mass spectrometry (MS), LC-MS and SFC-MS, each have strengths and weaknesses. These techniques have been used to study the stereospecificity associated with biogenesis of Allium sulfinyl flavorants; the effects of sulfur fertility on the pungency of hydroponically cultivated onions; and the decomposition of garlic and onion distilled oil components, bis(2-propenyl) disulfide and bis(1-propenyl) disulfide, respectively.
C1 US FDA,CTR FOOD SAFETY & APPL NUTR,WASHINGTON,DC 20204.
RP BLOCK, E (reprint author), SUNY ALBANY,DEPT CHEM,ALBANY,NY 12222, USA.
RI Block, Eric/D-3989-2014
NR 40
TC 19
Z9 19
U1 1
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 SIXTEENTH ST NW, WASHINGTON, DC 20036
SN 0097-6156
BN 0-8412-2943-0
J9 ACS SYM SER
PY 1994
VL 564
BP 63
EP 79
PG 17
WC Chemistry, Multidisciplinary; Chemistry, Analytical; Food Science &
Technology
SC Chemistry; Food Science & Technology
GA BB10R
UT WOS:A1994BB10R00006
ER
PT J
AU HANSEN, DK
GRAFTON, TF
AF HANSEN, DK
GRAFTON, TF
TI COMPARISON OF DEXAMETHASONE-INDUCED EMBRYOTOXICITY IN-VITRO IN MOUSE AND
RAT EMBRYOS
SO TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS
LA English
DT Article
DE DEXAMETHASONE; GLUCOCORTICOID; GROWTH RETARDATION; RODENT WHOLE EMBRYO
CULTURE; SPECIES DIFFERENCES; GENETIC SUSCEPTIBILITY
ID INDUCED CLEFT-PALATE; H-2 HISTOCOMPATIBILITY REGION; GLUCOCORTICOID
RECEPTORS; CORTICOSTERONE; CORTISOL; INVITRO; GROWTH; MICE; PHENYTOIN;
PLASMA
AB Previous work demonstrated that rat embryos were more susceptible to the growth retardation effect of the synthetic glucocorticoid dexamethasone (DEX) in vivo than were mouse embryos. The purpose of this study was to examine this species difference using an in vitro system. Embryos of CD rats and CD-I mice were cultured in a whole embryo culture system with concentrations of DEX from 5 to 250 mu g/ml. Rat embryos were explanted on day 9 of gestation (GD 9: plug day = GD 0), while mouse embryos were removed on GD 8. After 48 h in culture, each viable embryo was evaluated for morphological score, and the number of somite pairs, crown-rump, and head lengths, as well as DNA and protein concentrations were determined. A reduced morphological score was observed for mouse embryos at 5 mu g DEX/ml, but a significant decrease in this parameter was only observed at DEX concentrations of greater than or equal to 100 mu g/ml in rat embryos. Significant reductions in the number of somite pairs were observed at 25 mu g/ml for mouse embryos and 100 mu g/ml for rat embryos. Crown-rump and head lengths as well as DNA and protein concentrations were significantly decreased at 100 mu g/ml in mouse embryos and 150 mu g/ml in rat embryos. Therefore, in vitro mouse embryos were adversely affected by lower concentrations of DEX than were rat embryos for each of the six end points examined in this study. This species sensitivity in vitro could be due to inherent genetic differences or to the slightly different developmental stages evaluated using the culture system. The species sensitivity observed in vivo may be due to a maternal difference in the pharmacodynamics of the drug. (C) 1994 Wiley-Liss, Inc.
RP HANSEN, DK (reprint author), US FDA,NATL CTR TOXICOL RES,DIV REPROD & DEV TOXICOL,3900 NCTR DR,JEFFERSON,AR 72079, USA.
FU FDA HHS [FDA 224-89-0008]
NR 50
TC 8
Z9 8
U1 0
U2 1
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0270-3211
J9 TERATOGEN CARCIN MUT
JI Teratogenesis Carcinog. Mutagen.
PY 1994
VL 14
IS 6
BP 281
EP 289
DI 10.1002/tcm.1770140605
PG 9
WC Oncology; Genetics & Heredity; Toxicology
SC Oncology; Genetics & Heredity; Toxicology
GA QH229
UT WOS:A1994QH22900004
PM 7709365
ER
PT S
AU LIN, LJ
AF LIN, LJ
BE Parliment, TH
Morello, MJ
McGorrin, RJ
TI REGULATORY STATUS OF MAILLARD REACTION FLAVORS
SO THERMALLY GENERATED FLAVORS: MAILLARD, MICROWAVE, AND EXTRUSION
PROCESSES
SE ACS SYMPOSIUM SERIES
LA English
DT Article; Proceedings Paper
CT Symposium on Thermally Generated Flavors: Maillard, Microwave, and
Extrusion Processes, at the 204th National Meeting of the
American-Chemical-Society
CY AUG 23-28, 1992
CL WASHINGTON, DC
SP AMER CHEM SOC, DIV AGR & FOOD CHEM
ID PRODUCTS; AMINES
AB Maillard reaction flavors have been introduced into the food supply based on manufacturers' conclusions that the scientific community has considered them to be GRAS. At the present time, FDA does not have enough information to disagree with such conclusions. An analytical method is being developed to determine the amounts and identities of heterocyclic amines which may be present in those flavors. This information is needed to clarify the GRAS status of Maillard reaction flavors.
RP LIN, LJ (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 9
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 SIXTEENTH ST NW, WASHINGTON, DC 20036
SN 0097-6156
BN 0-8412-2742-X
J9 ACS SYM SER
PY 1994
VL 543
BP 7
EP 15
PG 9
WC Chemistry, Multidisciplinary; Chemistry, Analytical; Food Science &
Technology
SC Chemistry; Food Science & Technology
GA BA14Q
UT WOS:A1994BA14Q00002
ER
PT B
AU LESTER, DS
AF LESTER, DS
BE Lakowicz, JR
TI INCORPORATION OF FLUORESCENTLY-LABELED LIPIDS INTO LIVING BRAIN-SLICES
SO TIME-RESOLVED LASER SPECTROSCOPY IN BIOCHEMISTRY IV, PROCEEDINGS OF
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
(SPIE)
LA English
DT Proceedings Paper
CT 4th Biennial Conference on Time-Resolved Laser Spectroscopy in
Biochemistry
CY JAN 24-26, 1994
CL LOS ANGELES, CA
SP SOC PHOTO OPT INSTRUMENTAT ENGINEERS, BRIMROSE CORP, COHERENT LASER GR, HAMAMATSU CORP, ISS, INC, LASER FOCUS WORLD, ICONIX, PHOTON SPECTRA, PROGRAMMED TEST SOURCES, INC, SLM INSTRUMENTS, INC, SPECTRA PHYS LASERS, SPEX IND
C1 CDER,FDA,DIV RES & TESTING,LAUREL,MD 20708.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPIE - INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA PO BOX 10, BELLINGHAM, WA 98227-0010
BN 0-8194-1432-8
J9 P SOC PHOTO-OPT INS
PY 1994
VL 2137
BP 39
EP 48
DI 10.1117/12.182742
PG 10
WC Biochemistry & Molecular Biology; Spectroscopy
SC Biochemistry & Molecular Biology; Spectroscopy
GA BB27F
UT WOS:A1994BB27F00004
ER
PT J
AU WHITEHURST, VE
JOSEPH, X
ALLEVA, FR
VICK, JA
WHITTAKER, P
ZHANG, J
FRY, BE
BALAZS, T
AF WHITEHURST, VE
JOSEPH, X
ALLEVA, FR
VICK, JA
WHITTAKER, P
ZHANG, J
FRY, BE
BALAZS, T
TI ENHANCEMENT OF ACUTE MYOCARDIAL LESIONS BY ASTHMA DRUGS IN RATS
SO TOXICOLOGIC PATHOLOGY
LA English
DT Article
DE BETA-AGONISTS; METHYLXANTHINES; HEAVY RATS; MYOCARDIAL NECROSIS; SERUM
IONS
AB Asthma morbidity and mortality have risen significantly in the last 10 years. The reasons for the increase are multifactorial. One proposed explanation is possible myocardial toxicity arising from the use of beta-agonists alone or in combination with methylxanthines. Previous studies have shown that beta-agonists given alone and beta-agonist/methylxanthine combinations given at higher than recommended clinical doses induced dose-related cardiotoxicity and sudden death in rats. The objective of the present study was to determine whether or not beta-agonists given alone and in combination with methylxanthines at recommended clinical doses also induce cardiotoxicity and sudden death in rats. The beta-agonists, isoproterenol hydrochloride (15 mug/kg), fenoterol hydrobromide (40 mug/kg), and terbutaline hemisulfate (0.4 mg/kg) were given in single sc doses separately and concurrently with the methylxanthines aminophylline hydrate (20 mg/kg) and caffeine (40 mg/kg), which were given ip to a susceptible animal model, the heavy Sprague-Dawley rat. Beta-agonist-induced myocardial toxicity (necrosis) was observed. The toxicity was enhanced by aminophylline resulting in the sudden death (most likely due to ventricular fibrillation) of some animals. A decrease in serum iron levels was observed in rats of all beta-agonist and/or methylxanthine-treated groups.
C1 US FDA,CTR FOOD SAFETY & APPL NUTR,WASHINGTON,DC 20204.
RP WHITEHURST, VE (reprint author), US FDA,CTR DRUG EVALUAT & RES,PARKLAWN BLDG,ROOM 17B45,WASHINGTON,DC 20204, USA.
NR 0
TC 6
Z9 6
U1 0
U2 0
PU SOC TOXICOLOGIC PATHOLOGISTS
PI LAWRENCE
PA 1041 NEW HAMPSHIRE ST PO BOX 368, LAWRENCE, KS 66044
SN 0192-6233
J9 TOXICOL PATHOL
JI Toxicol. Pathol.
PD JAN-FEB
PY 1994
VL 22
IS 1
BP 72
EP 76
PG 5
WC Pathology; Toxicology
SC Pathology; Toxicology
GA NP825
UT WOS:A1994NP82500010
PM 7915431
ER
PT J
AU UENG, TH
UENG, YF
CHOU, MW
AF UENG, TH
UENG, YF
CHOU, MW
TI REGIOSELECTIVE METABOLISM OF BENZO[A]PYRENE AND
7-CHLOROBENZ[A]ANTHRACENE BY FISH LIVER-MICROSOMES
SO TOXICOLOGY LETTERS
LA English
DT Article
DE BENZO[A]PYRENE; 7-CHLOROBENZ[A]ANTHRACENE; FISH LIVER MICROSOME
ID POLYNUCLEAR AROMATIC-HYDROCARBONS; TRANS-DIHYDRODIOL METABOLITES;
STEREOSELECTIVE METABOLISM; RAINBOW-TROUT; ABSOLUTE-CONFIGURATIONS;
STENOTOMUS-CHRYSOPS; SALMO-GAIRDNERI; DIOL EPOXIDES;
7-BROMOBENZANTHRACENE; 3-METHYLCHOLANTHRENE
AB Many polycyclic aromatic hydrocarbons (PAHs) and chlorinated PAHs in the environment are potent mutagens and carcinogens. Using benzo[a]pyrene (BaP) and 7-chlorobenz[a]anthracene (7-Cl-BA) as representatives of PAHs and chlorinated PAHs, respectively, we studied the metabolism of these compounds in liver microsomes of Tilapia (Oreochromis hybrid), one of the most common fish in south Asia. The regioselective metabolism of BaP and 7-Cl-BA by the fish liver microsomes resulted in the formation of hydroxylated and trans-dihydrodiol metabolites of both BaP and 7-Cl-BA. The metabolites were purified by HPLC and identified by both UV/VIS and mass spectroscopic methods. The fish liver microsomes metabolized BaP to form BaP-7,8-dihydrodiol (11%), 3-hydroxy-BaP (17%), and 9-hydroxy-BaP (22%) as the major products and metabolized 7-Cl-BA to form 7-Cl-BA trans-8,9-dihydrodiol as the major metabolite (40%). The Tilapia liver microsomal P-450 enzyme activities were inducible by pretreatment with 3-methylcholanthrene (3-MC), which increased microsomal aryl hydrocarbon hydroxylase and 7-ethoxyresorufin O-deethylase activities by 74- and 360-fold, respectively. The induction of these enzymes by 3-MC was greater in fish microsomes than in rat liver. This study is the first to demonstrate the regioselective metabolism of BaP and 7-Cl-BA by fish liver microsomes.
C1 NATL CTR TOXICOL RES,DIV NUTR TOXICOL,JEFFERSON,AR 72079.
NATL TAIWAN UNIV,COLL MED,INST TOXICOL,TAIPEI 10018,TAIWAN.
NR 26
TC 13
Z9 14
U1 0
U2 2
PU ELSEVIER SCI IRELAND LTD
PI CLARE
PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
IRELAND
SN 0378-4274
J9 TOXICOL LETT
JI Toxicol. Lett.
PD JAN
PY 1994
VL 70
IS 1
BP 89
EP 99
PG 11
WC Toxicology
SC Toxicology
GA MV387
UT WOS:A1994MV38700010
PM 8310461
ER
PT J
AU SCOTT, ML
VOAK, D
PHILLIPS, PK
HOPPE, PA
KOCHMAN, SA
AF SCOTT, ML
VOAK, D
PHILLIPS, PK
HOPPE, PA
KOCHMAN, SA
TI REVIEW OF THE PROBLEMS INVOLVED IN USING ENZYMES IN BLOOD-GROUP SEROLOGY
- PROVISION OF FREEZE-DRIED ICSH/ISBT PROTEASE ENZYME AND ANTI-D
REFERENCE-STANDARDS
SO VOX SANGUINIS
LA English
DT Review
ID PROTEOLYTIC-ENZYMES; PAPAIN
AB Proteolytic enzyme preparations and techniques used routinely in blood group serology for the detection of atypical patient antibodies prior to transfusion vary widely and are often poorly standardised. Recent advances have been made in the use of biochemical methods to standardise and stabilise the potency of the enzyme preparations used. A joint working party of the International Council for Standardization in Haematology (ICSH) and the International Society of Blood Transfusion (ISBT) has investigated possibilities for the provision of standards for the protease preparations and techniques. The specification for these standards was that the performance of enzyme reference preparation in the reference technique should be of equivalent sensitivity to the ICSH/ISBT LISS spin indirect antiglobulin test using a titration series of a reference weak anti-D, and be free from false-positive reactions. The working party circulated materials for evaluation in inter-laboratory trials, followed by a laboratory workshop meeting to achieve agreement on the specification for reference materials and methods. Reference freeze-dried papain at 0.6 azoalbumin units and weak anti-D preparations (91/562) have been prepared and validated to meet these specifications. The performance of a test enzyme preparation in the technique for which it is recommended for use should be at least equal to that of the reference papain preparation, by the reference two-stage technique in terms of sensitivity, using a titration series of the reference anti-D, and freedom from false-positive reactions, using six fresh inert sera. The reference papain and weak anti-D can also be used to calibrate the level of proteolytic activity required in other procedures in blood group serology, such as new technology methods for antibody detection, and automated and microplate cell grouping procedures. These preparations and an agreed method for their use are now available from listed centres as ICSH/ISBT and Food and Drug Administration reference materials.
C1 UNIV CAMBRIDGE,E ANGLIAN BLOOD TRANSFUS CTR,DIV TRANSFUS MED,CAMBRIDGE,ENGLAND.
NATL INST BIOL STAND & CONTROLS,S MIMMS,HERTS,ENGLAND.
US FDA,ROCKVILLE,MD.
RP SCOTT, ML (reprint author), INT BLOOD GRP REFERENCE LAB,SOUTHMEAD RD,BRISTOL BS10 5ND,AVON,ENGLAND.
NR 26
TC 17
Z9 17
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0042-9007
J9 VOX SANG
JI Vox Sang.
PY 1994
VL 67
IS 1
BP 89
EP 98
PG 10
WC Hematology
SC Hematology
GA NX717
UT WOS:A1994NX71700024
PM 7975466
ER
PT J
AU HEREDIA, A
GUO, ZP
YU, MW
MASON, BL
EPSTEIN, JS
HEWLETT, IK
AF HEREDIA, A
GUO, ZP
YU, MW
MASON, BL
EPSTEIN, JS
HEWLETT, IK
TI DETECTION OI HIV-1 BY RNA PCR IN FACTOR-VIII CONCENTRATES
SO VOX SANGUINIS
LA English
DT Letter
ID PLASMA; HEAT
C1 US FDA,CTR BIOL EVALUAT & RES,OFF BLOOD RES & REVIEW,DIV HEMATOL,PLASMA DERIVAT LAB,DTTD,ROCKVILLE,MD 20852.
US FDA,DIV TRANSFUS & TRANSMITTED DIS,MOLEC VIROL LAB,ROCKVILLE,MD 20852.
NR 7
TC 5
Z9 5
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0042-9007
J9 VOX SANG
JI Vox Sang.
PY 1994
VL 67
IS 4
BP 402
EP 403
PG 2
WC Hematology
SC Hematology
GA PW922
UT WOS:A1994PW92200013
PM 7701813
ER
PT J
AU SORIANO, V
DRONDA, F
GONZALEZLOPEZ, A
CHAVES, F
BRAVO, R
GUTIERREZ, M
HEREDIA, A
HEWLETT, I
AF SORIANO, V
DRONDA, F
GONZALEZLOPEZ, A
CHAVES, F
BRAVO, R
GUTIERREZ, M
HEREDIA, A
HEWLETT, I
TI HIV-1 CAUSING AIDS AND DEATH IN A SERONEGATIVE INDIVIDUAL
SO VOX SANGUINIS
LA English
DT Letter
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HOMOSEXUAL MEN; INFECTION; ANTIBODY;
PATIENT; COHORT; TYPE-1
C1 HOSP GEN PENITENCIARIO,DEPT MICROBIOL,MADRID,SPAIN.
US FDA,CBER,MOLEC VIROL LAB,KENSINGTON,MD.
RP SORIANO, V (reprint author), INST SALUD CARLOS 3,DEPT INFECT DIS,C RAFAEL CALVO 7,2 A,E-28010 MADRID,SPAIN.
RI Chaves, Fernando/C-6176-2016
NR 11
TC 34
Z9 34
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0042-9007
J9 VOX SANG
JI Vox Sang.
PY 1994
VL 67
IS 4
BP 410
EP 411
PG 2
WC Hematology
SC Hematology
GA PW922
UT WOS:A1994PW92200018
PM 7701817
ER
PT J
AU SORIANO, V
GUTIERREZ, M
HEREDIA, A
BRAVO, R
HEWLETT, I
GONZALEZLAHOZ, J
AF SORIANO, V
GUTIERREZ, M
HEREDIA, A
BRAVO, R
HEWLETT, I
GONZALEZLAHOZ, J
TI EVALUATION OF DIFFERENT SUPPLEMENTARY ASSAYS FOR THE CONFIRMATION OF
HIV-1 AND HIV-2 INFECTIONS
SO VOX SANGUINIS
LA English
DT Letter
ID WESTERN-BLOT; IMMUNODEFICIENCY
C1 US FDA,CBER,MOLEC VIROL LAB,BETHESDA,MD.
RP SORIANO, V (reprint author), INST SALUD CARLOS III,CTR INVEST CLIN,CALLE RAFAEL CALVO 7 2A,E-28010 MADRID,SPAIN.
NR 8
TC 2
Z9 2
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0042-9007
J9 VOX SANG
JI Vox Sang.
PY 1994
VL 66
IS 1
BP 82
EP 83
PG 2
WC Hematology
SC Hematology
GA MR731
UT WOS:A1994MR73100017
PM 8146990
ER
PT B
AU CLAUSING, P
REUM, K
BRUCKNER, R
AF CLAUSING, P
REUM, K
BRUCKNER, R
BE Bunyan, J
TI SOCIAL BEHAVIOUR AFTER INTRAPERITONEAL INJECTION - A COMPARISON WITH THE
DISTURBANCE INDEX METHOD
SO WELFARE AND SCIENCE
LA English
DT Proceedings Paper
CT 5th Symposium of the
Federation-of-European-Laboratory-Animal-Science-Associations - Welfare
and Science
CY JUN 08-11, 1993
CL BRIGHTON, ENGLAND
SP FED EUROPEAN LAB ANIM SCI ASSOC, LAB ANIM SCI ASSOC
C1 NATL CTR TOXICOL RES,DIV NEUROTOXICOL,JEFFERSON,AR 72079.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ROYAL SOC MEDICINE PRESS
PI LONDON
PA CHANDOS HOUSE, 2 QUEEN ANNE ST, LONDON, ENGLAND W1M 0BR
BN 1-85315-240-4
PY 1994
BP 73
EP 76
PG 4
WC Veterinary Sciences; Zoology
SC Veterinary Sciences; Zoology
GA BC83A
UT WOS:A1994BC83A00017
ER
PT J
AU CASH, J
ESSIEN, EM
FURESZ, J
GUST, I
HARDEGREE, C
JEFFCOATE, S
LEMOINE, P
LYNG, J
MEDUNITSIN, NV
HAIJUN, Z
AF CASH, J
ESSIEN, EM
FURESZ, J
GUST, I
HARDEGREE, C
JEFFCOATE, S
LEMOINE, P
LYNG, J
MEDUNITSIN, NV
HAIJUN, Z
TI WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION, GENEVA, 13-20
OCTOBER 1992
SO WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION
SE WHO TECHNICAL REPORT SERIES
LA English
DT Article
ID TYPHOID-FEVER; VACCINE
AB This report presents the recommendations of a WHO Expert Committee commissioned to coordinate activities leading to the adoption of international requirements for the production and control of vaccines and other biologicals and the establishment of international biological reference materials. The report starts with a discussion of general issues brought to the Committee's attention and provides information on the status and development of reference materials for various antibiotics, antibodies, antigens, blood products, cytokines, growth factors and endocrinological substances. The second part of the report, of particular relevance to manufacturers and national control authorities, contains three specific sets of requirements: for the collection, processing and quality control of blood, blood components and plasma derivatives; for Vi polysaccharide typhoid vaccine; and for measles, mumps, rubella and combined vaccines. Also included are amendments to the three sets of requirements concerned with rabies vaccines for human and veterinary use.
C1 NATL INST MED RES,LAGOS,NIGERIA.
BUR BIOLOG,DRUGS DIRECTORATE,OTTAWA,ON,CANADA.
CSL LTD,RES & DEV,PARKVILLE,VIC,AUSTRALIA.
US FDA,CTR DRUGS & BIOL,OFF BIOL EVALUAT & RES,BETHESDA,MD.
NATL INST BIOL STAND & CONTROLS,DEPT ENDOCRINOL,POTTERS BAR,HERTS,ENGLAND.
INST HYG & EPIDEMIOL,B-1050 BRUSSELS,BELGIUM.
STATENS SERUM INST,BIOL STANDARDIZAT LAB,DK-2300 COPENHAGEN,DENMARK.
MINIST HLTH,TARASEVICH STATE INST STANDARDIZAT & CONTROL MED,MOSCOW,RUSSIA.
NATL INST CONTROL PHARMACEUT & BIOL PROD,BEIJING,PEOPLES R CHINA.
RP CASH, J (reprint author), SCOTTISH NATL BLOOD TRANSFUS SERV,HEADQUARTERS MED UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND.
NR 22
TC 2
Z9 3
U1 2
U2 2
PU WORLD HEALTH ORGANIZATION
PI GENEVA
PA 1211 27 GENEVA, SWITZERLAND
SN 0512-3054
J9 WHO TECH REP SER
PY 1994
VL 840
BP 1
EP 218
PG 218
WC Medicine, General & Internal
SC General & Internal Medicine
GA BC83M
UT WOS:A1994BC83M00001
ER
PT B
AU BARTON, AL
AF BARTON, AL
BE Kendall, RJ
Lacher, TE
TI ECOLOGICAL RISK ASSESSMENT IN THE OFFICE-OF-PESTICIDE-PROGRAMS
SO WILDLIFE TOXICOLOGY AND POPULATION MODELING: INTEGRATED STUDIES OF
AGROECOSYSTEMS
SE SETAC SPECIAL PUBLICATIONS SERIES
LA English
DT Proceedings Paper
CT 9th Pellston Workshop on The Population Ecology and Wildlife Toxicology
of Agricultural Pesticide Use: A Modeling Initiative for Avian Species
CY JUL 22-28, 1990
CL KIAWAH ISLAND, SC
SP SOC ENVIRONM TOXICOL & CHEM
DE FIFRA; TIER TESTING; RISK ASSESSMENT; QUOTIENT METHOD; WEIGHT OF
EVIDENCE
C1 US FDA,OFF PESTICIDE PROGRAMS,DIV ENVIRONM FATE & EFFECTS,WASHINGTON,DC 20204.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU LEWIS PUBLISHERS INC
PI BOCA RATON
PA 2000 CORPORATE BLVD NW, BOCA RATON, FL 33431
BN 0-87371-591-8
J9 SETAC SP P
PY 1994
BP 27
EP 31
PG 5
WC Ecology; Environmental Sciences; Toxicology; Zoology
SC Environmental Sciences & Ecology; Toxicology; Zoology
GA BZ61G
UT WOS:A1994BZ61G00003
ER
PT B
AU FITE, E
AF FITE, E
BE Kendall, RJ
Lacher, TE
TI THE ENVIRONMENTAL-PROTECTION-AGENCY AVIAN PESTICIDE ASSESSMENT MODEL
SO WILDLIFE TOXICOLOGY AND POPULATION MODELING: INTEGRATED STUDIES OF
AGROECOSYSTEMS
SE SETAC SPECIAL PUBLICATIONS SERIES
LA English
DT Proceedings Paper
CT 9th Pellston Workshop on The Population Ecology and Wildlife Toxicology
of Agricultural Pesticide Use: A Modeling Initiative for Avian Species
CY JUL 22-28, 1990
CL KIAWAH ISLAND, SC
SP SOC ENVIRONM TOXICOL & CHEM
DE WILDLIFE; AVIAN; PESTICIDE ASSESSMENT MODEL; PESTICIDE REGISTRATION;
FIELD TESTS; LABORATORY TOXICITY TESTS
C1 US FDA,OFF PESTICIDE PROGRAMS,WASHINGTON,DC 20204.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU LEWIS PUBLISHERS INC
PI BOCA RATON
PA 2000 CORPORATE BLVD NW, BOCA RATON, FL 33431
BN 0-87371-591-8
J9 SETAC SP P
PY 1994
BP 519
EP 530
PG 12
WC Ecology; Environmental Sciences; Toxicology; Zoology
SC Environmental Sciences & Ecology; Toxicology; Zoology
GA BZ61G
UT WOS:A1994BZ61G00048
ER
PT B
AU BROWN, DG
ANDERSON, MP
WAGNER, RF
SCHNEIDER, AC
AF BROWN, DG
ANDERSON, MP
WAGNER, RF
SCHNEIDER, AC
GP INT NEURAL NETWORK SOC
TI FINITE TRAINING SAMPLE-SIZE EFFECTS ON NEURAL-NETWORK
PATTERN-CLASSIFICATION IN LOW-DIMENSIONAL FEATURE SPACE
SO WORLD CONGRESS ON NEURAL NETWORKS-SAN DIEGO - 1994 INTERNATIONAL NEURAL
NETWORK SOCIETY ANNUAL MEETING, VOL 1
LA English
DT Proceedings Paper
CT 1994 International-Neural-Network-Society Annual Meeting - World
Congress on Neural Networks-San Diego
CY JUN 05-09, 1994
CL SAN DIEGO, CA
SP INT NEURAL NETWORK SOC
C1 US FDA,CTR DEVICES & RADIL HLTH,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LAWRENCE ERLBAUM ASSOC PUBL
PI MAHWAH
PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430
BN 0-8058-1745-X
PY 1994
BP A96
EP A101
PG 6
WC Computer Science, Artificial Intelligence; Engineering, Biomedical;
Engineering, Chemical
SC Computer Science; Engineering
GA BB69D
UT WOS:A1994BB69D00014
ER
PT J
AU PURI, RK
LELAND, P
AF PURI, RK
LELAND, P
TI TUMOR-NECROSIS-FACTOR UP-REGULATES INTERLEUKIN-4 RECEPTORS ON MURINE
SARCOMA-CELLS
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
ID IL-4 RECEPTORS; UP-REGULATION; FACTOR-I; GAMMA-INTERFERON; IFN-GAMMA;
T-CELLS; EXPRESSION; ALPHA; LYMPHOCYTES; LINES
RP PURI, RK (reprint author), US FDA,CTR BIOL EVALUAT & RES,DIV CELLULAR & GENE THERAPIES,MOLEC TUMOR BIOL LAB,HFM-530,BETHESDA,MD 20892, USA.
NR 25
TC 9
Z9 9
U1 0
U2 0
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD DEC 30
PY 1993
VL 197
IS 3
BP 1424
EP 1430
DI 10.1006/bbrc.1993.2636
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MP928
UT WOS:A1993MP92800056
PM 8280160
ER
PT J
AU RUSSELL, SM
KEEGAN, AD
HARADA, N
NAKAMURA, Y
NOGUCHI, M
LELAND, P
FRIEDMANN, MC
MIYAJIMA, A
PURI, RK
PAUL, WE
LEONARD, WJ
AF RUSSELL, SM
KEEGAN, AD
HARADA, N
NAKAMURA, Y
NOGUCHI, M
LELAND, P
FRIEDMANN, MC
MIYAJIMA, A
PURI, RK
PAUL, WE
LEONARD, WJ
TI INTERLEUKIN-2 RECEPTOR GAMMA-CHAIN - A FUNCTIONAL COMPONENT OF THE
INTERLEUKIN-4 RECEPTOR
SO SCIENCE
LA English
DT Article
ID GROWTH SIGNAL TRANSDUCTION; HUMAN IL-2 RECEPTOR; T-CELL LINE;
BETA-CHAIN; LIGAND-BINDING; GM-CSF; SUBUNIT; PROLIFERATION; EXPRESSION;
CLONING
AB The interleukin-2 (IL-2) receptor gamma chain (IL-2Rgamma) is an essential component of high- and intermediate-affinity IL-2 receptors. IL-2Rgamma was demonstrated to be a component of the IL-4 receptor on the basis of chemical cross-linking data, the ability of IL-2Rgamma to augment IL-4 binding affinity, and the requirement for IL-2Rgamma in IL-4-mediated phosphorylation of insulin receptor substrate-1. The observation that IL-2Rgamma is a functional component of the IL-4 receptor, together with the finding that IL-2Rgamma associates with the IL-7 receptor, begins to elucidate why deficiency of this common gamma chain (gamma(c)) has a profound effect on lymphoid function and development, as seen in X-linked severe combined immunodeficiency.
C1 NHLBI,PULM & MOLEC IMMUNOL SECT,BETHESDA,MD 20892.
NIAID,IMMUNOL LAB,BETHESDA,MD 20892.
DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304.
US FDA,CTR BIOL EVALUAT & RES,DIV CELLULAR & GENE THERAPIES,BETHESDA,MD 20892.
RI Russell, Sarah/B-9341-2009
OI Russell, Sarah/0000-0001-5826-9641
NR 51
TC 767
Z9 774
U1 3
U2 11
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005
SN 0036-8075
J9 SCIENCE
JI Science
PD DEC 17
PY 1993
VL 262
IS 5141
BP 1880
EP 1883
DI 10.1126/science.8266078
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MM511
UT WOS:A1993MM51100038
PM 8266078
ER
PT J
AU FRADKIN, JE
MILLS, JL
SCHONBERGER, LB
WYSOWSKI, DK
THOMSON, R
DURAKO, SJ
ROBISON, LL
AF FRADKIN, JE
MILLS, JL
SCHONBERGER, LB
WYSOWSKI, DK
THOMSON, R
DURAKO, SJ
ROBISON, LL
TI RISK OF LEUKEMIA AFTER TREATMENT WITH PITUITARY GROWTH-HORMONE
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID UNITED-STATES; MEDULLOBLASTOMA; EPIDEMIOLOGY; CHILDREN; HISTORY
AB Objective.-To determine whether pituitary-derived human growth hormone treatment increases the subsequent risk of developing leukemia and lymphoma.
Design.-Cohort study.
Setting.-United States.
Participants.-A total of 6284 recipients of pituitary-derived human growth hormone distributed by the National Hormone and Pituitary Program between 1963 and 1985.
Main Outcome Measures.-Leukemia and lymphoma.
Results.-Three cases of leukemia occurred in 59736 patient-years of follow-up from the start of growth hormone therapy to case ascertainment at interview; this number was not significantly higher (P=.23) than the 1.66 cases expected in the US age-, race-, and gender-matched general population. Three additional cases, found in an extended follow-up that provided 83 917 person-years of risk, yielded a minimum rate of leukemia that was significantly increased (six cases found, 2.26 expected; P=.028). The relative risk of leukemia in pituitary growth hormone recipients compared with the general population was 1.8 (90% confidence interval [CI], 0.82 to 7.5) for the defined follow-up and 2.6 (90% CI, 1.2 to 5.2) for the extended follow-up. Five of the six subjects who developed leukemia had antecedent cranial tumors (four craniopharyngioma, one astrocytoma) as the cause of growth hormone deficiency, and four had received radiotherapy. There was no increase in leukemia in patients with idiopathic growth hormone deficiency. The association of leukemia and craniopharyngioma was significant (P<.001). There was no excess of lymphoma in the cohort.
Conclusions.-This cohort of growth hormone recipients had a significantly increased rate of leukemia compared with the age-, race-, and gender-matched general population. However, the upper bound CI of the relative risk in our population (5.2) is well below the other estimates (7.6). Compared with the general population, our study population had more possible risk factors for leukemia (radiation, tumor) that may have contributed to the excess observed. The clustering of cases of leukemia in craniopharyngioma patients should be further evaluated.
C1 NICHHD,BETHESDA,MD 20892.
CTR DIS CONTROL & PREVENT,ATLANTA,GA.
US FDA,ROCKVILLE,MD 20857.
WESTAT CORP,ROCKVILLE,MD.
UNIV MINNESOTA,MINNEAPOLIS,MN 55455.
RP FRADKIN, JE (reprint author), NIDDKD,DIV DIABET ENDOCRINOL & METAB DIS,WESTWOOD BLDG,ROOM 621,BETHESDA,MD 20892, USA.
NR 28
TC 93
Z9 93
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD DEC 15
PY 1993
VL 270
IS 23
BP 2829
EP 2832
DI 10.1001/jama.270.23.2829
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA MK941
UT WOS:A1993MK94100032
PM 8133622
ER
PT J
AU GREENBERG, AS
EGAN, JJ
WEK, SA
MOOS, MC
LONDOS, C
KIMMEL, AR
AF GREENBERG, AS
EGAN, JJ
WEK, SA
MOOS, MC
LONDOS, C
KIMMEL, AR
TI ISOLATION OF CDNAS FOR PERILIPIN-A AND PERILIPIN-B - SEQUENCE AND
EXPRESSION OF LIPID DROPLET-ASSOCIATED PROTEINS OF ADIPOCYTES
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE CDNA CLONING; GENE EXPRESSION; ADIPOCYTE DIFFERENTIATION; LIPOLYSIS
ID GENE-EXPRESSION; APOLIPOPROTEINS; LIPOLYSIS; KINASE
AB The major cAMP-dependent protein kinase (A-kinase) substrate in adipocytes is perilipin, a protein found exclusively at the surface of the lipid storage droplets. Using anti-perilipin serum, we have isolated two related classes of full-length coding cDNAs, designated perilipin A and B, from a rat adipocyte cDNA expression library. The two cDNAs derive from two mRNA species that arise by differential splicing. The mRNAs are predicted to encode perilipins A and B, proteins of 517 aa (56,870 Da) and 422 aa (46,420 Da), respectively, which share a common 406-aa N-terminal sequence. The predicted perilipin A contains peptides present in proteolytic digests of the purified 62-kDa form of perilipin from rat adipocytes, as well as the requisite consensus A-kinase phosphorylation sites. Like perilipin A, the B form is expressed in adipocytes and is associated with lipid storage droplets. Modeling of predicted secondary structures fails to reveal an underlying basis for the tenacious association of perilipins with lipid droplets. These proteins exhibit a significant sequence relationship (almost-equal-to 65% similarity through 105 aa) with only one other known protein, the adipocyte differentiation-related protein (ADRP). Like the perilipins, ADRP appears to be adipocyte-specific, which suggests that they interact in a related intracellular pathway. The molecular probes for perilipins A and B described here will permit detailed analyses of their functional role(s) in lipid metabolism.
C1 CTR BIOL EVALUAT & RES,MOLEC PHARMACOL LAB,BETHESDA,MD 20892.
RP GREENBERG, AS (reprint author), NIDDKD,CELLULAR & DEV BIOL LAB,BETHESDA,MD 20892, USA.
NR 28
TC 189
Z9 195
U1 3
U2 11
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 15
PY 1993
VL 90
IS 24
BP 12035
EP 12039
DI 10.1073/pnas.90.24.12035
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MM515
UT WOS:A1993MM51500123
PM 7505452
ER
PT J
AU GOERING, PL
KISH, CL
FISHER, BR
AF GOERING, PL
KISH, CL
FISHER, BR
TI STRESS PROTEIN-SYNTHESIS INDUCED BY CADMIUM-CYSTEINE IN RAT-KIDNEY
SO TOXICOLOGY
LA English
DT Article
DE CADMIUM; CADMIUM-CYSTEINE; HEAT-SHOCK PROTEINS; KIDNEY; STRESS PROTEINS
ID HEAT-SHOCK PROTEINS; RENAL DYSFUNCTION; GENE-EXPRESSION; EXPOSURE;
CELLS; INJURY; NEPHROTOXICITY; INDUCTION; METALLOTHIONEIN; ARSENITE
AB Biomarkers are important tools which enable toxicologists to reliably predict and detect ex- posures to xenobiotics and resultant cell injury, ultimately improving risk assessments. Since the de novo synthesis of stress proteins can be detected early after exposure to some agents, analysis of toxicant-induced changes in gene expression, i.e. alterations in patterns of protein synthesis, may be useful to develop as biomarkers of exposure and toxicity. We are utilizing various xenobiotics as tools to study stress protein synthesis in target organs in order to evaluate the target tissue-specificity of this response. Previous data from this laboratory have demonstrated that induction of stress proteins in rat liver, but not kidney, after acute exposure to CdCl2 precedes hepatotoxicity. Since kidney is a target tissue after chronic Cd exposure, it was of interest to examine stress protein synthesis in this tissue. However, dose-limiting hepatotoxicity precluded this evaluation. Cd complexed with molecules such as cysteine (cys) or metallothionein has been used in acute dosing regimens as a tool in order to study the nephrotoxicity of Cd. Therefore, this study was undertaken in order to evaluate Cd-induced stress protein synthesis in an important tissue known to be injured after chronic exposure, i.e. kidney. Specific objectives included comparing stress protein synthesis in rat kidney and liver after acute exposure to Cd-cys and CdCl2, determining the Cd threshold concentration for renal stress protein synthesis and assessing the relationship between stress protein synthesis and nephropathy. Male rats were exposed to equivalent doses of Cd as CdCl2 or Cd-cysteine (molar ratio Cd:cys=1:15). Kidney Cd concentrations increased 5-fold after i.v. injection of Cd-cys compared to CdCl2, mimicking Cd distribution following chronic exposure. After exposure to Cd, tissue slices were incubated with S-35-methionine. Slices were subsequently homogenized and centrifuged, and the 16000 g supernatants were subjected to SDS-polyacrylamide gel electrophoresis. Proteins which had incorporated S-35-methionine were detected by autoradiography. De novo synthesis of 70, 90 and 110 kDa proteins was enhanced in liver, but not in kidney, 4 h after injection of 2 mg Cd/kg as CdCl2. In contrast, dose-related increases in synthesis of these proteins were observed in kidney 4 h after injection of 1 and 2 mg Cd/kg as Cd-cys, but not at lower dosages. In addition, synthesis of a 68 kDa kidney protein was inhibited at 2 mg Cd/kg as Cd-cys. The threshold for Cd-induced stress protein synthesis was shown to be between 4 and 8 mu g Cd/g tissue. These alterations in protein synthesis in kidney occurred at tissue Cd concentrations lower than those which resulted in renal injury, as assessed by histopathology and PAH uptake into renal slices. Thus, altered patterns of protein synthesis may serve as markers of cell injury or indicators of cellular stress in target organs.
RP GOERING, PL (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,OFF SCI & TECHNOL,DIV LIFE SCI,HLTH SCI BRANCH,ROCKVILLE,MD 20857, USA.
NR 40
TC 20
Z9 20
U1 1
U2 4
PU ELSEVIER SCI IRELAND LTD
PI CLARE
PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
IRELAND
SN 0300-483X
J9 TOXICOLOGY
JI Toxicology
PD DEC 15
PY 1993
VL 85
IS 1
BP 25
EP 39
DI 10.1016/0300-483X(93)90081-3
PG 15
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA MQ124
UT WOS:A1993MQ12400002
PM 8291068
ER
PT J
AU OSAWA, Y
DARBYSHIRE, JF
MEYER, CA
ALAYASH, AI
AF OSAWA, Y
DARBYSHIRE, JF
MEYER, CA
ALAYASH, AI
TI DIFFERENTIAL SUSCEPTIBILITIES OF THE PROSTHETIC HEME OF HEMOGLOBIN-BASED
RED-CELL SUBSTITUTES - IMPLICATIONS IN THE DESIGN OF SAFER AGENTS
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
ID BIS(3,5-DIBROMOSALICYL) FUMARATE; LIPID-PEROXIDATION; BLOOD SUBSTITUTE;
IRON RELEASE; CROSS-LINK; MYOGLOBIN; DEGRADATION; PROTEIN; AUTOXIDATION;
HEMOLYSIS
AB One approach to the development of an effective red cell substitute has been chemical modification of human hemoglobin to optimize oxygen transport and plasma half-life. Human hemoglobin A(0) and two of these modified hemoglobins, one prepared from the cross-linking of the alpha-chains at lysine residue 99 by bis(3,5-dibromosalicyl)fumarate (Hb-DBBF) and the other by acylation of lysine residue 82 of the beta-chain by mono-(3,5-dibromosalicyl)fumarate (Hb-FMDA), were tested by HPLC for their susceptibility to oxidative damage caused by H2O2. Such oxidative insult may occur during ischemia and reperfusion of tissues after transfusion of red cell substitutes to patients with hypovolemic shock and trauma. Hb-DBBF was extremely susceptible to damage of its heme and protein moieties with stoichiometric amounts of H2O2, whereas Hb-FMDA was highly resistant, even at 10-fold molar excess and at an acidic pH of 4.7. Hemoglobin A(0) was of intermediate susceptibility, exhibiting alteration of heme and protein moieties at acidic but not neutral pH. Since the degradation of heme can release the potentially toxic agent iron, Hb-FMDA may be a more promising candidate than Hb-DBBF for development as a red cell substitute. A similar approach may be used to assess the susceptibility of other hemoglobin-based red cell substitutes to oxidative damage in order to determine the molecular basis of heme and protein alteration.
C1 US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892.
RP OSAWA, Y (reprint author), NHLBI,CHEM PHARMACOL LAB,BLDG 10,RM 8N110,BETHESDA,MD 20892, USA.
NR 39
TC 38
Z9 38
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0006-2952
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD DEC 14
PY 1993
VL 46
IS 12
BP 2299
EP 2305
DI 10.1016/0006-2952(93)90621-3
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MN604
UT WOS:A1993MN60400023
PM 8274164
ER
PT J
AU KESSLER, DA
MERKATZ, RB
TEMPLE, R
AF KESSLER, DA
MERKATZ, RB
TEMPLE, R
TI FDA POLICY ON WOMEN IN DRUG TRIALS - REPLY
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
RP KESSLER, DA (reprint author), US FDA,ROCKVILLE,MD 20857, USA.
NR 1
TC 1
Z9 1
U1 0
U2 0
PU MASS MEDICAL SOC
PI BOSTON
PA 10 SHATTUCK, BOSTON, MA 02115
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 9
PY 1993
VL 329
IS 24
BP 1815
EP 1816
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA MK096
UT WOS:A1993MK09600015
ER
PT J
AU NIGHTINGALE, SL
AF NIGHTINGALE, SL
TI MEDWATCH CONFERENCE COSPONSORED BY THE FDA AND THE AMA
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
RP NIGHTINGALE, SL (reprint author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD DEC 8
PY 1993
VL 270
IS 22
BP 2669
EP 2669
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA MJ821
UT WOS:A1993MJ82100006
PM 8133573
ER
PT J
AU NIGHTINGALE, SL
AF NIGHTINGALE, SL
TI TREATMENT IND FOR NON-INSULIN-DEPENDENT DIABETES-MELLITUS
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
RP NIGHTINGALE, SL (reprint author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD DEC 8
PY 1993
VL 270
IS 22
BP 2669
EP 2669
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA MJ821
UT WOS:A1993MJ82100005
PM 8133573
ER
PT J
AU NIGHTINGALE, SL
AF NIGHTINGALE, SL
TI NEW LABEL WOULD ADVISE CONSUMERS TO CONSULT PHYSICIAN BEFORE TAKING
ASPIRIN FOR THE HEART
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
RP NIGHTINGALE, SL (reprint author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD DEC 8
PY 1993
VL 270
IS 22
BP 2669
EP 2669
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA MJ821
UT WOS:A1993MJ82100004
PM 8133573
ER
PT J
AU PAVLIAK, V
NASHED, EM
POZSGAY, V
KOVAC, P
KARPAS, A
CHU, CY
SCHNEERSON, R
ROBBINS, JB
GLAUDEMANS, CPJ
AF PAVLIAK, V
NASHED, EM
POZSGAY, V
KOVAC, P
KARPAS, A
CHU, CY
SCHNEERSON, R
ROBBINS, JB
GLAUDEMANS, CPJ
TI BINDING OF THE O-ANTIGEN OF SHIGELLA-DYSENTERIAE TYPE-1 AND TYPE-26
RELATED SYNTHETIC FRAGMENTS TO A MONOCLONAL IGM ANTIBODY
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID STREPTOCOCCUS-PNEUMONIAE; ENTERIC INFECTIONS; RURAL BANGLADESH;
POLYSACCHARIDE; LIGANDS; LIPOPOLYSACCHARIDE; SPECIFICITY; DEXTRAN;
SHIGELLA-DYSENTERIAE-1; VIRULENCE
AB Shigella dysenteriae type 1 possesses an O-antigen whose repeating unit is -->3-alpha-L-Rhap-(1-->3)-alpha-L-Rhap-(1-->2)-alpha-D-Galp-(1-->3)-alpha-D-GlcpNAc-(1-->, where Rhap is rhamnopyranosyl, Galp is galactopyranosyl, and Glcp is glucopyranosyl. Using ligand-induced protein fluorescence change, we have measured the affinities of a monoclonal murine IgM for 26 fragments of, or related to, the structure of the O-polysaccharide and of the IgM Fab for the intact O-specific bacterial polysaccharide. Synthetic saccharides used were methyl glycosides to ensure an anomerically defined pyranosyl ring conformation. The galactosyl residue is the only monosaccharide of the antigenic epitope that shows quantifiable binding: approximately 3.0 kcal/mol of binding free energy, depending on the structure and conformation of the fragment it is a part of. Addition of an alpha-(1-->2)-linked rhamnosyl residue increases the free energy of binding significantly. We propose this rhamnopyranosyl-alpha-(1-->2)-galactopyranosyl disaccharide to be the basic determinant of the Shigella O-polysaccharide. Further extension (by linkages as in the natural antigen) of this oligosaccharidic ligand toward the upstream end (in an oligo- (or poly-)saccharide, such as A-->B-->C-->D-->E-->m, where A, B, C, D, and E are sugars and m is any moiety, such as methyl, we define A as the glycosyl- or upstream terminus, and E as the glycoside- or downstream terminus) by rhamnosyl and N-acetylglucosaminyl moieties improves the binding only minimally. The antibody is quite specific for the rhamnosyl-alpha-(1-->2)-galactosyl sequence but less so for the nature of the attachment to the galactosyl residue on the downstream side. Measurements using IgM Fab and the intact O-specific polysaccharide show that the antibody can bind internal segments on the antigen chain. The free energy of binding of this antibody for the disaccharide determinant varies from -DELTAG of 4.7 to 5.1 kcal/mol, depending on its flanking residues.
C1 NIDDKD,BETHESDA,MD 20892.
US FDA,CTR BIOL RES & REVIEW,BETHESDA,MD 20892.
NICHHD,BETHESDA,MD 20892.
NR 60
TC 39
Z9 40
U1 0
U2 1
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 5
PY 1993
VL 268
IS 34
BP 25797
EP 25802
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA MK100
UT WOS:A1993MK10000076
PM 7503987
ER
PT J
AU WU, YS
LAI, JS
FU, PP
AF WU, YS
LAI, JS
FU, PP
TI SYNTHESIS OF THE BIOLOGICALLY REACTIVE BAY-REGION DIOL EPOXIDE OF THE
MUTAGENIC ENVIRONMENTAL CONTAMINANT 1-NITROBENZO[A]PYRENE
SO JOURNAL OF ORGANIC CHEMISTRY
LA English
DT Article
ID POLYCYCLIC AROMATIC-HYDROCARBONS; HAMSTER OVARY CELLS;
SALMONELLA-TYPHIMURIUM; NITRATION; 3-NITROBENZOPYRENE; FLUORANTHENE;
MONONITROBENZOPYRENES; 6-NITROBENZOPYRENE; IDENTIFICATION;
DERIVATIVES
C1 PROVIDENCE UNIV,INST APPL CHEM,TAICHUNG,TAIWAN.
NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
NR 30
TC 15
Z9 15
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0022-3263
J9 J ORG CHEM
JI J. Org. Chem.
PD DEC 3
PY 1993
VL 58
IS 25
BP 7283
EP 7285
DI 10.1021/jo00077a063
PG 3
WC Chemistry, Organic
SC Chemistry
GA ML307
UT WOS:A1993ML30700063
ER
PT J
AU MILLER, HI
GUNARY, D
AF MILLER, HI
GUNARY, D
TI SERIOUS FLAWS IN THE HORIZONTAL APPROACH TO BIOTECHNOLOGY RISK
SO SCIENCE
LA English
DT Editorial Material
RP MILLER, HI (reprint author), US FDA,OFF BIOTECHNOL,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.
NR 12
TC 13
Z9 13
U1 0
U2 1
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005
SN 0036-8075
J9 SCIENCE
JI Science
PD DEC 3
PY 1993
VL 262
IS 5139
BP 1500
EP 1501
DI 10.1126/science.8248795
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MK329
UT WOS:A1993MK32900012
PM 8248795
ER
PT J
AU MALOZOWSKI, S
MAMALAKI, E
PLETI, M
ARMANDO, I
GOLDSTEIN, D
MERRIAM, GR
AF MALOZOWSKI, S
MAMALAKI, E
PLETI, M
ARMANDO, I
GOLDSTEIN, D
MERRIAM, GR
TI INDUCTION OF REVERSIBLE GROWTH-RETARDATION AND GROWTH-HORMONE DEFICIENCY
BY BLOCKADE OF NOREPINEPHRINE SYNTHESIS IN THE RAT
SO ACTA ENDOCRINOLOGICA
LA English
DT Article
ID MESSENGER-RIBONUCLEIC-ACID; ADULT MALE-RAT; MONOSODIUM GLUTAMATE;
PLASMA-LEVELS; FEMALE RATS; SECRETION; MALNUTRITION; HYPOTHALAMUS;
INHIBITION; EXPRESSION
AB Norepinephrine is a major regulator of the release of growth hormone. Diethyldithiocarbamate, a dopamine-P-hydroxylase inhibitor, reduces norepinephrine synthesis and acutely inhibits growth hormone (GH) secretion. To investigate the long-term effects of dopamine-beta-hydroxylase blockade on growth, we administered diethyldithiocarbamate (0, 40, 100 or 400 mg/kg sc b.i.d.) to 21-day-old female rats for 10 days. Food intake, body weight, and tail length were measured twice a week. Plasma GH levels and hypothalamic dopamine and norepinephrine content were measured; messenger ribonucleic acids (mRNAs) for GH-releasing hormone and somatostatin were determined by quantitative in situ hybridization. Diethyldithiocarbamate administration decreased GH levels (p < 0.05) and retarded growth in a dose-dependent manner (p < 0.05), without altering food intake. Co-administration of GH partially reversed the growth retardation in diethyldithiocarbamate-treated animals (p < 0.05). Diethyldithiocarbamate treatment also increased the hypothalamic dopamine/norepinephrine ratio (1.13 vs 0.41 control, p < 0.05). Local levels of GH-releasing hormone and somatostatin mRNA were not altered by treatment. After discontinuation of diethyldithiocarbamate, growth rates returned to normal or transiently even to supranormal values. Norepinephrine synthesis blockade with diethyldithiocarbamate provides a model for reversible growth retardation, in which GH levels are decreased in the absence of decreased GH-releasing hormone mRNA. These results support a role for norepinephrine in the regulation of normal growth.
C1 NICHHD,DEV ENDOCRINOL BRANCH,BETHESDA,MD 20892.
NIMH,CLIN NEUROENDOCRINOL BRANCH,BETHESDA,MD 20892.
NINCDS,CLIN NEUROSCI BRANCH,BETHESDA,MD.
AMER LAKE VAMC,SEATTLE,WA.
UNIV WASHINGTON,DIV METAB ENDOCRINOL & NUTR,SEATTLE,WA.
RP MALOZOWSKI, S (reprint author), US FDA,DIV METAB & ENDOCRINE DRUG PROD,5600 FISHERS LANE,HFD 510,ROCKVILLE,MD 20857, USA.
NR 32
TC 1
Z9 1
U1 0
U2 0
PU SCANDINAVIAN UNIVERSITY PRESS
PI OSLO
PA PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO,
NORWAY
SN 0001-5598
J9 ACTA ENDOCRINOL-COP
JI Acta Endocrinol.
PD DEC
PY 1993
VL 129
IS 6
BP 554
EP 558
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA MV578
UT WOS:A1993MV57800014
PM 7906468
ER
PT J
AU NOUSO, K
BATTULA, N
THORGEIRSSON, SS
HIGASHI, T
TSUJI, T
AF NOUSO, K
BATTULA, N
THORGEIRSSON, SS
HIGASHI, T
TSUJI, T
TI RECOMBINANT MOUSE CYTOCHROMES P-1-450 AND P-3-450 - ENZYMATIC
CHARACTERIZATION OF THE HEMOPROTEIN EXPRESSED IN HUMAN-CELLS INFECTED
WITH RECOMBINANT VACCINIA VIRUS
SO ACTA MEDICA OKAYAMA
LA English
DT Article
DE CYTOCHROME P-450; VACCINIA VIRUS; KINETICS
ID METABOLIC-ACTIVATION; STABLE EXPRESSION; MAMMALIAN-CELLS; CDNA;
AFLATOXIN-B1; PURIFICATION; INDUCTION; SEQUENCES; SYSTEM; DNA
AB We expressed mouse cytochrome P-1-450 and P-3-450 using recombinant vaccinia virus gene expression system in HeLa cells that were devoid of significant basal levels of P-450. HeLa cells were infected with the recombinant vaccinia virus containing either mouse cytochrome P-1-450 or P-3-450 cDNA, and the cell lysates were analyzed for the kinetics of P-450 enzyme activity and protein expression at the same time. 7-Ethoxycoumarin O-deethylase and ethoxyresorufin O-deethylase activities were measured as an expression of the cytochrome P-450 enzyme activities. Both cell lines began to express these enzyme activities as early as 12h after infection. The activities increased linearly up to the 24h time point, and were kept for 36h. Western immunoblot analysis showed that these cytochrome P-450 protiens were detected at 16h and reached maximum quantity at 24h after infection. These data showed a good correlation between cytochrome P-450 enzyme activity and protein concentration throughout the process of P-450 gene expression by vaccinia virus vector, suggesting a complete formation of cytochrome P-450 holoenzyme from the early stage of the protein expression.
C1 US FDA, DIV ANTIVIRAL DRUG PROD, KENSINGTON, MD 20857 USA.
NCI, EXPTL CARCINOGENESIS LAB, BETHESDA, MD 20892 USA.
RP NOUSO, K (reprint author), OKAYAMA UNIV, SCH MED, DEPT INTERNAL MED 1, OKAYAMA 700, JAPAN.
NR 27
TC 1
Z9 1
U1 0
U2 0
PU OKAYAMA UNIV MED SCHOOL
PI OKAYAMA
PA EDITORIAL OFFICE, ACTA MEDICA OKAYAMA OKAYAMA UNIVERSITY MEDICAL SCHOOL
2-5-1 SHIKATA-CHO, KITA-KU, OKAYAMA, 700-8558, JAPAN
SN 0386-300X
J9 ACTA MED OKAYAMA
JI Acta Med. Okayama
PD DEC
PY 1993
VL 47
IS 6
BP 377
EP 382
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MP007
UT WOS:A1993MP00700004
PM 8128911
ER
PT J
AU RHEINSTEIN, PH
AF RHEINSTEIN, PH
TI THE GENERIC DRUG APPROVAL PROCESS
SO AMERICAN FAMILY PHYSICIAN
LA English
DT Article
RP RHEINSTEIN, PH (reprint author), US FDA,ROCKVILLE,MD 20857, USA.
NR 0
TC 7
Z9 7
U1 1
U2 1
PU AMER ACAD FAMILY PHYSICIANS
PI KANSAS CITY
PA 8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797
SN 0002-838X
J9 AM FAM PHYSICIAN
JI Am. Fam. Physician
PD DEC
PY 1993
VL 48
IS 8
BP 1357
EP 1360
PG 4
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA MK883
UT WOS:A1993MK88300001
PM 8249762
ER
PT J
AU WYSOWSKI, DK
FOURCROY, JL
AF WYSOWSKI, DK
FOURCROY, JL
TI HEPATOTOXICITY COMPLICATING FLUTAMIDE TREATMENT OF HIRSUTISM - REPLY
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Letter
RP WYSOWSKI, DK (reprint author), US FDA,ROCKVILLE,MD 20857, USA.
NR 3
TC 2
Z9 2
U1 0
U2 1
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572
SN 0003-4819
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD DEC 1
PY 1993
VL 119
IS 11
BP 1150
EP 1150
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA MJ335
UT WOS:A1993MJ33500021
ER
PT J
AU ETTE, EI
AF ETTE, EI
TI INTERPRETATION OF SIMULATION STUDIES FOR EFFICIENT ESTIMATION OF
POPULATION PHARMACOKINETIC PARAMETERS (VOL 27, PG 1034, 1993)
SO ANNALS OF PHARMACOTHERAPY
LA English
DT Correction, Addition
RP ETTE, EI (reprint author), US FDA,CTR DRUG EVALUAT & RES,DIV BIOPHARMACEUT,ROCKVILLE,MD 20857, USA.
NR 1
TC 4
Z9 4
U1 0
U2 0
PU HARVEY WHITNEY BOOKS CO
PI CINCINNATI
PA PO BOX 42696, CINCINNATI, OH 45242
SN 1060-0280
J9 ANN PHARMACOTHER
JI Ann. Pharmacother.
PD DEC
PY 1993
VL 27
IS 12
BP 1548
EP 1548
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA ML629
UT WOS:A1993ML62900038
ER
PT J
AU SAGRIPANTI, JL
ROUTSON, LB
LYTLE, CD
AF SAGRIPANTI, JL
ROUTSON, LB
LYTLE, CD
TI VIRUS INACTIVATION BY COPPER OR IRON IONS ALONE AND IN THE PRESENCE OF
PEROXIDE
SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY
LA English
DT Note
AB Cupric and ferric ions were able to inactivate five enveloped or nonenveloped, single- or double-stranded DNA or RNA viruses. The virucidal effect of these metals was enhanced by the addition of peroxide, particularly for copper(II). Under the conditions of our test, mixtures of copper(II) ions and peroxide were more efficient than glutaraldehyde in inactivating phiX174, T7, phi6, Junin, and herpes simplex viruses. The substances described here should be able to inactivate most, if not all, viruses that have been found contaminating medical devices.
RP SAGRIPANTI, JL (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,DIV LIFE SCI,12709 TWINBROOK PKWY,ROCKVILLE,MD 20852, USA.
NR 11
TC 48
Z9 49
U1 1
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0099-2240
J9 APPL ENVIRON MICROB
JI Appl. Environ. Microbiol.
PD DEC
PY 1993
VL 59
IS 12
BP 4374
EP 4376
PG 3
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA MK854
UT WOS:A1993MK85400061
PM 8285724
ER
PT J
AU FERGUSON, SA
RACEY, FD
PAULE, MG
HOLSON, RR
AF FERGUSON, SA
RACEY, FD
PAULE, MG
HOLSON, RR
TI BEHAVIORAL-EFFECTS OF METHYLAZOXYMETHANOL-INDUCED MICRENCEPHALY
SO BEHAVIORAL NEUROSCIENCE
LA English
DT Article
ID PREFRONTAL CORTICAL-LESIONS; MICROENCEPHALIC RATS; SELECTIVE ATTENTION;
MENTAL-RETARDATION; PRENATAL EXPOSURE; NEONATAL RAT; CORTEX; BRAIN;
AMPHETAMINE; HYPERACTIVITY
AB This study was prompted by reports of functionally normal humans with micrencephaly or cortical hypoplasia. Methylazoxymethanol acetate (MAM) treatment, which induces micrencephaly in rats, was administered by injection (20 mg/kg) on gestational day 14. Prior to weaning and into adulthood, offspring were assessed on many behavioral tests. There were 3 findings. First, MAM rats (forebrain weight less than 2/3 of controls) were not profoundly hyperactive. Increased activity was seen only on prolonged tests or after amphetamine administration. Second, MAM rats were hypoactive in some conditions. These rats were light shy and less likely to explore lighted areas. MAM rats appeared hyperreactive to environmental stimuli, but not hyperactive. Finally, no MAM effect on behavior was as large as that on brain weight. Thus, as with clinical findings, rat micrencephalics are more remarkable for functional sparing than for behavioral abnormalities.
C1 US FDA,NATL CTR TOXICOL RES,DIV REPROD & DEV TOXICOL,JEFFERSON,AR 72079.
RP FERGUSON, SA (reprint author), US FDA,NATL CTR TOXICOL RES,DIV NEUROTOXICOL,3900 NCTR DR,JEFFERSON,AR 72079, USA.
NR 57
TC 38
Z9 38
U1 0
U2 0
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242
SN 0735-7044
J9 BEHAV NEUROSCI
JI Behav. Neurosci.
PD DEC
PY 1993
VL 107
IS 6
BP 1067
EP 1076
PG 10
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA MP936
UT WOS:A1993MP93600017
PM 8136060
ER
PT J
AU HEYES, MP
SAITO, K
MAJOR, EO
MILSTIEN, S
MARKEY, SP
VICKERS, JH
AF HEYES, MP
SAITO, K
MAJOR, EO
MILSTIEN, S
MARKEY, SP
VICKERS, JH
TI A MECHANISM OF QUINOLINIC ACID FORMATION BY BRAIN IN INFLAMMATORY
NEUROLOGICAL DISEASE - ATTENUATION OF SYNTHESIS FROM L-TRYPTOPHAN BY
6-CHLOROTRYPTOPHAN AND 4-CHLORO-3-HYDROXYANTHRANILATE
SO BRAIN
LA English
DT Article
ID INFECTED RHESUS MACAQUES; CEREBROSPINAL-FLUID; KYNURENIC ACID;
RAT-BRAIN; INDOLEAMINE 2,3-DIOXYGENASE; HUNTINGTONS-DISEASE;
3-HYDROXYANTHRANILIC ACID; NEUROACTIVE KYNURENINES; INTERFERON-GAMMA;
NEURONAL DEGENERATION
AB Quinolinic acid (QUIN), kynurenic acid (KYNA) and L-kynurenine (L-KYN) are neuroactive kynurenine pathway metabolites that accumulate in inflammatory neurological diseases. These increases were attributed to the induction of indoleamine-2,3-dioxygenase (IDO), the enzyme that converts L-tryptophan into L-KYN. Direct conversion of L-tryptophan into QUIN by brain tissue occurs in conditions of CNS inflammation, but not by normal brain tissue. To investigate whether increased activity of enzymes distal to IDO may determine L-KYN conversion to QUIN, rhesus macaques were inoculated with poliovirus directly into the spinal cord, as a model of focal inflammatory neurological disease (FASEB J. 6, 2977-2989, 1992). Induction of spinal cord IDO (35.9-fold) accompanied smaller, but proportional increases in kynurenine-3-hydroxylase (2.4-fold) and kynureninase (2.3-fold) activities, which were correlated to CSF and tissue QUIN levels, as well as to measures of inflammatory lesions. 3-Hydroxyanthranilate-3,4-dioxygenase activity was unchanged. Cerebrospinal fluid KYNA levels increased in proportion to both IDO activity and L-KYN accumulation, though kynurenine aminotransferase activity was unaffected. Cerebrospinal fluid neopterin, a marker of macrophage and immune activation, accumulated in proportion to the responsive enzymes and metabolites. The cell types involved in producing QUIN were investigated in vitro. Human foetal brain cultures consisting of astrocytes and neurons converted large quantities of [C-13(6)]L-tryptophan into L-KYN when stimulated by gamma-interferon, but very little [C-13(6)]QUIN was formed unless macrophages (THP-1 cells) were first added to the cultures (to model a key component of brain inflammation). [C-13(6),]L-Tryptophan was converted into [C-13(6)]QUIN by either gamma-interferon stimulated macrophages, or following intracisternal administration into poliovirus-infected macaques. Inhibitors of the kynurenine pathway, 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilic acid, attenuated [C-13(6)],QUIN formation by macrophages, and when co-infused with [C-13(6)]L-tryptophan into poliovirus-infected macaques. These results suggest roles for increased activities of IDO, kynurenine-3-hydroxylase and kynureninase in accelerating the synthesis of QUIN, L-KYN and KYNA in conditions of brain inflammation. Macrophage infiltrates, and perhaps microglia, are important sources of QUIN, whereas constitutive brain cells and macrophages are sources of L-KYN. Drugs that inhibit kynurenine pathway enzymes attenuate QUIN formation in the CNS, and provide tools to examine the consequences of reduced QUIN accumulation.
C1 NIMH, NEUROCHEM LAB, BETHESDA, MD 20892 USA.
NINCDS, VIRAL & MOLEC PATHOGENESIS LAB, BETHESDA, MD 20892 USA.
US FDA, CTR BIOL EVALUAT & RES, PATHOBIOL & PRIMATOL LAB, BETHESDA, MD USA.
RP HEYES, MP (reprint author), NIMH, CLIN SCI LAB, ANALYT BIOCHEM SECT, BLDG 10, ROOM 3D40, BETHESDA, MD 20892 USA.
NR 90
TC 126
Z9 128
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
J9 BRAIN
JI Brain
PD DEC
PY 1993
VL 116
BP 1425
EP 1450
PN 6
PG 26
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA MW136
UT WOS:A1993MW13600008
PM 8293279
ER
PT J
AU SEIMIYA, H
TSURUO, T
AF SEIMIYA, H
TSURUO, T
TI DIFFERENTIAL EXPRESSION OF PROTEIN-TYROSINE-PHOSPHATASE GENES DURING
PHORBOL ESTER-INDUCED DIFFERENTIATION OF HUMAN LEUKEMIA U937 CELLS
SO CELL GROWTH & DIFFERENTIATION
LA English
DT Article
ID POLYMERASE CHAIN-REACTION; LEUKOCYTE-COMMON ANTIGEN; ROUS-SARCOMA VIRUS;
HEMATOPOIETIC-CELLS; SEQUENCE HOMOLOGY; SH2 DOMAIN; RECEPTOR; CLONING;
KINASE; CD45
AB Some human leukemia cell lines, such as HL-60 and U937, differentiate to monocyte/macrophage by treatment with chemicals such as phorbol ester or 1,25-dihydroxy vitamin D3. In this report, we demonstrate that cellular protein tyrosine phosphatase (PTPase) activity (especially in cytosol) in monoblastoid leukemia U937 cells increased up to 2-fold during the course of monocytic differentiation. We have cloned 13 PTPase-related gene fragments from the differentiated U937 cells using the reverse transcription-polymerase chain reaction method. Two of these were found to be genes of novel isozymes, PTP-U1 and PTP-U2. We investigated the changes in expression of each isozyme during the differentiation of the cells and found that nine isozymes (both cytosolic and transmembranous) were expressed more in the differentiated cells than in the undifferentiated cells. Among them, PTP-U1 and PTP-U2 were greatly induced by phorbol ester. Interestingly, there were two cytosolic isozymes that were down-regulated during the course of differentiation. Our present data suggest that the functions of the PTPase isozyme during monocytic maturation are not always equivalent to each other, and tyrosine dephosphorylation may participate in several different pathways of signal transduction during the differentiation of leukemia cells.
C1 US BUR RADIOL HLTH,INST MOLEC & CELLULAR BIOSCI,1-1-1 YAYOI,BUNKYO KU,ROCKVILLE,MD 20852.
NR 55
TC 33
Z9 33
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA PUBLIC LEDGER BLDG, SUITE 816, 150 S. INDEPENDENCE MALL W.,
PHILADELPHIA, PA 19106
SN 1044-9523
J9 CELL GROWTH DIFFER
JI Cell Growth Differ.
PD DEC
PY 1993
VL 4
IS 12
BP 1033
EP 1039
PG 7
WC Cell Biology
SC Cell Biology
GA ML312
UT WOS:A1993ML31200009
PM 8117617
ER
PT J
AU WEBSTER, PA
ROBERTS, DW
MOSS, MM
BENSON, RW
KEARNS, GL
AF WEBSTER, PA
ROBERTS, DW
MOSS, MM
BENSON, RW
KEARNS, GL
TI IMMUNOCHEMICAL CONFIRMATION OF CHRONIC ACETAMINOPHEN (APAP) TOXICITY IN
CHILDREN
SO CLINICAL RESEARCH
LA English
DT Meeting Abstract
C1 UNIV ARKANSAS MED SCI HOSP,DEPT PEDIAT,LITTLE ROCK,AR 72205.
NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086
SN 0009-9279
J9 CLIN RES
JI Clin. Res.
PD DEC
PY 1993
VL 41
IS 4
BP A758
EP A758
PG 1
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MN948
UT WOS:A1993MN94800231
ER
PT J
AU SCHEUPLEIN, RJ
AF SCHEUPLEIN, RJ
TI USE OF CELL-PROLIFERATION DATA IN CANCER RISK ASSESSMENT - FDA VIEW
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article; Proceedings Paper
CT Symposium on Cell Proliferation and Chemical Carcinogenesis
CY JAN 14-16, 1992
CL RESEARCH TRIANGLE PARK, NC
ID CARCINOGENESIS
AB The possible uses of cell proliferation data in cancer risk assessment can be divided into three categories: direct use of mathematical models that incorporate rates of cell proliferation, use of experimental data on secondary mechanisms produced by cell proliferation, and using studies of cellular growth rates to extend the dose range of bioassay data. These three approaches are briefly discussed and some indication of their potential application to cancer risk assessment is outlined.
RP SCHEUPLEIN, RJ (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,OFF TOXICOL SCI,WASHINGTON,DC 20204, USA.
NR 5
TC 3
Z9 3
U1 0
U2 0
PU NATL INST ENVIRON HEALTH SCI
PI RES TRIANGLE PK
PA PO BOX 12233, RES TRIANGLE PK, NC 27709
SN 0091-6765
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD DEC
PY 1993
VL 101
SU 5
BP 139
EP 141
DI 10.2307/3431857
PG 3
WC Environmental Sciences; Public, Environmental & Occupational Health;
Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Toxicology
GA NB891
UT WOS:A1993NB89100022
PM 8013401
ER
PT J
AU JAMES, SJ
MILLER, BJ
CROSS, DR
MCGARRITY, LJ
MORRIS, SM
AF JAMES, SJ
MILLER, BJ
CROSS, DR
MCGARRITY, LJ
MORRIS, SM
TI THE ESSENTIALITY OF FOLATE FOR THE MAINTENANCE OF DEOXYNUCLEOTIDE
PRECURSOR POOLS, DNA-SYNTHESIS, AND CELL-CYCLE PROGRESSION IN
PHA-STIMULATED LYMPHOCYTES
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article; Proceedings Paper
CT Symposium on Cell Proliferation and Chemical Carcinogenesis
CY JAN 14-16, 1992
CL RESEARCH TRIANGLE PARK, NC
ID FRAGILE SITE EXPRESSION; TRIPHOSPHATE POOL; MAMMALIAN-CELLS;
MUTAGENESIS; NUCLEOTIDES; HYDROXYUREA; METABOLISM; IMBALANCE; REPAIR
AB The fidelity and progression of DNA synthesis is critically dependent on the correct balance and availability of the deoxynucleoside triphosphate (dNTP) precursors for the polymerases involved in DNA replication and repair. Because folate-derived one-carbon groups are essential for the de novo synthesis of both purines and pyrimidines, the purpose of this study was to determine the effect of folate deprivation on deoxynucleotide pool levels and cell cycle progression. Primary cultures of phytohemagglutin (PHA)-stimulated splenocytes were used as the cellular model. T-cells and macrophages were purified from spleen cell suspensions obtained from F344 rats and recombined in culture. The cells were harvested after a 66-hr incubation with PHA and analyzed for nucleotide levels by reverse-phase HPLC with diode array detection. The proportion of cells in the different phases of the cell cycle was determined by bivariate flow cytometric measurement of bromodeoxyuridine (BrdU) incorporation and DNA content (propidium iodide staining). PHA-stimulated T-cells cultured in medium lacking folate and methionine manifested significant decreases in the deoxynucleotides dCTP, dTMP, dGTP, and dATP relative to cells cultured in complete medium. The reduction in dNTP pools was associated with a decrease in the corresponding ribonucleotide pools. Flow cytometric analysis revealed a 2-fold increase in S and G(2)/mitosis (G(2)/M) DNA content in PHA-stimulated cells cultured in the medium lacking folate and methionine, which suggests a delay in cell cycle progression. These alterations in DNA content were accompanied by a 5-fold decrease in BrdU incorporation relative to PHA-stimulated cells cultured in complete medium. Supplementation of the deficient medium with folate resulted in normalization of dNTP content and BrdU incorporation. The data are consistent with the interpretation that folate deprivation results in reduced dNTP levels that may retard DNA synthesis and cell cycle progression.
RP JAMES, SJ (reprint author), NATL CTR TOXICOL RES,JEFFERSON,AR 72079, USA.
NR 19
TC 19
Z9 19
U1 0
U2 1
PU NATL INST ENVIRON HEALTH SCI
PI RES TRIANGLE PK
PA PO BOX 12233, RES TRIANGLE PK, NC 27709
SN 0091-6765
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD DEC
PY 1993
VL 101
SU 5
BP 173
EP 178
DI 10.2307/3431864
PG 6
WC Environmental Sciences; Public, Environmental & Occupational Health;
Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Toxicology
GA NB891
UT WOS:A1993NB89100029
PM 8013406
ER
PT J
AU LU, MH
HINSON, WG
HE, DS
TURTURRO, A
HART, RW
AF LU, MH
HINSON, WG
HE, DS
TURTURRO, A
HART, RW
TI HEPATIC NUCLEAR PLOIDY DISTRIBUTION OF DIETARY-RESTRICTED MICE
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article; Proceedings Paper
CT Symposium on Cell Proliferation and Chemical Carcinogenesis
CY JAN 14-16, 1992
CL RESEARCH TRIANGLE PARK, NC
ID FLOW CYTOMETRIC ANALYSIS; MOUSE HEPATOCYTE PLOIDY; CELL-CYCLE ANALYSIS;
FOOD RESTRICTION; POLYPLOIDY; AGE; LIVER; HYPOTHESIS; KINETICS
AB Hepatic parenchymal cells in most adult mammals are polyploid, with most of the cells in the quiescent or low-proliferation state. Polyploidization has been related to carcinogenesis and aging, and both end points are significantly affected by dietary restriction (DR). Direct measures of hepatic nuclear polyploidization in DR B6C3F(1) mice have not been examined. We examined the effect of DR on distributions of nuclear ploidy in both sexes and on different age groups of B6C3F(1) mice. Differences between young and old male mice and between old male and female mice were also compared. Hepatic nuclear ploidy values were measured by flow cytometry. The DNA histograms were analyzed for the percentage of nuclei having different classes of DNA content by gating channels between the areas under the peaks of diploid, tetraploid, and octaploid. The results indicate that 1 or 26 months of DR started at 4 months of age did not alter hepatic nuclear ploidy distributions in young and old mice. Our data suggest that in the male mouse, polyploidization is established by 5 months of age for hepatic nuclei and that ploidy classes are affected by sex at 30 months of age. For females, effects in the octaploid nuclei are seen as a result of DR.
RP LU, MH (reprint author), NATL CTR TOXICOL RES,NCTR DR,JEFFERSON,AR 72079, USA.
NR 40
TC 5
Z9 5
U1 0
U2 0
PU NATL INST ENVIRON HEALTH SCI
PI RES TRIANGLE PK
PA PO BOX 12233, RES TRIANGLE PK, NC 27709
SN 0091-6765
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD DEC
PY 1993
VL 101
SU 5
BP 229
EP 233
PG 5
WC Environmental Sciences; Public, Environmental & Occupational Health;
Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Toxicology
GA NB891
UT WOS:A1993NB89100038
PM 8013412
ER
PT J
AU WYSOWSKI, DK
AF WYSOWSKI, DK
TI USE OF FERTILITY DRUGS IN THE UNITED-STATES, 1973 THROUGH 1991
SO FERTILITY AND STERILITY
LA English
DT Note
RP WYSOWSKI, DK (reprint author), US FDA,OFF EPIDEMIOL & BIOSTAT,DIV EPIDEMIOL & SURVEILLANCE,ROCKVILLE,MD 20857, USA.
NR 4
TC 44
Z9 44
U1 0
U2 1
PU AMER SOC REPRODUCTIVE MEDICINE
PI BIRMINGHAM
PA 1209 MONTGOMERY HIGHWAY, BIRMINGHAM, AL 35216-2809
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD DEC
PY 1993
VL 60
IS 6
BP 1096
EP 1098
PG 3
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA MK846
UT WOS:A1993MK84600030
PM 7902301
ER
PT J
AU SHACKELFORD, ME
COLLINS, TFX
WELSH, JJ
BLACK, TN
AMES, MJ
CHI, RK
ODONNELL, MW
AF SHACKELFORD, ME
COLLINS, TFX
WELSH, JJ
BLACK, TN
AMES, MJ
CHI, RK
ODONNELL, MW
TI FETAL DEVELOPMENT IN RATS FED AIN-76A DIETS SUPPLEMENTED WITH EXCESS
CALCIUM
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
ID ZN AVAILABILITY; ZINC; PHYTATE
AB This study was designed to evaluate the developmental effects of moderate dietary calcium increases in rats fed nutritionally adequate diets. Female Charles River CD/VAF Plus rats were given 0.50 (control), 0.75, 1.00 or 1.25% dietary calcium as calcium carbonate in AIN-76A diets for 6 wk before mating, during mating and for 20 days of gestation. On gestation day 20, the animals were killed and caesarean sections were performed. Both the non-pregnant and pregnant rats in the 0.75, 1.00 and 1.25% groups ate slightly more than did the control group during most of the intervals measured, but not all the increases were statistically significant. There was no consistent pattern of increase or decrease in weight gain. No dose-related changes were found in maternal clinical findings, the average number of implantations, resorptions and viable foetuses, or foetal length or weight. Under the conditions of the study, there were no statistically significant increases as compared with the control group in the litter incidence regarding specific external, visceral or skeletal variations of the foetuses. Dietary calcium was neither foetotoxic nor teratogenic at the concentrations used.
RP SHACKELFORD, ME (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,WASHINGTON,DC 20204, USA.
NR 29
TC 3
Z9 3
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0278-6915
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD DEC
PY 1993
VL 31
IS 12
BP 953
EP 961
DI 10.1016/0278-6915(93)90004-I
PG 9
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA MU071
UT WOS:A1993MU07100004
PM 8282279
ER
PT J
AU OLEMPSKABEER, ZS
KUZNESOF, PM
DINOVI, M
SMITH, MJ
AF OLEMPSKABEER, ZS
KUZNESOF, PM
DINOVI, M
SMITH, MJ
TI PLANT BIOTECHNOLOGY AND FOOD SAFETY
SO FOOD TECHNOLOGY
LA English
DT Article
ID ENGINEERING HERBICIDE RESISTANCE; TRANSGENIC PLANTS; GENE-TRANSFER;
DETOXIFYING ENZYME; ETHYLENE SYNTHESIS; TOBACCO RESISTANT;
SOLANUM-TUBEROSUM; CROP IMPROVEMENT; VIRUS-INFECTION; ALPHA-AMYLASE
RP OLEMPSKABEER, ZS (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,200 C ST,WASHINGTON,DC 20204, USA.
NR 99
TC 7
Z9 7
U1 1
U2 1
PU INST FOOD TECHNOLOGISTS
PI CHICAGO
PA SUITE 300 221 N LASALLE ST, CHICAGO, IL 60601-1291
SN 0015-6639
J9 FOOD TECHNOL-CHICAGO
JI Food Technol.
PD DEC
PY 1993
VL 47
IS 12
BP 64
EP &
PG 0
WC Food Science & Technology
SC Food Science & Technology
GA MN146
UT WOS:A1993MN14600012
ER
PT J
AU GILMAN, SC
BONNER, MJ
PELLMAR, TC
AF GILMAN, SC
BONNER, MJ
PELLMAR, TC
TI EFFECT OF OXIDATIVE STRESS ON EXCITATORY AMINO-ACID RELEASE BY CEREBRAL
CORTICAL SYNAPTOSOMES
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Note
DE CHLORAMINE-T; OXIDATION; FREE RADICAL; EXCITATORY; SYNAPTOSOME;
ASPARTATE
ID ALTERS NEURONAL EXCITABILITY; GUINEA-PIG; CHLORAMINE-T; D-ASPARTATE;
BRAIN SYNAPTOSOMES; GLUTAMATE RELEASE; OXYGEN RADICALS; HUMAN-DISEASE;
PRESSURE; ISCHEMIA
AB Previous studies in our laboratory have suggested that an oxidation reaction is responsible for the actions of free radicals to decrease synaptic Potentials. Recently we observed that free radicals both decreased depolarization-induced vesicular release and enhanced basal, nonvesicular release of the excitatory amino acid, [H-3]L-glutamate. In order to evaluate the contribution of oxidative reactions to this latter effect, we evaluated the actions of the oxidizing agent chloramine-T on synaptosomal release of excitatory amino acids, using [H-3]D-aspartate as the exogenous label. Basal and depolarization evoked [H-3]D-aspartate release were calcium-independent and nonvesicular. Chloramine-T pretreatment significantly increased basal release, while having no effect on high K+-evoked release. These data suggest that an oxidative process can mimic the free radical increase of basal release, as well as the decrease in synaptic potentials. On the other hand, the calcium-independent-evoked release may involve a different mechanism. Our results demonstrate that under basal, nondepolarizing conditions, oxidative stress exerts an adverse effect on the presynaptic nerve terminal, resulting in an increased release of potentially damaging excitatory amino acid neurotransmitters.
C1 US FDA,DIV TOXICOL REVIEW,WASHINGTON,DC 20204.
RP GILMAN, SC (reprint author), ARMED FORCES RADIOBIOL RES INST,DEPT PHYSIOL,8901 WISCONSIN AVE,BETHESDA,MD 20814, USA.
NR 36
TC 22
Z9 22
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0891-5849
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD DEC
PY 1993
VL 15
IS 6
BP 671
EP 675
DI 10.1016/0891-5849(93)90172-Q
PG 5
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA MJ387
UT WOS:A1993MJ38700015
PM 7908006
ER
PT J
AU TAI, SS
LEE, CJ
WINTER, RE
AF TAI, SS
LEE, CJ
WINTER, RE
TI HEMIN UTILIZATION IS RELATED TO VIRULENCE OF STREPTOCOCCUS-PNEUMONIAE
SO INFECTION AND IMMUNITY
LA English
DT Note
ID PNEUMOCOCCAL TOXIN PNEUMOLYSIN; FERRIC IRON TRANSPORT; INFLUENZAE
TYPE-B; ESCHERICHIA-COLI; CORYNEBACTERIUM-DIPHTHERIAE;
NEISSERIA-MENINGITIDIS; HEMOPHILUS-INFLUENZAE; SYSTEM; TRANSFERRIN;
MUTANT
AB Streptococcus pneumoniae is a causative agent for bacterial pneumonia, otitis media, meningitis, and bacteremia. Mechanisms for acquisition of iron by this organism under low-iron conditions were investigated. Siderophore production was not detected by either chemical or biological methods. Its utilization of iron-containing compounds found in human hosts was tested. Both hemin and hemoglobin supported the full growth of S. pneumoniae in a culture lacking other iron sources, while lactoferrin and transferrin failed to do so. A mutant defective in hemin utilization was isolated and was less virulent than wild-type S. pneumoniae in experimental animals.
C1 ARIZONA STATE UNIV,DEPT MICROBIOL,TEMPE,AZ 85287.
US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892.
RP TAI, SS (reprint author), HOWARD UNIV,DEPT MICROBIOL,WASHINGTON,DC 20059, USA.
NR 43
TC 68
Z9 69
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD DEC
PY 1993
VL 61
IS 12
BP 5401
EP 5405
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA MH823
UT WOS:A1993MH82300065
PM 8225615
ER
PT J
AU TAGA, K
CHERNEY, B
TOSATO, G
AF TAGA, K
CHERNEY, B
TOSATO, G
TI IL-10 INHIBITS APOPTOTIC CELL-DEATH IN HUMAN T-CELLS STARVED OF IL-2
SO INTERNATIONAL IMMUNOLOGY
LA English
DT Article
DE CELL SURVIVAL; DNA FRAGMENTATION; PROGRAMMED CELL DEATH
ID CYTOKINE PRODUCTION; B-CELLS; DIFFERENTIATION FACTOR; STIMULATORY
FACTOR; IMMUNE-SYSTEM; TH2 CLONES; GROWTH; INTERLEUKIN-10; EXPRESSION;
SURVIVAL
AB IL-10 was originally described as an inhibitory factor produced by murine T(h)2 lymphocytes that suppresses IFN-gamma production by activated murine T(h)1 lymphocytes. In this study, we have analyzed the effect of human IL-10 on human T cell death induced by IL-2 deprivation. IL-2-dependent T lymphocytes rapidly die when deprived of IL-2. This cell death was found to involve loss of cell volume, chromatin condensation, and DNA fragmentation, all characteristic of apoptosis. After 2 days incubation in culture medium without IL-2, the viability of TM11 cells (a tetanus toxoid-specific T cell line) and of activated peripheral blood T cells decreased from >98% to 34.3 (+/- 2.9) and 39.7 (+/- 5.5)% respectively. Addition of purified human IL-10 (100 U/ml) to these IL-2-starved cells significantly improved cell viability (66.0 +/- 6.0 and 73.1 +/- 12.3% respectively, P = 0.0051). This protective effect of IL-10 was dose-dependent and was neutralized by the anti-human IL-10 mAb 19F1. It was neither accompanied by T cell growth stimulation as judged by [H-3]thymidine incorporation nor neutralized by anti-IL-2 or anti-IL-2 receptor (CD25) antibodies. Analysis of DNA after separation on agarose gels revealed that IL-10 inhibits DNA fragmentation in IL-2-starved T cells. T cells protected from death by IL-10 were indistinguishable from IL-10-untreated viable T cells in the ability to proliferate in response to IL-2. Thus, another property of IL-10 is to promote the survival of IL-2-dependent T cells otherwise destined to die by apoptosis.
RP TAGA, K (reprint author), CTR BIOL EVALUAT & RES,IMMUNOL LAB,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.
NR 52
TC 111
Z9 111
U1 1
U2 2
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0953-8178
J9 INT IMMUNOL
JI Int. Immunol.
PD DEC
PY 1993
VL 5
IS 12
BP 1599
EP 1608
DI 10.1093/intimm/5.12.1599
PG 10
WC Immunology
SC Immunology
GA MP959
UT WOS:A1993MP95900012
PM 8312229
ER
PT J
AU KESSLER, DA
MERKATZ, RB
SCHAPIRO, R
AF KESSLER, DA
MERKATZ, RB
SCHAPIRO, R
TI A CALL FOR HIGHER STANDARDS FOR BREAST IMPLANTS
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
RP KESSLER, DA (reprint author), US FDA,OFF COMMISS,HF-1,ROCKVILLE,MD 20857, USA.
NR 6
TC 32
Z9 32
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD DEC 1
PY 1993
VL 270
IS 21
BP 2607
EP 2608
DI 10.1001/jama.270.21.2607
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA MJ266
UT WOS:A1993MJ26600030
PM 8230647
ER
PT J
AU GOULD, JA
LIEBLER, B
BAIER, R
BENSON, J
BORETOS, J
CALLAHAN, T
CANTY, E
COMPTON, R
MARLOWE, D
OHOLLA, R
PAGE, B
PAULSON, J
SWANSON, C
AF GOULD, JA
LIEBLER, B
BAIER, R
BENSON, J
BORETOS, J
CALLAHAN, T
CANTY, E
COMPTON, R
MARLOWE, D
OHOLLA, R
PAGE, B
PAULSON, J
SWANSON, C
TI BIOMATERIALS AVAILABILITY - DEVELOPMENT OF A CHARACTERIZATION STRATEGY
FOR INTERCHANGING SILICONE POLYMERS IN IMPLANTABLE MEDICAL DEVICES
SO JOURNAL OF APPLIED BIOMATERIALS
LA English
DT Article
C1 HLTH IND MANUFACTURES ASSOC,1200 G ST NW,SUITE 400,WASHINGTON,DC 20005.
BAXTER HEALTHCARE CORP,ROUND LAKE,IL.
SUNY BUFFALO,BUFFALO,NY 14260.
US FDA,ROCKVILLE,MD 20857.
VENTRITEX INC,SUNNYVALE,CA.
NUSIL SILICONE TECHNOL,CARPINTERIA,CA.
JOHNSON & JOHNSON,NEW BRUNSWICK,NJ.
ETHICON INC,SOMERVILLE,NJ 08876.
MEDTRONIC INC,MINNEAPOLIS,MN 55418.
NR 5
TC 4
Z9 4
U1 0
U2 1
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 1045-4861
J9 J APPL BIOMATER
JI J. Appl. Biomater.
PD WIN
PY 1993
VL 4
IS 4
BP 355
EP 358
DI 10.1002/jab.770040410
PG 4
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA MH534
UT WOS:A1993MH53400009
PM 10172007
ER
PT J
AU EDIGER, MN
PETTIT, GH
SAUERBREY, R
AF EDIGER, MN
PETTIT, GH
SAUERBREY, R
TI DIFFUSE REFLECTIVITY MEASUREMENTS OF POLYIMIDE DURING ARGON FLUORIDE
EXCIMER-LASER ABLATION
SO JOURNAL OF APPLIED PHYSICS
LA English
DT Note
ID TIME-RESOLVED REFLECTIVITY; DYNAMICS; POLYMERS
AB The diffuse reflectivity of polyimide during Pulsed 193-nm excimer laser irradiation has been compared to the specular reflectivity of the material over the fluence range 0.6-190 mJ/cm2. Diffuse reflectivity is observed to decrease with increasing fluence by a factor of approximately 3 over the intensity range, and remains a roughly constant fraction (0.3-0.4) of total target reflectivity. These results indicate that appreciable scattering of reflected laser radiation out of the specular direction does not occur under ablation conditions, and therefore cannot account for the specularly reflected pulse truncation observed previously.
C1 RICE UNIV,DEPT ELECT & COMP ENGN,HOUSTON,TX 77251.
RP EDIGER, MN (reprint author), FDA CTR DEVICES & RADIOL HLTH,MAIL STOP HFZ-134,ROCKVILLE,MD 20857, USA.
NR 8
TC 2
Z9 2
U1 0
U2 0
PU AMER INST PHYSICS
PI WOODBURY
PA CIRCULATION FULFILLMENT DIV, 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2999
SN 0021-8979
J9 J APPL PHYS
JI J. Appl. Phys.
PD DEC 1
PY 1993
VL 74
IS 11
BP 6982
EP 6984
DI 10.1063/1.355049
PG 3
WC Physics, Applied
SC Physics
GA MJ712
UT WOS:A1993MJ71200075
ER
PT J
AU KORFMACHER, WA
BLOOM, J
CHURCHWELL, MI
GETEK, TA
HANSEN, EB
HOLDER, CL
MCMANUS, KT
AF KORFMACHER, WA
BLOOM, J
CHURCHWELL, MI
GETEK, TA
HANSEN, EB
HOLDER, CL
MCMANUS, KT
TI CHARACTERIZATION OF 3 RIFAMYCINS VIA ELECTROSPRAY MASS-SPECTROMETRY AND
HPLC THERMOSPRAY MASS-SPECTROMETRY
SO JOURNAL OF CHROMATOGRAPHIC SCIENCE
LA English
DT Article
ID LIQUID-CHROMATOGRAPHIC ASSAY; RIFAMPICIN; IONIZATION; ANTIBIOTICS;
METABOLITES; DOXYLAMINE; SAMPLES; SERUM
C1 US FDA,NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
TEXMS,HOUSTON,TX 77060.
NR 20
TC 16
Z9 17
U1 0
U2 0
PU PRESTON PUBLICATIONS INC
PI NILES
PA 7800 MERRIMAC AVE PO BOX 48312, NILES, IL 60648
SN 0021-9665
J9 J CHROMATOGR SCI
JI J. Chromatogr. Sci.
PD DEC
PY 1993
VL 31
IS 12
BP 498
EP 501
PG 4
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA MK571
UT WOS:A1993MK57100002
PM 8120121
ER
PT J
AU BURBA, DJ
COLLIER, MA
DEFAULT, LE
HANSONPAINTON, O
THOMPSON, HC
HOLDER, CL
AF BURBA, DJ
COLLIER, MA
DEFAULT, LE
HANSONPAINTON, O
THOMPSON, HC
HOLDER, CL
TI IN-VIVO KINETIC-STUDY ON UPTAKE AND DISTRIBUTION OF INTRAMUSCULAR
TRITIUM-LABELED POLYSULFATED GLYCOSAMINOGLYCAN IN EQUINE BODY-FLUID
COMPARTMENTS AND ARTICULAR-CARTILAGE IN AN OSTEOCHONDRAL DEFECT MODEL
SO JOURNAL OF EQUINE VETERINARY SCIENCE
LA English
DT Article
AB The uptake and distribution of intramuscularly (IM) administered tritium-labeled polysulfated glycosaminoglycan (H-3-PSGAG) in serum, synovial fluid, and articular cartilage of eight horses was quantitated, and hyaluronic acid (HA) concentration of the middle carpal joint was evaluated in a pharmacokinetic study. A full-thickness articular cartilage defect, created on the distal articular surface of the left radial carpal bone of each horse served as an osteochondral defect model. H-3-PSGAG (500 mg) was injected IM, between 14 and 35 days after creation of the defects. Scintillation analysis of serum and synovial fluid, collected from both middle carpal joints at specific predetermined times up to 96 hours post-injection, revealed mean H-3-PSGAG concentrations peaked at 2 hours post-injection. H-3-PSGAG was detected in cartilage and subchondral bone 96 hours post-injection in samples from all eight horses. There were no statistically significant differences in H-3-PSGAG concentration of synovial fluid or cartilage between cartilage defect and control (right middle carpal) joints.
HA assay of synovial fluid revealed concentrations significantly increased at 24, 48, and 96 hours post-injection in both joints. The concentration nearly doubled 48 hours post-injection. However, no statistically significant differences were found between synovial concentrations of HA in cartilage defect and control joints.
H-3-PSGAG administered IM to horses, was distributed in the blood, synovial fluid, and articular cartilage. HA concentrations in synovial fluid increased after IM administration of polysulfated glycosaminoglycan.
C1 OKLAHOMA STATE UNIV,BOREN VET MED TEACHING HOSP,COLL VET MED,DEPT EQUINE SURG & MED,STILLWATER,OK 74078.
UNIV OKLAHOMA,HLTH SCI CTR,COLL MED,DEPT PATHOL,OKLAHOMA CITY,OK 73190.
US FDA,NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
NR 0
TC 6
Z9 6
U1 0
U2 1
PU WILLIAM E JONES DVM
PI LAKE ELSINORE
PA 20225 GRAND AVE, LAKE ELSINORE, CA 92330
SN 0737-0806
J9 J EQUINE VET SCI
JI J. Equine Vet. Sci.
PD DEC
PY 1993
VL 13
IS 12
BP 696
EP 703
DI 10.1016/S0737-0806(06)81570-4
PG 8
WC Veterinary Sciences
SC Veterinary Sciences
GA MK833
UT WOS:A1993MK83300011
ER
PT J
AU DEMITRIUS, CA
DURAN, AP
CHAMBERLAIN, VC
HITCHINS, VM
AF DEMITRIUS, CA
DURAN, AP
CHAMBERLAIN, VC
HITCHINS, VM
TI COMPARISON OF EUROPEAN AND UNITED-STATES BIOLOGICAL INDICATORS FOR
ETHYLENE-OXIDE STERILIZATION
SO JOURNAL OF INDUSTRIAL MICROBIOLOGY
LA English
DT Article
DE BIOLOGICAL INDICATORS; ETHYLENE OXIDE; MEDICAL DEVICES; INTERNATIONAL
STANDARDS
AB Biological indicators (BIs) are used to monitor ethylene oxide (EO) gas sterilization processes for medical devices. Several European and United States BIs for EO sterilization were evaluated for resistance according to both United States Pharmacopeia (USP) XXI and United Kingdom's (UK) tests for D-values. US BIs are B. subtilis var. niger spores on paper strips or disc carriers, while European BIs use aluminum strips, quartz sand, or cotton yarn. Numerous BIs per run and runs per lot, as well as 2-3 different lots of BIs from each manufacturer, were examined. Both British a US BIs met their respective label claims for rates of inactivation when tested against British and USP EO test parameters, respectively. However, Danish BIs, on cotton yarn or quartz sand, were not inactivated following USP specifications during the exposure dwell times tested (600 mg L-1 EO, 54-degrees-C, 60% RH, 0-110 min). The Danish BIs will require further testing in order for us to determine if their B. subtilis spores are unusually resistant to EO or if the spore carrier substrates protect the spores from the sterilizing gas. In conclusion, the British and American BIs for EO sterilization are equivalent in resistance despite differences in carrier substrate, recovery conditions, calculation methods for D-values, and the labeled sterilization conditions for use.
C1 US FDA,CTR DEVICES & RADIOL HLTH HFZ112,5600 FISHERS LANE,ROCKVILLE,MD 20857.
US FDA,MIDWEST LAB MICROBIOL INVEST,MINNEAPOLIS,MN 55401.
NR 7
TC 3
Z9 3
U1 0
U2 0
PU STOCKTON PRESS
PI BASINGSTOKE
PA HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS
SN 0169-4146
J9 J IND MICROBIOL
JI J. Indust. Microbiol.
PD DEC
PY 1993
VL 12
IS 6
BP 399
EP 402
DI 10.1007/BF01569671
PG 4
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA PR144
UT WOS:A1993PR14400006
ER
PT J
AU CIOFI, P
CROWLEY, WR
PILLEZ, A
SCHMUED, LL
TRAMU, G
MAZZUCA, M
AF CIOFI, P
CROWLEY, WR
PILLEZ, A
SCHMUED, LL
TRAMU, G
MAZZUCA, M
TI PLASTICITY IN EXPRESSION OF IMMUNOREACTIVITY FOR NEUROPEPTIDE-Y,
ENKEPHALINS AND NEUROTENSIN IN THE HYPOTHALAMIC TUBEROINFUNDIBULAR
DOPAMINERGIC SYSTEM DURING LACTATION IN MICE
SO JOURNAL OF NEUROENDOCRINOLOGY
LA English
DT Note
DE ARCUATE NUCLEUS; LACTATION; MEDIAN EMINENCE; PROLACTIN;
TUBEROINFUNDIBULAR
ID RAT; NEURONS
AB In lactating nursing vs lactating pup-deprived mice, single or multiple immunolabeling was performed to compare immunoreactivities (ir) for neuropeptide Y (NPY), enkephalins (ENK) and neurotensin (NT) in the tyrosine hydroxylase (TH)-ir hypothalamic tubero-infundibular dopaminergic (TIDA) system. NPY-, ENK- and NT-irs were intensely expressed and co-existed in virtually all TH-ir endings in the median eminence (ME) of nursing mice. Removal of the pups induced a marked depletion of the peptide-irs from the ME TH-ir endings. In the arcuate nucleus (ARC) of colchicine-treated nursing mice which received peripheral injections of Fluoro-Gold (FG) to retrogradely label neuroendocrine cells, virtually all dorsal A12 TH-ir perikarya simultaneously expressed, with individual variations, NPY-, ENK- and NT-irs, and all contained FG. These results suggest that the synthesis of NPY, ENK and NT is enhanced in TIDA neurons during lactation and that these neuromessengers may be co-released together with DA from the ME to regulate the suckling-induced prolactin secretion at the hypothalamic and/or pituitary levels.
C1 UNIV TENNESSEE CTR HLTH SCI,DEPT PHARMACOL,MEMPHIS,TN 38163.
NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
UNIV BORDEAUX 1,NEUROCYTOCHIM FONCTIONNELLE LAB,CNRS,URA 339,F-33405 TALENCE,FRANCE.
RP CIOFI, P (reprint author), INSERM,U156,PL VERDUN,F-59045 LILLE,FRANCE.
FU NHLBI NIH HHS [HO-13703]
NR 12
TC 43
Z9 44
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0953-8194
J9 J NEUROENDOCRINOL
JI J. Neuroendocrinol.
PD DEC
PY 1993
VL 5
IS 6
BP 599
EP 602
DI 10.1111/j.1365-2826.1993.tb00528.x
PG 4
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA MM533
UT WOS:A1993MM53300001
PM 8680430
ER
PT J
AU LAJVARDI, A
MAZARIN, GI
GILLESPIE, MB
SATCHITHANANDAM, S
CALVERT, RJ
AF LAJVARDI, A
MAZARIN, GI
GILLESPIE, MB
SATCHITHANANDAM, S
CALVERT, RJ
TI STARCHES OF VARIED DIGESTIBILITIES DIFFERENTIALLY MODIFY INTESTINAL
FUNCTION IN RATS
SO JOURNAL OF NUTRITION
LA English
DT Article
DE STARCH; COLON; PH; THYMIDINE KINASE; RATS
ID DIETARY FIBER; CELL-PROLIFERATION; CARCINOGENESIS; CONSUMPTION; COLON;
RAW; PH
AB Starches of different digestibilities may enter the colon to different extents and alter colonic function. Male Fischer 344 rats were fed diets containing 25% cooked potato starch, arrowroot starch, high amylose cornstarch or raw potato starch for 6 wk. Fecal weight, transit time, colonic thymidine kinase activity (a marker for cell proliferation), and weight, starch content and pH of the cecum and proximal and distal colon were measured. Raw potato starch was much less completely digested than high amylose cornstarch, resulting in a 32-fold greater amount of undigested starch entering the cecum in the raw potato starch group. Both the high amylose cornstarch and raw potato starch diets significantly enhanced fecal weight and produced large intestinal hypertrophy, effects that were greatest in the raw potato starch group. Raw potato starch feeding was associated with the highest level of thymidine kinase activity, although the differences in thymidine kinase activity among the four groups were not significant. This diet also produced a 50% longer transit time. Entry of a large amount of raw potato starch into the colon resulted in greater luminal acidity, greater luminal bulk and slower transit. A much smaller amount of starch entered the colon in the high amylose cornstarch group and resulted in fecal bulking but no alteration in transit.
C1 US FDA,DIV NUTR,MOD-1,HFS-451,LAUREL,MD 20708.
NR 30
TC 14
Z9 15
U1 0
U2 1
PU AMER INST NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0022-3166
J9 J NUTR
JI J. Nutr.
PD DEC
PY 1993
VL 123
IS 12
BP 2059
EP 2066
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA ML888
UT WOS:A1993ML88800003
PM 8263598
ER
PT J
AU JORDAN, DD
AF JORDAN, DD
TI OPTICAL CRYSTALLOGRAPHIC CHARACTERISTICS OF SOME USP DRUGS
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
AB Optical crystallographic data were determined on a variety of newer USP drugs for which data had not been previously obtained. The ingredients in an unknown sample can be identified by polarized light microscopy by mounting small amounts of the material in successive specific refractive index liquids and determining refractive indices, optic sign, type of extinction, estimated 2V angle, and other optical characteristics for each ingredient present. This information can then be compared with the data listed on known drugs and excipients and all of the ingredients can be identified. To aid in the identification of unknown drugs, optical crystallographic data obtained on 52 of the newer USP drugs are presented.
RP JORDAN, DD (reprint author), US FDA,SE REG LAB,60 8TH ST NE,ATLANTA,GA 30309, USA.
NR 7
TC 9
Z9 9
U1 2
U2 2
PU AMER PHARMACEUTICAL ASSN
PI WASHINGTON
PA 2215 CONSTITUTION AVE NW, WASHINGTON, DC 20037
SN 0022-3549
J9 J PHARM SCI
JI J. Pharm. Sci.
PD DEC
PY 1993
VL 82
IS 12
BP 1269
EP 1271
DI 10.1002/jps.2600821218
PG 3
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA MJ541
UT WOS:A1993MJ54100017
PM 8308710
ER
PT J
AU POGUE, GP
CAO, XQ
SINGH, NK
NAKHASI, HL
AF POGUE, GP
CAO, XQ
SINGH, NK
NAKHASI, HL
TI 5' SEQUENCES OF RUBELLA-VIRUS RNA STIMULATE TRANSLATION OF CHIMERIC RNAS
AND SPECIFICALLY INTERACT WITH 2 HOST-ENCODED PROTEINS
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID CAP-INDEPENDENT TRANSLATION; SUBGENOMIC MESSENGER-RNA; RIBOSOMAL ENTRY
SITE; STEM-LOOP STRUCTURE; POLIOVIRUS RNA; STRAND RNA; UNTRANSLATED
REGION; FUNCTIONAL-ANALYSIS; NONCODING REGION; CELL-PROTEINS
AB Sequences at the 5' and 3' ends of the rubella virus (RV) genomic RNA can potentially form stable stem-loop (SL) structures that are postulated to be involved in virus replication. We have analyzed the function of these putative SL structures in RNA translation by constructing chimeric chloramphenicol acetyltransferase (CAT) RNAs, flanked either by both 5'- and 3'-terminal sequence domains from the RV genome or several deletion derivatives of the same sequences. After in vitro transcription of chimeric RNAs, the translational efficiencies of these RNAs were compared by the rabbit reticulocyte lysate translation system. For in vivo translation studies, the level of CAT activity was measured for chimeric RV/CAT RNAs expressed in transfected cells by the adenovirus major late promoter. Both in vivo and in vitro translation activities of the chimeric RNAs revealed that the presence of 5' and 3' SL sequences of RV RNA, in correct (+) orientation and context [5'(+)SL and 3'(+)SL, respectively] was necessary for efficient translation of chimeric RV/CAT RNAs. The presence of the RV 5'(+)SL sequence had the primary enhancing effect on translation. To identify host proteins which interact with the 5'(+)SL which may be involved in RV RNA translation, RNA gel-shift and UV cross-linking assays were employed. Two host proteins 59 and 52 kDa in size, present in cytosolic extracts from both uninfected and RV-infected cells, specifically interacted with the RV 5'(+)SL RNA. Direct binding comparisons between wild-type and mutant 5'(+)SL RNAs demonstrated that sequences in and around the bulge region of the terminal stem domain of this structure constituted a protein binding determinant. Human serum, qualified for anti-Ro/SS-A antigen specificity, immunoprecipitated 59- and 52-kDa protein-RNA complexes containing the RV 5'(+)SL RNA. However, poly- and monoclonal antisera raised against the recombinant 60- and 52-kDa Ro proteins failed to precipitate complexes containing the 5'(+)SL RNA. The identity of the proteins binding this RV cis-acting element remains to be determined; however, their role in RV translation is discussed.
C1 US FDA,OFF THERAPEUT RES & REV,CTR BIOL EVALUAT & RES,DIV HEMATOL PROD,MOLEC PHARMACOL LAB,BETHESDA,MD 20892.
NR 42
TC 37
Z9 37
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD DEC
PY 1993
VL 67
IS 12
BP 7106
EP 7117
PG 12
WC Virology
SC Virology
GA MG307
UT WOS:A1993MG30700025
PM 7693967
ER
PT J
AU VARRICCHIO, F
OBIRI, NI
HAAS, GP
PURI, RK
AF VARRICCHIO, F
OBIRI, NI
HAAS, GP
PURI, RK
TI IMMUNOSTAINING OF INTERLEUKIN-4 RECEPTOR ON HUMAN RENAL-CELL CARCINOMA
SO LYMPHOKINE AND CYTOKINE RESEARCH
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; HUMAN-MONOCYTES; CROSS-LINKAGE; GROWTH-FACTOR;
FC-EPSILON; T-CELLS; EXPRESSION; IDENTIFICATION; MICROENVIRONMENT;
LYMPHOKINE
AB Immunocytochemistry on three primary cultures of RCC tumor cells and immunohistochemistry on rive frozen sections of RCC were performed by utilizing a monoclonal antibody (M-57) to human IL-4R. We found that all three RCC tumor cell cytospin preparations stained with anti-IL-4R monoclonal antibody. Tumor cells stained with IgG control did not show any staining. Similarly, rive histologically proven RCC frozen sections prepared from nephrectomy specimens had moderate to intense immunoreactivity to IL-4 receptor antibody. RCC sections stained with normal mouse IgG2b showed only background type staining. Frozen section prepared from uninvolved kidney showed only nonspeciflc staining. A now cytometric analysis of primary cultures of RCC tumor cells confirmed the immunohistochemical data and showed that almost all of the cells were positive for IL-4 receptor expression. These results demonstrate that human RCC express immunoreactive IL4 receptors, which may be a target for diagnosis and therapy by an anti-IL-4 receptor antibody fused to toxins or radionuclides or alternatively by IL-4 toxins.
C1 US FDA,CTR BIOL EVALUAT & RES,DIV CELLULAR & GENE THERAPIES,HFM 530,BLDG 29A,ROOM 2B23,BETHESDA,MD 20892.
US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20892.
WAYNE STATE UNIV,SCH MED,DEPT UROL,DETROIT,MI 48201.
NR 27
TC 23
Z9 23
U1 1
U2 2
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
SN 0277-6766
J9 LYMPHOKINE CYTOK RES
JI Lymphokine Cytokine Res.
PD DEC
PY 1993
VL 12
IS 6
BP 465
EP 469
PG 5
WC Biochemistry & Molecular Biology; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA MN508
UT WOS:A1993MN50800006
PM 8123763
ER
PT J
AU CHO, BP
AF CHO, BP
TI STRUCTURE OF OXIDATIVELY DAMAGED NUCLEIC-ACID ADDUCTS - PH-DEPENDENCE OF
THE C-13 NMR-SPECTRA OF 8-OXOGUANOSINE AND 8-OXOADENOSINE
SO MAGNETIC RESONANCE IN CHEMISTRY
LA English
DT Article
DE C-13 NMR; PH DEPENDENCE; H-C-13 COUPLING CONSTANTS; TAUTOMERS;
IONIZATION; PROTONATION; NUCLEIC ACID ADDUCTS
ID MAGNETIC-RESONANCE; DNA TEMPLATES; BASE-PAIRS; N-15;
8-HYDROXY-2'-DEOXYGUANOSINE; 8-HYDROXYDEOXYGUANOSINE; SPECTROSCOPY;
CONFORMATION; TAUTOMERISM; PROTONATION
AB C-13 NMR spectra of two C-8-oxo purine nucleosides, 8-oxoguanosine and 8-oxoadenosine, were recorded as a function of pH. The pH dependence of C-13 chemical shifts and C-13-H-1 coupling constants associated with the purine carbon resonances was analyzed to probe the sites and extent of ionization and protonation of these oxidatively damaged nucleic acid adducts. In the course of this study, it was found that the C-2' and C-3' resonances of the ribofuranosyl sugar ring can be conveniently assigned on the basis of their unique pH-independent H-1-coupling spectral patterns in aqueous solution.
C1 NATL CTR TOXICOL RES,DIV BIOCHEM TOXICOL,JEFFERSON,AR 72079.
NR 26
TC 16
Z9 16
U1 0
U2 2
PU JOHN WILEY & SONS LTD
PI W SUSSEX
PA BAFFINS LANE CHICHESTER, W SUSSEX, ENGLAND PO19 1UD
SN 0749-1581
J9 MAGN RESON CHEM
JI Magn. Reson. Chem.
PD DEC
PY 1993
VL 31
IS 12
BP 1048
EP 1053
DI 10.1002/mrc.1260311204
PG 6
WC Chemistry, Multidisciplinary; Chemistry, Physical; Spectroscopy
SC Chemistry; Spectroscopy
GA MM777
UT WOS:A1993MM77700003
ER
PT J
AU DAVID, M
GRIMLEY, PM
FINBLOOM, DS
LARNER, AC
AF DAVID, M
GRIMLEY, PM
FINBLOOM, DS
LARNER, AC
TI A NUCLEAR TYROSINE PHOSPHATASE DOWN-REGULATES INTERFERON-INDUCED
GENE-EXPRESSION
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID DNA-BINDING PROTEIN; FC-GAMMA RECEPTOR; TRANSCRIPTION FACTOR; STIMULATED
TRANSCRIPTION; ALPHA-INTERFERON; CYTOPLASMIC ACTIVATION; HUMAN-CELLS;
IFN-GAMMA; PHOSPHORYLATION; INDUCTION
AB Alpha and gamma interferons rapidly induce several early response genes in primary human diploid fibroblasts. The transcription rates of these genes are maximal after 1 h of interferon treatment and return to basal levels within 8 h. Three different interferon-activated DNA-binding complexes (ISGF3, GAF, and FcRFgamma) that are responsible for transcriptional activation of cellular genes have been characterized. Assembly of these complexes requires tyrosine phosphorylation of one or more of the protein components. In this report, we demonstrate that a nuclear tyrosine phosphatase is responsible for the deactivation of these interferon-regulated transcription factors and the subsequent transcriptional downregulation of the corresponding genes. Furthermore, tyrosine phosphorylation is required for nuclear localization of the 91-kDa protein that is part of all three interferon-induced transcription complexes. These results provide the first evidence for a nuclear tyrosine phosphatase activity as a mechanism of transcriptional regulation.
C1 CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,8800 ROCKVILLE PIKE,BETHESDA,MD 20892.
UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,BETHESDA,MD 20892.
NR 32
TC 88
Z9 88
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0270-7306
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD DEC
PY 1993
VL 13
IS 12
BP 7515
EP 7521
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA MJ341
UT WOS:A1993MJ34100034
PM 8246969
ER
PT J
AU SZABO, G
WEAVER, JL
PINE, PS
ASZALOS, A
AF SZABO, G
WEAVER, JL
PINE, PS
ASZALOS, A
TI SPECIFIC DISENGAGEMENT OF CELL-BOUND ANTI-LAM-1 (ANTI-L-SELECTIN)
ANTIBODIES BY AURINTRICARBOXYLIC ACID
SO MOLECULAR IMMUNOLOGY
LA English
DT Article
ID RECEPTOR; EPITOPES; BINDING; LAM-1; HIV
AB Brief treatment of human peripheral blood lymphocytes with the potential anti-HIV compound aurintricarboxylic acid (ATA) prompts the selective release of already bound L-selectin-specific anti-leu8 and anti-LAM1-1 antibodies from the cells. Two other anti-LAM1 antibodies, anti-LAM1-3 and anti-LAM1-5 stay antigen-bound at the same time. interestingly, the ATA-sensitive anti-leu8 strongly competes with the ATA-resistant anti-LAM1-3 for binding. Photobleaching fluorescence resonance energy transfer (pFRET) measurements on flow-sorted cells suggests that these two antibodies compete for the same epitope, while anti-LAM1-5-FITC and anti-Leu8-PE bind to distinct sites, although they also compete for binding. Combining the data on competition, pFRET and ATA effect, we suggest that the ATA sensitive anti-leu8 and resistant anti-LAM1-3 bind to overlapping but non-identical epitopes. This remarkably specific effect may be exploited for designing anti-inflammatory drugs that modulate leukocyte adhesion.
C1 UNIV MED SCH DEBRECEN,DEPT BIOPHYS,H-4012 DEBRECEN,HUNGARY.
RP SZABO, G (reprint author), US FDA,DIV RES & TESTING,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 13
TC 2
Z9 2
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD DEC
PY 1993
VL 30
IS 18
BP 1689
EP 1694
DI 10.1016/0161-5890(93)90444-G
PG 6
WC Biochemistry & Molecular Biology; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA MP674
UT WOS:A1993MP67400010
PM 7505884
ER
PT J
AU HART, RW
TURTURRO, A
AF HART, RW
TURTURRO, A
TI DIETARY RESTRICTIONS, FREE-RADICALS, ELECTROPHILES AND GENE STABILITY -
PREFACE
SO MUTATION RESEARCH
LA English
DT Editorial Material
RP HART, RW (reprint author), NATL CTR TOXICOL RES,FOOD & DRUG ADM,DIV BIOMETRY & RISK ASSESSMENT,3900 NCTR RD,HFT-020,JEFFERSON,AR 72079, USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-8262
J9 MUTAT RES
PD DEC
PY 1993
VL 295
IS 4-6
BP 149
EP 150
DI 10.1016/0921-8734(93)90016-V
PG 2
WC Genetics & Heredity; Toxicology
SC Genetics & Heredity; Toxicology
GA MV034
UT WOS:A1993MV03400001
ER
PT J
AU TURTURRO, A
DUFFY, PH
HART, RW
AF TURTURRO, A
DUFFY, PH
HART, RW
TI MODULATION OF TOXICITY BY DIET AND DIETARY MACRONUTRIENT RESTRICTION
SO MUTATION RESEARCH
LA English
DT Article
DE FOOD RESTRICTION; PROTEIN RESTRICTION; FAT RESTRICTION; INDUCED
TOXICITY; FIBER; RISK ASSESSMENT
ID CHRONIC CALORIC RESTRICTION; MALE FISCHER-344 RAT; LOW-PROTEIN-DIET;
MAMMARY TUMORIGENESIS; COLON CARCINOGENESIS; SOYBEAN PROTEIN; WHEAT
BRAN; HIGH-FAT; METABOLISM; FIBER
AB Restriction of diet and macronutrients has been reported to modulate the toxicity of numerous chemical agents. Of the various forms of restriction studied, using nutritionally adequate diets, food restriction (FR) appears to be most effective, but protein restriction (PR), fat restriction (FtR), carbohydrate restriction (CbR), and excess of dietary fiber (FE) also affect toxicity and the spontaneous diseases that define the background incidence in toxicity tests. The heterogeneity of the dietary macronutrients complicates simple analysis of their effects. Additionally, the interrelationships between these various components in the complex dietary mixture often make experiments difficult to interpret.
Despite these complexities, a simple model is presented, which considers the effects of dietary manipulations on the individual steps in the interaction of organism and agent, and puts the varied effects that can occur within an organism into context. Ultimately, many of the effects of dietary modulation on these steps in toxicogenesis can be considered as changing agent exposure and the biologically available dose. The effects of macronutrient restriction are discussed in terms of effects on agent at the interface of organism and toxicant, agent disposition, agent metabolism, and repair of toxicant-induced damage at the level of the genome. After illustrating the influence of these nutritional effects on the chronic bioassay, using mouse liver tumors as an example, the significance of these effects for chronic and short-term testing is discussed. Additionally, methods to address the impact of nutritional factors on toxicity testing are suggested.
RP TURTURRO, A (reprint author), NATL CTR TOXICOL RES,FOOD & DRUG ADM,DIV BIOMETRY & RISK ASSESSMENT,3900 NCTR RD,HFT-020,JEFFERSON,AR 72079, USA.
NR 78
TC 38
Z9 38
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-8262
J9 MUTAT RES
PD DEC
PY 1993
VL 295
IS 4-6
BP 151
EP 164
DI 10.1016/0921-8734(93)90017-W
PG 14
WC Genetics & Heredity; Toxicology
SC Genetics & Heredity; Toxicology
GA MV034
UT WOS:A1993MV03400002
PM 7507554
ER
PT J
AU FEUERS, RJ
WEINDRUCH, R
HART, RW
AF FEUERS, RJ
WEINDRUCH, R
HART, RW
TI CALORIC RESTRICTION, AGING, AND ANTIOXIDANT ENZYMES
SO MUTATION RESEARCH
LA English
DT Article
DE ANTIOXIDANTS; AGING; CATALASE; FREE RADICALS; SUPEROXIDE DISMUTASE;
CALORIC RESTRICTION
ID MITOCHONDRIAL-DNA MUTATIONS; DIETARY RESTRICTION; HEART-MITOCHONDRIA;
SKELETAL-MUSCLE; RAT-LIVER; DEGENERATIVE DISEASES; SUPEROXIDE RADICALS;
LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; FOOD RESTRICTION
AB The basic mechanisms of aging and its retardation by caloric restriction (CR) remain unclear. One suggested means by which CR could retard aging is based on production of mitochondrial free radicals, and efficiency of their subsequent metabolism. Currently, there is little information concerning the influences of age and CR on the rates of in vivo mitochondrial free radical production. However, evidence for CR-induced modulation of free radical detoxification capacities is mounting. The direction of the influence of CR on free radical detoxification is tissue-specific, These effects are broad and appear to provide positive advantage.
C1 NATL CTR TOXICOL RES,DIV BIOMETRY & RISK ASSESSMENT,JEFFERSON,AR 72079.
UNIV WISCONSIN,DEPT MED,MADISON,WI 53706.
GRECC,VA,MADISON,WI 53706.
RP FEUERS, RJ (reprint author), NATL CTR TOXICOL RES,DIV GENET TOXICOL,3900 NCTR RD,JEFFERSON,AR 72079, USA.
NR 60
TC 63
Z9 63
U1 2
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-8262
J9 MUTAT RES
PD DEC
PY 1993
VL 295
IS 4-6
BP 191
EP 200
DI 10.1016/0921-8734(93)90020-4
PG 10
WC Genetics & Heredity; Toxicology
SC Genetics & Heredity; Toxicology
GA MV034
UT WOS:A1993MV03400005
PM 7507557
ER
PT J
AU MANJGALADZE, M
CHEN, S
FRAME, LT
SENG, JE
DUFFY, PH
FEUERS, RJ
HART, RW
LEAKEY, JEA
AF MANJGALADZE, M
CHEN, S
FRAME, LT
SENG, JE
DUFFY, PH
FEUERS, RJ
HART, RW
LEAKEY, JEA
TI EFFECTS OF CALORIC RESTRICTION ON RODENT DRUG AND CARCINOGEN
METABOLIZING ENZYMES - IMPLICATIONS FOR MUTAGENESIS AND CANCER
SO MUTATION RESEARCH
LA English
DT Review
DE CALORIC RESTRICTION; DRUG METABOLISM; CYTOCHROME P450
ID GROWTH-HORMONE SECRETION; MALE FISCHER-344 RAT; FOOD RESTRICTION;
MESSENGER-RNA; DIETARY RESTRICTION; GENE-EXPRESSION; HUMAN-LIVER;
GLUCOCORTICOID SULFOTRANSFERASES; HEPATIC CYTOCHROMES-P-450;
UDP-GLUCURONYLTRANSFERASE
AB Caloric restriction in rodents results in increased longevity and a decreased rate of spontaneous and chemically induced neoplasia. The low rates of spontaneous neoplasia and other pathologies have made calorically restricted rodents attractive for use in chronic bioassays. However, caloric restriction also alters hepatic drug metabolizing enzyme (DME) expression and so may also alter the biotransformation rates of test chemicals. These alterations in DME expression may be divided into two types: (1) those that are the direct result of caloric restriction itself and are detectable from shortly after the restriction is initiated; (2) those which are the result of pathological conditions that are delayed by caloric restriction. These latter alterations do not usually become apparent until late in the life of the organism. In rats, the largest direct effect of caloric restriction on liver DMEs is an apparent de-differentiation of sex-specific enzyme expression. This includes a 40-70% decrease in cytochrome P450 2C11 (CYP2C11) expression in males and a 20-30% reduction of corticosterone sulfotransferase activity in females. Changes in DME activities that occur late in life in calorically restricted rats include a stimulation of CYP2E1-dependent 4-nitrophenol hydroxylase activity and a delay in the disappearance of male-specific enzyme activities in senescent males. It is probable that altered DME expression is associated with altered metabolic activation of chemical carcinogens. For example the relative expression of hepatic CYP2C11 in ad libitum-fed or calorically restricted rats of different ages is closely correlated with the amount of genetic damage in 2-acetylaminofluorene- or aflatoxin B-1-pretreated hepatocytes isolated from rats of the same age and caloric intake. This suggests that altered hepatic drug and carcinogen metabolism in calorically restricted rats can influence the carcinogenicity of test chemicals.
C1 NATL CTR TOXICOL RES, DIV BIOMETRY & RISK ASSESSMENT, JEFFERSON, AR 72079 USA.
NATL CTR TOXICOL RES, DIV GENET TOXICOL, JEFFERSON, AR 72079 USA.
UNIV ARKANSAS MED SCI HOSP, DEPT INTERDISCIPLINARY TOXICOL, LITTLE ROCK, AR 72205 USA.
NR 143
TC 50
Z9 50
U1 1
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-8262
J9 MUTAT RES
JI Mutat. Res.
PD DEC
PY 1993
VL 295
IS 4-6
BP 201
EP 222
DI 10.1016/0921-8734(93)90021-T
PG 22
WC Genetics & Heredity; Toxicology
SC Genetics & Heredity; Toxicology
GA MV034
UT WOS:A1993MV03400006
PM 7507558
ER
PT J
AU CHOU, MW
KONG, J
CHUNG, KT
HART, RW
AF CHOU, MW
KONG, J
CHUNG, KT
HART, RW
TI EFFECT OF CALORIC RESTRICTION ON THE METABOLIC-ACTIVATION OF XENOBIOTICS
SO MUTATION RESEARCH
LA English
DT Article
DE CALORIC RESTRICTION; AFLATOXIN B1; BENZO[A]PYRENE; XENOBIOTIC
METABOLIZING ENZYMES; AFB1-DNA ADDUCT; BP-DNA ADDUCT
ID DNA ADDUCT FORMATION; FOOD RESTRICTION; RAT-LIVER; FISCHER-344 RAT;
DIETARY FACTORS; MODIFYING ROLE; DIOL EPOXIDES; AFLATOXIN-B1;
CARCINOGENESIS; INVITRO
AB The effect of caloric restriction (CR) on xenobiotic metabolizing enzyme activities results in alterations in the metabolic activation of chemical carcinogens, with a resultant impact on DNA-carcinogen adduct formation and DNA repair. Using aflatoxin B1 (AFB1) and benzo[a]pyrene (BP) as model carcinogens, we studied the effect of CR on the metabolic activation of these carcinogens and carcinogen-induced DNA damage and repair in terms of AFB1-DNA and BP-DNA adduct formation and removal. Male Fischer 344 rats fed calorie restricted diets (60% of the food consumption for ad libitum-fed rats) showed a reduction in the metabolic activation of AFB1 and decrease in both the in vitro and in vivo AFB1-DNA adduct formation. However, CR increased the activity of BP metabolizing enzymes resulting in an enhancement of BP-DNA adduct formation. Our results indicate that the effect of CR on metabolic activation of xenobiotics is dependent upon the selected xenobiotic metabolizing enzymes whose activities may be significantly altered by CR, and upon the nature of the chemical carcinogens which exert different structure-activity relationships during the process of chemically induced carcinogenesis.
C1 NATL CTR TOXICOL RES,DIV BIOMETRY & RISK ASSESSMENT,JEFFERSON,AR 72079.
MEMPHIS STATE UNIV,DEPT BIOL,MEMPHIS,TN 38152.
RP CHOU, MW (reprint author), NATL CTR TOXICOL RES,DIV NUTRIT TOXICOL,HFT-140,3900 NCTR RD,JEFFERSON,AR 72079, USA.
FU PHS HHS [NC 92B02]
NR 57
TC 27
Z9 32
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-8262
J9 MUTAT RES
PD DEC
PY 1993
VL 295
IS 4-6
BP 223
EP 235
DI 10.1016/0921-8734(93)90022-U
PG 13
WC Genetics & Heredity; Toxicology
SC Genetics & Heredity; Toxicology
GA MV034
UT WOS:A1993MV03400007
PM 7507559
ER
PT J
AU RANDERATH, K
ZHOU, GD
HART, RW
TURTURRO, A
RANDERATH, E
AF RANDERATH, K
ZHOU, GD
HART, RW
TURTURRO, A
RANDERATH, E
TI BIOMARKERS OF AGING - CORRELATION OF DNA I-COMPOUND LEVELS WITH MEDIAN
LIFE-SPAN OF CALORICALLY RESTRICTED AND AD-LIBITUM FED RATS AND MICE
SO MUTATION RESEARCH
LA English
DT Article
DE DNA MODIFICATIONS; I-COMPOUNDS; LIFE-SPAN; BIOMARKERS; CALORIC
RESTRICTION; RAT; MOUSE; P-32 POSTLABELING
ID SPRAGUE-DAWLEY RATS; CHOLINE-DEVOID DIET; LIVER DNA; CELLULAR
SENESCENCE; OXIDATIVE DAMAGE; AGE; REDUCTION; ADDUCTS; CANCER; KIDNEY
AB I-compounds are species-, tissue-, genotype-, gender-, and diet-dependent bulky DNA modifications whose levels increase with animal age. While a few of these DNA modifications represent oxidation products, the majority of I-compounds appear to be derived from as yet unidentified endogenous DNA-reactive intermediates other than reactive oxygen species. Circadian rhythms of certain I-compounds in rodent liver imply that levels of these DNA modifications are precisely regulated. Caloric restriction (CR), the currently most effective method available to retard aging and carcinogenesis, has been previously shown to elicit significant elevations of I-compound levels in tissue DNA from Brown-Norway (BN) and F-344 rats as compared to age-matched ad libitum fed (AL) animals. The present investigation has extended this work by examining liver and kidney DNA I-compound levels in three genotypes of rats (F-344, BN, and F-344 x BN) and two genotypes of mice (C57BL/6N and B6D2F1) under identical experimental conditions in order to determine whether correlations exist between I-compound levels, measured in middle-aged animals, and median lifespan. Levels of a number of liver and kidney I-compounds were found to display genotype- and diet-dependent, statistically significant positive linear correlations with median lifespan in both species. In particular, the longer-lived hybrid F-344 x BN rats and B6D2F1 mice tended to exhibit higher I-compound levels than the parent strains. CR enhanced I-compound levels substantially in both rats and mice. Thus, I-compounds, measured at middle age, reflected the functional capability ('health') of the organism at old age, suggesting their predictive value as biomarkers of aging. The positive linear correlations between levels of certain I-compounds (designated as type I) and lifespan suggest that these modifications may be functionally important and thus not represent endogenous DNA lesions (type II), whose levels would be expected to correlate inversely with lifespan.
C1 NATL CTR TOXICOL RES,DIV BIOMETRY & RISK ASSESSMENT,JEFFERSON,AR 72079.
RP RANDERATH, K (reprint author), BAYLOR COLL MED,DEPT PHARMACOL,DIV TOXICOL,HOUSTON,TX 77030, USA.
FU NCI NIH HHS [R37 CA 32157]; NIA NIH HHS [R01 AG 07750]; NIEHS NIH HHS
[P42 ES 04917]
NR 68
TC 27
Z9 27
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-8262
J9 MUTAT RES
PD DEC
PY 1993
VL 295
IS 4-6
BP 247
EP 263
DI 10.1016/0921-8734(93)90024-W
PG 17
WC Genetics & Heredity; Toxicology
SC Genetics & Heredity; Toxicology
GA MV034
UT WOS:A1993MV03400009
PM 7507561
ER
PT J
AU SRIVASTAVA, VK
MILLER, S
SCHROEDER, MD
HART, RW
BUSBEE, D
AF SRIVASTAVA, VK
MILLER, S
SCHROEDER, MD
HART, RW
BUSBEE, D
TI AGE-RELATED-CHANGES IN EXPRESSION AND ACTIVITY OF DNA-POLYMERASE ALPHA -
SOME EFFECTS OF DIETARY RESTRICTION
SO MUTATION RESEARCH
LA English
DT Article
DE DNA SYNTHESIS; DNA POLYMERASE; DIETARY RESTRICTION; AGING; FIDELITY OF
SYNTHESIS; ACCESSORY PROTEIN
ID SENESCENT HUMAN-FIBROBLASTS; CYCLE-DEPENDENT GENES; CELL-CYCLE;
DECREASED FIDELITY; WI-38 FIBROBLASTS; ACCESSORY PROTEIN; SYNTHESIS
INVITRO; STRAND SYNTHESIS; GROWTH-FACTORS; AGING MICE
AB DNA polymerase (alpha (pol alpha) purified from human diploid fibroblasts (HDF) and from livers of C57BL/6N mice showed age-related decreases in: (1) mRNA levels; (2) the amount of enzyme isolated per cell; and (3) enzyme activity (HDF); as well as: a) the amount of enzyme isolated; b) the specific activity; and c) the enzyme fidelity (liver). Hepatic pol alpha from dietary restricted (DR) mice exhibited less of a decline in specific activity and copied synthetic DNA templates with relatively higher fidelity than did enzymes from animals fed ad libitum (AL). Pol alpha from fetal-derived HDF exhibited increased expression compared with aged donor-derived HDF, with both fetal and old cell pol alpha in normal cells being expressed at lower levels than in their transformed cell corollaries. Treatment of human pol alpha from aged donor-derived HDF with a pol alpha accessory protein isolated from log phase murine cells resulted in increased pol alpha binding of DNA and increased pol alpha activity. However, highly active pol alpha isolated from fetal-derived or transformed HDF, or from transformed murine cells, showed little or no activity enhancement in the presence of accessory protein. These data indicate that, as a function of increased age, there is a decrease in pol alpha expression and specific activity in HDF, as well as decreases in specific activity and fidelity of pol alpha in essentially amitotic murine hepatic tissues. Dietary restriction impedes the age-related declines in both activity and fidelity of hepatic pol alpha in mice. The data further indicate that transformation of slowly dividing HDF is associated with increased expression of pol alpha, but suggest that increased expression alone is not sufficient to explain the difference in polymerase activity levels between parental and transformed HDF. Lastly, the data suggest that interaction of pol alpha with an essential accessory protein may be altered as a function of age, an alteration that appears to be correlated with the decline in pol alpha DNA binding and specific activity.
C1 TEXAS A&M UNIV, COLL VET MED, DEPT ANAT & PUBL HLTH, COLL STN, TX 77843 USA.
NATL CTR TOXICOL RES, DIV BIOMETRY & RISK ASSESSMENT, JEFFERSON, AR 72075 USA.
FU NIA NIH HHS [AG07739, AG06347]
NR 89
TC 17
Z9 17
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-8262
J9 MUTAT RES
JI Mutat. Res.
PD DEC
PY 1993
VL 295
IS 4-6
BP 265
EP 280
DI 10.1016/0921-8734(93)90025-X
PG 16
WC Genetics & Heredity; Toxicology
SC Genetics & Heredity; Toxicology
GA MV034
UT WOS:A1993MV03400010
PM 7507562
ER
PT J
AU HASS, BS
HART, RW
LU, MH
LYNCOOK, BD
AF HASS, BS
HART, RW
LU, MH
LYNCOOK, BD
TI EFFECTS OF CALORIC RESTRICTION IN ANIMALS ON CELLULAR FUNCTION, ONCOGENE
EXPRESSION, AND DNA METHYLATION IN-VITRO
SO MUTATION RESEARCH
LA English
DT Article
DE CALORIC RESTRICTION; CELLULAR PROLIFERATION, TRANSFORMATION; ONCOGENE
ACTIVATION; DNA METHYLATION
ID MYC PROTOONCOGENE EXPRESSION; DIETARY RESTRICTION; EMBRYO FIBROBLASTS;
GLUCOSE STARVATION; PANCREATIC-CANCER; MICE; CELLS; PROLIFERATION; RATS;
RAS
AB While the life-extending and disease-modulating effects of caloric restriction (CR) are well documented in whole animal studies and in correlative experiments using cells taken from CR animals, very few studies have used cells in culture after their removal from the CR-fed animal. In using this in vivo --> in vitro approach we have attempted to examine the proposition that the effects of CR can be transferred to individual cells by analyzing the cellular functions of proliferation and transformation, the activation of oncogenes, and the methylation of DNA as a function only of diet. Pancreatic acinar cells excised from CR-fed Brown-Norway rats and placed in rich medium showed different responses compared to cells from ad libitum (AL)-fed controls. CR had the effect of slowing growth rate and protecting against spontaneous and N-methyl-N'-nitro-N-nitrosoguanidine(MNNG)-induced transformation over 14 passages of cells in culture. At the molecular level, cells from the CR animals showed reduced c-Ha-ras oncogene expression and mutation as well as reduced mutation of the p53 suppressor gene. CR also increased genomic methylation of ras DNA. We conclude that the effects of CR treatment of the animal are transferred to individual cells and note that these responses (decreased proliferation and transformation; depressed oncogene expression and mutation and decreased suppressor gene mutation; and increased oncogene methylation) are cellular and molecular analogs of in vivo weight loss, life extension, and carcinogenesis modulation, which are hallmarks of CR in the whole animal. The fact that these responses are seen generations after the cells are removed from the CR-treated animal indicates that CR causes a permanent predisposition of pancreatic acinar cells to these modulated responses and shows the value of the in vivo --> in vitro protocol in studies that relate diet to cellular and molecular function.
C1 NATL CTR TOXICOL RES,FOOD & DRUG ADM,DIV BIOMETRY & RISK ASSESSMENT,JEFFERSON,AR 72079.
RP HASS, BS (reprint author), NATL CTR TOXICOL RES,FOOD & DRUG ADM,DIV NUTRIT TOXICOL,3900 NCTR RD,HFT-140,JEFFERSON,AR 72079, USA.
NR 50
TC 59
Z9 60
U1 2
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-8262
J9 MUTAT RES
PD DEC
PY 1993
VL 295
IS 4-6
BP 281
EP 289
DI 10.1016/0921-8734(93)90026-Y
PG 9
WC Genetics & Heredity; Toxicology
SC Genetics & Heredity; Toxicology
GA MV034
UT WOS:A1993MV03400011
PM 7507563
ER
PT J
AU LU, ZB
DOUTHITT, MP
TAFFS, RE
RAN, YX
NORWOOD, LP
CHUMAKOV, KM
AF LU, ZB
DOUTHITT, MP
TAFFS, RE
RAN, YX
NORWOOD, LP
CHUMAKOV, KM
TI QUANTITATIVE ASPECTS OF THE MUTANT ANALYSIS BY PCR AND RESTRICTION
ENZYME CLEAVAGE (MAPREC)
SO PCR-METHODS AND APPLICATIONS
LA English
DT Article
ID POLYMERASE CHAIN-REACTION; POLIOVIRUS VACCINE; SEQUENCE; RNA; DNA
AB Quantitation of virus revertants by PCR and restriction enzyme cleavage may give nonlinear results and, in some cases, produce artifacts caused by nucleotide misincorporation and heteroduplex formation, occurring during PCR. Modifications of the procedure allowed us to overcome these problems and develop a highly sensitive and reliable method of mutant quantitation. This procedure can be used to assess the quality of live vaccines and to study heterogeneity of viral and bacterial populations.
RP LU, ZB (reprint author), US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892, USA.
NR 10
TC 26
Z9 26
U1 0
U2 0
PU COLD SPRING HARBOR LAB PRESS
PI PLAINVIEW
PA 1 BUNGTOWN RD, PLAINVIEW, NY 11724
SN 1054-9803
J9 PCR METH APPL
JI PCR-Methods Appl.
PD DEC
PY 1993
VL 3
IS 3
BP 176
EP 180
PG 5
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA MM596
UT WOS:A1993MM59600006
PM 8118399
ER
PT J
AU REVELLE, LK
DOUB, WH
WILSON, RT
HARRIS, MH
RUTTER, AM
AF REVELLE, LK
DOUB, WH
WILSON, RT
HARRIS, MH
RUTTER, AM
TI IDENTIFICATION AND ISOLATION OF CHLORHEXIDINE DIGLUCONATE IMPURITIES
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE CHLORHEXIDINE DIGLUCONATE; IMPURITIES; IDENTIFICATION; ISOLATION;
HPLC-MS; FLASH CHROMATOGRAPHY; HPLC-UV
ID LIQUID-CHROMATOGRAPHY; MASS-SPECTROMETRY; RESOLUTION; PRODUCTS
AB We report the identification of 11 impurities in variously stressed chlorhexidine digluconate (CHG) solutions. The structural assignment of each CHG impurity involved tentative identification from HPLC-MS data followed by synthesis of the appropriate standard, isolation of the impurity from the CHG solution by flash chromatography, and comparison of HPLC-MS, HPLC-UV, and NMR data of the impurity with the standard. Six of the synthetic impurity standards represent new compounds. Degradation studies of CHG solutions systematically stressed by heat, light, and low pH are reported with identification and approximate quantification of resulting impurities. Degradation mechanisms were proposed for each set of stress conditions applied to CHG solutions. Parallels were noted between the way CHG degrades in the thermospray interface of the HPLC-MS and the way CHG degrades with shelf time. Similarities were noted in the synthetic starting materials of CHG and the final degradation products.
C1 USDA,FSIS MIDWESTERN LAB,ST LOUIS,MO 63115.
RP REVELLE, LK (reprint author), US FDA,DIV DRUG ANAL,1114 MARKET ST,ROOM 1002,ST LOUIS,MO 63101, USA.
NR 19
TC 12
Z9 12
U1 2
U2 12
PU PLENUM PUBL CORP
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013
SN 0724-8741
J9 PHARMACEUT RES
JI Pharm. Res.
PD DEC
PY 1993
VL 10
IS 12
BP 1777
EP 1784
DI 10.1023/A:1018986501194
PG 8
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA MN096
UT WOS:A1993MN09600014
PM 8302766
ER
PT J
AU LYTLE, CD
WAGNER, SJ
PRODOUZ, KN
AF LYTLE, CD
WAGNER, SJ
PRODOUZ, KN
TI ANTIVIRAL ACTIVITY OF GILVOCARCIN-V PLUS UVA RADIATION
SO PHOTOCHEMISTRY AND PHOTOBIOLOGY
LA English
DT Article
ID HERPES-VIRUS; INACTIVATION; REACTIVATION; INHIBITION; LIGHT
AB Gilvocarcin V (GV), a coumarin, is a nucleic acid photosensitizer that is phototoxic to bacteria and mammalian cells at picomolar levels in the presence of near-W radiation (UVA). We evaluated the effectiveness of GV plus UVA for inactivation of several viruses, including herpes simplex virus, type 1 (HSV) and the bacterial viruses phi X174, T7, PRD 1 and phi 6. Some inactivation of the bacterial viruses was observed with UVA radiation alone (4-50% survival at 26 kJ/m(2)). Additional photosensitized inactivation was observed only with T7 and phi 6 at 2.0 mu M GV. On the other hand, HSV was photoinactivated with concentrations of GV three orders of magnitude lower (1.0 nM). Similar to the case with UV (254 nm) inactivation, the GV-UVA survival curve for HSV indicated multicomponent inactivation kinetics, which could not be explained by photobleaching of GV. The wide range of photosensitivities of these viruses to GV cannot be adequately explained by models based only on viral nucleic acid content or presence of lipid envelopes.
C1 AMER RED CROSS,JEROME H HOLLAND LAB,ROCKVILLE,MD.
US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD.
RP LYTLE, CD (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.
NR 16
TC 5
Z9 5
U1 0
U2 1
PU AMER SOC PHOTOBIOLOGY
PI AUGUSTA
PA BIOTECH PARK, 1021 15TH ST, SUITE 9, AUGUSTA, GA 30901-3158
SN 0031-8655
J9 PHOTOCHEM PHOTOBIOL
JI Photochem. Photobiol.
PD DEC
PY 1993
VL 58
IS 6
BP 818
EP 821
DI 10.1111/j.1751-1097.1993.tb04976.x
PG 4
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MQ238
UT WOS:A1993MQ23800008
PM 8310002
ER
PT J
AU MILLER, SA
BEER, JZ
STRICKLAND, AG
ZMUDZKA, BZ
AF MILLER, SA
BEER, JZ
STRICKLAND, AG
ZMUDZKA, BZ
TI SPECTRAL EFFECTS IN ACTIVATION OF THE HUMAN-IMMUNODEFICIENCY-VIRUS
PROMOTER BY PSORALENS PLUS ULTRAVIOLET-A TREATMENT
SO PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE
LA English
DT Article
DE HIV PROMOTER ACTIVATION; CELL KILLING; UV RADIATION SPECTRUM;
8-METHOXYPSORALEN; PUVA
ID PSORIASIS; PHOTOPHERESIS; EXPRESSION; TYPE-1; INVIVO; MICE
AB The effects of PUVA treatment on HIV promoter activation and cell killing in HIV cat/HeLa cells were studied using two UV sources, a UVASUN sunlamp and a WAR Photoactivation Chamber. A 4 to 5 times higher dose of ultraviolet radiation was required from the UVASUN lamp than from the UVAR lamps: 1) to activate the HIV promoter in the presence of 0.1 or 1.0 mu g/ml 8-MOP and 2) to reduce cell survival to a level of 10%, in the presence of 0.1 or 1.0 mu g/ml 8-MOP. In addition, exposures performed with a fixed dose of 20 kJ/m(2) at varying concentrations of 8-MOP, required a 4.7 times higher combined PUVA dose from the UVASUN lamp than from the UVAR lamps. Two possible sources of these differences were analyzed: (1) the presence of UVB + UVA2 (280-340 nm) in the radiation emitted by the UVAR, but not the UVASUN lamp, and its potential biological activity independent of 8-MOP, and (2) the difference in the overlap of the emission spectra of the two lamps with the absorption spectrum of 8-MOP. The area of overlap was higher for the UVAR lamp than for the UVASUN lamp by a factor of 4.6, which is close to the difference between these two lamps in induction of the HIV promoter and killing HeLa cells. This indicates that the effectiveness of a particular UVA source used in combination with 8-MOP can be predicted by its congruence to the absorption spectrum of the photosensitizing drug.
RP MILLER, SA (reprint author), US FDA,CTR DEVICES & RADIOL HLTH HFZ134,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.
NR 21
TC 0
Z9 0
U1 0
U2 0
PU MUNKSGAARD INT PUBL LTD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 0905-4383
J9 PHOTODERMATOL PHOTO
JI Photodermatol. Photoimmunol. Photomed.
PD DEC
PY 1993
VL 9
IS 6
BP 262
EP 267
PG 6
WC Dermatology
SC Dermatology
GA MK546
UT WOS:A1993MK54600006
ER
PT J
AU LYTLE, CD
CYR, WH
BEER, JZ
MILLER, SA
JAMES, RH
LANDRY, RJ
JACOBS, ME
KACZMAREK, RG
SHARKNESS, CM
GAYLOR, D
DEGRUIJL, FR
VANDERLEUN, JC
AF LYTLE, CD
CYR, WH
BEER, JZ
MILLER, SA
JAMES, RH
LANDRY, RJ
JACOBS, ME
KACZMAREK, RG
SHARKNESS, CM
GAYLOR, D
DEGRUIJL, FR
VANDERLEUN, JC
TI AN ESTIMATION OF SQUAMOUS-CELL CARCINOMA RISK FROM ULTRAVIOLET-RADIATION
EMITTED BY FLUORESCENT LAMPS
SO PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE
LA English
DT Article
DE ULTRAVIOLET RADIATION; SQUAMOUS CELL CARCINOMA; FLUORESCENT LAMP; RISK
ASSESSMENT
ID CUTANEOUS MALIGNANT-MELANOMA; SKIN-CANCER; UV-B; OUTDOOR; MUTAGENICITY;
ASSOCIATION; PSORIASIS; EXPOSURE; SUNBURN; INDOOR
AB The risk of squamous cell carcinoma (SCC) from ultraviolet radiation (UV) emitted by unfiltered fluorescent lamps was assessed. The assessment employed a mathematical power model based on human epidemiological data, which relates the SCC incidence in the United States white population to ambient solar UV. The annual numbers of new SCC on anatomical sites chronically exposed to solar UV (head/face/neck and hands) were estimated for indoor workers. Then the number of SCC that may be caused by additional UV exposure from indoor fluorescent lighting was estimated: the lifetime exposure of indoor workers to typical fluorescent lighting (if unfiltered) may add 3.9% (1.6-12%) to the risk from solar W, resulting in the induction of an additional 1500 (600-4500) SCC per annum in the United States. This calculated projection must be compared with the 110,000 SCC caused by solar exposure. Thus, this analysis suggests there may be a small increased risk of SCC from exposure to UV-emitting fluorescent lamps.
C1 UNIV UTRECHT,UTRECHT,NETHERLANDS.
NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
RP LYTLE, CD (reprint author), CTR DEVICES & RADIOL HLTH,HFZ-112,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.
NR 52
TC 8
Z9 8
U1 0
U2 5
PU MUNKSGAARD INT PUBL LTD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 0905-4383
J9 PHOTODERMATOL PHOTO
JI Photodermatol. Photoimmunol. Photomed.
PD DEC
PY 1993
VL 9
IS 6
BP 268
EP 274
PG 7
WC Dermatology
SC Dermatology
GA MK546
UT WOS:A1993MK54600007
ER
PT J
AU SWANN, JP
AF SWANN, JP
TI ACTIVISTS AND ADVOCATES - TORONTO HEALTH DEPARTMENT, 1883-1983 -
MACDOUGALL,H
SO PUBLIC HISTORIAN
LA English
DT Book Review
RP SWANN, JP (reprint author), US FDA,BETHESDA,MD 20014, USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU UNIV CALIF PRESS
PI BERKELEY
PA JOURNALS DEPT 2120 BERKELEY WAY, BERKELEY, CA 94720
SN 0272-3433
J9 PUBL HISTORIAN
JI Public Hist.
PD WIN
PY 1993
VL 15
IS 1
BP 84
EP 85
PG 2
WC History
SC History
GA KQ401
UT WOS:A1993KQ40100011
ER
PT J
AU CAIRNS, T
LUKE, MA
CHIU, KS
NAVARRO, D
SIEGMUND, EG
AF CAIRNS, T
LUKE, MA
CHIU, KS
NAVARRO, D
SIEGMUND, EG
TI MULTIRESIDUE PESTICIDE ANALYSIS BY ION-TRAP TECHNOLOGY - A CLEANUP
APPROACH FOR MASS-SPECTRAL ANALYSIS
SO RAPID COMMUNICATIONS IN MASS SPECTROMETRY
LA English
DT Article
ID CHEMICAL-IONIZATION; CHROMATOGRAPHY
AB Previous studies using the ion trap as a potential replacement for an array of element-sensitive detectors indicated that only semi-quantitative results at the 50-100 ppb range could be obtained for 245 pesticides because of interfering endogenous sample matrix-compounds. The development of a new clean-up procedure for a wide range or fruits and vegetables, specifically for use in an ion trap, has been undertaken to improve recoveries at the low ppm level to within analytically acceptable ranges (80-120%). This clean-up involved the use of three solid-phase extractions. The use of a C-18 SepPak column removed the majority of hydrocarbon-like molecules while the anion-exchange column (QMA) removed all colored compounds and flavors, and finally the use of an aminopropyl column removed all sugars. Preliminary results from this study using 24 selected pesticides in four different sample matrices have indicated an acceptable improvement over previous results.
RP CAIRNS, T (reprint author), US FDA,DEPT HLTH & HUMAN SERV,OFF REGULATORY AFFAIRS,DIST LAB,1521 W PICO BLVD,LOS ANGELES,CA 90015, USA.
NR 7
TC 47
Z9 51
U1 0
U2 5
PU JOHN WILEY & SONS LTD
PI W SUSSEX
PA BAFFINS LANE CHICHESTER, W SUSSEX, ENGLAND PO19 1UD
SN 0951-4198
J9 RAPID COMMUN MASS SP
JI Rapid Commun. Mass Spectrom.
PD DEC
PY 1993
VL 7
IS 12
BP 1070
EP 1076
DI 10.1002/rcm.1290071203
PG 7
WC Chemistry, Analytical; Spectroscopy
SC Chemistry; Spectroscopy
GA MM787
UT WOS:A1993MM78700002
ER
PT J
AU DOERGE, DR
BAJIC, S
LOWES, S
AF DOERGE, DR
BAJIC, S
LOWES, S
TI MULTIRESIDUE ANALYSIS OF SULFONAMIDES USING LIQUID-CHROMATOGRAPHY WITH
ATMOSPHERIC-PRESSURE CHEMICAL-IONIZATION MASS-SPECTROMETRY
SO RAPID COMMUNICATIONS IN MASS SPECTROMETRY
LA English
DT Article
ID SULFAMETHAZINE; RESIDUES; HUMANS; MILK
AB Sulfonamide antibiotics are widely used to prevent bacterial infections in livestock, and residues are commonly found in milk and meat. This is of toxicological and regulatory concern because sulfamethazine produces thyroid tumors in rodents. Unadulterated milk was purified using solid-phase extraction and six sulfonamides were added prior to analysis by liquid chromatography coupled to atmospheric pressure chemical ionization mass spectrometry. The mass spectra of all sulfonamides consisted exclusively of protonated molecules at low sampling cone voltage and, under these conditions, estimated detection limits were 0.05-0.5 ng, corresponding to 0.25-2.5 ppb in milk. The response curve for sulfamethazine was linear over a concentration range (1.25-20 ppb) that encompasses the regulatory level of interest in milk (10 ppb). Increasing the sampling cone voltage caused collision-induced dissociation of sulfonamides that resulted in formation of ions that are diagnostic for the variable heterocyclic base and constant sulfanilyl portions of the molecule. At intermediate sampling cone voltages, multiple fragment ions were formed with reproducible intensity ratios. This process can be used to provide additional confirmation of target sulfonamides. Monitoring a common fragment ion formed at high sampling cone voltage permitted class-specific multiresidue detection of the six sulfonamides with minimal losses in sensitivity. An analytical method is proposed for the detection, confirmation and quantification of sulfonamides and metabolites in milk with sensitivity equal to or greater than those obtained with less specific methods involving liquid chromatography with a UV detector. The relative simplicity of this technique and the availability of benchtop instrumentation suggests that routine screening and confirmation analyses of sulfonamide contaminants in milk is practicable.
C1 FISONS INSTRUMENTS VG BIOTECH,ALTRINCHAM WA14 5RZ,CHESHIRE,ENGLAND.
RP DOERGE, DR (reprint author), NATL CTR TOXICOL RES,JEFFERSON,AR 72079, USA.
NR 17
TC 38
Z9 38
U1 0
U2 2
PU JOHN WILEY & SONS LTD
PI W SUSSEX
PA BAFFINS LANE CHICHESTER, W SUSSEX, ENGLAND PO19 1UD
SN 0951-4198
J9 RAPID COMMUN MASS SP
JI Rapid Commun. Mass Spectrom.
PD DEC
PY 1993
VL 7
IS 12
BP 1126
EP 1130
DI 10.1002/rcm.1290071214
PG 5
WC Chemistry, Analytical; Spectroscopy
SC Chemistry; Spectroscopy
GA MM787
UT WOS:A1993MM78700013
ER
PT J
AU WHITTAKER, P
VANDERVEEN, JE
DINOVI, MJ
KUZNESOF, PM
DUNKEL, VC
AF WHITTAKER, P
VANDERVEEN, JE
DINOVI, MJ
KUZNESOF, PM
DUNKEL, VC
TI TOXICOLOGICAL PROFILE, CURRENT USE, AND REGULATORY ISSUES ON EDTA
COMPOUNDS FOR ASSESSING USE OF SODIUM IRON EDTA FOR FOOD FORTIFICATION
SO REGULATORY TOXICOLOGY AND PHARMACOLOGY
LA English
DT Article
RP WHITTAKER, P (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,WASHINGTON,DC 20204, USA.
NR 20
TC 19
Z9 19
U1 1
U2 4
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0273-2300
J9 REGUL TOXICOL PHARM
JI Regul. Toxicol. Pharmacol.
PD DEC
PY 1993
VL 18
IS 3
BP 419
EP 427
DI 10.1006/rtph.1993.1067
PG 9
WC Medicine, Legal; Pharmacology & Pharmacy; Toxicology
SC Legal Medicine; Pharmacology & Pharmacy; Toxicology
GA MK583
UT WOS:A1993MK58300005
PM 8128003
ER
PT J
AU BOWERS, J
BROWN, B
SPRINGER, J
TOLLEFSON, L
LORENTZEN, R
HENRY, S
AF BOWERS, J
BROWN, B
SPRINGER, J
TOLLEFSON, L
LORENTZEN, R
HENRY, S
TI RISK ASSESSMENT FOR AFLATOXIN - AN EVALUATION BASED ON THE MULTISTAGE
MODEL
SO RISK ANALYSIS
LA English
DT Article
DE AFLATOXIN; RISK ASSESSMENT; CANCER POTENCY; MULTISTAGE MODELS
ID HEPATITIS-B VIRUS; PRIMARY LIVER-CANCER; HEPATOCELLULAR-CARCINOMA;
TRANSGENIC MICE; EXPOSURE; HEPATOCARCINOGENS; PATHOGENESIS; ACTIVATION;
INFECTION; CHINA
AB Lifetime cancer potency of alfatoxin was assessed based on the Yeh et al. study from China in which both aflatoxin exposure and hepatitis B prevalence were measured. This study provides the best available information for estimating the carcinogenic risk posed by aflatoxin to the U.S. population. Cancer potency of aflatoxin was estimated using a biologically motivated risk assessment model. The best estimate of aflatoxin potency was 9 (mg/kg/day)-1 for individuals negative for hepatitis B and 230 (mg/kg/day)-1 for individuals positive for hepatitis B.
RP BOWERS, J (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 30
TC 8
Z9 8
U1 1
U2 3
PU PLENUM PUBL CORP
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013
SN 0272-4332
J9 RISK ANAL
JI Risk Anal.
PD DEC
PY 1993
VL 13
IS 6
BP 637
EP 642
DI 10.1111/j.1539-6924.1993.tb01325.x
PG 6
WC Public, Environmental & Occupational Health; Mathematics,
Interdisciplinary Applications; Social Sciences, Mathematical Methods
SC Public, Environmental & Occupational Health; Mathematics; Mathematical
Methods In Social Sciences
GA MN631
UT WOS:A1993MN63100005
PM 8310162
ER
PT J
AU SHAW, LM
BONNER, HS
FIELDS, L
LIEBERMAN, R
AF SHAW, LM
BONNER, HS
FIELDS, L
LIEBERMAN, R
TI THE USE OF CONCENTRATION MEASUREMENTS OF PARENT DRUG AND METABOLITES
DURING CLINICAL-TRIALS
SO THERAPEUTIC DRUG MONITORING
LA English
DT Article; Proceedings Paper
CT 3RD INTERNATIONAL CONGRESS OF THERAPEUTIC DRUG MONITORING AND CLINICAL
TOXICOLOGY
CY MAY 25-28, 1993
CL PHILADELPHIA, PA
SP INT ASSOC THERAPEUT DRUG MONITORING & CLIN TOXICOL
DE CLINICAL TRIALS; PHARMACOKINETICS; PHARMACODYNAMICS; ETHYOL;
IMMUNOSUPPRESSIVE DRUGS; CYCLOSPORINE-G; MYCOPHENOLIC ACID
ID CYCLOSPORINE; PHARMACOKINETICS; RS-61443; BLOOD
AB The need for well-designed pharmacokinetic (PK) and pharmacodynamic (PD) studies early in the development of new drugs is described. In this review we illustrate the application and cost-effectiveness of optimal sampling theory in PK study design for ongoing clinical trial studies of ethyol, a chemoprotector drug. The importance of careful selection of the appropriate biological fluid in which to measure drug concentration at the earliest possible stage of new drug development is described in the context of the development of new immunosuppressive drugs. We focus on the requirement for well-validated analytical methodology in PK-PD studies, described in a discussion of the analytical methodology in use in clinical trials of two immunosuppressive agents, cyclosporin G and RS-61443 (mycophenolate mofetil).
C1 UNIV PENN,MED CTR,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104.
US FDA,CTR DRUG EVALUAT & RES,ROCKVILLE,MD 20857.
NR 23
TC 8
Z9 8
U1 0
U2 0
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0163-4356
J9 THER DRUG MONIT
JI Ther. Drug Monit.
PD DEC
PY 1993
VL 15
IS 6
BP 483
EP 487
DI 10.1097/00007691-199312000-00005
PG 5
WC Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology
SC Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology
GA MH845
UT WOS:A1993MH84500005
PM 8122281
ER
PT J
AU LIEBERMAN, R
NELSON, R
AF LIEBERMAN, R
NELSON, R
TI DOSE-RESPONSE AND CONCENTRATION RESPONSE RELATIONSHIPS - CLINICAL AND
REGULATORY PERSPECTIVES
SO THERAPEUTIC DRUG MONITORING
LA English
DT Article; Proceedings Paper
CT 3RD INTERNATIONAL CONGRESS OF THERAPEUTIC DRUG MONITORING AND CLINICAL
TOXICOLOGY
CY MAY 25-28, 1993
CL PHILADELPHIA, PA
SP INT ASSOC THERAPEUT DRUG MONITORING & CLIN TOXICOL
DE DOSE-RESPONSE RELATIONSHIPS; CONCENTRATION; RESPONSE RELATIONSHIP;
REGULATORY PERSPECTIVES
ID LIVER
AB There are a number of effective but highly toxic drugs that exhibit a narrow therapeutic index and marked intersubject variability in pharmacokinetics (PK). Examples of these drugs include digoxin, theophylline, aminoglycosides, and anticancer (methotrexate) and immunosuppressive agents (cyclosporin A and FK-506). Optimal therapy with such drugs requires therapeutic drug monitoring (TDM) in order to safely obtain the desired clinical effects. The success of concentration-guided therapy with these drugs underscores the importance of using TDM and pharmacodynamic response (PD) to establish an appropriate balance of efficacy and toxicity through individualization of dosing. Although dose control has been the traditional paradigm for defining efficacy, safety, and dose response, it has recently been proposed that a concentration-oriented strategy of drug evaluation may facilitate the discovery of optimal doses and expedite new drug approval. However, as in medical therapeutics, the implementation of concentration-guided drug development may add to the complexity and cost. Therefore, it is important to assess the relative merits and limitations of dose-response and concentration-response (CR) strategies for establishing rational dosage information (e.g., a useful therapeutic range). Critical factors that have. an effect on the ability to characterize dose-response/concentration-response relationships in clinical trials include study design, compliance, method of analysis, and sources of pharmacologic (PK-PD) variability. In this report, we describe the state of the art, based on a selected survey of successful dose-response studies. We give an example of a promising alternative strategy for evaluating CR for an immunosuppressive drug (FK-506) based on target drug concentrations extrapolated from preclinical models.
RP LIEBERMAN, R (reprint author), US FDA,CTR DRUG EVALUAT & RES,STAFF COLL,PARKLAWN BLDG,ROOM 9B-04,ROCKVILLE,MD 20857, USA.
NR 11
TC 10
Z9 12
U1 1
U2 2
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0163-4356
J9 THER DRUG MONIT
JI Ther. Drug Monit.
PD DEC
PY 1993
VL 15
IS 6
BP 498
EP 502
DI 10.1097/00007691-199312000-00008
PG 5
WC Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology
SC Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology
GA MH845
UT WOS:A1993MH84500008
PM 8122284
ER
PT J
AU MCMICHAEL, J
LIEBERMAN, R
DOYLE, H
MCCAULEY, J
VANTHIEL, D
THOMSON, A
FUNG, J
STARZL, TE
AF MCMICHAEL, J
LIEBERMAN, R
DOYLE, H
MCCAULEY, J
VANTHIEL, D
THOMSON, A
FUNG, J
STARZL, TE
TI COMPUTER-GUIDED CONCENTRATION-CONTROLLED TRIALS IN AUTOIMMUNE DISORDERS
SO THERAPEUTIC DRUG MONITORING
LA English
DT Article; Proceedings Paper
CT 3RD INTERNATIONAL CONGRESS OF THERAPEUTIC DRUG MONITORING AND CLINICAL
TOXICOLOGY
CY MAY 25-28, 1993
CL PHILADELPHIA, PA
SP INT ASSOC THERAPEUT DRUG MONITORING & CLIN TOXICOL
DE CONCENTRATION-CONTROLLED ARTIFICIAL INTELLIGENCE; DYNAMIC DOSING;
AUTOIMMUNE DISEASES
ID FK-506
AB A randomized concentration-controlled clinical trial (RCCCT) is an alternate experimental design to the standard dose-controlled study. In a RCCCT, patients are randomly assigned to predefined plasma or blood drug concentration ranges (low, medium, and high). With the caveat that concentration ranges are sufficiently separated, this design should enhance the ability to discover important concentration response relationships. FK-506, a potent and promising immunosuppressive agent for prevention and treatment of graft rejection, has shown significant clinical activity in some immune-mediated disorders. To implement the RCCCT design, a novel FK-506 intelligent dosing system (IDS) was used to guide all doses to prospectively achieve the target concentration range specified in the study protocol. Patients enrolled in these trials suffered from a variety of autoimmune disorders, including multiple sclerosis, primary biliary cirrhosis, psoriasis, autoimmune chronic active hepatitis, and nephrotic syndrome. We observed excellent predictive performance of the IDS for all patients. The accuracy (mean prediction error) of the IDS was -0.022 ng/ml and the precision (standard deviation of the prediction error) was 0.119 ng/ml. Thus, the IDS is both accurate and reproducible for autoimmune patients. We conclude that the RCCCT design, guided by an accurate and precise IDS, is an informative and cost-effective approach for evaluation of efficacy and safety of effective but highly toxic agents.
C1 US FDA,CTR DRUG EVALUAT & RES,STAFF COLL,ROCKVILLE,MD 20857.
OKLAHOMA TRANSPLANT INST,OKLAHOMA CITY,OK.
RP MCMICHAEL, J (reprint author), UNIV PITTSBURGH,INST TRANSPLANTAT,3601 5TH AVE,5C FALK CLIN,PITTSBURGH,PA 15213, USA.
RI Fung, John/A-2679-2012
NR 4
TC 6
Z9 6
U1 0
U2 1
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0163-4356
J9 THER DRUG MONIT
JI Ther. Drug Monit.
PD DEC
PY 1993
VL 15
IS 6
BP 510
EP 513
DI 10.1097/00007691-199312000-00010
PG 4
WC Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology
SC Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology
GA MH845
UT WOS:A1993MH84500010
PM 7510078
ER
PT J
AU DHAWAN, S
WEEKS, BS
ABBASI, F
GRALNICK, HR
NOTKINS, AL
KLOTMAN, ME
YAMADA, KM
KLOTMAN, PE
AF DHAWAN, S
WEEKS, BS
ABBASI, F
GRALNICK, HR
NOTKINS, AL
KLOTMAN, ME
YAMADA, KM
KLOTMAN, PE
TI INCREASED EXPRESSION OF ALPHA-4-BETA-1 AND ALPHA-5-BETA-1 INTEGRINS ON
HTLV-1-INFECTED LYMPHOCYTES
SO VIROLOGY
LA English
DT Note
ID TROPICAL SPASTIC PARAPARESIS; T-CELL RECOGNITION; HTLV-I; ADHESION
MOLECULES; FIBRONECTIN; VIRUS; ANTIBODIES; RECEPTOR; BINDING; VLA-4
C1 NIDR,DEV BIOL LAB,BETHESDA,MD 20892.
NCI,CTR CLIN,HEMATOL SERV,BETHESDA,MD 20892.
NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892.
RP DHAWAN, S (reprint author), US FDA,MOLEC VIROL LAB,ROCKVILLE,MD 20852, USA.
RI klotman, mary/A-1921-2016
NR 32
TC 32
Z9 32
U1 1
U2 1
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0042-6822
J9 VIROLOGY
JI Virology
PD DEC
PY 1993
VL 197
IS 2
BP 778
EP 781
DI 10.1006/viro.1993.1656
PG 4
WC Virology
SC Virology
GA MH092
UT WOS:A1993MH09200032
PM 7504369
ER
PT J
AU WANG, JH
RAZZAQUE, A
AF WANG, JH
RAZZAQUE, A
TI MAPPING AND DNA-SEQUENCE ANALYSIS OF THE CYTOMEGALOVIRUS TRANSFORMING
DOMAIN-III (MTRIII)
SO VIRUS RESEARCH
LA English
DT Article
DE CYTOMEGALOVIRUS; TRANSFORMING DNA; MTRIII
ID IMMEDIATE-EARLY GENE; PROMOTER-REGULATORY REGION; EPSTEIN-BARR VIRUS;
KAPOSIS SARCOMA; STRAIN AD169; PLASMID DNA; C127 CELLS; CMV DNA;
EXPRESSION; FRAGMENTS
AB The transforming activity of XbaI fragment E (map units 0.685-0.770) of human cytomegalovirus Towne strain was originally localized in two terminal segments, 3 kb XbaI-BamHI EM (mtrII) and 7.5 kb BamHI-XbaI EJ (mtrIII). Three immediate-early genes, IE1 to IE3, are located in the same region (map unit 0.685-0.770), and IE1 is located in the EJ fragment. IE1 protein increases chromatin transcriptional activity and causes alteration in chromatin conformation. In this study, we have investigated the potential transforming activity of IE1, IE1 plus its promoter-regulatory region (IE P/R), and the remaining fragment of EJ after deletion of IE1 plus IE P/R. Our results clearly demonstrate that IE1 or IE1 plus IE P/R is not involved in transformation, and that the transforming activity of mtrIII is located in a 2.1 kb SalI-XbaI subfragment of EJ. DNA sequence analysis reveals four putative open reading frames (ORFs) Ll, L2, L3 and R1 in the 2.1 kb fragment. The data from the deletion clones of the 2.1 kb fragment and also by disruption of individual ORFs by restriction enzyme digestion, suggest that a complete ORF L3 or R1 may be essential but not sufficient for the transforming activity. Because significant reduction in transforming activity is obtained by interrupting ORFs L1 and L2, these ORFs may be required for the full transforming activity.
C1 CBER,FDA,DIV VIRAL PROD,DNA VIRUS RES LAB,8800 ROCKVILLE PIKE,BETHESDA,MD 20892.
NR 44
TC 2
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-1702
J9 VIRUS RES
JI Virus Res.
PD DEC
PY 1993
VL 30
IS 3
BP 221
EP 238
DI 10.1016/0168-1702(93)90092-2
PG 18
WC Virology
SC Virology
GA MK285
UT WOS:A1993MK28500001
PM 8109157
ER
PT J
AU NIGHTINGALE, SL
AF NIGHTINGALE, SL
TI MEDICAL DEVICE TRACKING RULE
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
RP NIGHTINGALE, SL (reprint author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.
NR 1
TC 7
Z9 7
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD NOV 17
PY 1993
VL 270
IS 19
BP 2283
EP 2283
DI 10.1001/jama.270.19.2283
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA MF993
UT WOS:A1993MF99300006
PM 8230583
ER
PT J
AU FREASLUTZ, DL
CORRELL, PH
DOUGHERTY, SF
PLUZNIK, DH
KARLSSON, S
AF FREASLUTZ, DL
CORRELL, PH
DOUGHERTY, SF
PLUZNIK, DH
KARLSSON, S
TI IDENTIFICATION OF RETROVIRAL ENHANCERS PROMOTERS FOR EFFICIENT
EXPRESSION OF HUMAN GLUCOCEREBROSIDASE IN MACROPHAGES
SO BLOOD
LA English
DT Meeting Abstract
C1 NINCDS,MOLEC & MED GENET SECT,DEV & METAB NEUROL BRANCH,BETHESDA,MD 20892.
US FDA,CTR BIOLOG EVALUAT & RES,DIV HEMATOL PROD,BETHESDA,MD 20014.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
19106-3399
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 15
PY 1993
VL 82
IS 10
SU 1
BP A32
EP A32
PG 1
WC Hematology
SC Hematology
GA MJ682
UT WOS:A1993MJ68200118
ER
PT J
AU JAIN, VK
SHIMA, T
JUDDE, JG
MAX, EE
MAGRATH, IT
AF JAIN, VK
SHIMA, T
JUDDE, JG
MAX, EE
MAGRATH, IT
TI HIGH-LEVELS OF IMMUNOGLOBULIN ENHANCER ACTIVITY IN EBV TRANSFORMED HUMAN
FETAL LIVER PRO-B CELLS MAY BE RELEVANT TO THE GENESIS OF THE
TRANSLOCATIONS SEEN IN BURKITTS-LYMPHOMA
SO BLOOD
LA English
DT Meeting Abstract
C1 NIH,PEDIAT BRANCH,BETHESDA,MD 20892.
US FDA,CBER,BETHESDA,MD 20014.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
19106-3399
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 15
PY 1993
VL 82
IS 10
SU 1
BP A189
EP A189
PG 1
WC Hematology
SC Hematology
GA MJ682
UT WOS:A1993MJ68200742
ER
PT J
AU KEVILLE, EA
ALAYASH, AI
RYAN, BAB
TERLE, DA
VOSTAL, JG
AF KEVILLE, EA
ALAYASH, AI
RYAN, BAB
TERLE, DA
VOSTAL, JG
TI POTENTIATION OF PLATELET ACTIVATION BY PURIFIED HUMAN HEMOGLOBIN
SO BLOOD
LA English
DT Meeting Abstract
C1 US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20014.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
19106-3399
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 15
PY 1993
VL 82
IS 10
SU 1
BP A606
EP A606
PG 1
WC Hematology
SC Hematology
GA MJ682
UT WOS:A1993MJ68202407
ER
PT J
AU MURGO, AJ
CONTRERA, JG
SISTARE, FD
AF MURGO, AJ
CONTRERA, JG
SISTARE, FD
TI EVIDENCE FOR SEPARATE CALCIUM SIGNALING PURINOCEPTORS FOR
ADENOSINE-DIPHOSPHATE AND URIDINE TRIPHOSPHATE IN THE DAMI HUMAN
MEGAKARYOCYTIC LEUKEMIA-CELL LINE
SO BLOOD
LA English
DT Meeting Abstract
C1 US FDA,CTR DRUG EVALUAT & RES,LAUREL,MD.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
19106-3399
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 15
PY 1993
VL 82
IS 10
SU 1
BP A72
EP A72
PG 1
WC Hematology
SC Hematology
GA MJ682
UT WOS:A1993MJ68200276
ER
PT J
AU PASTAKIA, KB
TERLE, DA
BROWNSON, NE
POINDEXTER, BJ
AF PASTAKIA, KB
TERLE, DA
BROWNSON, NE
POINDEXTER, BJ
TI AMPHOTERICIN B-INDUCED ABNORMALITIES IN HUMAN PLATELETS
SO BLOOD
LA English
DT Meeting Abstract
C1 US FDA,CTR BIOL EVALUAT & RES,DIV HEMATOL,BETHESDA,MD 20014.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
19106-3399
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 15
PY 1993
VL 82
IS 10
SU 1
BP A162
EP A162
PG 1
WC Hematology
SC Hematology
GA MJ682
UT WOS:A1993MJ68200631
ER
PT J
AU VOSTAL, JG
KEVILLE, EA
TERLE, DA
FRATANTONI, JC
AF VOSTAL, JG
KEVILLE, EA
TERLE, DA
FRATANTONI, JC
TI CAMP INHIBITS PLATELET TYROSINE PHOSPHORYLATION BY PREVENTING CYTOSOLIC
CALCIUM ELEVATION
SO BLOOD
LA English
DT Meeting Abstract
C1 US FDA,CTR BIOL RES & EVALUAT,BETHESDA,MD 20014.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
19106-3399
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 15
PY 1993
VL 82
IS 10
SU 1
BP A157
EP A157
PG 1
WC Hematology
SC Hematology
GA MJ682
UT WOS:A1993MJ68200611
ER
PT J
AU YAMAUCHI, A
BLOOM, ET
AF YAMAUCHI, A
BLOOM, ET
TI REQUIREMENT OF THIOL COMPOUNDS AS REDUCING AGENTS FOR IL-2-MEDIATED
INDUCTION OF LAK ACTIVITY AND PROLIFERATION OF HUMAN NK CELLS
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID DNA-BINDING ACTIVITY; TOXIC LYMPHOCYTES-T; CYTOLYTIC LYMPHOCYTES;
TARGET-CELL; TRANSCRIPTION FACTOR; OXIDATION-REDUCTION; REDOX
REGULATION; SERINE ESTERASE; GRANZYME-A; GLUTATHIONE
AB Thiol-related compounds, such as L-cystine, 2-ME or reduced glutathione (GSH), are important in many lymphoid cell activation pathways. We investigated their role in IL-2-generated lymphokine-activated killer (LAK) activity in human NK (CD16+ and/or CD56+) cells. Depletion of GSH and L-Cystine, but not L-leucine or glycine, from medium used during culture of NK cells with IL-2 inhibited LAK and proliferative activities, whereas IL-2-independent lytic function of NK cells remained intact. Addition of L-cysteine, 2-ME or GSH, but not methylated analogs of these compounds (which cannot function as proton donors) to L-cystine/GSH-depleted medium restored proliferative response of NK cells and LAK generation. In the presence of L-buthionine-(S,R)-sulfoximine, an inhibitor of GSH synthesis, IL-2-induced LAK activity and proliferation of NK cells in medium without L-cystine and GSH, could be restored, at least in part, by addition of GSH, but not 2-ME or L-cystine. Furthermore, intracellular GSH levels were depressed in cells cultured in L-cystine/GSH-depleted medium but could be restored by the addition of 2-ME. The results suggest that (1) L-cystine or thiol containing compounds such as L-cysteine, 2-ME, or GSH are necessary for effective IL-2-activation of human NK cells, (2) these compounds must be functional proton-donors, i.e., reducing agents, implying regulation of the IL-2 activation pathway by oxidation-reduction, and (3) GSH synthesis is necessary for the activation. Experiments were performed to begin to dissect the redox-sensitive step(s) in LAK development. Depletion of reducing agents had no effect on internalization of rIL-2. In contrast, intracellular granzyme A activity was significantly depressed in NK cells cultured with rIL-2 in L-cystine/GSH-depleted medium compared with those cultured in medium in which L-cystine levels had been replenished. The findings suggest that step(s) in the transduction of the IL-2 signal in NK cells, between the internalization of IL-2 and the maturation of the lytic mechanism, are subject to regulation by oxidation-reduction.
C1 US FDA,CBER,DCGT,HFM-518,8800 ROCKVILLE PIKE,BETHESDA,MD 20892.
NR 46
TC 49
Z9 50
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD NOV 15
PY 1993
VL 151
IS 10
BP 5535
EP 5544
PG 10
WC Immunology
SC Immunology
GA MF995
UT WOS:A1993MF99500043
PM 8228244
ER
PT J
AU DONNELLY, RP
CROFFORD, LJ
FREEMAN, SL
BURAS, J
REMMERS, E
WILDER, RL
FENTON, MJ
AF DONNELLY, RP
CROFFORD, LJ
FREEMAN, SL
BURAS, J
REMMERS, E
WILDER, RL
FENTON, MJ
TI TISSUE-SPECIFIC REGULATION OF IL-6 PRODUCTION BY IL-4 -
DIFFERENTIAL-EFFECTS OF IL-4 ON NUCLEAR FACTOR-KAPPA-B ACTIVITY IN
MONOCYTES AND FIBROBLASTS
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; HUMAN RECOMBINANT INTERLEUKIN-4;
HEPATOCYTE-STIMULATING FACTOR; GENE-EXPRESSION; ENDOTHELIAL-CELLS;
RHEUMATOID-ARTHRITIS; TRANSCRIPTION FACTOR; BLOOD MONOCYTES;
FACTOR-ALPHA; HUMAN PROINTERLEUKIN-1-BETA
AB IL-4 inhibits production of certain proinflammatory cytokines, including IL-1beta, TNF-alpha, and IL-6, by activated monocytes. Although monocytes are a major source of IL-6, other cell types such as fibroblasts and endothelial cells can also express this cytokine. To determine whether IL-4 inhibits IL-6 expression in non-hemopoietic cells, we investigated the effects of IL-4 on IL-6 production in both primary human fibroblasts and fibroblast lines. Rheumatoid synovial fibroblasts were evaluated in these studies because, like monocytes, they produce high levels of IL-6 when stimulated with IL-1. Although peripheral blood monocytes did not constitutively express IL-6 mRNA or protein, stimulation with IL-1 or LPS induced de novo IL-6 expression in these cells. In contrast, synovial fibroblasts displayed a significant basal level of IL-6 production, which was markedly increased after stimulation with IL-1. IL-4 suppressed IL-6 expression in monocytes, but did not inhibit IL-6 production in synovial fibroblasts. The inability of IL-4 to suppress IL-6 synthesis in rheumatoid synovial fibroblasts was not caused by a lack of IL-4R and was not unique to these cells because IL-4 also failed to inhibit IL-6 production in normal fibroblast lines derived from other tissues. Inhibition of IL-6 production by IL-4 in monocytes was associated with decreased nuclear NF-kappaB levels. However, IL-4 does not globally suppress the activity of all DNA-binding proteins because IL-4 treatment did not reduce the levels of NF-IL-6 or NF-IL-1betaB in the same cells. Because NF-kappaB activation is required for transcription of many cytokine genes, including IL-6, the ability of IL-4 to suppress NF-kappaB activity in monocytes suggests a potential mechanism by which this molecule may inhibit the expression of multiple cytokines.
C1 NIAMSD,ARTHRITIS & RHEUMAT BRANCH,BETHESDA,MD 20892.
BOSTON UNIV,MED CTR,DEPT MED,BOSTON,MA 02118.
BOSTON UNIV,MED CTR,EVANS MEM DEPT CLIN RES,BOSTON,MA 02118.
RP DONNELLY, RP (reprint author), US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BLDG 29A,ROOM 2B-11,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.
RI Crofford, Leslie/J-8010-2013
FU NIAID NIH HHS [AI 29088]
NR 65
TC 83
Z9 83
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD NOV 15
PY 1993
VL 151
IS 10
BP 5603
EP 5612
PG 10
WC Immunology
SC Immunology
GA MF995
UT WOS:A1993MF99500050
PM 8228249
ER
PT J
AU GRAKOUI, A
MCCOURT, DW
WYCHOWSKI, C
FEINSTONE, SM
RICE, CM
AF GRAKOUI, A
MCCOURT, DW
WYCHOWSKI, C
FEINSTONE, SM
RICE, CM
TI A 2ND HEPATITIS-C VIRUS-ENCODED PROTEINASE
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE POLYPROTEIN PROCESSING; FLAVIVIRUS; ANTIVIRAL
ID YELLOW-FEVER VIRUS; WEST NILE FLAVIVIRUS; NONSTRUCTURAL PROTEINS;
EXPRESSION; SITES; PESTIVIRUSES; POLYPROTEIN; SEQUENCES; CLEAVAGES;
DOMAIN
AB Host and viral proteinases are believed to be required for the production of at least nine hepatitis C virus (HCV)-specific polyprotein cleavage products. Although several cleavages appear to be catalyzed by host signal peptidase or the HCV NS3 serine proteinase, the enzyme responsible for cleavage at the 2/3 site has not been identified. In this report, we have defined the 2/3 cleavage site and obtained evidence which suggests that this cleavage is mediated by a second HCV-encoded proteinase, located between aa 827 and 1207. This region encompasses the C-terminal portion of the 23-kDa NS2 protein, the 2/3 cleavage site, and the serine proteinase domain of NS3. Efficient processing at the 2/3 site was observed in mammalian cells, Escherichia coli, and in plant or animal cell-free translation systems in the absence of microsomal membranes. Cleavage at the 2/3 site was abolished by alanine substitutions for NS2 residues His-952 or Cys-993 but was unaffected by several other substitution mutations, including those that inactivate NS3 serine proteinase function. Mutations abolishing cleavage at the 2/3 site did not block cleavage at other sites in the HCV polyprotein. Cotransfection experiments indicate that the 2/3 site can be cleaved in trans, which should facilitate purification and further characterization of this enzyme.
C1 WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,660 S EUCLID AVE,ST LOUIS,MO 63110.
WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110.
US FDA,CTR EVALUAT & BIOL RES,DIV VIROL,BETHESDA,MD 20014.
FU NCI NIH HHS [CA57973]
NR 29
TC 335
Z9 345
U1 0
U2 4
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 15
PY 1993
VL 90
IS 22
BP 10583
EP 10587
DI 10.1073/pnas.90.22.10583
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MH322
UT WOS:A1993MH32200036
PM 8248148
ER
PT J
AU SCALLET, AC
BINIENDA, Z
CAPUTO, FA
HALL, S
PAULE, MG
ROUNTREE, RL
SCHMUED, L
SOBOTKA, T
SLIKKER, W
AF SCALLET, AC
BINIENDA, Z
CAPUTO, FA
HALL, S
PAULE, MG
ROUNTREE, RL
SCHMUED, L
SOBOTKA, T
SLIKKER, W
TI DOMOIC ACID-TREATED CYNOMOLGUS MONKEYS (MACACA-FASCICULARIS) - EFFECTS
OF DOSE ON HIPPOCAMPAL NEURONAL AND TERMINAL DEGENERATION
SO BRAIN RESEARCH
LA English
DT Article
DE EXCITOTOXIN; KAINIC ACID; IMMUNOHISTOCHEMISTRY; FINK-HEIMER (SILVER)
DEGENERATION; C-FOS; GFAP; SEAFOOD; EMESIS
ID SUSTAINED ELECTRICAL-STIMULATION; EPILEPTIC BRAIN-DAMAGE; KAINIC ACID;
MACACA-FASCICULARIS; FOS EXPRESSION; PERFORANT PATH; RATS; PATTERNS;
MICE; NEUROTOXICITY
AB Domoic acid is a tricarboxylic amino acid (structurally related to kainic acid and glutamic acid) that is found in the environment as a contaminant of some seafood. To determine the nature of any neurological damage caused by domoate, as well as the minimum neurotoxic dose, juvenile and adult monkeys were dosed intravenously with domoate at one of a range of doses from 0.25 to 4 mg/kg. When animals were perfused one week later, histochemical staining using a silver method to reveal degenerating axons and cell bodies showed two distinct types of hippocampal lesions. One lesion, termed 'Type A', was a small focal area of silver grains restricted to CA2 stratum lucidum, the site of greatest kainic acid receptor concentration in the brain. Type A lesions occurred over a dose range of 0.5 to 2.0 mg/kg in juvenile animals and 0.5 to 1.0 mg/kg in adult animals. No mortality occurred in any of the juvenile monkeys, but one juvenile animal that received 4.0 mg/kg sustained a second type of lesion, termed 'Type B', characterized by widespread damage to pyramidal neurons and axon terminals of CA4, CA3, CA2, CA1, and subiculum subfields of the hippocampus. Doses of more than 1.0 mg/kg in the adult monkeys either proved lethal or resulted in Type B lesions. Induction of c-fos protein had occurred in the hippocampal dentate gyrus and CA1 regions of moribund animals perfused within hours of their initial dose. Our results show that relatively low doses of domoic acid selectively effect mossy fiber terminals, that larger (near lethal) doses damage hippocampal pyramidal neurons and their axons, that some moribund monkeys had experienced limbic seizures prior to death, and that adult animals are more sensitive to domoic acid than juveniles.
C1 US FDA,CTR FOOD SAFETY & NUTR,WASHINGTON,DC 20204.
RP SCALLET, AC (reprint author), US FDA,NATL CTR TOXICOL RES,DIV NEUROTOXICOL,HFT-132,3900 NCTR DR,JEFFERSON,AR 72079, USA.
NR 31
TC 55
Z9 58
U1 2
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
J9 BRAIN RES
JI Brain Res.
PD NOV 12
PY 1993
VL 627
IS 2
BP 307
EP 313
DI 10.1016/0006-8993(93)90335-K
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA ME690
UT WOS:A1993ME69000018
PM 8298975
ER
PT J
AU ARAKI, T
KENIMER, JG
NISHIMUNE, A
SUGIYAMA, H
YOSHIMURA, R
KIYAMA, H
AF ARAKI, T
KENIMER, JG
NISHIMUNE, A
SUGIYAMA, H
YOSHIMURA, R
KIYAMA, H
TI IDENTIFICATION OF THE METABOTROPIC GLUTAMATE RECEPTOR-1 PROTEIN IN THE
RAT TRIGEMINAL GANGLION
SO BRAIN RESEARCH
LA English
DT Note
DE MGLUR1; SOMATIC SENSATION; MONOCLONAL ANTIBODY; IMMUNOBLOTTING;
IMMUNOHISTOCHEMISTRY; TRIGEMINAL GANGLION
ID AMINO-ACID RECEPTORS; DORSAL HORN; SIGNAL TRANSDUCTION; EXPRESSION;
NEURONS; FAMILY; GENES; BRAIN
AB Anti-metabotropic glutamate receptor-1 monoclonal antibody was raised and applied for immunohistochemistry in the rat trigeminal ganglion. The antibody detected 145-kDa single band of protein in the immunoblot analysis. In immunohistochemistry, neurons in the trigeminal ganglion showed immunostaining with various intensity, almost irrespective of their cell size. The results indicate that metabotropic glutamate receptors play an important role in somatic sensation together with ionotropic ones.
C1 OSAKA UNIV,SCH MED,DEPT NEUROANAT,BIOMED RES CTR,SUITA,OSAKA 565,JAPAN.
US FDA,CELLULAR PHYSIOL LAB,BETHESDA,MD 20892.
KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN.
RP ARAKI, T (reprint author), OSAKA UNIV,SCH MED,DEPT ANAT & NEUROSCI,2-2 YAMADOAKA,SUITA,OSAKA 565,JAPAN.
RI Kiyama, Hiroshi/M-8867-2014;
OI Kiyama, Hiroshi/0000-0001-5963-046X; Araki,
Toshiyuki/0000-0003-3625-2042
NR 34
TC 10
Z9 10
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
J9 BRAIN RES
JI Brain Res.
PD NOV 12
PY 1993
VL 627
IS 2
BP 341
EP 344
DI 10.1016/0006-8993(93)90339-O
PG 4
WC Neurosciences
SC Neurosciences & Neurology
GA ME690
UT WOS:A1993ME69000022
PM 8298977
ER
PT J
AU BEAUCAGE, SL
IYER, RP
AF BEAUCAGE, SL
IYER, RP
TI THE SYNTHESIS OF SPECIFIC RIBONUCLEOTIDES AND UNRELATED PHOSPHORYLATED
BIOMOLECULES BY THE PHOSPHORAMIDITE METHOD
SO TETRAHEDRON
LA English
DT Review
ID D-MYO-INOSITOL; SOLID-PHASE SYNTHESIS; CASEIN-RELATED PEPTIDES;
PHOSPHITE-TRIESTER PHOSPHORYLATION; TERT-BUTYL
N,N-DIETHYLPHOSPHORAMIDITE; INFLUENZAE TYPE-B; SERINE-CONTAINING
PEPTIDES; MYOINOSITOL 1,4,5-TRISPHOSPHATE ANALOGS;
PHOSPHOTYROSINE-CONTAINING PEPTIDES; PHOSPHOSERYL-CONTAINING PEPTIDES
RP US FDA, CTR BIOL EVALUAT & RES, DIV HEMATOL PROD, BETHESDA, MD 20892 USA.
NR 267
TC 74
Z9 74
U1 1
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0040-4020
J9 TETRAHEDRON
JI Tetrahedron
PD NOV 12
PY 1993
VL 49
IS 46
BP 10441
EP 10488
DI 10.1016/S0040-4020(01)81543-X
PG 48
WC Chemistry, Organic
SC Chemistry
GA MG235
UT WOS:A1993MG23500002
ER
PT J
AU KESSLER, DA
AF KESSLER, DA
TI POSTMARKETING SURVEILLANCE - BEYOND MEDWATCH - REPLY
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
RP KESSLER, DA (reprint author), US FDA,ROCKVILLE,MD 20857, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD NOV 10
PY 1993
VL 270
IS 18
BP 2180
EP 2180
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA ME816
UT WOS:A1993ME81600023
ER
PT J
AU NIGHTINGALE, SL
AF NIGHTINGALE, SL
TI METERED-DOSE INHALERS - DRUG-DELIVERY OVER THE LIFE OF A CANISTER -
REPLY
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
RP NIGHTINGALE, SL (reprint author), US FDA,ROCKVILLE,MD 20857, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD NOV 3
PY 1993
VL 270
IS 17
BP 2051
EP 2051
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA MD882
UT WOS:A1993MD88200012
ER
PT J
AU BIRX, DL
LEWIS, MG
VAHEY, M
TENCER, K
ZACK, PM
BROWN, CR
JAHRLING, PB
TOSATO, G
BURKE, D
REDFIELD, R
AF BIRX, DL
LEWIS, MG
VAHEY, M
TENCER, K
ZACK, PM
BROWN, CR
JAHRLING, PB
TOSATO, G
BURKE, D
REDFIELD, R
TI ASSOCIATION OF INTERLEUKIN-6 IN THE PATHOGENESIS OF ACUTELY FATAL
SIV(SMM/PBJ-14) IN PIGTAILED MACAQUES
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR NECROSIS FACTOR; LONG TERMINAL
REPEATS; GENE-EXPRESSION; TRANSCRIPTION FACTOR; SOOTY MANGABEYS;
GROWTH-FACTOR; FACTOR-ALPHA; T-CELLS; INFECTION
AB Infection with a variant of simian immunodeficiency virus (SIVsmm/PBj-14) causes death in juvenile pigtailed macaques awithin 8 days of infection. The primary pathology is localized to the lymphoid tissues of the gut and spleen. Although the virus is present, the lesions are most consistent with acute reactive inflammation. We studied the serum and tissues for evidence of acute cytokine production often associated with acute inflammation. One factor, IL-6, was found to be significantly increased (>1000-fold) over all other measured cytokines in all the pigtailed macaques who died acutely. Increased levels of IL-6 were found both in the serum and in the inflamed tissues. mRNA for IL-6 was found in the tissues with the highest protein levels of IL-6. The marked increase in IL-6 and IL-6 mRNA correlated with the virus levels in the tissues and serum as determined by viral isolation, immunohistochemistry, and Northern blot analysis. These findings suggest that the underlying pathogenesis of primary tissue damage, necrosis, and death by PBj-14 is the induction of cytokine production. Although the presence of the virus may be critical for the initiation of these events, the intense inflammatory reaction is associated with the cause of death.
C1 HENRY M JACKSON FDN ADVANCEMENT MIL MED,ROCKVILLE,MD 20850.
WRAIR,DIV RETROVIROL,ROCKVILLE,MD 20850.
USA,MED RES INST INFECT DIS,DEPT PATHOL,FREDERICK,MD 21702.
USA,MED RES INST INFECT DIS,DIV DIS ASSESSMENT,FREDERICK,MD 21702.
US FDA,CTR BIOL EVALUAT & RES,IMMUNOL LAB,BETHESDA,MD.
RP BIRX, DL (reprint author), WALTER REED ARMY INST RES,DEPT RETROVIRAL RES,13 TAFT COURT,ROCKVILLE,MD 20850, USA.
OI /0000-0002-5704-8094
FU NIAID NIH HHS [NIAID 1U01A125619-01]
NR 34
TC 26
Z9 26
U1 0
U2 0
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV
PY 1993
VL 9
IS 11
BP 1123
EP 1129
DI 10.1089/aid.1993.9.1123
PG 7
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA MK130
UT WOS:A1993MK13000011
PM 8312054
ER
PT J
AU KIM, I
YETLEY, EA
CALVO, MS
AF KIM, I
YETLEY, EA
CALVO, MS
TI VARIATIONS IN IRON-STATUS MEASURES DURING THE MENSTRUAL-CYCLE
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE IRON; HEMOGLOBIN; MENSTRUATION; FERRITIN; TRANSFERRIN SATURATION;
NHANES-II
ID PROGESTERONE; DEFICIENCY
AB To determine whether normal physiologic changes associated with hormone fluctuations over the menstrual cycle affect concentrations of iron-status indicators, we examined data from 1712 women aged 18-44 y from the Second National Health and Nutrition Examination Survey (NHANES II) after adjusting for potential confounders. Adjusted mean values of hemoglobin (Hb), transferrin saturation (TS), and serum ferritin (SF) were lowest for women whose blood was drawn during menses and highest for women examined in luteal or late luteal phase of the menstrual cycle (Hb = 130 vs 133 g/L; TS = 21.2% vs 24.8%, P < 0.01 for both; and SF = 17.2 vs 24.0 mug/L, P < 0.05). The prevalence estimate of impaired iron status was significantly higher for women whose blood was drawn during the menstrual phase than for women whose blood was drawn during the luteal and late luteal phases. Our findings suggest that the phases of the menstrual cycle affect the concentration or values of iron-status indicators. These cyclic variations in indicators of iron status are a potential source of error when iron status is assessed in large population surveys that include women of reproductive age.
C1 CTR DIS CONTROL & PREVENT,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,PUBL HLTH PRACTICE STAFF,ATLANTA,GA.
US FDA,CTR FOOD SAFETY & APPL NUTR,OFF PREMARKET APPROVAL,WASHINGTON,DC 20204.
US FDA,CTR FOOD SAFETY & APPL NUTR,OFF SPECIAL NUTR,WASHINGTON,DC 20204.
NR 33
TC 38
Z9 40
U1 1
U2 2
PU AMER SOC CLINICAL NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-2310, BETHESDA, MD 20814-3998
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD NOV
PY 1993
VL 58
IS 5
BP 705
EP 709
PG 5
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA ME259
UT WOS:A1993ME25900020
PM 8237879
ER
PT J
AU PARK, YMK
YETLEY, EA
AF PARK, YMK
YETLEY, EA
TI INTAKES AND FOOD SOURCES OF FRUCTOSE IN THE UNITED-STATES
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE FRUCTOSE INTAKE; FOOD SOURCES OF FRUCTOSE; FRUCTOSE AVAILABILITY;
GLUCOSE-FRUCTOSE RATIO
ID ENERGY-INTAKE; DIETARY; CHILDREN
AB Examination of the per capita disappearance data for sweeteners and other sources of fructose showed that during the past two decades there was a considerable increase in the availability of free fructose in the food supply. However, the availability of the total amount of fructose, which includes both free and bound fructose, has remained relatively constant. Estimates of the average daily intake of fructose, based on the 1977-78 USDA Nationwide Food Consumption Survey, ranged from 15 g for infants to 54 g for males aged 15-18 y with a mean of 37 g for the total population. These values represent 7-9% of the energy intake (8% for the total population). For most sex/age groups nonalcoholic beverages (eg, soft drinks and fruit-flavored drinks) and grain products (eg, sweet bakery products) were the major sources of fructose; fruits and fruit products were the major sources of naturally occurring fructose; nonalcoholic beverages were the major sources of added fructose.
RP US FDA, OFF SPECIAL NUTR, HFS-465, 200 C ST SW, WASHINGTON, DC 20204 USA.
NR 31
TC 17
Z9 17
U1 1
U2 4
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD NOV
PY 1993
VL 58
IS 5
SU S
BP 737
EP 747
PG 11
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA MF185
UT WOS:A1993MF18500004
ER
PT J
AU MERKATZ, R
AF MERKATZ, R
TI PROGRESS NOTES ON WOMENS HEALTH
SO AMERICAN JOURNAL OF NURSING
LA English
DT Article
RP MERKATZ, R (reprint author), US FDA,ROCKVILLE,MD 20857, USA.
NR 10
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0002-936X
J9 AM J NURS
JI Am. J. Nurs.
PD NOV
PY 1993
VL 93
IS 11
BP 75
EP &
PG 0
WC Nursing
SC Nursing
GA MF661
UT WOS:A1993MF66100026
ER
PT J
AU FOULKES, MA
DEYTON, LR
ELLENBERG, SS
AF FOULKES, MA
DEYTON, LR
ELLENBERG, SS
TI COMMUNITY-BASED HIV TRIALS ARE RIGOROUS, SAYS NIH
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Letter
C1 US FDA,ROCKVILLE,MD.
RP FOULKES, MA (reprint author), NIAID,BETHESDA,MD 20892, USA.
NR 4
TC 0
Z9 0
U1 0
U2 0
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572
SN 0003-4819
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD NOV 1
PY 1993
VL 119
IS 9
BP 956
EP 957
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA MD711
UT WOS:A1993MD71100027
PM 8215014
ER
PT J
AU HONIG, PK
SEVKA, MJ
AF HONIG, PK
SEVKA, MJ
TI VENTRICULAR-FIBRILLATION AND ANOXIC ENCEPHALOPATHY SECONDARY TO
ASTEMIZOLE OVERDOSE - COMMENT
SO ANNALS OF PHARMACOTHERAPY
LA English
DT Letter
RP HONIG, PK (reprint author), US FDA,CTR DRUG EVALUAT & RES,DIV PULM & ONCOL DRUG PROD,ROCKVILLE,MD 20857, USA.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU HARVEY WHITNEY BOOKS CO
PI CINCINNATI
PA PO BOX 42696, CINCINNATI, OH 45242
SN 1060-0280
J9 ANN PHARMACOTHER
JI Ann. Pharmacother.
PD NOV
PY 1993
VL 27
IS 11
BP 1407
EP 1407
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MG743
UT WOS:A1993MG74300026
PM 8286824
ER
PT J
AU MICELI, GA
WATKINS, WD
RIPPEY, SR
AF MICELI, GA
WATKINS, WD
RIPPEY, SR
TI DIRECT PLATING PROCEDURE FOR ENUMERATING VIBRIO-VULNIFICUS IN OYSTERS
(CRASSOSTREA-VIRGINICA)
SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY
LA English
DT Article
ID CYTOTOXIN-HEMOLYSIN GENE; MARINE VIBRIO; ENVIRONMENT; AGAR;
IDENTIFICATION; VIRULENCE; CHOLERAE
AB A procedure for enumerating and identifying Vibrio vulnificus in oysters was developed and evaluated. This method consists of growth on a direct plating medium (VVE medium) for isolating the organism from shellfish tissues, followed by biochemical tests for differentiating and identifying presumptively positive isolates. Densities of V. vulnificus are reliably obtained in 2 to 4 days, and as few as 10 culturable cells per 100 g can be identified. The procedure was evaluated by using a DNA probe technique specific for the cytotoxin-hemolysin gene of V. vulnificus and gas chromatographic analysis of the fatty acid contents of positive isolates. Only 3.2 and 0.4% of the isolates gave false-positive and false-negative results, respectively. The average level of recovery on WE medium for 33 strains, including both clinical and environmental isolates, was 92% of the level of recovery obtained with brain heart infusion agar supplemented with 1% NaCl. The densities of V. vulniificus in oyster homogenates and individual oysters harvested from gulf and Atlantic coastal waters revealed that seasonally high levels occurred. The WE medium procedure facilitated enumeration of this pathogen in molluscan shellfish and had a distinct advantage over the widely used most-probable-number procedure for V. vulnificus enumeration, which requires 5 to 7 days and often gives improbable and imprecise results.
C1 US FDA,NE TECH SERV UNIT,N KINGSTOWN,RI 02852.
UNIV RHODE ISL,DEPT MICROBIOL,KINGSTON,RI 02881.
NR 28
TC 21
Z9 21
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0099-2240
J9 APPL ENVIRON MICROB
JI Appl. Environ. Microbiol.
PD NOV
PY 1993
VL 59
IS 11
BP 3519
EP 3524
PG 6
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA ME660
UT WOS:A1993ME66000001
PM 8285658
ER
PT J
AU MILLER, HI
HUTTNER, SL
BEACHY, R
AF MILLER, HI
HUTTNER, SL
BEACHY, R
TI RISK ASSESSMENT EXPERIMENTS FOR GENETICALLY-MODIFIED PLANTS
SO BIO-TECHNOLOGY
LA English
DT Article
C1 SCRIPPS RES INST, DIV PLANT BIOL, LA JOLLA, CA 92037 USA.
UNIV CALIF LOS ANGELES, SYST WIDE BIOTECHNOL RES & EDUC PROGRAM, LOS ANGELES, CA 90024 USA.
RP MILLER, HI (reprint author), US FDA, OFF BIOTECHNOL, ROOM 15-61, 5600 FISHERS LANE, ROCKVILLE, MD 20816 USA.
NR 11
TC 6
Z9 7
U1 0
U2 3
PU NATURE PUBLISHING CO
PI NEW YORK
PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707
SN 0733-222X
J9 BIO-TECHNOL
JI Bio-Technology
PD NOV
PY 1993
VL 11
IS 11
BP 1323
EP 1324
PG 2
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA MF872
UT WOS:A1993MF87200033
ER
PT J
AU TELLO, D
GOLDBAUM, FA
MARIUZZA, RA
YSERN, X
SCHWARZ, FP
POLJAK, RJ
AF TELLO, D
GOLDBAUM, FA
MARIUZZA, RA
YSERN, X
SCHWARZ, FP
POLJAK, RJ
TI 3-DIMENSIONAL STRUCTURE AND THERMODYNAMICS OF ANTIGEN-BINDING BY
ANTILYSOZYME ANTIBODIES
SO BIOCHEMICAL SOCIETY TRANSACTIONS
LA English
DT Article; Proceedings Paper
CT 647th Meeting of the Biochemical-Society
CY JUL 20-23, 1993
CL UNIV SHEFFIELD, SHEFFIELD, UNITED KINGDOM
SP BIOCHEM SOC
HO UNIV SHEFFIELD
ID PROTEIN-PROTEIN RECOGNITION; MONOCLONAL-ANTIBODY; FAB FRAGMENTS;
COMPLEX; RESOLUTION; D1.3; FV
C1 NATL INST STAND & TECHNOL,ROCKVILLE,MD 20850.
UNIV MARYLAND,INST BIOTECHNOL,CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20850.
US FDA,CTR DRUG EVALUAT & RES,ROCKVILLE,MD 20857.
RP TELLO, D (reprint author), INST PASTEUR,F-75724 PARIS 15,FRANCE.
NR 21
TC 52
Z9 53
U1 0
U2 0
PU PORTLAND PRESS
PI LONDON
PA 59 PORTLAND PLACE, LONDON, ENGLAND W1N 3AJ
SN 0300-5127
J9 BIOCHEM SOC T
JI Biochem. Soc. Trans.
PD NOV
PY 1993
VL 21
IS 4
BP 943
EP 946
PG 4
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA MN412
UT WOS:A1993MN41200029
PM 8132099
ER
PT J
AU DOERGE, DR
CLAYTON, J
FU, PP
WOLFE, DA
AF DOERGE, DR
CLAYTON, J
FU, PP
WOLFE, DA
TI ANALYSIS OF POLYCYCLIC AROMATIC-HYDROCARBONS USING LIQUID-CHROMATOGRAPHY
PARTICLE-BEAM MASS-SPECTROMETRY
SO BIOLOGICAL MASS SPECTROMETRY
LA English
DT Article
ID ISOTOPE-DILUTION; INTERFACE
AB Methods employing liquid chromatography with particle beam mass spectrometric (LC/PBMS) detection were developed to detect and quantify polycyclic aromatic hydrocarbons (PAH) and oxygenated metabolites in sediment and water samples from the Exxon Valdez oil spill in Alaska. PAH containing four or more rings and selected hydroxy and dione derivatives gave nanogram detection limits. The mass spectra from PAH were identical to those in a standard electron impact library and underivatized oxygenated PAH spectra consisted of molecular and diagnostic fragment ions. Sensitivity for PBMS detection was inversely correlated with PAH volatility, suggesting that losses of the more volatile PAH occur through the momentum separator interface. These results suggest that LC/PBMS is a useful companion technique to GC/MS for the analysis of PAH and environmental metabolites, especially for higher-molecular-weight congeners.
C1 SCI APPLICAT INT CORP,SAN DIEGO,CA 92121.
NOAA,ROCKVILLE,MD 20852.
RP DOERGE, DR (reprint author), NATL CTR TOXICOL RES,JEFFERSON,AR 72079, USA.
NR 32
TC 13
Z9 14
U1 0
U2 2
PU JOHN WILEY & SONS LTD
PI W SUSSEX
PA BAFFINS LANE CHICHESTER, W SUSSEX, ENGLAND PO19 1UD
SN 1052-9306
J9 BIOL MASS SPECTROM
JI Biol. Mass Spectrom.
PD NOV
PY 1993
VL 22
IS 11
BP 654
EP 660
DI 10.1002/bms.1200221106
PG 7
WC Biophysics; Spectroscopy
SC Biophysics; Spectroscopy
GA ME268
UT WOS:A1993ME26800005
ER
PT J
AU RUHL, S
FELDMAN, GM
AKAHANE, K
PLUZNIK, DH
AF RUHL, S
FELDMAN, GM
AKAHANE, K
PLUZNIK, DH
TI INTERFERON-GAMMA ANTAGONIZES INTERLEUKIN-6-INDUCED EXPRESSION OF
INTERLEUKIN-4 RECEPTORS IN MURINE MYELOID CELLS BY A TRANSCRIPTIONAL
MECHANISM
SO BLOOD
LA English
DT Article
ID HEMATOPOIETIC PROGENITOR CELLS; STIMULATORY FACTOR-I; COLONY FORMATION;
LEUKEMIC-CELLS; IL-4 RECEPTOR; IFN-GAMMA; MOLECULAR-CLONING; IMMUNE
INTERFERON; RECOMBINANT HUMAN; GENE-EXPRESSION
C1 US FDA,CTR BIOL EVALUAT & RES,DIV HEMATOL PROD,BLDG 29A,ROOM 3B-19,8800 ROCKVILLE PIKE,BETHESDA,MD 20892.
US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20014.
NR 57
TC 4
Z9 4
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
19106-3399
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 1
PY 1993
VL 82
IS 9
BP 2641
EP 2648
PG 8
WC Hematology
SC Hematology
GA ME657
UT WOS:A1993ME65700007
PM 8219219
ER
PT J
AU AZIZ, KJ
MAXIM, PE
AF AZIZ, KJ
MAXIM, PE
TI THE FDAS PERSPECTIVE ON THE EVALUATION OF TUMOR-MARKER TESTS
SO CLINICAL CHEMISTRY
LA English
DT Article; Proceedings Paper
CT 16TH ANNUAL ARNOLD O BECKMAN CONF IN CLINICAL CHEMISTRY : CLINICAL
LABORATORY TESTING IN CANCER PATIENT DIAGNOSIS AND MANAGEMENT
CY FEB 07-08, 1993
CL LAKE BUENA VISTA, FL
SP ARNOLD & MABEL BECKMAN FDN
DE GOVERNMENT REGULATION OF MEDICAL DEVICES
AB Cancer marker tests are often proposed for three intended uses: screening, diagnosis, and monitoring. For each intended use, performance characteristics need to be well defined. The utility of a marker in a given setting depends heavily on two predominant performance characteristics-sensitivity and specificity. These parameters must be established with respect to the intended clinical use of the marker. The value of the marker in a particular situation also depends on the effectiveness of therapy for the malignancy. In reviewing a cancer marker test, the US Food and Drug Administration focuses on both the proposed intended use statement and the clinical utility of the marker. The sponsor is expected to provide specific claims data in support of the safety and effectiveness of the device through well-designed and -executed clinical studies. Several cancer markers are already available. In the future, new markers are anticipated that may greatly expand the range of usefulness in cancer diagnosis screening and monitoring.
C1 US FDA,CTR DEVICES & RADIOL HLTH,OFF DEVICE EVALUAT,DIV CLIN LAB DEVICES,IMMUNOL BRANCH,ROCKVILLE,MD 20850.
US FDA,CTR DEVICES & RADIOL HLTH,OFF DEVICE EVALUAT,DIV CLIN LAB DEVICES,TOXICOL BRANCH,ROCKVILLE,MD 20850.
RP AZIZ, KJ (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,OFF DEVICE EVALUAT,DIV CLIN LAB DEVICES,CLIN CHEM BRANCH,ROCKVILLE,MD 20850, USA.
NR 6
TC 13
Z9 13
U1 0
U2 0
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526
SN 0009-9147
J9 CLIN CHEM
JI Clin. Chem.
PD NOV
PY 1993
VL 39
IS 11B
BP 2439
EP 2443
PN 2
PG 5
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA MF589
UT WOS:A1993MF58900011
PM 8222256
ER
PT J
AU BREUNINGER, LM
DEMPSEY, WL
UHL, J
MURASKO, DM
AF BREUNINGER, LM
DEMPSEY, WL
UHL, J
MURASKO, DM
TI HYDROCORTISONE REGULATION OF INTERLEUKIN-6 PROTEIN-PRODUCTION BY A
PURIFIED POPULATION OF HUMAN PERIPHERAL-BLOOD MONOCYTES
SO CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; HEPATOCYTE-STIMULATING FACTOR; HYBRIDOMA
GROWTH-FACTOR; IL-6 MESSENGER-RNA; LIPOPOLYSACCHARIDE LPS;
RHEUMATOID-ARTHRITIS; MONONUCLEAR-CELLS; ENDOTHELIAL-CELLS; MULTIPLE
FORMS; FACTOR-ALPHA
C1 US FDA,DIV ANTIVIRAL DRUG PROD,ROCKVILLE,MD 20857.
STERLING WINTHROP,DEPT INFLAMMAT,RENSSELAR,NY 12144.
RP BREUNINGER, LM (reprint author), MED COLL PENN,DEPT MICROBIOL & IMMUNOL,2900 QUEEN LANE,PHILADELPHIA,PA 19129, USA.
FU NIA NIH HHS [AG03934]; NIMH NIH HHS [MH19129]; PHS HHS [R
N00014-87-0386]
NR 54
TC 46
Z9 49
U1 0
U2 1
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0090-1229
J9 CLIN IMMUNOL IMMUNOP
JI Clin. Immunol. Immunopathol.
PD NOV
PY 1993
VL 69
IS 2
BP 205
EP 214
DI 10.1006/clin.1993.1171
PG 10
WC Immunology; Pathology
SC Immunology; Pathology
GA MC285
UT WOS:A1993MC28500012
PM 8403558
ER
PT J
AU BELL, WL
CRAWFORD, IL
SHIU, GK
AF BELL, WL
CRAWFORD, IL
SHIU, GK
TI REDUCED BIOAVAILABILITY OF MOISTURE-EXPOSED CARBAMAZEPINE RESULTING IN
STATUS EPILEPTICUS
SO EPILEPSIA
LA English
DT Article
DE CARBAMAZEPINE; BIOAVAILABILITY; STATUS EPILEPTICUS; HUMIDITY; DRUG
TOXICITY
ID INVITRO
AB A 28-year-old man with seizures well controlled with carbamazepine (CBZ) and valproate (VPA) developed generalized convulsive status epilepticus three days after his CBZ tablets became wet during a rainstorm while he was camping out. He continued the CBZ but avoided ingesting obviously disintegrating tablets. The VPA was not exposed to excessive moisture. Previous random CBZ blood levels had been in the range of 9-13 mu g/ml; at the time of admission to the emergency room the level had decreased to 3.8 mu g/ml. The VPA level did not change significantly from baseline. The moisture-exposed CBZ tablets were of expected weight but were swollen and enlarged. Analysis of these tablets by USP paddle method 2 demonstrated a mean dissolution of 16% at 60 min as compared with >80% for fresh CBZ tablets. After final dissolution of the moisture-exposed CBZ tablets, normal quantities of active drug were noted. We propose that poor dissolution of moisture-exposed CBZ tablets results in reduced bioavailability. We urge caution in the packaging and storage of CBZ to avoid exposure to moisture.
C1 UNIV TEXAS,SW MED CTR,DEPT NEUROL,DALLAS,TX.
US FDA,BIOPHARMACEUT RES BRANCH,WASHINGTON,DC 20204.
NR 9
TC 10
Z9 10
U1 0
U2 1
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0013-9580
J9 EPILEPSIA
JI Epilepsia
PD NOV-DEC
PY 1993
VL 34
IS 6
BP 1102
EP 1104
DI 10.1111/j.1528-1157.1993.tb02140.x
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA MM460
UT WOS:A1993MM46000020
PM 8243363
ER
PT J
AU BEGLEY, TH
HOLLIFIELD, HC
AF BEGLEY, TH
HOLLIFIELD, HC
TI RECYCLED POLYMERS IN FOOD-PACKAGING - MIGRATION CONSIDERATIONS
SO FOOD TECHNOLOGY
LA English
DT Article
RP BEGLEY, TH (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 6
TC 40
Z9 40
U1 1
U2 6
PU INST FOOD TECHNOLOGISTS
PI CHICAGO
PA SUITE 300 221 N LASALLE ST, CHICAGO, IL 60601-1291
SN 0015-6639
J9 FOOD TECHNOL-CHICAGO
JI Food Technol.
PD NOV
PY 1993
VL 47
IS 11
BP 109
EP 112
PG 4
WC Food Science & Technology
SC Food Science & Technology
GA MG821
UT WOS:A1993MG82100016
ER
PT J
AU WAMER, WG
RONG, W
TIMMER, WC
KORNHAUSER, A
AF WAMER, WG
RONG, W
TIMMER, WC
KORNHAUSER, A
TI OXIDATIVE DAMAGE TO DNA IN PSORALEN PHOTOSENSITIZED CYTOTOXICITY
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Meeting Abstract
C1 US FDA,CTR FOOD SAFETY & APPL NUTR,WASHINGTON,DC 20204.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0891-5849
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD NOV
PY 1993
VL 15
IS 5
BP 529
EP 529
DI 10.1016/0891-5849(93)90404-I
PG 1
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA MD267
UT WOS:A1993MD26700220
ER
PT J
AU URANO, T
TRUCKSESS, MW
PAGE, SW
AF URANO, T
TRUCKSESS, MW
PAGE, SW
TI AUTOMATED AFFINITY LIQUID-CHROMATOGRAPHY SYSTEM FOR ONLINE ISOLATION,
SEPARATION, AND QUANTITATION OF AFLATOXINS IN METHANOL-WATER EXTRACTS OF
CORN OR PEANUTS
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
ID POST-COLUMN DERIVATIZATION; SAMPLE CLEANUP; ANIMAL FEEDS; FOODS
AB An automated liquid chromatography (LC) procedure has been developed for the determination of aflatoxins in corn and peanuts. The automated LC system consists of the following: two pumps, an autosampler, an isolation column (immunoaffinity or methacrylate copolymer), an automated switching valve, a C18 column, an electrochemical cell, a fluorescence detector, and a data system. Filtered methanol: water (75:25) extracts of the test portions are injected into the LC system. With the switch in position 1, water is pumped through the autosampler and isolation column and then discarded. With the switch in position 2, the mobile phase consisting of methanol:acetonitrile:water (26:18:56), 1 mM KBr, and 1 mM HNO3 is pumped through the isolation column, C18 column, electrochemical cell, and detector. Aflatoxins B1 and G1 react with electrochemically generated bromine to form fluorescent derivatives. Both isolation columns can be used for >50 injections. Recovery of aflatoxins from both commodities spiked at 5-30 ng/g was about 85%.
C1 US FDA,CTR FOOD SAFETY & APPL NUTR,DIV NAT PROD,WASHINGTON,DC 20204.
NR 13
TC 8
Z9 8
U1 1
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0021-8561
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD NOV
PY 1993
VL 41
IS 11
BP 1982
EP 1985
DI 10.1021/jf00035a031
PG 4
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
Technology
SC Agriculture; Chemistry; Food Science & Technology
GA MH755
UT WOS:A1993MH75500031
ER
PT J
AU MOSSOBA, MM
MCDONALD, RE
PROSSER, AR
AF MOSSOBA, MM
MCDONALD, RE
PROSSER, AR
TI GAS-CHROMATOGRAPHIC MATRIX-ISOLATION FOURIER-TRANSFORM INFRARED
SPECTROSCOPIC DETERMINATION OF TRANS-MONOUNSATURATED AND SATURATED
FATTY-ACID METHYL-ESTERS IN PARTIALLY HYDROGENATED MENHADEN OIL
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
ID CHOLESTEROL LEVELS; GC-FTIR; SPECTROMETRY; IDENTIFICATION; QUANTITATION
AB Elaidic acid (t-18:1) has been the focus of a literature debate about its effect on blood cholesterol levels. A method is presented that can accurately quantify the level of t-18:1, a single geometric isomer, in hydrogenated menhaden oil. Fatty acid methyl esters (FAMEs) were determined by Fourier transform infrared spectroscopy. The t-18:1 FAME and related trans-monounsaturated and saturated compounds were quantitated by linear regression analysis from the intensities of the 971- and 1121-cm-1 infrared bands, respectively. The 971-cm-1 band is produced for trans geometric isomers only; thus, interference from cis isomers, due to GC peak overlap, is eliminated. At an iodine value of 78, the t-18:1 composition of hydrogenated menhaden oil was 2.6% by weight. The use of internal standards was essential for quantitation. Satisfactory repeatability was achieved for quantitation of FAMEs from duplicate high-performance liquid chromatographic fractions; the t-18:1 FAME weight percent varied by 7.4%.
C1 US FDA,NATL CTR FOOD SAFETY & TECHNOL,SUMMIT ARGO,IL 60501.
US FDA,DIV FOOD PROC & PACKAGING,OFF PLANT & DAIRY FOODS & BEVERAGES,SUMMIT ARGO,IL 60501.
RP MOSSOBA, MM (reprint author), US FDA,DIV GEN SCI SUPPORT,OFF SCI ANAL & SUPPORT,WASHINGTON,DC 20204, USA.
NR 16
TC 14
Z9 14
U1 0
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0021-8561
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD NOV
PY 1993
VL 41
IS 11
BP 1998
EP 2002
DI 10.1021/jf00035a035
PG 5
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
Technology
SC Agriculture; Chemistry; Food Science & Technology
GA MH755
UT WOS:A1993MH75500035
ER
PT J
AU HEIKES, DL
AF HEIKES, DL
TI PROCEDURE FOR SUPERCRITICAL-FLUID EXTRACTION AND GAS-CHROMATOGRAPHIC
DETERMINATION OF CHLORINATED FATTY-ACID BLEACHING ADDUCTS IN FLOUR AND
FLOUR-CONTAINING FOOD ITEMS UTILIZING ACID HYDROLYSIS-METHYLATION AND
FLORISIL COLUMN CLEANUP TECHNIQUES
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
ID CARBON-DIOXIDE; PRODUCTS
AB The identification of chlorinated fatty acid adducts formed during the bleaching of flour with chlorine and chlorine dioxide was previously accomplished utilizing chemical ionization mass spectrometry. The current, and subsequent, research has culminated in the formation of a method that has been used to quantify six different classes of isomers of these adducts in flour and flour-containing table-ready food items. The bleaching adducts were extracted with supercritical carbon dioxide and purified via acid hydrolysis-methylation and Florisil column chromatography. Determination was accomplished with gas chromatography using electrolytic conductivity detection (GC-ELCD). The most prominent adducts were the dichlorooctadecenoic acid isomers [18:1 (Cl, CI)] and isomers of chlorohydroxyoctadecenoic acid [18:1 (Cl, OH)] with maximum levels of each in excess of 40 ppm in cakes, cookies, and biscuits and in excess of 300 ppm in bleached flour. Recoveries of each synthesized compound from sweet rolls ranged from 79.4% to 105%.
RP HEIKES, DL (reprint author), US FDA,CTR TOTAL DIET RES,11510 W 80TH ST,LENEXA,KS 66214, USA.
NR 6
TC 8
Z9 8
U1 1
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0021-8561
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD NOV
PY 1993
VL 41
IS 11
BP 2034
EP 2037
DI 10.1021/jf00035a042
PG 4
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
Technology
SC Agriculture; Chemistry; Food Science & Technology
GA MH755
UT WOS:A1993MH75500042
ER
PT J
AU MCNEAL, TP
NYMAN, PJ
DIACHENKO, GW
HOLLIFIELD, HC
AF MCNEAL, TP
NYMAN, PJ
DIACHENKO, GW
HOLLIFIELD, HC
TI SURVEY OF BENZENE IN FOODS BY USING HEADSPACE CONCENTRATION TECHNIQUES
AND CAPILLARY GAS-CHROMATOGRAPHY
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
ID VOLATILE FLAVOR COMPONENTS; EGGS
AB Recently, the combination of sodium or potassium benzoate with ascorbic acid was shown to produce low levels (ng/g) of benzene in fruit-flavored soft drinks. The presence of benzene also was reported in butter, eggs, meat, and certain fruits; levels of these findings ranged from 0.5 ng/g in buffer to 500-1900 ng/g in eggs. Because benzoates are widely used as food preservatives, a limited survey of other foods containing added benzoate salts was conducted to investigate the potential for benzene formation. Selected foods that did not contain added benzoates but were previously reported to contain benzene were analyzed for comparison. More than 50 foods were analyzed by purge-and-trap or static headspace concentration and capillary gas chromatography. Benzene was quantitated by using the method of standard additions, and its identity was confirmed by mass selective detection. Results of this limited survey show that foods without added benzoates (including eggs) contained benzene at levels equal to or less than 2 ng/g. Slightly higher levels were present in some foods and beverages containing both ascorbic acid and sodium benzoate.
RP MCNEAL, TP (reprint author), US FDA,DIV FOOD & CHEM TECHNOL,WASHINGTON,DC 20204, USA.
NR 11
TC 34
Z9 35
U1 1
U2 10
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD NOV-DEC
PY 1993
VL 76
IS 6
BP 1213
EP 1219
PG 7
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA ML245
UT WOS:A1993ML24500008
PM 8286958
ER
PT J
AU TROTTER, WJ
DICKERSON, R
AF TROTTER, WJ
DICKERSON, R
TI PESTICIDE-RESIDUES IN COMPOSITED MILK COLLECTED THROUGH THE
UNITED-STATES PASTEURIZED MILK NETWORK
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
AB The U.S. Food and Drug Administration (FDA) has implemented a comprehensive monitoring program to determine the incidence and levels of organohalogen pesticide residues in milk representing most of the U.S. supply consumed in metropolitan areas. Residue findings for 806 composite milks collected through the Pasteurized Milk Program by the U.S. Environmental Protection Agency (EPA) in 1990-1991 are reported. Milk was collected on a monthly basis from 63 stations selected by EPA for radionuclide monitoring. These stations provide an estimated 80% of the milk delivered to U.S. population centers. At each station, milk from selected sources had been composited to represent the milk routinely consumed in its metropolitan area. Portions of these composites were forwarded to an FDA contract laboratory for pesticide residue analysis. Pesticide residues were found in 398 (49.4%) of 806 test samples, on the basis of a 0.0005 ppm limit of detection for each residue on a whole-product basis. A total of 455 occurrences of pesticide residues were found; p,p'-DDE and dieldrin accounted for 384 (84.4%) of these occurrences. The highest level was 0.01 9 ppm p,p'-DDE.
C1 WOODSON TENENT LABS INC,MEMPHIS,TN 38101.
RP TROTTER, WJ (reprint author), US FDA,DIV CONTAMINANTS CHEM,WASHINGTON,DC 20204, USA.
NR 7
TC 14
Z9 14
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD NOV-DEC
PY 1993
VL 76
IS 6
BP 1220
EP 1225
PG 6
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA ML245
UT WOS:A1993ML24500009
PM 8286959
ER
PT J
AU RUPP, HS
MUNNS, RK
LONG, AR
AF RUPP, HS
MUNNS, RK
LONG, AR
TI SIMULTANEOUS DETERMINATION OF NITROFURAZONE AND FURAZOLIDONE IN SHRIMP
(PENAEUS-VANNAMEI) MUSCLE-TISSUE BY LIQUID-CHROMATOGRAPHY WITH UV
DETECTION
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
ID ANTIBACTERIALS
AB A liquid chromatographic (LC) method was developed for the simultaneous determination of nitroturazone (NFZ) and furazolidone (FZD) in shrimp muscle tissue. The drugs are extracted from the tissue with acetonitrile, and the lipids and lipophilic pigments are removed from the extract with hexane. The remaining acetonitrile extract is evaporated by rotary evaporation, and the resultant residues are dissolved with LC-grade water, applied to a preconditioned C18 solid-phase extraction column, and eluted with acetonitrile. The acetonitrile eluant is then dried under nitrogen, and the resultant drug residues are dissolved with mobile phase and filtered. The drugs are determined by LC by using a C18 reversed-phase (octyldecylsilyl Hypersil) column, a mobile phase of acetonitrile-1% aqueous acetic acid (25 + 75, v/v), and a photodiode array UV detector at 375 nm. NFZ and FZD were determined in shrimp tissue at each of 5 spiking levels (64, 32, 16, 8, and 4 ng drug/g tissue). Absolute recoveries ranged from 70.6 to 78.4%, and relative standard deviations ranged from 4.0 to 13.6%. The limit of detection of pure standard of each drug was approximately the equivalent of 1 ng drug/g tissue, and the limit of determination in a sample was 4 ng drug/g tissue.
RP RUPP, HS (reprint author), US FDA,DENVER FED CTR,ANIM DRUGS RES CTR,POB 25087,DENVER,CO 80225, USA.
NR 12
TC 3
Z9 4
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD NOV-DEC
PY 1993
VL 76
IS 6
BP 1235
EP 1239
PG 5
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA ML245
UT WOS:A1993ML24500012
PM 8286962
ER
PT J
AU JUNE, GA
SHERROD, PS
AMAGUANA, RM
ANDREWS, WH
HAMMACK, TS
AF JUNE, GA
SHERROD, PS
AMAGUANA, RM
ANDREWS, WH
HAMMACK, TS
TI EFFECTIVENESS OF THE BACTERIOLOGICAL-ANALYTICAL MANUAL CULTURE METHOD
FOR THE RECOVERY OF SHIGELLA-SONNEI FROM SELECTED FOODS
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
ID OUTBREAK
AB The relative retention of the indigenous morphological, biochemical, and serological characteristics by Shigella sonnei was tested under various storage conditions (room temperature, refrigeration, freezing at -20-degrees-C and at -70-degrees-C, and lyophilization). The use of a selective (desoxycholate citrate) agar rather than a nonselective (brain heart infusion) agar gave a lower conversion rate of smooth to rough colonies, and the percentage of rough colonies derived from cultures stored for prolonged periods increased under all conditions. With respect to biochemical characteristics, there were no major differences in the reactions of smooth vs rough variants. For serological characteristics, smooth variants agglutinated more readily in homologous antisera than did rough variants. S. sonnei populations maintained at -70-degrees-C with glycerol remained reasonably stable and were used in recovery studies. Up to six foods (potato salad, chicken salad, cooked salad shrimp, lettuce, raw ground beef, and raw oysters) were inoculated with unstressed, chill-stressed, or freeze-stressed S. sonnei cells. Test portions (25 g) were inoculated with serial 10-fold dilutions of culture and subsequently analyzed by the culture method described in the U.S. Food and Drug Administration's Bacteriological Analytical Manual. It was found that the method was relatively ineffective for the recovery of S. sonnei from raw ground beef and raw oysters.
RP JUNE, GA (reprint author), US FDA,DIV MICROBIOL STUDIES,200 C ST SW,WASHINGTON,DC 20204, USA.
NR 17
TC 15
Z9 15
U1 1
U2 2
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD NOV-DEC
PY 1993
VL 76
IS 6
BP 1240
EP 1248
PG 9
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA ML245
UT WOS:A1993ML24500013
PM 8286963
ER
PT J
AU MCNEAL, TP
HOLLIFIELD, HC
AF MCNEAL, TP
HOLLIFIELD, HC
TI DETERMINATION OF VOLATILE CHEMICALS RELEASED FROM
MICROWAVE-HEAT-SUSCEPTOR FOOD-PACKAGING
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
ID CYCLIC OLIGOMERS; MIGRATION; PLASTICS
AB Microwave heat susceptors that convert electromagnetic energy to heat attain high temperatures that make it possible to cook some foods to golden crispness in a microwave oven. Susceptors are typically packaged with foods intended for microwave use, e.g., waffles, pizzas, and french fries. The high temperatures >302-degrees-F used to cook some foods release trace levels of volatile chemicals from metalized polyester film, adhesive, and paper packaging materials; these volatile chemicals may be absorbed by the food. We simulated microwave susceptor cooking conditions and developed protocols by using headspace concentration capillary gas chromatography and mass spectrometry to identify volatile chemicals released from heated susceptors. We purchased a limited, cross-sectional sample of local retail microwave food products packaged with susceptors and used our protocol to analyze 10 different susceptor products. Although more than 140 unique chromatographic peaks were tabulated, only 44 volatile chemicals were identified, including 1,1,1-trichloroethane, benzene, and 2-(2-butoxyethoxy)ethanol, which were derived primarily from the paper and adhesive susceptor components. No one susceptor contained all the identified substances. The standard additions technique was the preferred method for quantitation. Trichloroethane and 2-(2-butoxyethoxy)ethanol were present in several products at 75-122 mug/in.2 of susceptor surface area. Benzene was found in 3 susceptors at less-than-or-equal-to 0.22 mug/in.2 levels. Examination indicates that adhesives used in more recent susceptor products were reformulated to remove even this trace level of benzene.
RP MCNEAL, TP (reprint author), US FDA,DIV FOOD & CHEM TECHNOL,WASHINGTON,DC 20204, USA.
NR 22
TC 16
Z9 16
U1 2
U2 5
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD NOV-DEC
PY 1993
VL 76
IS 6
BP 1268
EP 1275
PG 8
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA ML245
UT WOS:A1993ML24500017
PM 8286967
ER
PT J
AU CHASE, GW
LANDEN, WO
SOLIMAN, AGM
EITENMILLER, RR
AF CHASE, GW
LANDEN, WO
SOLIMAN, AGM
EITENMILLER, RR
TI METHOD MODIFICATION FOR LIQUID-CHROMATOGRAPHIC DETERMINATION OF
THIAMINE, RIBOFLAVIN, AND PYRIDOXINE IN MEDICAL FOODS
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
AB A reversed-phase ion pair liquid chromatographic method developed for the simultaneous determination of thiamine (B1), riboflavin (B2), and pyridoxine (B6) in perchloric acid extracts of infant formulas was modified to include medical foods. UV detection of B1 and B2 was replaced by fluorescence detection, which resulted in improved sensitivity and specificity. B1 was detected by fluorescence after conversion to thiochrome by a postcolumn reaction with sodium hydroxide and potassium ferricyanide. The method uses a mobile phase of water, acetonitrile, hexanesulfonic acid sodium salt, ammonium hydroxide, and phosphoric acid adjusted to pH 3.6. The column is a 300 x 3.9 mm Nova Pak C18. Limits of detection were 0.05 mug/mL for B1 and B2 and 0.01 mug/mL for B6 by fluorescence detection. The system reproducibility was evaluated by completing 10 repetitive determinations on a medical food that gave a coefficient of variation of 5.9, 6.0, and 10.7% for B1, B2, and B6, respectively. Mean recoveries (n = 10) were 111, 96.3, and 113% for B1, B2, and B6, respectively. The results compared favorably with those by AOAC Official Methods 942.23, 940.33, and 961.15 for B1, B2, and B6, respectively.
C1 UNIV GEORGIA,DEPT FOOD SCI & TECHNOL,ATHENS,GA 30602.
RP CHASE, GW (reprint author), US FDA,ATLANTA CTR NUTRIENT ANAL,60 8TH ST NE,ATLANTA,GA 30309, USA.
NR 3
TC 16
Z9 17
U1 1
U2 4
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD NOV-DEC
PY 1993
VL 76
IS 6
BP 1276
EP 1280
PG 5
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA ML245
UT WOS:A1993ML24500018
PM 8286968
ER
PT J
AU CHICHILA, TMP
GILVYDIS, DM
AF CHICHILA, TMP
GILVYDIS, DM
TI DETERMINATION OF PARAQUAT AND DIQUAT IN LOW-MOISTURE FOOD CROPS USING
SILICA COLUMN CLEANUP AND LIQUID-CHROMATOGRAPHY WITH UV DETECTION
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
AB A sample cleanup method was developed for the determination of paraquat (PQ) and diquat (DQ) in low-moisture food crops. Low-moisture commodities, such as milled dry navy beans, are digested in acid. PQ and DO are isolated from the digestates by using a 4 g column of preconditioned silica gel. The analytes are concentrated and then determined by liquid chromatography with a silica analytical column, sodium chloride as an ion-pairing reagent, and acetonitrile as an organic modifier. PD and DO are determined simultaneously with a diode array UV absorbance detector. Recoveries for PQ and DO were determined on 3 different fortified low-moisture crops. Fortification levels ranged from 0.01 to 0.30 ppm; average recoveries ranged from 47.5% (DQ) to 95.3% (PQ).
RP CHICHILA, TMP (reprint author), US FDA,PESTICIDES & IND CHEM RES CTR,DETROIT,MI 48207, USA.
NR 6
TC 21
Z9 21
U1 2
U2 7
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD NOV-DEC
PY 1993
VL 76
IS 6
BP 1323
EP 1328
PG 6
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA ML245
UT WOS:A1993ML24500025
PM 8286972
ER
PT J
AU MATUSIK, JE
EILERS, PP
WALDRON, EM
CONRAD, SM
SPHON, JA
AF MATUSIK, JE
EILERS, PP
WALDRON, EM
CONRAD, SM
SPHON, JA
TI CONFIRMATION OF IDENTITIES OF PROPYLENE AND ETHYLENE GLYCOLS IN
ANCHOVIES BY TANDEM MASS-SPECTROMETRY
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
AB A gas chromatographic/tandem mass spectrometric (GC/MS/MS) method has been developed for confirming the identity of propylene and ethylene glycols added to bait fish for preservation. Bait fish are occasionally illegally diverted to human food use. The bait fish were extracted with methanol, the extract was centrifuged and filtered, and the filtrate was concentrated 10-fold and then analyzed by GC/MS/MS. The glycols were separated chromatographically without derivatization or preliminary cleanup. Isobutane positive ion chemical ionization was used to generate the protonated molecular ion species of each glycol. Product-ion MS/MS experiments were performed to obtain spectra to confirm the identities of propylene and ethylene glycols. The identities of these 2 compounds in anchovy extracts were successfully confirmed by this approach.
C1 US FDA,CTR FOOD SAFETY & APPL NUTR,DIV SEAFOOD RES,WASHINGTON,DC 20204.
RP MATUSIK, JE (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,DIV CONTAMINANTS CHEM,WASHINGTON,DC 20204, USA.
NR 5
TC 2
Z9 2
U1 0
U2 1
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD NOV-DEC
PY 1993
VL 76
IS 6
BP 1344
EP 1347
PG 4
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA ML245
UT WOS:A1993ML24500027
PM 8286973
ER
PT J
AU NIEMANN, RA
AF NIEMANN, RA
TI DETERMINATION OF FORMETANATE HYDROCHLORIDE IN SELECTED FRUITS BY
COUPLED-COLUMN CATION-EXCHANGE LIQUID-CHROMATOGRAPHY
SO JOURNAL OF AOAC INTERNATIONAL
LA English
DT Article
AB A strong cation exchange (SCX) liquid chromatographic (LC) method is described for determination of formetanate hydrochloride residue in pome, citrus, and stone fruits. A test portion of fruit, homogenized with the peel left on, was blended with acidified acetonitrile and filtered. A portion of extract was finely filtered, and a 500 muL aliquot (ca 0.2 g test sample equivalent) was loaded onto an SCX solid-phase extraction (SPE) LC column, which replaced the injection loop of the LC injection valve. Cations were selectively enriched; noncations were eluted by acetonitrile in a pre-separation cleanup. Turning the valve to the inject position coupled the SPE column to an SCX analytical column for separation and detection at 250 nm. The mobile phase was 0.4M pH 3.0 ammonium phosphate buffer-water-acetonitrile (50 + 25 + 25). Formetanate cation was quantitated by peak area and regression coefficients from a 5-point linear calibration covering a 100-fold range. Recovery of duplicate fortifications of apple, pear, orange, and peach averaged 89-99% at the respective U.S. tolerances of 3, 3, 4, or 5 ppm and averaged 93-99% at one-tenth of the respective tolerance level. Peel pigments or variable peel bulk of crop varieties tested, as well as other endogenous fruit material, contributed interference that was below the 0.02 ppm limit of detection. In a 1991 limited survey comprising 15 samples, none were found violative. Residues were found in 2 samples, but only 1 measurement was quantifiable, near the 0.06 ppm limit of quantitation.
RP NIEMANN, RA (reprint author), US FDA,DIV CONTAMINANTS CHEM,WASHINGTON,DC 20204, USA.
NR 4
TC 9
Z9 9
U1 0
U2 0
PU AOAC INTERNATIONAL
PI GAITHERSBURG
PA 481 NORTH FREDRICK AVE, STE 500, GAITHERSBURG, MD 20877-2504
SN 1060-3271
J9 J AOAC INT
JI J. AOAC Int.
PD NOV-DEC
PY 1993
VL 76
IS 6
BP 1362
EP 1368
PG 7
WC Chemistry, Analytical; Food Science & Technology
SC Chemistry; Food Science & Technology
GA ML245
UT WOS:A1993ML24500029
PM 8286975
ER
PT J
AU JOHNSON, JM
TANNER, LA
AF JOHNSON, JM
TANNER, LA
TI POSTMARKETING SURVEILLANCE - CURRICULUM FOR THE CLINICAL PHARMACOLOGIST
.2. CLINICAL AND REGULATORY CONSIDERATIONS
SO JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article
ID ADVERSE DRUG-REACTIONS; FLUOROQUINOLONES; FOOD
AB This is the second of a two-part series that develops a curriculum on postmarketing surveillance. With the ongoing emphasis on drug safety and possible earlier marketing of drugs, this becomes an essential element of clinical pharmacology training. The usual educational focus on drug safety is a pharmacokinetic or pharmacodynamic perspective on a specific drug or drug class, perhaps in the context of clinical trial study design and analysis. This curriculum complements this approach and provides an overview of drug safety surveillance from regulatory and epidemiologic perspectives.
RP JOHNSON, JM (reprint author), US FDA,CTR DRUG EVALUAT & RES,DIV EPIDEMIOL & SURVEILLANCE,HFD-730,ROCKVILLE,MD 20857, USA.
NR 16
TC 1
Z9 2
U1 0
U2 0
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0091-2700
J9 J CLIN PHARMACOL
JI J. Clin. Pharmacol.
PD NOV
PY 1993
VL 33
IS 11
BP 1015
EP 1022
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MJ272
UT WOS:A1993MJ27200003
PM 8300884
ER
PT J
AU MANDLER, R
CHU, CC
PAUL, WE
MAX, EE
SNAPPER, CM
AF MANDLER, R
CHU, CC
PAUL, WE
MAX, EE
SNAPPER, CM
TI INTERLEUKIN-5 INDUCES S-MU-S-GAMMA-1 DNA REARRANGEMENT IN B-CELLS
ACTIVATED WITH DEXTRAN-ANTI-IGD ANTIBODIES AND INTERLEUKIN-4 - A
3-COMPONENT MODEL FOR IG CLASS SWITCHING
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID HEAVY-CHAIN SWITCH; GROWTH-FACTOR-BETA; INTERFERON-GAMMA;
EPSILON-TRANSCRIPTS; LYMPHOCYTES-B; INDUCTION; LINE; LIPOPOLYSACCHARIDE;
IL-5; RECOMBINATION
AB The cellular signals required for induction of immunoglobulin (Ig) class switching are only partially understood. Two processes that are considered to be necessary for such induction are DNA synthesis and germline constant heavy (C(H)) gene transcription. We now show that an additional signal, as mediated by interleukin 5 (IL-5), is also required. To induce proliferation of resting B cells, but not Ig secretion, we utilized anti-IgD antibodies conjugated to dextran (alphadelta-dex). The addition of IL-4, a well-established switch factor for the IgG1 subclass, to alphadelta-dex-activated cell cultures failed to induce IgG1 secretion or mIgG1+ cells unless IL-5 was also present. While IL-4 stimulated an increase in germline gamma1 RNA in alphadelta-dex-activated cells, this effect could neither be induced nor enhanced by IL-5. By contrast, IL-5 strongly enhanced steady-state levels of productive gamma1 RNA induced by alphadelta-dex and IL-4, suggesting that IL-5 stimulated IgG1 switch rearrangement. To test this possibility we measured switch (S)mu-Sgamma1 DNA recombination events using a newly developed assay, digestion circularization polymerase chain reaction (DC-PCR). We demonstrated that IL-5 was necessary for induction of Smu-S-gamma1 DNA rearrangement in alphadelta-dex plus IL-4-activated cells but that it had little effect on rearrangement in the absence of IL-4. Our data strongly suggest, therefore, a three-component model for induction of Ig class switching. This model includes germline C(H) gene transcription, DNA synthesis, and a third component that is necessary for recombination.
C1 UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,4301 JONES BRIDGE RD,BETHESDA,MD 20814.
NIAID,IMMUNOL LAB,BETHESDA,MD 20892.
US FDA,DIV CYTOKINE BIOL,BETHESDA,MD 20892.
FU NIAID NIH HHS [AI32560]
NR 46
TC 39
Z9 39
U1 0
U2 1
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021
SN 0022-1007
J9 J EXP MED
JI J. Exp. Med.
PD NOV 1
PY 1993
VL 178
IS 5
BP 1577
EP 1586
DI 10.1084/jem.178.5.1577
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA MD953
UT WOS:A1993MD95300012
PM 8228808
ER
PT J
AU MATSUZAWA, M
POTEMBER, RS
STENGER, DA
KRAUTHAMER, V
AF MATSUZAWA, M
POTEMBER, RS
STENGER, DA
KRAUTHAMER, V
TI CONTAINMENT AND GROWTH OF NEUROBLASTOMA-CELLS ON CHEMICALLY PATTERNED
SUBSTRATES
SO JOURNAL OF NEUROSCIENCE METHODS
LA English
DT Article
DE CHEMICALLY PATTERNED SUBSTRATE; SELF-ASSEMBLED MONOLAYER FILM; UV
IRRADIATION; NONADHESIVE SURFACE; SK-N-SH NEUROBLASTOMA CELL; CELL
CONTAINMENT; CELL GROWTH
ID COPLANAR MOLECULAR ASSEMBLIES; MONOLAYERS; OUTGROWTH; GUIDANCE;
ADHESION; SURFACE; CULTURE; NEURONS
AB Patterned substrates offer the promise of controlled positioning and directional guidance of growing neurites. Therefore, they could be useful for constructing small neuronal networks with defined geometry in vitro. We have fabricated chemically patterned substrates using self-assembled monolayer films with a lithographic mask technique and demonstrated the feasibility for geometrically patterning neuroblastoma cells in culture. N-octadecyltrichlorosilane (OTS) was chemically bonded to glass and fused silica substrates, rendering the surface hydrophobic and non-adhesive to cells. Using surface analysis techniques,:we have confirmed that OTS films were true monolayers and can be photocleaved from the surface by deep W irradiation. An adhesive pattern of n-(2-aminoethyl-3-aminopropyl)trimethoxy was formed on a selectively irradiated OTS surface via a deep W lithographic procedure. The chemically patterned surface was then seeded with SK-N-SH human neuroblastoma cells, and cellular attachment and growth were monitored by optical microscopy. The use of 2-dimensional substrates supported the containment and growth of neuroblastoma cells within the pattern for at least 15 days in culture. These chemical patterns may also be useful in controlled arrangements of heart cells or muscle cells on prosthetic implant devices.
C1 JOHNS HOPKINS UNIV,APPL PHYS LAB,LAUREL,MD 20703.
USN,RES LAB,CTR BIOMOLEC SCI & ENGN,WASHINGTON,DC 20375.
US FDA,CTR DEVICES & RADIOL HLTH,DIV PHYS SCI,ROCKVILLE,MD 20857.
NR 17
TC 42
Z9 43
U1 2
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0270
J9 J NEUROSCI METH
JI J. Neurosci. Methods
PD NOV
PY 1993
VL 50
IS 2
BP 253
EP 260
DI 10.1016/0165-0270(93)90014-I
PG 8
WC Biochemical Research Methods; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA MK824
UT WOS:A1993MK82400014
PM 8107505
ER
PT J
AU SATCHITHANANDAM, S
REICKS, M
CALVERT, RJ
CASSIDY, MM
KRITCHEVSKY, D
AF SATCHITHANANDAM, S
REICKS, M
CALVERT, RJ
CASSIDY, MM
KRITCHEVSKY, D
TI COCONUT OIL AND SESAME OIL AFFECT LYMPHATIC ABSORPTION OF CHOLESTEROL
AND FATTY-ACIDS IN RATS
SO JOURNAL OF NUTRITION
LA English
DT Article
DE SESAME OIL; COCONUT OIL; LYMPH; CHOLESTEROL; RATS; FATTY ACIDS
ID METABOLISM; TRANSPORT; FIBER
AB Five groups of male Wistar rats weighing approximately 200 g consumed 12 or 24% sesame oil or coconut oil diets or a control diet (14% corn oil) ad libitum for 4 wk. The thoracic ducts of these rats were cannulated, and a lipid emulsion containing [H-3]cholesterol and [C-14]oleic acid was given through a duodenal catheter. Lymph was collected for 24 h and the isotopic tracers for cholesterol and fatty acid were measured. Rats fed the 24% sesame oil diet had significantly lower lymphatic cholesterol and fatty acid compared with the control group. Absorption of oleic acid in rats fed 24% coconut oil was significantly greater than in controls during 0-8 h but was not significantly different during 0-24 h. There were no differences among groups in the distribution of cholesterol and oleic acid either in the lymph lipoproteins or in the lipid classes. The significant reduction in lymph cholesterol and fatty acids due to sesame oil feeding may be an important factor in reducing hypercholesterolemia.
C1 GEORGE WASHINGTON UNIV,SCH MED & HLTH SCI,DEPT PHYSIOL,WASHINGTON,DC 20037.
WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104.
RP SATCHITHANANDAM, S (reprint author), US FDA,DIV NUTR,LAUREL,MD 20708, USA.
NR 23
TC 14
Z9 13
U1 0
U2 1
PU AMER INST NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0022-3166
J9 J NUTR
JI J. Nutr.
PD NOV
PY 1993
VL 123
IS 11
BP 1852
EP 1858
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA MF526
UT WOS:A1993MF52600011
PM 8229300
ER
PT J
AU VOGEL, PF
AF VOGEL, PF
TI EVALUATING OUT-OF-SPECIFICATION LABORATORY RESULTS
SO JOURNAL OF PARENTERAL SCIENCE AND TECHNOLOGY
LA English
DT Editorial Material
C1 US FDA,CDER,ROCKVILLE,MD 20855.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU PARENTERAL DRUG ASSOC, INC
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE, 620, BETHESDA, MD 20814
SN 0279-7976
J9 J PARENT SCI TECHN
PD NOV-DEC
PY 1993
VL 47
IS 6
BP 276
EP 280
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MY208
UT WOS:A1993MY20800002
PM 8120730
ER
PT J
AU DECAMP, WH
AF DECAMP, WH
TI CHIRAL DRUGS - THE FDA PERSPECTIVE ON MANUFACTURING AND CONTROL
SO JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
LA English
DT Article; Proceedings Paper
CT 4th International Symposium on Pharmaceutical and Biomedical Analysis
(PBAN 93)
CY APR 18-21, 1993
CL BALTIMORE, MD
DE STEREOCHEMISTRY; CHIRAL DRUGS; IDENTITY TESTS; ASSAYS; STABILITY; CHIRAL
HPLC; POLARIMETRY; ENANTIOMERS; RACEMATES
ID RESOLUTION; STEREOCHEMISTRY; PHASES
AB On 27 May 1992, the FDA announced the availability of a policy statement on the development of stereoisomeric drugs. This: statement has significant implications for the chemist who is working on the development and validation of analytical controls for chiral drug substances and products. The testing of the bulk drug, the manufacturing of the finished product, the design of stability testing protocols, and the labelling of the drug must all take the chirality of the active ingredient into consideration.
RP DECAMP, WH (reprint author), US FDA,CTR DRUG EVALUAT & RES,DIV ANTIINFECT DRUG PROD,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.
NR 17
TC 61
Z9 62
U1 1
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0731-7085
J9 J PHARMACEUT BIOMED
JI J. Pharm. Biomed. Anal.
PD NOV-DEC
PY 1993
VL 11
IS 11-12
BP 1167
EP 1172
DI 10.1016/0731-7085(93)80100-F
PG 6
WC Chemistry, Analytical; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA MQ354
UT WOS:A1993MQ35400020
PM 8123731
ER
PT J
AU HYMAN, FN
KLONTZ, KC
TOLLEFSON, L
AF HYMAN, FN
KLONTZ, KC
TOLLEFSON, L
TI EATING AS A HAZARD TO HEALTH - PREVENTING, TREATING DENTAL INJURIES
CAUSED BY FOREIGN OBJECTS IN FOOD
SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION
LA English
DT Article
AB The Food and Drug Administration maintains a passive surveillance system for reporting and follow-up of complaints related to food items. The most commonly reported complaint is the discovery of foreign objects in food. The most common injuries are abrasions to the throat and buccal mucosa. Although dentists are qualified to treat oral injury resulting from foreign object ingestion, more physicians than dental professionals treat soft tissue trauma.
RP HYMAN, FN (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,EPIDEMIOL BRANCH,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.
NR 7
TC 1
Z9 1
U1 0
U2 0
PU AMER DENTAL ASSN
PI CHICAGO
PA 211 E CHICAGO AVE, CHICAGO, IL 60611
SN 0002-8177
J9 J AM DENT ASSOC
JI J. Am. Dent. Assoc.
PD NOV
PY 1993
VL 124
IS 11
BP 65
EP 69
PG 5
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA MG952
UT WOS:A1993MG95200013
PM 7901252
ER
PT J
AU YURAWECZ, MP
MOLINA, AA
MOSSOBA, M
KU, Y
AF YURAWECZ, MP
MOLINA, AA
MOSSOBA, M
KU, Y
TI ESTIMATION OF CONJUGATED OCTADECATRIENES IN EDIBLE FATS AND OILS
SO JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY
LA English
DT Article
DE BORON TRIFLUORIDE; CONJUGATED LINOLEIC ACID; CONJUGATED TRIENES;
METHYLATION
ID LINOLEIC-ACID; SEED OIL; CHRYSOBALANACEAE; IDENTIFICATION; SPECTROMETRY;
DERIVATIVES; BEEF
AB Interest in conjugated-diene fatty acids in foods has recently been increased by discovery of their antioxidant and anticarcinogenic properties. Conjugated octadecatrienes (COTs), members of another group of fatty acids, are also present in foods. COTs are formed during the processing of vegetable oils as the result of the dehydration of secondary oxidation products of linoleic acid. Little information is available concerning the occurrence and nutritional properties of COTs in edible oils. Levels of COTs, determined in 27 vegetable oils by ultraviolet (UV) spectroscopy, ranged from not detected (<0.001) to 0.2%. Determination of COTs by gas chromatography of the methyl esters, obtained by transesterification at room temperature with sodium methoxide/methanol, gave lower levels (not detected, 0.051%) than did determination by UV spectroscopy. Methylation with boron trifluoride produced COTs from naturally occurring moieties in the oils and, therefore, is not recommended.
RP YURAWECZ, MP (reprint author), USFDA,CTR FOOD SAFETY & APPL NUTR,200 C ST SW,HFS-175,WASHINGTON,DC 20204, USA.
NR 19
TC 28
Z9 29
U1 0
U2 3
PU AMER OIL CHEMISTS SOC
PI CHAMPAIGN
PA 1608 BROADMOOR DRIVE, CHAMPAIGN, IL 61821-0489
SN 0003-021X
J9 J AM OIL CHEM SOC
JI J. Am. Oil Chem. Soc.
PD NOV
PY 1993
VL 70
IS 11
BP 1093
EP 1099
DI 10.1007/BF02632148
PG 7
WC Chemistry, Applied; Food Science & Technology
SC Chemistry; Food Science & Technology
GA MF295
UT WOS:A1993MF29500007
ER
PT J
AU GOLDING, H
BLUMENTHAL, R
MANISCHEWITZ, J
LITTMAN, DR
DIMITROV, DS
AF GOLDING, H
BLUMENTHAL, R
MANISCHEWITZ, J
LITTMAN, DR
DIMITROV, DS
TI CELL-FUSION MEDIATED BY INTERACTION OF A HYBRID CD4.CD8 MOLECULE WITH
THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE GLYCOPROTEIN DOES OCCUR
AFTER A LONG LAG TIME
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID RECOMBINANT VACCINIA VIRUSES; HTLV-III/LAV ENVELOPE; CD4+ CELLS;
MONOCLONAL-ANTIBODIES; CD4-MEDIATED FUSION; SYNCYTIUM FORMATION;
MEMBRANE-FUSION; INITIAL-STAGES; INFECTION; HIV
AB Several domains of CD4 have been suggested to play a critical role in events that follow its binding to the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (gp120-gp41). It has been reported previously that cells expressing a chimeric molecule consisting of the first 177 residues of human CD4 attached to residues from the hinge, transmembrane, and cytoplasmic domains of human CD8 did not form syncytia with HIV-1-infected cells (L. Poulin, L. A. Evans, S. Tang, A. Barboza, H. Legg, D. R. Littman, and J. A. Levy, J. Virol. 65:4893-4901, 1991). In contrast, we found that the hybrid CD4.CD8 molecule expressed in human cells did render them susceptible to fusion with cells expressing HIV-1IIIB or HIV-1RF envelope glycoproteins encoded by vaccinia virus recombinants, but only after long lag times. The lag time of membrane fusion mediated by the hybrid CD4.CD8 molecule was fivefold longer than that for the wild-type CD4 molecule. However, the rate of binding to and the affinity of soluble gp120 for membrane-associated CD4.CD8 were the same as for CD4. Both molecules were laterally mobile, as determined by patching experiments. Coexpression of the CD4.CD8 chimera with wild-type CD4 did not lead to interference in fusion but had an additive effect. Therefore, the proximal membrane domains of CD4 play an important role in determining the kinetics of postbinding events leading to membrane fusion. We hypothesize that the long lag time is due to the inability of the CD4.CD8-gp120-gp41 complex to undergo the rapid conformational changes which occur during the fusion mediated by wild-type CD4.
C1 NCI, MEMBRANE STRUCT & FUNCT SECT, BETHESDA, MD 20892 USA.
US FDA, DIV VIROL, BETHESDA, MD 20892 USA.
UNIV CALIF SAN FRANCISCO, SCH MED, HOWARD HUGHES MED INST, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA.
NR 38
TC 17
Z9 17
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD NOV
PY 1993
VL 67
IS 11
BP 6469
EP 6475
PG 7
WC Virology
SC Virology
GA MC016
UT WOS:A1993MC01600016
PM 8411350
ER
PT J
AU CHO, BP
BELAND, FA
MARQUES, MM
AF CHO, BP
BELAND, FA
MARQUES, MM
TI ONE-DIMENSIONAL MULTIPLE-QUANTUM FILTRATION H-1-NMR SPECTRA OF A 15-MER
DNA DUPLEX MODIFIED BY THE CARCINOGEN 4-AMINOBIPHENYL
SO MAGNETIC RESONANCE IN CHEMISTRY
LA English
DT Article
DE MULTIPLE QUANTUM FILTRATION; CARCINOGEN-MODIFIED DNA DUPLEX;
4-AMINOBIPHENYL
ID 1ST BASE; CODON-61
AB The selective detection of the arylamine aromatic protons in a 15-mer DNA duplex modified by the carcinogen 4-aminobiphenyl was accomplished using one-dimensional multiple quantum filtration experiments.
C1 NATL CTR TOXICOL RES,DIV BIOCHEM TOXICOL,JEFFERSON,AR 72079.
IST,CTR QUIM ESTRUTURAL,P-1096 LISBON,PORTUGAL.
RI Marques, M. Matilde/E-2535-2012
OI Marques, M. Matilde/0000-0002-7526-4962
NR 8
TC 0
Z9 0
U1 0
U2 1
PU JOHN WILEY & SONS LTD
PI W SUSSEX
PA BAFFINS LANE CHICHESTER, W SUSSEX, ENGLAND PO19 1UD
SN 0749-1581
J9 MAGN RESON CHEM
JI Magn. Reson. Chem.
PD NOV
PY 1993
VL 31
IS 11
BP 1008
EP 1010
DI 10.1002/mrc.1260311110
PG 3
WC Chemistry, Multidisciplinary; Chemistry, Physical; Spectroscopy
SC Chemistry; Spectroscopy
GA ML561
UT WOS:A1993ML56100009
ER
PT J
AU NAIR, J
ROUSE, DA
BAI, GH
MORRIS, SL
AF NAIR, J
ROUSE, DA
BAI, GH
MORRIS, SL
TI THE RPSL GENE AND STREPTOMYCIN RESISTANCE IN SINGLE AND MULTIPLE
DRUG-RESISTANT STRAINS OF MYCOBACTERIUM-TUBERCULOSIS
SO MOLECULAR MICROBIOLOGY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS INFECTION; POLYMERASE CHAIN-REACTION;
ESCHERICHIA-COLI; CHLAMYDOMONAS-REINHARDTII; SEQUENCE-ANALYSIS;
MULTIDRUG; OUTBREAK; MUTANTS; OPERON
AB The recent emergence of indolent and rapidly fatal drug-resistant strains of Mycobacterium tuberculosis has renewed interest in defining the molecular mechanisms of drug resistance in the tubercle bacilli. In this report, we have examined the mechanism of resistance to streptomycin (Sm) in M. tuberculosis through the cloning and nucleotide sequence analysis of the gene encoding the ribosomal S12 protein (rpsL gene) from streptomycin-resistant strains and their streptomycin-sensitive parental strains. We have demonstrated that five singly Sm(R) M. tuberculosis strains and an Sm(R) isolate that has reduced sensitivity to multiple antibiotics have identical point mutations at codon 43 of the rpsL gene. Mutations at this same site confer Sm(R) in Escherichia coli. In contrast, two other multiple drug-resistant M. tuberculosis strains that are resistant to Sm have rpsL genes that have the same nucleotide sequence as their drug-sensitive parent strains, suggesting that different resistance mechanisms are involved in these strains.
C1 US FDA,CTR BIOL EVALUAT & RES,MYCOBACTERIA LAB,8800 ROCKVILLE PIKE,BETHESDA,MD 20892.
KOREAN NATL TUBERCULOSIS ASSOC,KOREAN INST TUBERCULOSIS,SEOUL 137140,SOUTH KOREA.
NR 31
TC 87
Z9 100
U1 1
U2 12
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0950-382X
J9 MOL MICROBIOL
JI Mol. Microbiol.
PD NOV
PY 1993
VL 10
IS 3
BP 521
EP 527
DI 10.1111/j.1365-2958.1993.tb00924.x
PG 7
WC Biochemistry & Molecular Biology; Microbiology
SC Biochemistry & Molecular Biology; Microbiology
GA MF565
UT WOS:A1993MF56500008
PM 7968530
ER
PT J
AU MINCHIN, RF
KADLUBAR, FF
ILETT, KF
AF MINCHIN, RF
KADLUBAR, FF
ILETT, KF
TI ROLE OF ACETYLATION IN COLORECTAL-CANCER
SO MUTATION RESEARCH
LA English
DT Article
DE COLORECTAL CANCER; ACETYLATION PHENOTYPE; HETEROCYCLIC AMINES
ID ARYLAMINE N-ACETYLTRANSFERASE; HUMAN LIVER;
2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP;
METABOLIC-ACTIVATION; HETEROCYCLIC AMINES; AROMATIC-AMINES; EXPRESSION;
COLON; POLYMORPHISM; CARCINOGENS
AB Acetylator phenotype is a common genetic trait in humans as well as other mammals. It results from the presence of several mutations in one of the genes encoding for arylamine N-acetyltransferase. The polymorphism has been associated with several disease states including colorectal cancer. Several epidemiological studies suggest that rapid acetylators are more susceptible to colorectal cancer than slow acetylators. Moreover, individuals that are both rapid acetylators and exhibit a high cytochrome P450 1A2 activity appear to have an even higher risk of colorectal cancer. These observations not only suggest an interesting genetic link to non-familial colon cancer but also suggest that carcinogens that are activated by N-acetyltransferase and cytochrome P450 1A2 may contribute to the etiology of this disease. Heterocyclic amines present in cooked food such as ''well done'' red meat are carcinogenic in experimental animals forming tumours in several target tissues including the small intestines. We have shown that human polymorphic N-acetyltransferase is present in human colon tissue and that it is capable of activating several heterocyclic amine carcinogens present in cooked food. These studies provide good circumstantial evidence that rapid acetylators may be predisposed to colorectal cancer.
C1 NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
RP MINCHIN, RF (reprint author), UNIV WESTERN AUSTRALIA,DEPT PHARMACOL,DRUG METAB & TOXICOL SECT,NEDLANDS,WA 6009,AUSTRALIA.
NR 32
TC 58
Z9 58
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-8262
J9 MUTAT RES
PD NOV
PY 1993
VL 290
IS 1
BP 35
EP 42
DI 10.1016/0027-5107(93)90030-J
PG 8
WC Genetics & Heredity; Toxicology
SC Genetics & Heredity; Toxicology
GA ME719
UT WOS:A1993ME71900005
PM 7694097
ER
PT J
AU GHOSH, C
DICK, RM
ALI, SF
AF GHOSH, C
DICK, RM
ALI, SF
TI IRON ASCORBATE-INDUCED LIPID-PEROXIDATION CHANGES MEMBRANE FLUIDITY AND
MUSCARINIC CHOLINERGIC RECEPTOR-BINDING IN RAT FRONTAL-CORTEX
SO NEUROCHEMISTRY INTERNATIONAL
LA English
DT Article
ID OXYGEN FREE-RADICALS; FLUORESCENCE POLARIZATION; ACID; INVITRO
AB Lipid peroxidation (LP) is a complex process which involves the formation of lipid free radicals and leads to oxidative damage. LP has also been implicated in several neurodegenerative diseases as well as aging. In the present study, we evaluated the effects of the induction of LP in vitro on muscarinic cholinergic (Mch) receptor binding and membrane fluidity in rat brain. Membranes from the rat frontal cortex were peroxidized by adding ferrous sulphate (84 muM) and ascorbic acid (400 muM). Peroxidation was measured as the amount of thiobarbituric acid reactive products formed (nmol malondialdehyde/mg protein). Mch receptor binding was measured 10, 20 and 30 min after peroxidation. Membrane fluidity was evaluated by fluorescence polarization studies using two probes; 1,6-diphenyl-1,3,5-hexatriene (DPH) and 1-[4(trimethylamino)phenyl]-1,3,5-hexatriene (TMA-DPH). Significant alterations in Mch receptor binding (decreased B(max) and increased K(d)) were found after peroxidation. Membrane fluidity was also significantly decreased after peroxidation as observed with both probes. The decrease in membrane fluidity was due to an increased cholesterol to phospholipid molar ratio after peroxidation. These data suggest that lipid peroxidation induces changes in membrane dynamics as detected by the fluorescent probes and such changes in membrane microviscosity may be the cause for alterations in Mch receptor kinetics.
C1 NATL CTR TOXICOL RES,DIV NEUROTOXICOL,NEUROCHEM LAB,HFT-132,NCTR DR,JEFFERSON,AR 72079.
NE LOUISIANA UNIV,SCH PHARM,DIV PHARMACOL & TOXICOL,MONROE,LA 71209.
UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205.
NR 29
TC 58
Z9 59
U1 1
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0197-0186
J9 NEUROCHEM INT
JI Neurochem. Int.
PD NOV
PY 1993
VL 23
IS 5
BP 479
EP 484
DI 10.1016/0197-0186(93)90133-P
PG 6
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA MD851
UT WOS:A1993MD85100011
PM 8251930
ER
PT J
AU BUFFALO, EA
GILLAM, MP
ALLEN, RR
PAULE, MG
AF BUFFALO, EA
GILLAM, MP
ALLEN, RR
PAULE, MG
TI ACUTE EFFECTS OF CAFFEINE ON SEVERAL OPERANT BEHAVIORS IN RHESUS-MONKEYS
SO PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
LA English
DT Note
DE CAFFEINE; MACACA MULATTA; OPERANT BEHAVIOR; TIME ESTIMATION; INCREMENTAL
REPEATED ACQUISITION; LEARNING; COLOR AND POSITION DISCRIMINATION;
TEMPORAL RESPONSE DIFFERENTIATION; TIME ESTIMATION; DELAYED
MATCHING-TO-SAMPLE; SHORT-TERM MEMORY; MOTIVATION; ATTENTION; FOOD
REINFORCEMENT
ID TEST BATTERY; MARIJUANA SMOKE; PERFORMANCE
AB The acute effects of 1,3-trimethylxanthine (caffeine) were assessed using an operant test battery (OTB) of complex food-reinforced tasks that are thought to depend upon relatively specific brain functions, such as motivation to work for food (progressive ratio, PR), learning (incremental repeated acquisition, IRA), color and position discrimination (conditioned position responding, CPR), time estimation (temporal response differentiation, TRD), and short-term memory and attention (delayed matching-to-sample, DMTS). Endpoints included response rates (RR), accuracies (ACC), and percent task completed (PTC). Caffeine sulfate (0.175-20.0 mg/kg, IV), given 15 min pretesting, produced significant dose-dependent decreases in TRD percent task completed and accuracy at doses greater-than-or-equal-to 5.6 mg/kg. Caffeine produced no systematic effects on either DMTS or PR responding, but low doses tended to enhance performance in both IRA and CPR tasks. Thus, in monkeys, performance of an operant task designed to model time estimation is more sensitive to the disruptive effects of caffeine than is performance of the other tasks in the OTB.
C1 NATL CTR TOXICOL RES,DIV NEUROTOXICOL,JEFFERSON,AR 72079.
NATL CTR TOXICOL RES,COMP BASED SYST INC,JEFFERSON,AR 72079.
UNIV ARKANSAS MED SCI HOSP,DEPT PHARMACOL & TOXICOL,LITTLE ROCK,AR 72205.
UNIV ARKANSAS MED SCI HOSP,DEPT PEDIAT,LITTLE ROCK,AR 72205.
NR 19
TC 19
Z9 19
U1 1
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0091-3057
J9 PHARMACOL BIOCHEM BE
JI Pharmacol. Biochem. Behav.
PD NOV
PY 1993
VL 46
IS 3
BP 733
EP 737
DI 10.1016/0091-3057(93)90570-J
PG 5
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA ME097
UT WOS:A1993ME09700033
PM 8278453
ER
PT J
AU BEER, JZ
OLVEY, KM
MILLER, SA
THOMAS, DP
GODAR, DE
AF BEER, JZ
OLVEY, KM
MILLER, SA
THOMAS, DP
GODAR, DE
TI NONNUCLEAR DAMAGE AND CELL-LYSIS ARE INDUCED BY UVA, BUT NOT UVB OR UVC,
RADIATION IN 3 STRAINS OF L5178Y CELLS
SO PHOTOCHEMISTRY AND PHOTOBIOLOGY
LA English
DT Article
ID MOUSE LYMPHOMA-CELLS; ULTRAVIOLET-LIGHT; ESCHERICHIA-COLI; MEMBRANE
DAMAGE; ATOPIC-DERMATITIS; ACTION SPECTRA; INACTIVATION; MUTAGENESIS;
RADIOSENSITIVITY; TUMORIGENICITY
AB The potential to induce non-nuclear changes in mammalian cells has been examined for (1) UVA 1 radiation (340-400 nm, UVASUN 2000 lamp), (2) UVA + UVB (peak at 313 nm) radiation (FS20 lamp), and (3) UVC (254 nm) radiation (G15T8 lamp). The effects of irradiation were monitored in vitro using three strains of L5178Y (LY) mouse lymphoma cells that markedly differ in sensitivity to UV radiation. Comparisons were made for the effects of approximately equitoxic fluences that reduced cell survival to 1-15%. Depending on the cell strain, the fluences ranged from 830 to 1600 kJ/m(2) for the UVASUN lamp, 75 to 390 J/m(2) for the FS20 lamp and 3.8 to 17.2 J/m(2) for the G15T8 lamp. At the exposure level used in this study, irradiation with the UVASUN, but not the FS20 or G15T8, lamp induced a variety of non-nuclear changes including damage to cytoplasmic organelles and increased plasma membrane permeability and cell lysis. Cell lysis and membrane permeabilization were induced by the UVA1 emission of the UVASUN lamp, but not by its visible + IR components (>400 nm). The results show that the plasma membrane and other organelles of LY cells are highly sensitive to UVA1 but not to UVB or UVC radiation. Also UVA1, but not UVB or UVC radiation, causes rapid and extensive lysis of LY cells. In conclusion, non-nuclear damage contributes substantially to UVA cytotoxicity in all three strains of LY cells.
RP BEER, JZ (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20857, USA.
FU FDA HHS [FDA223-88-6076]
NR 41
TC 30
Z9 30
U1 0
U2 2
PU AMER SOC PHOTOBIOLOGY
PI AUGUSTA
PA BIOTECH PARK, 1021 15TH ST, SUITE 9, AUGUSTA, GA 30901-3158
SN 0031-8655
J9 PHOTOCHEM PHOTOBIOL
JI Photochem. Photobiol.
PD NOV
PY 1993
VL 58
IS 5
BP 676
EP 681
DI 10.1111/j.1751-1097.1993.tb04951.x
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA ML057
UT WOS:A1993ML05700009
PM 8284323
ER
PT J
AU BARRETT, HH
YAO, J
ROLLAND, JP
MYERS, KJ
AF BARRETT, HH
YAO, J
ROLLAND, JP
MYERS, KJ
TI MODEL OBSERVERS FOR ASSESSMENT OF IMAGE QUALITY
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article; Proceedings Paper
CT COLLOQUIUM ON IMAGES OF SCIENCE : SCIENCE OF IMAGES
CY JAN 13-14, 1992
CL NATL ACAD SCI, WASHINGTON, DC
SP UNIV CHICAGO, CTR IMAGE SCI, DIGITAL EQUIPMENT, R R DONNELLEY & SONS, EASTMAN KODAK, POLAROID, NATL ACAD SCI
HO NATL ACAD SCI
ID HOTELLING TRACE CRITERION; COMPUTER-AIDED DIAGNOSIS; DETECTION
PERFORMANCE; SYSTEMS; NOISE; OPTIMIZATION; SNR
AB Image quality can be defined objectively in terms of the performance of some ''observer'' (either a human or a mathematical model) for some task of practical interest. If the end user of the image will be a human, model observers are used to predict the task performance of the human, as measured by psychophysical studies, and hence to serve as the basis for optimization of image quality. In this paper, we consider the task of detection of a weak signal in a noisy image. The mathematical observers considered include the ideal Bayesian, the nonprewhitening matched filter, a model based on linear-discriminant analysis and referred to as the Hotelling observer, and the Hotelling and Bayesian observers modified to account for the spatial-frequency-selective channels in the human visual system. The theory behind these observer models is briefly reviewed, and several psychophysical studies relating to the choice among them are summarized. Only the Hotelling model with channels is mathematically tractable in all cases considered here and capable of accounting for all of these data. This model requires no adjustment of parameters to fit the data and is relatively insensitive to the details of the channel mechanism. We therefore suggest it as a useful model observer for the purpose of assessing and optimizing image quality with respect to simple detection tasks.
C1 UNIV N CAROLINA,DEPT COMP SCI,CHAPEL HILL,NC 27599.
UNIV ARIZONA,CTR OPT SCI,TUCSON,AZ 85724.
US FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20857.
RP BARRETT, HH (reprint author), UNIV ARIZONA,DEPT RADIOL,TUCSON,AZ 85724, USA.
FU NCI NIH HHS [P01 CA23417, R01 CA52643]
NR 38
TC 308
Z9 309
U1 1
U2 12
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 1
PY 1993
VL 90
IS 21
BP 9758
EP 9765
DI 10.1073/pnas.90.21.9758
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MF296
UT WOS:A1993MF29600006
PM 8234311
ER
PT J
AU CAIRNS, T
CHIU, KS
NAVARRO, D
SIEGMUND, E
AF CAIRNS, T
CHIU, KS
NAVARRO, D
SIEGMUND, E
TI MULTIRESIDUE PESTICIDE ANALYSIS BY ION-TRAP MASS-SPECTROMETRY
SO RAPID COMMUNICATIONS IN MASS SPECTROMETRY
LA English
DT Article
ID CHROMATOGRAPHY
AB The ion trap has been demonstrated to be able to detect and quantify 245 target pesticides extracted vis the Luke method while providing concurrent confirmation of presence via full scan data at the sub-ppm level. The precision and accuracy of the analytical approach was determined to be no greater than 15% relative standard deviation. A comparision study of over 100 incurred residues analyzed by the ion trap and gas chromatography with an array of element-selective detectors has indicated that sample clean-up will probably be necessary before quantification is acceptable for all target compounds. The data obtained using a combination of gas chromatography and mass spectrometry and presented for 250 target pesticides constitutes the basic information required to duplicate and extend the methodology.
RP CAIRNS, T (reprint author), US FDA,OFF REGULATORY AFFAIRS,DEPT HLTH & HUMAN SERV,LOS ANGELES DIST LAB,1521 W PICO BLVD,LOS ANGELES,CA 90015, USA.
NR 5
TC 41
Z9 42
U1 0
U2 1
PU JOHN WILEY & SONS LTD
PI W SUSSEX
PA BAFFINS LANE CHICHESTER, W SUSSEX, ENGLAND PO19 1UD
SN 0951-4198
J9 RAPID COMMUN MASS SP
JI Rapid Commun. Mass Spectrom.
PD NOV
PY 1993
VL 7
IS 11
BP 971
EP 988
DI 10.1002/rcm.1290071104
PG 18
WC Chemistry, Analytical; Spectroscopy
SC Chemistry; Spectroscopy
GA MG241
UT WOS:A1993MG24100003
PM 8280916
ER
PT J
AU SCIALLI, AR
FLYNN, TJ
GIBSON, RR
AF SCIALLI, AR
FLYNN, TJ
GIBSON, RR
TI RAT EMBRYO CULTURE TO DETECT NUTRITIONAL DEFICIENCY IN WOMEN WITH POOR
REPRODUCTIVE HISTORIES
SO REPRODUCTIVE TOXICOLOGY
LA English
DT Article
DE SPONTANEOUS ABORTION; HABITUAL; NUTRITIONAL DEFICIENCIES; AMINO ACIDS;
RAT WHOLE EMBRYO CULTURE; IN VITRO METHODS
ID HUMAN-SERUM; ORGANOGENESIS; ABORTION; INVITRO; SYSTEM
AB The cause of habitual early pregnancy loss is not known for most affected couples. It has been proposed that a deficiency of amino acids or other nutrients may contribute to early embryo loss, and an assay based on culture of rat embryos in human serum has been proposed to evaluate women with poor reproductive histories. We tested this assay in women with unexplained infertility (n = 27), habitual abortion (n = 15), and normal midtrimester pregnancies (n = 10) by examining the ability of subject's serum to support the normal development of rat embryos in culture with and without supplemental vitamins and amino acids. Nonpregnant women with nutrient deficiencies identified in this manner were given oral supplements or placebo and were retested. A similar proportion of women in each group had serum that was unable to support the normal development of rat embryos without supplemental vitamins and amino acids. When oral supplements were used, most sera were able to support normal embryo growth. There were no seroconversions on placebo. In spite of the apparent success in producing seroconversions on oral supplementation, only two women conceived, one on the placebo treatment and one on nutritional supplements. Because serum nutrient deficiencies identified by rat embryo culture could not distinguish normal pregnant women from women with unexplained infertility or habitual abortion, and because of the low pregnancy rates, we could not confirm the utility of this assay for the general population of women with habitual abortion. If subtle nutritional deficiencies play a role in early pregnancy loss, it may require a more homogeneous population of women with, for example, a history of five or more spontaneous pregnancy losses.
C1 US FDA,CTR FOOD SAFETY & APPL NUTR,DIV TOXICOL RES,LAUREL,MD.
RP SCIALLI, AR (reprint author), GEORGETOWN UNIV,MED CTR,DEPT OBSTET & GYNECOL,3 PHC,3800 RESERVOIR RD NW,WASHINGTON,DC 20007, USA.
OI Flynn, Thomas/0000-0002-7248-0643
NR 16
TC 3
Z9 3
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0890-6238
J9 REPROD TOXICOL
JI Reprod. Toxicol.
PD NOV-DEC
PY 1993
VL 7
IS 6
BP 581
EP 587
DI 10.1016/0890-6238(93)90034-5
PG 7
WC Reproductive Biology; Toxicology
SC Reproductive Biology; Toxicology
GA MN544
UT WOS:A1993MN54400003
PM 8118108
ER
PT J
AU NEWHALL, J
MORSE, S
NUTTER, C
AF NEWHALL, J
MORSE, S
NUTTER, C
TI NONCULTURE TESTS FOR GENITAL-TRACT CHLAMYDIAL INFECTION - IS THE
GOVERNMENT THE ANSWER TO OUR PROBLEMS - RESPONSE
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Letter
C1 US FDA,WASHINGTON,DC 20204.
RP NEWHALL, J (reprint author), CTR DIS CONTROL & PREVENT,ATLANTA,GA 30333, USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0148-5717
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD NOV-DEC
PY 1993
VL 20
IS 6
BP 353
EP 355
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA MH998
UT WOS:A1993MH99800012
ER
PT J
AU HANSEN, DK
AF HANSEN, DK
TI IN-VITRO EFFECTS OF FOLATE DERIVATIVES ON VALPROATE-INDUCED NEURAL-TUBE
DEFECTS IN MOUSE AND RAT EMBRYOS
SO TOXICOLOGY IN VITRO
LA English
DT Article; Proceedings Paper
CT 3rd Symposium on Vertebrate Whole Embryo Culture
CY NOV 08-11, 1992
CL BASEL, SWITZERLAND
ID FOLINIC ACID; CALCIUM VALPROATE; INVITRO; SUPPLEMENTATION;
TERATOGENICITY; CULTURE; EMBRYOTOXICITY; CARBAMAZEPINE; METABOLITES;
PHENOTYPE
AB The anticonvulsant drug valproic acid (VPA), produces neural tube defects in mouse and rat embryos treated in vivo or in vitro; The mechanism for the drug's embryotoxic effect is unknown, but 5-formyltetrahydrofolate has been reported to decrease the incidence of VPA-induced neural tube defects in mice treated in vivo. In the present study we have examined the ability of 5-formyltetrahydrofolate, tetrahydrofolate, 5-methyltetrahydrofolate and folic acid to protect against VPA-induced neural tube defects in CD-1 mouse or CD rat embryos grown in a whole embryo culture system. Mouse embryos with 2-5 somite pairs were cultured for 48 hr beginning on gestation day 8; presomite stage rat embryos were cultured beginning on gestation day 9 (for both species gestation day 0 was taken as the day a vaginal sperm plug was found). VPA at 1.2 mM (rats) or 1.8 mM (mice) produced a high incidence of open neural tubes. None of the folate derivatives in concentrations up to 100 mu g/ml was able to decrease the incidence of VPA-induced defects in either species. These data suggest that folate is not involved in the mechanism of VPA-induced neural tube defects.
RP HANSEN, DK (reprint author), US FDA,NATL CTR TOXICOL RES,DIV REPROD & DEV TOXICOL,JEFFERSON,AR 72079, USA.
NR 44
TC 7
Z9 8
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0887-2333
J9 TOXICOL IN VITRO
JI Toxicol. Vitro
PD NOV
PY 1993
VL 7
IS 6
BP 735
EP 742
DI 10.1016/0887-2333(93)90075-G
PG 8
WC Toxicology
SC Toxicology
GA MU042
UT WOS:A1993MU04200009
PM 20732274
ER
PT J
AU WILLIAMS, MS
AF WILLIAMS, MS
TI SINGLE-RADIAL-IMMUNODIFFUSION AS AN IN-VITRO POTENCY ASSAY FOR HUMAN
INACTIVATED VIRAL VACCINES
SO VETERINARY MICROBIOLOGY
LA English
DT Article; Proceedings Paper
CT Conf on Characterization and Quantitation of Immunogens in Veterinary
Biologics
CY MAY 05-06, 1992
CL AMES, IA
SP NATL VET SERV LABS, VET SURGEONS, ANIM PLANT HLTH INSPECT SERV, USDA, CTR IMMUN ENHANCEMENT DOMEST ANIM
ID VIRUS; ANTIGEN; REACTOGENICITY; A/USSR/77; ADULTS; RABIES
AB Single-radial-immunodiffusion (SRID) assays have been used to determine the potency of all human inactivated influenza virus vaccines licensed by the Food and Drug Administration for use in the United States since 1978. SRID replaced less reliable tests which were based on the aggregation of erythrocytes by the hemagglutinins of influenza viruses. Similar SRID assays have been used experimentally to determine the potency of inactivated polio and rabies vaccines. In each case, the assays are based on the diffusion of viral antigen into an agarose gel containing specific antibodies to the antigen being measured. For influenza and rabies, disruption of the virions with a detergent is necessary to permit the diffusion of the appropriate antigens, where as with polio, intact virions are allowed to diffuse. The interaction between antigen and antibody produces a zone of precipitation whose size is directly proportional to the amount of antigen applied. A potency value for unknowns is obtained by comparing the sizes of zones produced by unknown preparations to the sizes of zones obtained with a calibrated reference of known antigen content. Once the specific reference antigens and antibodies are prepared and the test standardized, it is a remarkably simple technique which unlike agglutination assays is very reproducible, relatively unaffected by minor variations in test conditions and is far less time consuming and cumbersome than in vivo assays for potency such as those done by inoculating mice or monkeys. More importantly, clinical studies demonstrate that standardization of influenza vaccines by SRID provides a better correlate of human immunogenicity than previous methods.
RP WILLIAMS, MS (reprint author), US FDA,CTR BIOL EVALUAT & RES,DIV VIROL,RESP VIRUSES LAB,BETHESDA,MD 20014, USA.
NR 21
TC 45
Z9 47
U1 1
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1135
J9 VET MICROBIOL
JI Vet. Microbiol.
PD NOV
PY 1993
VL 37
IS 3-4
BP 253
EP 262
DI 10.1016/0378-1135(93)90027-5
PG 10
WC Microbiology; Veterinary Sciences
SC Microbiology; Veterinary Sciences
GA MM915
UT WOS:A1993MM91500007
PM 8116186
ER
PT J
AU HABIG, WH
AF HABIG, WH
TI POTENCY TESTING OF BACTERIAL VACCINES FOR HUMAN USE
SO VETERINARY MICROBIOLOGY
LA English
DT Article; Proceedings Paper
CT Conf on Characterization and Quantitation of Immunogens in Veterinary
Biologics
CY MAY 05-06, 1992
CL AMES, IA
SP NATL VET SERV LABS, VET SURGEONS, ANIM PLANT HLTH INSPECT SERV, USDA, CTR IMMUN ENHANCEMENT DOMEST ANIM
AB The potency tests for bacterial vaccines are quite diverse. For some products (pertussis, cholera, anthrax, typhoid and BCG vaccines) these are specified as Additional Standards in the Code of Federal Regulations. For other products (tetanus and diphtheria toxoids, plague vaccine) the testing is done according to so-called Minimum Requirements, which have less regulatory authority than Additional Standards. Still other products (eg., polysaccharide conjugate vaccines, acellular pertussis vaccine, live oral typhoid) are tested according to individualized criteria that are contained in their specific Product License Applications. For some products there is inadequate knowledge of the pathogenic mechanisms and/or protective factors to design valid in vitro potency tests. In these cases, animal testing with subsequent serologic evaluation or challenge testing is often necessary. Examples would include vaccines such as cholera and plague vaccines. The FDA supports the elimination of animal testing when suitable alternatives are available. Thus, many of the potency tests, especially for newer products, rely on in vitro characterization. For example, the immunogenicity of conventional polysaccharide vaccines is largely proportional to their molecular weight. Potency testing therefore relies heavily on physical characterization in terms of composition, molecular weight, and quantity.
RP HABIG, WH (reprint author), US FDA,CTR BIOL EVALUAT & RES,DIV BACTERIAL PROD,HFB 601,BETHESDA,MD 20014, USA.
NR 6
TC 9
Z9 9
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1135
J9 VET MICROBIOL
JI Vet. Microbiol.
PD NOV
PY 1993
VL 37
IS 3-4
BP 343
EP 351
DI 10.1016/0378-1135(93)90033-4
PG 9
WC Microbiology; Veterinary Sciences
SC Microbiology; Veterinary Sciences
GA MM915
UT WOS:A1993MM91500013
PM 8116190
ER
PT J
AU WARD, JM
SHELDON, W
AF WARD, JM
SHELDON, W
TI EXPRESSION OF MONONUCLEAR PHAGOCYTE ANTIGENS IN HISTIOCYTIC SARCOMA OF
MICE
SO VETERINARY PATHOLOGY
LA English
DT Article
DE HISTIOCYTIC SARCOMA; MONONUCLEAR PHAGOCYTE SYSTEM; MICE; RETICULUM CELL
SARCOMA; TYPE A
ID MALIGNANT HISTIOCYTOSIS; CELL; ORIGIN; LYMPHOMAS; PATHOLOGY
AB Twenty cases of histiocytic sarcoma in 15 female and five male (384 to 722 days of age) hybrid F-1 (C57BL/6 x BALB/c) or F-2 (F-1 x F-1) mice were studied for expression of mononuclear phagocyte and other antigens. Histiocytic sarcomas were found most often in liver, uterus, spleen, and lung. Tissues fixed in Bouin's fluid provided preservation of antigen immunoreactivity, using avidin biotin peroxidase complex immunohistochemistry, with monoclonal and polyclonal antibodies. The mononuclear phagocyte antigens, lysozyme and Mac-2 (a galactose-specific lectin that binds IgE), were found in 60-70% of the cases. The receptor for the macrophage colony-stimulating factor (CSF-1), c-fms, was expressed in 2/20 (10%) of the cases. Mouse immunoglobulins were not found in histiocytic sarcoma cells. In uterine histiocytic sarcomas, previously reported as Schwannomas because of their histologic appearance, S-100 protein was not expressed by tumor cells, although they usually expressed Mac-2 and lysozyme. Hyaline droplets were found in the renal tubules of only 2/19 cases. Our studies provide evidence that murine histiocytic sarcoma expresses antigens (Mac-2, lysozyme, c-fms) found in cells of the mononuclear phagocyte series, in contrast to the B-cen origin of many human histiocytic tumors.
C1 NATL CTR TOXICOL RES,PATHOL ASSOCIATES INC,JEFFERSON,AR.
RP WARD, JM (reprint author), NCI,FREDERICK CANC RES & DEV CTR,OFF LAB ANIM SCI,VET & TUMOR PATHOL SECT,FAIRVIEW 201,FREDERICK,MD 21701, USA.
FU NCI NIH HHS [N01-CO-74102]
NR 30
TC 11
Z9 11
U1 0
U2 0
PU AMER COLL VET PATHOLOGIST
PI LAWRENCE
PA 810 EAST 10TH STREET, LAWRENCE, KS 66044
SN 0300-9858
J9 VET PATHOL
JI Vet. Pathol.
PD NOV
PY 1993
VL 30
IS 6
BP 560
EP 565
PG 6
WC Pathology; Veterinary Sciences
SC Pathology; Veterinary Sciences
GA MN540
UT WOS:A1993MN54000010
PM 8116150
ER
PT J
AU YAFAL, AG
KAPLAN, G
RACANIELLO, VR
HOGLE, JM
AF YAFAL, AG
KAPLAN, G
RACANIELLO, VR
HOGLE, JM
TI CHARACTERIZATION OF POLIOVIRUS CONFORMATIONAL ALTERATION MEDIATED BY
SOLUBLE CELL RECEPTORS
SO VIROLOGY
LA English
DT Note
ID HELA-CELLS; LOW PH; INVITRO; NEUTRALIZATION; RHINOVIRUS; INHIBITION;
WIN-51711; ARILDONE; TYPE-1; ENTRY
C1 HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,240 LONGWOOD AVE,BOSTON,MA 02115.
US FDA,CTR BIOL EVALUAT & RES,DIV VIRAL PROD,BETHESDA,MD 20892.
COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032.
NR 27
TC 44
Z9 44
U1 0
U2 1
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0042-6822
J9 VIROLOGY
JI Virology
PD NOV
PY 1993
VL 197
IS 1
BP 501
EP 505
DI 10.1006/viro.1993.1621
PG 5
WC Virology
SC Virology
GA MB621
UT WOS:A1993MB62100061
ER
PT J
AU SCHMUED, LC
BELTRAMINO, C
SLIKKER, W
AF SCHMUED, LC
BELTRAMINO, C
SLIKKER, W
TI INTRACRANIAL INJECTION OF FLUOROGOLD RESULTS IN THE DEGENERATION OF
LOCAL BUT NOT RETROGRADELY LABELED NEURONS
SO BRAIN RESEARCH
LA English
DT Article
DE FLUOROGOLD; NEUROTOXICITY; AXONAL TRACER; NEUROPATHOLOGY
ID LONG-TERM
AB Small volumes of either Fluoro-Gold (hydroxy-stilbamidine) or physiological saline were pressure injected into the striatum of adult rats. This paradigm is essentially the same as that used by neuroscientists who inject small quantities of Fluoro-Gold into brain structures to reveal neuronal connections. Using a modified de Olmos' cupric-silver technique, virtually no degeneration could be detected as the result of saline injection at any time point examined. However, comparable injections of Fluoro-Gold resulted in conspicuous cell body and terminal degeneration within the striatum 1-10 days post injection. Terminal degeneration within the substantia nigra pars reticulata could also be seen 2-10 days after injection. Examination of cells of the compacta region revealed conspicuous retrograde uptake of Fluoro-Gold, although none of these cells exhibited any evidence of neuronal degeneration at any postoperative time examined.
C1 UNIV VIRGINIA,SCH MED,DEPT OTOLARYNGOL,CHARLOTTESVILLE,VA 22905.
RP SCHMUED, LC (reprint author), NATL CTR TOXICOL RES,DIV NEUROTOXICOL,JEFFERSON,AR 72079, USA.
FU NIA NIH HHS [NIEHS 1AG 6725.05]; NICHD NIH HHS [NBD HD07323]
NR 14
TC 20
Z9 20
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
J9 BRAIN RES
JI Brain Res.
PD OCT 29
PY 1993
VL 626
IS 1-2
BP 71
EP 77
DI 10.1016/0006-8993(93)90564-4
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA MC801
UT WOS:A1993MC80100009
PM 8281454
ER
PT J
AU MILLER, FW
AF MILLER, FW
TI MYOSITIS-SPECIFIC AUTOANTIBODIES - TOUCHSTONES FOR UNDERSTANDING THE
INFLAMMATORY MYOPATHIES
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID TRANSFER RNA-SYNTHETASE; SIGNAL RECOGNITION PARTICLE; DERMATOMYOSITIS;
POLYMYOSITIS; DISEASE; PICORNAVIRUS; ANTIBODIES; ANTI-JO-1
RP MILLER, FW (reprint author), US FDA,CTR BIOL EVALUAT & RES,MOLEC IMMUNOL LAB,N29,ROOM 507,HFM-521,BETHESDA,MD 20892, USA.
OI Miller, Frederick/0000-0003-2831-9593
NR 30
TC 82
Z9 85
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 20
PY 1993
VL 270
IS 15
BP 1846
EP 1849
DI 10.1001/jama.270.15.1846
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA MB464
UT WOS:A1993MB46400029
PM 8411528
ER
PT J
AU BRIGHT, RA
FARUP, CE
MARINACDABIC, D
KACZMAREK, RG
MOORE, RM
AF BRIGHT, RA
FARUP, CE
MARINACDABIC, D
KACZMAREK, RG
MOORE, RM
TI REPORTED NATIONAL PATTERNS OF USE OF THE MATERNAL TEST FOR SERUM
ALPHA-FETOPROTEIN
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Meeting Abstract
C1 US FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20857.
RI Bright, Roselie/D-2240-2016
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHNS HOPKINS UNIV SCHOOL HYGIENE PUB HEALTH
PI BALTIMORE
PA 111 MARKET PLACE, STE 840, BALTIMORE, MD 21202-6709
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD OCT 15
PY 1993
VL 138
IS 8
BP 658
EP 658
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA MH147
UT WOS:A1993MH14700266
ER
PT J
AU CHEN, M
TANNER, A
GALLOTORRES, H
AF CHEN, M
TANNER, A
GALLOTORRES, H
TI ANAPHYLACTOID-ANAPHYLACTIC REACTIONS ASSOCIATED WITH ONDANSETRON
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Letter
RP CHEN, M (reprint author), US FDA,ROCKVILLE,MD 20857, USA.
NR 0
TC 13
Z9 13
U1 0
U2 2
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572
SN 0003-4819
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD OCT 15
PY 1993
VL 119
IS 8
BP 862
EP 862
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA MB496
UT WOS:A1993MB49600026
PM 8379613
ER
PT J
AU ZAPATA, G
ROLLER, PP
CROWLEY, J
VANN, WF
AF ZAPATA, G
ROLLER, PP
CROWLEY, J
VANN, WF
TI THE ROLE OF CYSTEINE RESIDUES 129 AND 329 IN ESCHERICHIA-COLI K1
CMP-NEUAC SYNTHASE
SO BIOCHEMICAL JOURNAL
LA English
DT Article
ID ACETYLNEURAMINIC ACID SYNTHETASE; SITE-DIRECTED MUTAGENESIS;
CELL-ADHESION MOLECULE; JAPAN SENDAI VIRUS; ELECTROPHORETIC TRANSFER;
HEMAGGLUTINATING VIRUS; POLYACRYLAMIDE GELS; PERTUSSIS TOXIN;
DYE-BINDING; SIALIC-ACID
AB N-Acetylneuraminic acid cytidyltransferase (CMP-NeuAc synthase) of Escherichia coli K1 is sensitive to mercurials and has cysteine residues only at positions 129 and 329. The role of these residues in the catalytic activity and structure of the protein has been investigated by site-directed mutagenesis and chemical modification. The enzyme is inactivated by the thiol-specific reagent dithiodipyridine. Inactivation by this reagent is decreased in the presence of the nucleotide substrate CTP, suggesting that a thiol residue is at or near the active site. Site-directed mutagenesis of either residue Cys-129 to serine or Cys-329 to selected amino acids has minor effects on the specific activity of the enzyme, suggesting that cysteine is not essential for catalysis and that a disulphide bond is not an essential structural component. The limited reactivity of the enzyme to other thiol-blocking reagents suggests that its cysteine residues are partially exposed. The accessibility and role of the cysteine residues in enzyme structure were investigated by fluorescence, c.d. and denaturation studies of wild-type and mutant enzymes. The mutation of Cys-129 to serine makes the enzyme more sensitive to heat and chemical denaturation, but does not cause gross changes in the protein structure as judged by the c.d. spectrum. The mutant containing Ser-129 instead of Cys-129 has a complex denaturation pathway similar to that of wild-type E. coli K1 CMP-NeuAc synthase consisting of several partially denatured states. Cys-329 reacts more readily with N-[C-14]ethylmaleimide when the enzyme is in a heat-induced relaxed state. Cys-129 is less reactive and is probably a buried residue.
C1 CTR BIOL EVALUAT & RES,BACTERIAL POLYSACCHARIDES LAB,8800 ROCKVILLE PIKE,BETHESDA,MD 20892.
NCI,MED CHEM LAB,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,BETHESDA,MD 20892.
NR 36
TC 7
Z9 7
U1 0
U2 0
PU PORTLAND PRESS
PI LONDON
PA 59 PORTLAND PLACE, LONDON, ENGLAND W1N 3AJ
SN 0264-6021
J9 BIOCHEM J
JI Biochem. J.
PD OCT 15
PY 1993
VL 295
BP 485
EP 491
PN 2
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA ME516
UT WOS:A1993ME51600021
PM 8240247
ER
PT J
AU VOSTAL, JG
FRATANTONI, JC
AF VOSTAL, JG
FRATANTONI, JC
TI ECONAZOLE INHIBITS THAPSIGARGIN-INDUCED PLATELET CALCIUM INFLUX BY
MECHANISMS OTHER THAN CYTOCHROME-P-450 INHIBITION
SO BIOCHEMICAL JOURNAL
LA English
DT Article
ID INTRACELLULAR CA2+ STORES; CARBON-MONOXIDE; ENTRY; AGGREGATION;
CA-2+-ATPASE; ACTIVATION; PUMPS
AB Cytochrome P-450 has been suggested as a mediator of the signal between depleted platelet calcium stores and an increase in plasma membrane permeability to calcium which follows depletion of the stores. This hypothesis is based on the observations that inhibitors of cytochrome P-450, such as the imidazole antifungal agents, also inhibit influx of a calcium surrogate (manganese) into calcium-depleted platelets. We tested the effects of econazole and of a cytochrome P-450 inhibitor, carbon monoxide (CO), on thapsigargin (TG)-induced platelet Ca-45(2+) influx. TG specifically depletes internal calcium stores and activates store-regulated calcium influx. Econazole blocked Ca-45(2+) influx when it was added before TG (IC50 11 muM). Econazole at a concentration (20 muM) that inhibited 83% of TG-induced calcium influx was not inhibitory to TG-induced calcium efflux from Ca-45(2+)-loaded platelets, and did not affect calcium fluxes in resting platelets. This econazole concentration was also inhibitory to calcium influx even when it was added after the stores had been calcium-depleted by EGTA and TG for 15 min and the signal to increase calcium influx had already been generated. Inhibition of cytochrome P-450 with CO bubbled through platelet suspensions did not change calcium influx in resting cells and potentiated TG-induced calcium influx (160% of control calcium accumulation at 20 min). This effect appeared to be concentration-dependent, such that a 5 min exposure to CO produced a greater influx potentiation than a 3 min exposure. These observations indicate that (1) cytochrome P-450 does not mediate store-regulated calcium influx. and (2) econazole probably inhibits store-regulated calcium influx by an alternative mechanism. such as interaction with plasma membrane calcium channels.
RP VOSTAL, JG (reprint author), US FDA,CTR BIOL EVALUAT & RES,DIV HEMATOL,BLDG 29,ROOM 323,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.
NR 32
TC 40
Z9 40
U1 0
U2 2
PU PORTLAND PRESS
PI LONDON
PA 59 PORTLAND PLACE, LONDON, ENGLAND W1N 3AJ
SN 0264-6021
J9 BIOCHEM J
JI Biochem. J.
PD OCT 15
PY 1993
VL 295
BP 525
EP 529
PN 2
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA ME516
UT WOS:A1993ME51600026
PM 8240252
ER
PT J
AU BENNETT, WP
COLBY, TV
TRAVIS, WD
BORKOWSKI, A
JONES, RT
LANE, DP
METCALF, RA
SAMET, JM
TAKESHIMA, Y
GU, JR
VAHAKANGAS, KH
SOINI, Y
PAAKKO, P
WELSH, JA
TRUMP, BF
HARRIS, CC
AF BENNETT, WP
COLBY, TV
TRAVIS, WD
BORKOWSKI, A
JONES, RT
LANE, DP
METCALF, RA
SAMET, JM
TAKESHIMA, Y
GU, JR
VAHAKANGAS, KH
SOINI, Y
PAAKKO, P
WELSH, JA
TRUMP, BF
HARRIS, CC
TI P53 PROTEIN ACCUMULATES FREQUENTLY IN EARLY BRONCHIAL NEOPLASIA
SO CANCER RESEARCH
LA English
DT Article
ID WILD-TYPE P53; CELL-CYCLE; BREAST-CANCER; LUNG-CANCER; COLORECTAL
TUMORIGENESIS; RESPIRATORY EPITHELIUM; SV40-TRANSFORMED CELLS;
ESOPHAGEAL CANCER; TRANSFORMED-CELLS; TUMOR SUPPRESSOR
AB p53 mutations are common in human lung cancer and frequently generate levels of p53 protein that are detectable by immunohistochemistry. For this reason, p53 protein accumulation is a candidate biomarker, but little is known about its timing or frequency in multistage bronchial carcinogenesis. We studied human lung tissues containing preinvasive squamous neoplasms from 34 donors with and without lung cancer. Nuclear p53 protein was present in 0% of normal mucosas, 6.7% of squamous metaplasias, 29.5% of mild dysplasias, 26.9% of moderate dysplasias, 59.7% of severe dysplasias, 58.5% of carcinomas in situ, 67.5% of microinvasive carcinomas, and 79.5% of invasive tumors. These data indicate that (a) p53 protein accumulates in about 30% of the earliest recognized neoplastic lesions (i.e., mild dysplasia), (b) there is an increasing frequency of p53 protein accumulation starting with mild dysplasia, and (c) p53 protein accumulates infrequently in normal or metaplastic mucosa. In a subset of six patients whose most advanced lesion was carcinoma in situ without evidence of invasive cancer, p53 protein was detected in 0% of normal mucosas, 8.3% of squamous metaplasias, 37.5% of mild dysplasias, 12.5% of moderate dysplasias, 93.8% of severe dysplasias, and 55% of carcinoma in situ lesions. These data show clearly that p53 alterations can occur before invasion and suggest that the frequency is similar to that observed in the full series. Since two-thirds or more of lung cancers have p53 alterations, the timing and frequency of p53 protein accumulation make the p53 tumor suppressor gene an attractive marker for early diagnosis and evaluation of chemoprevention agents.
C1 NCI,HUMAN CARCINOGENESIS LAB,BLDG 37,ROOM 2C01,BETHESDA,MD 20892.
MAYO CLIN & MAYO FDN,DEPT PATHOL,ROCHESTER,MN 55905.
NCI,PATHOL LAB,BETHESDA,MD 20892.
UNIV MARYLAND,DEPT PATHOL,BALTIMORE,MD 21201.
UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND.
US FDA,BETHESDA,MD 20014.
UNIV NEW MEXICO,CTR CANC,ALBUQUERQUE,NM 87131.
SHANGHAI CANC INST,SHANGHAI,PEOPLES R CHINA.
UNIV OULU,DEPT PHARMACOL & TOXICOL,SF-90100 OULU 10,FINLAND.
UNIV OULU,DEPT PATHOL,SF-90100 OULU 10,FINLAND.
RI Lane, David/C-4920-2008
NR 56
TC 204
Z9 205
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA PUBLIC LEDGER BLDG, SUITE 816, 150 S. INDEPENDENCE MALL W.,
PHILADELPHIA, PA 19106
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD OCT 15
PY 1993
VL 53
IS 20
BP 4817
EP 4822
PG 6
WC Oncology
SC Oncology
GA MB993
UT WOS:A1993MB99300018
PM 8402667
ER
PT J
AU ABE, R
KOZAK, CA
FOOPHILLIPS, M
ROBERTS, J
PRINCIPATO, MAC
AF ABE, R
KOZAK, CA
FOOPHILLIPS, M
ROBERTS, J
PRINCIPATO, MAC
TI INVOLVEMENT OF MULTIPLE FACTORS IN THE CLONAL DELETION OF SELF-REACTIVE
T-CELLS
SO CELLULAR IMMUNOLOGY
LA English
DT Article
ID MAMMARY-TUMOR VIRUS; MAJOR HISTOCOMPATIBILITY COMPLEX; LONG TERMINAL
REPEAT; OPEN READING FRAME; MHC GENE-PRODUCTS; I-E; NEGATIVE SELECTION;
IMPARTS REACTIVITY; MLS SYSTEM; MOUSE
C1 NIAID,MOLEC MICROBIOL LAB,BETHESDA,MD 20892.
UNIFORMED SERV UNIV HLTH SCI,NAVAL MED RES INST,IMMUNE CELL BIOL PROGRAM,BETHESDA,MD 20814.
UNIFORMED SERV UNIV HLTH SCI,DEPT MED,BETHESDA,MD 20814.
US FDA,IMMUNOBIOL BRANCH,DIV VIRULENCE ASSESSMENT,LAUREL,MD 20708.
RP ABE, R (reprint author), NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892, USA.
NR 53
TC 0
Z9 0
U1 0
U2 1
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0008-8749
J9 CELL IMMUNOL
JI Cell. Immunol.
PD OCT 15
PY 1993
VL 151
IS 2
BP 425
EP 436
DI 10.1006/cimm.1993.1251
PG 12
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA MC136
UT WOS:A1993MC13600017
PM 7691421
ER
PT J
AU KESSLER, DA
SIEGEL, JP
NOGUCHI, PD
ZOON, KC
FEIDEN, KL
WOODCOCK, J
AF KESSLER, DA
SIEGEL, JP
NOGUCHI, PD
ZOON, KC
FEIDEN, KL
WOODCOCK, J
TI REGULATION OF SOMATIC-CELL THERAPY AND GENE-THERAPY BY THE
FOOD-AND-DRUG-ADMINISTRATION
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID TUMOR-INFILTRATING LYMPHOCYTES; IMMUNOTHERAPY; MELANOMA; HUMANS
C1 US FDA,OFF COMMISSIONER,ROCKVILLE,MD 20857.
US FDA,CTR BIOL EVALUAT & RES,ROCKVILLE,MD 20857.
NR 11
TC 90
Z9 90
U1 0
U2 1
PU MASS MEDICAL SOC
PI BOSTON
PA 10 SHATTUCK, BOSTON, MA 02115
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 14
PY 1993
VL 329
IS 16
BP 1169
EP 1173
DI 10.1056/NEJM199310143291607
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA MA667
UT WOS:A1993MA66700007
PM 8377782
ER
PT J
AU GANLEY, CJ
HUNG, HMJ
TEMPLE, R
AF GANLEY, CJ
HUNG, HMJ
TEMPLE, R
TI MORE ON THE SURVIVAL AND VENTRICULAR ENLARGEMENT TRIAL
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
RP GANLEY, CJ (reprint author), US FDA,ROCKVILLE,MD 20857, USA.
NR 0
TC 11
Z9 11
U1 0
U2 0
PU MASS MEDICAL SOC
PI BOSTON
PA 10 SHATTUCK, BOSTON, MA 02115
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 14
PY 1993
VL 329
IS 16
BP 1204
EP 1205
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA MA667
UT WOS:A1993MA66700030
PM 8377799
ER
PT J
AU NIGHTINGALE, SL
AF NIGHTINGALE, SL
TI NEW MULTIPLE-SCLEROSIS PRODUCT LICENSED
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
RP NIGHTINGALE, SL (reprint author), US FDA, OFF HLTH AFFAIRS, PARKLAWN BLDG, 5600 FISHERS LN, ROCKVILLE, MD 20857 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 13
PY 1993
VL 270
IS 14
BP 1672
EP 1672
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA MA294
UT WOS:A1993MA29400006
ER
PT J
AU NIGHTINGALE, SL
AF NIGHTINGALE, SL
TI NEW EPILEPSY DRUG APPROVED FOR ADULTS AND CHILDREN
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
RP NIGHTINGALE, SL (reprint author), US FDA, OFF HLTH AFFAIRS, PARKLAWN BLDG, 5600 FISHERS LN, ROCKVILLE, MD 20857 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 13
PY 1993
VL 270
IS 14
BP 1672
EP 1672
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA MA294
UT WOS:A1993MA29400005
ER
PT J
AU NIGHTINGALE, SL
AF NIGHTINGALE, SL
TI APPROPRIATE USE OF LOW-MOLECULAR-WEIGHT HEPARINS (LMWHS)
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
RP NIGHTINGALE, SL (reprint author), US FDA, OFF HLTH AFFAIRS, PARKLAWN BLDG, 5600 FISHERS LN, ROCKVILLE, MD 20857 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 13
PY 1993
VL 270
IS 14
BP 1672
EP 1672
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA MA294
UT WOS:A1993MA29400007
ER
PT J
AU CHO, BP
KIM, M
HARVEY, RG
AF CHO, BP
KIM, M
HARVEY, RG
TI SYNTHESIS AND CONFORMATIONAL-ANALYSIS OF NITROPOLYCYCLIC FLUORANTHENES
SO JOURNAL OF ORGANIC CHEMISTRY
LA English
DT Article
ID POLYCYCLIC AROMATIC-HYDROCARBONS; ELECTROPHILIC SUBSTITUTION;
DERIVATIVES; NITRATION
AB Nitroarenes are ubiquitous environmental pollutants some of which exhibit mutagenic and tumorigenic activities. The first systematic investigation of the nitration reactions of the polycyclic fluoranthenes, a major class of nonalternant polyarenes, is described. The specific hydrocarbons studied were benz[e]acephenanthrylene (1), benz[a]aceanthrylene (2), indeno[1,2,3-cd]pyrene (3), indeno[1,2,3-hi]chrysene (4), dibenz[a,e]aceanthrylene (5), dibenz[a,j]aceanthrylene (6), and dibenz[e,k]acephenanthrylene (7). The nitration of all hydrocarbons, except 1, proceeded with remarkable regioselectivity to provide a single mononitro product. In the case of 1, 17 % of a second mononitro isomer was isolated. The structures of the resulting mononitrofluoranthenes (8-15) were fully characterized by analysis of their high-resolution COSY, long-range COSY, and NOESY NMR spectra and by comparison with the spectra of the parent hydrocarbons. The observed nitration sites of the polycyclic fluoranthenes were in excellent agreement with theoretical predictions made by the DEWAR-PI method based on the relative energies of the Wheland intermediates for substitutions at various ring positions. The availability of the complete H-1 chemical shift assignments of the nitropolycyclic fluoranthenes (8-15), together with those of the parent hydrocarbons (1-7) and their UV-visible spectral data, enabled the molecular conformations of the nitro groups to be probed.
C1 NATL CTR TOXICOL RES,DIV BIOCHEM TOXICOL,JEFFERSON,AR 72079.
UNIV CHICAGO,BEN MAY INST,CHICAGO,IL 60637.
RP CHO, BP (reprint author), UNIV RHODE ISL,COLL PHARM,DEPT MED CHEM,KINGSTON,RI 02881, USA.
NR 20
TC 12
Z9 12
U1 1
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0022-3263
J9 J ORG CHEM
JI J. Org. Chem.
PD OCT 8
PY 1993
VL 58
IS 21
BP 5788
EP 5796
DI 10.1021/jo00073a045
PG 9
WC Chemistry, Organic
SC Chemistry
GA MB560
UT WOS:A1993MB56000045
ER
PT J
AU VENABLE, RM
ZHANG, YH
HARDY, BJ
PASTOR, RW
AF VENABLE, RM
ZHANG, YH
HARDY, BJ
PASTOR, RW
TI MOLECULAR-DYNAMICS SIMULATIONS OF A LIPID BILAYER AND OF HEXADECANE - AN
INVESTIGATION OF MEMBRANE FLUIDITY
SO SCIENCE
LA English
DT Article
ID BIOLOGICAL-MEMBRANES; ROTATIONAL DIFFUSION; PHOSPHOLIPID BILAYER;
RELAXATION; PARAMETERS; CRYSTALS; MICELLE; CHAIN; MODEL
AB Molecular dynamics simulations of a fluid-phase dipalmitoyl phosphatidylcholine lipid bilayer in water and of neat hexadecane are reported and compared with nuclear magnetic resonance spin-lattice relaxation and quasi-elastic neutron scattering data. On the 100-picosecond time scale of the present simulations, there is effectively no difference in the reorientational dynamics of the carbons in the membrane interior and in pure hexadecane. Given that the calculated fast reorientational correlation times and the ''microscopic'' lateral diffusion of the lipids show excellent agreement with the experimental results, it is concluded that the apparently high viscosity of the membrane is more closely related to molecular interactions on the surface rather than in the interior.
C1 US FDA,CTR BIOL EVALUAT & RES,BIOPHYS LAB,8800 ROCKVILLE PIKE,BETHESDA,MD 20892.
NR 40
TC 283
Z9 283
U1 5
U2 40
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005
SN 0036-8075
J9 SCIENCE
JI Science
PD OCT 8
PY 1993
VL 262
IS 5131
BP 223
EP 226
DI 10.1126/science.8211140
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MA665
UT WOS:A1993MA66500029
PM 8211140
ER
PT J
AU TAKIMOTO, CH
VOELLER, DB
STRONG, JM
ANDERSON, L
CHU, E
ALLEGRA, CJ
AF TAKIMOTO, CH
VOELLER, DB
STRONG, JM
ANDERSON, L
CHU, E
ALLEGRA, CJ
TI EFFECTS OF 5-FLUOROURACIL SUBSTITUTION ON THE RNA CONFORMATION AND
IN-VITRO TRANSLATION OF THYMIDYLATE SYNTHASE MESSENGER-RNA
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID RESISTANT KB CELLS; DIHYDROFOLATE-REDUCTASE; CARCINOMA-CELLS;
CYTO-TOXICITY; RIBOSOMAL-RNA; HUMAN-BREAST; INHIBITION; COMBINATION;
ACID
AB In vitro transcribed thymidylate synthase (TS) mRNA which is 100% substituted with 5-fluorouracil (FUra) was analyzed for changes in mRNA secondary structure, for alterations in translational efficiency, and for evidence of translational miscoding in vitro. FUra substitution in TS mRNA results in an altered migration pattern in non-denaturing RNA gels and in decreased hyperchromicity in RNA melting temperature studies, consistent with a change in mRNA secondary structure. However, no change in the translational efficiency of FUra-substituted TS mRNA is seen compared to control TS mRNA in either rabbit reticulocyte lysate or wheat germ extract in vitro translation systems. Analysis of the in vitro translation product of FUra-substituted TS mRNA by Western immunoblotting, isoelectric focusing, 5-fluoro-2'-deoxyuridine 5'-monophosphate binding, and TS catalytic activity experiments shows no difference compared to control TS mRNA. We conclude that the in vitro translation products of FUra-substituted and control TS mRNA are identical. Our findings do not support the hypothesis that changes in the mRNA template are responsible for the RNA-directed cytotoxicity of FUra.
C1 US FDA, CTR DRUG EVALUAT & RES, DIV CLIN PHARMACOL, OFF RES RESOURCES, ROCKVILLE, MD 20850 USA.
RP TAKIMOTO, CH (reprint author), NATL NAVAL MED CTR, NCI,DIV CANC TREATMENT,MED ONCOL BRANCH,BLDG 8, RM 5101, BETHESDA, MD 20814 USA.
NR 31
TC 19
Z9 19
U1 0
U2 1
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 5
PY 1993
VL 268
IS 28
BP 21438
EP 21442
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA MA288
UT WOS:A1993MA28800115
PM 8407987
ER
PT J
AU FUHR, U
DOEHMER, J
BATTULA, N
WOLFEL, C
FLICK, I
KUDLA, C
KEITA, Y
STAIB, AH
AF FUHR, U
DOEHMER, J
BATTULA, N
WOLFEL, C
FLICK, I
KUDLA, C
KEITA, Y
STAIB, AH
TI BIOTRANSFORMATION OF METHYLXANTHINES IN MAMMALIAN-CELL LINES
GENETICALLY-ENGINEERED FOR EXPRESSION OF SINGLE CYTOCHROME-P450 ISOFORMS
- ALLOCATION OF METABOLIC PATHWAYS TO ISOFORMS AND INHIBITORY EFFECTS OF
QUINOLONES
SO TOXICOLOGY
LA English
DT Article; Proceedings Paper
CT MEETING ON APPLICATION OF CELLULAR SYSTEMS IN DRUG METABOLISM AND
TOXICITY STUDIES
CY JUL 21-24, 1991
CL OTZENHAUSEN, SAARLAND, GERMANY
SP STIFT VOLKSWAGENWERK, BAYER, GOEDECKE, HOECHST, PIERRE FABRE MEDICAMENT LAB, RHONE POULENC RORER, ROUSSELLL UCLAF
HO OTZENHAUSEN
DE CAFFEINE; CYTOCHROME-P450; CYTOCHROME P450IA2; GENE EXPRESSION;
METABOLISM; METHYLXANTHINES; PEFLOXACIN; PIPEMIDIC ACID; QUINOLONES; RAT
LIVER EPITHELIAL CELLS; V79 CHINESE HAMSTER CELLS
ID HUMAN-LIVER-MICROSOMES; CHINESE-HAMSTER-CELLS; THEOPHYLLINE METABOLISM;
CAFFEINE METABOLISM; STABLE EXPRESSION; RAT HEPATOCYTES; V79; CDNA;
CYTOCHROMES-P-450; HYDROXYLATION
AB V79 Chinese hamster cells genetically engineered for stable expression of single forms of rat cytochromes P450IA1, P450IA2, P450IIB1, human P450IA2, and rat liver epithelial cells expressing murine P450IA2 were used to allocate metabolic pathways of methylxanthines to specific isoforms and to test the suitability of such cell lines for investigations on drug interactions occurring at the cytochrome expressed. The cell lines were exposed to caffeine and/or theophylline and concentrations of metabolites formed in the medium were determined by HPLC. Caffeine was metabolized by human, rat and murine P450IA2, resulting in the formation of four primary demethylated and hydroxylated metabolites. However, there were differences in the relative amounts of the metabolites. The human and the mouse P450IA2 isoforms predominantly mediated 3-demethylation of caffeine. The rat cytochrome P450IA2 mediated both 3-demethylation and 1-demethylation of caffeine to a similar extent. The results support the hypothesis that caffeine plasma clearance is a specific in vivo probe for determining human P450IA2 activity. Addition of the quinolone antibiotic agents pipemidic acid or pefloxacin, both known to inhibit caffeine metabolism in vivo and in human liver microsomes, reduced formation rates of all metabolites of caffeine in cells expressing rat and human P450IA2. Theophylline was mainly metabolized via 8-hydroxylation. All cell lines tested were able to carry out this reaction, with highest activities in cell lines expressing rat or human P450IA2, or rat P450IA1.
C1 TECH UNIV MUNICH,INST TOXIKOL & UMWELTHYG,W-8000 MUNICH 2,GERMANY.
US FDA,DIV ANTIVIRAL DRUG PROD,KENSINGTON,MD 20895.
UNIV MAINZ,INST TOXICOL,W-6500 MAINZ,GERMANY.
RP FUHR, U (reprint author), UNIV HOSP FRANKFURT,DEPT CLIN PHARMACOL,THEODOR STERN KAI 7,D-60590 FRANKFURT,GERMANY.
NR 37
TC 17
Z9 18
U1 0
U2 0
PU ELSEVIER SCI IRELAND LTD
PI CLARE
PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
IRELAND
SN 0300-483X
J9 TOXICOLOGY
JI Toxicology
PD OCT 5
PY 1993
VL 82
IS 1-3
BP 169
EP 189
DI 10.1016/0300-483X(93)90064-Y
PG 21
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA MC363
UT WOS:A1993MC36300013
PM 8236273
ER
PT J
AU KESSLER, DA
AF KESSLER, DA
TI CHANGING THE CULTURE OF MEDICINE - THE FDAS MEDWATCH PROGRAM
SO ACADEMIC MEDICINE
LA English
DT Article
RP KESSLER, DA (reprint author), US FDA,WASHINGTON,DC 20204, USA.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU HANLEY & BELFUS INC
PI PHILADELPHIA
PA 210 S 13TH ST, PHILADELPHIA, PA 19107
SN 1040-2446
J9 ACAD MED
JI Acad. Med.
PD OCT
PY 1993
VL 68
IS 10
BP 776
EP 777
DI 10.1097/00001888-199310000-00008
PG 2
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA MC301
UT WOS:A1993MC30100011
PM 8397603
ER
PT J
AU XIAO, Y
VONTUNGELN, LS
CHOU, MW
HART, RW
FU, PP
AF XIAO, Y
VONTUNGELN, LS
CHOU, MW
HART, RW
FU, PP
TI EFFECT OF CALORIC RESTRICTION ON THE METABOLISM OF
7-BROMOBENZ[A]ANTHRACENE AND 7-FLUOROBENZ[A]ANTHRACENE BY MALE B6C3F(1),
MOUSE-LIVER MICROSOMES - REDUCTION OF METABOLIC-ACTIVATION PATHWAY
SO AGE
LA English
DT Article
ID MALE-RATS; STEREOSELECTIVE METABOLISM; FISCHER-344 RATS; FOOD
RESTRICTION; ENZYMES; BENZOPYRENE; SYSTEM
AB The effect of caloric restriction (CR) on the in vitro metabolism of 7-bromobenz[a]anthracene (7-Br-BA) and 7-fluorobenz[a]anthracene (7-F-BA) by liver microsomes isolated from 5- and 12-month-old male B6C3F(1) mice was studied. Mice were fed ad libitum (AL), or starting at 14 weeks of age, received 60% of the calories consumed by control mice. After microsomal incubation, metabolites were separated by HPLC and their structures identified by comparison of their spectra with known standards. The metabolites formed were: trans-3,4-dihydrodiol, trans-5,6-dihydrodiol, trans-8,9-dihydrodiol and trans-10,11-dihydrodiol, 5,6-epoxide, and 4-, 5-, 6-, 8-, and 9-phenolic derivatives. The formation of the 7-Br-BA trans-3,4-dihydrodiol and 7-F-BA trans-3,4-dihydrodiol, the proximate mutagens of 7-Br-BA and 7-F-BA, respectively, was lower in microsomal incubation mixtures derived from the 5-month-old CR mice as compared to those from the AL. These results suggest that CR can diminish the genotoxicity of polycyclic aromatic hydrocarbons by directly altering metabolic activation.
C1 CHINESE ACAD PREVENT MED,INST NUTR & FOOD HYG,BEIJING,PEOPLES R CHINA.
NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
NR 32
TC 7
Z9 7
U1 0
U2 0
PU AMER AGING ASSOC
PI CHESTER
PA 2129 PROVIDENCE AVENUE, CHESTER, PA 19013
SN 0161-9152
J9 AGE
JI Age
PD OCT
PY 1993
VL 16
IS 4
BP 160
EP 165
DI 10.1007/BF02434993
PG 6
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA NA507
UT WOS:A1993NA50700004
ER
PT J
AU XIAO, Y
VONTUNGELN, LS
CHOU, MW
HART, RW
FU, PP
AF XIAO, Y
VONTUNGELN, LS
CHOU, MW
HART, RW
FU, PP
TI EFFECT OF CALORIC RESTRICTION ON THE STEREOSELECTIVE METABOLISM OF
7-CHLOROBENZ[A]ANTHRACENE BY MALE B6C3F(1) MOUSE-LIVER MICROSOMES
SO AGE
LA English
DT Article
ID TRANS-DIHYDRODIOL METABOLITES; MALE-RATS; ABSOLUTE-CONFIGURATIONS; FOOD
RESTRICTION; FISCHER-344 RAT; ENZYMES; 7-BROMOBENZANTHRACENE; SYSTEM
AB The effect of caloric restriction (CR) on the stereoselective metabolism of 7-chlorobenz[a]anthracene (7-Cl-BA) by liver microsomes of 5- and 12-month-old male B6C3F(1) mice was studied. Mice were fed ad libitum (AL), or starting at 14 weeks of age, received 60% of the calories consumed by control mice. After microsomal incubation, metabolites were extracted with ethyl acetate, purified by reversed-phase HPLC, and identified by analysis of their UV-visible and mass spectral data. The following ten metabolites were identified: 7-Cl-BA trans-3,4-dihydrodiol, 7-Cl-BA trans-5,6-dihydrodiol, 7-Cl-BA trans-8,9-dihydrodiol, 7-Cl-BA trans-10,11-dihydrodiol, 7-Cl-BA 5,6-epoxide, and 4-, 5-, 6-, 8-, and 9-OH-7-Cl-BA. Contrary to the metabolism of 7-Br-BA and 7-F-BA, the formation of 7-Cl-BA trans-3,4-dihydrodiol in AL and CR microsomes were equivalent regardless of age. 7-Cl-BA trans-8,9-dihydrodiol from liver microsomes of 5-month-old CR mice contained 95% of the R,R enantiomer and 5% of the S,S enantiomer, and thus had an optical purity of 90%. By comparison, the 7-Cl-BA trans-8,9-dihydrodiol formed from liver microsomes of 5-month-old AL mice had an optical purity of 68%. On the other hand, the optical purity of 7-Cl-BA trans-10,11-dihydrodiol formed from the AL microsomes was higher than that from CR microsomes. Thus, these results suggest that caloric restriction can alter the stereoselectivity of the cytochrome P-450 isozymes.
C1 NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
CHINESE ACAD PREVENT MED,INST NUTR & FOOD HYG,BEIJING,PEOPLES R CHINA.
NR 25
TC 5
Z9 5
U1 0
U2 0
PU AMER AGING ASSOC
PI CHESTER
PA 2129 PROVIDENCE AVENUE, CHESTER, PA 19013
SN 0161-9152
J9 AGE
JI Age
PD OCT
PY 1993
VL 16
IS 4
BP 166
EP 172
DI 10.1007/BF02434994
PG 7
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA NA507
UT WOS:A1993NA50700005
ER
PT J
AU ORAVECZ, T
NORCROSS, MA
AF ORAVECZ, T
NORCROSS, MA
TI COSTIMULATORY PROPERTIES OF THE HUMAN CD4 MOLECULE - ENHANCEMENT OF
CD3-INDUCED T-CELL ACTIVATION BY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
THROUGH VIRAL ENVELOPE GLYCOPROTEIN GP120
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID LYMPHOCYTES-T; HIV-INFECTION; MONOCLONAL-ANTIBODIES; SIGNAL
TRANSDUCTION; KINASE P56LCK; CROSS-LINKING; HTLV-III; RECEPTOR; ANTIGEN;
RESPONSES
AB This study was designed to investigate the T cell-costimulatory activity of ligands binding to different regions on the human CD4 molecule. We assayed the costimulatory properties of a panel of CD4 MAbs, intact HIV, and viral envelope glycoproteins in CD3-induced activation of resting T cell subpopulations. Our data using MAbs reveal epitope-specific variations in the functional activities of CD4 MAbs under specific conditions in which CD3 and CD4 molecules are co-cross-linked. We show that both naive and memory CD4+ T cell subsets are susceptible to CD4-mediated costimulation, which overcomes the functional differences between the two cell populations in responsiveness to CD3 MAbs. We show for the first time that, analogous to CD4 MAbs, preparations of HIV and viral envelope glycoprotein gp120 are also potent costimulators of T cell proliferation and IL-2 production. On the basis of these results we propose possible mechanisms for polyclonal cell activation in the course of HIV infection and suggest that viral inhibitory and costimulatory effects may together disrupt the normal balanced function of the immune system, leading to AIDS.
C1 NIH,US FDA,CTR BIOL EVALUAT & RES,DIV HEMATOL PROD,BLDG 29A,ROOM 3B10,BETHESDA,MD 20892.
NR 50
TC 16
Z9 16
U1 1
U2 1
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 1993
VL 9
IS 10
BP 945
EP 955
DI 10.1089/aid.1993.9.945
PG 11
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA MF842
UT WOS:A1993MF84200003
PM 7506554
ER
PT J
AU SHIRAI, A
KLINMAN, DM
AF SHIRAI, A
KLINMAN, DM
TI IMMUNIZATION WITH RECOMBINANT GP160 PROLONGS THE SURVIVAL OF HIV-1
TRANSGENIC MICE
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; RENAL-DISEASE; HOMOSEXUAL MEN; INFECTION;
TYPE-1; NEUTRALIZATION; ANTIBODIES; PROTECTION; SPECTRUM; GENES
AB A strain of mouse transgenic for the env gene of the HIV-1 virus was used to study the immunogenicity of a gp160-derived vaccine (the protein encoded by the HIV env gene) and its effect on disease progression. Untreated transgenic mice frequently developed a rapidly progressive renal disease similar to that affecting approximately 10% of HIV-infected humans. When transgenic mice were immunized with recombinant purified gp160, their edema, proteinuria, and serum BUN levels were substantially reduced and their survival prolonged (p < 0.01). The increased longevity of immunized transgenic mice correlated with the production of IgG antibodies reactive with gp160.
C1 US FDA,CTR BIOL EVALUAT & RES,DIV VIRAL PROD,RETROVIRAL IMMUNOL SECT,BLDG 29A,ROOM 3D10,BETHESDA,MD 20892.
NR 24
TC 14
Z9 14
U1 0
U2 1
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 1993
VL 9
IS 10
BP 979
EP 983
DI 10.1089/aid.1993.9.979
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA MF842
UT WOS:A1993MF84200007
PM 8280480
ER
PT J
AU GOLDENTHAL, KL
CAVAGNARO, JA
ALVING, CR
VOGEL, FR
AF GOLDENTHAL, KL
CAVAGNARO, JA
ALVING, CR
VOGEL, FR
TI SAFETY EVALUATION OF VACCINE ADJUVANTS -
NATIONAL-COOPERATIVE-VACCINE-DEVELOPMENT-MEETING-WORKING-GROUP
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID IMMUNOLOGICAL ADJUVANTS; CLINICAL-TRIAL; VIRUS VACCINE; INFLUENZA;
IMMUNOTHERAPY; INTERFERON
C1 NIAID, DIV AIDS,VACCINE RES & DEV BRANCH,SOLAR BLDG, ROOM 2B06, BETHESDA, MD 20892 USA.
US FDA, CTR BIOL EVALUAT & RES, BETHESDA, MD 20892 USA.
WALTER REED ARMY INST RES, DEPT MEMBRANE BIOCHEM, WASHINGTON, DC 20307 USA.
NR 35
TC 24
Z9 27
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 1993
VL 9
SU 1
BP S47
EP S51
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA ME188
UT WOS:A1993ME18800034
ER
PT J
AU LAWRENCE, DN
ESPARZA, J
ZOON, KC
AF LAWRENCE, DN
ESPARZA, J
ZOON, KC
TI CONSIDERATIONS ON CRITERIA FOR COMMENCEMENT OF HIV VACCINE EFFICACY
TRIALS - A WORKING GROUP SUMMARY
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
C1 WHO,VACCINE DEV UNIT,GLOBAL PROGRAMME AIDS,CH-1211 GENEVA 27,SWITZERLAND.
US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892.
RP LAWRENCE, DN (reprint author), NIAID,DIV AIDS,ROOM 2B09,SOLAR BLDG,6003 EXECUT BLVD,BETHESDA,MD 20892, USA.
NR 0
TC 8
Z9 8
U1 0
U2 1
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 1993
VL 9
SU 1
BP S65
EP S69
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA ME188
UT WOS:A1993ME18800038
ER
PT J
AU ZOON, KC
AF ZOON, KC
TI THE EMERGING PARTNERSHIP - FOOD-AND-DRUG-ADMINISTRATION AND HIV VACCINE
EFFICACY TRIALS
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
RP ZOON, KC (reprint author), CTR BIOL EVALUAT & RES,ROOM 130,BLDG 29,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 1993
VL 9
SU 1
BP S141
EP S142
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA ME188
UT WOS:A1993ME18800112
ER
PT J
AU WEIS, C
LITTLEFIELD, N
JACKSON, CD
AF WEIS, C
LITTLEFIELD, N
JACKSON, CD
TI A DIRECT FLUOROMETRIC ASSAY FOR DNA IN ALKALINE SUCROSE GRADIENTS USING
HOECHST 33258 DYE
SO AMERICAN BIOTECHNOLOGY LABORATORY
LA English
DT Note
ID CELLS-INVITRO; 33258-HOECHST; DAMAGE; REPAIR
RP WEIS, C (reprint author), NATL CTR TOXICOL RES,DIV NUTR TOXICOL,1 NCTR DR,JEFFERSON,AR 72079, USA.
NR 12
TC 1
Z9 1
U1 0
U2 1
PU INT SCIENTIFIC COMMUN INC
PI SHELTON
PA PO BOX 870, 30 CONTROLS DRIVE, SHELTON, CT 06484-0870
SN 0749-3223
J9 AM BIOTECHNOL LAB
JI Am. Biotechnol. Lab.
PD OCT
PY 1993
VL 11
IS 11
BP 50
EP &
PG 0
WC Biotechnology & Applied Microbiology; Medical Laboratory Technology
SC Biotechnology & Applied Microbiology; Medical Laboratory Technology
GA MB477
UT WOS:A1993MB47700004
PM 7691089
ER
PT J
AU BURKHART, G
SCHULTE, PA
ROBINSON, C
SIEBER, WK
VOSSENAS, P
RINGEN, K
AF BURKHART, G
SCHULTE, PA
ROBINSON, C
SIEBER, WK
VOSSENAS, P
RINGEN, K
TI JOB TASKS, POTENTIAL EXPOSURES, AND HEALTH RISKS OF LABORERS EMPLOYED IN
THE CONSTRUCTION-INDUSTRY
SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE
LA English
DT Article
DE LABORER; CONSTRUCTION; SAND HOG; HAULER; UNSKILLED TRADES; OCCUPATIONAL
HAZARDS; NOISE; OSHA EXEMPTIONS; FATAL INJURIES; ECZEMA; BLACK
MORTALITY; NO-COLLAR WORKERS
ID PROPORTIONATE MORTALITY RATIO; OCCUPATION; CANCER; INJURIES; PAINTERS
AB Construction laborers have some of the highest death rates of any occupation in the United States. There has been very little systematic research focused exclusively on ''laborers'' as opposed to other workers in the construction industry. We reviewed the English language literature and various data bases describing the occupational tasks, exposures, and work-related health risks of construction laborers. The sources of information included 1) occupational mortality surveillance data collected by the states of California and Washington and the National Institute for Occupational Safety and Health (NIOSH); 2) National Occupational Exposure Survey; 3) national fatality data; 4) cancer registry data; and 5) case reports of specific causes of morbidity. While the literature reported that construction laborers have increased risk for mesothelioma, on-the-job trauma, acute lead poisoning, musculoskeletal injury, and dermatitis, the work relatedness of excess risks for all-cause mortality, cirrhosis, cerebrovascular disease, chronic obstructive pulmonary disease, ischemic heart disease, and leukemia is less clear. Furthermore, while laborers are known to be potentially exposed to asbestos, noise, and lead, and the NIOSH Job Exposure Matrix describes other potential hazardous exposures, little research has characterized other possible exposures and no research has been found that describes the exposures associated with specific job tasks. More advanced study designs are needed that include a better understanding of the job tasks and exposures to construction laborers, in order to evaluate specific exposure-disease relationships and to develop intervention programs aimed at reducing the rate of work-related diseases. (C) 1993 Wiley-Liss, Inc.
C1 NIOSH,4676 COLUMBIA PKWY,MS-R42,CINCINNATI,OH 45226.
US FDA,ROCKVILLE,MD 20857.
NR 46
TC 48
Z9 50
U1 0
U2 7
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0271-3586
J9 AM J IND MED
JI Am. J. Ind. Med.
PD OCT
PY 1993
VL 24
IS 4
BP 413
EP 425
DI 10.1002/ajim.4700240407
PG 13
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA LY622
UT WOS:A1993LY62200006
PM 8250061
ER
PT J
AU MANGER, RL
LEJA, LS
LEE, SY
HUNGERFORD, JM
WEKELL, MM
AF MANGER, RL
LEJA, LS
LEE, SY
HUNGERFORD, JM
WEKELL, MM
TI TETRAZOLIUM-BASED CELL BIOASSAY FOR NEUROTOXINS ACTIVE ON
VOLTAGE-SENSITIVE SODIUM-CHANNELS - SEMIAUTOMATED ASSAY FOR SAXITOXINS,
BREVETOXINS, AND CIGUATOXINS
SO ANALYTICAL BIOCHEMISTRY
LA English
DT Article
ID COLORIMETRIC ASSAY; ACTIVATION; TOXICITY; TOXINS; GROWTH
RP MANGER, RL (reprint author), US FDA,SEAFOOD PROD RES CTR,BOTHELL,WA 98041, USA.
NR 20
TC 162
Z9 175
U1 1
U2 14
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0003-2697
J9 ANAL BIOCHEM
JI Anal. Biochem.
PD OCT
PY 1993
VL 214
IS 1
BP 190
EP 194
DI 10.1006/abio.1993.1476
PG 5
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA MA042
UT WOS:A1993MA04200029
PM 8250223
ER
PT J
AU CARSON, JL
STROM, BL
DUFF, A
GUPTA, A
SHAW, M
LUNDIN, FE
DAS, K
AF CARSON, JL
STROM, BL
DUFF, A
GUPTA, A
SHAW, M
LUNDIN, FE
DAS, K
TI ACUTE-LIVER-DISEASE ASSOCIATED WITH ERYTHROMYCINS, SULFONAMIDES, AND
TETRACYCLINES
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
DE HEPATITIS, TOXIC; ERYTHROMYCIN; SULFONAMIDES; TETRACYCLINES;
HOSPITALIZATION
ID TRIMETHOPRIM-SULFAMETHOXAZOLE; INTRAHEPATIC CHOLESTASIS; HEPATIC
CHOLESTASIS; SKIN RASH; HEPATOTOXICITY; SULFASALAZINE; MINOCYCLINE;
ETHYLSUCCINATE; FAILURE
AB Objective: To determine whether erythromycins, sulfonamides, and tetracyclines are associated with an increased risk for acute hepatitis.
Design: Case-control study.
Setting: Medicaid billing data from Michigan and Florida between 1980 and 1987.
Patients: The 107 cases included patients hospitalized with acute symptomatic hepatitis without an identifiable cause of liver disease noted in the medical record. Four controls per case were randomly selected and were matched for age, sex, and state.
Results: Five cases (4.7%) and four controls (0.9%) were exposed to erythromycins, yielding an odds ratio of 5.2 (95% CI, 1.1 to 26.6). No case or control was exposed to erythromycin estolate. Eight cases (7.5%) and three controls (0.7%) were exposed to oral sultonamides, yielding an odds ratio of 11.4 (CI, 2.7 to 67.8). All (except one control) had received trimethoprimsulfamethoxazole. Five cases (4.7%) and four controls (0.9%) were exposed to tetracyclines, yielding an odds ratio of 5.2 (CI, 1.4 to 19.7). The results did not change substantively for erythromycin or sulfonamides after adjustment using multiple logistic regression for age, sex, state, and use of other hepatotoxic drugs. With tetracyclines, however, the odds ratio decreased to 3.6 (CI, 0.9 to 14.3). Associations were also seen with isoniazid (P = 0.008) and rifampicin (P = 0.04). The number of patients developing acute symptomatic liver disease resulting in hospitalization for each million patients treated with a 10-day course of erythromycin was 2.28 cases; for sulfonamides, this figure was 4.8 cases; and for tetracycline, the figure was 1.56 cases.
Conclusion: Erythromycin, sulfonamides, and tetracyclines are associated with acute symptomatic hepatitis resulting in hospitalization. Given the widespread use of these drugs, they will be among the more common drugs associated with hepatitis.
C1 UNIV PENN,SCH MED,CTR CLIN EPIDEMIOL & BIOSTAT,PHILADELPHIA,PA 19104.
HLTH INFORMAT DESIGNS INC,ARLINGTON,VA.
US FDA,DIV DRUG & BIOL PROD EXPERIENCE,EPIDEMIOL DEV BRANCH,ROCKVILLE,MD 20857.
RP CARSON, JL (reprint author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DIV GEN INTERNAL MED,97 PATERSON ST,NEW BRUNSWICK,NJ 08903, USA.
FU FDA HHS [FD-U-000079]
NR 58
TC 50
Z9 51
U1 2
U2 2
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572
SN 0003-4819
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD OCT 1
PY 1993
VL 119
IS 7
BP 576
EP 583
PN 1
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA MA291
UT WOS:A1993MA29100005
PM 8363168
ER
PT J
AU LEVY, AS
HEATON, AW
AF LEVY, AS
HEATON, AW
TI WEIGHT CONTROL PRACTICES OF UNITED-STATES ADULTS TRYING TO LOSE WEIGHT
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article; Proceedings Paper
CT CONF ON METHODS FOR VOLUNTARY WEIGHT-LOSS AND CONTROL
CY MAR 30-APR 01, 1992
CL BETHESDA, MD
SP NIH, NUTR COORDINATING COMM, NIH, OFF MED APPL RES
ID BEHAVIOR; OBJECTIVES
AB Objective: To estimate the relative prevalence of different types and combinations of practices among weight-loss practitioners and to describe the relations between individual characteristics and various features of weight-loss regimens.
Design: A telephone survey of a random digit-dialed probability sample of adults in the continental United States who reported that they were trying to lose weight.
Participants: A total of 1431 persons 18 years or older who were attempting to lose weight.
Measurements: Self-reports of a detailed inventory of more than 35 specific practices that might be used as part of a voluntary weight-loss plan, along with information about individual characteristics such as current weight, weight-loss history, demographic profile, motivations to lose weight, sources of information, and knowledge about diet and health.
Results: The average respondent had a current weight-loss attempt lasting from 5 to 6 months, had tried a similar plan before, and had averaged one attempt a year for the past 2 years. Seventy-one percent of women and 62% of men reported that they were both changing their diet and exercising more as part of a current weight-loss attempt. Frequently reported weight-loss practices included weighing oneself regularly (71% and 70% for women and men, respectively), walking (58% and 44%), using diet soft drinks (52% and 45%), taking vitamins and minerals (33% and 26%), counting calories (25% and 17%), skipping meals (21% and 20%), using commercial meal replacements, (15% and 13%), taking diet pills (14% and 7%), and participating in organized weight-loss programs (13% and 5%). Sex, education, and overweight status influenced the choice of a weight-loss practice.
Conclusions: Individual approaches to weight-loss vary and are characterized by their duration and by their recurrent nature. Policy efforts should be directed toward increasing the long-term effectiveness of individual weight-loss plans.
RP LEVY, AS (reprint author), USDA,CTR FOOD SAFETY & APPL NUTR,DIV MARKET STUDIES,HFS-727,200 C ST NW,WASHINGTON,DC 20204, USA.
NR 13
TC 140
Z9 142
U1 1
U2 5
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572
SN 0003-4819
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD OCT 1
PY 1993
VL 119
IS 7
BP 661
EP 666
PN 2
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA MA330
UT WOS:A1993MA33000007
PM 8363193
ER
PT J
AU DATTA, AR
KOTHARY, MH
AF DATTA, AR
KOTHARY, MH
TI EFFECTS OF GLUCOSE, GROWTH TEMPERATURE, AND PH ON LISTERIOLYSIN-O
PRODUCTION IN LISTERIA-MONOCYTOGENES
SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY
LA English
DT Note
ID EXPRESSION; QUANTITIES; PROTEINS; GENE
AB Expression of listeriolysin O of Listeria monocytogenes as a function of different growth conditions was studied by performing a direct hemolysin assay, immunoblotting experiments, and an enzyme-linked immunosorbent assay. Expression of listeriolysin O was reduced at a lower growth temperatures (26-degrees-C) and at higher glucose concentrations (greater-than-or-equal-to 0.3%) in the growth media. The effect of glucose appeared to be due to a change in the pH of the growth media.
RP DATTA, AR (reprint author), US FDA,DIV MICROBIOL,WASHINGTON,DC 20204, USA.
NR 14
TC 52
Z9 54
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0099-2240
J9 APPL ENVIRON MICROB
JI Appl. Environ. Microbiol.
PD OCT
PY 1993
VL 59
IS 10
BP 3495
EP 3497
PG 3
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA MA353
UT WOS:A1993MA35300051
PM 8250571
ER
PT J
AU HELLMAN, KB
PICCIOLO, GL
MUELLER, EP
AF HELLMAN, KB
PICCIOLO, GL
MUELLER, EP
TI BIOMATERIALS AND BIOTECHNOLOGY
SO BIO-TECHNOLOGY
LA English
DT Note
RP HELLMAN, KB (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20852, USA.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU NATURE PUBLISHING CO
PI NEW YORK
PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707
SN 0733-222X
J9 BIO-TECHNOL
JI Bio-Technology
PD OCT
PY 1993
VL 11
IS 10
BP 1179
EP 1180
PG 2
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA LZ373
UT WOS:A1993LZ37300031
PM 7764101
ER
PT J
AU SAXTON, WL
NEWTON, RT
RORBERG, J
SUTTON, J
JOHNSON, LE
AF SAXTON, WL
NEWTON, RT
RORBERG, J
SUTTON, J
JOHNSON, LE
TI POLYCYCLIC AROMATIC-HYDROCARBONS IN SEAFOOD FROM THE GULF OF ALASKA
FOLLOWING A MAJOR CRUDE-OIL SPILL
SO BULLETIN OF ENVIRONMENTAL CONTAMINATION AND TOXICOLOGY
LA English
DT Article
RP SAXTON, WL (reprint author), US FDA,POB 3012,BOTHELL,WA 98041, USA.
NR 4
TC 11
Z9 12
U1 0
U2 3
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010
SN 0007-4861
J9 B ENVIRON CONTAM TOX
JI Bull. Environ. Contam. Toxicol.
PD OCT
PY 1993
VL 51
IS 4
BP 515
EP 522
PG 8
WC Environmental Sciences; Toxicology
SC Environmental Sciences & Ecology; Toxicology
GA LR467
UT WOS:A1993LR46700007
PM 8400653
ER
PT J
AU JAMISDOW, CA
KLECKER, RW
SAROSY, G
REED, E
COLLINS, JM
AF JAMISDOW, CA
KLECKER, RW
SAROSY, G
REED, E
COLLINS, JM
TI STEADY-STATE PLASMA-CONCENTRATIONS AND EFFECTS OF TAXOL FOR A
250-MG/M(2) DOSE IN COMBINATION WITH GRANULOCYTE-COLONY-STIMULATING
FACTOR IN PATIENTS WITH OVARIAN-CANCER
SO CANCER CHEMOTHERAPY AND PHARMACOLOGY
LA English
DT Article
DE TAXOL; HPLC; PROTEIN BINDING; PHARMACOKINETICS; OVARIAN CANCER
ID PHASE-I TRIAL; INFUSION; MELANOMA; TUBULIN; AGENTS
AB Taxol, a natural product initially isolated from the stem bark of the western yew Taxus brevifolia, is undergoing phase II and III evaluation due to its reported activity against a variety of tumors. Previous studies have described correlations between plasma concentrations and toxicity when taxol is given (a) at lower doses, (b) for shorter infusion times, and (c) without granulocyte-colony-stimulating factor. Because the 24-h infusion schedule is most commonly used in current clinical trials, we attempted to correlate steady-state plasma concentrations of taxol achieved with a 24-h continuous i.v. infusion with toxicities and responses. Plasma samples from 48 refractory ovarian cancer patients were obtained 1-2 h prior to the end of the first taxol infusion. Taxol concentrations were measured by high-performance liquid chromatography (HPLC). Interpatient variation of taxol plasma concentrations was small (mean +/- SD, 0.85 +/- 0.21 muM. Total taxol body clearance was 256 +/- 72 ml min-1 m-2 (mean +/- SD). Taxol plasma protein binding was 88.4% +/- 1.3% (mean +/- SD, n = 9). Grade 3-4 hematologic toxicity, mainly leukopenia, occurred in 92% of the patients. The leukopenia was transient and did not warrant a reduction in the dose of taxol. Grade 3-4 nonhematologic toxicity occurred in 8% of the patients. No severe hypersensitivity reaction or grade 3-4 neurotoxicity was observed. Correlations of plasma concentrations and toxicities were not feasible due to the high frequency of hematologic effects and the low frequency of nonhematologic toxicity. The low degree of interpatient variation in plasma concentrations hindered the development of correlations with response.
C1 NCI,DIV CANC TREATMENT,CLIN ONCOL PROGRAM,MED BRANCH,BETHESDA,MD 20892.
RP JAMISDOW, CA (reprint author), US FDA,CTR DRUG EVALUAT & RES,DIV CLIN PHARMACOL,OFF RES RESOURCES,4 RES COURT,ROOM 314,ROCKVILLE,MD 20850, USA.
RI Ain, Kenneth/A-5179-2012
OI Ain, Kenneth/0000-0002-2668-934X
NR 19
TC 72
Z9 73
U1 0
U2 0
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010
SN 0344-5704
J9 CANCER CHEMOTH PHARM
JI Cancer Chemother. Pharmacol.
PD OCT
PY 1993
VL 33
IS 1
BP 48
EP 52
DI 10.1007/BF00686022
PG 5
WC Oncology; Pharmacology & Pharmacy
SC Oncology; Pharmacology & Pharmacy
GA MC707
UT WOS:A1993MC70700008
PM 7505722
ER
PT J
AU BLACK, PL
PHILLIPS, H
TRIBBLE, HR
PENNINGTON, R
SCHNEIDER, M
TALMADGE, JE
AF BLACK, PL
PHILLIPS, H
TRIBBLE, HR
PENNINGTON, R
SCHNEIDER, M
TALMADGE, JE
TI ANTITUMOR RESPONSE TO RECOMBINANT MURINE INTERFERON-GAMMA CORRELATES
WITH ENHANCED IMMUNE FUNCTION OF ORGAN-ASSOCIATED, BUT NOT RECIRCULATING
CYTOLYTIC T-LYMPHOCYTES AND MACROPHAGES
SO CANCER IMMUNOLOGY IMMUNOTHERAPY
LA English
DT Article
DE MURINE INTERFERON-GAMMA; ANTITUMOR RESPONSE; ORGAN-ASSOCIATED CTL;
MACROPHAGES; IMMUNOTHERAPY
ID PHASE-I TRIAL; CHRONIC GRANULOMATOUS-DISEASE; KILLER CELL-ACTIVITY;
CANCER-PATIENTS; HYDROGEN-PEROXIDE; IFN-GAMMA; ACTIVATION; INDUCTION;
INDUCERS; MELANOMA
AB The mechanism of therapeutic activity for recombinant murine interferon-gamma (rMu IFNgamma) in the treatment of metastatic disease was investigated by comparing effector cell augmentation with therapeutic activity in mice bearing experimental lung metastases (B16-BL6 melanoma). Effector cell functions in spleen, peripheral blood, and lung (the tumor-bearing organ) were tested after 1 week and 3 weeks of rMu IFNgamma administration (i. v. three times per week). Natural killer (NK), lymphokine-activated killer (LAK), cytolytic T lymphocyte (CTL) activities against specific and nonspecific targets, and macrophage tumoristatic activity were measured. rMu IFNgamma demonstrated immunomodulatory activity in most assays of immune function. The optimal therapeutic protocol of rMu IFNgamma (2.5 x 10(6) U/kg, three times per week) prolonged survival and decreased the number of pulmonary metastatic foci. This therapeutic activity was correlated with specific CTL activity from pulmonary parenchymal mononuclear cells (PPMC), but not from spleen or blood. Macrophage tumoristatic activity in PPMC also correlated with therapeutic activity, but activity in alveolar macrophages did not. However, therapeutic activity did not correlate with NK or LAK activity at any site. These results demonstrate that the optimal therapeutic protocol is the same as the optimal immunomodulatory dose for pulmonary CTL and macrophage activities. Furthermore, while immunological monitoring may help to optimize treatment protocols, current monitoring procedures that use readily accessible sites, particularly peripheral blood, may not accurately predict the therapeutic efficacy of biological response modifiers in clinical trials.
RP BLACK, PL (reprint author), US FDA,DIV ANTIVIRAL DRUG PROD,HFD-530,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.
RI Talmadge, James/A-5916-2008
OI Talmadge, James/0000-0002-6328-6056
FU PHS HHS [N01-23910]
NR 44
TC 9
Z9 9
U1 0
U2 0
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010
SN 0340-7004
J9 CANCER IMMUNOL IMMUN
JI Cancer Immunol. Immunother.
PD OCT
PY 1993
VL 37
IS 5
BP 299
EP 306
DI 10.1007/BF01518452
PG 8
WC Oncology; Immunology
SC Oncology; Immunology
GA LZ720
UT WOS:A1993LZ72000004
PM 8402733
ER
PT J
AU LI, EE
HEFLICH, RH
DELCLOS, KB
AF LI, EE
HEFLICH, RH
DELCLOS, KB
TI TRANS-1,2-DIHYDRO-1,2-DIHYDROXY-6-AMINOCHRYSENE IS METABOLIZED TO FORM A
MAJOR ADDUCT WITH DEOXYGUANOSINE AND PRODUCES MUTATIONS IN THE HPRT GENE
OF CHINESE-HAMSTER OVARY CELLS AT G-C BASEPAIRS
SO CARCINOGENESIS
LA English
DT Article
ID DIPLOID HUMAN FIBROBLASTS; POLYCYCLIC AROMATIC-HYDROCARBONS;
DIHYDROFOLATE-REDUCTASE MUTANTS; NEWBORN MOUSE ASSAY; DNA-BASE CHANGES;
CODING REGION; SEQUENCE-ANALYSIS; EXCISION REPAIR; 6-NITROCHRYSENE;
TUMORIGENICITY
AB 6-Nitrochrysene can be activated to genotoxic derivatives by two major metabolic pathways: nitroreduction to N-hydroxy-6-aminochrysene, and a combination of ring-oxidation and nitroreduction that involves the intermediate formation of trans-1,2-dihydro-1,2-dihydroxy-6-aminochrysene (6-AC-1,2-dihydrodiol). The DNA adduct formed from this latter pathway was evaluated by reacting individual deoxynucleoside 5'-monophosphates with 6-AC-1,2-dihydrodiol in the presence of liver microsomal enzymes from 3-methylcholanthrene-pretreated rats. Binding was greatest to deoxyguanosine monophosphate and the major deoxyguanosine (dG) adduct co-chromatographed with the single major adduct formed from the microsome-catalyzed reaction of 6-AC-1,2-dihydrodiol with DNA. In order to characterize the mutational changes associated with the 6-AC-1,2-dihydrodiol pathway, we analyzed the mutational spectrum produced by 6-AC-1,2-dihydrodiol in the hypoxanthine-guanine phosphoribosyl-transferase (hprt) gene of CHO-K1 cells. cDNA was synthesized from the RNA of 28 6-thioguanine-resistant mutants, the hprt coding region amplified by the polymerase chain reaction, and the DNA products directly sequenced. Twenty independent primary mutations were found: 12 G:C --> T:A transversions, three G:C --> C:G transversions, one G:C --> A:T transition, one A:T --> T:A transversion, two -1 frameshift mutations in sequences containing consecutive guanines, and one 11 bp deletion. All G:C basepair substitutions had the mutated dG on the non-transcribed strand and 86% of the G:C basepair substitutions had one purine 3' to the mutated dG. The pattern of 6-AC-1,2-dihydrodiol-induced basepair substitutions was distinct from the pattern observed in solvent control mutants. These results are consistent with the formation of a promutagenic dG adduct from a metabolite of 6-AC-1,2-dihydrodiol.
C1 NATL CTR TOXICOL RES,DIV BIOCHEM,JEFFERSON,AR 72079.
NATL CTR TOXICOL RES,DIV GENET TOXICOL,JEFFERSON,AR 72079.
UNIV ARKANSAS MED SCI HOSP,DEPT PHARMACOL & TOXICOL,LITTLE ROCK,AR 72205.
NR 38
TC 17
Z9 17
U1 0
U2 0
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD OCT
PY 1993
VL 14
IS 10
BP 2109
EP 2114
DI 10.1093/carcin/14.10.2109
PG 6
WC Oncology
SC Oncology
GA MD319
UT WOS:A1993MD31900020
PM 8222062
ER
PT J
AU SEGERBACK, D
KADERLIK, KR
TALASKA, G
DOOLEY, KL
KADLUBAR, FF
AF SEGERBACK, D
KADERLIK, KR
TALASKA, G
DOOLEY, KL
KADLUBAR, FF
TI P-32 POSTLABELING ANALYSIS OF DNA-ADDUCTS OF
4,4'-METHYLENEBIS(2-CHLOROANILINE) IN TARGET AND NONTARGET TISSUES IN
THE DOG AND THEIR IMPLICATIONS FOR HUMAN RISK ASSESSMENT
SO CARCINOGENESIS
LA English
DT Article
ID POST-LABELING ANALYSIS; URINARY-BLADDER; COVALENT BINDING;
AROMATIC-AMINES; CARCINOGEN; INVIVO; INVITRO; 4-AMINOBIPHENYL;
ENHANCEMENT; MUTAGENESIS
AB 4,4'-Methylenebis(2-chloroaniline) (MOCA) has considerable human occupational exposure and it induces urinary bladder tumors in the dog, a species that has been often used as a model for aromatic amine-induced urinary bladder carcinogenesis in humans. Metabolic activation and formation of DNA adducts are considered to be critical steps in this process; and two major C8-adenine adducts have been shown to be formed in vitro by reaction with the proximate carcinogenic metabolite N-hydroxy-MOCA. MOCA-DNA adducts have also been detected in vivo in treated rats and in exfoliated urothelium of a worker accidentally exposed to MOCA. Thus, the aim of this study was to detect and quantify DNA adducts in the urinary bladder of dogs exposed to MOCA and thereby provide data that could be useful for risk assessment after human exposure to MOCA. Beagle dogs were treated with single and multiple doses of MOCA and DNA adduct levels were determined in liver and bladder epithelium. After a single dose, adduct levels in the liver were 1.5-fold higher than that in the bladder epithelium. Adduct levels in these two organs increased 3- to 5-fold after 10 doses and adducts in the liver were then 2.8-fold higher than that in the bladder epithelium. The levels found in these two organs after single exposures were compared, per unit exposure dose, with that reported for other carcinogenic aromatic amines. The comparison showed that MOCA was as effective in DNA adduct formation as most other potent urinary bladder carcinogens. These results suggest that MOCA may have high carcinogenic potential in humans and are consistent with the recent classification of MOCA as a probable human carcinogen.
C1 NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
FU FDA HHS [NIOSH/FDA 224-88-0003]
NR 28
TC 8
Z9 8
U1 0
U2 1
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD OCT
PY 1993
VL 14
IS 10
BP 2143
EP 2147
DI 10.1093/carcin/14.10.2143
PG 5
WC Oncology
SC Oncology
GA MD319
UT WOS:A1993MD31900027
PM 8222068
ER
PT J
AU SHADDOCK, JG
SNAWDER, JE
CASCIANO, DA
AF SHADDOCK, JG
SNAWDER, JE
CASCIANO, DA
TI CRYOPRESERVATION AND LONG-TERM STORAGE OF PRIMARY RAT HEPATOCYTES -
EFFECTS ON SUBSTRATE-SPECIFIC CYTOCHROME P450-DEPENDENT ACTIVITIES AND
UNSCHEDULED DNA-SYNTHESIS
SO CELL BIOLOGY AND TOXICOLOGY
LA English
DT Article
DE RAT HEPATOCYTES; CRYOPRESERVATION; LONG-TERM STORAGE; UNSCHEDULED DNA
SYNTHESIS; CYTOCHROME P450S; CULTURE VIABILITY
ID REPAIR ASSAY; LIQUID-NITROGEN; LIVER-CELLS; CULTURE; INDUCTION;
PRESERVATION; MAINTENANCE; CARCINOGENS; ACTIVATION; METABOLISM
AB The effects of cryopreservation and long-term storage on substrate-specific cytochrome P450-dependent activities and unscheduled DNA synthesis were studied in freshly isolated and cryopreserved hepatocytes derived from adult male Fischer 344 and Sprague-Dawley rats. Primary rat hepatocytes were isolated via an in situ collagenase perfusion technique, cryopreserved at -196 degrees C, and thawed at 5 weeks and 104 and 156 weeks post-freezing. In Fischer 344 and Sprague-Dawley rats, cryopreserved hepatocytes were equivalent or similar to freshly isolated hepatocytes in substrate-specific activities for 7-ethoxyresorufin-O-deethylase and dimethylnitrosamine-N-demethylase and unscheduled DNA synthesis responses. No significant differences in activities toward 7-ethoxyresorufin-O-deethylase and dimethylnitrosamine-N-demethylase, the substrate-specific activities for cytochromes P4501A1 and P4501A2 and cytochrome P4502E1, respectively, were observed between freshly isolated and cryopreserved hepatocytes. Similar unscheduled DNA synthesis responses, a measure of DNA damage and repair, were observed after exposure to the genotoxic carcinogens 2-acetylamino-fluorene, 7,12-dimethylbenz[a]anthracene, and dimethylnitrosamine; although some decreases were also observed in Fischer 344 hepatocytes after 104 weeks and Sprague-Dawley hepatocytes after 156 weeks in the highest concentrations tested. These results suggest that cryopreserved hepatocytes, stored for extended periods of time in liquid nitrogen, are metabolically equivalent to freshly isolated hepatocytes in their ability to activate precarcinogens.
C1 NATL CTR TOXICOL RES,DIV BIOCHEM TOXICOL,JEFFERSON,AR 72079.
UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM,LITTLE ROCK,AR.
UNIV ARKANSAS MED SCI HOSP,DEPT MOLEC BIOL & TOXICOL,LITTLE ROCK,AR.
RP SHADDOCK, JG (reprint author), NATL CTR TOXICOL RES,DIV GENET TOXICOL,HFT-120,NCTR DR,JEFFERSON,AR 72079, USA.
NR 34
TC 7
Z9 7
U1 0
U2 0
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0742-2091
J9 CELL BIOL TOXICOL
JI Cell Biol. Toxicol.
PD OCT-DEC
PY 1993
VL 9
IS 4
BP 345
EP 357
DI 10.1007/BF00754463
PG 13
WC Cell Biology; Toxicology
SC Cell Biology; Toxicology
GA NA480
UT WOS:A1993NA48000004
PM 8039011
ER
PT J
AU VANDERVEEN, JE
AF VANDERVEEN, JE
TI INGREDIENT LABELING UPDATE
SO CEREAL FOODS WORLD
LA English
DT Article
RP VANDERVEEN, JE (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,WASHINGTON,DC 20204, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CEREAL CHEMISTS
PI ST PAUL
PA 3340 PILOT KNOB RD, ST PAUL, MN 55121-2097
SN 0146-6283
J9 CEREAL FOOD WORLD
JI Cereal Foods World
PD OCT
PY 1993
VL 38
IS 10
BP 770
EP 770
PG 1
WC Food Science & Technology
SC Food Science & Technology
GA MF027
UT WOS:A1993MF02700007
ER
PT J
AU ALAYASH, AI
RYAN, BAB
FRATANTONI, JC
AF ALAYASH, AI
RYAN, BAB
FRATANTONI, JC
TI OXIDATION REACTIONS OF HUMAN, OPOSSUM (DIDELPHIS-VIRGINIANA) AND SPOT
(LEIOSTOMUS-XANTHURUS) HEMOGLOBINS - A SEARCH FOR A CORRELATION WITH
SOME STRUCTURAL-FUNCTIONAL PROPERTIES
SO COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR
BIOLOGY
LA English
DT Article
ID SPECIES-RELATED VARIATIONS; TISSUE ANTIOXIDANT STATUS; HYDROXYL
RADICALS; HYDROGEN-PEROXIDE; OXYHEMOGLOBIN; CONSEQUENCES; ERYTHROCYTES;
GENERATION; MYOGLOBIN; IRON
AB 1. Relative to human HbA, opossum (Didelphis virginiana) hemoglobin was found to be more susceptible to autoxidation. While the initial rate of autoxidation of spot (Leiostomus xanthurus) hemoglobin is close to that of HbA, complete oxidation occurs in 50 hr.
2. Direct addition of hydrogen peroxide (H2O2) induced oxidation of hemoglobins in a definite order: spot Hb > HbA > opossum Hb. Excess H2O2 led to heme degradation and precipitation that occurred much faster for spot Hb than the case with other proteins.
3. Exposure of hemoglobins to a continuous flux of H2O2, generated by the glucose/glucose oxidase system, induced the formation of heterogenous protein-associated oxidation products.
4. Differential reactivity among these hemoglobins under the same or different oxidative conditions, with respect to methemoglobin formation and stability of the ferric form, may reflect the differences in the local heme environment of these proteins.
RP ALAYASH, AI (reprint author), US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20014, USA.
NR 36
TC 6
Z9 7
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0305-0491
J9 COMP BIOCHEM PHYS B
JI Comp. Biochem. Physiol. B-Biochem. Mol. Biol.
PD OCT
PY 1993
VL 106
IS 2
BP 427
EP 432
DI 10.1016/0305-0491(93)90324-X
PG 6
WC Biochemistry & Molecular Biology; Zoology
SC Biochemistry & Molecular Biology; Zoology
GA LW236
UT WOS:A1993LW23600032
PM 8243064
ER
PT J
AU PRIVAL, MJ
PEIPERL, MD
BELL, SJ
AF PRIVAL, MJ
PEIPERL, MD
BELL, SJ
TI DETERMINATION OF COMBINED BENZIDINE IN FD-AND-C YELLOW NO-5
(TARTRAZINE), USING A HIGHLY SENSITIVE ANALYTICAL METHOD
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; SULFONATED AROMATIC-AMINES;
REDUCTION; DERIVATIZATION; DIAZOTIZATION; METABOLISM
AB 53 samples of FD & C Yellow No. 5 (tartrazine; Colour Index No. 19140) were examined for combined benzidine. These samples, which represent separate lots from 12 dye distributors, were submitted to the US FDA for certification between 28 February 1990 and 27 June 1991. A method was developed to reduce the dye matrix with dithionite so that combined benzidine present in the form of azo or disazo dyes would be converted to free benzidine. Reduction was followed by extraction, diazotization and coupling with pyrazolone T, and the total benzidine present was quantitated as benzidine-pyrazolone T disazo dye (BZPT) by HPLC with detection at 500 nm. The limit of quantitation for benzidine in FD & C Yellow No. 5 by this method is 5 ng/g. 25 samples of FD & C Yellow No. 5 were found to contain 7-83 ng/g of combined benzidine that was released by dithionite reduction. 23 of these samples were from the same manufacturer. The identity of the BZPT from two FD & C Yellow No. 5 samples was confirmed by spectral analysis using HPLC with a photodiode array detector.
C1 US FDA,CTR FOOD SAFETY & APPL NUTR,COLOR TECHNOL BRANCH HFS126,WASHINGTON,DC 20204.
RP PRIVAL, MJ (reprint author), US FDA,CTR FOOD SAFETY & APPL NUTR,GENET TOXICOL BRANCH HFS236,WASHINGTON,DC 20204, USA.
NR 15
TC 8
Z9 8
U1 3
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0278-6915
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD OCT
PY 1993
VL 31
IS 10
BP 751
EP 758
DI 10.1016/0278-6915(93)90147-Q
PG 8
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA ME109
UT WOS:A1993ME10900009
PM 8225134
ER
PT J
AU DEVOID, DE
MINKOFF, H
GOEDERT, J
BISWAS, R
DIBISCEGLIE, AM
AF DEVOID, DE
MINKOFF, H
GOEDERT, J
BISWAS, R
DIBISCEGLIE, AM
TI PERINATAL TRANSMISSION OF HEPATITIS-C
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 UNESCO,DEPT PEDIAT,F-75700 PARIS,FRANCE.
NIH,LIVER DIS SECT,BETHESDA,MD 20892.
NIH,VIRAL EPIDEMIOL SECT,BETHESDA,MD 20892.
SUNY HLTH SCI CTR,NEW YORK,NY.
US FDA,CBER,HEPATITIS LAB,ROCKVILLE,MD 20857.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
19106-3399
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 1993
VL 18
IS 4
BP A229
EP A229
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA LY995
UT WOS:A1993LY99500687
ER
EF